Case ID,Suspect Product Names,Suspect Product Active Ingredients,Reason for Use,Reactions,Serious,Outcomes,Sex,Event Date,Latest FDA Received Date,Case Priority,Patient Age,Patient Weight,Sender,Reporter Type,Report Source,Concomitant Product Names,Latest Manufacturer Received Date,Initial FDA Received Date,Country where Event occurred,Reported to Manufacturer?,Manufacturer Control Number,Literature Reference,Compounded Flag
22875391,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Exposure Via Skin Contact;Accidental Exposure To Product;Device Leakage,Non-Serious,Non-Serious,Male,AUG-2023,19-OCT-2023,Non-Expedited,69 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-OCT-2023,29-AUG-2023,US,Not Specified,US-SA-2023SA258801,-,-
22952760,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Leakage;Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,17-OCT-2023,Non-Expedited,69 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,10-OCT-2023,18-SEP-2023,US,Not Specified,US-SA-2023SA280459,-,-
22794605,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product;Exposure Via Skin Contact,Non-Serious,Non-Serious,Male,-,17-OCT-2023,Non-Expedited,61 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,06-OCT-2023,07-AUG-2023,US,Not Specified,US-SA-2023SA238595,-,-
22984830,Soliqua 100/33,Insulin Glargine\Lixisenatide,Blood Cholesterol Abnormal;Blood Pressure Abnormal;Diabetes Mellitus;Gastrointestinal Disorder,Exposure Via Skin Contact;Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,13-OCT-2023,Non-Expedited,65 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin;Fenofibrate;Omeprazole;Atorvastatin;Farxiga,05-OCT-2023,26-SEP-2023,US,Not Specified,US-SA-2023SA288937,-,-
22968511,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Aspartate Aminotransferase Increased;Alanine Aminotransferase Increased;Hepatitis,Serious,Other Outcomes,Male,SEP-2023,06-OCT-2023,Expedited,62 YR,75 KG,Sanofi Aventis,Healthcare Professional,Not Specified,Metformin;Ezetimibe;Amlodipine;Empagliflozin;Pitavastatin;Enalapril,30-SEP-2023,21-SEP-2023,TH,Not Specified,TH-SA-2023SA284213,-,-
22966576,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Vision Blurred;Blood Glucose Increased;Drug Ineffective,Non-Serious,Non-Serious,Male,-,03-OCT-2023,Non-Expedited,45 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,25-SEP-2023,21-SEP-2023,US,Not Specified,US-SA-2023SA287462,-,-
22756505,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Drug Ineffective,Non-Serious,Non-Serious,Female,-,01-OCT-2023,Non-Expedited,81 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,25-SEP-2023,27-JUL-2023,US,Not Specified,US-SA-2023SA227849,-,-
23011079,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Dementia Alzheimer's Type,Serious,Other Outcomes,Male,-,29-SEP-2023,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,22-SEP-2023,29-SEP-2023,US,Not Specified,US-SA-2023SA294069,-,-
23010189,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment;Hypoacusis,Non-Serious,Non-Serious,Male,-,29-SEP-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-SEP-2023,29-SEP-2023,US,Not Specified,US-SA-2023SA290422,-,-
23002237,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Increased;Product Dose Omission Issue,Non-Serious,Non-Serious,Male,SEP-2023,28-SEP-2023,Non-Expedited,45 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-SEP-2023,28-SEP-2023,US,Not Specified,US-SA-2023SA290310,-,-
22864886,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Neoplasm;Blood Glucose Increased;Product Storage Error;Myocardial Infarction;Inappropriate Schedule Of Product Administration;Renal Disorder;Lack Of Injection Site Rotation;Morning Sickness;Amnesia;Dizziness;Cerebrovascular Accident;Kidney Contusion;Device Mechanical Issue;Product Dose Omission Issue;Abdominal Pain;Tumour Pain;Nausea,Serious,Hospitalized;Other Outcomes,Female,-,28-SEP-2023,Expedited,55 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,14-SEP-2023,25-AUG-2023,US,Not Specified,US-SA-2023SA256562,-,-
22718668,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Drug Ineffective,Non-Serious,Non-Serious,Male,-,28-SEP-2023,Non-Expedited,77 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,21-SEP-2023,18-JUL-2023,US,Not Specified,US-SA-2023SA217162,-,-
22993363,-,Miglitol;Dapagliflozin;Insulin Degludec\Liraglutide,Blood Glucose Increased,Gastrooesophageal Reflux Disease;Abdominal Distension;Vomiting;Diarrhoea;Nausea;Dyspepsia,Serious,Other Outcomes;Hospitalized,Male,28-AUG-2023,27-SEP-2023,Expedited,Not Specified,74.5 KG,Astrazeneca,Healthcare Professional,Not Specified,-,19-SEP-2023,27-SEP-2023,Not Specified,Not Specified,CN-AstraZeneca-2023A216525,-,-
22990620,-,Acarbose;Dapagliflozin;Insulin Degludec\Liraglutide,Blood Glucose Decreased;Dizziness;Nausea;Product Used For Unknown Indication,Dizziness;Nausea,Serious,Hospitalized;Other Outcomes,Male,19-AUG-2023,27-SEP-2023,Expedited,73 YR,61 KG,Astrazeneca,Healthcare Professional,Not Specified,Promethazine Hydrochloride;Pantoprazole Sodium,19-SEP-2023,27-SEP-2023,Not Specified,Not Specified,CN-AstraZeneca-2023A216715,-,-
22990021,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Product Dispensing Error,Non-Serious,Non-Serious,Female,-,27-SEP-2023,Non-Expedited,67 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-SEP-2023,27-SEP-2023,US,Not Specified,US-SA-2023SA287469,-,-
22982328,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Male,MAR-2023,26-SEP-2023,Non-Expedited,74 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-SEP-2023,26-SEP-2023,US,Not Specified,US-SA-2023SA285950,-,-
22982245,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Post Procedural Infection;Cholecystectomy;Blood Glucose Increased,Serious,Other Outcomes,Male,2023,26-SEP-2023,Expedited,56 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,14-SEP-2023,26-SEP-2023,BR,Not Specified,BR-NOVOPROD-1116775,-,-
22937679,Xultophy 100/3.6;Rybelsus,Semaglutide;Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Angina Pectoris,Serious,Hospitalized;Other Outcomes,Female,-,26-SEP-2023,Expedited,68 YR,68 KG,Novo Nordisk,Healthcare Professional,Not Specified,Promestriene;Metoprolol Succinate;Nitrofurantoin;Xigduo Xr;Losartan Potassium;Aspirin,15-SEP-2023,13-SEP-2023,BR,Not Specified,BR-NOVOPROD-1110495,-,-
22659334,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Liquid Product Physical Issue;Blood Glucose Increased;Drug Ineffective,Non-Serious,Non-Serious,Female,-,26-SEP-2023,Non-Expedited,53 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Basaglar,21-SEP-2023,30-JUN-2023,US,Not Specified,US-SA-2023SA199641,-,-
22979539,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Exposure Via Skin Contact;Accidental Exposure To Product,Non-Serious,Non-Serious,Male,15-SEP-2023,25-SEP-2023,Non-Expedited,59 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-SEP-2023,25-SEP-2023,US,Not Specified,US-SA-2023SA283975,-,-
22976957,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Product Dispensing Error,Non-Serious,Non-Serious,Male,-,25-SEP-2023,Non-Expedited,68 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-SEP-2023,25-SEP-2023,US,Not Specified,US-SA-2023SA284971,-,-
22976102,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Pancreatic Operation,Serious,Other Outcomes,Male,-,25-SEP-2023,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,14-SEP-2023,25-SEP-2023,JP,Not Specified,JP-NOVOPROD-1118430,-,-
22965586,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Dementia,Serious,Other Outcomes,Male,-,21-SEP-2023,Expedited,83 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-SEP-2023,21-SEP-2023,US,Not Specified,US-SA-2023SA283457,-,-
22964064,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Hand Fracture,Serious,Hospitalized,Female,-,21-SEP-2023,Expedited,74 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,12-SEP-2023,21-SEP-2023,JP,Not Specified,JP-NOVOPROD-1116484,-,-
22962297,Glucobay,Acarbose;Insulin Degludec\Liraglutide;Dapagliflozin,Type 2 Diabetes Mellitus,Nausea;Blood Glucose Decreased;Abdominal Discomfort;Dizziness,Serious,Hospitalized;Other Outcomes,Male,AUG-2023,20-SEP-2023,Expedited,73 YR,61 KG,Bayer,Healthcare Professional,Not Specified,Insulin Degludec,19-SEP-2023,20-SEP-2023,CN,Not Specified,CN-BAYER-2023A132128,-,-
22961515,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Female,11-SEP-2023,20-SEP-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,12-SEP-2023,20-SEP-2023,US,Not Specified,US-SA-2023SA280816,-,-
22961482,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Ocular Discomfort;Diarrhoea;Vomiting,Non-Serious,Non-Serious,Male,MAR-2023,20-SEP-2023,Non-Expedited,82 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-SEP-2023,20-SEP-2023,US,Not Specified,US-SA-2023SA286208,-,-
22959600,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Nausea;Abdominal Distension;Gastric Mucosal Lesion;Diarrhoea,Serious,Hospitalized,Female,02-SEP-2023,20-SEP-2023,Expedited,63 YR,55 KG,Novo Nordisk,Healthcare Professional,Not Specified,Dapagliflozin,08-SEP-2023,20-SEP-2023,CN,Not Specified,CN-NOVOPROD-1116382,-,-
22955518,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Nausea;Product Storage Error,Non-Serious,Non-Serious,Female,03-SEP-2023,18-SEP-2023,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-SEP-2023,18-SEP-2023,US,Not Specified,US-SA-2023SA278247,-,-
22954834,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Device Failure;Hypoglycaemic Unconsciousness,Serious,Other Outcomes,Female,JUN-2023,18-SEP-2023,Expedited,78 YR,69 KG,Novo Nordisk,Consumer,Not Specified,Empagliflozin,05-SEP-2023,18-SEP-2023,CO,Not Specified,CO-NOVOPROD-1091586,-,-
22954741,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Blood Cholesterol Abnormal;Blood Triglycerides Abnormal;Diuretic Therapy;Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Bacterial Infection;Neoplasm;Nephrectomy,Serious,Other Outcomes;Hospitalized,Female,2023,18-SEP-2023,Expedited,67 YR,97 KG,Novo Nordisk,Consumer,Not Specified,Losartan;Verapamil;Hydrochlorothiazide;Atorvastatin;Furosemide,06-SEP-2023,18-SEP-2023,MX,Not Specified,MX-NOVOPROD-1113578,-,-
22852839,-,Insulin Glargine\Lixisenatide,Hyperlipidaemia;Hypertension;Osteoporosis;Type 2 Diabetes Mellitus,Alanine Aminotransferase Increased,Serious,Other Outcomes,Male,14-AUG-2023,18-SEP-2023,Expedited,62 YR,65 KG,Sanofi Aventis,Healthcare Professional,Not Specified,Vitamin D Nos;Irbesartan;Calcium Citrate Malate;Imrecoxib;Methylcobalamin;Epalrestat;Atorvastatin Calcium;Alpha Lipoic Acid;Betahistine Hydrochloride;Niacin;Amlodipine Besylate;Metformin,12-SEP-2023,23-AUG-2023,CN,Not Specified,CN-SA-2023SA253162,-,-
22941509,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,14-SEP-2023,Non-Expedited,43 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-SEP-2023,14-SEP-2023,US,Not Specified,US-SA-2023SA276095,-,-
22810414,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Issue;Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,14-SEP-2023,Non-Expedited,85 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,07-SEP-2023,10-AUG-2023,US,Not Specified,US-SA-2023SA243648,-,-
22934377,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Dose Omission In Error,Non-Serious,Non-Serious,Male,-,12-SEP-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,06-SEP-2023,12-SEP-2023,US,Not Specified,US-SA-2023SA274260,-,-
22928064,Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Lispro,Diabetes Mellitus,Hypoglycaemia;Contraindicated Product Administered;Weight Increased,Non-Serious,Non-Serious,Female,-,11-SEP-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,05-SEP-2023,11-SEP-2023,US,Not Specified,US-SA-2023SA272357,-,-
22927392,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Vomiting;Tremor,Serious,Other Outcomes,Female,07-AUG-2023,11-SEP-2023,Expedited,76 YR,55.5 KG,Novo Nordisk,Healthcare Professional,Not Specified,-,28-AUG-2023,11-SEP-2023,CN,Not Specified,CN-NOVOPROD-1109545,-,-
22916046,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Wrong Technique In Product Usage Process;Product Storage Error,Non-Serious,Non-Serious,Male,-,07-SEP-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-SEP-2023,07-SEP-2023,US,Not Specified,US-SA-2023SA270199,-,-
22911290,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Injection Site Pain,Non-Serious,Non-Serious,Male,-,06-SEP-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-SEP-2023,06-SEP-2023,US,Not Specified,US-SA-2023SA270082,-,-
16768929,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 1 Diabetes Mellitus,Accidental Exposure To Product;Device Operational Issue;Incorrect Dose Administered By Device;Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Female,-,06-SEP-2023,Non-Expedited,62 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,31-AUG-2023,03-SEP-2019,US,Not Specified,US-SA-2019SA239702,-,-
22896308,Toujeo;Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Glargine,Diabetes Mellitus,Wrong Product Administered,Non-Serious,Non-Serious,Female,-,01-SEP-2023,Non-Expedited,85 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,25-AUG-2023,01-SEP-2023,US,Not Specified,US-SA-2023SA262123,-,-
22888023,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Male,-,31-AUG-2023,Non-Expedited,69 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-AUG-2023,31-AUG-2023,US,Not Specified,US-SA-2023SA258037,-,-
22887882,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Off Label Use;Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Female,-,31-AUG-2023,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,25-AUG-2023,31-AUG-2023,US,Not Specified,US-SA-2022SA058016,-,-
22887669,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Exposure Via Skin Contact;Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,31-AUG-2023,Non-Expedited,77 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-AUG-2023,31-AUG-2023,US,Not Specified,US-SA-2023SA260813,-,-
22849032,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Nervousness,Non-Serious,Non-Serious,Female,-,31-AUG-2023,Non-Expedited,77 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,22-AUG-2023,22-AUG-2023,US,Not Specified,US-SA-2023SA255325,-,-
22877259,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Exposure Via Skin Contact;Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,29-AUG-2023,Non-Expedited,72 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-AUG-2023,29-AUG-2023,US,Not Specified,US-SA-2023SA259977,-,-
22876820,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Latent Autoimmune Diabetes In Adults,Weight Decreased;Diabetic Ketoacidosis,Serious,Hospitalized;Other Outcomes,Male,-,29-AUG-2023,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,18-AUG-2023,29-AUG-2023,JP,Not Specified,JP-NOVOPROD-1096307,-,-
22870132,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration;Accidental Exposure To Product,Non-Serious,Non-Serious,Female,-,27-AUG-2023,Non-Expedited,73 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-AUG-2023,27-AUG-2023,US,Not Specified,US-SA-2023SA257650,-,-
22866120,Metformin,Metformin Hydrochloride;Insulin Degludec;Insulin Degludec\Liraglutide,Pancreatogenous Diabetes,Drug Ineffective,Serious,Other Outcomes,Male,-,25-AUG-2023,Expedited,Not Specified,Not Specified,Mylan,Healthcare Professional,Not Specified,-,17-AUG-2023,25-AUG-2023,JP,Not Specified,JP-MYLANLABS-2023M1088438,"Yamada T, Asahara S-I, Kimura-Koyanagi M, Tamori Y, Muramae N, Mori K, et al. Distinct hypoglycemic effect of different formulations of a fixed ratio of basal insulin plus glucagon-like peptide-1 receptor agonist in a patient with pancreatic diabetes. Diabet-Int 2023;14(3):294-297.. 2023;14(3):294-297",-
22864020,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Hypoglycaemia,Non-Serious,Non-Serious,Male,-,25-AUG-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-AUG-2023,25-AUG-2023,US,Not Specified,US-SA-2023SA256086,-,-
22856271,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,-,25-AUG-2023,Non-Expedited,67 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-AUG-2023,23-AUG-2023,US,Not Specified,US-SA-2023SA252669,-,-
22849695,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Fear Of Injection,Non-Serious,Non-Serious,Female,-,22-AUG-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-AUG-2023,22-AUG-2023,US,Not Specified,US-SA-2023SA255393,-,-
22849322,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Incorrect Dose Administered,Non-Serious,Non-Serious,Female,-,22-AUG-2023,Non-Expedited,72 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-AUG-2023,22-AUG-2023,US,Not Specified,US-SA-2023SA251221,-,-
22848703,Soliqua 100/33;Lantus,Insulin Glargine;Insulin Glargine\Lixisenatide,-,Wrong Product Administered,Non-Serious,Non-Serious,Male,-,22-AUG-2023,Non-Expedited,61 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,15-AUG-2023,22-AUG-2023,US,Not Specified,US-SA-2023SA250327,-,-
22848701,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,-,22-AUG-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-AUG-2023,22-AUG-2023,US,Not Specified,US-SA-2023SA253067,-,-
22841995,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product;Exposure Via Skin Contact,Non-Serious,Non-Serious,Male,-,21-AUG-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,16-AUG-2023,21-AUG-2023,US,Not Specified,US-SA-2021SA405374,-,-
22837136,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Female,08-AUG-2023,18-AUG-2023,Non-Expedited,78 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-AUG-2023,18-AUG-2023,US,Not Specified,US-SA-2023SA248419,-,-
22835484,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Drug Ineffective,Non-Serious,Non-Serious,Female,-,18-AUG-2023,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-AUG-2023,18-AUG-2023,US,Not Specified,US-SA-2023SA251435,-,-
22726564,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Mechanical Issue;Hypoglycaemia;Loss Of Consciousness,Serious,Other Outcomes,Female,2023,18-AUG-2023,Expedited,76 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,15-AUG-2023,20-JUL-2023,US,Not Specified,US-SA-2023SA219120,-,-
22819878,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Decreased;Incorrect Dose Administered;Intentional Product Use Issue,Non-Serious,Non-Serious,Male,2023,17-AUG-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-AUG-2023,14-AUG-2023,US,Not Specified,US-SA-2023SA246359,-,-
22205745,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Memory Impairment;Abdominal Pain Upper;Vomiting;Vision Blurred;Accidental Exposure To Product;Blood Glucose Increased;Intraocular Pressure Increased;Diarrhoea,Non-Serious,Non-Serious,Male,APR-2023,17-AUG-2023,Non-Expedited,81 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,07-AUG-2023,13-APR-2023,US,Not Specified,US-SA-2023SA113251,-,-
22826333,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,16-AUG-2023,Non-Expedited,64 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-AUG-2023,16-AUG-2023,US,Not Specified,US-SA-2023SA248645,-,-
22826226,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Chest Discomfort;Diarrhoea,Non-Serious,Non-Serious,Male,-,16-AUG-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Farxiga,09-AUG-2023,16-AUG-2023,US,Not Specified,US-SA-2023SA246217,-,-
22632615,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Coronary Artery Disease;Diabetes Mellitus,Malnutrition;Weight Decreased;Wound;Fall;Condition Aggravated;Blood Glucose Fluctuation;Plantar Fasciitis;Sarcopenia,Serious,Hospitalized;Other Outcomes,Male,16-MAY-2023,16-AUG-2023,Expedited,79 YR,81 KG,Novo Nordisk,Healthcare Professional,Not Specified,Metformin Hydrochloride,04-AUG-2023,23-JUN-2023,FR,Not Specified,FR-NOVOPROD-1080003,-,-
22822899,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Off Label Use;Product Storage Error,Non-Serious,Non-Serious,Male,-,15-AUG-2023,Non-Expedited,71 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-AUG-2023,15-AUG-2023,US,Not Specified,US-SA-2023SA245358,-,-
22812551,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Off Label Use,Non-Serious,Non-Serious,Male,-,11-AUG-2023,Non-Expedited,60 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-AUG-2023,11-AUG-2023,US,Not Specified,US-SA-2023SA242702,-,-
22808537,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Male,-,10-AUG-2023,Non-Expedited,68 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-AUG-2023,10-AUG-2023,US,Not Specified,US-SA-2023SA243815,-,-
22806543,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Exposure Via Skin Contact;Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,10-AUG-2023,Non-Expedited,69 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-AUG-2023,10-AUG-2023,US,Not Specified,US-SA-2023SA242866,-,-
22749731,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Increased;Accidental Exposure To Product,Non-Serious,Non-Serious,Male,JUL-2023,10-AUG-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,08-AUG-2023,26-JUL-2023,US,Not Specified,US-SA-2023SA224047,-,-
22803648,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Drug Ineffective,Non-Serious,Non-Serious,Male,-,09-AUG-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,03-AUG-2023,09-AUG-2023,US,Not Specified,US-SA-2023SA240584,-,-
22802596,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,09-AUG-2023,Non-Expedited,63 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,04-AUG-2023,09-AUG-2023,US,Not Specified,US-SA-2021SA109609,-,-
22801909,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration;Off Label Use,Non-Serious,Non-Serious,Male,-,09-AUG-2023,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,04-AUG-2023,09-AUG-2023,US,Not Specified,US-SA-2023SA240782,-,-
22788435,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Exposure Via Skin Contact;Accidental Exposure To Product,Non-Serious,Non-Serious,Female,-,08-AUG-2023,Non-Expedited,44 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,31-JUL-2023,04-AUG-2023,US,Not Specified,US-SA-2023SA235205,-,-
22791886,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Prescribing Error,Non-Serious,Non-Serious,Female,-,07-AUG-2023,Non-Expedited,45 YR,104 KG,Sanofi Aventis,Consumer,Not Specified,-,31-JUL-2023,07-AUG-2023,US,Not Specified,US-SA-2023SA235274,-,-
22791569,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Diarrhoea,Serious,Life Threatening,Male,12-JUL-2023,07-AUG-2023,Expedited,59 YR,78 KG,Novo Nordisk,Healthcare Professional,Not Specified,Acarbose,27-JUL-2023,07-AUG-2023,CN,Not Specified,CN-NOVOPROD-1097783,-,-
22788337,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Drug Ineffective;Chronic Obstructive Pulmonary Disease;Diabetes Mellitus Inadequate Control;Memory Impairment;Emphysema,Serious,Other Outcomes,Female,-,04-AUG-2023,Non-Expedited,69 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-AUG-2023,04-AUG-2023,US,Not Specified,US-SA-2023SA236490,-,-
22666110,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product;Blood Glucose Increased,Non-Serious,Non-Serious,Female,26-JUN-2023,04-AUG-2023,Non-Expedited,74 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,02-AUG-2023,03-JUL-2023,US,Not Specified,US-SA-2023SA199855,-,-
22784415,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Diabetes Mellitus Inadequate Control,Serious,Other Outcomes,Female,-,03-AUG-2023,Non-Expedited,72 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-AUG-2023,03-AUG-2023,US,Not Specified,US-SA-2023SA236460,-,-
22781159,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Lung Neoplasm Malignant,Serious,Other Outcomes,Male,JUN-2023,03-AUG-2023,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-JUL-2023,03-AUG-2023,US,Not Specified,US-SA-2023SA232730,-,-
22776174,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Product Usage Process,Non-Serious,Non-Serious,Female,-,02-AUG-2023,Non-Expedited,65 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-JUL-2023,02-AUG-2023,US,Not Specified,US-SA-2023SA233628,-,-
22775752,-,Insulin Glargine\Lixisenatide,-,Epilepsy,Serious,Other Outcomes,Not Specified,-,02-AUG-2023,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,27-JUL-2023,02-AUG-2023,DE,Not Specified,DE-SA-2023SA232687,-,-
22764435,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,02-AUG-2023,Non-Expedited,63 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,25-JUL-2023,31-JUL-2023,US,Not Specified,US-SA-2023SA228026,-,-
22771950,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Injection Site Pain;Hunger;Weight Increased,Non-Serious,Non-Serious,Female,2023,01-AUG-2023,Non-Expedited,60 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-JUL-2023,01-AUG-2023,US,Not Specified,US-SA-2023SA233650,-,-
22770072,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Prescribing Issue;Product Administration Error,Non-Serious,Non-Serious,Female,-,01-AUG-2023,Non-Expedited,59 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,25-JUL-2023,01-AUG-2023,US,Not Specified,US-SA-2023SA229915,-,-
22728327,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Delivery System Issue;Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,01-AUG-2023,Non-Expedited,71 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,27-JUL-2023,20-JUL-2023,US,Not Specified,US-SA-2023SA219604,-,-
22768029,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Male,APR-2023,31-JUL-2023,Non-Expedited,58 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-JUL-2023,31-JUL-2023,US,Not Specified,US-SA-2023SA225341,-,-
22762943,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,-,29-JUL-2023,Non-Expedited,69 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-JUL-2023,29-JUL-2023,US,Not Specified,US-SA-2023SA230071,-,-
22756225,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Diarrhoea,Non-Serious,Non-Serious,Female,JUL-2023,27-JUL-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,25-JUL-2023,27-JUL-2023,US,Not Specified,US-SA-2023SA229188,-,-
22750916,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Increased;Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Male,-,26-JUL-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-JUL-2023,26-JUL-2023,US,Not Specified,US-SA-2023SA224000,-,-
22749676,Soliqua 100/33,Insulin Glargine\Lixisenatide,Product Used For Unknown Indication,Abdominal Pain Upper;Pancreatitis,Serious,Other Outcomes,Not Specified,-,26-JUL-2023,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,21-JUL-2023,26-JUL-2023,JP,Not Specified,JP-SA-2023SA222269,-,-
22728840,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 1 Diabetes Mellitus,Decreased Appetite;Blood Glucose Increased;Weight Decreased,Non-Serious,Non-Serious,Female,-,26-JUL-2023,Non-Expedited,55 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Ozempic;Mounjaro,19-JUL-2023,20-JUL-2023,US,Not Specified,US-SA-2023SA218826,-,-
22744956,Pioglitazone Hydrochloride And Metformin Hydrochloride,Metformin Hydrochloride\Pioglitazone Hydrochloride;Ondansetron;Dexamethasone;Gliclazide;Ixazomib;Pioglitazone Hydrochloride,Blood Glucose Increased;Diabetes Mellitus;Muscle Spasms;Plasma Cell Myeloma;Premedication;Product Used For Unknown Indication,Off Label Use;Neoplasm Skin;Abdominal Pain Upper;Covid-19;Clostridium Difficile Colitis;Constipation;Haemorrhoids;Drug Ineffective;Hypoaesthesia;Transient Ischaemic Attack;Cataract;Haemorrhoidal Haemorrhage;Chest Pain;Dyspnoea;Vulvovaginal Mycotic Infection;Cardiomegaly;Neuropathy Peripheral;Pneumonia;Product Use Issue;Fall;Chest Discomfort;Cardiac Failure;Pain In Extremity;Blood Pressure Increased,Serious,Other Outcomes;Hospitalized,Female,-,25-JUL-2023,Expedited,67 YR,Not Specified,Sandoz,Healthcare Professional,Not Specified,Pantoprazole Sodium;Potassium Chloride;Revlimid;Hydralazine;Baclofen;Metoprolol;Amlodipine;Aspirin;Atenolol;Quinine;Cyclophosphamide;Nitroglycerin;Furosemide;Rosuvastatin;Prednisone;Ferrous Fumarate;Acyclovir;Terazosin Hydrochloride;Empagliflozin;Epoetin Alfa;Linagliptin,12-JUL-2023,25-JUL-2023,CA,Not Specified,CA-002147023-NVSC2023CA005723,-,-
22742338,Lantus;Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Glargine,-,Product Dispensing Error,Non-Serious,Non-Serious,Female,-,24-JUL-2023,Non-Expedited,56 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-JUL-2023,24-JUL-2023,US,Not Specified,US-SA-2023SA217052,-,-
22728326,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Fluctuation;Muscle Spasms,Non-Serious,Non-Serious,Female,17-JUL-2023,24-JUL-2023,Non-Expedited,71 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,17-JUL-2023,20-JUL-2023,US,Not Specified,US-SA-2023SA219053,-,-
22726560,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Dysarthria;Hypoglycaemia;Unresponsive To Stimuli;Device Issue,Serious,Other Outcomes,Female,25-MAR-2023,24-JUL-2023,Expedited,76 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,17-JUL-2023,20-JUL-2023,US,Not Specified,US-SA-2023SA219290,-,-
22722648,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Urinary Tract Infection;Visual Impairment,Serious,Hospitalized,Female,-,24-JUL-2023,Expedited,66 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Humalog,14-JUL-2023,19-JUL-2023,US,Not Specified,US-SA-2023SA217236,-,-
22717836,Nesina,Alogliptin Benzoate;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Vomiting;Drug Ineffective,Serious,Hospitalized,Female,07-JUL-2023,24-JUL-2023,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,-,14-JUL-2023,18-JUL-2023,CN,Not Specified,CN-TAKEDA-2023TUS070120,-,-
22714751,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Alcoholic Pancreatitis,Serious,Hospitalized,Male,09-JUL-2023,24-JUL-2023,Expedited,6 DEC,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Amlodipine;Vonoprazan Fumarate,13-JUL-2023,18-JUL-2023,JP,Not Specified,JP-NOVOPROD-1091608,-,-
22681182,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Male,JUN-2023,24-JUL-2023,Non-Expedited,53 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,19-JUL-2023,07-JUL-2023,US,Not Specified,US-SA-2023SA206823,-,-
22647679,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Cognitive Disorder;Device Issue;Injection Site Haemorrhage;Blood Glucose Abnormal;Visual Impairment,Non-Serious,Non-Serious,Male,-,24-JUL-2023,Non-Expedited,69 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,19-JUL-2023,28-JUN-2023,US,Not Specified,US-SA-2023SA195006,-,-
22043540,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Intentional Product Use Issue,Non-Serious,Non-Serious,Male,-,21-JUL-2023,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,17-JUL-2023,28-FEB-2023,US,Not Specified,US-SA-2023SA065693,-,-
22728194,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Female,-,20-JUL-2023,Non-Expedited,61 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin,18-JUL-2023,20-JUL-2023,US,Not Specified,US-SA-2023SA219928,-,-
22724336,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Headache,Non-Serious,Non-Serious,Not Specified,2023,19-JUL-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,14-JUL-2023,19-JUL-2023,US,Not Specified,US-SA-2023SA217470,-,-
22722879,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,-,19-JUL-2023,Non-Expedited,49 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-JUL-2023,19-JUL-2023,US,Not Specified,US-SA-2023SA216740,-,-
22722522,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 1 Diabetes Mellitus,Accidental Exposure To Product;Product Use In Unapproved Indication,Non-Serious,Non-Serious,Male,13-JUL-2023,19-JUL-2023,Non-Expedited,78 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-JUL-2023,19-JUL-2023,US,Not Specified,US-SA-2023SA217210,-,-
22722327,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Dispensing Error,Non-Serious,Non-Serious,Female,-,19-JUL-2023,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-JUL-2023,19-JUL-2023,US,Not Specified,US-SA-2023SA215913,-,-
22722315,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,19-JUL-2023,Non-Expedited,52 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-JUL-2023,19-JUL-2023,US,Not Specified,US-SA-2023SA215963,-,-
22676932,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Eating Disorder;Blood Glucose Increased;Delirium;Diabetes Mellitus Inadequate Control;Hypoglycaemia,Serious,Hospitalized;Other Outcomes,Male,2023,18-JUL-2023,Expedited,89 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Novorapid,13-JUL-2023,06-JUL-2023,KR,Not Specified,KR-SA-2023SA201861,-,-
22672633,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Fatigue;Affect Lability;Blood Pressure Increased;Agitation;Heart Rate Increased;Cardiac Disorder;Blood Glucose Abnormal;Palpitations,Serious,Hospitalized,Female,2023,18-JUL-2023,Expedited,54 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,10-JUL-2023,05-JUL-2023,CN,Not Specified,CN-SA-2023SA201716,-,-
22639267,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Postprandial Hypoglycaemia;Hypertension,Serious,Hospitalized,Male,16-JUN-2023,18-JUL-2023,Expedited,63 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,12-JUL-2023,26-JUN-2023,CN,Not Specified,CN-SA-2023SA190814,-,-
22712161,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Weight Decreased;Blood Glucose Fluctuation;Decreased Appetite,Non-Serious,Non-Serious,Male,2023,17-JUL-2023,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-JUL-2023,17-JUL-2023,US,Not Specified,US-SA-2023SA213423,-,-
22709679,Soliqua 100/33;Mounjaro,Tirzepatide;Insulin Glargine\Lixisenatide,Product Used For Unknown Indication,Malaise;Nausea,Non-Serious,Non-Serious,Female,08-JUL-2023,17-JUL-2023,Non-Expedited,Not Specified,Not Specified,Eli Lilly And Co,Consumer,Not Specified,-,11-JUL-2023,17-JUL-2023,US,Not Specified,US-ELI_LILLY_AND_COMPANY-US202307006621,-,-
22711856,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Nausea;Therapy Cessation;Palpitations,Non-Serious,Non-Serious,Female,04-JUL-2023,14-JUL-2023,Direct,72 YR,73.35 KG,Fda-Ctu,Healthcare Professional,Not Specified,Metformin,-,14-JUL-2023,Not Specified,Not Specified,-,-,-
22700662,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment;Accidental Exposure To Product;Condition Aggravated,Non-Serious,Non-Serious,Female,-,13-JUL-2023,Non-Expedited,74 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-JUL-2023,13-JUL-2023,US,Not Specified,US-SA-2023SA211841,-,-
22625317,Metformin;Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Metformin Hydrochloride,Diabetes Mellitus;Hypertension,Lactic Acidosis,Serious,Other Outcomes;Hospitalized;Life Threatening,Female,19-MAR-2023,12-JUL-2023,Expedited,73 YR,Not Specified,Ranbaxy,Healthcare Professional,Not Specified,Furosemide,27-JUN-2023,21-JUN-2023,IT,Not Specified,IT-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-394468,-,-
22690934,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Intentional Product Misuse,Non-Serious,Non-Serious,Female,-,11-JUL-2023,Non-Expedited,82 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-JUL-2023,11-JUL-2023,US,Not Specified,US-SA-2023SA209292,-,-
22690476,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,11-JUL-2023,Non-Expedited,57 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-JUL-2023,11-JUL-2023,US,Not Specified,US-SA-2023SA209492,-,-
22687404,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Product Storage Error;Injection Site Bruising,Non-Serious,Non-Serious,Female,-,10-JUL-2023,Non-Expedited,78 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,05-JUL-2023,10-JUL-2023,US,Not Specified,US-SA-2023SA206969,-,-
22677994,Lantus;Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Glargine,Type 2 Diabetes Mellitus,Dysstasia;Contraindicated Product Administered;Hypoaesthesia;Blood Glucose Increased;Malaise;Device Mechanical Issue,Non-Serious,Non-Serious,Male,-,10-JUL-2023,Non-Expedited,81 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,05-JUL-2023,06-JUL-2023,US,Not Specified,US-SA-2023SA203272,-,-
22301058,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Mobility Decreased;Accidental Exposure To Product;Cataract,Serious,Other Outcomes,Male,-,10-JUL-2023,Non-Expedited,47 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,03-JUL-2023,09-MAY-2023,US,Not Specified,US-SA-2023SA141224,-,-
22673144,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Female,-,05-JUL-2023,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,03-JUL-2023,05-JUL-2023,US,Not Specified,US-SA-2023SA203769,-,-
22672785,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Male,-,05-JUL-2023,Non-Expedited,69 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin,29-JUN-2023,05-JUL-2023,US,Not Specified,US-SA-2023SA200898,-,-
22669186,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Female,-,04-JUL-2023,Non-Expedited,67 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Lyumjev,29-JUN-2023,04-JUL-2023,US,Not Specified,US-SA-2023SA201481,-,-
22669180,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product;Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Female,-,04-JUL-2023,Non-Expedited,69 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-JUN-2023,04-JUL-2023,US,Not Specified,US-SA-2023SA202110,-,-
22669171,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Illness,Non-Serious,Non-Serious,Female,-,04-JUL-2023,Non-Expedited,39 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-JUN-2023,04-JUL-2023,US,Not Specified,US-SA-2023SA202736,-,-
22639239,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,General Physical Health Deterioration;Cholecystectomy;Laparotomy;Blood Urea Increased;Effusion;Pancreatitis Necrotising;Blood Pressure Decreased;Biliary Catheter Insertion;Pancreatitis Acute;Blood Creatinine Increased,Serious,Hospitalized;Other Outcomes,Female,16-JUN-2023,04-JUL-2023,Expedited,64 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,17-JUN-2023,26-JUN-2023,RU,Not Specified,RU-SA-2023SA190312,-,-
22654119,Metformin;Soliqua 100/33,Insulin Glargine\Lixisenatide;Metformin Hydrochloride,Type 2 Diabetes Mellitus,Blood Glucose Decreased,Non-Serious,Non-Serious,Male,-,03-JUL-2023,Non-Expedited,63 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-JUN-2023,29-JUN-2023,US,Not Specified,US-SA-2023SA197403,-,-
22660061,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,26-JUN-2023,30-JUN-2023,Non-Expedited,47 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-JUN-2023,30-JUN-2023,US,Not Specified,US-SA-2023SA198258,-,-
22653979,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Female,-,29-JUN-2023,Non-Expedited,46 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-JUN-2023,29-JUN-2023,US,Not Specified,US-SA-2023SA196778,-,-
22653975,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,-,29-JUN-2023,Non-Expedited,68 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Novolin R,26-JUN-2023,29-JUN-2023,US,Not Specified,US-SA-2023SA196698,-,-
22650934,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Nausea;Diarrhoea;Pneumonia Bacterial,Serious,Hospitalized,Female,05-JUN-2023,28-JUN-2023,Expedited,65 YR,65 KG,Novo Nordisk,Consumer,Not Specified,-,19-JUN-2023,28-JUN-2023,CN,Not Specified,CN-NOVOPROD-1081607,-,-
22648684,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,28-JUN-2023,Non-Expedited,67 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-JUN-2023,28-JUN-2023,US,Not Specified,US-SA-2023SA194995,-,-
22643602,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Vomiting;Gait Disturbance;Intraocular Pressure Increased;Vision Blurred;Nausea,Non-Serious,Non-Serious,Not Specified,-,27-JUN-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,22-JUN-2023,27-JUN-2023,US,Not Specified,US-SA-2023SA193681,-,-
22310606,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Drug Ineffective;Stress;Blood Glucose Increased;Diabetes Mellitus Inadequate Control,Serious,Other Outcomes,Female,2023,27-JUN-2023,Non-Expedited,83 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,26-JUN-2023,11-MAY-2023,US,Not Specified,US-SA-2023SA144942,-,-
22187706,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Issue;Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,27-JUN-2023,Non-Expedited,71 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,26-JUN-2023,08-APR-2023,US,Not Specified,US-SA-2023SA108238,-,-
22161655,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,27-JUN-2023,Non-Expedited,71 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,26-JUN-2023,31-MAR-2023,US,Not Specified,US-SA-2023SA101800,-,-
22641275,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Drug Ineffective;Contusion,Non-Serious,Non-Serious,Female,-,26-JUN-2023,Non-Expedited,76 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-JUN-2023,26-JUN-2023,US,Not Specified,US-SA-2023SA193056,-,-
22638718,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,26-JUN-2023,Non-Expedited,51 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Levemir,21-JUN-2023,26-JUN-2023,US,Not Specified,US-SA-2023SA191758,-,-
22397611,Xultophy 100/3.6,Insulin Degludec\Liraglutide;Azosemide,Product Used For Unknown Indication;Rheumatic Disorder;Type 2 Diabetes Mellitus,Dehydration;Constipation,Serious,Hospitalized,Female,OCT-2022,26-JUN-2023,Expedited,8 DEC,46 KG,Novo Nordisk,Healthcare Professional,Not Specified,Predonine;Mitiglinide Calcium Hydrate;Metformin Hydrochloride,12-JUN-2023,02-JUN-2023,JP,Not Specified,JP-NOVOPROD-1058442,-,-
22629413,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Incorrect Dose Administered,Non-Serious,Non-Serious,Male,-,22-JUN-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-JUN-2023,22-JUN-2023,US,Not Specified,US-SA-2023SA186594,-,-
22628768,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,MAY-2023,22-JUN-2023,Non-Expedited,63 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-JUN-2023,22-JUN-2023,US,Not Specified,US-SA-2023SA190200,-,-
22627115,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Dizziness;Diarrhoea;Vomiting;Nausea;Abdominal Pain,Serious,Other Outcomes,Female,30-MAY-2023,22-JUN-2023,Expedited,77 YR,62.2 KG,Novo Nordisk,Healthcare Professional,Not Specified,-,09-JUN-2023,22-JUN-2023,CN,Not Specified,CN-NOVOPROD-1077392,-,-
22624687,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Visual Impairment,Non-Serious,Non-Serious,Female,-,21-JUN-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-JUN-2023,21-JUN-2023,US,Not Specified,US-SA-2023SA188346,-,-
22220713,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Agranulocytosis,Serious,Other Outcomes,Not Specified,-,21-JUN-2023,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,19-JUN-2023,18-APR-2023,JP,Not Specified,JP-SAKK-2023SA117249AA,-,-
22622376,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 1 Diabetes Mellitus,Off Label Use,Non-Serious,Non-Serious,Male,-,20-JUN-2023,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,16-JUN-2023,20-JUN-2023,US,Not Specified,US-SA-2023SA187946,-,-
22620457,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Wrong Technique In Product Usage Process,Non-Serious,Non-Serious,Male,-,20-JUN-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-JUN-2023,20-JUN-2023,US,Not Specified,US-SA-2023SA186976,-,-
22619663,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Aphasia,Non-Serious,Non-Serious,Female,-,20-JUN-2023,Non-Expedited,65 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,16-JUN-2023,20-JUN-2023,US,Not Specified,US-SA-2023SA187443,-,-
22619634,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,03-JUN-2023,20-JUN-2023,Non-Expedited,55 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-JUN-2023,20-JUN-2023,US,Not Specified,US-SA-2023SA184009,-,-
22605622,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration;Blood Glucose Increased,Non-Serious,Non-Serious,Female,2021,19-JUN-2023,Non-Expedited,73 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-JUN-2023,15-JUN-2023,US,Not Specified,US-SA-2023SA182169,-,-
22612923,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,17-JUN-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-JUN-2023,17-JUN-2023,US,Not Specified,US-SA-2023SA182155,-,-
22611935,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Female,-,17-JUN-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-JUN-2023,17-JUN-2023,US,Not Specified,US-SA-2023SA184315,-,-
22611069,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Colon Cancer,Serious,Other Outcomes;Hospitalized,Male,2023,16-JUN-2023,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-JUN-2023,16-JUN-2023,US,Not Specified,US-SA-2023SA184110,-,-
22604713,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Rash,Non-Serious,Non-Serious,Female,-,15-JUN-2023,Non-Expedited,83 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,12-JUN-2023,15-JUN-2023,US,Not Specified,US-SA-2023SA181260,-,-
22604658,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Glycosylated Haemoglobin Decreased,Non-Serious,Non-Serious,Male,-,15-JUN-2023,Non-Expedited,72 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-JUN-2023,15-JUN-2023,US,Not Specified,US-SA-2023SA181255,-,-
22536105,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Fluctuation;Abnormal Sleep-Related Event;Blood Glucose Decreased,Non-Serious,Non-Serious,Female,05-JUN-2023,15-JUN-2023,Non-Expedited,76 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Levemir,09-JUN-2023,08-JUN-2023,US,Not Specified,US-SA-2023SA174350,-,-
22595578,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Incorrect Dose Administered,Non-Serious,Non-Serious,Male,-,13-JUN-2023,Non-Expedited,84 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-JUN-2023,13-JUN-2023,US,Not Specified,US-SA-2023SA178984,-,-
22593540,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Female,-,13-JUN-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-JUN-2023,13-JUN-2023,US,Not Specified,US-SA-2023SA179811,-,-
22593311,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error;Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Female,-,13-JUN-2023,Non-Expedited,69 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-JUN-2023,13-JUN-2023,US,Not Specified,US-SA-2023SA177642,-,-
22593120,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Hospitalisation,Serious,Hospitalized,Male,-,13-JUN-2023,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,Insulin Lispro,01-JUN-2023,13-JUN-2023,JP,Not Specified,JP-NOVOPROD-1074200,-,-
22270705,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Hypertension;Thrombosis;Type 2 Diabetes Mellitus,Device Mechanical Issue;Device Failure;Device Issue;Wrong Technique In Product Usage Process;Blood Glucose Increased,Serious,Other Outcomes,Female,-,13-JUN-2023,30-DAY,Not Specified,64 KG,Novo Nordisk,Consumer,Not Specified,Nifedipine;Acenocoumarol;Losartan;Amlodipine,01-JUN-2023,01-MAY-2023,MX,Not Specified,MX-NOVOPROD-1056706,-,-
22587088,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,06-JUN-2023,12-JUN-2023,Non-Expedited,69 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-JUN-2023,12-JUN-2023,US,Not Specified,US-SA-2023SA176330,-,-
22541644,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Product Storage Error;Amnesia,Serious,Other Outcomes,Male,-,09-JUN-2023,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,18-MAY-2023,09-JUN-2023,US,Not Specified,US-NOVOPROD-1074877,-,-
22536087,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Glycosylated Haemoglobin Increased;Headache;Blood Glucose Fluctuation,Non-Serious,Non-Serious,Female,-,08-JUN-2023,Non-Expedited,60 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,05-JUN-2023,08-JUN-2023,US,Not Specified,US-SA-2023SA173555,-,-
22535726,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product;Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Female,-,08-JUN-2023,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,02-JUN-2023,08-JUN-2023,US,Not Specified,US-SA-2023SA173187,-,-
22534919,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Pancreatitis,Serious,Other Outcomes,Not Specified,-,08-JUN-2023,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-MAY-2023,08-JUN-2023,US,Not Specified,US-SA-2023SA175003,-,-
22391462,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,08-JUN-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,05-JUN-2023,01-JUN-2023,US,Not Specified,US-SA-2023SA167115,-,-
22527793,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Female,-,06-JUN-2023,Non-Expedited,61 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-JUN-2023,06-JUN-2023,US,Not Specified,US-SA-2023SA171584,-,-
22526214,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus;Type 2 Diabetes Mellitus,Pollakiuria;Urinary Tract Infection;Glycosylated Haemoglobin Increased;Back Pain;Vaginal Discharge;Paraesthesia;Blood Pressure Systolic Increased;Loss Of Personal Independence In Daily Activities;Hypoaesthesia,Serious,Disabled,Female,08-MAR-2022,06-JUN-2023,Expedited,61 YR,99 KG,Sanofi Aventis,Healthcare Professional,Not Specified,Lansoprazole;Metformin;Pregabalin;Domperidone;Cilostazol;Metronidazole\Nystatin;Amlodipine;Atorvastatin;Dapagliflozin;Fluconazole;Candesartan,08-MAR-2022,06-JUN-2023,ID,Not Specified,ID-SA-2023SA172476,-,-
22525177,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Memory Impairment,Non-Serious,Non-Serious,Female,-,06-JUN-2023,Non-Expedited,64 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-JUN-2023,06-JUN-2023,US,Not Specified,US-SA-2023SA170353,-,-
22524334,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Malaise;Therapy Interrupted,Non-Serious,Non-Serious,Female,-,06-JUN-2023,Non-Expedited,Not Specified,75 KG,Takeda,Healthcare Professional,Not Specified,Vitamin D3,30-MAY-2023,06-JUN-2023,US,Not Specified,US-TAKEDA-2023TUS054375,-,-
22283475,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product;Blood Glucose Increased,Non-Serious,Non-Serious,Female,01-MAY-2023,06-JUN-2023,Non-Expedited,87 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,02-JUN-2023,04-MAY-2023,US,Not Specified,US-SA-2023SA138544,-,-
22519633,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Increased;Drug Ineffective;Product Storage Error,Non-Serious,Non-Serious,Female,-,05-JUN-2023,Non-Expedited,56 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,31-MAY-2023,05-JUN-2023,US,Not Specified,US-SA-2023SA168882,-,-
22343700,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product;Hypersensitivity,Non-Serious,Non-Serious,Male,-,05-JUN-2023,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,31-MAY-2023,19-MAY-2023,US,Not Specified,US-SA-2023SA155045,-,-
22398601,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Female,-,02-JUN-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,29-MAY-2023,02-JUN-2023,US,Not Specified,US-SA-2023SA167053,-,-
22381200,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Skin Discolouration;Vomiting;Chest Pain;Incorrect Route Of Product Administration;Pruritus,Non-Serious,Non-Serious,Male,24-MAY-2023,30-MAY-2023,Non-Expedited,64 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,25-MAY-2023,30-MAY-2023,US,Not Specified,US-SA-2023SA163050,-,-
22377204,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Hospitalisation,Serious,Hospitalized,Female,-,29-MAY-2023,Expedited,43 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,17-MAY-2023,29-MAY-2023,JP,Not Specified,JP-NOVOPROD-1067019,-,-
22377167,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Hepatocellular Carcinoma,Serious,Other Outcomes,Female,2021,29-MAY-2023,Expedited,74 YR,49 KG,Novo Nordisk,Healthcare Professional,Not Specified,-,16-MAY-2023,29-MAY-2023,JP,Not Specified,JP-NOVOPROD-1066860,-,-
22205009,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Pancreatic Carcinoma;Pigmentation Disorder,Serious,Other Outcomes,Female,-,29-MAY-2023,Expedited,70 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Synjardy;Dulaglutide,17-MAY-2023,13-APR-2023,EG,Not Specified,EG-NOVOPROD-1047257,-,-
18977433,Soliqua 100/33;Toujeo Max;Toujeo,Insulin Glargine;Insulin Glargine;Insulin Glargine\Lixisenatide,Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,-,29-MAY-2023,Non-Expedited,77 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,24-MAY-2023,06-MAR-2021,US,Not Specified,US-SA-2021SA067836,-,-
22371801,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Male,-,26-MAY-2023,Non-Expedited,41 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,24-MAY-2023,26-MAY-2023,US,Not Specified,US-SA-2023SA161473,-,-
22370580,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Male,-,26-MAY-2023,Non-Expedited,65 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,24-MAY-2023,26-MAY-2023,US,Not Specified,US-SA-2023SA161682,-,-
22359983,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Injection Site Discolouration,Non-Serious,Non-Serious,Not Specified,-,24-MAY-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-MAY-2023,24-MAY-2023,US,Not Specified,US-SA-2023SA159193,-,-
22357503,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,MAY-2023,24-MAY-2023,Non-Expedited,65 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-MAY-2023,24-MAY-2023,US,Not Specified,US-SA-2023SA157130,-,-
22357498,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Female,-,24-MAY-2023,Non-Expedited,76 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,22-MAY-2023,24-MAY-2023,US,Not Specified,US-SA-2023SA158406,-,-
22357336,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Gastrointestinal Disorder,Non-Serious,Non-Serious,Female,-,24-MAY-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,18-MAY-2023,24-MAY-2023,US,Not Specified,US-SA-2023SA158733,-,-
22355236,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment;Cataract,Serious,Other Outcomes,Female,APR-2023,23-MAY-2023,Expedited,73 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-MAY-2023,23-MAY-2023,US,Not Specified,US-SA-2023SA156237,-,-
22355188,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Atrial Fibrillation;Extra Dose Administered,Serious,Other Outcomes,Female,-,23-MAY-2023,Expedited,75 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,18-MAY-2023,23-MAY-2023,US,Not Specified,US-SA-2023SA155522,-,-
22354882,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Male,-,23-MAY-2023,Non-Expedited,81 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-MAY-2023,23-MAY-2023,US,Not Specified,US-SA-2023SA157453,-,-
22354144,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Male,-,23-MAY-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,17-MAY-2023,23-MAY-2023,US,Not Specified,US-SA-2023SA155451,-,-
22349416,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Cough;Visual Impairment;Eye Haemorrhage;Eye Swelling,Serious,Other Outcomes,Male,-,22-MAY-2023,Expedited,70 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,17-MAY-2023,22-MAY-2023,US,Not Specified,US-SA-2023SA154827,-,-
22347361,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Headache,Non-Serious,Non-Serious,Male,MAY-2023,21-MAY-2023,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,16-MAY-2023,21-MAY-2023,US,Not Specified,US-SA-2023SA154412,-,-
22343259,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accident;Decreased Activity,Non-Serious,Non-Serious,Female,2023,19-MAY-2023,Non-Expedited,65 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,17-MAY-2023,19-MAY-2023,US,Not Specified,US-SA-2023SA154573,-,-
22339643,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Female,-,18-MAY-2023,Non-Expedited,73 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-MAY-2023,18-MAY-2023,US,Not Specified,US-SA-2023SA151330,-,-
22338670,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,18-MAY-2023,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-MAY-2023,18-MAY-2023,US,Not Specified,US-SA-2023SA151604,-,-
22338096,Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Glargine,Type 2 Diabetes Mellitus,Product Prescribing Issue;Blood Glucose Decreased;Inappropriate Schedule Of Product Administration;Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,18-MAY-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Glipizide,12-MAY-2023,18-MAY-2023,US,Not Specified,US-SA-2023SA150470,-,-
22338095,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Fluctuation;Glycosylated Haemoglobin Increased;Product Prescribing Issue,Non-Serious,Non-Serious,Female,-,18-MAY-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Basaglar;Glipizide,12-MAY-2023,18-MAY-2023,US,Not Specified,US-SA-2023SA151967,-,-
22333102,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Surgery,Non-Serious,Non-Serious,Female,2022,17-MAY-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-MAY-2023,17-MAY-2023,US,Not Specified,US-SA-2023SA149624,-,-
22331424,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Rash,Non-Serious,Non-Serious,Female,-,17-MAY-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-MAY-2023,17-MAY-2023,US,Not Specified,US-SA-2023SA151068,-,-
22226564,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Pruritus;Formication;Product Dispensing Error,Non-Serious,Non-Serious,Male,-,17-MAY-2023,Non-Expedited,55 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,15-MAY-2023,19-APR-2023,US,Not Specified,US-SA-2023SA118893,-,-
21945945,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Drug Ineffective,Non-Serious,Non-Serious,Female,-,17-MAY-2023,Non-Expedited,53 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,15-MAY-2023,02-FEB-2023,US,Not Specified,US-SA-2023SA036454,-,-
21581839,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Diabetes Mellitus Inadequate Control;Device Issue;Blood Glucose Increased,Serious,Other Outcomes,Male,-,17-MAY-2023,Non-Expedited,79 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,15-MAY-2023,11-NOV-2022,US,Not Specified,US-SA-2022SA457063,-,-
22325224,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Abdominal Pain Upper;Blood Glucose Decreased;Weight Decreased;Tremor;Diarrhoea;Glycosylated Haemoglobin Increased;Blood Glucose Increased;Malaise,Serious,Other Outcomes,Female,NOV-2022,16-MAY-2023,Expedited,83 YR,40.82 KG,Sanofi Aventis,Consumer,Not Specified,-,10-MAY-2023,16-MAY-2023,CR,Not Specified,CR-SA-2023SA149728,-,-
22325181,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Intentional Product Use Issue,Non-Serious,Non-Serious,Female,10-MAY-2023,16-MAY-2023,Non-Expedited,79 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-MAY-2023,16-MAY-2023,US,Not Specified,US-SA-2023SA148622,-,-
22323596,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Increased;Poor Quality Product Administered;Product Storage Error;Ligament Rupture,Serious,Hospitalized,Female,JAN-2023,16-MAY-2023,Expedited,66 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,05-MAY-2023,16-MAY-2023,KR,Not Specified,KR-SA-2023SA142384,-,-
22323489,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Visual Impairment,Non-Serious,Non-Serious,Female,-,16-MAY-2023,Non-Expedited,56 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-MAY-2023,16-MAY-2023,US,Not Specified,US-SA-2023SA150191,-,-
22322206,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Drug Ineffective;Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Female,-,16-MAY-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Novolin N,11-MAY-2023,16-MAY-2023,US,Not Specified,US-SA-2023SA149058,-,-
22318179,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product;Incorrect Dose Administered,Non-Serious,Non-Serious,Female,-,15-MAY-2023,Non-Expedited,62 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-MAY-2023,15-MAY-2023,US,Not Specified,US-SA-2023SA147379,-,-
22318170,Soliqua 100/33;Skyrizi,Risankizumab-Rzaa;Insulin Glargine\Lixisenatide,Psoriasis,Psoriasis,Non-Serious,Non-Serious,Female,-,15-MAY-2023,Non-Expedited,40 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,05-MAY-2023,15-MAY-2023,US,Not Specified,US-SA-2023SA141899,-,-
22302613,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Fluctuation;Confusional State;Kidney Infection,Serious,Other Outcomes,Female,-,15-MAY-2023,Expedited,73 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,11-MAY-2023,10-MAY-2023,US,Not Specified,US-SA-2023SA142278,-,-
22315070,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,-,12-MAY-2023,Non-Expedited,53 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-MAY-2023,12-MAY-2023,US,Not Specified,US-SA-2023SA146278,-,-
22313613,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Visual Impairment,Non-Serious,Non-Serious,Female,-,12-MAY-2023,Non-Expedited,69 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-MAY-2023,12-MAY-2023,US,Not Specified,US-SA-2023SA147583,-,-
22310700,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Male,-,11-MAY-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-MAY-2023,11-MAY-2023,US,Not Specified,US-SA-2023SA144880,-,-
22303251,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error;Visual Impairment;Cataract,Serious,Other Outcomes,Female,-,10-MAY-2023,Expedited,88 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-MAY-2023,10-MAY-2023,US,Not Specified,US-SA-2023SA144281,-,-
22303130,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Injection Site Pruritus,Non-Serious,Non-Serious,Male,-,10-MAY-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,09-MAY-2023,10-MAY-2023,US,Not Specified,US-SA-2023SA143998,-,-
22302977,Soliqua 100/33,Insulin Glargine\Lixisenatide,Product Used For Unknown Indication,Chelation Therapy;Drug Effect Less Than Expected,Non-Serious,Non-Serious,Not Specified,-,10-MAY-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,04-MAY-2023,10-MAY-2023,US,Not Specified,US-SA-2023SA140551,-,-
22301539,Soliqua 100/33;Farxiga,Dapagliflozin Propanediol;Insulin Glargine\Lixisenatide,-,Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,10-MAY-2023,Non-Expedited,Not Specified,Not Specified,Astrazeneca,Consumer,Not Specified,-,17-APR-2023,10-MAY-2023,Not Specified,Not Specified,US-AstraZeneca-2023A092764,-,-
22231940,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,10-MAY-2023,Non-Expedited,79 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,04-MAY-2023,20-APR-2023,US,Not Specified,US-SA-2023SA122705,-,-
22301053,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,09-MAY-2023,Non-Expedited,69 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-MAY-2023,09-MAY-2023,US,Not Specified,US-SA-2023SA137739,-,-
22300994,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Intentional Product Use Issue;Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Male,-,09-MAY-2023,Non-Expedited,59 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,03-MAY-2023,09-MAY-2023,US,Not Specified,US-SA-2023SA141086,-,-
22300762,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Prescribing Issue,Non-Serious,Non-Serious,Female,-,09-MAY-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-APR-2023,09-MAY-2023,US,Not Specified,US-SA-2023SA137749,-,-
22109246,Soliqua 100/33;Lantus Solostar,Insulin Glargine;Gliclazide;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Peripheral Swelling;Dyspnoea;Contraindicated Product Administered;Blood Glucose Increased,Serious,Hospitalized,Female,JAN-2023,08-MAY-2023,Expedited,71 YR,109 KG,Sanofi Aventis,Consumer,Not Specified,Glucophage,04-MAY-2023,17-MAR-2023,LB,Not Specified,LB-SA-2023SA085099,-,-
22290103,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,05-MAY-2023,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Lantus Solostar,01-MAY-2023,05-MAY-2023,US,Not Specified,US-SA-2023SA137830,-,-
22286142,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Decreased Appetite;Nausea;Asthenia,Serious,Other Outcomes,Male,24-APR-2023,05-MAY-2023,Expedited,54 YR,64 KG,Novo Nordisk,Healthcare Professional,Not Specified,-,27-APR-2023,05-MAY-2023,CN,Not Specified,CN-NOVOPROD-1058529,-,-
22289306,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Vomiting;Intraocular Pressure Increased;Exposure Via Skin Contact;Accidental Exposure To Product;Gait Disturbance;Vision Blurred;Nausea,Serious,Required Intervention,Not Specified,03-APR-2023,04-MAY-2023,Direct,82 YR,87.75 KG,Fda-Ctu,Consumer,Not Specified,Propranolol;Clonazepam;Simvastatin;Metformin;Vitamins,-,04-MAY-2023,Not Specified,Y,-,-,-
22284876,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,04-MAY-2023,Non-Expedited,64 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,02-MAY-2023,04-MAY-2023,US,Not Specified,US-SA-2023SA138663,-,-
22279762,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Headache;Laryngitis,Non-Serious,Non-Serious,Female,FEB-2023,03-MAY-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-APR-2023,03-MAY-2023,US,Not Specified,US-SA-2023SA135940,-,-
22277921,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Female,-,03-MAY-2023,Non-Expedited,79 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-APR-2023,03-MAY-2023,US,Not Specified,US-SA-2023SA135779,-,-
22185485,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Decreased;Accidental Exposure To Product;Intentional Product Use Issue,Non-Serious,Non-Serious,Male,01-APR-2023,03-MAY-2023,Non-Expedited,64 YR,81.6 KG,Sanofi Aventis,Consumer,Not Specified,-,28-APR-2023,07-APR-2023,US,Not Specified,US-SA-2023SA108070,-,-
21674661,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Female,-,03-MAY-2023,Non-Expedited,85 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-APR-2023,02-DEC-2022,US,Not Specified,US-SA-2022SA492689,-,-
22275576,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Female,-,02-MAY-2023,Non-Expedited,80 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-APR-2023,02-MAY-2023,US,Not Specified,US-SA-2023SA132987,-,-
22258182,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Contraindicated Product Administered;Drug Effective For Unapproved Indication;Intentional Product Misuse;Illness,Serious,Hospitalized,Male,-,01-MAY-2023,Expedited,74 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,21-APR-2023,27-APR-2023,US,Not Specified,US-SA-2023SA128893,-,-
22268549,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,30-APR-2023,Non-Expedited,73 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,24-APR-2023,30-APR-2023,US,Not Specified,US-SA-2023SA129797,-,-
22262481,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Hospitalisation,Serious,Hospitalized,Female,-,28-APR-2023,Expedited,80 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,19-APR-2023,28-APR-2023,JP,Not Specified,JP-NOVOPROD-1055615,-,-
22262449,Xultophy 100/3.6,Insulin Degludec\Liraglutide;Dapagliflozin,Type 2 Diabetes Mellitus,Hypoglycaemic Encephalopathy,Serious,Hospitalized,Male,2022,28-APR-2023,Expedited,82 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,17-APR-2023,28-APR-2023,JP,Not Specified,JP-NOVOPROD-1055549,"Kurosaka K, et al. A case which was difficult to identify the consciousness disturbed in an elderly man who was considered as having hypoglycaemic encephalopathy and euglycemic ketoacidosis concomitantly. The 685th Kanto regional association held by the Kanto branch of the Japanese so. 2023",-
22257059,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,27-APR-2023,Non-Expedited,60 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-APR-2023,27-APR-2023,US,Not Specified,US-SA-2023SA127923,-,-
22252347,Xultophy 100/3.6;Metformin;Tresiba,Insulin Degludec;Metformin Hydrochloride;Insulin Degludec\Liraglutide,Ankylosing Spondylitis;Dyslipidaemia;Hypertension;Hypertonic Bladder;Product Used For Unknown Indication;Prophylaxis Against Gastrointestinal Ulcer;Type 2 Diabetes Mellitus,Acute Kidney Injury;Osteomyelitis;Arthritis Bacterial;Myositis;Joint Abscess,Serious,Other Outcomes;Hospitalized,Female,-,26-APR-2023,Expedited,62 YR,Not Specified,Aurobindo,Healthcare Professional,Not Specified,Indomethacin Sodium;Rosuvastatin;Diclofenac Sodium;Omeprazole;Voltaren;Solifenacin;Perindopril,14-APR-2023,26-APR-2023,CA,Not Specified,CA-AUROBINDO-AUR-APL-2023-032465,-,-
22250672,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Mucormycosis;Injection Site Reaction,Serious,Other Outcomes,Not Specified,-,25-APR-2023,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,20-APR-2023,25-APR-2023,PH,Not Specified,PH-SA-2023SA126967,-,-
22131349,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Male,-,25-APR-2023,Non-Expedited,69 YR,122.47 KG,Sanofi Aventis,Consumer,Not Specified,-,20-APR-2023,23-MAR-2023,US,Not Specified,US-SA-2023SA092009,-,-
22235385,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,20-APR-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,17-APR-2023,20-APR-2023,US,Not Specified,US-SA-2023SA120565,-,-
22235287,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Hypoacusis;Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,20-APR-2023,Non-Expedited,68 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-APR-2023,20-APR-2023,US,Not Specified,US-SA-2023SA121728,-,-
22226960,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 1 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,10-APR-2023,19-APR-2023,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-APR-2023,19-APR-2023,US,Not Specified,US-SA-2023SA117158,-,-
22175072,Metformin;Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Metformin Hydrochloride,Diabetes Mellitus;Hypertension,Lactic Acidosis,Serious,Life Threatening;Hospitalized,Female,19-MAR-2023,19-APR-2023,Expedited,73 YR,Not Specified,Novartis,Healthcare Professional,Not Specified,Furosemide,17-APR-2023,05-APR-2023,IT,Not Specified,NVSC2023IT077583,-,-
22218620,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 1 Diabetes Mellitus,Product Use In Unapproved Indication;Dermatitis Allergic,Serious,Other Outcomes,Female,23-JAN-2023,17-APR-2023,Expedited,69 YR,82 KG,Sanofi Aventis,Healthcare Professional,Not Specified,Metformin;Meldonium;Cyanocobalamin;Pyridoxine;Aspirin;Gliclazide;Lisinopril,12-APR-2023,17-APR-2023,RU,Not Specified,RU-SA-2023SA114938,-,-
22217051,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Malaise;Nasopharyngitis,Non-Serious,Non-Serious,Female,-,17-APR-2023,Non-Expedited,53 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-APR-2023,17-APR-2023,US,Not Specified,US-SA-2023SA115501,-,-
22216655,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Intentional Product Use Issue;Drug Ineffective,Non-Serious,Non-Serious,Female,-,17-APR-2023,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-APR-2023,17-APR-2023,US,Not Specified,US-SA-2023SA117459,-,-
22211827,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Dispensing Error,Non-Serious,Non-Serious,Female,-,14-APR-2023,Non-Expedited,81 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-APR-2023,14-APR-2023,US,Not Specified,US-SA-2023SA115490,-,-
22209597,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,06-APR-2023,14-APR-2023,Non-Expedited,59 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-APR-2023,14-APR-2023,US,Not Specified,US-SA-2023SA114637,-,-
22196902,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,06-APR-2023,13-APR-2023,Non-Expedited,81 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,07-APR-2023,11-APR-2023,US,Not Specified,US-SA-2023SA111798,-,-
22194963,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Gallbladder Obstruction;Cholecystitis Infective;Cholelithiasis,Serious,Other Outcomes;Hospitalized,Female,24-JAN-2023,11-APR-2023,Expedited,49 YR,47 KG,Novo Nordisk,Consumer,Not Specified,Omeprazole;Empagliflozin;Sertraline;Ciprofibrate,31-MAR-2023,11-APR-2023,CO,Not Specified,CO-NOVOPROD-1038145,-,-
22194958,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Anticoagulant Therapy;Blood Cholesterol Abnormal;Decreased Appetite;Hypertension;Supplementation Therapy;Type 2 Diabetes Mellitus,Phobia;Decreased Appetite;Renal Disorder;Dehydration;Constipation;Hypoglycaemia;Inflammation,Serious,Hospitalized,Female,JAN-2021,11-APR-2023,Expedited,75 YR,65 KG,Novo Nordisk,Consumer,Not Specified,Losartan;Rosuvastatin;Amlodipine Besylate;Vildagliptin;Norepinephrine;Glucophage Xr;Aspirin,31-MAR-2023,11-APR-2023,BR,Not Specified,BR-NOVOPROD-987673,-,-
22194684,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Intentional Product Use Issue,Non-Serious,Non-Serious,Female,03-APR-2023,11-APR-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,06-APR-2023,11-APR-2023,US,Not Specified,US-SA-2023SA110916,-,-
22053998,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Abortion Spontaneous;Product Use Issue;Maternal Exposure During Pregnancy,Serious,Other Outcomes,Female,10-FEB-2023,11-APR-2023,Expedited,26 YR,80 KG,Novo Nordisk,Consumer,Not Specified,-,31-MAR-2023,02-MAR-2023,UA,Not Specified,UA-NOVOPROD-1032224,-,-
22171038,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Decreased;Wrong Dose,Non-Serious,Non-Serious,Male,29-MAR-2023,10-APR-2023,Non-Expedited,80 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,30-MAR-2023,04-APR-2023,US,Not Specified,US-SA-2023SA103702,-,-
22185511,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Prescribing Error,Non-Serious,Non-Serious,Male,-,07-APR-2023,Non-Expedited,64 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,04-APR-2023,07-APR-2023,US,Not Specified,US-SA-2023SA107821,-,-
22182035,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Female,-,06-APR-2023,Non-Expedited,73 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,03-APR-2023,06-APR-2023,US,Not Specified,US-SA-2023SA105309,-,-
22176797,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Female,-,05-APR-2023,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,03-APR-2023,05-APR-2023,US,Not Specified,US-SA-2023SA106684,-,-
22176743,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Prescribing Issue,Non-Serious,Non-Serious,Female,-,05-APR-2023,Non-Expedited,72 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,31-MAR-2023,05-APR-2023,US,Not Specified,US-SA-2023SA104766,-,-
22172872,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Prescribed Underdose,Non-Serious,Non-Serious,Female,-,04-APR-2023,Non-Expedited,68 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-MAR-2023,04-APR-2023,US,Not Specified,US-SA-2023SA099633,-,-
22170763,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Asthenopia;Malignant Neoplasm Of Eye,Serious,Other Outcomes,Male,2023,04-APR-2023,Expedited,69 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-MAR-2023,04-APR-2023,US,Not Specified,US-SA-2023SA103136,-,-
22169482,Inipomp;Lyrica;Kardegic;Vidaza;Sectral;Xarelto,Rivaroxaban;Insulin Degludec\Liraglutide;Febuxostat;Acebutolol Hydrochloride;Ezetimibe\Simvastatin;Manidipine;Furosemide;Azacitidine;Aspirin Dl-Lysine;Venetoclax;Irbesartan;Pregabalin;Pantoprazole Sodium;Cholecalciferol,Atrial Fibrillation;Diabetes Mellitus;Gastrooesophageal Reflux Disease;Hypercholesterolaemia;Hypertension;Hyperuricaemia;Intermittent Claudication;Myelodysplastic Syndrome;Oedema Due To Cardiac Disease;Vascular Disorder Prophylaxis;Vitamin D Deficiency,Sudden Death,Serious,Died,Male,2021,04-APR-2023,Expedited,84 YR,Not Specified,Johnson And Johnson,Healthcare Professional,Not Specified,-,15-SEP-2021,04-APR-2023,FR,Not Specified,FR-JNJFOC-20210934152,-,-
22167458,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Female,-,03-APR-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-MAR-2023,03-APR-2023,US,Not Specified,US-SA-2023SA099705,-,-
22165949,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Amylase Increased;Malaise;Vomiting,Serious,Hospitalized,Female,-,03-APR-2023,Expedited,63 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,29-MAR-2023,03-APR-2023,RU,Not Specified,RU-SA-2023SA101198,-,-
22015064,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Inappropriate Schedule Of Product Administration;Blood Glucose Increased;Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,03-APR-2023,Non-Expedited,73 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Victoza,28-MAR-2023,21-FEB-2023,US,Not Specified,US-SA-2023SA055927,-,-
21579127,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Dispensing Error;Wrong Technique In Device Usage Process;Injection Site Pain;Injection Site Bruising,Non-Serious,Non-Serious,Female,-,03-APR-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,29-MAR-2023,10-NOV-2022,US,Not Specified,US-SA-2022SA460616,-,-
22161168,Tresiba;Xultophy 100/3.6;Metformin,Metformin Hydrochloride;Insulin Degludec\Liraglutide;Insulin Degludec,Ankylosing Spondylitis;Dyslipidaemia;Hypertension;Hypertonic Bladder;Product Used For Unknown Indication;Prophylaxis Against Gastrointestinal Ulcer;Type 2 Diabetes Mellitus,Joint Abscess;Acute Kidney Injury;Infective Myositis;Osteomyelitis;Arthritis Bacterial,Serious,Other Outcomes;Hospitalized,Female,-,31-MAR-2023,Expedited,62 YR,Not Specified,Teva,Healthcare Professional,Not Specified,Indomethacin Sodium;Rosuvastatin;Solifenacin;Perindopril;Diclofenac Diethylamine;Omeprazole,21-MAR-2023,31-MAR-2023,CA,Not Specified,CA-TEVA-2023-CA-2870562,-,-
22161166,Tresiba,Insulin Degludec;Metformin Hydrochloride;Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Myositis;Osteomyelitis;Acute Kidney Injury;Arthritis Bacterial;Joint Abscess,Serious,Other Outcomes;Hospitalized,Female,-,31-MAR-2023,Expedited,62 YR,Not Specified,Teva,Healthcare Professional,Not Specified,Solifenacin;Rosuvastatin;Indomethacin Sodium;Diclofenac Sodium;Omeprazole;Perindopril,21-MAR-2023,31-MAR-2023,CA,Not Specified,CA-TEVA-2023-CA-2870949,-,-
22158949,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Frustration Tolerance Decreased;Irritability;Blood Glucose Decreased,Non-Serious,Non-Serious,Male,-,31-MAR-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-MAR-2023,31-MAR-2023,US,Not Specified,US-SA-2023SA097973,-,-
22156314,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,30-MAR-2023,Non-Expedited,76 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-MAR-2023,30-MAR-2023,US,Not Specified,US-SA-2023SA098515,-,-
22056965,Xultophy 100/3.6;Metgluco,Metformin Hydrochloride;Insulin Degludec\Liraglutide;Imeglimin,Type 2 Diabetes Mellitus,Glycosylated Haemoglobin Increased;Diarrhoea;Blood Glucose Decreased,Serious,Hospitalized,Male,-,30-MAR-2023,Expedited,65 YR,82 KG,Emd Serono Inc,Healthcare Professional,Not Specified,-,22-MAR-2023,03-MAR-2023,Not Specified,Not Specified,JP-EMD Serono-9351888,-,-
22151633,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Throat Clearing;Cough,Non-Serious,Non-Serious,Male,-,29-MAR-2023,Non-Expedited,59 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-MAR-2023,29-MAR-2023,US,Not Specified,US-SA-2023SA095594,-,-
22115559,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injection Site Pain,Non-Serious,Non-Serious,Female,-,29-MAR-2023,Non-Expedited,59 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,24-MAR-2023,20-MAR-2023,US,Not Specified,US-SA-2023SA087927,-,-
22148314,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,28-MAR-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,22-MAR-2023,28-MAR-2023,US,Not Specified,US-SA-2023SA094421,-,-
22144369,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Hypertension;Hyperuricaemia;Type 2 Diabetes Mellitus,Vomiting;Abdominal Pain Upper;Cholangitis;Glycosylated Haemoglobin Increased,Serious,Other Outcomes,Male,05-JAN-2022,28-MAR-2023,Expedited,65 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Febuxostat;Jardiance;Telmisartan,16-MAR-2023,28-MAR-2023,JP,Not Specified,JP-NOVOPROD-1043142,-,-
21543131,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Product Storage Error,Non-Serious,Non-Serious,Female,-,28-MAR-2023,Non-Expedited,77 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Novolog,23-MAR-2023,02-NOV-2022,US,Not Specified,US-SA-2022SA444398,-,-
22142924,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Product Storage Error,Non-Serious,Non-Serious,Female,-,27-MAR-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-MAR-2023,27-MAR-2023,US,Not Specified,US-SA-2023SA094486,-,-
22139808,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Nausea;Loss Of Consciousness;Vomiting,Serious,Other Outcomes,Female,16-JAN-2023,27-MAR-2023,Expedited,708 MTH,77 KG,Novo Nordisk,Consumer,Not Specified,-,15-MAR-2023,27-MAR-2023,UA,Not Specified,UA-NOVOPROD-1021871,-,-
21951319,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Leakage;Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,27-MAR-2023,Non-Expedited,67 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,23-MAR-2023,03-FEB-2023,US,Not Specified,US-SA-2023SA039037,-,-
21770791,Farxiga;Soliqua 100/33,Insulin Glargine\Lixisenatide;Dapagliflozin Propanediol,Type 2 Diabetes Mellitus,Diabetes Mellitus Inadequate Control;Glycosylated Haemoglobin Abnormal;Blood Glucose Increased;Device Issue,Serious,Other Outcomes,Male,NOV-2022,27-MAR-2023,Non-Expedited,72 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,23-MAR-2023,23-DEC-2022,US,Not Specified,US-SA-2022SA517394,-,-
22135629,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Knee Operation,Non-Serious,Non-Serious,Not Specified,-,24-MAR-2023,Non-Expedited,46 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-MAR-2023,24-MAR-2023,US,Not Specified,US-SA-2023SA093316,-,-
21582147,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Product Odour Abnormal,Non-Serious,Non-Serious,Male,-,24-MAR-2023,Non-Expedited,73 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,22-MAR-2023,11-NOV-2022,US,Not Specified,US-SA-2022SA462146,-,-
22131513,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,23-MAR-2023,Non-Expedited,71 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-MAR-2023,23-MAR-2023,US,Not Specified,US-SA-2023SA091850,-,-
22125144,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,22-MAR-2023,Non-Expedited,71 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,16-MAR-2023,22-MAR-2023,US,Not Specified,US-SA-2023SA087618,-,-
20077769,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Male,-,22-MAR-2023,Non-Expedited,56 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-MAR-2023,16-NOV-2021,US,Not Specified,US-SA-2021SA368952,-,-
22121565,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,14-MAR-2023,21-MAR-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,15-MAR-2023,21-MAR-2023,US,Not Specified,US-SA-2023SA085787,-,-
22119315,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Male,-,21-MAR-2023,Non-Expedited,69 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,17-MAR-2023,21-MAR-2023,US,Not Specified,US-SA-2023SA089221,-,-
22118079,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Death,Serious,Died,Male,-,21-MAR-2023,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,07-MAR-2023,21-MAR-2023,PK,Not Specified,PK-NOVOPROD-1036386,-,-
22115577,Metformin;Soliqua 100/33,Insulin Glargine\Lixisenatide;Metformin Hydrochloride,Type 2 Diabetes Mellitus,Renal Failure;Blood Glucose Increased,Serious,Other Outcomes,Male,-,20-MAR-2023,Expedited,79 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Farxiga,15-MAR-2023,20-MAR-2023,US,Not Specified,US-SA-2023SA085459,-,-
22114039,Farxiga;Soliqua 100/33,Insulin Glargine\Lixisenatide;Dapagliflozin Propanediol,-,Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,20-MAR-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-MAR-2023,20-MAR-2023,US,Not Specified,US-SA-2023SA087226,-,-
21999130,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Injection Site Pain;Incorrect Dose Administered,Non-Serious,Non-Serious,Male,-,20-MAR-2023,Non-Expedited,67 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-MAR-2023,16-FEB-2023,US,Not Specified,US-SA-2023SA051851,-,-
22108106,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Female,-,17-MAR-2023,Non-Expedited,76 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-MAR-2023,17-MAR-2023,US,Not Specified,US-SA-2023SA083903,-,-
22106984,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Female,-,17-MAR-2023,Non-Expedited,56 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-MAR-2023,17-MAR-2023,US,Not Specified,US-SA-2023SA083411,-,-
22106375,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Male,-,17-MAR-2023,Non-Expedited,74 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-MAR-2023,17-MAR-2023,US,Not Specified,US-SA-2023SA080666,-,-
22106277,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Drug Ineffective;Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,17-MAR-2023,Non-Expedited,67 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-MAR-2023,17-MAR-2023,US,Not Specified,US-SA-2023SA078833,-,-
22106212,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetic Neuropathy,Drug Ineffective;Product Use In Unapproved Indication,Non-Serious,Non-Serious,Female,-,17-MAR-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Toujeo,09-MAR-2023,17-MAR-2023,US,Not Specified,US-SA-2023SA080021,-,-
22105977,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,-,17-MAR-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-MAR-2023,17-MAR-2023,US,Not Specified,US-SA-2023SA080413,-,-
21842557,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Female,-,17-MAR-2023,Non-Expedited,68 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-MAR-2023,10-JAN-2023,US,Not Specified,US-SA-2023SA007110,-,-
22103162,Metformin;Tresiba;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Insulin Degludec;Metformin Hydrochloride,Ankylosing Spondylitis;Dyslipidaemia;Hypertension;Hypertonic Bladder;Product Used For Unknown Indication;Prophylaxis Against Gastrointestinal Ulcer;Type 2 Diabetes Mellitus,Joint Abscess;Myositis;Acute Kidney Injury;Osteomyelitis;Arthritis Bacterial,Serious,Hospitalized;Other Outcomes,Female,-,16-MAR-2023,Expedited,62 YR,Not Specified,Novartis,Healthcare Professional,Not Specified,Indomethacin Sodium;Omeprazole;Perindopril;Rosuvastatin;Diclofenac Sodium;Solifenacin;Voltaren,08-MAR-2023,16-MAR-2023,CA,Not Specified,NVSC2023CA055482,-,-
22049392,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Metformin Hydrochloride,Product Used For Unknown Indication,Lactic Acidosis,Serious,Hospitalized,Male,10-APR-2022,14-MAR-2023,Expedited,78 YR,Not Specified,Novartis,Healthcare Professional,Not Specified,Doxazosin;Candesartan Cilexetil\Hydrochlorothiazide;Dutasteride;Simvastatin;Fluoxetine Hydrochloride;Allopurinol,08-MAR-2023,01-MAR-2023,IT,Not Specified,NVSC2023IT044214,-,-
22085826,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Gait Disturbance;Dysstasia;Visual Impairment,Non-Serious,Non-Serious,Male,-,10-MAR-2023,Non-Expedited,63 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,06-MAR-2023,10-MAR-2023,US,Not Specified,US-SA-2023SA077255,-,-
22085760,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Diarrhoea,Non-Serious,Non-Serious,Female,07-MAR-2023,10-MAR-2023,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Metformin,07-MAR-2023,10-MAR-2023,US,Not Specified,US-SA-2023SA077447,-,-
22080076,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Drug-Induced Liver Injury,Serious,Other Outcomes,Female,-,09-MAR-2023,Expedited,80 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,13-FEB-2023,09-MAR-2023,JP,Not Specified,JP-NOVOPROD-1033265,"Nagayama K, et al.. A case of hepatic function disorder, which was considered to be drug induced, after introduction of GLP-1 receptor agonist.. Program and abstracts of the 59th Kinki Regional Meeting of the Japan Diabetes S. 2022;110",-
22079623,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Accidental Exposure To Product,Non-Serious,Non-Serious,Not Specified,-,09-MAR-2023,Non-Expedited,53 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,03-MAR-2023,09-MAR-2023,US,Not Specified,US-SA-2023SA074389,-,-
22078826,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,-,09-MAR-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,02-MAR-2023,09-MAR-2023,US,Not Specified,US-SA-2023SA075456,-,-
22076347,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Hospitalisation,Serious,Hospitalized,Female,-,09-MAR-2023,Expedited,9 DEC,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,27-FEB-2023,09-MAR-2023,JP,Not Specified,JP-NOVOPROD-1032859,-,-
22076344,Xultophy 100/3.6;Novorapid,Insulin Aspart;Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Syncope,Serious,Other Outcomes;Hospitalized,Female,-,09-MAR-2023,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Tresiba;Rybelsus;Xigduo Xr,27-FEB-2023,09-MAR-2023,SI,Not Specified,SI-NOVOPROD-1031997,-,-
21846105,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Hyperglycaemia;Device Loosening,Serious,Other Outcomes,Female,24-DEC-2022,09-MAR-2023,30-DAY,87 YR,82 KG,Novo Nordisk,Consumer,Not Specified,-,27-FEB-2023,11-JAN-2023,BR,Not Specified,BR-NOVOPROD-1008832,-,-
22075705,Metformin,Metformin Hydrochloride;Insulin Degludec\Liraglutide;Liraglutide;Semaglutide;Insulin Glargine;Dulaglutide;Insulin Degludec;Gliclazide,Type 2 Diabetes Mellitus,Type 1 Diabetes Mellitus;Weight Decreased;Diabetes Mellitus Inadequate Control;Hypoglycaemia,Serious,Other Outcomes,Female,-,08-MAR-2023,Expedited,62 YR,62 KG,Bausch And Lomb,Healthcare Professional,Not Specified,-,26-FEB-2023,08-MAR-2023,GR,Not Specified,GR-BAUSCH-BL-2023-003484,-,-
22069811,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Female,-,07-MAR-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Metformin,01-MAR-2023,07-MAR-2023,US,Not Specified,US-SA-2023SA072620,-,-
22067152,Metgluco;Jardiance;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Empagliflozin;Metformin Hydrochloride,Type 2 Diabetes Mellitus,Glycosylated Haemoglobin Increased;Skin Ulcer,Serious,Hospitalized,Male,FEB-2018,07-MAR-2023,Expedited,74 YR,82 KG,Emd Serono Inc,Healthcare Professional,Not Specified,Glimepiride;Miglitol;Linagliptin;Sitagliptin;Luseogliflozin;Dulaglutide,28-FEB-2023,07-MAR-2023,Not Specified,Not Specified,JP-EMD Serono-9377836,-,-
22066911,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Spinal Operation;Blood Glucose Increased;Grunting,Non-Serious,Non-Serious,Female,-,06-MAR-2023,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin,02-MAR-2023,06-MAR-2023,US,Not Specified,US-SA-2023SA071665,-,-
22062936,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product;Hypoacusis,Non-Serious,Non-Serious,Male,-,06-MAR-2023,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Metformin,28-FEB-2023,06-MAR-2023,US,Not Specified,US-SA-2023SA070833,-,-
22062899,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Prescribing Issue;Blood Glucose Fluctuation;Product Storage Error;Inappropriate Schedule Of Product Administration;Visual Impairment;Sluggishness,Non-Serious,Non-Serious,Male,-,06-MAR-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-FEB-2023,06-MAR-2023,US,Not Specified,US-SA-2023SA069800,-,-
22062883,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Urine Odour Abnormal;Nausea,Non-Serious,Non-Serious,Female,-,06-MAR-2023,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,02-MAR-2023,06-MAR-2023,US,Not Specified,US-SA-2023SA071895,-,-
22059671,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Dispensing Issue,Non-Serious,Non-Serious,Female,-,03-MAR-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-FEB-2023,03-MAR-2023,US,Not Specified,US-SA-2023SA068242,-,-
22059617,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Hypoacusis;Accidental Exposure To Product,Non-Serious,Non-Serious,Female,-,03-MAR-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin,28-FEB-2023,03-MAR-2023,US,Not Specified,US-SA-2023SA069514,-,-
22057015,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Neuroendocrine Tumour,Non-Serious,Non-Serious,Not Specified,-,03-MAR-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,28-FEB-2023,03-MAR-2023,US,Not Specified,US-SA-2023SA068655,-,-
21875752,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Blood Pressure Abnormal;Type 2 Diabetes Mellitus,Polypectomy;Infection;Blood Glucose Increased,Serious,Hospitalized,Male,MAR-2022,03-MAR-2023,Expedited,66 YR,100.6 KG,Novo Nordisk,Consumer,Not Specified,Metformin;Losartan,23-FEB-2023,18-JAN-2023,MX,Not Specified,MX-NOVOPROD-1010826,-,-
22054059,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus;Product Used For Unknown Indication,Papilloedema;Optic Neuritis,Serious,Hospitalized,Male,25-JAN-2023,02-MAR-2023,Expedited,Not Specified,93 KG,Novo Nordisk,Healthcare Professional,Not Specified,Dapagliflozin;Canagliflozin,20-FEB-2023,02-MAR-2023,SK,Not Specified,SK-NOVOPROD-1020912,-,-
21973312,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Glycosylated Haemoglobin Increased;Blood Glucose Increased;Needle Issue,Non-Serious,Non-Serious,Male,-,02-MAR-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,27-FEB-2023,09-FEB-2023,US,Not Specified,US-SA-2023SA045057,-,-
21609704,Victoza;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Liraglutide,Type 2 Diabetes Mellitus,Gastrointestinal Disorder;Dyspnoea,Non-Serious,Non-Serious,Male,22-AUG-2022,02-MAR-2023,Non-Expedited,70 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,17-NOV-2022,17-NOV-2022,US,Not Specified,US-NOVOPROD-954733,-,-
22047313,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Male,-,01-MAR-2023,Non-Expedited,77 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Novolin 70/30,24-FEB-2023,01-MAR-2023,US,Not Specified,US-SA-2023SA066266,-,-
22047302,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Female,24-FEB-2023,01-MAR-2023,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,24-FEB-2023,01-MAR-2023,US,Not Specified,US-SA-2023SA066172,-,-
22047263,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Memory Impairment,Non-Serious,Non-Serious,Female,-,01-MAR-2023,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Privigen,24-FEB-2023,01-MAR-2023,US,Not Specified,US-SA-2023SA065371,-,-
22041059,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Incorrect Dose Administered;Blood Glucose Decreased;Device Defective,Non-Serious,Non-Serious,Male,-,01-MAR-2023,Non-Expedited,64 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,27-FEB-2023,27-FEB-2023,US,Not Specified,US-SA-2023SA063978,-,-
22046624,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Biliary Obstruction;Cholecystitis Infective;Pancreatitis,Serious,Other Outcomes;Hospitalized,Male,19-DEC-2022,28-FEB-2023,Expedited,70 YR,59.5 KG,Novo Nordisk,Consumer,Not Specified,-,08-FEB-2023,28-FEB-2023,MX,Not Specified,MX-NOVOPROD-1023303,-,-
22045546,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Abnormal,Non-Serious,Non-Serious,Not Specified,-,28-FEB-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,23-FEB-2023,28-FEB-2023,US,Not Specified,US-SA-2023SA066600,-,-
22009014,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 1 Diabetes Mellitus,No Adverse Event,Non-Serious,Non-Serious,Not Specified,-,28-FEB-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,22-FEB-2023,20-FEB-2023,US,Not Specified,US-SA-2023SA054413,-,-
21966733,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Female,-,28-FEB-2023,Non-Expedited,69 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,22-FEB-2023,08-FEB-2023,US,Not Specified,US-SA-2023SA042639,-,-
22039251,Tresiba;Xultophy 100/3.6;Metformin,Metformin Hydrochloride;Insulin Degludec\Liraglutide;Insulin Degludec,Ankylosing Spondylitis;Dyslipidaemia;Hypertension;Hypertonic Bladder;Product Used For Unknown Indication;Prophylaxis Against Gastrointestinal Ulcer;Type 2 Diabetes Mellitus,Osteomyelitis;Infective Myositis;Arthritis Bacterial;Acute Kidney Injury;Joint Abscess,Serious,Other Outcomes;Hospitalized,Female,-,27-FEB-2023,Expedited,62 YR,Not Specified,Apotex,Healthcare Professional,Not Specified,Diclofenac Diethylamine;Solifenacin;Rosuvastatin;Omeprazole;Perindopril;Indomethacin Sodium,15-FEB-2023,27-FEB-2023,CA,Not Specified,CA-APOTEX-2023AP003815,-,-
22034194,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Female,-,24-FEB-2023,Non-Expedited,51 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,22-FEB-2023,24-FEB-2023,US,Not Specified,US-SA-2023SA061844,-,-
22026106,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Product Usage Process;Off Label Use;Inappropriate Schedule Of Product Administration;Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,23-FEB-2023,Non-Expedited,69 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,17-FEB-2023,23-FEB-2023,US,Not Specified,US-SA-2023SA059524,-,-
22023697,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product;Intentional Product Misuse,Non-Serious,Non-Serious,Male,-,23-FEB-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,17-FEB-2023,23-FEB-2023,US,Not Specified,US-SA-2023SA058521,-,-
22023695,Metformin;Tresiba,Insulin Degludec\Liraglutide;Insulin Degludec;Metformin Hydrochloride,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Arthritis Bacterial;Osteomyelitis;Myositis;Acute Kidney Injury;Joint Abscess,Serious,Hospitalized;Other Outcomes,Female,-,23-FEB-2023,Expedited,62 YR,Not Specified,Apotex,Healthcare Professional,Not Specified,Omeprazole;Diclofenac Sodium;Indomethacin Sodium;Solifenacin;Perindopril;Rosuvastatin,15-FEB-2023,23-FEB-2023,CA,Not Specified,CA-APOTEX-2023AP003758,-,-
22021051,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Female,-,22-FEB-2023,Non-Expedited,48 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-FEB-2023,22-FEB-2023,US,Not Specified,US-SA-2023SA055831,-,-
22018750,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,22-FEB-2023,Non-Expedited,73 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,17-FEB-2023,22-FEB-2023,US,Not Specified,US-SA-2023SA058592,-,-
21903346,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Abdominal Pain Upper;Vomiting;Pain;Illness;Headache;Nausea;Hypophagia,Non-Serious,Non-Serious,Female,18-JAN-2023,22-FEB-2023,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,16-FEB-2023,24-JAN-2023,US,Not Specified,US-SA-2023SA025471,-,-
22016778,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error;Covid-19,Non-Serious,Non-Serious,Female,-,21-FEB-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,17-FEB-2023,21-FEB-2023,US,Not Specified,US-SA-2023SA058426,-,-
22015066,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Incorrect Dose Administered;Blood Glucose Decreased,Non-Serious,Non-Serious,Male,-,21-FEB-2023,Non-Expedited,77 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,17-FEB-2023,21-FEB-2023,US,Not Specified,US-SA-2023SA058235,-,-
22015026,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,21-FEB-2023,Non-Expedited,65 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-FEB-2023,21-FEB-2023,US,Not Specified,US-SA-2023SA056104,-,-
22010991,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Female,-,20-FEB-2023,Non-Expedited,54 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,16-FEB-2023,20-FEB-2023,US,Not Specified,US-SA-2023SA056089,-,-
22009339,Metgluco;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Metformin Hydrochloride,Diabetes Mellitus;Product Used For Unknown Indication,Glycosylated Haemoglobin Increased;Urine Ketone Body Present;Dyspnoea Exertional;Blood Glucose Increased;Nausea,Serious,Hospitalized,Female,NOV-2022,20-FEB-2023,Expedited,58 YR,Not Specified,Emd Serono Inc,Healthcare Professional,Not Specified,-,10-FEB-2023,20-FEB-2023,Not Specified,Not Specified,JP-EMD Serono-9384605,-,-
21999248,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,16-FEB-2023,Non-Expedited,74 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-FEB-2023,16-FEB-2023,US,Not Specified,US-SA-2023SA051549,-,-
21995606,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Female,-,16-FEB-2023,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-FEB-2023,15-FEB-2023,US,Not Specified,US-SA-2023SA051668,-,-
21995660,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Prescribing Issue;Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Female,-,15-FEB-2023,Non-Expedited,61 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-FEB-2023,15-FEB-2023,US,Not Specified,US-SA-2023SA050610,-,-
20045199,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Leakage;Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,15-FEB-2023,Non-Expedited,62 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,10-FEB-2023,08-NOV-2021,US,Not Specified,US-SA-2021SA365871,-,-
21984754,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Male,03-FEB-2023,13-FEB-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-FEB-2023,13-FEB-2023,US,Not Specified,US-SA-2023SA047822,-,-
21983670,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Head And Neck Cancer,Serious,Other Outcomes,Male,-,13-FEB-2023,Expedited,69 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-FEB-2023,13-FEB-2023,US,Not Specified,US-SA-2023SA045731,-,-
21976013,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,-,10-FEB-2023,Non-Expedited,82 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-FEB-2023,10-FEB-2023,US,Not Specified,US-SA-2023SA046168,-,-
21975940,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Death,Serious,Died,Male,-,10-FEB-2023,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,30-JAN-2023,10-FEB-2023,CO,Not Specified,CO-NOVOPROD-1021114,-,-
21975043,Soliqua 100/33,Insulin Glargine\Lixisenatide,Product Used For Unknown Indication,Sudden Hearing Loss,Serious,Other Outcomes,Female,JAN-2023,09-FEB-2023,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-FEB-2023,09-FEB-2023,JP,Not Specified,JP-SAKK-2023SA043696AA,-,-
21751751,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,09-FEB-2023,Non-Expedited,65 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,06-FEB-2023,20-DEC-2022,US,Not Specified,US-SA-2022SA510469,-,-
21963859,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Illness;Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,07-FEB-2023,Non-Expedited,36 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,03-FEB-2023,07-FEB-2023,US,Not Specified,US-SA-2023SA042462,-,-
21959637,Soliqua 100/33,Insulin Glargine\Lixisenatide,Product Used For Unknown Indication,Hypoacusis,Non-Serious,Non-Serious,Male,-,06-FEB-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,31-JAN-2023,06-FEB-2023,US,Not Specified,US-SA-2023SA038414,-,-
21956301,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Expired Product Administered,Non-Serious,Non-Serious,Male,-,06-FEB-2023,Non-Expedited,57 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-FEB-2023,06-FEB-2023,US,Not Specified,US-SA-2023SA038935,-,-
21956300,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Intercepted Product Storage Error,Non-Serious,Non-Serious,Male,31-JAN-2023,06-FEB-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,01-FEB-2023,06-FEB-2023,US,Not Specified,US-SA-2023SA038814,-,-
21956299,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Eyelid Ptosis;Visual Impairment,Non-Serious,Non-Serious,Female,-,06-FEB-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,01-FEB-2023,06-FEB-2023,US,Not Specified,US-SA-2023SA039914,-,-
21956287,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,06-FEB-2023,Non-Expedited,82 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-FEB-2023,06-FEB-2023,US,Not Specified,US-SA-2023SA038749,-,-
21956217,Soliqua 100/33,Insulin Glargine\Lixisenatide,Breast Cancer;Type 2 Diabetes Mellitus,Diarrhoea;Back Pain;Dehydration,Non-Serious,Non-Serious,Female,-,06-FEB-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Letrozole,30-JAN-2023,06-FEB-2023,US,Not Specified,US-SA-2023SA038604,-,-
21197625,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Fatigue;Blood Glucose Increased;Lethargy;Dizziness,Non-Serious,Non-Serious,Female,-,06-FEB-2023,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,01-FEB-2023,10-AUG-2022,US,Not Specified,US-SA-2022SA323341,-,-
21953653,Soliqua 100/33,Insulin Glargine\Lixisenatide,Breast Cancer;Type 2 Diabetes Mellitus,Diarrhoea,Non-Serious,Non-Serious,Not Specified,-,04-FEB-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Letrozole,31-JAN-2023,04-FEB-2023,US,Not Specified,US-SA-2023SA038255,-,-
21951433,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment;Weight Increased,Non-Serious,Non-Serious,Female,-,03-FEB-2023,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,31-JAN-2023,03-FEB-2023,US,Not Specified,US-SA-2023SA037336,-,-
21857537,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,03-FEB-2023,Non-Expedited,58 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-JAN-2023,13-JAN-2023,US,Not Specified,US-SA-2023SA010756,-,-
21945902,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,-,02-FEB-2023,Non-Expedited,74 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-JAN-2023,02-FEB-2023,US,Not Specified,US-SA-2023SA035638,-,-
21945900,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Female,-,02-FEB-2023,Non-Expedited,59 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-JAN-2023,02-FEB-2023,US,Not Specified,US-SA-2023SA035986,-,-
21944937,Soliqua 100/33;Solostar;Farxiga,Dapagliflozin Propanediol;Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Glycosylated Haemoglobin Abnormal;Drug Ineffective;Diabetes Mellitus Inadequate Control;Device Issue,Serious,Other Outcomes,Male,-,02-FEB-2023,Expedited,72 YR,Not Specified,Astrazeneca,Consumer,Not Specified,-,25-JAN-2023,02-FEB-2023,Not Specified,Not Specified,US-AstraZeneca-2023A025019,-,-
21763452,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Hypoacusis;Device Defective;Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,02-FEB-2023,Non-Expedited,78 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,25-JAN-2023,21-DEC-2022,US,Not Specified,US-SA-2022SA514358,-,-
21935510,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Female,-,01-FEB-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-JAN-2023,01-FEB-2023,US,Not Specified,US-SA-2023SA033106,-,-
21935223,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Pruritus,Serious,Other Outcomes,Female,15-JAN-2023,01-FEB-2023,Expedited,72 YR,61 KG,Sanofi Aventis,Healthcare Professional,Not Specified,-,27-JAN-2023,01-FEB-2023,RU,Not Specified,RU-SA-2023SA033656,-,-
21933879,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,01-FEB-2023,Non-Expedited,65 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-JAN-2023,01-FEB-2023,US,Not Specified,US-SA-2023SA033462,-,-
21928466,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,01-FEB-2023,Non-Expedited,59 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,25-JAN-2023,30-JAN-2023,US,Not Specified,US-SA-2023SA030323,-,-
21223160,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,01-FEB-2023,Non-Expedited,63 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,25-JAN-2023,17-AUG-2022,US,Not Specified,US-SA-2022SA335504,-,-
21932835,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Weight Decreased,Non-Serious,Non-Serious,Male,-,31-JAN-2023,Non-Expedited,59 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Dupixent,26-JAN-2023,31-JAN-2023,US,Not Specified,US-SA-2023SA033323,-,-
21889059,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Renal Disorder;Blood Glucose Decreased;Cardiovascular Disorder,Non-Serious,Non-Serious,Male,-,30-JAN-2023,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,24-JAN-2023,20-JAN-2023,US,Not Specified,US-SA-2023SA020879,-,-
21923163,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Dizziness;Gastrointestinal Disorder,Non-Serious,Non-Serious,Male,-,29-JAN-2023,Non-Expedited,90 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,24-JAN-2023,29-JAN-2023,US,Not Specified,US-SA-2023SA030936,-,-
21921395,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Injection Site Erythema;Injection Site Rash;Injection Site Swelling,Non-Serious,Non-Serious,Not Specified,-,27-JAN-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,20-JAN-2023,27-JAN-2023,US,Not Specified,US-SA-2023SA026562,-,-
21920659,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Female,-,27-JAN-2023,Non-Expedited,55 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,24-JAN-2023,27-JAN-2023,US,Not Specified,US-SA-2023SA030020,-,-
21908268,Xultophy 100/3.6,Insulin Degludec\Liraglutide;Cosmetics,-,Klebsiella Infection;Liver Abscess;Hyperglycaemia;Mental Status Changes,Serious,Other Outcomes;Required Intervention;Hospitalized,Male,27-DEC-2022,24-JAN-2023,Direct,84 YR,64.41 KG,Fda-Ctu,Healthcare Professional,Not Specified,-,-,24-JAN-2023,Not Specified,Not Specified,-,-,-
21905848,Tresiba,Insulin Degludec;Insulin Degludec\Liraglutide;Metformin Hydrochloride,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Myositis;Arthritis Bacterial;Osteomyelitis;Acute Kidney Injury;Joint Abscess,Serious,Hospitalized;Other Outcomes,Female,-,24-JAN-2023,Expedited,62 YR,Not Specified,Bausch And Lomb,Healthcare Professional,Not Specified,Rosuvastatin;Omeprazole;Perindopril;Solifenacin;Indomethacin Sodium;Diclofenac Sodium,23-JAN-2023,24-JAN-2023,CA,Not Specified,CA-BAUSCH-BL-2023-001280,-,-
21905846,Tresiba;Xultophy 100/3.6;Metformin,Metformin Hydrochloride;Insulin Degludec\Liraglutide;Insulin Degludec,Ankylosing Spondylitis;Dyslipidaemia;Hypertension;Hypertonic Bladder;Product Used For Unknown Indication;Prophylaxis Against Gastrointestinal Ulcer;Type 2 Diabetes Mellitus,Infective Myositis;Arthritis Bacterial;Osteomyelitis;Acute Kidney Injury;Joint Abscess,Serious,Other Outcomes;Hospitalized,Female,-,24-JAN-2023,Expedited,62 YR,Not Specified,Bausch And Lomb,Healthcare Professional,Not Specified,Perindopril;Indomethacin Sodium;Diclofenac Diethylamine;Rosuvastatin;Omeprazole;Solifenacin,23-JAN-2023,24-JAN-2023,CA,Not Specified,CA-BAUSCH-BL-2023-001272,-,-
21901827,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Female,-,24-JAN-2023,Non-Expedited,47 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-JAN-2023,24-JAN-2023,US,Not Specified,US-SA-2023SA024072,-,-
21885398,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Inappropriate Schedule Of Product Administration;Visual Impairment,Non-Serious,Non-Serious,Female,-,24-JAN-2023,Non-Expedited,79 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin,17-JAN-2023,19-JAN-2023,US,Not Specified,US-SA-2023SA017977,-,-
21230098,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Female,-,24-JAN-2023,Non-Expedited,60 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,18-JAN-2023,18-AUG-2022,US,Not Specified,US-SA-2022SA332017,-,-
21901227,Xultophy 100/3.6;Ozempic,Semaglutide;Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Abdominal Pain Upper;Malaise;Drug Dose Titration Not Performed;Diarrhoea,Non-Serious,Non-Serious,Female,12-APR-2022,23-JAN-2023,Non-Expedited,75 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,12-SEP-2022,23-JAN-2023,US,Not Specified,US-NOVOPROD-933491,-,-
21899879,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Female,-,23-JAN-2023,Non-Expedited,62 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-JAN-2023,23-JAN-2023,US,Not Specified,US-SA-2023SA023195,-,-
21897726,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Female,-,23-JAN-2023,Non-Expedited,77 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,17-JAN-2023,23-JAN-2023,US,Not Specified,US-SA-2023SA021903,-,-
21400764,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Blood Glucose Abnormal;Diabetes Mellitus;Product Used For Unknown Indication;Thyroid Disorder,Device Delivery System Issue;Blood Glucose Increased;Device Loosening,Serious,Hospitalized;Other Outcomes,Female,20-SEP-2022,23-JAN-2023,30-DAY,70 YR,52 KG,Novo Nordisk,Consumer,Not Specified,Xigduo Xr;Levothyroxine Sodium,11-JAN-2023,03-OCT-2022,MX,Not Specified,MX-NOVOPROD-963532,-,-
21893058,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Intentional Product Misuse,Non-Serious,Non-Serious,Female,-,20-JAN-2023,Non-Expedited,76 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-JAN-2023,20-JAN-2023,US,Not Specified,US-SA-2023SA020885,-,-
21890922,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Female,-,20-JAN-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-JAN-2023,20-JAN-2023,US,Not Specified,US-SA-2023SA021562,-,-
21886745,Glucobay;Pioglitazone And Metformin,Metformin Hydrochloride\Pioglitazone Hydrochloride;Acarbose;Glimepiride,Diabetes Mellitus,Hypoglycaemia;Fall;Asthenia;Blood Glucose Abnormal,Serious,Hospitalized,Male,DEC-2022,19-JAN-2023,Expedited,76 YR,Not Specified,Bayer,Healthcare Professional,Not Specified,-,13-JAN-2023,19-JAN-2023,CN,Not Specified,CN-BAYER-2023A004620,-,-
21857544,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Leakage;Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,19-JAN-2023,Non-Expedited,68 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,17-JAN-2023,13-JAN-2023,US,Not Specified,US-SA-2023SA011342,-,-
21868310,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Dispensing Error;Cerebrovascular Accident,Serious,Other Outcomes,Female,SEP-2022,18-JAN-2023,Expedited,55 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-JAN-2023,16-JAN-2023,US,Not Specified,US-SA-2023SA012770,-,-
21746544,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Dementia;Impaired Driving Ability,Serious,Disabled;Other Outcomes,Male,-,18-JAN-2023,Expedited,82 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,16-JAN-2023,19-DEC-2022,CA,Not Specified,CA-SA-2022SA509747,-,-
21869261,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Drug Ineffective,Non-Serious,Non-Serious,Male,-,17-JAN-2023,Non-Expedited,54 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-JAN-2023,17-JAN-2023,US,Not Specified,US-SA-2023SA014341,-,-
21674801,Soliqua 100/33,Insulin Glargine\Lixisenatide;Unspecified Ingredient,Type 2 Diabetes Mellitus,Headache,Non-Serious,Non-Serious,Female,01-JUN-2019,17-JAN-2023,Non-Expedited,59 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,29-NOV-2022,02-DEC-2022,US,Not Specified,US-SA-2022SA491890,-,-
21347452,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,13-JAN-2023,Non-Expedited,85 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,11-JAN-2023,19-SEP-2022,US,Not Specified,US-SA-2022SA380308,-,-
21853457,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,12-JAN-2023,Non-Expedited,56 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-JAN-2023,12-JAN-2023,US,Not Specified,US-SA-2023SA010054,-,-
21180661,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Drug Ineffective;Diabetes Mellitus Inadequate Control;Blood Glucose Increased,Serious,Other Outcomes,Male,-,12-JAN-2023,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,10-JAN-2023,06-AUG-2022,US,Not Specified,US-SA-2022SA305820,-,-
21849406,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,04-JAN-2023,11-JAN-2023,Non-Expedited,77 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,05-JAN-2023,11-JAN-2023,US,Not Specified,US-SA-2023SA006839,-,-
21703355,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,11-JAN-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-JAN-2023,09-DEC-2022,US,Not Specified,US-SA-2022SA498310,-,-
21835281,Metformin;Plenvu;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Ascorbic Acid\Polyethylene Glycol 3350\Potassium Chloride\Sodium Ascorbate\Sodium Chloride\Sodium Sulfate;Metformin Hydrochloride,Anxiety;Colonoscopy;Constipation;Depression;Hypertension;Insulin-Requiring Type 2 Diabetes Mellitus;Parkinsonism,Ischaemic Hepatitis;Lactic Acidosis;Acute Kidney Injury;Intentional Product Use Issue;Coma Scale Abnormal;Hypovolaemic Shock;Dehydration;Hypernatraemia,Serious,Life Threatening,Female,05-DEC-2022,09-JAN-2023,Expedited,75 YR,80 KG,Novo Nordisk,Healthcare Professional,Not Specified,Ramipril;Polyethylene Glycols;Duloxetine Hydrochloride;Benserazide Hydrochloride\Levodopa,27-DEC-2022,09-JAN-2023,CH,Not Specified,CH-NOVOPROD-1006881,-,-
21831826,Xultophy 100/3.6;Metformin,Metformin Hydrochloride;Insulin Degludec\Liraglutide;Polyethylene Glycol 3350\Potassium\Sodium Chloride\Sodium Sulfate,Anxiety;Colonoscopy;Constipation;Depression;Diabetes Mellitus;Hypertension;Parkinsonism,Intentional Product Use Issue;Coma Scale Abnormal;Lactic Acidosis;Ischaemic Hepatitis;Dehydration;Hypovolaemic Shock;Hypernatraemia;Acute Kidney Injury,Serious,Life Threatening,Female,05-DEC-2022,06-JAN-2023,Expedited,75 YR,80 KG,Teva,Healthcare Professional,Not Specified,Ramipril;Polyethylene Glycols;Duloxetine Hydrochloride;Benserazide Hydrochloride\Levodopa,27-DEC-2022,06-JAN-2023,CH,Not Specified,CH-TEVA-2022-CH-2841553,-,-
21759057,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Septic Shock;Cholecystitis Acute;Decreased Appetite,Serious,Hospitalized;Other Outcomes,Male,12-NOV-2022,06-JAN-2023,Expedited,41 YR,86.5 KG,Novo Nordisk,Healthcare Professional,Not Specified,Atorvastatin;Vonoprazan Fumarate;Enalapril;Bisoprolol;Diltiazem Hydrochloride;Aspirin,27-DEC-2022,21-DEC-2022,JP,Not Specified,JP-NOVOPROD-983435,-,-
21825031,Plenvu;Metformin;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Metformin Hydrochloride;Ascorbic Acid\Polyethylene Glycol 3350\Potassium Chloride\Sodium Ascorbate\Sodium Chloride\Sodium Sulfate,Anxiety;Bowel Preparation;Constipation;Depression;Diabetes Mellitus;Hypertension;Parkinsonism;Sepsis,Inflammation;Ischaemic Hepatitis;Hypernatraemia;Hypovolaemic Shock;Intentional Product Use Issue;Dehydration;Acute Kidney Injury;Diarrhoea;Coma Scale Abnormal;Lactic Acidosis,Serious,Hospitalized;Life Threatening,Female,DEC-2022,05-JAN-2023,Expedited,75 YR,80 KG,Bausch And Lomb,Healthcare Professional,Not Specified,Polyethylene Glycols;Ramipril;Metronidazole;Ceftriaxone;Duloxetine Hydrochloride;Benserazide Hydrochloride\Levodopa,27-DEC-2022,05-JAN-2023,CH,Not Specified,CH-BAUSCH-BL-2023-000149,-,-
21822760,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Localised Infection,Non-Serious,Non-Serious,Male,-,05-JAN-2023,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,03-JAN-2023,05-JAN-2023,US,Not Specified,US-SA-2023SA003664,-,-
21821794,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Covid-19,Non-Serious,Non-Serious,Female,-,05-JAN-2023,Non-Expedited,74 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,03-JAN-2023,05-JAN-2023,US,Not Specified,US-SA-2023SA003154,-,-
21819669,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Female,-,04-JAN-2023,Non-Expedited,71 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,02-JAN-2023,04-JAN-2023,US,Not Specified,US-SA-2023SA002282,-,-
21809368,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Expired Product Administered,Non-Serious,Non-Serious,Male,-,03-JAN-2023,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-DEC-2022,03-JAN-2023,US,Not Specified,US-SA-2023SA001368,-,-
21787999,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Defective;Injection Site Haemorrhage,Non-Serious,Non-Serious,Male,-,02-JAN-2023,Non-Expedited,78 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,26-DEC-2022,28-DEC-2022,US,Not Specified,US-SA-2022SA522473,-,-
21756055,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Abnormal,Non-Serious,Non-Serious,Male,-,02-JAN-2023,Non-Expedited,62 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,28-DEC-2022,20-DEC-2022,US,Not Specified,US-SA-2022SA513204,-,-
21803477,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Female,DEC-2022,01-JAN-2023,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-DEC-2022,01-JAN-2023,US,Not Specified,US-SA-2022SA524645,-,-
21750948,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Increased;Device Issue,Non-Serious,Non-Serious,Male,14-DEC-2022,30-DEC-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,28-DEC-2022,19-DEC-2022,US,Not Specified,US-SA-2022SA508968,-,-
21784165,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,27-DEC-2022,Non-Expedited,54 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,22-DEC-2022,27-DEC-2022,US,Not Specified,US-SA-2022SA520027,-,-
21784122,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Musculoskeletal Disorder,Non-Serious,Non-Serious,Female,-,27-DEC-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,22-DEC-2022,27-DEC-2022,US,Not Specified,US-SA-2022SA519742,-,-
21780000,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,-,26-DEC-2022,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-DEC-2022,26-DEC-2022,US,Not Specified,US-SA-2022SA518810,-,-
21778852,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Female,19-DEC-2022,26-DEC-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,19-DEC-2022,26-DEC-2022,US,Not Specified,US-SA-2022SA516690,-,-
21776615,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Asthenia;Accidental Exposure To Product;Blood Glucose Abnormal,Non-Serious,Non-Serious,Male,12-DEC-2022,26-DEC-2022,Non-Expedited,76 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-DEC-2022,26-DEC-2022,US,Not Specified,US-SA-2022SA502998,-,-
21776428,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Feeling Abnormal;Decreased Appetite,Serious,Hospitalized,Female,-,26-DEC-2022,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,14-DEC-2022,26-DEC-2022,PK,Not Specified,PK-NOVOPROD-1002711,-,-
21449122,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Blood Glucose Increased,Product Storage Error;Blood Glucose Increased;Device Breakage;Product Leakage,Serious,Other Outcomes,Male,01-OCT-2022,23-DEC-2022,30-DAY,80 YR,95 KG,Novo Nordisk,Consumer,Not Specified,-,14-DEC-2022,13-OCT-2022,MX,Not Specified,MX-NOVOPROD-966072,-,-
21767378,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,22-DEC-2022,Non-Expedited,60 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-DEC-2022,22-DEC-2022,US,Not Specified,US-SA-2022SA514464,-,-
21767333,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Female,-,22-DEC-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,16-DEC-2022,22-DEC-2022,US,Not Specified,US-SA-2022SA513658,-,-
21754153,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Therapeutic Product Effect Decreased,Non-Serious,Non-Serious,Male,09-DEC-2022,20-DEC-2022,Non-Expedited,74 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-DEC-2022,20-DEC-2022,US,Not Specified,US-SA-2022SA511037,-,-
21753283,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,20-DEC-2022,Non-Expedited,71 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Tresiba;Janumet,14-DEC-2022,20-DEC-2022,US,Not Specified,US-SA-2022SA508761,-,-
21752979,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Hospitalisation,Serious,Hospitalized,Female,-,20-DEC-2022,Expedited,79 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,09-DEC-2022,20-DEC-2022,JP,Not Specified,JP-NOVOPROD-1002201,-,-
21752973,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Blood Sodium Abnormal,Serious,Hospitalized,Female,-,20-DEC-2022,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,09-DEC-2022,20-DEC-2022,CO,Not Specified,CO-NOVOPROD-1002687,-,-
21749494,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,19-DEC-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,13-DEC-2022,19-DEC-2022,US,Not Specified,US-SA-2022SA508666,-,-
21746840,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,19-DEC-2022,Non-Expedited,50 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-DEC-2022,19-DEC-2022,US,Not Specified,US-SA-2022SA509050,-,-
21670926,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Anxiety;Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Epicondylitis;Cataract Operation,Non-Serious,Non-Serious,Male,-,15-DEC-2022,Expedited,60 YR,100 KG,Novo Nordisk,Healthcare Professional,Not Specified,Amlodipine;Rosuvastatin;Bisoprolol Fumarate;Seretide;Nortriptyline;Xigduo Xr;Benicar Hct;Escitalopram,05-DEC-2022,02-DEC-2022,BR,Not Specified,BR-NOVOPROD-984944,-,-
21722621,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Cerebral Disorder,Non-Serious,Non-Serious,Female,-,13-DEC-2022,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-DEC-2022,13-DEC-2022,US,Not Specified,US-SA-2022SA502165,-,-
21721590,-,Insulin Glargine\Lixisenatide,Hypertension;Type 2 Diabetes Mellitus,Toe Amputation;Localised Infection;Blood Glucose Increased;Product Prescribing Issue;Inappropriate Schedule Of Product Administration;Diabetes Mellitus Inadequate Control,Serious,Other Outcomes;Hospitalized,Male,DEC-2020,13-DEC-2022,Expedited,67 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Spironolactone;Cilostazol;Nifedipine;Metformin;Furosemide;Telmisartan,07-DEC-2022,13-DEC-2022,MX,Not Specified,MX-SA-2022SA425533,-,-
21721195,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Increased;Product Dispensing Error,Non-Serious,Non-Serious,Female,-,13-DEC-2022,Non-Expedited,57 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-DEC-2022,13-DEC-2022,US,Not Specified,US-SA-2022SA501761,-,-
21713399,Actoplus Met;Actoplus Met Xr;Kazano;Metformin,Metformin Hydrochloride;Alogliptin Benzoate\Metformin Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Gastrointestinal Disorder,Non-Serious,Non-Serious,Not Specified,-,12-DEC-2022,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metoprolol;Levothyroxine;Lisinopril;Simvastatin,02-DEC-2022,12-DEC-2022,US,Not Specified,US-TAKEDA-2022TUS094038,-,-
21712940,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,12-DEC-2022,Non-Expedited,46 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,06-DEC-2022,12-DEC-2022,US,Not Specified,US-SA-2022SA500579,-,-
21671312,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Drug Ineffective,Non-Serious,Non-Serious,Male,-,09-DEC-2022,Non-Expedited,74 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,02-DEC-2022,02-DEC-2022,US,Not Specified,US-SA-2022SA492317,-,-
21700481,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Nervousness,Non-Serious,Non-Serious,Male,-,08-DEC-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,05-DEC-2022,08-DEC-2022,US,Not Specified,US-SA-2022SA498233,-,-
21700446,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 1 Diabetes Mellitus,Weight Increased,Non-Serious,Non-Serious,Female,-,08-DEC-2022,Non-Expedited,74 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin,05-DEC-2022,08-DEC-2022,US,Not Specified,US-SA-2022SA496986,-,-
21340153,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Device Mechanical Issue;Device Failure;Blood Glucose Increased,Serious,Other Outcomes,Female,02-SEP-2022,08-DEC-2022,30-DAY,70 YR,61 KG,Novo Nordisk,Consumer,Not Specified,-,26-NOV-2022,16-SEP-2022,BR,Not Specified,BR-NOVOPROD-957305,-,-
21693334,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product;Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Female,-,07-DEC-2022,Non-Expedited,40 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-DEC-2022,07-DEC-2022,US,Not Specified,US-SA-2022SA493193,-,-
21690921,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Intentional Product Misuse,Non-Serious,Non-Serious,Female,-,07-DEC-2022,Non-Expedited,60 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-DEC-2022,07-DEC-2022,US,Not Specified,US-SA-2022SA495063,-,-
21328716,Xultophy 100/3.6,Insulin Degludec\Liraglutide;Favezelimab;Pembrolizumab;Lenvatinib,Diabetes Mellitus;Renal Cell Carcinoma,Pancreatitis,Serious,Hospitalized,Female,25-AUG-2022,07-DEC-2022,Non-Expedited,63 YR,77.3 KG,Eisai,Healthcare Professional,Not Specified,Acetaminophen\Caffeine\Codeine Phosphate;Escitalopram;Duloxetine Hydrochloride;Empagliflozin\Metformin Hydrochloride;Aspirin;Glucerna;Acetaminophen;Atorvastatin;Dorzolamide Hydrochloride;Fentanyl;Cilazapril Anhydrous;Bisoprolol Fumarate;Omeprazole;Cholecalciferol,01-DEC-2022,13-SEP-2022,Not Specified,Not Specified,IL-Eisai Medical Research-EC-2022-122399,-,-
21665849,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Product Dose Confusion;Blood Glucose Increased;Device Use Confusion,Non-Serious,Non-Serious,Female,-,06-DEC-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-NOV-2022,01-DEC-2022,US,Not Specified,US-SA-2022SA489206,-,-
21680983,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Peripheral Swelling,Non-Serious,Non-Serious,Female,-,05-DEC-2022,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,30-NOV-2022,05-DEC-2022,US,Not Specified,US-SA-2022SA491925,-,-
21664218,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Hypoglycaemia,Non-Serious,Non-Serious,Male,-,05-DEC-2022,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,29-NOV-2022,30-NOV-2022,DE,Not Specified,DE-SA-2022SA487427,-,-
21319914,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Condition Aggravated;Drug Ineffective;Blood Glucose Fluctuation;Diabetes Mellitus Inadequate Control,Serious,Other Outcomes,Male,-,05-DEC-2022,Non-Expedited,65 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Humalog;Rybelsus;Tresiba,29-NOV-2022,11-SEP-2022,US,Not Specified,US-SA-2022SA367795,-,-
21678584,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Death,Serious,Died,Male,15-NOV-2022,03-DEC-2022,Expedited,81 YR,76 KG,Novo Nordisk,Healthcare Professional,Not Specified,-,23-NOV-2022,03-DEC-2022,KZ,Not Specified,KZ-NOVOPROD-984899,-,-
21674739,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Female,-,02-DEC-2022,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,29-NOV-2022,02-DEC-2022,US,Not Specified,US-SA-2022SA490576,-,-
21674702,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,-,02-DEC-2022,Non-Expedited,65 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,29-NOV-2022,02-DEC-2022,US,Not Specified,US-SA-2022SA490951,-,-
21674695,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,02-DEC-2022,Non-Expedited,64 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,29-NOV-2022,02-DEC-2022,US,Not Specified,US-SA-2022SA491263,-,-
21674676,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,02-DEC-2022,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-NOV-2022,02-DEC-2022,US,Not Specified,US-SA-2022SA488868,-,-
21674632,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,02-DEC-2022,Non-Expedited,44 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-NOV-2022,02-DEC-2022,US,Not Specified,US-SA-2022SA488495,-,-
21668646,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Intercepted Product Storage Error,Non-Serious,Non-Serious,Female,27-NOV-2022,01-DEC-2022,Non-Expedited,73 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-NOV-2022,01-DEC-2022,US,Not Specified,US-SA-2022SA487896,-,-
21668637,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Gastrointestinal Disorder,Non-Serious,Non-Serious,Not Specified,-,01-DEC-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,29-NOV-2022,01-DEC-2022,US,Not Specified,US-SA-2022SA490930,-,-
21667990,Levemir;Xultophy 100/3.6;Tresiba,Insulin Degludec;Insulin Degludec\Liraglutide;Insulin Detemir,Type 2 Diabetes Mellitus,Blood Glucose Abnormal;Blindness;Nausea;Hypoaesthesia;Life Expectancy Shortened;Gastrooesophageal Reflux Disease,Serious,Other Outcomes,Male,-,01-DEC-2022,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,18-NOV-2022,01-DEC-2022,FR,Not Specified,FR-NOVOPROD-984760,-,-
21666823,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Suicide Attempt;Depression,Serious,Other Outcomes,Male,-,01-DEC-2022,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-NOV-2022,01-DEC-2022,BR,Not Specified,BR-SA-2022SA488489,-,-
21649748,Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Lispro,Diabetes Mellitus;Hormone Replacement Therapy,Head Discomfort;Spinal Pain;Hyperhidrosis;Labile Blood Pressure;Headache;Memory Impairment;Pain,Serious,Other Outcomes,Female,-,28-NOV-2022,Expedited,81 YR,72 KG,Sanofi Aventis,Healthcare Professional,Not Specified,Levothyroxine Sodium,22-NOV-2022,28-NOV-2022,RU,Not Specified,RU-SA-2022SA480425,-,-
21639035,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Dyspnoea;Asthenia;Paraesthesia,Non-Serious,Non-Serious,Female,13-NOV-2022,24-NOV-2022,Non-Expedited,88 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Levemir,17-NOV-2022,24-NOV-2022,US,Not Specified,US-SA-2022SA479062,-,-
21635583,Toujeo;Novolog;Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Aspart;Insulin Glargine,Type 2 Diabetes Mellitus,Headache;Feeling Abnormal;Cough;Blood Glucose Fluctuation;Nausea,Non-Serious,Non-Serious,Female,25-APR-2022,23-NOV-2022,Non-Expedited,77 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,Lipitor;Metformin,20-MAY-2022,23-NOV-2022,US,Not Specified,US-NOVOPROD-946016,-,-
21634025,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,-,23-NOV-2022,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,16-NOV-2022,23-NOV-2022,US,Not Specified,US-SA-2022SA477825,-,-
21631914,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,23-NOV-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-NOV-2022,23-NOV-2022,US,Not Specified,US-SA-2022SA475057,-,-
21609272,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Pancreatitis;Musculoskeletal Pain;Abdominal Pain Upper,Serious,Other Outcomes,Female,-,23-NOV-2022,Expedited,62 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Gliclazide;Metformin,11-NOV-2022,17-NOV-2022,RU,Not Specified,RU-SA-2022SA467992,-,-
21622315,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,21-NOV-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-NOV-2022,21-NOV-2022,US,Not Specified,US-SA-2022SA470957,-,-
21614595,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Hospitalisation,Serious,Hospitalized,Male,-,18-NOV-2022,Expedited,80 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,09-NOV-2022,18-NOV-2022,JP,Not Specified,JP-NOVOPROD-980104,-,-
21570971,Soliqua 100/33;Pulmicort Turbuhaler,Budesonide;Acetaminophen;Insulin Glargine\Lixisenatide,Diabetes Mellitus;Hypertension;Pyrexia;Type 2 Diabetes Mellitus,Productive Cough;Pneumonia;Vomiting;Nausea;Blood Glucose Increased;Pyrexia,Serious,Other Outcomes,Female,-,18-NOV-2022,Expedited,50 YR,55 KG,Sanofi Aventis,Healthcare Professional,Not Specified,Amlodipine;Metformin;Glimepiride;Lansoprazole,14-NOV-2022,09-NOV-2022,ID,Not Specified,ID-SA-2022SA442816,-,-
21609722,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Respiratory Tract Irritation;Sedation;Abdominal Discomfort;Eye Pruritus;Eye Swelling;Upper-Airway Cough Syndrome;Rhinorrhoea;Nausea;Feeling Abnormal;Loss Of Personal Independence In Daily Activities;Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Female,2021,17-NOV-2022,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,20-SEP-2022,17-NOV-2022,US,Not Specified,US-NOVOPROD-962615,-,-
21609706,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Product Quality Issue;Asthenia;Blood Glucose Increased;Brain Fog;Nausea,Non-Serious,Non-Serious,Female,FEB-2022,17-NOV-2022,Non-Expedited,74 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,03-JUN-2022,17-NOV-2022,US,Not Specified,US-NOVOPROD-894183,-,-
21609703,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Blood Glucose Decreased,Serious,Other Outcomes,Male,-,17-NOV-2022,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,26-JUL-2022,17-NOV-2022,US,Not Specified,US-NOVOPROD-944096,-,-
20769119,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Vomiting;Oxygen Saturation Decreased,Serious,Hospitalized,Female,15-APR-2022,17-NOV-2022,Expedited,9 DEC,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Bisoprolol Fumarate;Amlodipine;Cilostazol;Sodium Picosulfate;Urapidil,09-NOV-2022,29-APR-2022,JP,Not Specified,JP-NOVOPROD-912375,-,-
21409042,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,16-NOV-2022,Non-Expedited,64 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-NOV-2022,04-OCT-2022,US,Not Specified,US-SA-2022SA399807,-,-
21594020,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Hospitalisation,Serious,Hospitalized,Female,-,15-NOV-2022,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,02-NOV-2022,15-NOV-2022,JP,Not Specified,JP-NOVOPROD-977659,-,-
21135292,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Device Malfunction;Product Packaging Quantity Issue;Wrong Technique In Device Usage Process,Serious,Other Outcomes,Male,-,15-NOV-2022,30-DAY,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,04-NOV-2022,27-JUL-2022,BR,Not Specified,BR-NOVOPROD-940191,-,-
21591240,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Male,-,14-NOV-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-NOV-2022,14-NOV-2022,US,Not Specified,US-SA-2022SA464166,-,-
21591181,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Decreased,Non-Serious,Non-Serious,Male,-,14-NOV-2022,Non-Expedited,72 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-NOV-2022,14-NOV-2022,US,Not Specified,US-SA-2022SA466458,-,-
21587266,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Sinus Disorder;Throat Clearing,Non-Serious,Non-Serious,Female,2022,14-NOV-2022,Non-Expedited,62 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-NOV-2022,14-NOV-2022,US,Not Specified,US-SA-2022SA319887,-,-
21587111,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Drug Ineffective,Non-Serious,Non-Serious,Not Specified,-,14-NOV-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-NOV-2022,14-NOV-2022,US,Not Specified,US-SA-2022SA464031,-,-
21573489,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Increased,Non-Serious,Non-Serious,Not Specified,-,14-NOV-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,01-NOV-2022,09-NOV-2022,US,Not Specified,US-SA-2022SA457523,-,-
21583046,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Product Prescribing Error,Non-Serious,Non-Serious,Female,-,11-NOV-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,04-NOV-2022,11-NOV-2022,US,Not Specified,US-SA-2022SA460935,-,-
21582185,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,11-NOV-2022,Non-Expedited,77 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-NOV-2022,11-NOV-2022,US,Not Specified,US-SA-2022SA462353,-,-
21582123,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 1 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,05-NOV-2022,11-NOV-2022,Non-Expedited,61 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-NOV-2022,11-NOV-2022,US,Not Specified,US-SA-2022SA462615,-,-
21567364,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Hypoacusis;Visual Impairment,Non-Serious,Non-Serious,Female,-,08-NOV-2022,Non-Expedited,82 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,31-OCT-2022,08-NOV-2022,US,Not Specified,US-SA-2022SA453196,-,-
21567281,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Male,-,08-NOV-2022,Non-Expedited,71 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,29-OCT-2022,08-NOV-2022,US,Not Specified,US-SA-2022SA454250,-,-
21567198,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Use Complaint,Non-Serious,Non-Serious,Female,-,08-NOV-2022,Non-Expedited,82 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-OCT-2022,08-NOV-2022,US,Not Specified,US-SA-2022SA069280,-,-
21547079,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Off Label Use,Non-Serious,Non-Serious,Male,-,03-NOV-2022,Non-Expedited,81 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,31-OCT-2022,03-NOV-2022,US,Not Specified,US-SA-2022SA453148,-,-
21339802,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Dispensing Error;Accidental Exposure To Product,Non-Serious,Non-Serious,Female,-,03-NOV-2022,Non-Expedited,74 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,25-OCT-2022,15-SEP-2022,US,Not Specified,US-SA-2022SA381448,-,-
21543064,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Weight Increased,Non-Serious,Non-Serious,Not Specified,-,02-NOV-2022,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,24-OCT-2022,02-NOV-2022,US,Not Specified,US-SA-2022SA443990,-,-
21538710,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Hospitalisation,Serious,Hospitalized,Male,-,02-NOV-2022,Expedited,9 DEC,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,25-OCT-2022,02-NOV-2022,JP,Not Specified,JP-NOVOPROD-974813,-,-
21537774,Soliqua 100/33,Insulin Glargine\Lixisenatide;Pioglitazone,Diabetes Mellitus,Weight Increased,Non-Serious,Non-Serious,Female,-,01-NOV-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,25-OCT-2022,01-NOV-2022,US,Not Specified,US-SA-2022SA449423,-,-
21537727,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product;Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Female,-,01-NOV-2022,Non-Expedited,59 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,22-OCT-2022,01-NOV-2022,US,Not Specified,US-SA-2022SA443202,-,-
21537591,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,01-NOV-2022,Non-Expedited,68 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-OCT-2022,01-NOV-2022,US,Not Specified,US-SA-2022SA439755,-,-
21531056,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Female,-,31-OCT-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-OCT-2022,31-OCT-2022,US,Not Specified,US-SA-2022SA444065,-,-
21505726,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Weight Increased;Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,30-OCT-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Ozempic,19-OCT-2022,26-OCT-2022,US,Not Specified,US-SA-2022SA429990,-,-
21522995,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Male,-,29-OCT-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-OCT-2022,29-OCT-2022,US,Not Specified,US-SA-2022SA434573,-,-
21521513,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Expired Product Administered,Non-Serious,Non-Serious,Female,18-OCT-2022,28-OCT-2022,Non-Expedited,71 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-OCT-2022,28-OCT-2022,US,Not Specified,US-SA-2022SA432920,-,-
21292805,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Device Delivery System Issue;Diabetic Foot Infection;Blood Glucose Increased,Serious,Hospitalized;Other Outcomes,Male,2022,28-OCT-2022,30-DAY,62 YR,73 KG,Novo Nordisk,Consumer,Not Specified,-,18-OCT-2022,05-SEP-2022,MX,Not Specified,MX-NOVOPROD-952218,-,-
21513688,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Female,-,27-OCT-2022,Non-Expedited,53 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-OCT-2022,27-OCT-2022,US,Not Specified,US-SA-2022SA431548,-,-
21436038,Toujeo;Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Glargine;Metformin Hydrochloride,Type 2 Diabetes Mellitus,Intentional Product Misuse;Administration Site Wound;Product Prescribing Issue;Product Dispensing Issue,Serious,Hospitalized,Female,SEP-2022,27-OCT-2022,Expedited,78 YR,80 KG,Sanofi Aventis,Healthcare Professional,Not Specified,Novorapid,18-OCT-2022,10-OCT-2022,RU,Not Specified,RU-SA-2022SA410105,-,-
21382921,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Accidental Exposure To Product,Non-Serious,Non-Serious,Female,17-SEP-2022,26-OCT-2022,Non-Expedited,68 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,14-OCT-2022,27-SEP-2022,US,Not Specified,US-SA-2022SA389407,-,-
21086293,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Papillary Thyroid Cancer,Serious,Other Outcomes;Hospitalized,Male,-,24-OCT-2022,Expedited,64 YR,92 KG,Novo Nordisk,Healthcare Professional,Not Specified,Empagliflozin;Pioglitazone;Metformin;Gliclazide,05-JUL-2022,15-JUL-2022,BR,Not Specified,BR-NOVOPROD-936769,-,-
21492530,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Drug Ineffective,Non-Serious,Non-Serious,Male,-,21-OCT-2022,Non-Expedited,79 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-OCT-2022,21-OCT-2022,US,Not Specified,US-SA-2022SA432063,-,-
21483910,Soliqua 100/33,Insulin Glargine\Lixisenatide,Enterocolitis;Intestinal Obstruction;Proctitis;Type 2 Diabetes Mellitus,Product Use In Unapproved Indication;Condition Aggravated;Enterocolitis,Serious,Other Outcomes,Female,-,20-OCT-2022,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Insulin Lispro;Apidra,12-OCT-2022,20-OCT-2022,RU,Not Specified,RU-SA-2022SA420624,-,-
21478646,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Female,-,19-OCT-2022,Non-Expedited,54 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,10-OCT-2022,19-OCT-2022,US,Not Specified,US-SA-2022SA420232,-,-
21475451,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Eye Operation,Non-Serious,Non-Serious,Female,-,19-OCT-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-OCT-2022,19-OCT-2022,US,Not Specified,US-SA-2022SA427768,-,-
21465728,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,19-OCT-2022,Non-Expedited,60 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Xigduo Xr;Lantus,12-OCT-2022,17-OCT-2022,US,Not Specified,US-SA-2022SA415561,-,-
21456147,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Abnormal,Non-Serious,Non-Serious,Female,-,19-OCT-2022,Non-Expedited,69 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Tresiba,10-OCT-2022,14-OCT-2022,US,Not Specified,US-SA-2022SA417917,-,-
21473199,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,18-OCT-2022,Non-Expedited,48 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,06-OCT-2022,18-OCT-2022,US,Not Specified,US-SA-2022SA411304,-,-
21455034,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Gait Disturbance;Anxiety,Non-Serious,Non-Serious,Female,-,14-OCT-2022,Non-Expedited,82 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-OCT-2022,14-OCT-2022,US,Not Specified,US-SA-2022SA419074,-,-
21447540,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Abnormal,Non-Serious,Non-Serious,Male,-,12-OCT-2022,Non-Expedited,60 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-OCT-2022,12-OCT-2022,US,Not Specified,US-SA-2022SA417065,-,-
21446315,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Intentional Product Misuse;Device Use Issue;Product Storage Error,Non-Serious,Non-Serious,Male,-,12-OCT-2022,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,04-OCT-2022,12-OCT-2022,US,Not Specified,US-SA-2022SA411883,-,-
21446307,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Accidental Exposure To Product,Non-Serious,Non-Serious,Female,-,12-OCT-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,04-OCT-2022,12-OCT-2022,US,Not Specified,US-SA-2022SA411570,-,-
21446239,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,12-OCT-2022,Non-Expedited,49 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,04-OCT-2022,12-OCT-2022,US,Not Specified,US-SA-2022SA411402,-,-
21443838,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Abdominal Pain;Constipation;Prostate Cancer,Serious,Other Outcomes,Male,01-DEC-2021,12-OCT-2022,Expedited,54 YR,64 KG,Novo Nordisk,Healthcare Professional,Not Specified,-,03-OCT-2022,12-OCT-2022,GR,Not Specified,GR-NOVOPROD-965680,-,-
21443153,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Visual Impairment;Vision Blurred,Non-Serious,Non-Serious,Female,-,12-OCT-2022,Non-Expedited,60 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,06-OCT-2022,12-OCT-2022,US,Not Specified,US-SA-2022SA415566,-,-
21421705,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Breakage;Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,12-OCT-2022,Non-Expedited,68 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Novolog,07-OCT-2022,07-OCT-2022,US,Not Specified,US-SA-2022SA408135,-,-
21441722,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Vomiting;Illness;Dyspnoea;Gait Disturbance;Blood Glucose Increased;Fear,Non-Serious,Non-Serious,Female,-,11-OCT-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,05-OCT-2022,11-OCT-2022,US,Not Specified,US-SA-2022SA413295,-,-
21058289,Soliqua 100/33,Insulin Glargine\Lixisenatide,Arrhythmia;Dyspepsia;Hypertension;Sedation;Type 2 Diabetes Mellitus,Blood Glucose Increased;Glycosylated Haemoglobin Increased;Glomerular Filtration Rate Decreased;Drug Ineffective;Off Label Use,Serious,Other Outcomes,Female,09-MAY-2022,07-OCT-2022,Expedited,63 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Levothyroxine;Pantoprazole;Samsca;Acenocoumarol;Olanzapine;Irbesartan;Cordarone,02-OCT-2022,08-JUL-2022,VN,Not Specified,VN-SA-2022SA264626,-,-
21418095,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,06-OCT-2022,Non-Expedited,58 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-SEP-2022,06-OCT-2022,US,Not Specified,US-SA-2022SA404497,-,-
21409130,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Pancreatitis;Blood Pressure Increased,Serious,Other Outcomes,Not Specified,-,04-OCT-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,29-SEP-2022,04-OCT-2022,US,Not Specified,US-SA-2022SA403918,-,-
19718790,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Male,-,04-OCT-2022,Non-Expedited,77 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-SEP-2022,18-AUG-2021,US,Not Specified,US-SA-2021SA270671,-,-
21404282,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Feeling Abnormal;Asthenia,Non-Serious,Non-Serious,Not Specified,-,03-OCT-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-SEP-2022,03-OCT-2022,US,Not Specified,US-SA-2022SA397270,-,-
21400755,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Hyperhidrosis;Covid-19;Clostridium Difficile Colitis;Urinary Tract Infection,Serious,Other Outcomes;Hospitalized,Female,2022,03-OCT-2022,Expedited,87 YR,78 KG,Novo Nordisk,Healthcare Professional,Not Specified,Hydrochlorothiazide;Glimepiride;Paroxetine;Quetiapine;Zolpidem;Simvastatin;Linagliptin;Benserazide\Levodopa;Puran,22-SEP-2022,03-OCT-2022,BR,Not Specified,BR-NOVOPROD-962722,-,-
21400453,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error;Visual Impairment,Non-Serious,Non-Serious,Female,SEP-2022,03-OCT-2022,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-SEP-2022,03-OCT-2022,US,Not Specified,US-SA-2022SA398885,-,-
21366907,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Increased;Intentional Product Misuse,Non-Serious,Non-Serious,Male,-,30-SEP-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,21-SEP-2022,23-SEP-2022,US,Not Specified,US-SA-2022SA385686,-,-
21392894,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Nervousness,Non-Serious,Non-Serious,Female,-,29-SEP-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-SEP-2022,29-SEP-2022,US,Not Specified,US-SA-2022SA399011,-,-
21392810,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Male,-,29-SEP-2022,Non-Expedited,72 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-SEP-2022,29-SEP-2022,US,Not Specified,US-SA-2022SA399277,-,-
21347520,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Pleural Mesothelioma,Serious,Died,Female,-,28-SEP-2022,Expedited,65 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,20-SEP-2022,19-SEP-2022,JP,Not Specified,JP-NOVOPROD-957789,-,-
21321545,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Cholangitis;Jaundice Cholestatic,Serious,Hospitalized;Other Outcomes,Male,2021,28-SEP-2022,Expedited,57 YR,66.4 KG,Novo Nordisk,Healthcare Professional,Not Specified,Lanreotide;Afinitor,21-SEP-2022,12-SEP-2022,JP,Not Specified,JP-NOVOPROD-953298,-,-
21382933,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Drug Ineffective,Non-Serious,Non-Serious,Female,-,27-SEP-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-SEP-2022,27-SEP-2022,US,Not Specified,US-SA-2022SA395929,-,-
21319232,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,27-SEP-2022,Non-Expedited,67 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,20-SEP-2022,11-SEP-2022,US,Not Specified,US-SA-2022SA361855,-,-
21314896,Metformin;Xultophy 100/3.6;Tresiba,Insulin Degludec\Liraglutide;Insulin Degludec;Metformin Hydrochloride,Ankylosing Spondylitis;Dyslipidaemia;Hypertension;Hypertonic Bladder;Product Used For Unknown Indication;Prophylaxis Against Gastrointestinal Ulcer;Type 2 Diabetes Mellitus,Osteomyelitis;Acute Kidney Injury;Arthritis Bacterial;Infective Myositis;Joint Abscess,Serious,Other Outcomes;Hospitalized,Female,04-APR-2022,27-SEP-2022,Expedited,62 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Diclofenac Diethylamine;Omeprazole;Indomethacin Sodium;Rosuvastatin;Perindopril;Solifenacin,05-JUL-2022,09-SEP-2022,CA,Not Specified,CA-NOVOPROD-955991,-,-
21374614,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Intentional Product Misuse;Stent Placement;Retinal Aneurysm,Serious,Hospitalized;Other Outcomes,Male,SEP-2021,26-SEP-2022,Expedited,58 YR,95.1 KG,Novo Nordisk,Healthcare Professional,Not Specified,Jardiance;Simvastatin;Manivasc;Metformin;Ramipril,15-SEP-2022,26-SEP-2022,BR,Not Specified,BR-NOVOPROD-961071,-,-
21373273,Admelog;Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Lispro,Diabetes Mellitus;Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Female,-,24-SEP-2022,Non-Expedited,64 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-SEP-2022,24-SEP-2022,US,Not Specified,US-SA-2022SA390046,-,-
21370996,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,23-SEP-2022,Non-Expedited,71 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-SEP-2022,23-SEP-2022,US,Not Specified,US-SA-2022SA393162,-,-
21369883,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Illness,Non-Serious,Non-Serious,Female,-,23-SEP-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Synjardy,20-SEP-2022,23-SEP-2022,US,Not Specified,US-SA-2022SA392749,-,-
21369228,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,23-SEP-2022,Non-Expedited,78 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-SEP-2022,23-SEP-2022,US,Not Specified,US-SA-2022SA386637,-,-
21368054,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Hypoacusis,Non-Serious,Non-Serious,Male,-,23-SEP-2022,Non-Expedited,64 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-SEP-2022,23-SEP-2022,US,Not Specified,US-SA-2022SA391544,-,-
21368035,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Intentional Product Misuse;Blood Glucose Decreased,Non-Serious,Non-Serious,Male,-,23-SEP-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-SEP-2022,23-SEP-2022,US,Not Specified,US-SA-2022SA390093,-,-
21367238,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Peripheral Swelling,Non-Serious,Non-Serious,Female,-,23-SEP-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,15-SEP-2022,23-SEP-2022,US,Not Specified,US-SA-2022SA385217,-,-
21367166,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,23-SEP-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,15-SEP-2022,23-SEP-2022,US,Not Specified,US-SA-2022SA386122,-,-
21367128,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Injection Site Pruritus;Injection Site Erythema;Injection Site Swelling,Non-Serious,Non-Serious,Male,-,23-SEP-2022,Non-Expedited,50 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,13-SEP-2022,23-SEP-2022,US,Not Specified,US-SA-2022SA381105,-,-
21366932,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Constipation,Non-Serious,Non-Serious,Not Specified,-,23-SEP-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Ozempic,14-SEP-2022,23-SEP-2022,US,Not Specified,US-SA-2022SA386117,-,-
21366826,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Female,-,23-SEP-2022,Non-Expedited,55 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-SEP-2022,23-SEP-2022,US,Not Specified,US-SA-2022SA385260,-,-
21260411,Tresiba;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Insulin Degludec,Cardiovascular Event Prophylaxis;Dyslipidaemia;Gastrooesophageal Reflux Disease;Hypertension;Product Used For Unknown Indication,Fibrous Dysplasia Of Bone,Serious,Other Outcomes;Hospitalized,Female,2018,23-SEP-2022,Expedited,50 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Ramipril;Nitroglycerin;Tranexamic Acid;Rabeprazole Sodium;Leuprolide Acetate;Metoprolol;Rabeprazole;Amlodipine;Lasix;Rosuvastatin;Iron;Rivaroxaban;Crestor;Metformin;Hydrochlorothiazide;Plavix,06-JUL-2022,26-AUG-2022,CA,Not Specified,CA-NOVOPROD-951874,-,-
21362450,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Non-Proliferative Retinopathy;Stent Placement,Serious,Other Outcomes;Hospitalized,Male,OCT-2020,22-SEP-2022,Expedited,69 YR,86.5 KG,Novo Nordisk,Healthcare Professional,Not Specified,Ciprofibrate;Rosuvastatin;Cholecalciferol;Allopurinol,12-SEP-2022,22-SEP-2022,BR,Not Specified,BR-NOVOPROD-958841,-,-
21357401,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Off Label Use;Neuroendocrine Tumour;Intestinal Polyp,Serious,Other Outcomes,Male,-,21-SEP-2022,Expedited,57 YR,76 KG,Novo Nordisk,Healthcare Professional,Not Specified,Dapagliflozin Propanediol\Metformin Hydrochloride,11-SEP-2022,21-SEP-2022,BR,Not Specified,BR-NOVOPROD-958286,-,-
21351454,Soliqua 100/33,Insulin Glargine\Lixisenatide;Mifepristone,Cushing's Syndrome;Product Used For Unknown Indication,Muscle Tightness;Hypophagia;Intentional Product Use Issue;Condition Aggravated;Blood Pressure Decreased;Fatigue;Pulse Abnormal;Muscle Spasms;Palpitations;Vomiting;Decreased Appetite;Nausea,Non-Serious,Non-Serious,Female,AUG-2022,19-SEP-2022,Non-Expedited,62 YR,98.4 KG,Sanofi Aventis,Consumer,Not Specified,Xanax;Kcl;Xigduo Xr;Ferrous Sulfate;Prilosec;Vitamin D Nos;Valsartan;Sotalol;Eliquis;Hydrochlorothiazide\Valsartan;Humalog;Lipitor,12-SEP-2022,19-SEP-2022,US,Not Specified,US-SA-2022SA382245,-,-
21350241,Soliqua 100/33;Lantus;Toujeo Max;Toujeo;Praluent;Lantus Solostar,Insulin Glargine;Alirocumab;Insulin Glargine;Insulin Glargine;Insulin Glargine;Insulin Glargine\Lixisenatide,Product Used For Unknown Indication,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,19-SEP-2022,Expedited,Not Specified,Not Specified,Regeneron,Healthcare Professional,Not Specified,-,24-JAN-2022,19-SEP-2022,US,Not Specified,"US-REGENERON PHARMACEUTICALS, INC.-2022-022112",-,-
21350240,Toujeo;Soliqua 100/33;Lantus;Toujeo Max;Lantus Solostar;Praluent,Alirocumab;Insulin Glargine;Insulin Glargine;Insulin Glargine;Insulin Glargine\Lixisenatide;Insulin Glargine,Product Used For Unknown Indication,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,19-SEP-2022,Expedited,Not Specified,Not Specified,Regeneron,Healthcare Professional,Not Specified,-,24-JAN-2022,19-SEP-2022,US,Not Specified,"US-REGENERON PHARMACEUTICALS, INC.-2022-022111",-,-
21349462,Metformin;Pioglitazone Hydrochloride And Metformin Hydrochloride,Metformin Hydrochloride\Pioglitazone Hydrochloride;Insulin Degludec;Insulin Aspart;Insulin Glulisine;Acarbose;Metformin Hydrochloride;Insulin Glargine;Insulin Nos,Monogenic Diabetes,Off Label Use;Drug Ineffective,Serious,Hospitalized,Female,-,19-SEP-2022,Expedited,8 YR,Not Specified,Mylan,Healthcare Professional,Not Specified,-,08-SEP-2022,19-SEP-2022,CN,Not Specified,CN-MYLANLABS-2022M1093810,"Li J, Wang X, Mao H, Wen L, Deng A, Li Y, et al. Precision therapy for three Chinese families with maturity-onset diabetes of the young (MODY12). Front-Endocrinol-(Lausanne) 2022;null:null.",-
21210175,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus;Type 2 Diabetes Mellitus,Skin Discolouration;Rash,Non-Serious,Non-Serious,Male,02-AUG-2022,19-SEP-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Farxiga;Metformin,14-SEP-2022,14-AUG-2022,US,Not Specified,US-SA-2022SA330871,-,-
21345277,Soliqua 100/33;Lantus Solostar;Toujeo Max;Praluent;Lantus;Toujeo,Insulin Glargine;Sodium;Alirocumab;Insulin Glargine;Insulin Glargine;Insulin Glargine;Insulin Glargine\Lixisenatide,Diabetes Mellitus;Product Used For Unknown Indication,Product Temperature Excursion Issue,Non-Serious,Non-Serious,Not Specified,-,16-SEP-2022,5-DAY,Not Specified,Not Specified,Regeneron,Healthcare Professional,Not Specified,-,21-JUL-2022,16-SEP-2022,US,Not Specified,"US-REGENERON PHARMACEUTICALS, INC.-2022-100316",-,-
21341742,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration;Weight Decreased;Dizziness,Non-Serious,Non-Serious,Female,-,16-SEP-2022,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-SEP-2022,16-SEP-2022,US,Not Specified,US-SA-2022SA376173,-,-
21340149,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Renal Surgery;Ureteric Operation;Bladder Operation,Serious,Other Outcomes;Hospitalized,Male,MAY-2022,16-SEP-2022,Expedited,59 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,06-SEP-2022,16-SEP-2022,MX,Not Specified,MX-NOVOPROD-956970,-,-
21327126,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Ankle Fracture;Product Storage Error;Fall,Non-Serious,Non-Serious,Male,-,15-SEP-2022,Non-Expedited,74 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-SEP-2022,13-SEP-2022,US,Not Specified,US-SA-2022SA373113,-,-
21326491,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Male,-,13-SEP-2022,Non-Expedited,62 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,06-SEP-2022,13-SEP-2022,US,Not Specified,US-SA-2022SA371635,-,-
21326488,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Prescribing Issue,Non-Serious,Non-Serious,Male,-,13-SEP-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,05-SEP-2022,13-SEP-2022,US,Not Specified,US-SA-2022SA371665,-,-
21326485,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Female,-,13-SEP-2022,Non-Expedited,58 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,06-SEP-2022,13-SEP-2022,US,Not Specified,US-SA-2022SA371640,-,-
21326390,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Dispensing Issue;Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,13-SEP-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,02-SEP-2022,13-SEP-2022,US,Not Specified,US-SA-2022SA369976,-,-
21079208,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Depression;Diabetes Mellitus;Hypertension,Hyperglycaemia;Device Failure,Serious,Other Outcomes,Female,-,13-SEP-2022,30-DAY,Not Specified,110 KG,Novo Nordisk,Consumer,Not Specified,Novorapid;Anafranil;Abilify Discmelt,02-SEP-2022,14-JUL-2022,EG,Not Specified,EG-NOVOPROD-937321,-,-
21325346,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Dispensing Error,Non-Serious,Non-Serious,Female,02-SEP-2022,12-SEP-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,02-SEP-2022,12-SEP-2022,US,Not Specified,US-SA-2022SA367933,-,-
21325329,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Preparation Error,Non-Serious,Non-Serious,Male,-,12-SEP-2022,Non-Expedited,72 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,02-SEP-2022,12-SEP-2022,US,Not Specified,US-SA-2022SA369004,-,-
21325271,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Dispensing Issue,Non-Serious,Non-Serious,Male,-,12-SEP-2022,Non-Expedited,59 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-SEP-2022,12-SEP-2022,US,Not Specified,US-SA-2022SA367492,-,-
21321749,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Intellectual Disability,Serious,Other Outcomes,Not Specified,-,12-SEP-2022,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,07-SEP-2022,12-SEP-2022,US,Not Specified,US-SA-2022SA372567,-,-
21319300,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Issue;Product Storage Error;Blood Glucose Fluctuation,Non-Serious,Non-Serious,Female,-,12-SEP-2022,Non-Expedited,76 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Metformin;Glipizide,29-AUG-2022,11-SEP-2022,US,Not Specified,US-SA-2022SA362680,-,-
21320093,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Drug Ineffective;Hypoacusis,Non-Serious,Non-Serious,Male,2022,11-SEP-2022,Non-Expedited,73 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,02-SEP-2022,11-SEP-2022,US,Not Specified,US-SA-2022SA369680,-,-
21319705,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Nausea,Non-Serious,Non-Serious,Female,-,11-SEP-2022,Non-Expedited,80 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,29-AUG-2022,11-SEP-2022,US,Not Specified,US-SA-2022SA361214,-,-
21319418,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Abdominal Pain Upper;Constipation,Non-Serious,Non-Serious,Male,-,11-SEP-2022,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,29-AUG-2022,11-SEP-2022,US,Not Specified,US-SA-2022SA361372,-,-
21319401,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Visual Impairment,Non-Serious,Non-Serious,Female,-,11-SEP-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,29-AUG-2022,11-SEP-2022,US,Not Specified,US-SA-2022SA363707,-,-
21319256,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Dose Omission In Error,Non-Serious,Non-Serious,Female,AUG-2022,11-SEP-2022,Non-Expedited,78 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-AUG-2022,11-SEP-2022,US,Not Specified,US-SA-2022SA362579,-,-
21319251,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Female,-,11-SEP-2022,Non-Expedited,65 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,29-AUG-2022,11-SEP-2022,US,Not Specified,US-SA-2022SA362398,-,-
21319247,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,30-AUG-2022,11-SEP-2022,Non-Expedited,68 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-AUG-2022,11-SEP-2022,US,Not Specified,US-SA-2022SA365125,-,-
21319136,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Increased;Off Label Use,Non-Serious,Non-Serious,Female,-,11-SEP-2022,Non-Expedited,80 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Glimepiride;Humulin 70/30,29-AUG-2022,11-SEP-2022,US,Not Specified,US-SA-2022SA361969,-,-
21318810,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Dispensing Error,Non-Serious,Non-Serious,Male,-,11-SEP-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,26-AUG-2022,11-SEP-2022,US,Not Specified,US-SA-2022SA360229,-,-
21318807,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,11-SEP-2022,Non-Expedited,55 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-AUG-2022,11-SEP-2022,US,Not Specified,US-SA-2022SA360708,-,-
21318704,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Dispensing Error,Non-Serious,Non-Serious,Female,-,11-SEP-2022,Non-Expedited,43 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,25-AUG-2022,11-SEP-2022,US,Not Specified,US-SA-2022SA360117,-,-
21318541,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,11-SEP-2022,Non-Expedited,61 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,25-AUG-2022,11-SEP-2022,US,Not Specified,US-SA-2022SA360113,-,-
21318378,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Back Pain,Non-Serious,Non-Serious,Male,2022,11-SEP-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,24-AUG-2022,11-SEP-2022,US,Not Specified,US-SA-2022SA358310,-,-
21318251,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Headache;Nausea,Non-Serious,Non-Serious,Male,-,11-SEP-2022,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-AUG-2022,11-SEP-2022,US,Not Specified,US-SA-2022SA359128,-,-
21318152,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Male,-,11-SEP-2022,Non-Expedited,51 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,24-AUG-2022,11-SEP-2022,US,Not Specified,US-SA-2022SA358140,-,-
21318144,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Female,-,11-SEP-2022,Non-Expedited,69 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-AUG-2022,11-SEP-2022,US,Not Specified,US-SA-2022SA355837,-,-
21318063,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,11-SEP-2022,Non-Expedited,50 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-AUG-2022,11-SEP-2022,US,Not Specified,US-SA-2022SA355077,-,-
21317739,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,AUG-2022,11-SEP-2022,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-AUG-2022,11-SEP-2022,US,Not Specified,US-SA-2022SA355795,-,-
21317335,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Wrong Technique In Product Usage Process,Non-Serious,Non-Serious,Female,-,11-SEP-2022,Non-Expedited,68 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-AUG-2022,11-SEP-2022,US,Not Specified,US-SA-2022SA347167,-,-
21317278,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,11-SEP-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,18-AUG-2022,11-SEP-2022,US,Not Specified,US-SA-2022SA346030,-,-
21317044,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Needle Issue;Device Mechanical Issue;Blood Glucose Abnormal;Injection Site Pain,Non-Serious,Non-Serious,Female,-,11-SEP-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,19-AUG-2022,11-SEP-2022,US,Not Specified,US-SA-2022SA344989,-,-
21316843,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,11-SEP-2022,Non-Expedited,67 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,16-AUG-2022,11-SEP-2022,US,Not Specified,US-SA-2022SA342688,-,-
21316772,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Female,-,11-SEP-2022,Non-Expedited,79 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,16-AUG-2022,11-SEP-2022,US,Not Specified,US-SA-2022SA342139,-,-
21316761,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Device Information Output Issue,Non-Serious,Non-Serious,Female,-,11-SEP-2022,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,17-AUG-2022,11-SEP-2022,US,Not Specified,US-SA-2022SA344323,-,-
21230044,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,11-SEP-2022,Non-Expedited,58 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-AUG-2022,18-AUG-2022,US,Not Specified,US-SA-2022SA337936,-,-
21296708,Lyumjev Kwikpen;Humalog;Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Lispro;Insulin Lispro,Diabetes Mellitus;Product Used For Unknown Indication,Feeling Abnormal;Cough;Eructation;Presyncope;Reflux Gastritis;Drug Ineffective;Blood Glucose Increased;Asthenia;Dizziness;Fatigue;Constipation;Diarrhoea,Non-Serious,Non-Serious,Female,-,06-SEP-2022,Non-Expedited,Not Specified,Not Specified,Eli Lilly And Co,Consumer,Not Specified,-,02-SEP-2022,06-SEP-2022,US,Not Specified,US-ELI_LILLY_AND_COMPANY-US202209002273,-,-
21292808,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Hypoglycaemia;Hypotension,Serious,Hospitalized,Not Specified,-,05-SEP-2022,Expedited,65 YR,78 KG,Novo Nordisk,Consumer,Not Specified,-,24-AUG-2022,05-SEP-2022,PK,Not Specified,PK-NOVOPROD-952705,-,-
21264053,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Hospitalisation,Serious,Hospitalized,Female,-,29-AUG-2022,Expedited,90 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,17-AUG-2022,29-AUG-2022,JP,Not Specified,JP-NOVOPROD-950940,-,-
21260897,Jardiance,Empagliflozin;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Prophylaxis;Product Used For Unknown Indication,Hypoacusis;Off Label Use;Glaucoma;Renal Disorder;Renal Pain,Serious,Other Outcomes,Female,2016,26-AUG-2022,Expedited,73 YR,65 KG,Takeda,Consumer,Not Specified,Vytorin;Bisoprolol Fumarate;Aspirin,18-JAN-2021,26-AUG-2022,MX,Not Specified,MX-TAKEDA-2022TJP071505,-,-
21259739,Cialis,Tadalafil;Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Diabetes Mellitus;Cardiovascular Disorder,Serious,Other Outcomes,Male,-,26-AUG-2022,Expedited,Not Specified,Not Specified,Takeda,Consumer,Not Specified,-,16-APR-2020,26-AUG-2022,MX,Not Specified,MX-TAKEDA-2022TJP071503,-,-
21258792,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Breast Cancer,Serious,Other Outcomes,Female,APR-2018,26-AUG-2022,Expedited,58 YR,98 KG,Takeda,Consumer,Not Specified,Ibuprofen;Exforge Hct;Acetaminophen;Olanzapine,18-SEP-2018,26-AUG-2022,MX,Not Specified,MX-TAKEDA-2022TJP071390,-,-
21257860,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus Inadequate Control,Myocardial Infarction,Serious,Other Outcomes,Male,-,26-AUG-2022,Expedited,Not Specified,Not Specified,Takeda,Consumer,Not Specified,Jardiance,28-SEP-2020,26-AUG-2022,MX,Not Specified,MX-TAKEDA-2022TJP071208,-,-
21257392,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Product Used For Unknown Indication,Rheumatic Disorder;Clavicle Fracture;Hypoglycaemia;Forearm Fracture;Fall;Bone Demineralisation,Serious,Other Outcomes,Female,2018,26-AUG-2022,Expedited,79 YR,75 KG,Takeda,Consumer,Not Specified,Duloxetine,05-NOV-2019,26-AUG-2022,MX,Not Specified,MX-TAKEDA-2022TJP071387,-,-
21255101,Trulicity,Dulaglutide;Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Neoplasm Malignant,Serious,Other Outcomes,Female,-,25-AUG-2022,Expedited,50 YR,Not Specified,Takeda,Consumer,Not Specified,-,19-MAR-2019,25-AUG-2022,MX,Not Specified,MX-TAKEDA-2022TJP071392,-,-
21253097,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Intentional Overdose;Toxicity To Various Agents;Suicide Attempt;Haematemesis,Serious,Other Outcomes;Hospitalized,Male,03-MAY-2022,25-AUG-2022,Expedited,51 YR,Not Specified,Mylan,Healthcare Professional,Not Specified,-,18-AUG-2022,25-AUG-2022,IT,Not Specified,IT-MYLANLABS-2022M1088612,-,-
21056038,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Device Failure;Blood Glucose Increased,Serious,Other Outcomes,Male,-,25-AUG-2022,30-DAY,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,16-AUG-2022,08-JUL-2022,US,Not Specified,US-NOVOPROD-934077,-,-
21243604,Novolog Mix 50/50;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Insulin Aspart,Diabetes Mellitus,Diabetic Neuropathy,Serious,Other Outcomes,Male,-,23-AUG-2022,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,09-AUG-2022,23-AUG-2022,US,Not Specified,US-NOVOPROD-950932,-,-
21241117,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,23-AUG-2022,Non-Expedited,67 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,17-AUG-2022,23-AUG-2022,US,Not Specified,US-SA-2022SA344764,-,-
20972079,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,No Adverse Event,Non-Serious,Non-Serious,Male,-,23-AUG-2022,Non-Expedited,73 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-JUN-2022,16-JUN-2022,US,Not Specified,US-SA-2022SA222884,-,-
21238646,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Male,-,22-AUG-2022,Non-Expedited,65 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-AUG-2022,22-AUG-2022,US,Not Specified,US-SA-2022SA338412,-,-
21207661,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Covid-19,Non-Serious,Non-Serious,Male,-,21-AUG-2022,Non-Expedited,81 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Paxlovid,10-AUG-2022,12-AUG-2022,US,Not Specified,US-SA-2022SA323707,-,-
21170477,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Cough;Tuberculosis,Serious,Other Outcomes,Male,02-JUN-2022,19-AUG-2022,Expedited,47 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,11-AUG-2022,04-AUG-2022,PK,Not Specified,PK-SA-2022SA314502,-,-
21200434,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Dizziness;Asthenia;Neoplasm Malignant,Serious,Other Outcomes,Female,-,17-AUG-2022,Expedited,71 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,10-AUG-2022,11-AUG-2022,US,Not Specified,US-SA-2022SA328524,-,-
20857101,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Rhinorrhoea;Seasonal Allergy;Dysphonia;Product Storage Error;Blood Glucose Increased;Product Quality Issue;Cough,Non-Serious,Non-Serious,Male,-,17-AUG-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,09-AUG-2022,20-MAY-2022,US,Not Specified,US-SA-2022SA176075,-,-
21214189,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Covid-19;Sepsis;Urinary Tract Infection;Nephrolithiasis;Anger,Serious,Hospitalized,Female,-,16-AUG-2022,Expedited,62 YR,80 KG,Novo Nordisk,Healthcare Professional,Not Specified,Xigduo Xr;Aspirin\Dihydroxyaluminum Aminoacetate Anhydrous\Magnesium Carbonate;Vytorin;Omeprazole;Diovan;Pristiq Extended-Release,04-AUG-2022,16-AUG-2022,BR,Not Specified,BR-NOVOPROD-946211,-,-
21053542,-,Insulin Glargine\Lixisenatide,Diabetes Mellitus Management;Type 2 Diabetes Mellitus,Pleural Effusion,Serious,Hospitalized,Male,23-JUN-2021,16-AUG-2022,Expedited,62 YR,57.8 KG,Sanofi Aventis,Healthcare Professional,Not Specified,Empagliflozin;Spironolactone;Febuxostat;Piperacillin And Tazobactam;Atorvastatin;Furosemide;Azithromycin,12-AUG-2022,07-JUL-2022,PH,Not Specified,PH-SA-2021SA407010,-,-
21023446,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Accidental Exposure To Product;Injection Site Haemorrhage,Non-Serious,Non-Serious,Female,27-JUN-2022,16-AUG-2022,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,09-AUG-2022,29-JUN-2022,US,Not Specified,US-SA-2022SA250447,-,-
21213415,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Product Usage Process;Injection Site Haemorrhage,Non-Serious,Non-Serious,Male,-,15-AUG-2022,Non-Expedited,61 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-AUG-2022,15-AUG-2022,US,Not Specified,US-SA-2022SA329491,-,-
21213177,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Blood Cholesterol Increased;Blood Triglycerides Increased;Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Dehydration;Blood Cholesterol Increased;Blood Triglycerides Increased;Hyperglycaemia;Paraesthesia;Product Availability Issue;Blood Glucose Increased;Hypoglycaemia;Decreased Appetite;Weight Decreased,Serious,Hospitalized;Other Outcomes,Female,01-JUN-2021,15-AUG-2022,Expedited,35 YR,71 KG,Novo Nordisk,Consumer,Not Specified,Atorvastatin;Rosuvastatin,02-AUG-2022,15-AUG-2022,CO,Not Specified,CO-NOVOPROD-828865,-,-
21207687,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,12-AUG-2022,Non-Expedited,71 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-AUG-2022,12-AUG-2022,US,Not Specified,US-SA-2022SA330375,-,-
21207628,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Hypotension,Non-Serious,Non-Serious,Male,JUL-2022,12-AUG-2022,Non-Expedited,73 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Losartan,04-AUG-2022,12-AUG-2022,US,Not Specified,US-SA-2022SA323577,-,-
21176638,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Parkinson's Disease;Diabetes Mellitus Inadequate Control;Tremor,Serious,Other Outcomes,Female,JUN-2022,12-AUG-2022,Expedited,70 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,05-AUG-2022,05-AUG-2022,KR,Not Specified,KR-SA-2022SA314660,-,-
21202981,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Nausea,Non-Serious,Non-Serious,Male,-,11-AUG-2022,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,09-AUG-2022,11-AUG-2022,US,Not Specified,US-SA-2022SA329232,-,-
21200465,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Nausea,Serious,Hospitalized,Female,-,11-AUG-2022,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,09-AUG-2022,11-AUG-2022,US,Not Specified,US-SA-2022SA329316,-,-
21198299,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Female,-,11-AUG-2022,Non-Expedited,62 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,04-AUG-2022,11-AUG-2022,US,Not Specified,US-SA-2022SA323859,-,-
21197740,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Nausea,Non-Serious,Non-Serious,Male,25-JUL-2022,10-AUG-2022,Non-Expedited,55 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,08-AUG-2022,10-AUG-2022,US,Not Specified,US-SA-2022SA326629,-,-
21197395,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Male,-,10-AUG-2022,Non-Expedited,65 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-AUG-2022,10-AUG-2022,US,Not Specified,US-SA-2022SA320639,-,-
21195884,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Rheumatoid Arthritis,Serious,Other Outcomes,Female,2020,10-AUG-2022,Expedited,81 YR,68 KG,Takeda,Consumer,Not Specified,-,01-AUG-2022,10-AUG-2022,MX,Not Specified,MX-TAKEDA-2022TJP069624,-,-
21193145,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Infection,Serious,Died,Female,-,10-AUG-2022,Expedited,72 YR,79.5 KG,Novo Nordisk,Healthcare Professional,Not Specified,Pregabalin;Cyclobenzaprine;Duloxetine;Ramipril;Metformin;Furosemide;Rosuvastatin;Levothyroxine,02-AUG-2022,10-AUG-2022,BR,Not Specified,BR-NOVOPROD-945591,-,-
21142988,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Anaphylactic Shock,Serious,Other Outcomes,Not Specified,23-JUL-2022,09-AUG-2022,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,03-AUG-2022,28-JUL-2022,JP,Not Specified,JP-SA-2022SA297388,-,-
21186318,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Male,-,08-AUG-2022,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,29-JUL-2022,08-AUG-2022,US,Not Specified,US-SA-2022SA316140,-,-
21186301,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,-,08-AUG-2022,Non-Expedited,73 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,28-JUL-2022,08-AUG-2022,US,Not Specified,US-SA-2022SA316759,-,-
21181408,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Female,-,06-AUG-2022,Non-Expedited,67 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-JUL-2022,06-AUG-2022,US,Not Specified,US-SA-2022SA310560,-,-
21181366,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Rash,Non-Serious,Non-Serious,Female,-,06-AUG-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,28-JUL-2022,06-AUG-2022,US,Not Specified,US-SA-2022SA312099,-,-
21180678,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Administration Error,Non-Serious,Non-Serious,Male,-,06-AUG-2022,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-JUL-2022,06-AUG-2022,US,Not Specified,US-SA-2022SA307372,-,-
21180633,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Prescribing Issue,Non-Serious,Non-Serious,Male,-,06-AUG-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-JUL-2022,06-AUG-2022,US,Not Specified,US-SA-2022SA308949,-,-
21152800,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration;Nausea,Non-Serious,Non-Serious,Female,-,06-AUG-2022,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,25-JUL-2022,30-JUL-2022,US,Not Specified,US-SA-2022SA303266,-,-
20904132,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Intestinal Obstruction,Serious,Hospitalized,Male,JAN-2022,04-AUG-2022,Expedited,46 YR,69.9 KG,Novo Nordisk,Healthcare Professional,Not Specified,-,28-JUL-2022,02-JUN-2022,JP,Not Specified,JP-NOVOPROD-922879,-,-
21154193,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Blood Glucose Abnormal;Cardiovascular Disorder;Hypertension,Thirst;Limb Injury,Serious,Hospitalized,Male,JUN-2022,01-AUG-2022,Expedited,79 YR,73 KG,Novo Nordisk,Consumer,Not Specified,Losartan,21-JUL-2022,01-AUG-2022,MX,Not Specified,MX-NOVOPROD-941675,-,-
21152988,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Hypoacusis,Non-Serious,Non-Serious,Female,-,30-JUL-2022,Non-Expedited,69 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,25-JUL-2022,30-JUL-2022,US,Not Specified,US-SA-2022SA303340,-,-
21152641,Praluent;Toujeo Max;Soliqua 100/33;Lantus;Lantus Solostar;Toujeo,Insulin Glargine;Insulin Glargine;Sodium;Insulin Glargine;Insulin Glargine\Lixisenatide;Insulin Glargine;Alirocumab,Diabetes Mellitus,Product Temperature Excursion Issue,Non-Serious,Non-Serious,Not Specified,-,30-JUL-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,21-JUL-2022,30-JUL-2022,US,Not Specified,US-SA-2022SA301603,-,-
21152228,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,30-JUL-2022,Non-Expedited,56 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-JUL-2022,30-JUL-2022,US,Not Specified,US-SA-2022SA293053,-,-
21152137,Lantus;Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Glargine,-,Drug Ineffective,Non-Serious,Non-Serious,Male,-,30-JUL-2022,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Ozempic,18-JUL-2022,30-JUL-2022,US,Not Specified,US-SA-2022SA293511,-,-
21151961,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Female,-,30-JUL-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-JUL-2022,30-JUL-2022,US,Not Specified,US-SA-2022SA296250,-,-
21145870,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Pneumonia,Serious,Died,Male,2022,29-JUL-2022,Expedited,10 DEC,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,20-JUL-2022,29-JUL-2022,JP,Not Specified,JP-NOVOPROD-941750,-,-
21130099,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Urinary Tract Infection;Hyperglycaemia,Serious,Hospitalized,Female,18-MAY-2022,26-JUL-2022,Expedited,58 YR,76.7 KG,Novo Nordisk,Healthcare Professional,Not Specified,Losartan Potassium;Glifage;Aspirin;Rosuvastatin;Ezetimibe;Metoprolol Succinate,16-JUL-2022,26-JUL-2022,BR,Not Specified,BR-NOVOPROD-940218,-,-
21108372,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Hypertensive Crisis;Paraesthesia;Femoroacetabular Impingement;Carotid Arteriosclerosis;Diplopia;Malaise;Hyperglycaemia;Asthenia;Osteoarthritis;Dizziness;Nausea,Serious,Hospitalized;Other Outcomes,Female,-,26-JUL-2022,Expedited,64 YR,74 KG,Novo Nordisk,Healthcare Professional,Not Specified,Metformin;Aspirin;Duloxetine;Gliclazide;Rosuvastatin;Dapagliflozin;Hydrochlorothiazide\Valsartan,15-JUL-2022,20-JUL-2022,BR,Not Specified,BR-NOVOPROD-937699,-,-
21050803,Soliqua 100/33,Insulin Glargine\Lixisenatide,Product Used For Unknown Indication,Gastrointestinal Hypomotility;Intestinal Obstruction,Serious,Other Outcomes,Not Specified,JUN-2022,26-JUL-2022,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,20-JUL-2022,07-JUL-2022,JP,Not Specified,JP-SAKK-2022SA259232AA,-,-
21123225,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,24-JUL-2022,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-JUL-2022,24-JUL-2022,US,Not Specified,US-SA-2022SA291361,-,-
21107992,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,21-JUL-2022,Non-Expedited,49 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-JUL-2022,20-JUL-2022,US,Not Specified,US-SA-2022SA276985,-,-
21108084,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product;Extra Dose Administered,Non-Serious,Non-Serious,Male,-,20-JUL-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-JUL-2022,20-JUL-2022,US,Not Specified,US-SA-2022SA282788,-,-
21097446,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Dyslipidaemia;Hypertension;Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Pyelonephritis Acute;Hydronephrosis;Hyperglycaemia,Serious,Hospitalized,Female,01-AUG-2020,19-JUL-2022,Expedited,90 YR,52.4 KG,Novo Nordisk,Healthcare Professional,Not Specified,Amlodipine;Urapidil;Pravastatin Sodium,08-JUL-2022,19-JUL-2022,JP,Not Specified,JP-NOVOPROD-934112,-,-
21097430,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Urinary Tract Infection,Serious,Hospitalized,Female,-,19-JUL-2022,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,05-JUL-2022,19-JUL-2022,US,Not Specified,US-NOVOPROD-937218,-,-
21096021,Lantus Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Glargine,-,Vomiting,Non-Serious,Non-Serious,Female,-,18-JUL-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-JUL-2022,18-JUL-2022,US,Not Specified,US-SA-2022SA284881,-,-
21073128,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Issue;Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,18-JUL-2022,Non-Expedited,65 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,11-JUL-2022,12-JUL-2022,US,Not Specified,US-SA-2022SA273683,-,-
21086365,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Incorrect Dose Administered,Non-Serious,Non-Serious,Male,-,15-JUL-2022,Non-Expedited,74 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-JUL-2022,15-JUL-2022,US,Not Specified,US-SA-2022SA273093,-,-
21086282,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Atrioventricular Block,Serious,Other Outcomes,Male,-,15-JUL-2022,Expedited,32 YR,103 KG,Novo Nordisk,Healthcare Professional,Not Specified,Rosuvastatin;Glifage,04-JUL-2022,15-JUL-2022,BR,Not Specified,BR-NOVOPROD-935731,-,-
21086044,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Multiple Use Of Single-Use Product,Non-Serious,Non-Serious,Female,-,15-JUL-2022,Non-Expedited,51 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-JUL-2022,15-JUL-2022,US,Not Specified,US-SA-2022SA275608,-,-
21056016,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Covid-19,Serious,Hospitalized,Male,-,15-JUL-2022,Expedited,50 YR,84 KG,Novo Nordisk,Healthcare Professional,Not Specified,Dapagliflozin Propanediol\Metformin Hydrochloride;Testosterone Cypionate,07-JUL-2022,08-JUL-2022,BR,Not Specified,BR-NOVOPROD-935369,-,-
21084996,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Male,-,14-JUL-2022,Non-Expedited,62 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,07-JUL-2022,14-JUL-2022,US,Not Specified,US-SA-2022SA273776,-,-
21060044,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,14-JUL-2022,Non-Expedited,41 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-JUL-2022,08-JUL-2022,US,Not Specified,US-SA-2022SA258443,-,-
20639575,Lantus;Toujeo;Soliqua 100/33;Admelog;Lantus Solostar;Toujeo Max,Insulin Glargine;Insulin Glargine;Insulin Lispro;Insulin Glargine\Lixisenatide;Insulin Glargine;Insulin Glargine,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,14-JUL-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,14-MAR-2022,26-MAR-2022,US,Not Specified,US-SA-2022SA090081,-,-
21073964,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Drug Ineffective;Diabetes Mellitus Inadequate Control,Serious,Other Outcomes,Female,-,13-JUL-2022,Non-Expedited,55 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,08-JUL-2022,13-JUL-2022,US,Not Specified,US-SA-2022SA274645,-,-
21061280,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injection Site Pain,Non-Serious,Non-Serious,Female,-,09-JUL-2022,Non-Expedited,64 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,06-JUL-2022,09-JUL-2022,US,Not Specified,US-SA-2022SA268500,-,-
21035886,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,08-JUL-2022,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-JUN-2022,01-JUL-2022,US,Not Specified,US-SA-2022SA254638,-,-
20500135,-,Insulin Glargine\Lixisenatide,Cervical Spinal Stenosis;Constipation;Essential Hypertension;Insomnia;Lumbar Spinal Stenosis;Neuropathy Peripheral;Type 2 Diabetes Mellitus;Type V Hyperlipidaemia,Insomnia;Cervical Spinal Stenosis;Lumbar Spinal Stenosis,Serious,Disabled,Not Specified,23-FEB-2020,08-JUL-2022,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Atorvastatin Calcium;Acetaminophen;Zyprexa Zydis;Metformin Hydrochloride;Gabapentin;Amlodipine Besylate\Hydrochlorothiazide\Olmesartan Medoxomil;Pregabalin;Glimepiride;Tramadol Hydrochloride,29-JUN-2022,22-FEB-2022,MX,Not Specified,MX-SA-2020SA050225,-,-
20493864,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,No Adverse Event,Non-Serious,Non-Serious,Male,-,08-JUL-2022,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-FEB-2022,21-FEB-2022,US,Not Specified,US-SA-2022SA052398,-,-
21040869,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Incorrect Dose Administered,Non-Serious,Non-Serious,Male,OCT-2021,04-JUL-2022,Non-Expedited,56 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,24-JUN-2022,04-JUL-2022,US,Not Specified,US-SA-2022SA248883,-,-
21038165,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Deafness;Covid-19;Hepatic Steatosis;Hyperglycaemia;Blood Glucose Increased,Serious,Other Outcomes,Female,05-DEC-2019,04-JUL-2022,Expedited,56 YR,111.5 KG,Novo Nordisk,Healthcare Professional,Not Specified,Metformin;Gliclazide,21-JUN-2022,04-JUL-2022,BR,Not Specified,BR-NOVOPROD-931622,-,-
20949230,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Pain;Type 2 Diabetes Mellitus,Tachycardia;Hypertension;Kidney Infection,Serious,Hospitalized,Male,23-APR-2022,04-JUL-2022,Expedited,76 YR,70 KG,Novo Nordisk,Consumer,Not Specified,Acetaminophen,23-JUN-2022,13-JUN-2022,CO,Not Specified,CO-NOVOPROD-920712,-,-
21034459,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Blood Glucose Abnormal;Cerebrovascular Accident,Serious,Other Outcomes,Female,-,01-JUL-2022,Expedited,51 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-JUN-2022,01-JUL-2022,US,Not Specified,US-SA-2022SA253344,-,-
21032801,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Sciatica,Serious,Hospitalized,Male,MAY-2022,01-JUL-2022,Expedited,58 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,25-JUN-2022,01-JUL-2022,DE,Not Specified,DE-SA-2022SA252813,-,-
20804306,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Blood Cholesterol Abnormal;Blood Triglycerides Abnormal;Hypertension;Type 2 Diabetes Mellitus,Device Defective;Product Leakage;Blood Glucose Increased;Feeling Abnormal;Device Breakage,Serious,Other Outcomes,Female,22-APR-2022,01-JUL-2022,30-DAY,59 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,Telmisartan;Allopurinol;Atorvastatin,20-JUN-2022,09-MAY-2022,MX,Not Specified,MX-NOVOPROD-913927,-,-
21029271,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Hypoacusis,Non-Serious,Non-Serious,Male,-,30-JUN-2022,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-JUN-2022,30-JUN-2022,US,Not Specified,US-SA-2022SA252655,-,-
21023349,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Limb Discomfort,Non-Serious,Non-Serious,Female,-,29-JUN-2022,Non-Expedited,77 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-JUN-2022,29-JUN-2022,US,Not Specified,US-SA-2022SA251938,-,-
20915499,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,29-JUN-2022,Non-Expedited,87 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,23-JUN-2022,04-JUN-2022,US,Not Specified,US-SA-2022SA191051,-,-
21019368,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,28-JUN-2022,Non-Expedited,64 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,22-JUN-2022,28-JUN-2022,US,Not Specified,US-SA-2022SA243928,-,-
21013614,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Malaise,Non-Serious,Non-Serious,Female,-,28-JUN-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,17-JUN-2022,27-JUN-2022,US,Not Specified,US-SA-2022SA236744,-,-
20826230,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus;Product Used For Unknown Indication,Hunger;Food Craving;Anxiety;Compulsions;Coronary Artery Disease;Dyspnoea,Serious,Other Outcomes,Female,-,28-JUN-2022,Expedited,73 YR,72.5 KG,Novo Nordisk,Healthcare Professional,Not Specified,Escitalopram;Metformin Hydrochloride,15-JUN-2022,13-MAY-2022,BR,Not Specified,BR-NOVOPROD-915719,-,-
21013794,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Female,-,27-JUN-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-JUN-2022,27-JUN-2022,US,Not Specified,US-SA-2022SA241029,-,-
21013681,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,27-JUN-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-JUN-2022,27-JUN-2022,US,Not Specified,US-SA-2022SA243917,-,-
21013533,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Female,-,27-JUN-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,17-JUN-2022,27-JUN-2022,US,Not Specified,US-SA-2022SA236228,-,-
21013511,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Glycosylated Haemoglobin Decreased,Non-Serious,Non-Serious,Male,-,27-JUN-2022,Non-Expedited,68 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,17-JUN-2022,27-JUN-2022,US,Not Specified,US-SA-2022SA173878,-,-
21013261,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error;Product Temperature Excursion Issue,Non-Serious,Non-Serious,Male,-,27-JUN-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,16-JUN-2022,27-JUN-2022,US,Not Specified,US-SA-2022SA235515,-,-
21012927,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,27-JUN-2022,Non-Expedited,69 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-JUN-2022,27-JUN-2022,US,Not Specified,US-SA-2022SA232668,-,-
21012923,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Use Issue;Intentional Product Misuse,Non-Serious,Non-Serious,Male,-,27-JUN-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-JUN-2022,27-JUN-2022,US,Not Specified,US-SA-2022SA231193,-,-
21008200,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Plasma Cell Myeloma,Serious,Other Outcomes,Male,-,27-JUN-2022,Expedited,59 YR,103 KG,Novo Nordisk,Healthcare Professional,Not Specified,Bupropion;Rosuvastatin;Olmesartan;Ciprofibrate;Dapagliflozin Propanediol\Metformin Hydrochloride,15-JUN-2022,27-JUN-2022,BR,Not Specified,BR-NOVOPROD-929163,-,-
20971883,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,27-JUN-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-JUN-2022,16-JUN-2022,US,Not Specified,US-SA-2022SA221991,-,-
20948147,Apidra,Insulin Glulisine;Insulin Glargine\Lixisenatide,Diabetes Mellitus,Product Prescribing Issue,Non-Serious,Non-Serious,Female,-,24-JUN-2022,Expedited,83 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,10-JUN-2022,11-JUN-2022,IT,Not Specified,IT-SA-2022SA217965,-,-
20755690,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Internal Haemorrhage,Serious,Other Outcomes;Hospitalized,Not Specified,-,24-JUN-2022,Expedited,80 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,20-APR-2022,27-APR-2022,US,Not Specified,US-SA-2022SA143660,-,-
20949871,Soliqua 100/33;Lantus Solostar,Insulin Glargine;Insulin Glargine\Lixisenatide,-,Sudden Death,Serious,Other Outcomes;Died,Female,25-MAY-2022,22-JUN-2022,Expedited,74 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-JUN-2022,13-JUN-2022,US,Not Specified,US-SA-2022SA218689,-,-
20979746,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Discomfort,Non-Serious,Non-Serious,Female,-,20-JUN-2022,Non-Expedited,59 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-JUN-2022,20-JUN-2022,US,Not Specified,US-SA-2022SA233691,-,-
20978488,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,No Adverse Event,Non-Serious,Non-Serious,Male,-,18-JUN-2022,Non-Expedited,61 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-JUN-2022,18-JUN-2022,US,Not Specified,US-SA-2022SA230590,-,-
20978186,Toujeo;Soliqua 100/33;Lantus,Insulin Glargine;Insulin Glargine\Lixisenatide;Insulin Glargine,-,Product Storage Error,Non-Serious,Non-Serious,Female,-,18-JUN-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,08-JUN-2022,18-JUN-2022,US,Not Specified,US-SA-2022SA228078,-,-
20972014,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Female,-,16-JUN-2022,Non-Expedited,54 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-JUN-2022,16-JUN-2022,US,Not Specified,US-SA-2022SA221207,-,-
20971643,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Accidental Exposure To Product,Non-Serious,Non-Serious,Female,-,16-JUN-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,06-JUN-2022,16-JUN-2022,US,Not Specified,US-SA-2022SA213262,-,-
20971618,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Multiple Use Of Single-Use Product;Product Storage Error;Product Temperature Excursion Issue,Non-Serious,Non-Serious,Male,-,16-JUN-2022,Non-Expedited,62 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,06-JUN-2022,16-JUN-2022,US,Not Specified,US-SA-2022SA214617,-,-
20971141,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Decreased,Non-Serious,Non-Serious,Female,03-JUN-2022,16-JUN-2022,Non-Expedited,43 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,06-JUN-2022,16-JUN-2022,US,Not Specified,US-SA-2022SA212964,-,-
20971072,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Intentional Product Misuse;Visual Impairment,Non-Serious,Non-Serious,Male,-,16-JUN-2022,Non-Expedited,65 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-JUN-2022,16-JUN-2022,US,Not Specified,US-SA-2022SA220524,-,-
20971060,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Temperature Excursion Issue,Non-Serious,Non-Serious,Not Specified,-,16-JUN-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,06-JUN-2022,16-JUN-2022,US,Not Specified,US-SA-2022SA216216,-,-
20971011,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Female,-,16-JUN-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,06-JUN-2022,16-JUN-2022,US,Not Specified,US-SA-2022SA213053,-,-
20970903,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,16-JUN-2022,Non-Expedited,69 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-JUN-2022,16-JUN-2022,US,Not Specified,US-SA-2022SA216923,-,-
20970412,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,16-JUN-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,02-JUN-2022,16-JUN-2022,US,Not Specified,US-SA-2022SA213455,-,-
20969815,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error;Drug Effect Less Than Expected,Non-Serious,Non-Serious,Male,-,16-JUN-2022,Non-Expedited,51 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-MAY-2022,16-JUN-2022,US,Not Specified,US-SA-2022SA200368,-,-
20969800,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,16-JUN-2022,Non-Expedited,72 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-MAY-2022,16-JUN-2022,US,Not Specified,US-SA-2022SA222818,-,-
20835555,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Hypoglycaemia;Intentional Product Use Issue,Serious,Life Threatening;Hospitalized,Female,-,16-JUN-2022,Non-Expedited,77 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Lantus,07-JUN-2022,16-MAY-2022,US,Not Specified,US-SA-2022SA171701,-,-
20787070,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 1 Diabetes Mellitus,Product Use In Unapproved Indication,Non-Serious,Non-Serious,Not Specified,-,16-JUN-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,27-APR-2022,05-MAY-2022,US,Not Specified,US-SA-2022SA154837,-,-
20639528,Soliqua 100/33,Insulin Glargine\Lixisenatide;Metformin Hydrochloride,Type 2 Diabetes Mellitus,Hypoglycaemia;Vision Blurred;Blood Glucose Decreased;Diarrhoea;Blood Glucose Fluctuation;Device Use Issue;Asthenia;Blood Glucose Increased;Incorrect Dose Administered;Visual Impairment,Non-Serious,Non-Serious,Male,2022,16-JUN-2022,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,09-JUN-2022,26-MAR-2022,US,Not Specified,US-SA-2022SA087616,-,-
20550977,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Device Breakage,Non-Serious,Non-Serious,Male,24-FEB-2022,16-JUN-2022,Non-Expedited,48 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,09-JUN-2022,04-MAR-2022,US,Not Specified,US-SA-2022SA067109,-,-
20954670,Metact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Hospitalisation,Serious,Hospitalized,Female,-,14-JUN-2022,Expedited,9 DEC,Not Specified,Takeda,Healthcare Professional,Not Specified,-,10-JUN-2022,14-JUN-2022,JP,Not Specified,JP-TAKEDA-2022TJP058116,-,-
20951407,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Product Dose Omission Issue;Visual Impairment;Cataract;Amnesia;Cerebrovascular Accident,Serious,Other Outcomes,Female,-,13-JUN-2022,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-JUN-2022,13-JUN-2022,US,Not Specified,US-SA-2022SA221044,-,-
20762798,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Gangrene,Serious,Hospitalized,Male,-,10-JUN-2022,Expedited,75 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,02-JUN-2022,28-APR-2022,LB,Not Specified,LB-NOVOPROD-911031,-,-
20889470,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Constipation;Decreased Appetite;Nausea;Angina Pectoris,Serious,Other Outcomes,Male,-,08-JUN-2022,Expedited,55 YR,109 KG,Novo Nordisk,Healthcare Professional,Not Specified,Gliclazide;Ezetimibe\Simvastatin;Losartan;Canagliflozin;Metformin;Bupropion Hydrochloride;Topiramate,29-MAY-2022,30-MAY-2022,BR,Not Specified,BR-NOVOPROD-920828,-,-
20917691,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Hospitalisation,Serious,Hospitalized,Female,-,06-JUN-2022,Expedited,9 DEC,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,26-MAY-2022,06-JUN-2022,JP,Not Specified,JP-NOVOPROD-923593,-,-
20916305,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Somnolence,Non-Serious,Non-Serious,Female,-,04-JUN-2022,Non-Expedited,60 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,31-MAY-2022,04-JUN-2022,US,Not Specified,US-SA-2022SA207000,-,-
20916234,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Hypoglycaemia,Non-Serious,Non-Serious,Female,-,04-JUN-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,31-MAY-2022,04-JUN-2022,US,Not Specified,US-SA-2022SA207241,-,-
20915979,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Male,-,04-JUN-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-MAY-2022,04-JUN-2022,US,Not Specified,US-SA-2022SA197550,-,-
20915569,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Male,-,04-JUN-2022,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,24-MAY-2022,04-JUN-2022,US,Not Specified,US-SA-2022SA195174,-,-
20915211,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Hypersensitivity;Cough;Sneezing,Non-Serious,Non-Serious,Female,-,04-JUN-2022,Non-Expedited,79 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-MAY-2022,04-JUN-2022,US,Not Specified,US-SA-2022SA190810,-,-
20914336,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Wrong Technique In Product Usage Process;Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,04-JUN-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,20-MAY-2022,04-JUN-2022,US,Not Specified,US-SA-2022SA183086,-,-
20914331,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Injection Site Reaction,Non-Serious,Non-Serious,Female,-,04-JUN-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,18-MAY-2022,04-JUN-2022,US,Not Specified,US-SA-2022SA182361,-,-
20909416,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Somnolence;Blood Glucose Increased;Nocturia;Dyspepsia;Covid-19;Vomiting,Serious,Hospitalized;Other Outcomes,Male,AUG-2021,03-JUN-2022,Expedited,67 YR,93.8 KG,Novo Nordisk,Healthcare Professional,Not Specified,Levofloxacin;Cobalamin;Metformin;Rosuvastatin;Cholecalciferol,23-MAY-2022,03-JUN-2022,BR,Not Specified,BR-NOVOPROD-921924,-,-
20909415,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus;Product Used For Unknown Indication,Diabetes Mellitus Inadequate Control;Hepatic Steatosis;Constipation;Thyroid Cyst;Muscle Spasms;Pain In Extremity;Stent Placement;Hypoglycaemia;Chest Pain;Intentional Product Misuse;Restenosis,Serious,Other Outcomes,Female,16-MAY-2018,03-JUN-2022,Expedited,63 YR,70.8 KG,Novo Nordisk,Healthcare Professional,Not Specified,Ezetimibe;Metformin;Rosuvastatin,23-MAY-2022,03-JUN-2022,BR,Not Specified,BR-NOVOPROD-921955,-,-
20894570,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Diabetic Metabolic Decompensation;High Density Lipoprotein Decreased;Bradycardia;Syncope;Vomiting;Hyperglycaemia;Low Density Lipoprotein Increased;Blood Glucose Increased;Treatment Noncompliance;Hypothyroidism;Blood Triglycerides Increased,Serious,Other Outcomes,Male,2020,31-MAY-2022,Expedited,39 YR,44.943 KG,Novo Nordisk,Healthcare Professional,Not Specified,Levothyroxine;Atorvastatin;Dapagliflozin Propanediol\Metformin Hydrochloride,20-MAY-2022,31-MAY-2022,BR,Not Specified,BR-NOVOPROD-921604,-,-
20888111,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Cataract;Wrong Technique In Device Usage Process;Retinopathy;Visual Impairment,Serious,Other Outcomes,Female,-,29-MAY-2022,Expedited,71 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,24-MAY-2022,29-MAY-2022,US,Not Specified,US-SA-2022SA191896,-,-
20882027,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus;Product Used For Unknown Indication,Weight Decreased;Fatigue;Off Label Use;Cardiac Ablation;Cardioversion,Serious,Other Outcomes,Male,JUN-2021,27-MAY-2022,Expedited,70 YR,109 KG,Novo Nordisk,Healthcare Professional,Not Specified,Synthroid,16-MAY-2022,27-MAY-2022,BR,Not Specified,BR-NOVOPROD-920450,-,-
20880610,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Renal Disorder;Fatigue;Blood Glucose Decreased,Non-Serious,Non-Serious,Male,-,26-MAY-2022,Non-Expedited,Not Specified,Not Specified,Takeda,Consumer,Not Specified,-,24-MAY-2022,26-MAY-2022,US,Not Specified,US-TAKEDA-2022TUS034995,-,-
20869734,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus;Product Used For Unknown Indication,Hyperglycaemia;Hypoglycaemia;Decreased Appetite;Arteriosclerosis;Sleep Disorder;Depression,Serious,Other Outcomes,Male,04-APR-2022,25-MAY-2022,Expedited,62 YR,81.5 KG,Novo Nordisk,Healthcare Professional,Not Specified,Venlafaxine Hydrochloride;Rosuvastatin;Clonazepam;Empagliflozin;Zolpidem,15-MAY-2022,25-MAY-2022,BR,Not Specified,BR-NOVOPROD-919439,-,-
20859596,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus;Product Used For Unknown Indication,Carotid Artery Occlusion;Insomnia;Phantom Limb Syndrome;Arteriosclerosis Coronary Artery;Aortic Dilatation;Left Atrial Enlargement;Aortic Arteriosclerosis;Blood Glucose Increased;Diastolic Dysfunction;Intentional Product Misuse;Cataract Operation,Serious,Other Outcomes,Female,APR-2021,23-MAY-2022,Expedited,73 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Vitamin D Nos;Metformin Hydrochloride,12-MAY-2022,23-MAY-2022,BR,Not Specified,BR-NOVOPROD-919160,-,-
20859594,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Hydrocephalus,Serious,Other Outcomes;Hospitalized,Male,-,23-MAY-2022,Expedited,78 YR,67.8 KG,Novo Nordisk,Healthcare Professional,Not Specified,Pioglitazone;Dapagliflozin,12-MAY-2022,23-MAY-2022,BR,Not Specified,BR-NOVOPROD-918500,-,-
20856980,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Dose Omission Issue;Accidental Exposure To Product;Product Leakage,Non-Serious,Non-Serious,Female,-,23-MAY-2022,Non-Expedited,77 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-MAY-2022,20-MAY-2022,US,Not Specified,US-SA-2022SA176022,-,-
20731474,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Drug Ineffective,Non-Serious,Non-Serious,Female,-,23-MAY-2022,Non-Expedited,68 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-APR-2022,20-APR-2022,US,Not Specified,US-SA-2022SA128765,-,-
20524764,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Device Defective,Non-Serious,Non-Serious,Female,-,23-MAY-2022,Non-Expedited,48 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,12-MAY-2022,28-FEB-2022,US,Not Specified,US-SA-2022SA061935,-,-
20857081,Lantus;Lantus Solostar;Toujeo;Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Glargine;Insulin Glargine;Insulin Glargine,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,20-MAY-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,13-MAY-2022,20-MAY-2022,US,Not Specified,US-SA-2022SA178329,-,-
20856733,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Injection Site Urticaria,Non-Serious,Non-Serious,Male,-,20-MAY-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Lantus,12-MAY-2022,20-MAY-2022,US,Not Specified,US-SA-2022SA176274,-,-
20747625,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Male,2022,20-MAY-2022,Non-Expedited,74 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,16-MAY-2022,25-APR-2022,US,Not Specified,US-SA-2022SA140914,-,-
20627036,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Pancreatic Enzymes Abnormal;Pancreatitis Acute,Serious,Hospitalized;Other Outcomes,Male,12-MAR-2022,20-MAY-2022,Expedited,62 YR,88.35 KG,Sanofi Aventis,Healthcare Professional,Not Specified,Metoprolol Succinate;Gliclazide;Jardiance;Metformin;Losartan;Rosuvastatin;Xultophy 100/3.6;Aspirin;Lantus,14-MAY-2022,23-MAR-2022,BR,Not Specified,BR-SA-2022SA094575,-,-
20849678,Pioglitazone And Metformin;Jardiance,Empagliflozin;Metformin Hydrochloride\Pioglitazone Hydrochloride,Hyperglycaemia,Pruritus;Off Label Use;Drug Eruption;Rash,Serious,Hospitalized,Female,10-JAN-2022,19-MAY-2022,Expedited,57 YR,53.500 KG,Boehringer Ingelheim,Consumer,Not Specified,-,12-MAY-2022,19-MAY-2022,CN,Not Specified,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-170569",-,-
20847160,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Angioplasty;Glycosuria;Proteinuria;Albuminuria;Tibia Fracture,Serious,Other Outcomes;Hospitalized,Female,21-NOV-2019,19-MAY-2022,Expedited,70 YR,64 KG,Novo Nordisk,Consumer,Not Specified,-,10-MAY-2022,19-MAY-2022,BR,Not Specified,BR-NOVOPROD-917467,-,-
20836679,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Amylase Increased;Gallbladder Disorder,Serious,Other Outcomes;Hospitalized,Male,-,17-MAY-2022,Expedited,70 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,06-MAY-2022,17-MAY-2022,BR,Not Specified,BR-NOVOPROD-916749,-,-
20835950,Elitek;Soliqua 100/33,Insulin Glargine\Lixisenatide;Rasburicase,-,Hyperglycaemia,Non-Serious,Non-Serious,Female,-,16-MAY-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-MAY-2022,16-MAY-2022,US,Not Specified,US-SA-2022SA174104,-,-
20831744,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus;Product Used For Unknown Indication,Neovascularisation;Polyp;Rectal Ulcer;Hunger;Product Dose Omission Issue;Anxiety;Arthralgia;Cough;Hyperglycaemia;Eye Oedema;Gynaecomastia;Discouragement;Gastrooesophageal Reflux Disease;Radiation Proctitis,Serious,Other Outcomes,Male,NOV-2018,16-MAY-2022,Expedited,63 YR,87 KG,Novo Nordisk,Healthcare Professional,Not Specified,Ezetimibe;Rosuvastatin;Pioglitazone Hydrochloride;Ciprofibrate;Sertraline Hydrochloride,04-MAY-2022,16-MAY-2022,BR,Not Specified,BR-NOVOPROD-916591,-,-
20762845,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus;Product Used For Unknown Indication,Heart Valve Calcification;Carotid Arteriosclerosis;Heart Valve Incompetence,Serious,Other Outcomes,Male,08-NOV-2021,16-MAY-2022,Expedited,60 YR,60 KG,Novo Nordisk,Healthcare Professional,Not Specified,Amlodipine Besylate\Indapamide\Perindopril Arginine;Metoprolol;Pioglitazone;Vitamin D Nos;Dapagliflozin Propanediol\Metformin Hydrochloride;Menaquinone 6,18-APR-2022,28-APR-2022,BR,Not Specified,BR-NOVOPROD-912318,-,-
20433278,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Cough;Incorrect Dose Administered,Non-Serious,Non-Serious,Male,-,14-MAY-2022,Non-Expedited,67 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,04-MAY-2022,05-FEB-2022,US,Not Specified,US-SA-2022SA033421,-,-
20829195,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Occupational Exposure To Product,Non-Serious,Non-Serious,Male,-,13-MAY-2022,Non-Expedited,63 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-MAY-2022,13-MAY-2022,US,Not Specified,US-SA-2022SA168699,-,-
20828919,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Tremor;Weight Decreased,Non-Serious,Non-Serious,Male,-,13-MAY-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,06-MAY-2022,13-MAY-2022,US,Not Specified,US-SA-2022SA165041,-,-
20828439,Toujeo Max;Lantus;Soliqua 100/33;Lantus Solostar,Insulin Glargine;Insulin Glargine\Lixisenatide;Insulin Glargine;Insulin Glargine,-,Intercepted Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,13-MAY-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,03-MAY-2022,13-MAY-2022,US,Not Specified,US-SA-2022SA160948,-,-
20828335,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Prescribing Issue;Inappropriate Schedule Of Product Administration;Cardiac Operation,Non-Serious,Non-Serious,Female,NOV-2021,13-MAY-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,03-MAY-2022,13-MAY-2022,US,Not Specified,US-SA-2022SA159616,-,-
20827992,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Nausea;Somnolence;Vomiting;Hypoglycaemia;Hyperhidrosis,Non-Serious,Non-Serious,Male,29-APR-2022,13-MAY-2022,Non-Expedited,67 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,04-MAY-2022,13-MAY-2022,US,Not Specified,US-SA-2022SA165604,-,-
20827986,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Needle Issue;Injection Site Pain,Non-Serious,Non-Serious,Female,-,13-MAY-2022,Non-Expedited,83 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,04-MAY-2022,13-MAY-2022,US,Not Specified,US-SA-2022SA162239,-,-
20804779,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus;Product Used For Unknown Indication,Peripheral Artery Occlusion,Serious,Other Outcomes;Hospitalized,Female,-,09-MAY-2022,Expedited,64 YR,98 KG,Novo Nordisk,Healthcare Professional,Not Specified,Simvastatin;Hydrochlorothiazide;Cilostazol;Vitamin B Complex,29-APR-2022,09-MAY-2022,BR,Not Specified,BR-NOVOPROD-915138,-,-
20804312,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus;Product Used For Unknown Indication,Cardio-Respiratory Arrest;Acute Myocardial Infarction,Serious,Other Outcomes,Male,JAN-2021,09-MAY-2022,Expedited,78 YR,105 KG,Novo Nordisk,Healthcare Professional,Not Specified,Metformin Hydrochloride;Empagliflozin;Glimepiride,27-APR-2022,09-MAY-2022,BR,Not Specified,BR-NOVOPROD-914459,-,-
20804311,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Covid-19;Therapeutic Product Ineffective;Hyperglycaemia,Serious,Hospitalized;Other Outcomes,Female,-,09-MAY-2022,Expedited,64 YR,94.7 KG,Novo Nordisk,Healthcare Professional,Not Specified,Metformin,26-APR-2022,09-MAY-2022,BR,Not Specified,BR-NOVOPROD-914061,-,-
20798489,Lantus Solostar;Soliqua 100/33;Toujeo Max;Lantus,Insulin Glargine;Insulin Glargine;Insulin Glargine\Lixisenatide;Insulin Glargine,-,Product Temperature Excursion Issue,Non-Serious,Non-Serious,Not Specified,-,07-MAY-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,03-MAY-2022,07-MAY-2022,US,Not Specified,US-SA-2022SA159303,-,-
20798487,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Prescribing Issue,Non-Serious,Non-Serious,Female,-,07-MAY-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,03-MAY-2022,07-MAY-2022,US,Not Specified,US-SA-2022SA160743,-,-
20471617,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Product Leakage,Non-Serious,Non-Serious,Male,-,07-MAY-2022,Non-Expedited,65 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,28-APR-2022,14-FEB-2022,US,Not Specified,US-SA-2022SA046726,-,-
20791233,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Abnormal,Non-Serious,Non-Serious,Female,-,05-MAY-2022,Non-Expedited,56 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,02-MAY-2022,05-MAY-2022,US,Not Specified,US-SA-2022SA158852,-,-
20788285,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 1 Diabetes Mellitus,Wrong Technique In Device Usage Process;Product Use In Unapproved Indication,Non-Serious,Non-Serious,Male,-,05-MAY-2022,Non-Expedited,67 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,29-APR-2022,05-MAY-2022,US,Not Specified,US-SA-2022SA156184,-,-
20787212,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Male,-,05-MAY-2022,Non-Expedited,68 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Novolog,28-APR-2022,05-MAY-2022,US,Not Specified,US-SA-2022SA155189,-,-
20781365,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Male,-,04-MAY-2022,Non-Expedited,64 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-APR-2022,04-MAY-2022,US,Not Specified,US-SA-2022SA142924,-,-
20781225,Trulicity;Soliqua 100/33,Insulin Glargine\Lixisenatide;Dulaglutide,Type 2 Diabetes Mellitus,Pruritus,Non-Serious,Non-Serious,Male,-,04-MAY-2022,Non-Expedited,Not Specified,Not Specified,Eli Lilly And Co,Consumer,Not Specified,-,29-APR-2022,04-MAY-2022,US,Not Specified,US-ELI_LILLY_AND_COMPANY-US202205000196,-,-
20742611,Soliqua 100/33;Pfizer-Biontech Covid-19 Vaccine;Moderna Covid-19 Vaccine,Elasomeran;Tozinameran;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Deafness;Tinnitus,Serious,Other Outcomes,Female,-,04-MAY-2022,Expedited,72 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,01-MAY-2022,24-APR-2022,US,Not Specified,US-SA-2022SA142853,-,-
20777991,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Urticaria;Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Male,-,03-MAY-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,21-APR-2022,03-MAY-2022,US,Not Specified,US-SA-2022SA144349,-,-
20777366,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Not Specified,-,03-MAY-2022,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-APR-2022,03-MAY-2022,US,Not Specified,US-SA-2022SA152471,-,-
20158313,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Drug Ineffective;Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,03-MAY-2022,Non-Expedited,57 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Prednisone,28-APR-2022,07-DEC-2021,US,Not Specified,US-SA-2021SA404460,-,-
20776667,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Dose Omission Issue,Non-Serious,Non-Serious,Female,22-APR-2022,02-MAY-2022,Non-Expedited,61 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,22-APR-2022,02-MAY-2022,US,Not Specified,US-SA-2022SA146057,-,-
20776308,Toujeo;Soliqua 100/33;Novolog,Insulin Aspart;Insulin Glargine\Lixisenatide;Insulin Glargine,Type 2 Diabetes Mellitus,Headache;Feeling Abnormal;Blood Glucose Fluctuation;Blood Glucose Decreased;Nausea;Cough,Non-Serious,Non-Serious,Female,25-APR-2022,02-MAY-2022,Non-Expedited,77 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin Hydrochloride;Lipitor,25-APR-2022,02-MAY-2022,US,Not Specified,US-SA-2022SA147749,-,-
20776277,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Use Issue,Non-Serious,Non-Serious,Female,-,02-MAY-2022,Non-Expedited,61 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,22-APR-2022,02-MAY-2022,US,Not Specified,US-SA-2022SA146719,-,-
20514889,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Incorrect Dose Administered;Device Leakage;Blood Glucose Increased;Device Defective,Non-Serious,Non-Serious,Male,-,02-MAY-2022,Non-Expedited,82 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Lantus,25-APR-2022,24-FEB-2022,US,Not Specified,US-SA-2022SA054246,-,-
20766139,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Off Label Use,Non-Serious,Non-Serious,Male,-,28-APR-2022,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,25-APR-2022,28-APR-2022,US,Not Specified,US-SA-2022SA151699,-,-
20765997,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Off Label Use,Non-Serious,Non-Serious,Male,-,28-APR-2022,Non-Expedited,67 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,22-APR-2022,28-APR-2022,US,Not Specified,US-SA-2022SA146673,-,-
20765063,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Gastroenteritis Viral;Pyrexia,Non-Serious,Non-Serious,Male,-,28-APR-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-APR-2022,28-APR-2022,US,Not Specified,US-SA-2022SA143796,-,-
20764971,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Device Issue;Device Breakage,Non-Serious,Non-Serious,Male,-,28-APR-2022,Non-Expedited,58 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-APR-2022,28-APR-2022,US,Not Specified,US-SA-2022SA141795,-,-
20764940,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Leakage,Non-Serious,Non-Serious,Female,-,28-APR-2022,Non-Expedited,61 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,20-APR-2022,28-APR-2022,US,Not Specified,US-SA-2022SA061945,-,-
20084913,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Drug Dose Omission By Device;Device Operational Issue,Non-Serious,Non-Serious,Male,10-NOV-2021,28-APR-2022,Non-Expedited,56 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,21-APR-2022,18-NOV-2021,US,Not Specified,US-SA-2021SA381232,-,-
20747574,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Device Issue;Cough;Off Label Use,Non-Serious,Non-Serious,Female,-,25-APR-2022,Non-Expedited,77 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-APR-2022,25-APR-2022,US,Not Specified,US-SA-2022SA142412,-,-
20747508,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Male,-,25-APR-2022,Non-Expedited,72 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-APR-2022,25-APR-2022,US,Not Specified,US-SA-2022SA141559,-,-
20747502,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Dispensing Issue,Non-Serious,Non-Serious,Not Specified,-,25-APR-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,18-APR-2022,25-APR-2022,US,Not Specified,US-SA-2022SA139423,-,-
20739345,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Hypertriglyceridaemia;Pancreatitis Acute,Serious,Life Threatening;Other Outcomes,Male,04-APR-2022,22-APR-2022,Expedited,58 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,19-APR-2022,22-APR-2022,SE,Not Specified,SE-SA-2022SA140507,-,-
20737823,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Pancreatic Carcinoma,Serious,Other Outcomes,Female,-,22-APR-2022,Expedited,68 YR,73.5 KG,Novo Nordisk,Healthcare Professional,Not Specified,"Metformin;Pneumococcal Vaccine, Polyvalent 23;Dapagliflozin",12-APR-2022,22-APR-2022,BR,Not Specified,BR-NOVOPROD-909858,-,-
20731614,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inflammation,Non-Serious,Non-Serious,Female,-,20-APR-2022,Non-Expedited,69 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-APR-2022,20-APR-2022,US,Not Specified,US-SA-2022SA136598,-,-
20717111,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Product Usage Process,Non-Serious,Non-Serious,Male,-,17-APR-2022,Non-Expedited,79 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-APR-2022,17-APR-2022,US,Not Specified,US-SA-2022SA128334,-,-
20653720,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Seasonal Allergy;Incorrect Dose Administered;Device Leakage;Blood Glucose Increased,Non-Serious,Non-Serious,Female,2022,17-APR-2022,Non-Expedited,51 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,12-APR-2022,30-MAR-2022,US,Not Specified,US-SA-2022SA106643,-,-
20708412,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Nervousness;Covid-19,Serious,Hospitalized,Female,-,14-APR-2022,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-APR-2022,14-APR-2022,US,Not Specified,US-SA-2022SA129746,-,-
20545538,Xigduo Xr;Soliqua 100/33;Travatan;Tramadol,Tramadol\Tramadol Hydrochloride;Timolol Maleate\Travoprost;Travoprost;Pregabalin;Insulin Glargine\Lixisenatide;Dapagliflozin Propanediol\Metformin Hydrochloride;Metformin Hydrochloride\Vildagliptin,Blood Glucose Increased;Dacryocystorhinostomy;Diabetes Mellitus;Diabetic Neuropathy;Glaucoma;Product Used For Unknown Indication,Sedation;Weight Decreased;Decreased Appetite;Nausea;Blood Glucose Increased;Blood Pressure Increased;Somnolence;Vomiting,Serious,Other Outcomes;Hospitalized,Female,OCT-2021,14-APR-2022,Expedited,Not Specified,80 KG,Novartis,Consumer,Not Specified,Exforge Hct;Hyaluronate Sodium,11-APR-2022,03-MAR-2022,MX,Not Specified,NVSC2022MX050320,-,-
20012548,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Haematochezia;Nausea;Helicobacter Infection;Vomiting,Serious,Hospitalized,Female,-,14-APR-2022,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,06-APR-2022,29-OCT-2021,GR,Not Specified,GR-NOVOPROD-860281,-,-
20706674,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Sars-Cov-2 Test Positive;Covid-19,Non-Serious,Non-Serious,Female,-,13-APR-2022,Non-Expedited,35 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-APR-2022,13-APR-2022,US,Not Specified,US-SA-2022SA126884,-,-
20703451,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Weight Decreased;Neoplasm Malignant,Serious,Other Outcomes,Male,-,13-APR-2022,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,05-APR-2022,13-APR-2022,IL,Not Specified,IL-NOVOPROD-907900,-,-
20701140,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,-,12-APR-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-APR-2022,12-APR-2022,US,Not Specified,US-SA-2022SA125070,-,-
20701054,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Product Usage Process;Device Leakage;Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Male,-,12-APR-2022,Non-Expedited,64 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,05-APR-2022,12-APR-2022,US,Not Specified,US-SA-2022SA120018,-,-
20447325,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Thyroid Disorder;Type 1 Diabetes Mellitus,Hypoglycaemia;Device Loosening;Device Issue,Serious,Other Outcomes,Female,NOV-2021,11-APR-2022,30-DAY,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,Jardiance;Levothyroxine Sodium,31-MAR-2022,09-FEB-2022,BR,Not Specified,BR-NOVOPROD-888269,-,-
20689675,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus;Product Used For Unknown Indication,Hypoglycaemia;Aphasia;Asthenia;Ischaemic Stroke,Serious,Hospitalized,Male,29-MAY-2021,08-APR-2022,Expedited,70 YR,71 KG,Novo Nordisk,Healthcare Professional,Not Specified,Metformin Hydrochloride;Aspirin,30-MAR-2022,08-APR-2022,IT,Not Specified,IT-NOVOPROD-904787,-,-
20686599,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 1 Diabetes Mellitus,Corrective Lens User;Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Female,-,07-APR-2022,Non-Expedited,57 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,31-MAR-2022,07-APR-2022,US,Not Specified,US-SA-2022SA115415,-,-
20681191,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Abnormal;Incorrect Dose Administered,Non-Serious,Non-Serious,Male,22-MAR-2022,06-APR-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Humalog,30-MAR-2022,06-APR-2022,US,Not Specified,US-SA-2022SA113611,-,-
20671342,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Dose Omission Issue,Non-Serious,Non-Serious,Female,-,04-APR-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-MAR-2022,04-APR-2022,US,Not Specified,US-SA-2022SA111671,-,-
20671228,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Intentional Product Misuse,Non-Serious,Non-Serious,Male,-,04-APR-2022,Non-Expedited,72 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,31-MAR-2022,04-APR-2022,US,Not Specified,US-SA-2022SA114903,-,-
20667359,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Suicide Attempt;Hypoglycaemia;Intentional Overdose,Serious,Hospitalized,Male,03-MAR-2022,04-APR-2022,Expedited,47 YR,80 KG,Novo Nordisk,Healthcare Professional,Not Specified,-,24-MAR-2022,04-APR-2022,JP,Not Specified,JP-NOVOPROD-898211,-,-
20667265,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error;Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Male,-,04-APR-2022,Non-Expedited,60 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-MAR-2022,04-APR-2022,US,Not Specified,US-SA-2022SA109126,-,-
20667235,Soliqua 100/33;Trulicity,Dulaglutide;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Pruritus,Non-Serious,Non-Serious,Male,-,04-APR-2022,Non-Expedited,67 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-MAR-2022,04-APR-2022,US,Not Specified,US-SA-2022SA112402,-,-
20667210,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Product Usage Process,Non-Serious,Non-Serious,Female,-,04-APR-2022,Non-Expedited,85 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,29-MAR-2022,04-APR-2022,US,Not Specified,US-SA-2022SA111553,-,-
20666508,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Incorrect Dose Administered By Device,Non-Serious,Non-Serious,Female,-,03-APR-2022,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-MAR-2022,03-APR-2022,US,Not Specified,US-SA-2022SA108423,-,-
20666499,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Vision Blurred,Non-Serious,Non-Serious,Female,-,03-APR-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-MAR-2022,03-APR-2022,US,Not Specified,US-SA-2022SA112413,-,-
20666356,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Female,-,03-APR-2022,Non-Expedited,60 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,24-MAR-2022,03-APR-2022,US,Not Specified,US-SA-2022SA105848,-,-
20666296,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Weight Increased,Non-Serious,Non-Serious,Not Specified,-,03-APR-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,24-MAR-2022,03-APR-2022,US,Not Specified,US-SA-2022SA104336,-,-
20448192,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Thyroid Cancer,Serious,Other Outcomes,Female,-,03-APR-2022,Expedited,57 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,27-MAR-2022,09-FEB-2022,EG,Not Specified,EG-SA-2022SA035462,-,-
20661467,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,General Physical Health Deterioration;Loss Of Consciousness,Serious,Other Outcomes,Female,-,01-APR-2022,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,22-MAR-2022,01-APR-2022,UA,Not Specified,UA-NOVOPROD-904052,-,-
20659096,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Female,-,31-MAR-2022,Non-Expedited,54 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,25-MAR-2022,31-MAR-2022,US,Not Specified,US-SA-2022SA107147,-,-
20655004,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Urinary Tract Infection;Cystitis;Back Pain,Non-Serious,Non-Serious,Female,-,30-MAR-2022,Non-Expedited,69 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin,21-MAR-2022,30-MAR-2022,US,Not Specified,US-SA-2022SA097842,-,-
20653626,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Fluctuation;Vomiting;Nausea,Non-Serious,Non-Serious,Female,-,30-MAR-2022,Non-Expedited,42 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,21-MAR-2022,30-MAR-2022,US,Not Specified,US-SA-2022SA099592,-,-
20640460,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Difficult To Use;Injection Site Haemorrhage,Non-Serious,Non-Serious,Female,-,30-MAR-2022,Non-Expedited,73 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,21-MAR-2022,27-MAR-2022,US,Not Specified,US-SA-2021SA330738,-,-
20650221,Soliqua 100/33,Insulin Glargine\Lixisenatide,Hyperglycaemia,Candida Infection;Swollen Tongue,Non-Serious,Non-Serious,Female,-,29-MAR-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,16-MAR-2022,29-MAR-2022,US,Not Specified,US-SA-2022SA095318,-,-
20090829,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Communication Disorder;Brain Injury,Serious,Other Outcomes,Male,-,29-MAR-2022,Expedited,64 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,22-MAR-2022,19-NOV-2021,US,Not Specified,US-SA-2021SA383859,-,-
20641458,Victoza,Liraglutide;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Palpitations;Chest Discomfort;Weight Increased;Asthma;Peripheral Swelling,Serious,Hospitalized,Female,07-MAR-2022,28-MAR-2022,Expedited,58 YR,91 KG,Novo Nordisk,Healthcare Professional,Not Specified,Linagliptin,17-MAR-2022,28-MAR-2022,CN,Not Specified,CN-NOVOPROD-902114,-,-
20583721,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,28-MAR-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,15-MAR-2022,11-MAR-2022,US,Not Specified,US-SA-2022SA077770,-,-
20640626,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Therapy Change,Non-Serious,Non-Serious,Female,-,27-MAR-2022,Non-Expedited,71 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-MAR-2022,27-MAR-2022,US,Not Specified,US-SA-2022SA097365,-,-
20311666,Soliqua 100/33,Insulin Glargine\Lixisenatide,Product Used For Unknown Indication,Dizziness;Drug Ineffective;Emotional Distress;Feeling Abnormal;Hyperglycaemia,Serious,Hospitalized,Male,-,27-MAR-2022,Expedited,65 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,21-MAR-2022,08-JAN-2022,CA,Not Specified,CA-SA-2021SA436532,-,-
20639512,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Road Traffic Accident,Non-Serious,Non-Serious,Female,-,26-MAR-2022,Non-Expedited,80 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-MAR-2022,26-MAR-2022,US,Not Specified,US-SA-2022SA089786,-,-
20624312,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Glycosylated Haemoglobin Increased;Multiple Use Of Single-Use Product,Non-Serious,Non-Serious,Female,-,26-MAR-2022,Non-Expedited,42 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-MAR-2022,22-MAR-2022,US,Not Specified,US-SA-2022SA090883,-,-
20455596,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,No Adverse Event,Non-Serious,Non-Serious,Female,-,24-MAR-2022,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Novorapid;Lantus,02-FEB-2022,10-FEB-2022,DE,Not Specified,DE-SA-2022SA038910,-,-
20580878,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Dyspnoea,Serious,Died,Female,16-FEB-2022,23-MAR-2022,Expedited,64 YR,120 KG,Novo Nordisk,Consumer,Not Specified,-,12-MAR-2022,11-MAR-2022,PK,Not Specified,PK-NOVOPROD-897679,-,-
20624264,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Extra Dose Administered,Non-Serious,Non-Serious,Female,-,22-MAR-2022,Non-Expedited,72 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-MAR-2022,22-MAR-2022,US,Not Specified,US-SA-2022SA088680,-,-
20624190,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Male,-,22-MAR-2022,Non-Expedited,61 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-MAR-2022,22-MAR-2022,US,Not Specified,US-SA-2022SA089533,-,-
20624111,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,22-MAR-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,10-MAR-2022,22-MAR-2022,US,Not Specified,US-SA-2022SA085813,-,-
20619595,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Benign Abdominal Neoplasm;Poor Quality Product Administered,Serious,Hospitalized,Female,-,22-MAR-2022,Expedited,71 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-MAR-2022,22-MAR-2022,US,Not Specified,US-SA-2022SA088791,-,-
20619425,Soliqua 100/33,Insulin Glargine\Lixisenatide;Lixisenatide,Diabetes Mellitus,Diabetic Ketoacidosis,Serious,Other Outcomes;Hospitalized,Not Specified,-,22-MAR-2022,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,10-MAR-2022,22-MAR-2022,US,Not Specified,US-SA-2022SA088698,-,-
20616140,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Male,-,21-MAR-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-MAR-2022,21-MAR-2022,US,Not Specified,US-SA-2022SA083469,-,-
20607233,Soliqua 100/33;Clopidogrel,Clopidogrel Bisulfate;Insulin Glargine\Lixisenatide,Diabetes Mellitus,Condition Aggravated;Intermittent Claudication;Arthralgia;Peripheral Arterial Occlusive Disease;Pain In Extremity,Serious,Hospitalized,Male,-,17-MAR-2022,Expedited,47 YR,96 KG,Sanofi Aventis,Consumer,Not Specified,-,06-MAR-2022,17-MAR-2022,SA,Not Specified,SA-SA-2022SA080443,-,-
20605229,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Dose Omission Issue,Non-Serious,Non-Serious,Female,-,17-MAR-2022,Non-Expedited,57 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-MAR-2022,17-MAR-2022,US,Not Specified,US-SA-2022SA083043,-,-
20575250,-,Insulin Glargine\Lixisenatide,Diabetes Mellitus;Dyslipidaemia,Hypoglycaemia,Non-Serious,Non-Serious,Male,-,17-MAR-2022,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Atorvastatin;Metformin,01-MAR-2022,10-MAR-2022,RO,Not Specified,RO-SA-2022SA059719,-,-
20603956,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Dose Omission Issue,Non-Serious,Non-Serious,Female,-,16-MAR-2022,Non-Expedited,68 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-MAR-2022,16-MAR-2022,US,Not Specified,US-SA-2022SA080597,-,-
20599306,Soliqua 100/33;Lantus;Toujeo,Insulin Glargine;Insulin Glargine;Insulin Glargine\Lixisenatide,Immunisation,Product Storage Error;Product Use In Unapproved Indication,Non-Serious,Non-Serious,Not Specified,-,15-MAR-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,07-MAR-2022,15-MAR-2022,US,Not Specified,US-SA-2022SA079934,-,-
20599123,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Memory Impairment;Cataract Operation,Non-Serious,Non-Serious,Female,-,15-MAR-2022,Non-Expedited,82 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,04-MAR-2022,15-MAR-2022,US,Not Specified,US-SA-2022SA079029,-,-
20362883,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Injection Site Discomfort;Urine Odour Abnormal;Off Label Use;Faeces Hard,Non-Serious,Non-Serious,Female,2021,15-MAR-2022,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-MAR-2022,21-JAN-2022,US,Not Specified,US-SA-2022SA017048,-,-
20590937,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,14-MAR-2022,Non-Expedited,62 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-MAR-2022,14-MAR-2022,US,Not Specified,US-SA-2022SA080805,-,-
20590933,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Male,-,14-MAR-2022,Non-Expedited,44 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-MAR-2022,14-MAR-2022,US,Not Specified,US-SA-2022SA079303,-,-
20590866,Fluzone Quadrivalent Nos;Tubersol;Apidra Solostar;Elitek;Lantus Solostar;Admelog;Soliqua 100/33;Flublok Quadrivalent Nos;Lantus;Apidra,Insulin Glulisine;Insulin Glargine;Influenza Virus Vaccine;Insulin Glargine\Lixisenatide;Insulin Glargine;Insulin Lispro;Rasburicase;Insulin Glulisine;Tuberculin Purified Protein Derivative;Influenza A Virus A/California/7/2009 X-179a (H1n1) Antigen (Formaldehyde Inactivated)\Influenza A Virus A/Texas/50/2012 X-223a (H3n2) Antigen (Formaldehyde Inactivated)\Influenza B Virus B/Brisbane/60/2008 Antigen (Formaldehyde Inactivated)\Influenza B Virus B/Massachusetts/2/2012 Antigen (Formalde,-,Product Temperature Excursion Issue,Non-Serious,Non-Serious,Not Specified,-,14-MAR-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,04-MAR-2022,14-MAR-2022,US,Not Specified,US-SA-2022SA076880,-,-
20590854,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment;Product Use Issue,Non-Serious,Non-Serious,Female,2021,14-MAR-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Sodium,04-MAR-2022,14-MAR-2022,US,Not Specified,US-SA-2022SA077819,-,-
20590844,Soliqua 100/33;Apidra;Lantus Solostar;Tubersol;Lantus;Admelog;Apidra Solostar;Flublok;Fluzone Quadrivalent Nos;Elitek,Rasburicase;Influenza A Virus A/California/7/2009 X-179a (H1n1) Antigen (Formaldehyde Inactivated)\Influenza A Virus A/Texas/50/2012 X-223a (H3n2) Antigen (Formaldehyde Inactivated)\Influenza B Virus B/Brisbane/60/2008 Antigen (Formaldehyde Inactivated)\Influenza B Virus B/Massachusetts/2/2012 Antigen (Formalde;Influenza A Virus A/California/7/2009 (H1n1) Recombinant Hemagglutinin Antigen\Influenza A Virus A/Victoria/361/2011 (H3n2) Recombinant Hemagglutinin Antigen\Influenza B Virus B/Wisconsin/1/2010 Recombinant Hemagglutinin Antigen;Insulin Glulisine;Insulin Lispro;Insulin Glargine;Tuberculin Purified Protein Derivative;Insulin Glargine;Insulin Glulisine;Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,14-MAR-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,04-MAR-2022,14-MAR-2022,US,Not Specified,US-SA-2022SA078188,-,-
20360730,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Issue;Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,14-MAR-2022,Non-Expedited,55 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,01-MAR-2022,21-JAN-2022,US,Not Specified,US-SA-2022SA015192,-,-
20582555,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Hospitalisation;Weight Increased;Glycosylated Haemoglobin Increased;Hypoglycaemia,Serious,Hospitalized,Female,2021,11-MAR-2022,Expedited,63 YR,89 KG,Sanofi Aventis,Healthcare Professional,Not Specified,Empagliflozin;Gliclazide;Metformin,08-MAR-2022,11-MAR-2022,SK,Not Specified,SK-SA-2022SA066564,-,-
20557013,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Ischaemic Stroke;Cerebrovascular Accident,Serious,Other Outcomes,Not Specified,08-MAR-2021,10-MAR-2022,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,28-FEB-2022,07-MAR-2022,MX,Not Specified,MX-SA-2021SA121248,-,-
20569862,Soliqua 100/33;Toujeo,Insulin Glargine;Insulin Glargine\Lixisenatide,-,Product Temperature Excursion Issue,Non-Serious,Non-Serious,Not Specified,-,09-MAR-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,01-MAR-2022,09-MAR-2022,US,Not Specified,US-SA-2022SA073335,-,-
20558770,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Cough;Feeling Jittery;Dizziness;Cardiac Disorder;Fatigue,Non-Serious,Non-Serious,Female,-,07-MAR-2022,Non-Expedited,78 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-FEB-2022,07-MAR-2022,US,Not Specified,US-SA-2022SA070013,-,-
20558707,Lantus;Soliqua 100/33;Toujeo;Admelog,Insulin Lispro;Insulin Glargine;Insulin Glargine\Lixisenatide;Insulin Glargine,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,07-MAR-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,25-FEB-2022,07-MAR-2022,US,Not Specified,US-SA-2022SA067850,-,-
20558291,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injection Site Pain,Non-Serious,Non-Serious,Male,-,07-MAR-2022,Non-Expedited,55 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-FEB-2022,07-MAR-2022,US,Not Specified,US-SA-2022SA068892,-,-
20558287,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Intentional Product Misuse,Non-Serious,Non-Serious,Male,-,07-MAR-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-FEB-2022,07-MAR-2022,US,Not Specified,US-SA-2022SA069269,-,-
20557386,Steglatro,Ertugliflozin Pidolate;Metformin Hydrochloride\Pioglitazone Hydrochloride,Blood Glucose Abnormal,Hospitalisation;Ketosis,Serious,Hospitalized,Male,21-FEB-2022,07-MAR-2022,Expedited,40 YR,Not Specified,Merck,Healthcare Professional,Not Specified,-,28-FEB-2022,07-MAR-2022,CN,Not Specified,CN-009507513-2203CHN001329,-,-
20518441,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Ill-Defined Disorder;Oedema Peripheral;Device Operational Issue;Injection Site Pain;Peripheral Swelling;Diabetic Neuropathy;Pain In Extremity,Non-Serious,Non-Serious,Female,-,07-MAR-2022,Non-Expedited,69 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,24-FEB-2022,25-FEB-2022,US,Not Specified,US-SA-2022SA055978,-,-
20561646,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Joint Swelling;Dizziness;Somnolence;Confusional State;Visual Impairment;Asthenia,Serious,Disabled,Male,02-MAR-2022,06-MAR-2022,Direct,72 DAY,1 LB,Fda-Ctu,Consumer,Not Specified,Metformin;Farxiga;Tamsulosin;Unspecified Ingredient,-,06-MAR-2022,Not Specified,Y,-,-,-
20553002,Admelog;Toujeo Max;Toujeo;Soliqua 100/33;Lantus Solostar,Insulin Glargine;Insulin Glargine\Lixisenatide;Insulin Glargine;Insulin Glargine;Insulin Lispro,-,Product Temperature Excursion Issue,Non-Serious,Non-Serious,Not Specified,-,04-MAR-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,25-FEB-2022,04-MAR-2022,US,Not Specified,US-SA-2022SA067657,-,-
20551430,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error;Cerebrovascular Accident,Serious,Other Outcomes,Male,-,04-MAR-2022,Expedited,69 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,25-FEB-2022,04-MAR-2022,US,Not Specified,US-SA-2022SA066774,-,-
20543921,Ozempic;Soliqua 100/33,Insulin Glargine\Lixisenatide;Semaglutide,Type 2 Diabetes Mellitus,Vascular Graft;Muscle Spasms;Constipation;Abdominal Discomfort,Serious,Hospitalized,Male,DEC-2021,03-MAR-2022,Expedited,77 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,22-FEB-2022,03-MAR-2022,US,Not Specified,US-NOVOPROD-896008,-,-
20543880,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Loss Of Consciousness,Serious,Other Outcomes,Male,-,03-MAR-2022,Expedited,7 DEC,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,22-FEB-2022,03-MAR-2022,JP,Not Specified,JP-NOVOPROD-887232,-,-
20535428,Fluzone High-Dose Quadrivalent;Soliqua 100/33;Toujeo;Fluzone Quadrivalent Nos;Lantus;Admelog,Insulin Lispro;Insulin Glargine;Influenza A Virus A/California/7/2009 X-179a (H1n1) Antigen (Formaldehyde Inactivated)\Influenza A Virus A/Texas/50/2012 X-223a (H3n2) Antigen (Formaldehyde Inactivated)\Influenza B Virus B/Brisbane/60/2008 Antigen (Formaldehyde Inactivated)\Influenza B Virus B/Massachusetts/2/2012 Antigen (Formalde;Insulin Glargine;Insulin Glargine\Lixisenatide;Influenza A Virus A/Michigan/45/2015 X-275 (H1n1) Antigen (Formaldehyde Inactivated)\Influenza A Virus A/Singapore/Infimh-16-0019/2016 Ivr-186 (H3n2) Antigen (Formaldehyde Inactivated)\Influenza B Virus B/Maryland/15/2016 Bx-69a Antigen (Formaldehyde Inactivated)\Influenza B Virus B/Phuket/3073/2013,-,Product Temperature Excursion Issue,Non-Serious,Non-Serious,Not Specified,-,02-MAR-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,23-FEB-2022,02-MAR-2022,US,Not Specified,US-SA-2022SA064992,-,-
20534562,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,02-MAR-2022,Non-Expedited,76 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Lantus,24-FEB-2022,02-MAR-2022,US,Not Specified,US-SA-2022SA062228,-,-
20532265,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Temperature Excursion Issue,Non-Serious,Non-Serious,Not Specified,-,01-MAR-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,22-FEB-2022,01-MAR-2022,US,Not Specified,US-SA-2022SA063748,-,-
20523413,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Use Issue;Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Male,-,28-FEB-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,16-FEB-2022,28-FEB-2022,US,Not Specified,US-SA-2022SA061423,-,-
20523296,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Biliary Dyskinesia,Non-Serious,Non-Serious,Male,-,27-FEB-2022,Non-Expedited,50 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,15-FEB-2022,27-FEB-2022,US,Not Specified,US-SA-2022SA057102,-,-
20484891,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Issue;Blood Glucose Increased;Product Dose Omission Issue,Non-Serious,Non-Serious,Female,-,23-FEB-2022,Non-Expedited,67 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Novolog,09-FEB-2022,17-FEB-2022,US,Not Specified,US-SA-2022SA042076,-,-
18679915,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Incorrect Dose Administered By Device;Device Leakage;Blood Glucose Increased,Serious,Other Outcomes,Female,21-DEC-2020,23-FEB-2022,30-DAY,70 YR,64 KG,Novo Nordisk,Consumer,Not Specified,-,15-FEB-2021,29-DEC-2020,MX,Not Specified,MX-NOVOPROD-777114,-,-
20500661,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,22-FEB-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-FEB-2022,22-FEB-2022,US,Not Specified,US-SA-2022SA052046,-,-
20500623,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Hyperglycaemia,Non-Serious,Non-Serious,Male,-,22-FEB-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,14-FEB-2022,22-FEB-2022,US,Not Specified,US-SA-2022SA054902,-,-
18411709,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Hypertension;Type 2 Diabetes Mellitus,Hyperglycaemia;Device Defective;Device Issue,Serious,Other Outcomes,Female,08-OCT-2020,22-FEB-2022,30-DAY,81 YR,62 KG,Novo Nordisk,Consumer,Not Specified,Diltiazem;Glimepiride,08-JAN-2021,21-OCT-2020,BR,Not Specified,BR-NOVOPROD-760551,-,-
18379344,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Device Failure;Drug Ineffective;Device Malfunction;Device Occlusion;Blood Glucose Increased,Serious,Hospitalized,Male,30-SEP-2020,22-FEB-2022,30-DAY,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,06-JAN-2021,13-OCT-2020,BR,Not Specified,BR-NOVOPROD-758296,-,-
20495611,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,21-FEB-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,14-FEB-2022,21-FEB-2022,US,Not Specified,US-SA-2022SA051306,-,-
20495361,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Impaired Work Ability;Pain In Extremity;Oedema Peripheral;Peripheral Swelling;Injection Site Pain;Spinal Cord Disorder;Diabetic Neuropathy,Serious,Other Outcomes;Disabled,Female,-,21-FEB-2022,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-FEB-2022,21-FEB-2022,US,Not Specified,US-SA-2022SA051792,-,-
20494099,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Temperature Excursion Issue,Non-Serious,Non-Serious,Not Specified,-,21-FEB-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-FEB-2022,21-FEB-2022,US,Not Specified,US-SA-2022SA048318,-,-
20477045,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,21-FEB-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-FEB-2022,15-FEB-2022,US,Not Specified,US-SA-2022SA037414,-,-
20492486,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Male,-,19-FEB-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-FEB-2022,19-FEB-2022,US,Not Specified,US-SA-2022SA046590,-,-
20488772,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Somnolence,Non-Serious,Non-Serious,Female,-,18-FEB-2022,Non-Expedited,68 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-FEB-2022,18-FEB-2022,US,Not Specified,US-SA-2022SA041523,-,-
20488555,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Gastric Infection,Serious,Other Outcomes;Hospitalized,Male,08-FEB-2022,18-FEB-2022,Expedited,83 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,10-FEB-2022,18-FEB-2022,CO,Not Specified,CO-SA-2022SA050117,-,-
20484971,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Use Issue;Blood Glucose Increased;Wrong Technique In Product Usage Process,Non-Serious,Non-Serious,Male,-,17-FEB-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-FEB-2022,17-FEB-2022,US,Not Specified,US-SA-2022SA046281,-,-
20484933,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,17-FEB-2022,Non-Expedited,79 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-FEB-2022,17-FEB-2022,US,Not Specified,US-SA-2022SA048121,-,-
20478743,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Feeling Abnormal,Non-Serious,Non-Serious,Female,-,16-FEB-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-FEB-2022,16-FEB-2022,US,Not Specified,US-SA-2022SA048330,-,-
20477936,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Knee Operation;Hospitalisation,Non-Serious,Non-Serious,Male,-,16-FEB-2022,Non-Expedited,74 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-FEB-2022,16-FEB-2022,US,Not Specified,US-SA-2022SA046176,-,-
20476848,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Product Usage Process,Non-Serious,Non-Serious,Female,-,15-FEB-2022,Non-Expedited,82 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-FEB-2022,15-FEB-2022,US,Not Specified,US-SA-2022SA045037,-,-
20476782,Soliqua 100/33,Insulin Glargine\Lixisenatide,Product Used For Unknown Indication,Hypoacusis,Non-Serious,Non-Serious,Male,-,15-FEB-2022,Non-Expedited,86 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,07-FEB-2022,15-FEB-2022,US,Not Specified,US-SA-2022SA045158,-,-
20471556,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus;Lung Disorder,Eye Disorder,Non-Serious,Non-Serious,Female,-,14-FEB-2022,Non-Expedited,72 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Prednisone,04-FEB-2022,14-FEB-2022,US,Not Specified,US-SA-2022SA043108,-,-
20471504,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Male,-,14-FEB-2022,Non-Expedited,50 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,03-FEB-2022,14-FEB-2022,US,Not Specified,US-SA-2022SA040677,-,-
20471479,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Expired Product Administered,Non-Serious,Non-Serious,Not Specified,-,14-FEB-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,03-FEB-2022,14-FEB-2022,US,Not Specified,US-SA-2022SA041232,-,-
20471428,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 1 Diabetes Mellitus,Product Use In Unapproved Indication;Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Female,-,14-FEB-2022,Non-Expedited,43 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,03-FEB-2022,14-FEB-2022,US,Not Specified,US-SA-2022SA038621,-,-
20465487,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Product Dose Omission Issue,Non-Serious,Non-Serious,Male,-,12-FEB-2022,Non-Expedited,67 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,01-FEB-2022,12-FEB-2022,US,Not Specified,US-SA-2022SA036578,-,-
20458588,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Persecutory Delusion,Serious,Other Outcomes,Female,-,11-FEB-2022,Expedited,76 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Itopride;Duloxetine;Arcoxia,03-FEB-2022,11-FEB-2022,MX,Not Specified,MX-NOVOPROD-889139,-,-
20458333,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Dose Omission Issue,Non-Serious,Non-Serious,Female,-,11-FEB-2022,Non-Expedited,45 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,31-JAN-2022,11-FEB-2022,US,Not Specified,US-SA-2022SA035307,-,-
20452248,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Pneumonia;Myocardial Infarction,Serious,Died;Other Outcomes;Hospitalized,Female,25-JAN-2022,10-FEB-2022,Expedited,67 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,31-JAN-2022,10-FEB-2022,CO,Not Specified,CO-SA-2022SA036291,-,-
20444778,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Temperature Excursion Issue,Non-Serious,Non-Serious,Not Specified,-,08-FEB-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,31-JAN-2022,08-FEB-2022,US,Not Specified,US-SA-2022SA035581,-,-
20442868,-,Insulin Glargine\Lixisenatide,-,Diabetic Ketoacidosis;Epididymitis;Blood Glucose Increased,Serious,Hospitalized;Other Outcomes,Male,17-JAN-2019,08-FEB-2022,Expedited,34 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Lantus,22-JAN-2019,08-FEB-2022,US,Not Specified,US-SA-2019SA023637,-,-
20440696,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Dose Omission Issue,Non-Serious,Non-Serious,Female,26-JAN-2022,07-FEB-2022,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-JAN-2022,07-FEB-2022,US,Not Specified,US-SA-2022SA030771,-,-
20437010,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Weight Increased,Non-Serious,Non-Serious,Female,-,07-FEB-2022,Non-Expedited,52 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,28-JAN-2022,07-FEB-2022,US,Not Specified,US-SA-2022SA034593,-,-
20435819,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Bundle Branch Block;Flatulence;Nausea;Myocardial Infarction;Abdominal Pain Lower,Serious,Hospitalized,Female,26-NOV-2021,07-FEB-2022,Expedited,70 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,28-JAN-2022,07-FEB-2022,US,Not Specified,US-NOVOPROD-888250,-,-
20434301,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Dose Omission Issue,Non-Serious,Non-Serious,Male,-,06-FEB-2022,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-JAN-2022,06-FEB-2022,US,Not Specified,US-SA-2022SA031226,-,-
20433217,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Injection Site Erythema;Injection Site Pain,Non-Serious,Non-Serious,Male,2021,05-FEB-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,25-JAN-2022,05-FEB-2022,US,Not Specified,US-SA-2022SA031623,-,-
20433032,Toujeo Max;Lantus Solostar;Toujeo;Praluent;Lantus;Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Glargine;Alirocumab;Insulin Glargine;Insulin Glargine;Insulin Glargine,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,05-FEB-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,24-JAN-2022,05-FEB-2022,US,Not Specified,US-SA-2022SA027926,-,-
20432919,Lantus;Lantus Solostar;Praluent;Soliqua 100/33;Toujeo;Toujeo Max,Insulin Glargine;Insulin Glargine;Insulin Glargine\Lixisenatide;Alirocumab;Insulin Glargine;Insulin Glargine,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,05-FEB-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,24-JAN-2022,05-FEB-2022,US,Not Specified,US-SA-2022SA030126,-,-
20429836,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Blood Glucose Increased;Parathyroid Hyperplasia;Dizziness,Serious,Other Outcomes,Female,-,04-FEB-2022,Expedited,77 YR,99.2 KG,Novo Nordisk,Healthcare Professional,Not Specified,Levothyroxine;Metformin Hydrochloride;Gliclazide,28-OCT-2020,04-FEB-2022,BR,Not Specified,BR-NOVOPROD-803898,-,-
20428339,Xultophy 100/3.6;Tahor,Atorvastatin Calcium;Polyethylene Glycol;Polyethylene Glycols;Aspirin;Potassium Chloride;Insulin Degludec\Liraglutide;Indapamide\Perindopril;Furosemide,Constipation;Diabetes Mellitus;Hypercholesterolaemia;Hypertension;Hypokalaemia;Oedema;Prophylaxis,Pancreatic Carcinoma,Serious,Life Threatening;Other Outcomes,Male,JUL-2019,04-FEB-2022,Expedited,74 YR,Not Specified,Aurobindo,Healthcare Professional,Not Specified,-,14-APR-2021,04-FEB-2022,FR,Not Specified,FR-AUROBINDO-AUR-APL-2019-053451,-,-
20166744,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Diabetic Retinopathy;Drug Titration Error;Hyperglycaemia;Cataract Operation,Non-Serious,Non-Serious,Female,23-SEP-2021,04-FEB-2022,Expedited,58 YR,58 KG,Novo Nordisk,Healthcare Professional,Not Specified,Rosuvastatin;Cholecalciferol;Hydrochlorothiazide;Olmesartan;Dapagliflozin Propanediol\Metformin Hydrochloride;Propranolol;Haloperidol,19-JAN-2022,09-DEC-2021,BR,Not Specified,BR-NOVOPROD-873174,-,-
20420767,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Glaucoma;Blindness Unilateral,Serious,Other Outcomes,Male,-,03-FEB-2022,Expedited,67 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,25-JAN-2022,03-FEB-2022,US,Not Specified,US-SA-2022SA028975,-,-
20409926,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Female,-,01-FEB-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-JAN-2022,01-FEB-2022,US,Not Specified,US-SA-2022SA022000,-,-
20408151,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Hospitalisation,Serious,Hospitalized,Female,-,01-FEB-2022,Expedited,49 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,21-JAN-2022,01-FEB-2022,JP,Not Specified,JP-NOVOPROD-886151,-,-
20406632,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,31-JAN-2022,Non-Expedited,72 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-JAN-2022,31-JAN-2022,US,Not Specified,US-SA-2022SA025065,-,-
20406509,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Eye Disorder,Non-Serious,Non-Serious,Female,-,31-JAN-2022,Non-Expedited,71 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-JAN-2022,31-JAN-2022,US,Not Specified,US-SA-2022SA024863,-,-
20394727,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Male,-,30-JAN-2022,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-JAN-2022,30-JAN-2022,US,Not Specified,US-SA-2022SA022173,-,-
20327675,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Weight Decreased;Diabetic Ketoacidosis;Hyperglycaemic Unconsciousness;Diabetes Mellitus Inadequate Control,Serious,Other Outcomes;Hospitalized,Female,27-DEC-2021,28-JAN-2022,Expedited,42 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Dapagliflozin,05-JAN-2022,12-JAN-2022,CO,Not Specified,CO-SA-2022SA008100,-,-
20380789,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,27-JAN-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,18-JAN-2022,27-JAN-2022,US,Not Specified,US-SA-2022SA019257,-,-
20378274,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Vomiting,Serious,Hospitalized,Male,-,26-JAN-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,18-JAN-2022,26-JAN-2022,US,Not Specified,US-SA-2022SA019835,-,-
20337677,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Decreased;Wrong Technique In Device Usage Process;Dizziness,Non-Serious,Non-Serious,Male,06-JAN-2022,25-JAN-2022,Non-Expedited,74 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,06-JAN-2022,14-JAN-2022,US,Not Specified,US-SA-2022SA007381,-,-
20308265,Soliqua 100/33,Insulin Glargine\Lixisenatide,Hypertension;Type 2 Diabetes Mellitus,Rash Macular;Swelling Face;Off Label Use;Angioedema,Serious,Other Outcomes,Female,19-DEC-2021,25-JAN-2022,Expedited,47 YR,73 KG,Sanofi Aventis,Healthcare Professional,Not Specified,Ceftriaxone;Enalapril;.Alpha.-Lipoic Acid;Bisoprolol;Indapamide;Choline Alfoscerate;Chloropyramine,28-DEC-2021,07-JAN-2022,RU,Not Specified,RU-SA-2021SA434200,-,-
20370931,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Therapeutic Response Decreased;Blood Glucose Increased;Blood Glucose Decreased;Vomiting;Fatigue,Non-Serious,Non-Serious,Male,-,24-JAN-2022,Non-Expedited,73 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-JAN-2022,24-JAN-2022,US,Not Specified,US-SA-2022SA018298,-,-
20368258,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 1 Diabetes Mellitus,Hepatitis Acute;Off Label Use;Drug-Induced Liver Injury,Serious,Hospitalized;Life Threatening,Male,22-DEC-2021,24-JAN-2022,Expedited,38 YR,42 KG,Novo Nordisk,Healthcare Professional,Not Specified,Rosuvastatin;Metformin Hydrochloride,13-JAN-2022,24-JAN-2022,JP,Not Specified,JP-NOVOPROD-880801,-,-
20368257,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Vomiting;Dizziness;Off Label Use,Serious,Hospitalized,Male,18-DEC-2021,24-JAN-2022,Expedited,61 YR,56.6 KG,Novo Nordisk,Healthcare Professional,Not Specified,Miglitol;Metformin Hydrochloride\Vildagliptin;Metformin Hydrochloride;Amaryl,13-JAN-2022,24-JAN-2022,JP,Not Specified,JP-NOVOPROD-878732,-,-
20365179,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Taste Disorder,Non-Serious,Non-Serious,Male,-,22-JAN-2022,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,12-JAN-2022,22-JAN-2022,US,Not Specified,US-SA-2022SA018630,-,-
20357052,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Product Administered,Non-Serious,Non-Serious,Male,-,20-JAN-2022,Non-Expedited,59 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-JAN-2022,20-JAN-2022,US,Not Specified,US-SA-2022SA014374,-,-
20350646,Soliqua 100/33;Ozempic,Insulin Glargine\Lixisenatide;Semaglutide,Type 2 Diabetes Mellitus,Abdominal Discomfort;Muscle Spasms;Vascular Graft;Constipation,Serious,Hospitalized,Male,DEC-2021,19-JAN-2022,Non-Expedited,77 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-JAN-2022,19-JAN-2022,US,Not Specified,US-SA-2022SA012334,-,-
20345881,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Accidental Exposure To Product,Non-Serious,Non-Serious,Male,-,18-JAN-2022,Non-Expedited,64 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-JAN-2022,18-JAN-2022,US,Not Specified,US-SA-2022SA012549,-,-
20341265,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Male,24-DEC-2021,17-JAN-2022,Non-Expedited,48 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-JAN-2022,17-JAN-2022,US,Not Specified,US-SA-2022SA009185,-,-
20340693,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,17-JAN-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,07-JAN-2022,17-JAN-2022,US,Not Specified,US-SA-2022SA008988,-,-
20337795,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Abnormal;Asthenia,Non-Serious,Non-Serious,Male,06-JAN-2022,14-JAN-2022,Non-Expedited,73 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-JAN-2022,14-JAN-2022,US,Not Specified,US-SA-2022SA008287,-,-
20337484,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,-,14-JAN-2022,Non-Expedited,86 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,03-JAN-2022,14-JAN-2022,US,Not Specified,US-SA-2022SA003939,-,-
20337200,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Use Issue,Non-Serious,Non-Serious,Female,-,14-JAN-2022,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,05-JAN-2022,14-JAN-2022,US,Not Specified,US-SA-2022SA006312,-,-
20008025,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Incorrect Dose Administered By Device;Musculoskeletal Stiffness;Device Defective;Muscle Spasms;Blood Glucose Decreased,Serious,Other Outcomes,Female,14-OCT-2021,14-JAN-2022,30-DAY,71 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,04-JAN-2022,28-OCT-2021,FR,Not Specified,FR-NOVOPROD-860451,-,-
20329000,Ozempic;Euthyrox;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Levothyroxine Sodium;Semaglutide;Gliclazide,Hypothyroidism;Type 2 Diabetes Mellitus,Cataract Subcapsular,Serious,Disabled,Female,21-JUL-2021,12-JAN-2022,Expedited,53 YR,135 KG,Provell Pharmaceuticals,Consumer,Not Specified,-,02-SEP-2021,12-JAN-2022,FR,Not Specified,FR-US-Provell Pharmaceuticals LLC-E2B_90085104,-,-
20325007,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Amenorrhoea,Serious,Disabled,Female,NOV-2021,11-JAN-2022,Expedited,42 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,04-JAN-2022,11-JAN-2022,MY,Not Specified,MY-SA-2022SA004994,-,-
20228231,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Claustrophobia;Pancreatic Carcinoma,Serious,Other Outcomes,Female,-,10-JAN-2022,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,04-JAN-2022,24-DEC-2021,IT,Not Specified,IT-SA-2021SA427330,-,-
20313789,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Incorrect Dose Administered,Non-Serious,Non-Serious,Female,-,09-JAN-2022,Non-Expedited,74 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-DEC-2021,09-JAN-2022,US,Not Specified,US-SA-2021SA433954,-,-
20313619,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Device Leakage;Device Breakage,Non-Serious,Non-Serious,Male,-,09-JAN-2022,Non-Expedited,68 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,27-DEC-2021,09-JAN-2022,US,Not Specified,US-SA-2021SA435782,-,-
20313573,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Temperature Excursion Issue,Non-Serious,Non-Serious,Not Specified,-,09-JAN-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,27-DEC-2021,09-JAN-2022,US,Not Specified,US-SA-2021SA433176,-,-
20313267,Soliqua 100/33;Lantus Solostar,Insulin Glargine\Lixisenatide;Insulin Glargine,-,Product Temperature Excursion Issue,Non-Serious,Non-Serious,Not Specified,-,09-JAN-2022,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,23-DEC-2021,09-JAN-2022,US,Not Specified,US-SA-2021SA432883,-,-
20288748,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Liver Function Test Increased,Serious,Other Outcomes,Male,20-OCT-2021,04-JAN-2022,Expedited,46 YR,87.4 KG,Novo Nordisk,Healthcare Professional,Not Specified,Diabex;Edarbi;Crestor,24-DEC-2021,04-JAN-2022,KR,Not Specified,KR-NOVOPROD-864851,-,-
20244500,Soliqua 100/33;Lantus Solostar,Insulin Glargine;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Fibromyalgia;Surgery;Device Issue;Agitation;Back Pain;Myocardial Infarction,Serious,Other Outcomes,Female,-,04-JAN-2022,Expedited,70 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,22-DEC-2021,29-DEC-2021,US,Not Specified,US-SA-2020SA025417,-,-
20156777,Metformin,Metformin Hydrochloride;Atorvastatin;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Abdominal Pain Lower;Treatment Noncompliance;Diarrhoea;Constipation;Seizure;Drug Intolerance,Serious,Other Outcomes,Female,JAN-2020,31-DEC-2021,Expedited,8 DEC,Not Specified,Teva,Healthcare Professional,Not Specified,Metformin;Metoprolol;Kcl;Alprazolam;Gliclazide;Furosemide;Spironolactone;Ramipril,22-DEC-2021,07-DEC-2021,CZ,Not Specified,CZ-TEVA-2021-CZ-1976546,Nekvapilova L. Achieving better compliance with Suliqua in an elderly patient with type 2 diabetes. KAZUISTIKY V DIABETOLOGII. 2021;19(3):34-36.,-
20199129,Metformin,Metformin Hydrochloride;Trazodone Hydrochloride;Perindopril Arginine;Insulin Glargine\Lixisenatide;Atorvastatin,Diabetes Mellitus;Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Insomnia;Abdominal Pain Lower;Diarrhoea;Treatment Noncompliance;Adverse Event;Drug Intolerance;Hospitalisation;Seizure;Adverse Drug Reaction;Constipation,Serious,Hospitalized;Other Outcomes,Female,JAN-2020,30-DEC-2021,Expedited,80 YR,86 KG,Mylan,Healthcare Professional,Not Specified,Furosemide;Potassium Chloride;Atorvastatin;Metformin;Metoprolol;Ramipril;Spironolactone;Alprazolam;Gliclazide,24-DEC-2021,17-DEC-2021,CZ,Not Specified,CZ-MYLANLABS-2021M1082107,Nekvapilova L.. Achieving better compliance with Suliqua in an elderly patient with type 2 diabetes. KAZUISTIKY V DIABETOLOGII. 2021;19(3):34-36,-
20247828,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Female,-,29-DEC-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-DEC-2021,29-DEC-2021,US,Not Specified,US-SA-2021SA432621,-,-
20247747,Soliqua 100/33;Toujeo,Insulin Glargine;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Dispensing Error,Non-Serious,Non-Serious,Male,-,29-DEC-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-DEC-2021,29-DEC-2021,US,Not Specified,US-SA-2021SA429706,-,-
20047993,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Rash;Angioedema,Serious,Other Outcomes,Male,-,29-DEC-2021,Expedited,56 YR,80 KG,Sanofi Aventis,Healthcare Professional,Not Specified,Dexamethasone,22-DEC-2021,09-NOV-2021,RU,Not Specified,RU-SA-2021SA365680,-,-
20228886,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Hypoacusis,Non-Serious,Non-Serious,Male,-,25-DEC-2021,Non-Expedited,64 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Humalog,20-DEC-2021,25-DEC-2021,US,Not Specified,US-SA-2021SA426859,-,-
20225756,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Hospitalisation,Serious,Hospitalized,Male,-,24-DEC-2021,Expedited,8 DEC,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,16-DEC-2021,24-DEC-2021,JP,Not Specified,JP-NOVOPROD-877742,-,-
19263597,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus;Product Used For Unknown Indication,Product Storage Error;Hyperglycaemia;Device Malfunction;Incorrect Dose Administered By Device,Serious,Other Outcomes,Female,-,24-DEC-2021,30-DAY,65 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,Humalog,16-DEC-2021,17-MAY-2021,PK,Not Specified,PK-NOVOPROD-811136,-,-
20224862,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,-,23-DEC-2021,Non-Expedited,57 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-DEC-2021,23-DEC-2021,US,Not Specified,US-SA-2021SA422955,-,-
20224834,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Male,-,23-DEC-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Trulicity,14-DEC-2021,23-DEC-2021,US,Not Specified,US-SA-2021SA421132,-,-
20222655,Metformin,Metformin Hydrochloride;Insulin Glargine\Lixisenatide;Atorvastatin,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Drug Intolerance;Treatment Noncompliance;Diarrhoea;Abdominal Pain Lower;Constipation;Seizure,Serious,Other Outcomes,Female,JAN-2020,23-DEC-2021,Expedited,8 DEC,Not Specified,Aurobindo,Healthcare Professional,Not Specified,Ramipril;Metoprolol;Furosemide;Alprazolam;Spironolactone;Kcl;Metformin;Gliclazide,09-DEC-2021,23-DEC-2021,CZ,Not Specified,CZ-AUROBINDO-AUR-APL-2021-053045,Nekvapilova L.. Dosazeni lepsi compliance u starsiho diabetika 2. (Achieving better compliance with Suliqua in an elderly patient with type 2 diabetes). KAZUISTIKY V DIABETOLOGII.. 2021;19(3):34-36,-
20218288,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Female,-,22-DEC-2021,Non-Expedited,76 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-DEC-2021,22-DEC-2021,US,Not Specified,US-SA-2021SA418304,-,-
20218153,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Off Label Use;Blood Glucose Abnormal,Non-Serious,Non-Serious,Female,-,22-DEC-2021,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-DEC-2021,22-DEC-2021,US,Not Specified,US-SA-2021SA422930,-,-
20214882,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Pulmonary Mass;Metastases To Lung,Serious,Other Outcomes,Female,-,22-DEC-2021,Expedited,67 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-DEC-2021,22-DEC-2021,US,Not Specified,US-SA-2021SA422188,-,-
20050152,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Feeling Abnormal;Glycosylated Haemoglobin Increased;Hyperhidrosis;Hypoglycaemia;Loss Of Consciousness;Injection Site Pain,Serious,Other Outcomes,Female,-,22-DEC-2021,Non-Expedited,51 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,01-NOV-2021,09-NOV-2021,US,Not Specified,US-SA-2021SA369222,-,-
20213223,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Male,-,21-DEC-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-DEC-2021,21-DEC-2021,US,Not Specified,US-SA-2021SA415203,-,-
20209534,Apidra;Toujeo;Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Glargine;Insulin Glulisine,Type 2 Diabetes Mellitus,Hypoglycaemia;Gingivitis;Glycosylated Haemoglobin Increased;Thyroid Cancer;Blood Glucose Increased,Serious,Other Outcomes,Male,2015,21-DEC-2021,Expedited,56 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-DEC-2021,21-DEC-2021,EC,Not Specified,EC-SA-2021SA420524,-,-
20208692,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Hyperglycaemia;Covid-19,Serious,Hospitalized,Male,01-AUG-2021,20-DEC-2021,Expedited,64 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Losartan;Rosuvastatin;Metformin;Dexamethasone,02-SEP-2020,20-DEC-2021,BR,Not Specified,BR-NOVOPROD-771258,-,-
20204348,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus;Product Used For Unknown Indication,Ventricular Extrasystoles,Serious,Hospitalized,Female,05-DEC-2021,20-DEC-2021,Expedited,6 DEC,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Amiodarone,09-DEC-2021,20-DEC-2021,JP,Not Specified,JP-NOVOPROD-876035,-,-
20179242,Metformin;Actos;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Pioglitazone Hydrochloride;Metformin Hydrochloride,Diabetes Mellitus,Hypoglycaemia;Syncope,Serious,Other Outcomes,Male,07-SEP-2021,14-DEC-2021,Expedited,88 YR,Not Specified,Mylan,Healthcare Professional,Not Specified,-,07-DEC-2021,14-DEC-2021,IT,Not Specified,IT-MYLANLABS-2021M1091392,-,-
20178179,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Male,-,13-DEC-2021,Non-Expedited,60 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-DEC-2021,13-DEC-2021,US,Not Specified,US-SA-2021SA412402,-,-
20178168,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Circumstance Or Information Capable Of Leading To Medication Error,Non-Serious,Non-Serious,Male,-,13-DEC-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-DEC-2021,13-DEC-2021,US,Not Specified,US-SA-2021SA412644,-,-
20176697,Nesina,Alogliptin Benzoate;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Drug-Induced Liver Injury,Serious,Hospitalized,Male,22-NOV-2021,13-DEC-2021,Expedited,46 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,-,02-DEC-2021,13-DEC-2021,CN,Not Specified,CN-TAKEDA-2021TJP127824,-,-
20174133,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Hospitalisation;Blindness;Hypoacusis;Disability,Serious,Hospitalized;Other Outcomes,Male,-,13-DEC-2021,Expedited,88 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,01-DEC-2021,13-DEC-2021,US,Not Specified,US-NOVOPROD-873044,-,-
20171847,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Female,-,10-DEC-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,03-DEC-2021,10-DEC-2021,US,Not Specified,US-SA-2021SA409944,-,-
20137998,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Condition Aggravated;Memory Impairment,Serious,Other Outcomes,Male,-,10-DEC-2021,Expedited,75 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Doxazosin;Metformin;Donepezil;Vortioxetine,01-DEC-2021,02-DEC-2021,BR,Not Specified,BR-NOVOPROD-870389,-,-
20166703,Metformin,Metformin Hydrochloride;Insulin Glargine\Lixisenatide,Product Used For Unknown Indication,Pancreatitis Acute,Serious,Hospitalized;Other Outcomes,Not Specified,-,09-DEC-2021,Expedited,62 YR,Not Specified,Mylan,Healthcare Professional,Not Specified,-,07-DEC-2021,09-DEC-2021,RO,Not Specified,RO-MYLANLABS-2021M1091308,-,-
20161663,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus;Product Used For Unknown Indication,Cardiac Contractility Decreased;Hyperglycaemia;Myocardial Infarction,Serious,Other Outcomes,Male,MAY-2021,08-DEC-2021,Expedited,49 YR,97.4 KG,Novo Nordisk,Healthcare Professional,Not Specified,Perindopril Arginine;Furosemide;Bisoprolol;Spironolactone;Entresto;Rosuvastatin;Xigduo Xr;Nebivolol,24-NOV-2021,08-DEC-2021,BR,Not Specified,BR-NOVOPROD-873661,-,-
19912651,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Communication Issue;Drug Ineffective,Non-Serious,Non-Serious,Female,-,08-DEC-2021,Non-Expedited,63 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,02-DEC-2021,04-OCT-2021,US,Not Specified,US-SA-2021SA322824,-,-
20152465,-,Glimepiride;Insulin Glargine\Lixisenatide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Diabetic Retinopathy;Bile Duct Stone;Diabetic Neuropathy;Balanoposthitis,Serious,Other Outcomes,Male,-,06-DEC-2021,Expedited,66 YR,93 KG,Mylan,Healthcare Professional,Not Specified,Glyburide\Metformin;Metformin;Empagliflozin;Sitagliptin;Insulin Lispro;Simvastatin,30-NOV-2021,06-DEC-2021,SK,Not Specified,SK-MYLANLABS-2021M1089247,-,-
20149864,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Dyslipidaemia;Type 2 Diabetes Mellitus,Prostate Cancer,Serious,Other Outcomes,Male,-,06-DEC-2021,Expedited,71 YR,99.1 KG,Novo Nordisk,Healthcare Professional,Not Specified,Rosuvastatin;Losartan;Gliclazide;Jardiance;Metformin Hydrochloride,25-NOV-2021,06-DEC-2021,BR,Not Specified,BR-NOVOPROD-871672,-,-
20147580,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Female,-,03-DEC-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-NOV-2021,03-DEC-2021,US,Not Specified,US-SA-2021SA396747,-,-
20147577,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Device Issue;Blood Glucose Increased,Non-Serious,Non-Serious,Male,22-NOV-2021,03-DEC-2021,Non-Expedited,59 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-NOV-2021,03-DEC-2021,US,Not Specified,US-SA-2021SA397026,-,-
20147560,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Drug Ineffective,Non-Serious,Non-Serious,Not Specified,-,03-DEC-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-NOV-2021,03-DEC-2021,US,Not Specified,US-SA-2021SA399662,-,-
20137996,Novorapid;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Insulin Aspart,Diabetes Mellitus,Pyelonephritis;Pain In Extremity;Covid-19,Serious,Hospitalized,Male,2020,02-DEC-2021,Expedited,74 YR,99 KG,Novo Nordisk,Healthcare Professional,Not Specified,Rosuvastatin;Ascorbic Acid\Cranberry;Manidipine Hydrochloride;Allopurinol;Indapamide;Empagliflozin;Duloxetine;Vitamin D Nos;Candesartan;Ezetimibe;Aspirin,18-NOV-2021,02-DEC-2021,BR,Not Specified,BR-NOVOPROD-869475,-,-
20133768,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Covid-19;Blood Glucose Increased;Glycosylated Haemoglobin Increased,Serious,Hospitalized,Male,2021,01-DEC-2021,Expedited,55 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,Jardiance;Pioglitazone Hydrochloride;Glimepiride\Metformin;Ciprofibrate,22-NOV-2021,01-DEC-2021,BR,Not Specified,BR-NOVOPROD-870397,-,-
20114929,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Product Usage Process,Non-Serious,Non-Serious,Male,-,01-DEC-2021,Non-Expedited,61 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,16-NOV-2021,25-NOV-2021,US,Not Specified,US-SA-2021SA387518,-,-
20132244,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment;Injury Associated With Device,Non-Serious,Non-Serious,Male,-,30-NOV-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-NOV-2021,30-NOV-2021,US,Not Specified,US-SA-2021SA395560,-,-
19734381,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Anticoagulant Therapy;Blood Cholesterol Abnormal;Diabetes Mellitus;Hypertension,Death,Serious,Died,Male,-,30-NOV-2021,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,Vildagliptin;Glucophage;Atorvastatin;Ecotrin;Jardiance;Hydrochlorothiazide\Telmisartan,13-AUG-2021,23-AUG-2021,ZA,Not Specified,ZA-NOVOPROD-838796,-,-
20127154,Soliqua 100/33,Insulin Glargine\Lixisenatide;Minocycline Hydrochloride,-,Skin Reaction,Non-Serious,Non-Serious,Male,-,29-NOV-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-NOV-2021,29-NOV-2021,US,Not Specified,US-SA-2021SA394919,-,-
20123614,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Osteopenia;Thyroid Mass,Serious,Other Outcomes,Female,-,29-NOV-2021,Expedited,61 YR,72 KG,Novo Nordisk,Healthcare Professional,Not Specified,Tacrolimus;Insulin Glargine;Atorvastatin;Prednisone;Mycophenolic Acid;Metformin,17-NOV-2021,29-NOV-2021,BR,Not Specified,BR-NOVOPROD-869091,-,-
20123584,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Surgery;Blood Glucose Increased,Serious,Other Outcomes;Hospitalized,Male,-,29-NOV-2021,Expedited,56 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Glimepiride;Olmesartan;Dapagliflozin;Nebivolol;Manidipine;Rosuvastatin;Dutasteride;Metformin;Hydrochlorothiazide,17-NOV-2021,29-NOV-2021,BR,Not Specified,BR-NOVOPROD-869031,-,-
20121230,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Product Dose Omission Issue,Non-Serious,Non-Serious,Male,-,27-NOV-2021,Non-Expedited,71 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-NOV-2021,27-NOV-2021,US,Not Specified,US-SA-2021SA391255,-,-
20114894,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Skin Reaction,Non-Serious,Non-Serious,Female,-,25-NOV-2021,Non-Expedited,77 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,16-NOV-2021,25-NOV-2021,US,Not Specified,US-SA-2021SA388310,-,-
20114860,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Tremor;Blood Glucose Abnormal,Non-Serious,Non-Serious,Female,-,25-NOV-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,16-NOV-2021,25-NOV-2021,US,Not Specified,US-SA-2021SA387290,-,-
20114822,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Increased;Pruritus;Burning Sensation;Drug Ineffective;Product Storage Error,Non-Serious,Non-Serious,Female,-,25-NOV-2021,Non-Expedited,68 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-NOV-2021,25-NOV-2021,US,Not Specified,US-SA-2021SA385439,-,-
20103666,Pioglitazone And Metformin;Jardiance,Empagliflozin;Metformin Hydrochloride\Pioglitazone Hydrochloride;Linagliptin,Blood Glucose Decreased,Product Use Issue;Urine Ketone Body Present,Non-Serious,Non-Serious,Male,10-OCT-2021,23-NOV-2021,Expedited,62 YR,60.000 KG,Boehringer Ingelheim,Consumer,Not Specified,-,22-NOV-2021,23-NOV-2021,CN,Not Specified,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-139920",-,-
19764178,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Angioplasty;Covid-19;Diabetes Mellitus Inadequate Control;Off Label Use;Catheterisation Cardiac;Blood Creatinine Increased,Serious,Hospitalized,Not Specified,APR-2021,23-NOV-2021,Expedited,74 YR,65 KG,Novo Nordisk,Healthcare Professional,Not Specified,Sertraline Hydrochloride;Losartan;Dapagliflozin Propanediol\Metformin Hydrochloride;Rosuvastatin;Clopidogrel;Isosorbide Dinitrate;Allopurinol;Furosemide,12-NOV-2021,30-AUG-2021,BR,Not Specified,BR-NOVOPROD-840317,-,-
20098681,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Glaucoma,Serious,Other Outcomes,Female,-,22-NOV-2021,Expedited,58 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-NOV-2021,22-NOV-2021,US,Not Specified,US-SA-2021SA386337,-,-
20097343,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Male,-,22-NOV-2021,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-NOV-2021,22-NOV-2021,US,Not Specified,US-SA-2021SA380956,-,-
20094821,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Pain;Hypoglycaemia;Chest Pain;Weight Increased,Serious,Hospitalized,Female,27-NOV-2020,22-NOV-2021,Expedited,67 YR,58 KG,Novo Nordisk,Healthcare Professional,Not Specified,Losartan Potassium;Vitamin D Nos;Dapagliflozin;Losartan;Rosuvastatin;Synthroid;Pitavastatin;Pioglitazone Hydrochloride;Metformin Hydrochloride,10-NOV-2021,22-NOV-2021,BR,Not Specified,BR-NOVOPROD-865886,-,-
20094809,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Hip Arthroplasty,Serious,Hospitalized,Female,12-AUG-2021,22-NOV-2021,Expedited,52 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,10-NOV-2021,22-NOV-2021,US,Not Specified,US-NOVOPROD-866497,-,-
20094120,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Female,-,22-NOV-2021,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-NOV-2021,22-NOV-2021,US,Not Specified,US-SA-2020SA375854,-,-
19881623,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Decreased;Extra Dose Administered;Covid-19;Device Issue,Serious,Hospitalized,Female,-,22-NOV-2021,Expedited,68 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,16-NOV-2021,24-SEP-2021,US,Not Specified,US-SA-2021SA312305,-,-
20090563,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Diarrhoea,Non-Serious,Non-Serious,Female,-,19-NOV-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-NOV-2021,19-NOV-2021,US,Not Specified,US-SA-2021SA380947,-,-
20075085,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Incorrect Dose Administered By Device;Device Issue;Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,19-NOV-2021,Non-Expedited,65 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-NOV-2021,16-NOV-2021,US,Not Specified,US-SA-2021SA376875,-,-
20064283,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Female,-,19-NOV-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-NOV-2021,12-NOV-2021,US,Not Specified,US-SA-2021SA374664,-,-
20085588,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Female,10-NOV-2021,18-NOV-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-NOV-2021,18-NOV-2021,US,Not Specified,US-SA-2021SA379419,-,-
19850460,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Operational Issue;Injection Site Bruising;Blindness,Serious,Other Outcomes;Disabled,Female,-,18-NOV-2021,Expedited,62 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,12-NOV-2021,17-SEP-2021,US,Not Specified,US-SA-2021SA304693,-,-
20061716,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Issue;Blood Glucose Increased;Drug Dose Omission By Device;Blindness,Serious,Disabled;Other Outcomes,Female,NOV-2021,16-NOV-2021,Expedited,52 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-NOV-2021,12-NOV-2021,US,Not Specified,US-SA-2021SA371950,-,-
20051470,Xultophy 100/3.6;Actos;Metformin,Metformin Hydrochloride;Pioglitazone Hydrochloride;Insulin Degludec\Liraglutide,Diabetes Mellitus,Hypoglycaemia;Syncope,Serious,Other Outcomes,Male,07-SEP-2021,16-NOV-2021,Expedited,88 YR,Not Specified,Aurobindo,Healthcare Professional,Not Specified,-,02-NOV-2021,10-NOV-2021,IT,Not Specified,IT-AUROBINDO-AUR-APL-2021-045555,-,-
20030706,Xultophy 100/3.6;Tresiba,Insulin Degludec;Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Drug Intolerance,Non-Serious,Non-Serious,Female,-,16-NOV-2021,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,11-MAY-2021,03-NOV-2021,US,Not Specified,US-NOVOPROD-812834,-,-
20067045,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Death,Serious,Died,Male,-,15-NOV-2021,Expedited,70 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,09-NOV-2021,15-NOV-2021,BR,Not Specified,BR-NOVOPROD-865703,-,-
20066844,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Malaise;Carotid Arteriosclerosis;Left Ventricular Dysfunction;Hyperglycaemia;Erectile Dysfunction;Dizziness;High Density Lipoprotein Decreased;Xeroderma,Serious,Other Outcomes,Male,-,15-NOV-2021,Expedited,53 YR,72.6 KG,Novo Nordisk,Healthcare Professional,Not Specified,Enalapril;Bisoprolol;Rosuvastatin;Ezetimibe;Aspirin;Losartan;Brilinta;Glucophage Xr;Jardiance,02-NOV-2021,15-NOV-2021,BR,Not Specified,BR-NOVOPROD-864386,-,-
20065634,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Intentional Product Misuse,Non-Serious,Non-Serious,Male,-,13-NOV-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,08-NOV-2021,13-NOV-2021,US,Not Specified,US-SA-2021SA373614,-,-
20065013,-,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Abdominal Pain,Non-Serious,Non-Serious,Female,-,13-NOV-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,08-NOV-2021,13-NOV-2021,US,Not Specified,US-SA-2021SA375515,-,-
20063444,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Thinking Abnormal;Cough,Non-Serious,Non-Serious,Female,-,12-NOV-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,02-NOV-2021,12-NOV-2021,US,Not Specified,US-SA-2021SA367960,-,-
19882764,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Drug Dose Omission By Device;Device Leakage;Blood Glucose Increased;Device Operational Issue,Non-Serious,Non-Serious,Female,-,12-NOV-2021,Non-Expedited,44 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,04-NOV-2021,24-SEP-2021,US,Not Specified,US-SA-2021SA311883,-,-
20059182,Xultophy 100/3.6;Actos;Metformin,Metformin Hydrochloride;Pioglitazone Hydrochloride;Insulin Degludec\Liraglutide,Diabetes Mellitus,Syncope;Hypoglycaemia,Serious,Other Outcomes,Male,07-SEP-2021,11-NOV-2021,Expedited,88 YR,Not Specified,Teva,Healthcare Professional,Not Specified,-,03-NOV-2021,11-NOV-2021,IT,Not Specified,IT-TEVA-2021-IT-1975143,-,-
20056156,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Glycosuria;Proteinuria;Acute Coronary Syndrome;Vitamin D Deficiency;Oedema Peripheral;Hyperglycaemia;Nausea;Hypoaesthesia,Serious,Other Outcomes,Male,-,11-NOV-2021,Expedited,70 YR,78.4 KG,Novo Nordisk,Healthcare Professional,Not Specified,Empagliflozin,02-NOV-2021,11-NOV-2021,BR,Not Specified,BR-NOVOPROD-861230,-,-
19713385,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Leakage;Blood Glucose Increased;Incorrect Dose Administered By Device,Non-Serious,Non-Serious,Male,-,11-NOV-2021,Non-Expedited,74 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,04-NOV-2021,17-AUG-2021,US,Not Specified,US-SA-2021SA269422,-,-
19688793,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Drug Ineffective;Diabetes Mellitus Inadequate Control,Serious,Hospitalized;Other Outcomes,Female,-,11-NOV-2021,Non-Expedited,74 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,04-NOV-2021,11-AUG-2021,US,Not Specified,US-SA-2021SA257514,-,-
19566737,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Inappropriate Schedule Of Product Administration;Device Leakage;Incorrect Dose Administered By Device,Non-Serious,Non-Serious,Female,-,11-NOV-2021,Non-Expedited,71 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,04-NOV-2021,14-JUL-2021,US,Not Specified,US-SA-2021SA228963,-,-
20054861,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Prescribing Issue,Non-Serious,Non-Serious,Female,-,10-NOV-2021,Non-Expedited,79 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,29-OCT-2021,10-NOV-2021,US,Not Specified,US-SA-2021SA369510,-,-
20052519,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Male,-,10-NOV-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-NOV-2021,10-NOV-2021,US,Not Specified,US-SA-2021SA367946,-,-
20051475,Metformin,Metformin Hydrochloride;Insulin Glargine\Lixisenatide,Product Used For Unknown Indication,Pancreatitis Acute,Serious,Other Outcomes;Hospitalized,Not Specified,-,10-NOV-2021,Expedited,62 YR,Not Specified,Aurobindo,Healthcare Professional,Not Specified,-,27-OCT-2021,10-NOV-2021,RO,Not Specified,RO-AUROBINDO-AUR-APL-2021-045601,-,-
19734713,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Decreased,Non-Serious,Non-Serious,Male,17-AUG-2021,10-NOV-2021,Non-Expedited,43 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Levothyroxine,04-NOV-2021,23-AUG-2021,US,Not Specified,US-SA-2021SA273745,-,-
19729940,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Operational Issue;Depressed Mood;Injection Site Pain,Non-Serious,Non-Serious,Male,-,10-NOV-2021,Non-Expedited,79 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,04-NOV-2021,21-AUG-2021,US,Not Specified,US-SA-2021SA228022,-,-
20049729,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Disability,Serious,Other Outcomes;Disabled,Female,-,09-NOV-2021,Non-Expedited,54 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,04-NOV-2021,09-NOV-2021,US,Not Specified,US-SA-2021SA369684,-,-
20048423,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Female,-,09-NOV-2021,Non-Expedited,64 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-NOV-2021,09-NOV-2021,US,Not Specified,US-SA-2021SA365557,-,-
19997436,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus;Product Used For Unknown Indication,Abdominal Distension;Anxiety;Diabetic Metabolic Decompensation;Asthenia;Hepatic Steatosis,Serious,Other Outcomes,Female,30-SEP-2021,09-NOV-2021,Expedited,51 YR,92.8 KG,Novo Nordisk,Healthcare Professional,Not Specified,Glifage;Dapagliflozin Propanediol\Metformin Hydrochloride;Xigduo Xr;Losartan;Letrozole;Rosuvastatin,29-OCT-2021,26-OCT-2021,BR,Not Specified,BR-NOVOPROD-859720,-,-
20044224,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error;Visual Impairment;Eye Disorder,Non-Serious,Non-Serious,Female,-,08-NOV-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,29-OCT-2021,08-NOV-2021,US,Not Specified,US-SA-2021SA363847,-,-
20042973,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Male,-,08-NOV-2021,Non-Expedited,62 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,02-NOV-2021,08-NOV-2021,US,Not Specified,US-SA-2021SA366562,-,-
20037660,Xultophy 100/3.6;Metformin,Metformin Hydrochloride;Insulin Degludec\Liraglutide;Pioglitazone,Diabetes Mellitus,Hypoglycaemia;Syncope;Spinal Cord Injury Sacral,Serious,Other Outcomes,Male,07-SEP-2021,05-NOV-2021,Expedited,88 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,26-OCT-2021,05-NOV-2021,IT,Not Specified,IT-NOVOPROD-860484,-,-
20036510,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Device Issue,Non-Serious,Non-Serious,Male,-,05-NOV-2021,Non-Expedited,65 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,29-OCT-2021,05-NOV-2021,US,Not Specified,US-SA-2021SA362744,-,-
20033466,-,Metformin Hydrochloride;Insulin Glargine\Lixisenatide,Product Used For Unknown Indication,Pancreatitis Acute,Serious,Hospitalized;Other Outcomes,Not Specified,-,04-NOV-2021,Expedited,62 YR,Not Specified,Bausch And Lomb,Healthcare Professional,Not Specified,-,29-OCT-2021,04-NOV-2021,RO,Not Specified,RO-BAUSCH-BL-2021-036126,-,-
20030705,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Injection Site Inflammation;Arteriosclerosis;Product Use Complaint;Arrhythmia;Memory Impairment;Injection Site Hypertrophy,Non-Serious,Non-Serious,Male,-,03-NOV-2021,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,11-JAN-2021,03-NOV-2021,US,Not Specified,US-NOVOPROD-780819,-,-
20030704,Xultophy 100/3.6;Humalog,Insulin Lispro;Insulin Degludec\Liraglutide,Diabetes Mellitus,Renal Failure,Serious,Other Outcomes,Male,JUN-2020,03-NOV-2021,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,27-JUL-2021,03-NOV-2021,US,Not Specified,US-NOVOPROD-833824,-,-
20030703,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Stress;Blood Glucose Increased;Eating Disorder,Non-Serious,Non-Serious,Female,NOV-2020,03-NOV-2021,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,25-FEB-2021,03-NOV-2021,US,Not Specified,US-NOVOPROD-791789,-,-
20030702,Xultophy 100/3.6;Humalog Kwikpen,Insulin Lispro;Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Hypoglycaemic Unconsciousness;Road Traffic Accident,Serious,Other Outcomes,Female,-,03-NOV-2021,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,06-AUG-2021,03-NOV-2021,US,Not Specified,US-NOVOPROD-837514,-,-
20030701,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Contusion,Non-Serious,Non-Serious,Female,-,03-NOV-2021,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,11-FEB-2021,03-NOV-2021,US,Not Specified,US-NOVOPROD-788568,-,-
20030700,Xultophy 100/3.6,Insulin Degludec\Liraglutide;Covid-19 Vaccine Nos,Product Used For Unknown Indication,Fatigue;Blood Glucose Increased;Back Pain,Non-Serious,Non-Serious,Female,04-JUN-2021,03-NOV-2021,Non-Expedited,58 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,04-JUN-2021,03-NOV-2021,US,Not Specified,US-NOVOPROD-820070,-,-
20030699,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Fatigue;Intentional Product Misuse;Sluggishness;Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,03-NOV-2021,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,20-OCT-2020,03-NOV-2021,US,Not Specified,US-NOVOPROD-763357,-,-
20030698,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus;Product Used For Unknown Indication,Blood Glucose Decreased;Product Quality Issue;Drug Ineffective;Blood Glucose Increased,Serious,Other Outcomes,Female,11-FEB-2021,03-NOV-2021,Non-Expedited,74 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,Humalog,30-JUN-2021,03-NOV-2021,US,Not Specified,US-NOVOPROD-787643,-,-
20030697,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Blood Glucose Increased;Expired Product Administered,Serious,Hospitalized,Male,-,03-NOV-2021,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,09-DEC-2020,03-NOV-2021,US,Not Specified,US-NOVOPROD-773239,-,-
20030696,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Eczema,Non-Serious,Non-Serious,Male,SEP-2020,03-NOV-2021,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,21-DEC-2020,03-NOV-2021,US,Not Specified,US-NOVOPROD-768812,-,-
20030695,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Covid-19,Non-Serious,Non-Serious,Male,20-DEC-2020,03-NOV-2021,Non-Expedited,72 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,07-JAN-2021,03-NOV-2021,US,Not Specified,US-NOVOPROD-779782,-,-
20030694,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Abdominal Pain Upper;Injection Site Hypoaesthesia;Back Pain;Insomnia,Non-Serious,Non-Serious,Male,SEP-2020,03-NOV-2021,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,12-OCT-2020,03-NOV-2021,US,Not Specified,US-NOVOPROD-760344,-,-
20030693,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Pancreatitis Acute,Serious,Other Outcomes,Male,2020,03-NOV-2021,Non-Expedited,60 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,19-NOV-2020,03-NOV-2021,US,Not Specified,US-NOVOPROD-769440,-,-
20030692,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Tremor;Device Failure;Product Dose Omission Issue,Non-Serious,Non-Serious,Male,-,03-NOV-2021,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,03-NOV-2020,03-NOV-2021,US,Not Specified,US-NOVOPROD-765847,-,-
20026198,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injury Associated With Device;Depressed Mood;Product Communication Issue,Non-Serious,Non-Serious,Female,-,02-NOV-2021,Non-Expedited,61 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,25-OCT-2021,02-NOV-2021,US,Not Specified,US-SA-2021SA360051,-,-
20025302,Actos;Xultophy 100/3.6;Metformin,Metformin Hydrochloride;Insulin Degludec\Liraglutide;Pioglitazone Hydrochloride,Diabetes Mellitus,Syncope;Hypoglycaemia,Serious,Other Outcomes,Male,07-SEP-2021,02-NOV-2021,Expedited,88 YR,Not Specified,Novartis,Healthcare Professional,Not Specified,-,28-OCT-2021,02-NOV-2021,IT,Not Specified,NVSC2021IT248089,-,-
20024938,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Decreased;Tremor,Non-Serious,Non-Serious,Male,-,02-NOV-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin Hydrochloride,26-OCT-2021,02-NOV-2021,US,Not Specified,US-SA-2021SA358307,-,-
20024919,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Female,25-OCT-2021,02-NOV-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-OCT-2021,02-NOV-2021,US,Not Specified,US-SA-2021SA359064,-,-
20023155,Metformin;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Metformin Hydrochloride;Pioglitazone,Diabetes Mellitus,Hypoglycaemia;Syncope,Serious,Other Outcomes,Male,07-SEP-2021,02-NOV-2021,Expedited,88 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,-,29-OCT-2021,02-NOV-2021,IT,Not Specified,IT-TAKEDA-2021TEU009236,-,-
20020557,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Intentional Product Misuse;Visual Impairment,Non-Serious,Non-Serious,Female,-,01-NOV-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-OCT-2021,01-NOV-2021,US,Not Specified,US-SA-2021SA358885,-,-
20009979,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,29-OCT-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,25-OCT-2021,29-OCT-2021,US,Not Specified,US-SA-2021SA354666,-,-
20007941,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Covid-19 Prophylaxis;Product Used For Unknown Indication,Back Pain;Blood Glucose Decreased;Bundle Branch Block Right;Intervertebral Disc Protrusion,Serious,Other Outcomes,Female,28-MAY-2021,28-OCT-2021,Expedited,61 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,Covid-19 Vaccine Nos,19-OCT-2021,28-OCT-2021,US,Not Specified,US-NOVOPROD-860308,-,-
20006562,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Decreased,Non-Serious,Non-Serious,Male,-,28-OCT-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,25-OCT-2021,28-OCT-2021,US,Not Specified,US-SA-2021SA355294,-,-
19998790,Lantus Solostar;Lantus;Soliqua 100/33;Apidra Solostar;Toujeo,Insulin Glargine;Insulin Glulisine;Insulin Glargine\Lixisenatide;Insulin Glargine;Insulin Glargine,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,26-OCT-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,21-OCT-2021,26-OCT-2021,US,Not Specified,US-SA-2021SA352081,-,-
19997269,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Male,AUG-2021,26-OCT-2021,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-OCT-2021,26-OCT-2021,US,Not Specified,US-SA-2021SA352088,-,-
19992793,-,Metformin Hydrochloride;Insulin Glargine\Lixisenatide,-,Pancreatitis Acute,Serious,Other Outcomes;Hospitalized,Not Specified,-,26-OCT-2021,Expedited,62 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,19-OCT-2021,26-OCT-2021,RO,Not Specified,RO-SA-2021SA350231,-,-
19993460,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus;Product Used For Unknown Indication,Acute Pulmonary Oedema;Coronary Artery Occlusion,Serious,Hospitalized,Female,-,25-OCT-2021,Expedited,76 YR,77 KG,Novo Nordisk,Healthcare Professional,Not Specified,Gliclazide;Metformin Hydrochloride;Ezetimibe;Rosuvastatin;Empagliflozin,13-OCT-2021,25-OCT-2021,BR,Not Specified,BR-NOVOPROD-857570,-,-
19988102,Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Lispro,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,22-OCT-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-OCT-2021,22-OCT-2021,US,Not Specified,US-SA-2021SA348783,-,-
19976781,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Male,-,21-OCT-2021,Non-Expedited,61 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-OCT-2021,21-OCT-2021,US,Not Specified,US-SA-2021SA343678,-,-
19977302,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Female,-,20-OCT-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-OCT-2021,20-OCT-2021,US,Not Specified,US-SA-2021SA343365,-,-
19970818,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Glomerular Filtration Rate Decreased,Non-Serious,Non-Serious,Male,-,20-OCT-2021,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,13-OCT-2021,20-OCT-2021,US,Not Specified,US-SA-2021SA343690,-,-
19966633,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Glycosylated Haemoglobin Abnormal;Blood Glucose Abnormal;Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Female,-,20-OCT-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,15-OCT-2021,18-OCT-2021,US,Not Specified,US-SA-2021SA342513,-,-
19972524,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Arthropathy;Gait Disturbance,Non-Serious,Non-Serious,Male,-,19-OCT-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-OCT-2021,19-OCT-2021,US,Not Specified,US-SA-2021SA345995,-,-
19966853,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Death,Serious,Died,Male,-,19-OCT-2021,Expedited,84 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,08-OCT-2021,19-OCT-2021,KZ,Not Specified,KZ-NOVOPROD-856106,-,-
19965584,-,Glimepiride;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Bile Duct Stone;Balanoposthitis;Diabetic Retinopathy;Diabetic Neuropathy,Serious,Other Outcomes,Male,-,18-OCT-2021,Expedited,66 YR,93 KG,Sanofi Aventis,Healthcare Professional,Not Specified,Insulin Lispro;Simvastatin;Sitagliptin;Metformin;Empagliflozin,11-OCT-2021,18-OCT-2021,SK,Not Specified,SK-SA-2021SA338452,-,-
19961212,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,16-OCT-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-OCT-2021,16-OCT-2021,US,Not Specified,US-SA-2021SA342109,-,-
19961053,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Male,-,16-OCT-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-OCT-2021,16-OCT-2021,US,Not Specified,US-SA-2021SA339780,-,-
19960888,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Hypoglycaemia,Serious,Other Outcomes,Male,-,16-OCT-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,09-OCT-2021,16-OCT-2021,US,Not Specified,US-SA-2021SA338056,-,-
19958731,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Covid-19 Pneumonia;Heart Rate Increased;Injection Site Haemorrhage,Serious,Hospitalized,Female,AUG-2021,15-OCT-2021,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,05-OCT-2021,15-OCT-2021,US,Not Specified,US-NOVOPROD-854539,-,-
19955620,Jardiance;Soliqua 100/33,Insulin Glargine\Lixisenatide;Empagliflozin,Product Used For Unknown Indication,Fungal Infection,Non-Serious,Non-Serious,Not Specified,-,13-OCT-2021,Non-Expedited,Not Specified,Not Specified,Boehringer Ingelheim,Consumer,Not Specified,-,13-OCT-2021,13-OCT-2021,US,Not Specified,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-132418",-,-
19870050,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Myocardial Infarction;Hyperglycaemia,Serious,Hospitalized,Male,AUG-2021,13-OCT-2021,Expedited,63 YR,55 KG,Novo Nordisk,Consumer,Not Specified,-,04-OCT-2021,23-SEP-2021,PK,Not Specified,PK-NOVOPROD-848516,-,-
19371642,Xultophy 100/3.6,Insulin Degludec\Liraglutide;Insulin Aspart,Product Used For Unknown Indication,Pulmonary Arterial Hypertension;Hyperglycaemia;Decreased Appetite;Covid-19;Aortic Aneurysm;Urinary Tract Infection;Aortic Valve Sclerosis;Weight Decreased,Serious,Hospitalized;Other Outcomes,Female,MAY-2020,13-OCT-2021,Expedited,80 YR,83.6 KG,Novo Nordisk,Consumer,Not Specified,Cannabidiol;Escitalopram;Levothyroxine;Donepezil;Rivaroxaban;Linagliptin;Metoprolol;Vildagliptin;Rosuvastatin;Vitamin D3;Empagliflozin;Hydroxyzine;Valsartan,04-OCT-2021,04-JUN-2021,BR,Not Specified,BR-NOVOPROD-817162,-,-
19941235,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Not Specified,05-OCT-2021,12-OCT-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,06-OCT-2021,12-OCT-2021,US,Not Specified,US-SA-2021SA334912,-,-
19943864,Toujeo Max;Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Glargine,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,11-OCT-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,06-OCT-2021,11-OCT-2021,US,Not Specified,US-SA-2021SA333894,-,-
19935732,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Nausea;Illness,Non-Serious,Non-Serious,Female,-,08-OCT-2021,Non-Expedited,82 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Praluent,04-OCT-2021,08-OCT-2021,US,Not Specified,US-SA-2021SA331402,-,-
19935422,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,08-OCT-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-OCT-2021,08-OCT-2021,US,Not Specified,US-SA-2021SA330705,-,-
19731723,Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Lispro,Diabetes Mellitus;Type 2 Diabetes Mellitus,Cardiac Arrest,Serious,Died;Other Outcomes,Male,20-JUL-2021,07-OCT-2021,Expedited,64 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,01-OCT-2021,20-AUG-2021,US,Not Specified,US-SA-2021SA243192,-,-
19642144,Metformin;Xultophy 100/3.6;Levemir;Humalog,Insulin Lispro;Insulin Detemir;Insulin Degludec\Liraglutide;Metformin Hydrochloride,Diabetes Mellitus;Product Used For Unknown Indication,Glycosylated Haemoglobin Increased;Renal Failure;Blood Pressure Increased,Serious,Other Outcomes,Male,JUN-2020,07-OCT-2021,Expedited,Not Specified,Not Specified,Eli Lilly And Co,Consumer,Not Specified,-,27-SEP-2021,30-JUL-2021,US,Not Specified,US-ELI_LILLY_AND_COMPANY-US202107010162,-,-
19890417,Xultophy 100/3.6;Vidaza;Sectral;Kardegic;Inipomp,Aspirin Dl-Lysine;Pantoprazole Sodium;Manidipine Hydrochloride;Pregabalin;Furosemide;Acebutolol Hydrochloride;Azacitidine;Cholecalciferol;Ezetimibe\Simvastatin;Rivaroxaban;Insulin Degludec\Liraglutide;Irbesartan;Febuxostat;Venetoclax,Atrial Fibrillation;Diabetes Mellitus;Gastrooesophageal Reflux Disease;Hypercholesterolaemia;Hypertension;Hyperuricaemia;Intermittent Claudication;Myelodysplastic Syndrome;Oedema Due To Cardiac Disease;Vascular Disorder Prophylaxis;Vitamin D Deficiency,Sudden Death,Serious,Died;Other Outcomes,Male,18-AUG-2021,06-OCT-2021,Expedited,84 YR,Not Specified,Validus,Healthcare Professional,Not Specified,-,24-SEP-2021,28-SEP-2021,FR,Not Specified,FR-VALIDUS PHARMACEUTICALS LLC-FR-VDP-2021-001729,-,-
19922476,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Female,-,05-OCT-2021,Non-Expedited,68 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,29-SEP-2021,05-OCT-2021,US,Not Specified,US-SA-2021SA326891,-,-
19922475,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,05-OCT-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,22-SEP-2021,05-OCT-2021,US,Not Specified,US-SA-2021SA317003,-,-
19912684,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,-,04-OCT-2021,Non-Expedited,60 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-SEP-2021,04-OCT-2021,US,Not Specified,US-SA-2021SA325396,-,-
19909682,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Drug Ineffective,Non-Serious,Non-Serious,Female,-,02-OCT-2021,Non-Expedited,Not Specified,Not Specified,Takeda,Consumer,Not Specified,-,30-SEP-2021,02-OCT-2021,US,Not Specified,US-TAKEDA-2021TUS060803,-,-
19908203,Soliqua 100/33,Insulin Glargine\Lixisenatide,Hypertension;Type 2 Diabetes Mellitus,Pyoderma Gangrenosum,Serious,Other Outcomes,Male,30-JUL-2021,01-OCT-2021,Expedited,76 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Metformin;Empagliflozin;Losartan,24-SEP-2021,01-OCT-2021,AR,Not Specified,AR-SA-2021SA321372,-,-
19902507,Soliqua 100/33,Insulin Glargine\Lixisenatide;Empagliflozin,-,Fungal Infection,Non-Serious,Non-Serious,Female,-,30-SEP-2021,Non-Expedited,60 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,24-SEP-2021,30-SEP-2021,US,Not Specified,US-SA-2021SA321370,-,-
19899060,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Hospitalisation,Serious,Hospitalized,Male,-,30-SEP-2021,Expedited,73 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,21-SEP-2021,30-SEP-2021,JP,Not Specified,JP-NOVOPROD-851213,-,-
19897360,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Impaired Gastric Emptying,Serious,Other Outcomes,Not Specified,-,30-SEP-2021,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-SEP-2021,30-SEP-2021,US,Not Specified,US-SA-2021SA316368,-,-
19845993,Sectral;Vidaza;Xultophy 100/3.6;Inipomp;Kardegic,Aspirin Dl-Lysine;Pantoprazole Sodium;Furosemide;Venetoclax;Insulin Degludec\Liraglutide;Azacitidine;Febuxostat;Manidipine Hydrochloride;Cholecalciferol;Acebutolol Hydrochloride;Irbesartan;Ezetimibe\Simvastatin;Rivaroxaban;Pregabalin,Atrial Fibrillation;Diabetes Mellitus;Gastrooesophageal Reflux Disease;Hypercholesterolaemia;Hypertension;Hyperuricaemia;Intermittent Claudication;Myelodysplastic Syndrome;Oedema Due To Cardiac Disease;Vascular Disorder Prophylaxis;Vitamin D Deficiency,Sudden Death,Serious,Other Outcomes;Died,Male,18-AUG-2021,30-SEP-2021,Expedited,84 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,24-SEP-2021,17-SEP-2021,FR,Not Specified,FR-SA-2021SA306208,-,-
19815374,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Hand Fracture;Anaemia;Fall,Serious,Other Outcomes,Female,-,29-SEP-2021,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,20-SEP-2021,10-SEP-2021,BR,Not Specified,BR-NOVOPROD-844482,-,-
19893383,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Female,-,28-SEP-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,22-SEP-2021,28-SEP-2021,US,Not Specified,US-SA-2021SA316201,-,-
19887592,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Throat Cancer,Serious,Other Outcomes,Male,2020,28-SEP-2021,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,17-SEP-2021,28-SEP-2021,US,Not Specified,US-NOVOPROD-849722,-,-
16453208,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Product Storage Error,Non-Serious,Non-Serious,Male,-,28-SEP-2021,Non-Expedited,71 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,22-SEP-2021,19-JUN-2019,US,Not Specified,US-SA-2019SA161906,-,-
19882765,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Operational Issue;Injury Associated With Device,Non-Serious,Non-Serious,Male,-,24-SEP-2021,Non-Expedited,53 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-SEP-2021,24-SEP-2021,US,Not Specified,US-SA-2021SA314089,-,-
19855428,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Device Issue;Injection Site Pain,Non-Serious,Non-Serious,Male,-,24-SEP-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,15-SEP-2021,20-SEP-2021,US,Not Specified,US-SA-2021SA305900,-,-
19870002,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Colitis Ischaemic,Serious,Hospitalized,Female,-,23-SEP-2021,Expedited,8 DEC,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,13-SEP-2021,23-SEP-2021,JP,Not Specified,JP-NOVOPROD-848198,-,-
19861418,Xarelto;Xultophy 100/3.6;Inipomp;Sectral;Kardegic;Vidaza;Lyrica,Pregabalin;Azacitidine;Venetoclax;Aspirin Dl-Lysine;Ezetimibe\Simvastatin;Furosemide;Cholecalciferol;Acebutolol Hydrochloride;Pantoprazole Sodium;Febuxostat;Insulin Degludec\Liraglutide;Rivaroxaban;Irbesartan;Manidipine,Atrial Fibrillation;Diabetes Mellitus;Gastrooesophageal Reflux Disease;Hypercholesterolaemia;Hypertension;Hyperuricaemia;Intermittent Claudication;Myelodysplastic Syndrome;Oedema Due To Cardiac Disease;Vascular Disorder Prophylaxis;Vitamin D Deficiency,Sudden Death,Serious,Died;Other Outcomes,Male,18-AUG-2021,21-SEP-2021,Expedited,84 YR,Not Specified,Pfizer,Healthcare Professional,Not Specified,-,12-SEP-2021,20-SEP-2021,FR,Not Specified,FR-PFIZER INC-202101193019,-,-
19861449,Xultophy 100/3.6;Vidaza;Lyrica Cr;Inipomp;Sectral;Kardegic;Xarelto,Rivaroxaban;Aspirin Dl-Lysine;Ezetimibe\Simvastatin;Venetoclax;Irbesartan;Cholecalciferol;Acebutolol Hydrochloride;Pregabalin;Pantoprazole Sodium;Azacitidine;Insulin Degludec\Liraglutide;Febuxostat;Furosemide;Manidipine,Atrial Fibrillation;Diabetes Mellitus;Gastrooesophageal Reflux Disease;Hypercholesterolaemia;Hypertension;Hyperuricaemia;Intermittent Claudication;Myelodysplastic Syndrome;Oedema Due To Cardiac Disease;Vascular Disorder Prophylaxis;Vitamin D Deficiency,Sudden Death,Serious,Died,Male,18-AUG-2021,20-SEP-2021,Expedited,84 YR,Not Specified,Organon,Healthcare Professional,Not Specified,-,14-SEP-2021,20-SEP-2021,FR,Not Specified,FR-ORGANON-O2109FRA001119,-,-
19860811,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Speech Disorder,Non-Serious,Non-Serious,Male,-,20-SEP-2021,Non-Expedited,67 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-SEP-2021,20-SEP-2021,US,Not Specified,US-SA-2021SA307399,-,-
19853342,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration;Visual Impairment,Non-Serious,Non-Serious,Female,-,19-SEP-2021,Non-Expedited,64 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-SEP-2021,19-SEP-2021,US,Not Specified,US-SA-2021SA304995,-,-
19853109,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error;Visual Impairment,Non-Serious,Non-Serious,Female,-,19-SEP-2021,Non-Expedited,77 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Lantus,10-SEP-2021,19-SEP-2021,US,Not Specified,US-SA-2021SA303638,-,-
19849782,Vidaza;Lyrica;Xultophy 100/3.6;Inipomp;Xarelto;Kardegic;Sectral,Acebutolol Hydrochloride;Aspirin Dl-Lysine;Rivaroxaban;Venetoclax;Febuxostat;Manidipine;Cholecalciferol;Ezetimibe\Simvastatin;Irbesartan;Pantoprazole Sodium;Insulin Degludec\Liraglutide;Furosemide;Pregabalin;Azacitidine,Atrial Fibrillation;Diabetes Mellitus;Gastrooesophageal Reflux Disease;Hypercholesterolaemia;Hypertension;Hyperuricaemia;Intermittent Claudication;Myelodysplastic Syndrome;Oedema Due To Cardiac Disease;Vascular Disorder Prophylaxis;Vitamin D Deficiency,Sudden Death,Serious,Other Outcomes;Died,Male,18-AUG-2021,17-SEP-2021,Expedited,84 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,-,12-SEP-2021,17-SEP-2021,FR,Not Specified,FR-TAKEDA-2021TEU007969,-,-
19843909,Xultophy 100/3.6;Inipomp;Sectral;Kardegic,Aspirin Dl-Lysine;Acebutolol Hydrochloride;Pantoprazole Sodium;Febuxostat;Insulin Degludec\Liraglutide;Azacitidine;Furosemide;Manidipine;Ezetimibe\Simvastatin;Venetoclax,Hypertension;Myelodysplastic Syndrome;Product Used For Unknown Indication,Sudden Death,Serious,Died,Male,18-AUG-2021,16-SEP-2021,Expedited,84 YR,Not Specified,Celgene,Healthcare Professional,Not Specified,Acebutolol Hydrochloride;Lactose Monohydrate;Irbesartan;Cholecalciferol;Insulin Degludec;Mannitol;Sorbitol;Hypromelloses;Povidone;Glycerin;Croscarmellose Sodium;Acebutolol;Simvastatin;Water;Talc;Ezetimibe;Furosemide;Propylene Glycol;Liraglutide,13-SEP-2021,16-SEP-2021,FR,Not Specified,FR-CELGENEUS-FRA-20210903414,-,-
19827025,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Female,-,14-SEP-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-SEP-2021,14-SEP-2021,US,Not Specified,US-SA-2021SA300537,-,-
19826458,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Dry Mouth,Non-Serious,Non-Serious,Male,-,13-SEP-2021,Non-Expedited,62 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-SEP-2021,13-SEP-2021,US,Not Specified,US-SA-2021SA299064,-,-
19824045,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,13-SEP-2021,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Glipizide;Metformin,08-SEP-2021,13-SEP-2021,US,Not Specified,US-SA-2021SA298730,-,-
19823709,Xarelto;Xultophy 100/3.6;Sectral;Vidaza;Lyrica;Kardegic;Inipomp,Pantoprazole Sodium;Furosemide;Aspirin Dl-Lysine;Cholecalciferol;Febuxostat;Irbesartan;Pregabalin;Azacitidine;Ezetimibe\Simvastatin;Acebutolol Hydrochloride;Insulin Degludec\Liraglutide;Venetoclax;Rivaroxaban;Manidipine,Atrial Fibrillation;Diabetes Mellitus;Gastrooesophageal Reflux Disease;Hypercholesterolaemia;Hypertension;Hyperuricaemia;Intermittent Claudication;Myelodysplastic Syndrome;Oedema Due To Cardiac Disease;Vascular Disorder Prophylaxis;Vitamin D Deficiency,Sudden Death,Serious,Died,Male,18-AUG-2021,13-SEP-2021,Expedited,84 YR,Not Specified,Abbvie,Healthcare Professional,Not Specified,-,09-SEP-2021,13-SEP-2021,FR,Not Specified,FR-ABBVIE-21K-056-4073311-00,-,-
19822748,Pioglitazone Hydrochloride And Metformin Hydrochloride,Metformin Hydrochloride\Pioglitazone Hydrochloride;Glipizide,Diabetes Mellitus,Oedema Peripheral;Dyspnoea,Serious,Hospitalized,Female,26-JUL-2021,13-SEP-2021,Expedited,49 YR,69 KG,Pfizer,Consumer,Not Specified,-,31-AUG-2021,13-SEP-2021,CN,Not Specified,CN-PFIZER INC-202101134350,-,-
19801782,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Weight Decreased;Hypoglycaemia;Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,08-SEP-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,31-AUG-2021,08-SEP-2021,US,Not Specified,US-SA-2021SA292162,-,-
19748078,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Pain;Acute Lymphocytic Leukaemia,Serious,Other Outcomes,Male,09-JUL-2021,08-SEP-2021,Expedited,35 YR,80 KG,Novo Nordisk,Healthcare Professional,Not Specified,-,27-AUG-2021,26-AUG-2021,MX,Not Specified,MX-NOVOPROD-840860,-,-
19798497,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Increased Appetite;Hyperglycaemia,Non-Serious,Non-Serious,Male,-,06-SEP-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,31-AUG-2021,06-SEP-2021,US,Not Specified,US-SA-2021SA292911,-,-
19790503,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Mobility Decreased;Walking Aid User,Serious,Disabled,Female,-,06-SEP-2021,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-SEP-2021,06-SEP-2021,US,Not Specified,US-SA-2021SA291659,-,-
19789007,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Hyperglycaemia,Non-Serious,Non-Serious,Male,-,06-SEP-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,31-AUG-2021,04-SEP-2021,US,Not Specified,US-SA-2021SA290860,-,-
19781898,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Drug Ineffective,Non-Serious,Non-Serious,Male,-,02-SEP-2021,Non-Expedited,61 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-AUG-2021,02-SEP-2021,US,Not Specified,US-SA-2021SA288307,-,-
19780033,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Lip Infection;Visual Impairment,Non-Serious,Non-Serious,Female,-,02-SEP-2021,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Novolog,12-AUG-2021,02-SEP-2021,US,Not Specified,US-SA-2021SA270561,-,-
19776598,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Male,-,01-SEP-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-SEP-2021,01-SEP-2021,US,Not Specified,US-SA-2021SA288975,-,-
19772732,Soliqua 100/33;Lantus,Insulin Glargine;Insulin Glargine\Lixisenatide;Amlodipine Besylate\Irbesartan,-,Product Use Issue;Myocardial Infarction,Serious,Other Outcomes,Male,18-JUL-2021,31-AUG-2021,Expedited,73 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-AUG-2021,31-AUG-2021,MX,Not Specified,MX-SA-2021SA280924,-,-
19772703,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Visual Impairment,Non-Serious,Non-Serious,Female,-,31-AUG-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-AUG-2021,31-AUG-2021,US,Not Specified,US-SA-2021SA287051,-,-
19768867,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Eructation,Non-Serious,Non-Serious,Male,-,31-AUG-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,25-AUG-2021,31-AUG-2021,US,Not Specified,US-SA-2021SA285571,-,-
19764446,Soliqua 100/33,Insulin Glargine\Lixisenatide,Immunisation;Type 2 Diabetes Mellitus,Cerebrovascular Accident,Serious,Other Outcomes,Male,19-MAR-2021,31-AUG-2021,Expedited,77 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Moderna Covid-19 Vaccine,24-AUG-2021,31-AUG-2021,US,Not Specified,US-SA-2021SA283579,-,-
19768307,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Hypoacusis;Device Issue,Non-Serious,Non-Serious,Male,28-APR-2021,30-AUG-2021,Non-Expedited,76 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-JAN-2021,30-AUG-2021,US,Not Specified,US-SA-2021SA034676,-,-
19763165,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Female,-,30-AUG-2021,Non-Expedited,73 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,25-AUG-2021,30-AUG-2021,US,Not Specified,US-SA-2021SA283936,-,-
19759521,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Vomiting;Nausea;Abdominal Pain;Obstructive Pancreatitis,Serious,Hospitalized;Other Outcomes,Male,-,29-AUG-2021,Non-Expedited,72 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,23-AUG-2021,29-AUG-2021,US,Not Specified,US-SA-2021SA282644,-,-
19758955,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Anaphylactic Reaction,Serious,Other Outcomes,Female,-,29-AUG-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,23-AUG-2021,29-AUG-2021,US,Not Specified,US-SA-2021SA282650,-,-
19748081,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Covid-19,Serious,Hospitalized,Female,AUG-2021,26-AUG-2021,Expedited,9 DEC,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Covid-19 Vaccine Nos,16-AUG-2021,26-AUG-2021,JP,Not Specified,JP-NOVOPROD-839734,-,-
19747831,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,25-AUG-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-AUG-2021,25-AUG-2021,US,Not Specified,US-SA-2021SA280656,-,-
19546525,Soliqua 100/33,Insulin Glargine\Lixisenatide;Voglibose;Solifenacin Succinate,Constipation;Hyperlipidaemia;Pollakiuria;Product Used For Unknown Indication;Rhinitis;Type 2 Diabetes Mellitus,Constipation;Abdominal Pain;Ileus Paralytic;Hyponatraemia,Serious,Other Outcomes;Hospitalized,Female,04-JUN-2021,25-AUG-2021,Expedited,53 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Glycerin;Sodium Picosulfate;Pravastatin Sodium;Metformin Hydrochloride;Vonoprazan Fumarate;Elobixibat;Fexofenadine Hydrochloride\Pseudoephedrine Hydrochloride;Trulicity;Novorapid,19-AUG-2021,15-JUL-2021,JP,Not Specified,JP-SAKK-2021SA228799AA,-,-
19745980,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Cholecystitis Infective,Serious,Hospitalized;Life Threatening;Required Intervention,Male,15-AUG-2021,24-AUG-2021,Direct,63 YR,107.55 KG,Fda-Ctu,Healthcare Professional,Health Professional,Azelastine;Levothyroxine;Sildenafil;Acetaminophen;Potassium Citrate;Ambien;Ibuprofen;Lisinopril;Singulair;Docusate;Aspirin;Metformin;Fenofibrate;Jardiance;Xyzal;Senna;Atorvastatin;Famotidine;Prevacid,-,24-AUG-2021,US,Not Specified,-,-,-
19736332,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injection Site Swelling;Injection Site Erythema;Diabetes Mellitus;Glycosylated Haemoglobin Increased,Serious,Other Outcomes,Not Specified,-,23-AUG-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-AUG-2021,23-AUG-2021,US,Not Specified,US-SA-2021SA276863,-,-
19736329,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Female,-,23-AUG-2021,Non-Expedited,65 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-AUG-2021,23-AUG-2021,US,Not Specified,US-SA-2021SA276677,-,-
19733729,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Multiple Use Of Single-Use Product;Visual Impairment,Non-Serious,Non-Serious,Female,-,23-AUG-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,16-AUG-2021,23-AUG-2021,US,Not Specified,US-SA-2021SA272420,-,-
19732928,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Incorrect Dose Administered By Device;Accidental Exposure To Product;Device Leakage,Non-Serious,Non-Serious,Female,-,23-AUG-2021,Non-Expedited,72 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-AUG-2021,23-AUG-2021,US,Not Specified,US-SA-2021SA272276,-,-
19732793,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Nausea,Non-Serious,Non-Serious,Male,10-AUG-2021,23-AUG-2021,Non-Expedited,69 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Glipizide,17-AUG-2021,23-AUG-2021,US,Not Specified,US-SA-2021SA274822,-,-
19723879,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Cognitive Disorder;Dementia;Prostate Cancer,Serious,Other Outcomes,Male,-,20-AUG-2021,Expedited,69 YR,77 KG,Novo Nordisk,Healthcare Professional,Not Specified,Pantoprazole;Colchicine;Pioglitazone;Tamsulosin;Hydrochlorothiazide\Telmisartan;Pregabalin;Mirtazapine;Aspirin;Vitamin D Nos;Alprazolam;Vitamin B12;Ciprofibrate;Rosuvastatin,11-AUG-2021,20-AUG-2021,BR,Not Specified,BR-NOVOPROD-838489,-,-
19727185,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Weight Decreased;Blood Glucose Decreased,Non-Serious,Non-Serious,Female,-,19-AUG-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-AUG-2021,19-AUG-2021,US,Not Specified,US-SA-2021SA271727,-,-
19722876,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,-,19-AUG-2021,Non-Expedited,84 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-AUG-2021,19-AUG-2021,US,Not Specified,US-SA-2021SA270045,-,-
19716972,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Ejection Fraction Decreased;Cardiac Failure;Coronary Artery Disease;Left Ventricular Dysfunction;Tachycardia,Serious,Other Outcomes,Male,-,19-AUG-2021,Expedited,37 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Lasix;Cholecalciferol;Xarelto;Atorvastatin;Ramipril,09-AUG-2021,19-AUG-2021,BE,Not Specified,BE-NOVOPROD-836886,-,-
19716732,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Illness;Weight Increased;Blood Glucose Increased;Drug Ineffective,Non-Serious,Non-Serious,Female,-,19-AUG-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Ozempic;Tradjenta,11-AUG-2021,19-AUG-2021,US,Not Specified,US-SA-2021SA270654,-,-
19660915,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Device Issue,Non-Serious,Non-Serious,Female,-,19-AUG-2021,Non-Expedited,73 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,11-AUG-2021,05-AUG-2021,US,Not Specified,US-SA-2021SA251096,-,-
19610053,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Rhabdomyolysis,Serious,Hospitalized,Female,-,18-AUG-2021,Expedited,73 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,10-AUG-2021,26-JUL-2021,JP,Not Specified,JP-NOVOPROD-831275,-,-
19710901,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error;Staphylococcal Infection,Serious,Other Outcomes,Female,-,17-AUG-2021,Expedited,51 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-AUG-2021,17-AUG-2021,US,Not Specified,US-SA-2021SA268598,-,-
19707994,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Visual Field Defect;Muscular Weakness;Sensory Disturbance;Balance Disorder;Walking Aid User,Serious,Other Outcomes,Male,-,17-AUG-2021,Expedited,72 YR,78 KG,Novo Nordisk,Healthcare Professional,Not Specified,Losartan;Fluconazole;Cholecalciferol;Empagliflozin;Pantoprazole;Rosuvastatin;Aspirin,03-AUG-2021,17-AUG-2021,BR,Not Specified,BR-NOVOPROD-836634,-,-
19413227,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Cardiac Pacemaker Insertion;Illness;Ammonia Increased,Non-Serious,Non-Serious,Male,04-JUN-2021,17-AUG-2021,Non-Expedited,61 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,11-AUG-2021,14-JUN-2021,US,Not Specified,US-SA-2021SA189344,-,-
19289743,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Abnormal;Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Female,2021,17-AUG-2021,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,11-AUG-2021,21-MAY-2021,US,Not Specified,US-SA-2021SA165542,-,-
19256804,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injection Site Pain,Non-Serious,Non-Serious,Female,-,17-AUG-2021,Non-Expedited,68 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,09-AUG-2021,13-MAY-2021,US,Not Specified,US-SA-2021SA151464,-,-
19194335,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Incorrect Dose Administered,Non-Serious,Non-Serious,Female,15-APR-2021,17-AUG-2021,Non-Expedited,61 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,11-AUG-2021,29-APR-2021,US,Not Specified,US-SA-2021SA129660,-,-
18776619,Soliqua 100/33;Kerlong,Insulin Glargine\Lixisenatide;Betaxolol Hydrochloride,Type 2 Diabetes Mellitus,Blood Glucose Decreased;Loss Of Consciousness;Malaise;Suspected Product Quality Issue,Serious,Other Outcomes,Female,DEC-2020,17-AUG-2021,Non-Expedited,60 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,11-AUG-2021,22-JAN-2021,US,Not Specified,US-SA-2021SA019086,-,-
16200216,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error;Blood Glucose Abnormal;Visual Impairment;Product Quality Issue;Drug Ineffective;Product Packaging Issue,Non-Serious,Non-Serious,Female,-,17-AUG-2021,Non-Expedited,80 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,09-AUG-2021,15-APR-2019,US,Not Specified,US-SA-2019SA104561,-,-
19711092,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Memory Impairment,Non-Serious,Non-Serious,Female,-,16-AUG-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-AUG-2021,16-AUG-2021,US,Not Specified,US-SA-2021SA266319,-,-
19707954,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Circumstance Or Information Capable Of Leading To Medication Error,Non-Serious,Non-Serious,Male,-,16-AUG-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-AUG-2021,16-AUG-2021,US,Not Specified,US-SA-2021SA265425,-,-
19248207,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Vertigo;Product Storage Error,Non-Serious,Non-Serious,Female,-,16-AUG-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,09-AUG-2021,12-MAY-2021,US,Not Specified,US-SA-2021SA146671,-,-
18868726,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Nausea;Blood Glucose Decreased;Cold Sweat;Suspected Product Quality Issue,Non-Serious,Non-Serious,Male,-,16-AUG-2021,Non-Expedited,49 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,10-AUG-2021,09-FEB-2021,US,Not Specified,US-SA-2021SA036167,-,-
19229579,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Operational Issue;Weight Increased;Drug Dose Omission By Device;Blood Glucose Abnormal,Non-Serious,Non-Serious,Female,-,13-AUG-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,09-AUG-2021,07-MAY-2021,US,Not Specified,US-SA-2021SA138562,-,-
19065315,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Depressed Mood;Blood Glucose Abnormal;Gait Disturbance,Non-Serious,Non-Serious,Female,-,13-AUG-2021,Non-Expedited,68 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,09-AUG-2021,27-MAR-2021,US,Not Specified,US-SA-2021SA091692,-,-
19691961,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Blood Glucose Increased;Appetite Disorder;Diabetic Retinopathy;Carotid Arteriosclerosis;Nausea;Constipation,Serious,Other Outcomes,Female,-,12-AUG-2021,Expedited,50 YR,89.9 KG,Novo Nordisk,Healthcare Professional,Not Specified,Hydrochlorothiazide;Losartan;Rosuvastatin;Metformin,30-JUL-2021,12-AUG-2021,BR,Not Specified,BR-NOVOPROD-835357,-,-
19642210,Metact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Hyperglycaemia,Oedema Peripheral;Thrombosis,Serious,Other Outcomes,Female,20-JUL-2021,10-AUG-2021,Expedited,82 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,-,02-AUG-2021,31-JUL-2021,JP,Not Specified,JP-TAKEDA-2021TJP067324,-,-
19679168,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Headache,Non-Serious,Non-Serious,Male,30-JUL-2021,09-AUG-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,02-AUG-2021,09-AUG-2021,US,Not Specified,US-SA-2021SA257636,-,-
19677364,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Pruritus;Nasal Congestion;Dyspnoea;Weight Increased;Hyperhidrosis;Therapeutic Response Unexpected;Sneezing;Diarrhoea;Product Prescribing Issue;Hunger,Non-Serious,Non-Serious,Female,-,09-AUG-2021,Non-Expedited,69 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Humalog;Trulicity,29-JUL-2021,09-AUG-2021,US,Not Specified,US-SA-2021SA255971,-,-
19656413,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Dispensing Issue;Product Storage Error,Non-Serious,Non-Serious,Female,-,04-AUG-2021,Non-Expedited,50 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-JUL-2021,04-AUG-2021,US,Not Specified,US-SA-2021SA249550,-,-
19652542,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration;Stress,Non-Serious,Non-Serious,Female,26-JUL-2021,03-AUG-2021,Non-Expedited,77 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-JUL-2021,03-AUG-2021,US,Not Specified,US-SA-2021SA251367,-,-
19652523,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Rash,Non-Serious,Non-Serious,Female,-,03-AUG-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Lipitor,26-JUL-2021,03-AUG-2021,US,Not Specified,US-SA-2021SA251818,-,-
19652497,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Male,-,03-AUG-2021,Non-Expedited,48 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-JUL-2021,03-AUG-2021,US,Not Specified,US-SA-2021SA251356,-,-
19648870,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Coronary Artery Stenosis;Myocardial Ischaemia;Dyspnoea,Serious,Other Outcomes,Female,-,03-AUG-2021,Expedited,75 YR,90 KG,Novo Nordisk,Healthcare Professional,Not Specified,-,24-JUL-2021,03-AUG-2021,BR,Not Specified,BR-NOVOPROD-833567,-,-
19648264,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Male,-,02-AUG-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-JUL-2021,02-AUG-2021,US,Not Specified,US-SA-2021SA248310,-,-
19645615,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Diabetic Retinopathy,Serious,Other Outcomes,Female,-,02-AUG-2021,Expedited,59 YR,94 KG,Novo Nordisk,Healthcare Professional,Not Specified,Gliclazide;Rosuvastatin;Metformin Hydrochloride;Dapagliflozin,20-JUL-2021,02-AUG-2021,BR,Not Specified,BR-NOVOPROD-832233,-,-
19081957,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Sudden Death,Serious,Died,Male,14-MAR-2021,02-AUG-2021,Expedited,Not Specified,96 KG,Novo Nordisk,Consumer,Not Specified,-,22-MAR-2021,01-APR-2021,PK,Not Specified,PK-NOVOPROD-798172,-,-
19639052,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Fatigue;Somnolence,Non-Serious,Non-Serious,Female,-,29-JUL-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-JUL-2021,29-JUL-2021,US,Not Specified,US-SA-2021SA246655,-,-
19638738,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Illness,Non-Serious,Non-Serious,Female,-,29-JUL-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Humalog;Caltrate;Glimepiride;Vitamin D3;Atorvastatin;Bisoprolol;Bayer Aspirin;Actos,15-JUL-2021,29-JUL-2021,US,Not Specified,US-SA-2021SA236704,-,-
19625131,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Inappropriate Schedule Of Product Administration;Cerebrovascular Accident,Serious,Hospitalized;Other Outcomes,Female,-,29-JUL-2021,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,Metformin,11-JUL-2021,29-JUL-2021,IT,Not Specified,IT-NOVOPROD-830172,-,-
19630886,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Male,-,28-JUL-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,22-JUL-2021,28-JUL-2021,US,Not Specified,US-SA-2021SA245119,-,-
19630655,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Dose Omission Issue,Non-Serious,Non-Serious,Male,JUL-2021,28-JUL-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-JUL-2021,28-JUL-2021,US,Not Specified,US-SA-2021SA241160,-,-
19630431,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 1 Diabetes Mellitus,Pulmonary Mass;Impaired Work Ability;Tremor;Inappropriate Schedule Of Product Administration;Blood Glucose Decreased,Serious,Disabled,Female,-,28-JUL-2021,Non-Expedited,69 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-JUL-2021,28-JUL-2021,US,Not Specified,US-SA-2021SA242072,-,-
19620298,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Covid-19;Skin Neoplasm Excision;Hyperglycaemia;Hypoglycaemia;Anxiety,Serious,Hospitalized;Other Outcomes,Female,-,28-JUL-2021,Expedited,84 YR,81 KG,Novo Nordisk,Healthcare Professional,Not Specified,Methylcobalamin;Alogliptin Benzoate\Metformin Hydrochloride;Rosuvastatin;Novorapid;Puran,15-JUL-2021,28-JUL-2021,BR,Not Specified,BR-NOVOPROD-831090,-,-
19610863,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Drug Interaction;Toxicity To Various Agents,Serious,Other Outcomes,Not Specified,-,26-JUL-2021,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Tacrolimus,20-JUL-2021,26-JUL-2021,HN,Not Specified,HN-SA-2021SA242823,-,-
19603078,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Not Specified,-,24-JUL-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-JUL-2021,24-JUL-2021,US,Not Specified,US-SA-2021SA241138,-,-
19602503,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Intercepted Product Storage Error,Non-Serious,Non-Serious,Female,-,24-JUL-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,16-JUL-2021,24-JUL-2021,US,Not Specified,US-SA-2021SA240160,-,-
19597665,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Breast Cancer;Glomerular Filtration Rate Decreased,Serious,Other Outcomes,Female,-,23-JUL-2021,Expedited,80 YR,82.7 KG,Novo Nordisk,Healthcare Professional,Not Specified,Venlafaxine Hydrochloride;Aspirin;Carvedilol;Furosemide;Clopidogrel;Metformin;Rosuvastatin;Sitagliptin;Spironolactone;Losartan;Dapagliflozin;Amiodarone,12-JUL-2021,23-JUL-2021,BR,Not Specified,BR-NOVOPROD-830193,-,-
19595748,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Female,-,23-JUL-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,15-JUL-2021,23-JUL-2021,US,Not Specified,US-SA-2021SA238102,-,-
19599382,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Decreased;Glycosylated Haemoglobin Abnormal,Non-Serious,Non-Serious,Female,-,22-JUL-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin,14-JUL-2021,22-JUL-2021,US,Not Specified,US-SA-2021SA236097,-,-
19596733,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Increased,Non-Serious,Non-Serious,Not Specified,-,22-JUL-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-JUL-2021,22-JUL-2021,US,Not Specified,US-SA-2021SA234021,-,-
19595287,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Use Complaint,Non-Serious,Non-Serious,Female,-,22-JUL-2021,Non-Expedited,62 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-JUL-2021,22-JUL-2021,US,Not Specified,US-SA-2021SA234551,-,-
19590484,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Memory Impairment,Non-Serious,Non-Serious,Female,-,21-JUL-2021,Non-Expedited,72 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-JUL-2021,21-JUL-2021,US,Not Specified,US-SA-2021SA231754,-,-
19570824,Januvia,Sitagliptin Phosphate;Gliclazide;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 1 Diabetes Mellitus;Type 2 Diabetes Mellitus,Hypoglycaemic Coma;Urinary Incontinence;Type 1 Diabetes Mellitus;Foaming At Mouth;Type 2 Diabetes Mellitus,Serious,Other Outcomes,Male,28-JUN-2021,21-JUL-2021,Expedited,65 YR,65 KG,Merck,Healthcare Professional,Not Specified,-,21-JUL-2021,16-JUL-2021,CN,Not Specified,CN-009507513-2107CHN005191,-,-
19580903,Soliqua 100/33;Ozempic,Semaglutide;Insulin Glargine\Lixisenatide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Benign Neoplasm Of Thyroid Gland;Blood Thyroid Stimulating Hormone Increased,Non-Serious,Non-Serious,Male,-,19-JUL-2021,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,Metformin,16-APR-2021,19-JUL-2021,US,Not Specified,US-NOVOPROD-805805,-,-
19556833,Metformin;Victoza,Liraglutide;Metformin Hydrochloride;Insulin Glargine\Lixisenatide,Product Used For Unknown Indication,Respiration Abnormal;Malaise;Cachexia;Blood Glucose Increased;Diabetes Mellitus,Serious,Other Outcomes,Not Specified,DEC-2020,15-JUL-2021,Expedited,Not Specified,Not Specified,Mylan,Consumer,Not Specified,Lixisenatide;Insulin Glargine,12-JUL-2021,15-JUL-2021,SE,Not Specified,SE-MYLANLABS-2021M1042257,-,-
19567482,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error;Product Dose Omission Issue,Non-Serious,Non-Serious,Male,06-JUL-2021,14-JUL-2021,Non-Expedited,63 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-JUL-2021,14-JUL-2021,US,Not Specified,US-SA-2021SA226413,-,-
19552634,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error;Vomiting;Abdominal Pain Upper;Nausea,Non-Serious,Non-Serious,Female,01-JUL-2021,14-JUL-2021,Non-Expedited,41 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,02-JUL-2021,14-JUL-2021,US,Not Specified,US-SA-2021SA223231,-,-
19532573,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Pancreatic Carcinoma,Serious,Other Outcomes,Male,-,14-JUL-2021,Expedited,83 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,01-JUL-2021,14-JUL-2021,US,Not Specified,US-SA-2021SA219921,-,-
19520901,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Diabetes Mellitus Inadequate Control,Serious,Other Outcomes,Female,-,14-JUL-2021,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,02-JUL-2021,12-JUL-2021,US,Not Specified,US-SA-2021SA221871,-,-
19526773,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Liver Disorder,Serious,Hospitalized,Male,-,13-JUL-2021,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,02-JUL-2021,13-JUL-2021,TN,Not Specified,TN-NOVOPROD-827490,-,-
19514529,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,-,10-JUL-2021,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-JUN-2021,10-JUL-2021,US,Not Specified,US-SA-2021SA218252,-,-
19514967,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Subcutaneous Abscess;Diabetes Mellitus Inadequate Control;Cellulitis;Abdominal Abscess;Hiv Test Positive,Serious,Other Outcomes,Male,JAN-2020,09-JUL-2021,Expedited,49 YR,120 KG,Novo Nordisk,Healthcare Professional,Not Specified,Metformin;Losartan;Glimepiride;Fenofibrate;Novorapid,30-MAY-2021,09-JUL-2021,BR,Not Specified,BR-NOVOPROD-822792,-,-
19508874,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Gait Disturbance;Cerebrovascular Accident;Hemiplegia,Serious,Other Outcomes;Disabled,Male,MAY-2021,08-JUL-2021,Expedited,81 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-JUN-2021,08-JUL-2021,US,Not Specified,US-SA-2021SA214603,-,-
19360249,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Breast Cancer Metastatic;Thoracic Vertebral Fracture;Breast Cancer Recurrent;Orthostatic Hypotension;Diastolic Dysfunction,Serious,Other Outcomes,Female,10-JUN-2020,08-JUL-2021,Expedited,75 YR,83.8 KG,Novo Nordisk,Consumer,Not Specified,Metformin;Ezetimibe;Aspirin;Rosuvastatin;Vitamin D3;Lisinopril;Empagliflozin;Calcium Carbonate,17-MAY-2021,01-JUN-2021,BR,Not Specified,BR-NOVOPROD-816988,-,-
19081961,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Myocardial Infarction,Serious,Hospitalized,Male,14-FEB-2021,07-JUL-2021,Expedited,Not Specified,86 KG,Novo Nordisk,Consumer,Not Specified,Glucophage,22-MAR-2021,01-APR-2021,PK,Not Specified,PK-NOVOPROD-798178,-,-
19490378,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Parathyroid Tumour Benign;Dizziness;Diabetes Mellitus Inadequate Control,Serious,Other Outcomes,Not Specified,-,05-JUL-2021,Expedited,77 YR,97.8 KG,Novo Nordisk,Consumer,Not Specified,Atenolol;Enalapril;Allopurinol;Gliclazide;Atorvastatin;Metformin Hydrochloride;Amlodipine,22-JUN-2021,05-JUL-2021,BR,Not Specified,BR-NOVOPROD-824633,-,-
19488864,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Female,-,02-JUL-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-JUN-2021,02-JUL-2021,US,Not Specified,US-SA-2021SA217849,-,-
19487749,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Female,-,02-JUL-2021,Non-Expedited,50 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-JUN-2021,02-JUL-2021,US,Not Specified,US-SA-2021SA212139,-,-
19484134,Xultophy 100/3.6;Novorapid,Insulin Aspart;Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Anxiety;Anaemia;Poor Quality Sleep;Adenocarcinoma;Hunger;Hypoglycaemia;Hyperglycaemia,Serious,Other Outcomes,Male,FEB-2021,01-JUL-2021,Expedited,73 YR,77.5 KG,Novo Nordisk,Healthcare Professional,Not Specified,Topiramate,20-JUN-2021,01-JUL-2021,BR,Not Specified,BR-NOVOPROD-824041,-,-
19479453,Soliqua 100/33,Insulin Glargine\Lixisenatide,Product Used For Unknown Indication,Angina Pectoris;Product Dose Omission Issue,Serious,Hospitalized;Other Outcomes,Not Specified,28-JUN-2021,01-JUL-2021,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,28-JUN-2021,01-JUL-2021,JP,Not Specified,JP-SA-2021SA212030,-,-
19469764,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Spinal Fracture;Injection Site Pain;Device Use Issue,Serious,Other Outcomes,Female,2021,01-JUL-2021,Expedited,68 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,21-JUN-2021,29-JUN-2021,US,Not Specified,US-SA-2021SA204306,-,-
19166898,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Fracture;Brain Stem Infarction,Serious,Other Outcomes;Died;Hospitalized,Male,31-MAR-2021,29-JUN-2021,Expedited,65 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,25-JUN-2021,21-APR-2021,JP,Not Specified,JP-SA-2021SA130469,-,-
19465816,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Circumstance Or Information Capable Of Leading To Medication Error,Non-Serious,Non-Serious,Female,-,26-JUN-2021,Non-Expedited,46 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,22-JUN-2021,26-JUN-2021,US,Not Specified,US-SA-2021SA209063,-,-
19463899,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,25-JUN-2021,Non-Expedited,76 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,17-JUN-2021,25-JUN-2021,US,Not Specified,US-SA-2021SA202767,-,-
19463876,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,-,25-JUN-2021,Non-Expedited,74 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Humalog,16-JUN-2021,25-JUN-2021,US,Not Specified,US-SA-2021SA203032,-,-
19454831,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Diabetic Coma,Serious,Other Outcomes,Female,-,23-JUN-2021,Expedited,44 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-JUN-2021,23-JUN-2021,MX,Not Specified,MX-SA-2021SA201531,-,-
19454109,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Male,-,23-JUN-2021,Non-Expedited,72 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,15-JUN-2021,23-JUN-2021,US,Not Specified,US-SA-2021SA201079,-,-
19453008,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,23-JUN-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,11-JUN-2021,23-JUN-2021,US,Not Specified,US-SA-2021SA199344,-,-
19448736,Lantus Solostar;Soliqua 100/33;Toujeo Max,Insulin Glargine;Insulin Glargine\Lixisenatide;Insulin Glargine,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,22-JUN-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,14-JUN-2021,22-JUN-2021,US,Not Specified,US-SA-2021SA198840,-,-
19278039,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injection Site Pain;Blood Glucose Increased;Device Issue;Incorrect Dose Administered By Device;Injection Site Haemorrhage,Non-Serious,Non-Serious,Male,2021,22-JUN-2021,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,10-JUN-2021,20-MAY-2021,US,Not Specified,US-SA-2021SA163631,-,-
19440740,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Incisional Hernia;Cholelithiasis;Gamma-Glutamyltransferase Increased;Urinary Tract Infection,Serious,Other Outcomes,Female,-,21-JUN-2021,Expedited,78 YR,66.2 KG,Novo Nordisk,Healthcare Professional,Not Specified,Metformin Hydrochloride,08-JUN-2021,21-JUN-2021,BR,Not Specified,BR-NOVOPROD-820662,-,-
19439719,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Female,-,20-JUN-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-JUN-2021,20-JUN-2021,US,Not Specified,US-SA-2021SA196628,-,-
19436909,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Dementia;Fall;Multiple Fractures,Serious,Other Outcomes,Female,-,18-JUN-2021,Expedited,74 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-JUN-2021,18-JUN-2021,US,Not Specified,US-SA-2021SA195066,-,-
19429937,Xultophy 100/3.6,Insulin Degludec\Liraglutide;Insulin Human,Diabetes Mellitus;Product Used For Unknown Indication,Hypoglycaemia;Acute Myocardial Infarction,Serious,Other Outcomes,Male,-,17-JUN-2021,Expedited,73 YR,83.2 KG,Novo Nordisk,Consumer,Not Specified,Amlodipine Besylate;Livalo;Losartan Potassium;Puran;Aspirin\Dihydroxyaluminum Aminoacetate Anhydrous\Magnesium Carbonate;Hydrochlorothiazide;Vildagliptin;Metformin Hydrochloride;Bisoprolol Fumarate,14-NOV-2020,17-JUN-2021,BR,Not Specified,BR-NOVOPROD-814007,-,-
19429846,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Female,-,17-JUN-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-JUN-2021,17-JUN-2021,US,Not Specified,US-SA-2021SA199751,-,-
19426045,Xultophy 100/3.6;Fiasp,Insulin Aspart;Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Product Use Issue;Peripheral Artery Occlusion;Hyperglycaemia;Diabetic Foot;Covid-19,Serious,Hospitalized;Other Outcomes,Male,JAN-2021,17-JUN-2021,Expedited,57 YR,77.5 KG,Novo Nordisk,Healthcare Professional,Not Specified,Xigduo Xr;Arava;Aspirin;Crestor;Nebivolol,07-JUN-2021,17-JUN-2021,BR,Not Specified,BR-NOVOPROD-820619,-,-
19426168,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Female,-,16-JUN-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-JUN-2021,16-JUN-2021,US,Not Specified,US-SA-2021SA195178,-,-
19414348,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Varicose Vein,Serious,Other Outcomes,Male,17-SEP-2018,16-JUN-2021,Expedited,50 YR,95.8 KG,Novo Nordisk,Healthcare Professional,Not Specified,Metformin Hydrochloride,01-JUN-2021,15-JUN-2021,BR,Not Specified,BR-NOVOPROD-820004,-,-
19239166,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Issue;Product Storage Error;Injury Associated With Device,Non-Serious,Non-Serious,Female,-,16-JUN-2021,Non-Expedited,81 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,04-JUN-2021,10-MAY-2021,US,Not Specified,US-SA-2021SA141726,-,-
19412843,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Abnormal;Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Female,-,14-JUN-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,04-JUN-2021,14-JUN-2021,US,Not Specified,US-SA-2021SA188204,-,-
19411191,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Sudden Death,Serious,Died,Male,31-MAY-2021,14-JUN-2021,Expedited,68 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Enalapril;Metformin Hydrochloride;Dapagliflozin;Torsemide;Crestor,02-JUN-2021,14-JUN-2021,UA,Not Specified,UA-NOVOPROD-818733,-,-
19408229,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,-,12-JUN-2021,Non-Expedited,41 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,07-JUN-2021,12-JUN-2021,US,Not Specified,US-SA-2021SA191602,-,-
19407454,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Decreased;Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Not Specified,-,12-JUN-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,02-JUN-2021,12-JUN-2021,US,Not Specified,US-SA-2021SA187806,-,-
19406810,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,12-JUN-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,08-JUN-2021,12-JUN-2021,US,Not Specified,US-SA-2021SA193764,-,-
19406923,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Coronary Artery Bypass;Dyspepsia,Serious,Hospitalized,Male,17-MAR-2021,11-JUN-2021,Expedited,74 YR,80 KG,Novo Nordisk,Healthcare Professional,Not Specified,Rosuvastatin;Enalapril;Jardiance;Ezetimibe;Metformin Hydrochloride;Aspirin,26-MAY-2021,11-JUN-2021,BR,Not Specified,BR-NOVOPROD-818813,-,-
19402211,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Covid-19,Serious,Hospitalized,Male,-,11-JUN-2021,Expedited,54 YR,84 KG,Novo Nordisk,Healthcare Professional,Not Specified,Xigduo Xr;Glifage;Glimepiride;Atorvastatin;Testosterone Cypionate,01-JUN-2021,11-JUN-2021,BR,Not Specified,BR-NOVOPROD-819307,-,-
19400831,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Decreased,Non-Serious,Non-Serious,Male,-,10-JUN-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Basaglar;Novolog,28-MAY-2021,10-JUN-2021,US,Not Specified,US-SA-2021SA182078,-,-
19399932,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Cardiac Failure;Anxiety,Serious,Hospitalized;Other Outcomes,Female,SEP-2020,10-JUN-2021,Expedited,54 YR,95.8 KG,Novo Nordisk,Healthcare Professional,Not Specified,Macrodantin;Atenolol;Pantoprazole;Furosemide;Puran;Jardiance;Topiramate;Warfarin;Digoxin;Zolpidem;Paroxetine,31-MAY-2021,10-JUN-2021,BR,Not Specified,BR-NOVOPROD-819195,-,-
19399768,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Fall;Fractured Coccyx;Inappropriate Schedule Of Product Administration;Obstruction Gastric;Benign Prostatic Hyperplasia;Corneal Bleeding;Blood Glucose Increased,Serious,Other Outcomes,Male,-,10-JUN-2021,Expedited,72 YR,108 KG,Novo Nordisk,Healthcare Professional,Not Specified,Ezetimibe;Alprazolam;Dapagliflozin;Rosuvastatin;Bisoprolol;Zolpidem,31-MAY-2021,10-JUN-2021,BR,Not Specified,BR-NOVOPROD-819131,-,-
19399218,Competact;Metformin,Metformin Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Metabolic Acidosis,Serious,Hospitalized,Female,24-NOV-2020,10-JUN-2021,Expedited,84 YR,Not Specified,Mylan,Healthcare Professional,Not Specified,Aspirin;Atenolol,07-JUN-2021,10-JUN-2021,IT,Not Specified,IT-MYLANLABS-2021M1033549,-,-
19397057,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Female,-,10-JUN-2021,Non-Expedited,73 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-MAY-2021,10-JUN-2021,US,Not Specified,US-SA-2021SA183551,-,-
19256169,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Issue;Blood Glucose Increased;Product Dose Omission Issue,Non-Serious,Non-Serious,Female,-,10-JUN-2021,Non-Expedited,69 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Metformin,28-MAY-2021,13-MAY-2021,US,Not Specified,US-SA-2021SA158973,-,-
19384778,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Covid-19,Serious,Died,Female,-,08-JUN-2021,Expedited,75 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,03-MAR-2021,08-JUN-2021,JP,Not Specified,JP-NOVOPROD-816755,-,-
19382898,Toujeo;Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Glargine,-,Injection Site Erythema;Injection Site Hypersensitivity,Non-Serious,Non-Serious,Not Specified,-,07-JUN-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Tresiba,24-MAY-2021,07-JUN-2021,US,Not Specified,US-SA-2021SA175298,-,-
19381186,Xultophy 100/3.6,Insulin Degludec\Liraglutide;Insulin Human,Product Used For Unknown Indication;Supplementation Therapy,Prostate Cancer,Serious,Hospitalized;Other Outcomes,Male,-,07-JUN-2021,Expedited,72 YR,81 KG,Novo Nordisk,Healthcare Professional,Not Specified,Carvedilol;Clopidogrel;Aspirin;Jardiance;Atorvastatin;Losartan Potassium;Vitamin D3;Vitamin B12;Omeprazole;Glifage;Hydrochlorothiazide,27-MAY-2021,07-JUN-2021,BR,Not Specified,BR-NOVOPROD-818316,-,-
19380567,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Asthenia;Nightmare;Confusional State;Road Traffic Accident;Dizziness;Renal Transplant,Serious,Other Outcomes,Female,-,07-JUN-2021,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,27-MAY-2021,07-JUN-2021,IL,Not Specified,IL-NOVOPROD-817458,-,-
19379634,Novorapid;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Insulin Aspart,Product Used For Unknown Indication,Eye Haemorrhage;Hypoglycaemia;Organic Acid Analysis Abnormal;Hyperglycaemia,Serious,Other Outcomes,Male,FEB-2020,07-JUN-2021,Expedited,56 YR,88 KG,Novo Nordisk,Consumer,Not Specified,Simvastatin;Clopidogrel;Losartan;Atenolol;Metformin;Aspirin;Amlodipine;Indapamide;Metformin Hydrochloride,26-MAY-2021,07-JUN-2021,BR,Not Specified,BR-NOVOPROD-817562,-,-
19377942,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,05-JUN-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,01-JUN-2021,05-JUN-2021,US,Not Specified,US-SA-2021SA183998,-,-
19377125,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,05-JUN-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-JUN-2021,05-JUN-2021,US,Not Specified,US-SA-2021SA183894,-,-
19376505,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus;Supplementation Therapy,Urinary Tract Infection;Peripheral Artery Stenosis;Apnoea;Peripheral Venous Disease;Cataract Operation;Dysuria;Arteriosclerosis;Arterial Occlusive Disease;Orthostatic Hypotension,Serious,Other Outcomes,Female,2018,04-JUN-2021,Expedited,74 YR,74 KG,Novo Nordisk,Healthcare Professional,Not Specified,Simvastatin;Enalapril Maleate;Empagliflozin;Indapamide;Metformin;Calcium Carbonate;Thiamine;Rosuvastatin;Pyridoxine;Cholecalciferol;Cyanocobalamin,22-MAY-2021,04-JUN-2021,BR,Not Specified,BR-NOVOPROD-816336,-,-
19372246,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Multiple Use Of Single-Use Product,Non-Serious,Non-Serious,Male,-,04-JUN-2021,Non-Expedited,52 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,24-MAY-2021,04-JUN-2021,US,Not Specified,US-SA-2021SA175295,-,-
19371638,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Neoplasm Malignant;Nerve Injury,Serious,Other Outcomes,Male,-,04-JUN-2021,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,26-MAY-2021,04-JUN-2021,US,Not Specified,US-NOVOPROD-816622,-,-
19362921,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Covid-19,Serious,Hospitalized,Male,JAN-2021,03-JUN-2021,Expedited,79 YR,116 KG,Novo Nordisk,Healthcare Professional,Not Specified,Allopurinol;Doxazosin Mesylate;Finasteride;Metformin,24-MAY-2021,03-JUN-2021,BR,Not Specified,BR-NOVOPROD-816757,-,-
19368586,Lantus Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Glargine,-,Macular Degeneration;Condition Aggravated;Cerebrovascular Accident;Initial Insomnia,Serious,Other Outcomes,Male,-,02-JUN-2021,Expedited,65 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-MAY-2021,02-JUN-2021,US,Not Specified,US-SA-2021SA172359,-,-
19362498,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Blood Glucose Increased;Limb Injury;Malignant Melanoma;Blood Glucose Decreased;Wound Infection,Serious,Other Outcomes,Female,-,02-JUN-2021,Expedited,63 YR,127.2 KG,Novo Nordisk,Healthcare Professional,Not Specified,Insulin Lispro;Rosuvastatin;Cholecalciferol;Metformin,21-MAY-2021,02-JUN-2021,BR,Not Specified,BR-NOVOPROD-816270,-,-
19358391,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Anxiety;Dyslipidaemia;Hypertension;Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Blood Glucose Decreased;Diabetes Mellitus Inadequate Control;Covid-19,Serious,Other Outcomes;Hospitalized,Male,DEC-2020,02-JUN-2021,Expedited,63 YR,118 KG,Novo Nordisk,Healthcare Professional,Not Specified,Losartan;Atorvastatin;Fluoxetine;Amlodipine;Pioglitazone;Dapagliflozin Propanediol\Metformin Hydrochloride;Ciprofibrate;Indapamide;Atenolol,21-MAY-2021,02-JUN-2021,BR,Not Specified,BR-NOVOPROD-816210,-,-
19353014,Novorapid;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Insulin Aspart,Product Used For Unknown Indication,Cardiac Failure,Serious,Hospitalized,Female,-,01-JUN-2021,Expedited,88 YR,101.1 KG,Novo Nordisk,Healthcare Professional,Not Specified,Atorvastatin;Entresto;Carvedilol;Spironolactone;Furosemide,18-MAY-2021,01-JUN-2021,BR,Not Specified,BR-NOVOPROD-817246,-,-
19352509,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,-,01-JUN-2021,Non-Expedited,63 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-MAY-2021,01-JUN-2021,US,Not Specified,US-SA-2021SA175550,-,-
19350126,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Hyperglycaemia;Myocardial Ischaemia;Weight Decreased,Serious,Other Outcomes,Male,2021,31-MAY-2021,Expedited,52 YR,83 KG,Novo Nordisk,Healthcare Professional,Not Specified,Metformin;Alogliptin Benzoate\Pioglitazone Hydrochloride,18-MAY-2021,31-MAY-2021,BR,Not Specified,BR-NOVOPROD-815361,-,-
19264062,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Covid-19;Blood Glucose Increased,Serious,Hospitalized,Female,-,31-MAY-2021,Expedited,46 YR,73 KG,Novo Nordisk,Healthcare Professional,Not Specified,Insulin Nos;Metformin;Rosuvastatin;Losartan And Hydrochlorothiazide;Gliclazide,20-MAY-2021,17-MAY-2021,BR,Not Specified,BR-NOVOPROD-811848,-,-
19224371,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Blood Pressure Increased;Blood Pressure Decreased;Myocardial Infarction,Serious,Hospitalized;Other Outcomes;Died,Female,21-APR-2021,31-MAY-2021,Expedited,45 YR,102 KG,Novo Nordisk,Consumer,Not Specified,Humulin 70/30,19-MAY-2021,06-MAY-2021,PK,Not Specified,PK-NOVOPROD-809489,-,-
19324994,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Renal Impairment,Serious,Other Outcomes,Not Specified,-,28-MAY-2021,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,17-MAY-2021,28-MAY-2021,US,Not Specified,US-SA-2021SA168149,-,-
19323753,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Surgery,Non-Serious,Non-Serious,Female,-,28-MAY-2021,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-MAY-2021,28-MAY-2021,US,Not Specified,US-SA-2021SA170285,-,-
19323225,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Asthenia;Blood Pressure Increased,Serious,Hospitalized,Female,28-APR-2021,28-MAY-2021,Expedited,55 YR,83 KG,Sanofi Aventis,Healthcare Professional,Not Specified,Metformin;Vildagliptin,17-MAY-2021,28-MAY-2021,RU,Not Specified,RU-SA-2021SA164829,-,-
19322250,Byetta;Soliqua 100/33;Metformin;Humalog;Victoza,Liraglutide;Insulin Lispro;Metformin Hydrochloride;Insulin Glargine\Lixisenatide;Glipizide;Exenatide,Type 2 Diabetes Mellitus,Weight Increased;Drug Intolerance;Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,28-MAY-2021,Non-Expedited,Not Specified,Not Specified,Eli Lilly And Co,Consumer,Not Specified,Lantus,30-APR-2021,28-MAY-2021,US,Not Specified,US-ELI_LILLY_AND_COMPANY-US202105003609,-,-
19322013,Xultophy 100/3.6,Insulin Degludec\Liraglutide;Insulin Aspart,Diabetes Mellitus;Hypertension,Nausea;Carotid Artery Occlusion;Coronary Artery Occlusion,Serious,Other Outcomes,Female,-,28-MAY-2021,Expedited,60 YR,75.4 KG,Novo Nordisk,Healthcare Professional,Not Specified,Aspirin;Bisoprolol;Candesartan Cilexetil\Hydrochlorothiazide;Metformin;Rosuvastatin;Ezetimibe,17-MAY-2021,28-MAY-2021,BR,Not Specified,BR-NOVOPROD-815357,-,-
19252196,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Covid-19,Serious,Hospitalized;Died,Male,17-FEB-2021,28-MAY-2021,Expedited,75 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,19-MAY-2021,13-MAY-2021,PK,Not Specified,PK-NOVOPROD-810576,-,-
19321381,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,-,27-MAY-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-MAY-2021,27-MAY-2021,US,Not Specified,US-SA-2021SA172998,-,-
19314796,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Male,-,27-MAY-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-MAY-2021,27-MAY-2021,US,Not Specified,US-SA-2021SA170287,-,-
19299112,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Cardio-Respiratory Arrest;Acute Myocardial Infarction,Serious,Other Outcomes,Male,JAN-2021,25-MAY-2021,Expedited,78 YR,198.5 KG,Novo Nordisk,Healthcare Professional,Not Specified,Jardiance;Glimepiride;Metformin Hydrochloride\Vildagliptin;Metformin Hydrochloride,15-MAY-2021,25-MAY-2021,BR,Not Specified,BR-NOVOPROD-814334,-,-
19297666,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Maternal Exposure During Pregnancy,Non-Serious,Non-Serious,Female,-,24-MAY-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,13-MAY-2021,24-MAY-2021,US,Not Specified,US-SA-2021SA166361,-,-
19295432,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Decreased,Serious,Hospitalized,Female,-,24-MAY-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-MAY-2021,24-MAY-2021,US,Not Specified,US-SA-2021SA162084,-,-
19295218,Soliqua 100/33;Toujeo Max;Lantus Solostar,Insulin Glargine;Insulin Glargine;Insulin Glargine\Lixisenatide,-,Product Temperature Excursion Issue,Non-Serious,Non-Serious,Not Specified,17-MAR-2021,24-MAY-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,12-MAY-2021,24-MAY-2021,US,Not Specified,US-SA-2021SA162170,-,-
19293117,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,24-MAY-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,14-MAY-2021,24-MAY-2021,US,Not Specified,US-SA-2021SA166480,-,-
19292846,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,24-MAY-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,13-MAY-2021,24-MAY-2021,US,Not Specified,US-SA-2021SA165114,-,-
19292531,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Delivery System Issue;Product Dose Omission Issue,Non-Serious,Non-Serious,Female,-,24-MAY-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-MAY-2021,24-MAY-2021,US,Not Specified,US-SA-2021SA164133,-,-
19287825,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Male,-,22-MAY-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-MAY-2021,22-MAY-2021,US,Not Specified,US-SA-2021SA165478,-,-
19287842,Soliqua 100/33,Insulin Glargine\Lixisenatide,Multiple Endocrine Neoplasia,Off Label Use,Non-Serious,Non-Serious,Not Specified,-,21-MAY-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,13-MAY-2021,21-MAY-2021,US,Not Specified,US-SA-2021SA163398,-,-
19285664,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Dose Omission Issue,Non-Serious,Non-Serious,Female,-,21-MAY-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-MAY-2021,21-MAY-2021,US,Not Specified,US-SA-2021SA163549,-,-
19277723,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Condition Aggravated;Cervical Radiculopathy;Aortic Arteriosclerosis;Renal Cyst;Nephrolithiasis;Hepatic Steatosis;Surgery;Neurogenic Bladder;Renal Neoplasm,Serious,Other Outcomes,Male,03-MAR-2021,20-MAY-2021,Expedited,55 YR,99.1 KG,Novo Nordisk,Healthcare Professional,Not Specified,Glyburide;Metformin Hydrochloride;Losartan;Rosuvastatin;Cholecalciferol,09-MAY-2021,20-MAY-2021,BR,Not Specified,BR-NOVOPROD-813203,-,-
19273201,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Cerebrovascular Accident,Serious,Hospitalized,Male,18-APR-2021,19-MAY-2021,Expedited,73 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,11-MAY-2021,19-MAY-2021,IL,Not Specified,IL-NOVOPROD-813130,-,-
19268101,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error;Nausea,Non-Serious,Non-Serious,Female,-,17-MAY-2021,Non-Expedited,65 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Trulicity,04-MAY-2021,17-MAY-2021,US,Not Specified,US-SA-2021SA154154,-,-
19266846,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Intentional Product Use Issue,Non-Serious,Non-Serious,Female,-,17-MAY-2021,Non-Expedited,60 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,05-MAY-2021,17-MAY-2021,US,Not Specified,US-SA-2021SA155267,-,-
19266845,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment;Product Storage Error,Non-Serious,Non-Serious,Female,-,17-MAY-2021,Non-Expedited,61 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,04-MAY-2021,17-MAY-2021,US,Not Specified,US-SA-2021SA152859,-,-
19265390,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Cough,Non-Serious,Non-Serious,Male,-,17-MAY-2021,Non-Expedited,40 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,05-MAY-2021,17-MAY-2021,US,Not Specified,US-SA-2021SA154428,-,-
19264653,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Nephropathy Toxic,Serious,Other Outcomes,Not Specified,-,17-MAY-2021,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,05-MAY-2021,17-MAY-2021,US,Not Specified,US-SA-2021SA155271,-,-
19262922,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Prophylaxis,Urinary Tract Infection,Serious,Hospitalized,Male,-,17-MAY-2021,Expedited,73 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Insulin Nos;Dapagliflozin;Metformin,05-MAY-2021,17-MAY-2021,BR,Not Specified,BR-NOVOPROD-811655,-,-
19206003,Soliqua 100/33;Lantus,Insulin Glargine;Insulin Glargine\Lixisenatide,Diabetes Mellitus;Hypertension,Blood Glucose Abnormal;Product Storage Error;Covid-19;Drug Ineffective,Serious,Hospitalized,Male,2020,17-MAY-2021,Expedited,65 YR,80 KG,Sanofi Aventis,Consumer,Not Specified,Jardiance;Diovan;Indapamide;Nebivolol,05-MAY-2021,03-MAY-2021,BR,Not Specified,BR-SA-2021SA135542,-,-
19257932,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Communication Issue;Product Use Issue;Sleep Disorder;Pollakiuria,Non-Serious,Non-Serious,Female,APR-2021,14-MAY-2021,Non-Expedited,79 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Tresiba;Multaq,30-APR-2021,14-MAY-2021,US,Not Specified,US-SA-2021SA149640,-,-
19257173,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Female,-,13-MAY-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-APR-2021,13-MAY-2021,US,Not Specified,US-SA-2021SA149612,-,-
19252228,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration;Visual Impairment,Non-Serious,Non-Serious,Male,29-APR-2021,13-MAY-2021,Non-Expedited,57 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,29-APR-2021,13-MAY-2021,US,Not Specified,US-SA-2021SA147559,-,-
19245223,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Diabetes Mellitus Inadequate Control;Product Storage Error,Serious,Other Outcomes,Female,-,13-MAY-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,30-APR-2021,11-MAY-2021,US,Not Specified,US-SA-2021SA145991,-,-
19248233,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Fall;Weight Decreased;Ankle Fracture,Serious,Other Outcomes,Female,2021,12-MAY-2021,Expedited,80 YR,157 KG,Novo Nordisk,Healthcare Professional,Not Specified,Metformin;Dapagliflozin,02-MAY-2021,12-MAY-2021,BR,Not Specified,BR-NOVOPROD-810250,-,-
19244176,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injury Associated With Device;Product Storage Error,Non-Serious,Non-Serious,Female,-,12-MAY-2021,Non-Expedited,81 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-APR-2021,12-MAY-2021,US,Not Specified,US-SA-2021SA150582,-,-
19243952,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Female,-,11-MAY-2021,Non-Expedited,85 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-APR-2021,11-MAY-2021,US,Not Specified,US-SA-2021SA143776,-,-
19243516,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Swelling Face,Non-Serious,Non-Serious,Male,-,11-MAY-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Lantus,27-APR-2021,11-MAY-2021,US,Not Specified,US-SA-2021SA143885,-,-
19243459,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Female,-,11-MAY-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-APR-2021,11-MAY-2021,US,Not Specified,US-SA-2021SA143881,-,-
19241520,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Increased;Irritability;Incorrect Dose Administered;Incorrect Drug Administration Rate;Crying;Frustration Tolerance Decreased;Injection Site Discharge;Hypophagia,Non-Serious,Non-Serious,Female,-,11-MAY-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-APR-2021,11-MAY-2021,US,Not Specified,US-SA-2021SA143358,-,-
19241416,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Gait Disturbance,Non-Serious,Non-Serious,Female,-,11-MAY-2021,Non-Expedited,77 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-APR-2021,11-MAY-2021,US,Not Specified,US-SA-2021SA149607,-,-
19242328,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Male,-,10-MAY-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-APR-2021,10-MAY-2021,US,Not Specified,US-SA-2021SA143654,-,-
19234168,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Dose Omission Issue;Blood Glucose Decreased,Non-Serious,Non-Serious,Female,-,08-MAY-2021,Non-Expedited,64 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-APR-2021,08-MAY-2021,US,Not Specified,US-SA-2021SA141721,-,-
19234085,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Intentional Product Use Issue,Non-Serious,Non-Serious,Female,-,08-MAY-2021,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-APR-2021,08-MAY-2021,US,Not Specified,US-SA-2021SA141719,-,-
19233779,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Breast Cancer,Serious,Other Outcomes,Female,-,07-MAY-2021,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,29-APR-2021,07-MAY-2021,US,Not Specified,US-NOVOPROD-808923,-,-
19233707,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,23-APR-2021,07-MAY-2021,Non-Expedited,86 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin,23-APR-2021,07-MAY-2021,US,Not Specified,US-SA-2021SA137925,-,-
19229726,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Inappropriate Schedule Of Product Administration;Multiple Use Of Single-Use Product,Non-Serious,Non-Serious,Male,-,07-MAY-2021,Non-Expedited,71 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-APR-2021,07-MAY-2021,US,Not Specified,US-SA-2021SA138976,-,-
19229568,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Weight Increased,Non-Serious,Non-Serious,Female,-,07-MAY-2021,Non-Expedited,67 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-APR-2021,07-MAY-2021,US,Not Specified,US-SA-2021SA134599,-,-
19148561,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Pain;Hyperglycaemia;Diabetes Mellitus Inadequate Control;Herpes Zoster;Product Storage Error,Serious,Other Outcomes;Hospitalized,Female,-,07-MAY-2021,Non-Expedited,73 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,26-APR-2021,16-APR-2021,US,Not Specified,US-SA-2021SA120878,-,-
19229232,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Malaise;Vertigo;Product Storage Error,Non-Serious,Non-Serious,Female,-,06-MAY-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-APR-2021,06-MAY-2021,US,Not Specified,US-SA-2021SA134692,-,-
19222770,Xultophy 100/3.6;Novorapid,Insulin Aspart;Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Erysipelas,Serious,Hospitalized,Female,2021,06-MAY-2021,Expedited,55 YR,82 KG,Novo Nordisk,Healthcare Professional,Not Specified,Jardiance;Allopurinol;Gabapentin;Atenolol;Losartan;Insulin Glargine;Amlodipine;Benfotiamine,26-APR-2021,06-MAY-2021,BR,Not Specified,BR-NOVOPROD-809097,-,-
19221875,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Pancreatitis,Serious,Other Outcomes,Female,-,05-MAY-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,22-APR-2021,05-MAY-2021,US,Not Specified,US-SA-2021SA139975,-,-
19221874,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Therapy Cessation;Neck Mass,Non-Serious,Non-Serious,Female,-,05-MAY-2021,Non-Expedited,49 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,22-APR-2021,05-MAY-2021,US,Not Specified,US-SA-2021SA138744,-,-
19218666,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Pancreatitis,Serious,Other Outcomes,Female,-,05-MAY-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,22-APR-2021,05-MAY-2021,US,Not Specified,US-SA-2021SA140369,-,-
19208278,Xultophy 100/3.6,Insulin Degludec\Liraglutide;Insulin Human,Product Used For Unknown Indication,Covid-19,Serious,Hospitalized,Female,-,03-MAY-2021,Expedited,61 YR,61.6 KG,Novo Nordisk,Healthcare Professional,Not Specified,Simvastatin;Xigduo Xr;Enalapril;Glyburide;Furosemide;Aspirin;Alogliptin Benzoate\Metformin Hydrochloride;Citalopram,22-APR-2021,03-MAY-2021,BR,Not Specified,BR-NOVOPROD-807261,-,-
19206218,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Cough,Non-Serious,Non-Serious,Male,-,03-MAY-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-APR-2021,03-MAY-2021,US,Not Specified,US-SA-2021SA132212,-,-
19200652,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Vascular Stent Occlusion,Serious,Other Outcomes,Male,-,30-APR-2021,Expedited,68 YR,66.5 KG,Novo Nordisk,Healthcare Professional,Not Specified,Glifage;Rosuvastatin;Ezetimibe;Cilostazol;Xigduo Xr;Clopidogrel,20-APR-2021,30-APR-2021,BR,Not Specified,BR-NOVOPROD-807054,-,-
19191840,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Drug Ineffective,Non-Serious,Non-Serious,Not Specified,-,28-APR-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,21-APR-2021,28-APR-2021,US,Not Specified,US-SA-2021SA138638,-,-
19185231,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Injection Site Urticaria;Injection Site Irritation;Injection Site Erythema,Non-Serious,Non-Serious,Female,2021,27-APR-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,13-APR-2021,27-APR-2021,US,Not Specified,US-SA-2021SA124246,-,-
19179118,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Jaundice;Kidney Infection,Serious,Died;Other Outcomes,Female,21-JAN-2021,26-APR-2021,Expedited,76 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,20-APR-2021,26-APR-2021,CO,Not Specified,CO-SA-2021SA135625,-,-
19174317,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blindness,Serious,Other Outcomes,Female,-,23-APR-2021,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-APR-2021,23-APR-2021,US,Not Specified,US-SA-2021SA124287,-,-
19173239,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Male,-,23-APR-2021,Non-Expedited,53 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,14-APR-2021,23-APR-2021,US,Not Specified,US-SA-2021SA126219,-,-
19172892,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Hypoglycaemic Unconsciousness;Blood Glucose Decreased;Malaise;Memory Impairment,Serious,Other Outcomes,Female,29-MAR-2021,23-APR-2021,Non-Expedited,72 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-APR-2021,23-APR-2021,US,Not Specified,US-SA-2021SA127731,-,-
19172517,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Female,-,23-APR-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,12-APR-2021,23-APR-2021,US,Not Specified,US-SA-2021SA123093,-,-
19170103,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Female,-,22-APR-2021,Non-Expedited,59 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-APR-2021,22-APR-2021,US,Not Specified,US-SA-2021SA133757,-,-
19167107,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 1 Diabetes Mellitus,Product Storage Error;Product Dose Omission Issue;Illness,Non-Serious,Non-Serious,Female,2021,22-APR-2021,Non-Expedited,90 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-APR-2021,22-APR-2021,US,Not Specified,US-SA-2021SA123083,-,-
19165390,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Frustration Tolerance Decreased,Non-Serious,Non-Serious,Female,-,21-APR-2021,Non-Expedited,69 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-APR-2021,21-APR-2021,US,Not Specified,US-SA-2021SA121760,-,-
19165203,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Headache,Non-Serious,Non-Serious,Male,-,21-APR-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,08-APR-2021,21-APR-2021,US,Not Specified,US-SA-2021SA119870,-,-
19064279,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Increased;Product Quality Issue;Expired Product Administered,Non-Serious,Non-Serious,Male,MAR-2021,21-APR-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,09-APR-2021,26-MAR-2021,US,Not Specified,US-SA-2021SA090172,-,-
19159089,Trulicity;Soliqua 100/33,Insulin Glargine\Lixisenatide;Dulaglutide,-,Drug Hypersensitivity,Non-Serious,Non-Serious,Not Specified,-,20-APR-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,07-APR-2021,20-APR-2021,US,Not Specified,US-SA-2021SA119916,-,-
19156279,Novorapid;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Insulin Aspart,Type 2 Diabetes Mellitus,Intentional Overdose;Hypoglycaemia;Suicide Attempt,Serious,Hospitalized;Other Outcomes,Male,06-APR-2021,20-APR-2021,Expedited,48 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Ipragliflozin L-Proline,07-APR-2021,20-APR-2021,JP,Not Specified,JP-NOVOPROD-802778,-,-
19154173,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Nausea;Vomiting;Product Dose Omission In Error,Non-Serious,Non-Serious,Female,2020,19-APR-2021,Non-Expedited,81 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,05-APR-2021,19-APR-2021,US,Not Specified,US-SA-2021SA113584,-,-
19153426,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Injection Site Pain,Non-Serious,Non-Serious,Male,-,19-APR-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,05-APR-2021,19-APR-2021,US,Not Specified,US-SA-2021SA114628,-,-
19151381,Xultophy 100/3.6;Fiasp,Insulin Aspart;Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Atrioventricular Block Complete,Serious,Hospitalized;Other Outcomes,Male,-,19-APR-2021,Expedited,84 YR,75 KG,Novo Nordisk,Healthcare Professional,Not Specified,Jardiance;Aspirin;Glyxambi;Furosemide;Metformin,08-APR-2021,19-APR-2021,BR,Not Specified,BR-NOVOPROD-804037,-,-
19147734,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Device Issue;Injury Associated With Device,Non-Serious,Non-Serious,Male,-,16-APR-2021,Non-Expedited,59 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-APR-2021,16-APR-2021,US,Not Specified,US-SA-2021SA117804,-,-
19146293,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Diabetes Mellitus Inadequate Control,Serious,Other Outcomes,Not Specified,-,16-APR-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,07-APR-2021,16-APR-2021,US,Not Specified,US-SA-2021SA118274,-,-
19142056,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,-,15-APR-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,02-APR-2021,15-APR-2021,US,Not Specified,US-SA-2021SA113654,-,-
19141840,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Diabetic Ketoacidosis;Blood Glucose Increased,Serious,Hospitalized;Other Outcomes,Male,20-MAR-2021,15-APR-2021,Expedited,68 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Metformin;Insulin Nos;Gabapentin,05-APR-2021,15-APR-2021,US,Not Specified,US-SA-2021SA115499,-,-
19141320,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Male,-,15-APR-2021,Non-Expedited,72 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,02-APR-2021,15-APR-2021,US,Not Specified,US-SA-2021SA113634,-,-
19140187,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Dose Omission Issue;Dementia,Serious,Other Outcomes,Male,31-MAR-2021,15-APR-2021,Expedited,66 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,02-APR-2021,15-APR-2021,US,Not Specified,US-SA-2021SA112722,-,-
19096108,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Liver Function Test Increased,Non-Serious,Non-Serious,Female,16-FEB-2021,15-APR-2021,Expedited,57 YR,62 KG,Novo Nordisk,Healthcare Professional,Not Specified,-,05-APR-2021,06-APR-2021,JP,Not Specified,JP-NOVOPROD-799909,-,-
19136652,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Oedema Peripheral,Non-Serious,Non-Serious,Male,-,14-APR-2021,Non-Expedited,80 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,31-MAR-2021,14-APR-2021,US,Not Specified,US-SA-2021SA111143,-,-
19132885,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Injection Site Erythema;Injection Site Pruritus,Non-Serious,Non-Serious,Not Specified,-,13-APR-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,30-MAR-2021,13-APR-2021,US,Not Specified,US-SA-2021SA111072,-,-
19130412,Soliqua 100/33,Insulin Glargine\Lixisenatide,Nausea,Nasal Congestion;Headache;Feeling Abnormal;Rhinorrhoea;Nausea;Visual Impairment;Diarrhoea;Retinal Artery Occlusion,Serious,Other Outcomes,Female,-,13-APR-2021,Expedited,71 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Zofran,31-MAR-2021,13-APR-2021,US,Not Specified,US-SA-2021SA112312,-,-
19130085,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Abdominal Pain Upper,Non-Serious,Non-Serious,Not Specified,-,13-APR-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,30-MAR-2021,13-APR-2021,US,Not Specified,US-SA-2021SA111533,-,-
19129346,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Male,-,13-APR-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-MAR-2021,13-APR-2021,US,Not Specified,US-SA-2021SA109780,-,-
19119248,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Male,29-MAR-2021,11-APR-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Novolog;Lantus,29-MAR-2021,11-APR-2021,US,Not Specified,US-SA-2021SA109197,-,-
19117555,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment;Cerebrovascular Accident;Hypoacusis,Serious,Other Outcomes,Male,2021,09-APR-2021,Expedited,69 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-MAR-2021,09-APR-2021,US,Not Specified,US-SA-2021SA112331,-,-
19117288,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Acute Myocardial Infarction,Serious,Other Outcomes,Male,-,09-APR-2021,Expedited,59 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Metformin;Insulin Lispro;Empagliflozin,14-SEP-2020,09-APR-2021,BR,Not Specified,BR-NOVOPROD-801712,-,-
19114852,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Feeling Abnormal;Headache;Nausea;Upper Respiratory Tract Infection,Non-Serious,Non-Serious,Male,2021,09-APR-2021,Non-Expedited,80 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-MAR-2021,09-APR-2021,US,Not Specified,US-SA-2021SA105890,-,-
19101913,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Male,-,07-APR-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,22-MAR-2021,07-APR-2021,US,Not Specified,US-SA-2021SA099901,-,-
19101707,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,07-APR-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,23-MAR-2021,07-APR-2021,US,Not Specified,US-SA-2021SA102328,-,-
19101277,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Neoplasm Malignant,Serious,Died,Male,-,07-APR-2021,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,31-MAR-2021,07-APR-2021,BR,Not Specified,BR-NOVOPROD-800899,-,-
19101270,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Hospitalisation,Serious,Hospitalized,Female,-,07-APR-2021,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,26-MAR-2021,07-APR-2021,BR,Not Specified,BR-NOVOPROD-800569,-,-
19098533,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Acute Myocardial Infarction,Serious,Other Outcomes,Male,-,06-APR-2021,Expedited,65 YR,91.3 KG,Novo Nordisk,Healthcare Professional,Not Specified,Glifage;Ciprofibrate;Jardiance;Rosuvastatin,10-SEP-2020,06-APR-2021,BR,Not Specified,BR-NOVOPROD-799606,-,-
19094577,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Dehydration;Blood Glucose Increased;Diarrhoea,Non-Serious,Non-Serious,Female,-,05-APR-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Humalog;Lantus,20-MAR-2021,05-APR-2021,US,Not Specified,US-SA-2021SA097763,-,-
19092524,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error;Visual Impairment,Non-Serious,Non-Serious,Male,-,05-APR-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-MAR-2021,05-APR-2021,US,Not Specified,US-SA-2021SA097713,-,-
19092070,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,05-APR-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-MAR-2021,05-APR-2021,US,Not Specified,US-SA-2021SA096517,-,-
19091274,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Wrong Technique In Product Usage Process,Non-Serious,Non-Serious,Female,-,05-APR-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-MAR-2021,05-APR-2021,US,Not Specified,US-SA-2021SA097835,-,-
19083432,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Female,-,01-APR-2021,Non-Expedited,36 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-MAR-2021,01-APR-2021,US,Not Specified,US-SA-2021SA095564,-,-
19081238,Ozempic;Soliqua 100/33,Insulin Glargine\Lixisenatide;Semaglutide,Blood Glucose Increased;Type 2 Diabetes Mellitus,Benign Neoplasm Of Thyroid Gland;Blood Thyroid Stimulating Hormone Increased,Non-Serious,Non-Serious,Male,-,31-MAR-2021,Non-Expedited,68 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin,17-MAR-2021,31-MAR-2021,US,Not Specified,US-SA-2021SA095044,-,-
19081174,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Wrong Technique In Product Usage Process,Non-Serious,Non-Serious,Female,-,31-MAR-2021,Non-Expedited,57 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,16-MAR-2021,31-MAR-2021,US,Not Specified,US-SA-2021SA094325,-,-
19073987,Soliqua 100/33,Insulin Glargine\Lixisenatide,Glycosylated Haemoglobin Increased,Blood Glucose Increased;Abdominal Pain;Renal Failure,Serious,Hospitalized;Other Outcomes,Female,-,30-MAR-2021,Expedited,66 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,17-MAR-2021,30-MAR-2021,US,Not Specified,US-SA-2021SA095986,-,-
19065318,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injury Associated With Device;Device Issue,Non-Serious,Non-Serious,Female,-,27-MAR-2021,Non-Expedited,54 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-MAR-2021,27-MAR-2021,US,Not Specified,US-SA-2021SA090020,-,-
19064258,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,26-MAR-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-MAR-2021,26-MAR-2021,US,Not Specified,US-SA-2021SA090249,-,-
19063629,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Male,2021,26-MAR-2021,Non-Expedited,51 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-MAR-2021,26-MAR-2021,US,Not Specified,US-SA-2021SA091926,-,-
19063622,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Cognitive Disorder;Nausea;Blood Glucose Decreased;Diabetes Mellitus Inadequate Control;Off Label Use,Serious,Other Outcomes,Female,-,26-MAR-2021,Non-Expedited,64 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-MAR-2021,26-MAR-2021,US,Not Specified,US-SA-2021SA091754,-,-
19057828,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Cardiac Arrest,Serious,Died,Male,-,25-MAR-2021,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,16-MAR-2021,25-MAR-2021,PK,Not Specified,PK-NOVOPROD-796699,-,-
18958521,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Diabetes Mellitus Inadequate Control;Drug Ineffective,Serious,Other Outcomes,Male,12-FEB-2021,25-MAR-2021,Non-Expedited,88 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,17-MAR-2021,02-MAR-2021,US,Not Specified,US-SA-2021SA060799,-,-
18654511,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Device Breakage,Non-Serious,Non-Serious,Female,-,25-MAR-2021,Non-Expedited,78 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,11-MAR-2021,23-DEC-2020,US,Not Specified,US-SA-2020SA362609,-,-
19058029,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Peripheral Swelling,Non-Serious,Non-Serious,Male,-,24-MAR-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,10-MAR-2021,24-MAR-2021,US,Not Specified,US-SA-2021SA089974,-,-
19058007,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Joint Swelling;Intentional Product Use Issue,Non-Serious,Non-Serious,Male,-,24-MAR-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,10-MAR-2021,24-MAR-2021,US,Not Specified,US-SA-2021SA088234,-,-
19055614,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,-,24-MAR-2021,Non-Expedited,67 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-MAR-2021,24-MAR-2021,US,Not Specified,US-SA-2021SA083514,-,-
19052268,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Male,-,24-MAR-2021,Non-Expedited,53 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-MAR-2021,24-MAR-2021,US,Not Specified,US-SA-2021SA083485,-,-
19002396,Humalog;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Insulin Lispro,Diabetes Mellitus,Respiratory Disorder;Cardiac Failure,Serious,Died;Hospitalized,Male,-,24-MAR-2021,Expedited,93 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,15-MAR-2021,12-MAR-2021,JP,Not Specified,JP-NOVOPROD-793445,-,-
18847672,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Pneumonia;Covid-19,Serious,Hospitalized;Died;Other Outcomes,Male,-,24-MAR-2021,Expedited,77 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-MAR-2021,04-FEB-2021,US,Not Specified,US-SA-2021SA032369,-,-
18994994,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Cardiac Disorder,Serious,Hospitalized,Male,12-FEB-2021,23-MAR-2021,Expedited,50 YR,78 KG,Novo Nordisk,Consumer,Not Specified,-,10-MAR-2021,11-MAR-2021,PK,Not Specified,PK-NOVOPROD-793909,-,-
19031901,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Female,-,19-MAR-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,05-MAR-2021,19-MAR-2021,US,Not Specified,US-SA-2021SA079628,-,-
19030358,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Myocardial Infarction,Serious,Hospitalized;Life Threatening,Female,22-DEC-2020,19-MAR-2021,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,08-MAR-2021,19-MAR-2021,US,Not Specified,US-NOVOPROD-794146,-,-
19020719,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Death,Serious,Died,Female,-,17-MAR-2021,Expedited,61 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,05-MAR-2021,17-MAR-2021,IE,Not Specified,IE-NOVOPROD-793796,-,-
18508922,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,10-NOV-2020,17-MAR-2021,Non-Expedited,74 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,03-MAR-2021,17-NOV-2020,US,Not Specified,US-SA-2020SA317293,-,-
19015801,Glyxambi;Soliqua 100/33;Ozempic,Semaglutide;Insulin Glargine\Lixisenatide;Empagliflozin\Linagliptin,-,Abdominal Discomfort,Non-Serious,Non-Serious,Male,-,16-MAR-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,02-MAR-2021,16-MAR-2021,US,Not Specified,US-SA-2021SA075929,-,-
19014981,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Issue;Device Leakage;Accidental Exposure To Product;Product Storage Error,Non-Serious,Non-Serious,Female,-,16-MAR-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,02-MAR-2021,16-MAR-2021,US,Not Specified,US-SA-2021SA075111,-,-
16878695,-,Lixisenatide;Insulin Glargine;Insulin Glargine\Lixisenatide,Diabetes Mellitus,Pancreatic Duct Stenosis;Diarrhoea;Pancreatic Atrophy;Weight Decreased;Decreased Appetite;Nausea,Serious,Other Outcomes,Male,01-MAR-2019,16-MAR-2021,Expedited,64 YR,72 KG,Sanofi Aventis,Healthcare Professional,Not Specified,Metformin;Aspirin;Losartan;Simvastatin,24-MAR-2020,02-OCT-2019,IT,Not Specified,IT-SA-2019SA170038,-,-
19013442,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Off Label Use,Non-Serious,Non-Serious,Not Specified,-,15-MAR-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,02-MAR-2021,15-MAR-2021,US,Not Specified,US-SA-2021SA076271,-,-
19006866,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Male,-,15-MAR-2021,Non-Expedited,77 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-MAR-2021,15-MAR-2021,US,Not Specified,US-SA-2021SA073587,-,-
19005865,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Visual Impairment,Non-Serious,Non-Serious,Female,-,14-MAR-2021,Non-Expedited,77 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-MAR-2021,14-MAR-2021,US,Not Specified,US-SA-2021SA071060,-,-
18996443,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Nausea;Feeling Abnormal;Renal Impairment,Serious,Other Outcomes,Female,25-FEB-2021,11-MAR-2021,Expedited,81 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-FEB-2021,11-MAR-2021,US,Not Specified,US-SA-2021SA069746,-,-
18587782,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Weight Decreased;Blood Glucose Increased,Non-Serious,Non-Serious,Female,2020,11-MAR-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,26-FEB-2021,07-DEC-2020,US,Not Specified,US-SA-2020SA346539,-,-
18990139,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Pulmonary Embolism,Serious,Died,Female,-,10-MAR-2021,Expedited,50 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Jardiance;Apidra,28-FEB-2021,10-MAR-2021,IL,Not Specified,IL-NOVOPROD-792253,-,-
18980366,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Ketoacidosis,Serious,Life Threatening;Hospitalized,Female,-,08-MAR-2021,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Xigduo Xr,25-FEB-2021,08-MAR-2021,GR,Not Specified,GR-NOVOPROD-791737,-,-
18977519,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Female,-,06-MAR-2021,Non-Expedited,55 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,24-FEB-2021,06-MAR-2021,US,Not Specified,US-SA-2021SA067416,-,-
18974046,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Female,22-FEB-2021,05-MAR-2021,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,22-FEB-2021,05-MAR-2021,US,Not Specified,US-SA-2021SA065013,-,-
18973884,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error;Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Male,2019,05-MAR-2021,Non-Expedited,73 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,22-FEB-2021,05-MAR-2021,US,Not Specified,US-SA-2021SA064290,-,-
18971836,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Female,-,05-MAR-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,22-FEB-2021,05-MAR-2021,US,Not Specified,US-SA-2021SA063941,-,-
18961139,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment;Device Issue;Drug Dose Omission By Device,Non-Serious,Non-Serious,Male,08-FEB-2021,02-MAR-2021,Non-Expedited,78 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-FEB-2021,02-MAR-2021,US,Not Specified,US-SA-2021SA052682,-,-
18875703,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Rash,Non-Serious,Non-Serious,Female,-,02-MAR-2021,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,01-FEB-2021,10-FEB-2021,US,Not Specified,US-NOVOPROD-785729,-,-
18805158,Soliqua 100/33,Insulin Glargine\Lixisenatide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Decreased Appetite;Nausea;Cholecystitis;Vomiting,Serious,Other Outcomes;Hospitalized,Male,18-DEC-2020,02-MAR-2021,Expedited,73 YR,82 KG,Sanofi Aventis,Healthcare Professional,Not Specified,Ipragliflozin L-Proline;Gliclazide;Metformin Hydrochloride,26-FEB-2021,29-JAN-2021,JP,Not Specified,JP-SAKK-2021SA024982AA,-,-
18728644,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Device Issue;Drug Dose Omission By Device;Blood Glucose Increased;Visual Impairment,Non-Serious,Non-Serious,Female,-,02-MAR-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,16-FEB-2021,12-JAN-2021,US,Not Specified,US-SA-2021SA006012,-,-
18952584,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Gait Disturbance,Non-Serious,Non-Serious,Male,-,01-MAR-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,16-FEB-2021,01-MAR-2021,US,Not Specified,US-SA-2021SA058840,-,-
18951974,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Headache;Blood Glucose Increased;Dehydration;Dry Skin;Feeling Abnormal;Insomnia;Dizziness,Non-Serious,Non-Serious,Female,-,01-MAR-2021,Non-Expedited,79 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,16-FEB-2021,01-MAR-2021,US,Not Specified,US-SA-2021SA057511,-,-
18948057,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Fatigue;Insomnia;Accidental Overdose,Non-Serious,Non-Serious,Female,-,26-FEB-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-FEB-2021,26-FEB-2021,US,Not Specified,US-SA-2021SA067288,-,-
18947637,Glifage;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Metformin Hydrochloride;Pioglitazone Hydrochloride,Diabetes Mellitus,Covid-19,Serious,Hospitalized,Male,JUL-2020,26-FEB-2021,Expedited,49 YR,77.6 KG,Novo Nordisk,Healthcare Professional,Not Specified,Insulin Nos,09-NOV-2020,26-FEB-2021,BR,Not Specified,BR-NOVOPROD-790671,-,-
18946371,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Female,-,26-FEB-2021,Non-Expedited,53 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin,15-FEB-2021,26-FEB-2021,US,Not Specified,US-SA-2021SA056960,-,-
18921132,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Illness,Non-Serious,Non-Serious,Female,-,22-FEB-2021,Non-Expedited,57 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-FEB-2021,22-FEB-2021,US,Not Specified,US-SA-2021SA049739,-,-
18916568,-,Metformin Hydrochloride\Pioglitazone Hydrochloride;Glyburide\Metformin,Hypertension;Hypothyroidism;Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Lactic Acidosis;Hypoglycaemia,Serious,Hospitalized;Other Outcomes,Female,-,19-FEB-2021,Expedited,80 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,Levothyroxine Sodium;Nebivolol Hydrochloride,16-FEB-2021,19-FEB-2021,IT,Not Specified,IT-TAKEDA-2021TEU001435,-,-
18339425,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Blood Glucose Abnormal;Pancreatic Carcinoma;Condition Aggravated,Serious,Other Outcomes,Male,JAN-2020,17-FEB-2021,Expedited,52 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Metformin Hydrochloride,08-FEB-2021,02-OCT-2020,JP,Not Specified,JP-NOVOPROD-756188,-,-
18898651,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Off Label Use;Metabolic Syndrome,Non-Serious,Non-Serious,Male,-,16-FEB-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,03-FEB-2021,16-FEB-2021,US,Not Specified,US-SA-2021SA046313,-,-
18887970,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Covid-19,Serious,Other Outcomes;Hospitalized,Male,-,12-FEB-2021,Expedited,87 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Lantus,04-FEB-2021,12-FEB-2021,US,Not Specified,US-SA-2021SA044953,-,-
18882861,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Dispensing Error,Non-Serious,Non-Serious,Male,JAN-2021,12-FEB-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,02-FEB-2021,12-FEB-2021,US,Not Specified,US-SA-2021SA042441,-,-
18875789,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Preparation Error;Product Storage Error,Non-Serious,Non-Serious,Female,-,10-FEB-2021,Non-Expedited,62 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-JAN-2021,10-FEB-2021,US,Not Specified,US-SA-2021SA038105,-,-
18875525,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Drug Ineffective;Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,10-FEB-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-FEB-2021,10-FEB-2021,US,Not Specified,US-SA-2021SA037266,-,-
18873396,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error;Incorrect Dose Administered By Product,Non-Serious,Non-Serious,Female,28-JAN-2021,10-FEB-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,29-JAN-2021,10-FEB-2021,US,Not Specified,US-SA-2021SA037747,-,-
18856093,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Abnormal;Product Dose Omission Issue,Non-Serious,Non-Serious,Male,-,09-FEB-2021,Non-Expedited,63 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,27-JAN-2021,06-FEB-2021,US,Not Specified,US-SA-2021SA035352,-,-
18863773,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Visual Impairment;Hypoacusis;Covid-19;Asthenia,Serious,Other Outcomes,Female,OCT-2020,08-FEB-2021,Expedited,81 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-JAN-2021,08-FEB-2021,US,Not Specified,US-SA-2021SA037064,-,-
18854666,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Male,-,05-FEB-2021,Non-Expedited,79 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,25-JAN-2021,05-FEB-2021,US,Not Specified,US-SA-2021SA031985,-,-
18854372,Victoza,Liraglutide;Insulin Glargine\Lixisenatide;Metformin Hydrochloride,Product Used For Unknown Indication,Cachexia;Blood Glucose Increased;Diabetes Mellitus;Malaise;Respiration Abnormal,Serious,Other Outcomes,Not Specified,DEC-2020,05-FEB-2021,Expedited,Not Specified,Not Specified,Bausch And Lomb,Consumer,Not Specified,Lixisenatide;Insulin Glargine,25-JAN-2021,05-FEB-2021,SE,Not Specified,SE-BAUSCH-BL-2021-003488,-,-
18850912,Victoza;Metformin,Metformin Hydrochloride;Liraglutide;Insulin Glargine\Lixisenatide,Product Used For Unknown Indication,Respiration Abnormal;Malaise;Cachexia;Diabetes Mellitus;Blood Glucose Increased,Serious,Other Outcomes,Not Specified,DEC-2020,05-FEB-2021,Expedited,Not Specified,Not Specified,Aurobindo,Consumer,Not Specified,Insulin Glargine;Lixisenatide,27-JAN-2021,05-FEB-2021,SE,Not Specified,SE-AUROBINDO-AUR-APL-2021-004433,-,-
18848407,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,04-FEB-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,26-JAN-2021,04-FEB-2021,US,Not Specified,US-SA-2021SA032119,-,-
18848337,Novorapid;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Insulin Aspart,Diabetes Mellitus,Hospitalisation,Serious,Hospitalized,Male,-,04-FEB-2021,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,27-JAN-2021,04-FEB-2021,JP,Not Specified,JP-NOVOPROD-784512,-,-
18843183,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error;Product Dose Omission Issue,Non-Serious,Non-Serious,Female,-,03-FEB-2021,Non-Expedited,65 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Novolog,25-JAN-2021,03-FEB-2021,US,Not Specified,US-SA-2021SA031625,-,-
18823117,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Gastrointestinal Disorder,Non-Serious,Non-Serious,Not Specified,-,02-FEB-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,22-JAN-2021,02-FEB-2021,US,Not Specified,US-SA-2021SA030919,-,-
18818486,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Covid-19,Serious,Hospitalized,Male,-,01-FEB-2021,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,21-JAN-2021,01-FEB-2021,BR,Not Specified,BR-NOVOPROD-783468,-,-
18811892,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Headache,Non-Serious,Non-Serious,Female,-,30-JAN-2021,Non-Expedited,64 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Valsartan;Metformin,21-JAN-2021,30-JAN-2021,US,Not Specified,US-SA-2021SA028007,-,-
18805672,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Cataract;Visual Impairment,Serious,Other Outcomes,Male,-,28-JAN-2021,Expedited,70 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin,21-JAN-2021,28-JAN-2021,US,Not Specified,US-SA-2021SA027018,-,-
18769695,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Drug Ineffective;Covid-19;Asthenia,Non-Serious,Non-Serious,Female,-,28-JAN-2021,Non-Expedited,59 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Lantus;Humalog,15-JAN-2021,21-JAN-2021,US,Not Specified,US-SA-2021SA017484,-,-
18255624,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Pancreatic Carcinoma,Serious,Other Outcomes,Female,APR-2020,28-JAN-2021,Expedited,61 YR,60 KG,Novo Nordisk,Healthcare Professional,Not Specified,Metformin Hydrochloride;Cholecalciferol;Levothyroxine;Gliclazide;Aspirin;Albuterol Sulfate;Simvastatin,18-JAN-2021,10-SEP-2020,BE,Not Specified,BE-NOVOPROD-750427,-,-
18791226,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Vision Blurred,Non-Serious,Non-Serious,Female,-,26-JAN-2021,Non-Expedited,78 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-JAN-2021,26-JAN-2021,US,Not Specified,US-SA-2021SA023705,-,-
16926214,Ranexa;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Ranolazine;Nimesulide;Omeprazole;Clindamycin,Acute Kidney Injury;Angina Pectoris;Chest Discomfort;Dental Operation,Constipation;Acute Kidney Injury;Dysbiosis;Dehydration;Diarrhoea;Asthenia;Gastroenteritis Viral,Serious,Hospitalized;Other Outcomes,Female,SEP-2019,26-JAN-2021,Expedited,80 YR,Not Specified,Pfizer,Healthcare Professional,Not Specified,Aspirin;Estriol;Isosorbide Dinitrate;Anoro Ellipta;Olopatadine;Fluticasone Furoate\Vilanterol Trifenatate;Cholecalciferol;Euthyrox;Irbesartan;Fexofenadine;Symbicort;Elidel,19-JAN-2021,16-OCT-2019,CH,Not Specified,CH-PFIZER INC-2019438755,-,-
18771312,Victoza,Liraglutide;Insulin Glargine\Lixisenatide;Metformin Hydrochloride,-,Malaise;Blood Glucose Increased;Diabetes Mellitus;Respiration Abnormal;Cachexia,Serious,Other Outcomes,Not Specified,DEC-2020,21-JAN-2021,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Insulin Glargine;Lixisenatide,26-DEC-2020,21-JAN-2021,SE,Not Specified,SE-SA-2020SA375535,-,-
18769893,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Operational Issue;Multiple Use Of Single-Use Product;Nervousness;Device Delivery System Issue,Non-Serious,Non-Serious,Female,-,21-JAN-2021,Non-Expedited,78 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Humalog,14-JAN-2021,21-JAN-2021,US,Not Specified,US-SA-2021SA017866,-,-
18522300,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Incorrect Dose Administered By Device;Blood Glucose Increased;Device Leakage,Non-Serious,Non-Serious,Female,-,21-JAN-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,14-JAN-2021,19-NOV-2020,US,Not Specified,US-SA-2020SA322951,-,-
18757694,Metformin,Metformin Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Metabolic Acidosis,Serious,Hospitalized,Female,24-NOV-2020,19-JAN-2021,Expedited,84 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,Aspirin;Atenolol,11-JAN-2021,19-JAN-2021,IT,Not Specified,IT-TAKEDA-2021TEU000378,-,-
18643586,Trulicity;Metact;Tresiba,Insulin Degludec;Metformin Hydrochloride\Pioglitazone Hydrochloride;Dulaglutide;Glimepiride,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Male,02-DEC-2019,19-JAN-2021,Expedited,75 YR,Not Specified,Eli Lilly And Co,Consumer,Not Specified,-,09-JAN-2021,21-DEC-2020,JP,Not Specified,JP-ELI_LILLY_AND_COMPANY-JP202012007055,-,-
18743539,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Male,-,15-JAN-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-JAN-2021,15-JAN-2021,US,Not Specified,US-SA-2021SA010488,-,-
18742674,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Metformin Hydrochloride,Diabetes Mellitus;Product Used For Unknown Indication,Metabolic Acidosis,Serious,Hospitalized,Female,24-NOV-2020,14-JAN-2021,Expedited,84 YR,Not Specified,Bausch And Lomb,Healthcare Professional,Not Specified,Aspirin;Atenolol,02-JAN-2021,14-JAN-2021,IT,Not Specified,IT-BAUSCH-BL-2021-000153,-,-
18487904,Xultophy 100/3.6;Ozempic,Semaglutide;Insulin Degludec\Liraglutide,Monogenic Diabetes,Wrong Product Administered;Diarrhoea;Dizziness;Prescription Drug Used Without A Prescription;Wrong Technique In Product Usage Process;Nausea;Malaise,Non-Serious,Non-Serious,Female,2020,14-JAN-2021,Non-Expedited,50 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,01-JUN-2020,10-NOV-2020,US,Not Specified,US-NOVOPROD-733560,-,-
17765678,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Operational Issue;Injection Site Pain,Non-Serious,Non-Serious,Female,2020,14-JAN-2021,Non-Expedited,74 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,11-JAN-2021,11-MAY-2020,US,Not Specified,US-SA-2020SA119154,-,-
18734531,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Male,-,13-JAN-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-JAN-2021,13-JAN-2021,US,Not Specified,US-SA-2021SA008007,-,-
18730240,Lantus;Fluzone Quadrivalent Nos;Apidra;Admelog;Soliqua 100/33;Flublok Quadrivalent Nos;Fluzone High-Dose Nos;Apidra Solostar;Lantus Solostar,Insulin Glargine;Insulin Glulisine;Influenza A Virus A/California/7/2009 X-179a (H1n1) Antigen (Formaldehyde Inactivated)\Influenza A Virus A/Victoria/210/2009 X-187 (H3n2) Antigen (Formaldehyde Inactivated)\Influenza B Virus B/Brisbane/60/2008 Antigen (Formaldehyde Inactivated);Influenza Virus Vaccine;Insulin Glargine\Lixisenatide;Insulin Lispro;Insulin Glargine;Influenza A Virus A/California/7/2009 X-179a (H1n1) Antigen (Formaldehyde Inactivated)\Influenza A Virus A/Texas/50/2012 X-223a (H3n2) Antigen (Formaldehyde Inactivated)\Influenza B Virus B/Brisbane/60/2008 Antigen (Formaldehyde Inactivated)\Influenza B Virus B/Massachusetts/2/2012 Antigen (Formalde;Insulin Glulisine,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,13-JAN-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,08-JAN-2021,12-JAN-2021,US,Not Specified,US-SA-2021SA006652,-,-
18731300,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,-,12-JAN-2021,Non-Expedited,68 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-JAN-2021,12-JAN-2021,US,Not Specified,US-SA-2021SA005808,-,-
18730226,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Drug Ineffective;Glycosylated Haemoglobin Abnormal;Weight Increased,Non-Serious,Non-Serious,Not Specified,-,12-JAN-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,07-JAN-2021,12-JAN-2021,US,Not Specified,US-SA-2021SA006751,-,-
18729605,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,-,12-JAN-2021,Non-Expedited,72 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-JAN-2021,12-JAN-2021,US,Not Specified,US-SA-2021SA006242,-,-
18726227,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Acarbose,Product Used For Unknown Indication,Substance Abuse;Intentional Product Misuse;Diarrhoea,Serious,Other Outcomes,Female,02-MAR-2020,11-JAN-2021,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,-,04-JAN-2021,11-JAN-2021,IT,Not Specified,IT-TAKEDA-2021TEU000196,-,-
18725023,Metformin;Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Metformin Hydrochloride,Diabetes Mellitus;Product Used For Unknown Indication,Metabolic Acidosis,Serious,Hospitalized,Female,24-NOV-2020,11-JAN-2021,Expedited,84 YR,Not Specified,Emd Serono Inc,Healthcare Professional,Not Specified,Atenolol;Aspirin,04-JAN-2021,11-JAN-2021,IT,Not Specified,IT-EMD SERONO-9211534,-,-
18702823,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Diabetes Mellitus;Blood Glucose Decreased;Hypokinesia;Syncope,Serious,Other Outcomes,Female,-,11-JAN-2021,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,29-DEC-2020,05-JAN-2021,US,Not Specified,US-SA-2020SA375689,-,-
18721312,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Hypoaesthesia;Fatigue,Serious,Other Outcomes,Male,16-JUL-2020,09-JAN-2021,Expedited,55 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,-,04-JAN-2021,09-JAN-2021,IT,Not Specified,IT-TAKEDA-2021TEU000195,-,-
18705416,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injection Site Pain;Arthropod Sting;Cerebrovascular Accident,Serious,Other Outcomes,Not Specified,2019,08-JAN-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,05-JAN-2021,06-JAN-2021,US,Not Specified,US-SA-2021SA003160,-,-
18708240,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Metformin Hydrochloride,Diabetes Mellitus;Product Used For Unknown Indication,Metabolic Acidosis,Serious,Hospitalized,Female,24-NOV-2020,06-JAN-2021,Expedited,84 YR,Not Specified,Novartis,Healthcare Professional,Not Specified,Aspirin;Atenolol,04-JAN-2021,06-JAN-2021,IT,Not Specified,NVSC2021IT000698,-,-
18485511,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Drug Ineffective;Diabetes Mellitus Inadequate Control,Serious,Other Outcomes,Not Specified,2020,06-JAN-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Novolog,05-JAN-2021,10-NOV-2020,US,Not Specified,US-SA-2020SA310196,-,-
18702225,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Impaired Driving Ability;Disability;Gait Inability,Serious,Other Outcomes;Disabled,Not Specified,-,05-JAN-2021,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Humalog,29-DEC-2020,05-JAN-2021,US,Not Specified,US-SA-2020SA376350,-,-
18689779,Xultophy 100/3.6;Ranexa,Ranolazine;Insulin Degludec\Liraglutide;Nimesulide;Omeprazole;Clindamycin,-,Acute Kidney Injury;Constipation;Asthenia;Diarrhoea,Serious,Other Outcomes;Hospitalized,Female,SEP-2019,31-DEC-2020,Expedited,80 YR,Not Specified,Astrazeneca,Healthcare Professional,Not Specified,Irbesartan;Isosorbide Dinitrate;Estriol;Aspirin;Fluticasone Furoate\Vilanterol Trifenatate;Symbicort;Cholecalciferol;Anoro Ellipta;Elidel;Fexofenadine;Euthyrox,23-DEC-2020,31-DEC-2020,CH,Not Specified,CH-ASTRAZENECA-2020SF75345,-,-
18688734,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Hypoglycaemia;Hypoglycaemic Unconsciousness,Serious,Other Outcomes;Hospitalized,Not Specified,26-JUL-2020,31-DEC-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,25-DEC-2020,31-DEC-2020,US,Not Specified,US-SA-2020SA375042,-,-
18687576,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Cataract Operation;Keratomileusis;Hypermetropia,Non-Serious,Non-Serious,Not Specified,-,31-DEC-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-DEC-2020,31-DEC-2020,US,Not Specified,US-SA-2020SA375257,-,-
18684042,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Cerebrovascular Accident,Serious,Other Outcomes,Not Specified,-,30-DEC-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,24-DEC-2020,30-DEC-2020,US,Not Specified,US-SA-2020SA372290,-,-
16947787,Xultophy 100/3.6;Ranexa,Ranolazine;Omeprazole;Clindamycin Hydrochloride;Nimesulide;Insulin Degludec\Liraglutide,Angina Pectoris;Product Used For Unknown Indication,Asthenia;Acute Kidney Injury;Dehydration;Constipation;Gastroenteritis Viral;Diarrhoea,Serious,Other Outcomes;Hospitalized,Female,SEP-2019,30-DEC-2020,Expedited,80 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Estriol;Elidel;Isosorbide Dinitrate;Cholecalciferol;Anoro Ellipta;Euthyrox;Fluticasone Furoate\Vilanterol Trifenatate;Symbicort;Fexofenadine;Aspirin;Irbesartan,23-DEC-2020,22-OCT-2019,CH,Not Specified,CH-NOVOPROD-690837,-,-
16932272,-,Ranolazine;Nimesulide;Clindamycin Palmitate Hydrochloride;Insulin Degludec\Liraglutide;Omeprazole,Angina Pectoris;Product Used For Unknown Indication,Diarrhoea;Asthenia;Constipation;Acute Kidney Injury,Serious,Hospitalized;Other Outcomes,Female,SEP-2019,30-DEC-2020,Expedited,80 YR,Not Specified,Gilead,Healthcare Professional,Not Specified,Pimecrolimus;Povidone;Aspirin;Irbesartan;Fexofenadine Hydrochloride;Isosorbide Dinitrate;Olopatadine Hydrochloride;Fluticasone Furoate\Vilanterol Trifenatate;Estriol;Levothyroxine Sodium;Cholecalciferol;Budesonide\Formoterol Fumarate Dihydrate,23-DEC-2020,17-OCT-2019,CH,Not Specified,CH-GILEAD-2019-0433168,-,-
18463750,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Oropharyngeal Pain;Condition Aggravated;Hypoxia;Dyspnoea,Serious,Hospitalized;Other Outcomes,Not Specified,01-OCT-2020,29-DEC-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Perindopril;Metformin;Amlodipine,22-DEC-2020,04-NOV-2020,RU,Not Specified,RU-SA-2020SA307194,-,-
18670508,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Hydrochlorothiazide,Diabetes Mellitus;Hypertension,Lactic Acidosis;Hyperkalaemia,Serious,Other Outcomes,Male,08-NOV-2020,28-DEC-2020,Expedited,61 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,-,21-DEC-2020,28-DEC-2020,IT,Not Specified,IT-TAKEDA-2020TEU012050,-,-
18661604,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment;Gastrooesophageal Reflux Disease;Pain;Malaise,Non-Serious,Non-Serious,Not Specified,2020,28-DEC-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-DEC-2020,24-DEC-2020,US,Not Specified,US-SA-2020SA364329,-,-
18160202,Xultophy 100/3.6;Tresiba;Novorapid,Insulin Aspart;Insulin Degludec;Insulin Degludec\Liraglutide,Asthma;Hypertension;Hyperuricaemia;Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Renal Cell Carcinoma;Diabetes Mellitus Inadequate Control;Death,Serious,Hospitalized;Died,Female,10-JUL-2020,23-DEC-2020,Expedited,77 YR,61 KG,Novo Nordisk,Healthcare Professional,Not Specified,Febuxostat;Singulair;Amlodipine Besylate\Azilsartan;Jardiance,16-DEC-2020,17-AUG-2020,JP,Not Specified,JP-NOVOPROD-746522,-,-
18617704,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Nausea;Body Temperature Decreased,Non-Serious,Non-Serious,Female,-,22-DEC-2020,Expedited,57 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,14-DEC-2020,15-DEC-2020,JP,Not Specified,JP-NOVOPROD-773553,-,-
18632886,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Decreased,Non-Serious,Non-Serious,Not Specified,-,18-DEC-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-DEC-2020,18-DEC-2020,US,Not Specified,US-SA-2020SA357881,-,-
18578888,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Ventricular Hypertrophy;Aortic Stenosis;Renal Transplant,Serious,Hospitalized;Other Outcomes,Male,21-NOV-2020,18-DEC-2020,Expedited,67 YR,83 KG,Novo Nordisk,Healthcare Professional,Not Specified,Pioglitazone,07-DEC-2020,04-DEC-2020,BR,Not Specified,BR-NOVOPROD-770603,-,-
18405052,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Drug Ineffective,Non-Serious,Non-Serious,Not Specified,OCT-2020,18-DEC-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,14-DEC-2020,20-OCT-2020,US,Not Specified,US-SA-2020SA289181,-,-
18627862,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,17-DEC-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,14-DEC-2020,17-DEC-2020,US,Not Specified,US-SA-2020SA359590,-,-
18625316,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Migraine;Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Not Specified,-,16-DEC-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-DEC-2020,16-DEC-2020,US,Not Specified,US-SA-2020SA358471,-,-
18624605,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Cataract;Visual Impairment,Serious,Other Outcomes,Not Specified,10-DEC-2020,16-DEC-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-DEC-2020,16-DEC-2020,US,Not Specified,US-SA-2020SA356494,-,-
18623872,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Dose Omission Issue;Pancreatitis;Blood Glucose Decreased,Serious,Hospitalized;Other Outcomes,Not Specified,-,16-DEC-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,11-DEC-2020,16-DEC-2020,US,Not Specified,US-SA-2020SA359188,-,-
18155868,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Tremor;Injection Site Pain;Device Operational Issue,Non-Serious,Non-Serious,Not Specified,-,16-DEC-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,09-DEC-2020,17-AUG-2020,US,Not Specified,US-SA-2020SA208807,-,-
18619124,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Decreased,Non-Serious,Non-Serious,Not Specified,-,15-DEC-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-DEC-2020,15-DEC-2020,US,Not Specified,US-SA-2020SA356583,-,-
18616779,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Diarrhoea;Glycosylated Haemoglobin Increased;Intestinal Resection;Weight Decreased;Blood Glucose Increased;Palpitations;Intentional Product Use Issue,Non-Serious,Non-Serious,Not Specified,2020,15-DEC-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Jardiance,09-DEC-2020,15-DEC-2020,US,Not Specified,US-SA-2020SA356439,-,-
18573909,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Covid-19;Necrosis,Serious,Other Outcomes;Hospitalized,Female,NOV-2020,15-DEC-2020,Expedited,65 YR,90 KG,Novo Nordisk,Healthcare Professional,Not Specified,-,04-DEC-2020,03-DEC-2020,LV,Not Specified,LV-NOVOPROD-770210,-,-
18440134,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Device Leakage,Non-Serious,Non-Serious,Not Specified,-,15-DEC-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,08-DEC-2020,29-OCT-2020,US,Not Specified,US-SA-2020SA300033,-,-
18395848,-,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Rash Papular;Rash Pruritic,Non-Serious,Non-Serious,Not Specified,2019,15-DEC-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Levothyroxine Sodium;Folic Acid;Metformin,12-OCT-2020,18-OCT-2020,SE,Not Specified,SE-SA-2019SA194073,-,-
18361255,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Glycosylated Haemoglobin Increased;Blood Glucose Increased;Neuropathy Peripheral,Serious,Other Outcomes,Not Specified,-,15-DEC-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,09-DEC-2020,08-OCT-2020,US,Not Specified,US-SA-2020SA271957,-,-
18603960,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment;Product Dose Omission Issue;Malaise;Device Issue,Non-Serious,Non-Serious,Not Specified,-,14-DEC-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,04-DEC-2020,11-DEC-2020,US,Not Specified,US-SA-2020SA351444,-,-
18606900,Soliqua 100/33;Tymlos,Abaloparatide;Insulin Glargine\Lixisenatide,Osteoporosis,Diarrhoea,Non-Serious,Non-Serious,Not Specified,-,12-DEC-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Altace;Effexor Xr;Magnesium;Aspirin;Biotin;Flumadine;Calcium\Vitamin D;Melatonin;Vitamin D3;Zinc;Crestor;Metoprolol Succinate;Furosemide,08-DEC-2020,12-DEC-2020,US,Not Specified,US-SA-2020SA354260,-,-
18607571,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Diabetes Mellitus Inadequate Control,Serious,Other Outcomes,Not Specified,-,11-DEC-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Trulicity;Xigduo Xr,04-DEC-2020,11-DEC-2020,US,Not Specified,US-SA-2020SA351292,-,-
18602107,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Urinary Tract Infection,Serious,Hospitalized,Male,-,10-DEC-2020,Expedited,39 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Linagliptin,02-OCT-2020,10-DEC-2020,BR,Not Specified,BR-NOVOPROD-771605,-,-
18601649,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Not Specified,-,10-DEC-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,04-DEC-2020,10-DEC-2020,US,Not Specified,US-SA-2020SA351442,-,-
18588569,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Not Specified,-,08-DEC-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Lantus,01-DEC-2020,08-DEC-2020,US,Not Specified,US-SA-2020SA346579,-,-
18583094,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Acute Myocardial Infarction,Serious,Other Outcomes,Male,-,06-DEC-2020,Expedited,65 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,26-NOV-2020,06-DEC-2020,BR,Not Specified,BR-NOVOPROD-771318,-,-
18580068,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Condition Aggravated;Hot Flush;Hyperhidrosis,Non-Serious,Non-Serious,Not Specified,-,04-DEC-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-NOV-2020,04-DEC-2020,US,Not Specified,US-SA-2020SA344988,-,-
18570707,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Nausea,Non-Serious,Non-Serious,Not Specified,-,02-DEC-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,16-SEP-2019,02-DEC-2020,US,Not Specified,US-SA-2020SA346842,-,-
18568120,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Product Dose Omission Issue;Device Issue,Non-Serious,Non-Serious,Not Specified,-,02-DEC-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,26-MAY-2020,02-DEC-2020,US,Not Specified,US-SA-2020SA137828,-,-
18339299,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Hyperhidrosis;Blood Glucose Decreased;Glycosylated Haemoglobin Decreased;Dizziness;Vision Blurred,Non-Serious,Non-Serious,Not Specified,-,01-DEC-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Metformin,24-NOV-2020,02-OCT-2020,US,Not Specified,US-SA-2020SA265743,-,-
18126367,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Headache;Product Storage Error;Diabetes Mellitus Inadequate Control,Serious,Other Outcomes,Not Specified,04-AUG-2020,01-DEC-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,24-NOV-2020,08-AUG-2020,US,Not Specified,US-SA-2020SA203205,-,-
14230152,Pioglitazone And Metformin,Metformin Hydrochloride\Pioglitazone Hydrochloride;Glimepiride,Diabetes Mellitus,Hypoglycaemia;Loss Of Consciousness,Serious,Died;Other Outcomes,Not Specified,01-JUN-2008,30-NOV-2020,Expedited,Not Specified,Not Specified,Cipla,Healthcare Professional,Not Specified,Vytorin,27-NOV-2020,28-NOV-2017,US,Not Specified,US-CIPLA LTD.-2016US05237,-,-
18557088,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Pruritus;Haematological Malignancy,Serious,Other Outcomes,Male,-,29-NOV-2020,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,20-OCT-2020,29-NOV-2020,JP,Not Specified,JP-NOVOPROD-762681,-,-
18553605,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Weight Decreased;Device Use Issue,Non-Serious,Non-Serious,Not Specified,-,27-NOV-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-NOV-2020,27-NOV-2020,US,Not Specified,US-SA-2020SA335313,-,-
18481904,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Diabetes Mellitus Inadequate Control;Product Quality Issue,Serious,Other Outcomes,Not Specified,OCT-2020,26-NOV-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,19-NOV-2020,09-NOV-2020,US,Not Specified,US-SA-2020SA309092,-,-
18286123,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Peripheral Coldness;Heart Rate Decreased;Therapeutic Product Effect Delayed;Blood Glucose Decreased;Weight Decreased;Dyspepsia;Injection Site Swelling,Non-Serious,Non-Serious,Not Specified,2020,26-NOV-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Lantus,19-NOV-2020,19-SEP-2020,US,Not Specified,US-SA-2020SA250111,-,-
18544511,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Diarrhoea;Blood Glucose Decreased;Dizziness,Non-Serious,Non-Serious,Not Specified,18-NOV-2020,25-NOV-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-NOV-2020,25-NOV-2020,US,Not Specified,US-SA-2020SA330796,-,-
18541560,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Covid-19;Diabetic Complication,Serious,Died,Not Specified,-,24-NOV-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,19-NOV-2020,24-NOV-2020,MX,Not Specified,MX-SA-2020SA333209,-,-
18539731,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Covid-19;Diabetic Complication,Serious,Died,Not Specified,-,24-NOV-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,19-NOV-2020,24-NOV-2020,MX,Not Specified,MX-SA-2020SA333210,-,-
18528085,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Injection Site Rash,Non-Serious,Non-Serious,Not Specified,-,24-NOV-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,17-NOV-2020,20-NOV-2020,US,Not Specified,US-SA-2020SA326536,-,-
18533256,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Not Specified,-,23-NOV-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,16-NOV-2020,23-NOV-2020,US,Not Specified,US-SA-2020SA326095,-,-
18532758,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blindness,Serious,Other Outcomes,Not Specified,-,23-NOV-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,16-NOV-2020,23-NOV-2020,US,Not Specified,US-SA-2020SA326477,-,-
18529992,Novolog;Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Aspart,Diabetes Mellitus;Product Used For Unknown Indication,Frustration Tolerance Decreased;Feeling Abnormal;Fatigue;Pollakiuria,Non-Serious,Non-Serious,Male,-,20-NOV-2020,Non-Expedited,47 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,04-DEC-2019,20-NOV-2020,US,Not Specified,US-NOVOPROD-701070,-,-
18522336,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment;Blood Glucose Abnormal;Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Not Specified,-,19-NOV-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin,12-NOV-2020,19-NOV-2020,US,Not Specified,US-SA-2020SA322905,-,-
18521171,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Visual Impairment,Non-Serious,Non-Serious,Not Specified,-,19-NOV-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-NOV-2020,19-NOV-2020,US,Not Specified,US-SA-2020SA323138,-,-
18458112,-,Insulin Glargine\Lixisenatide,-,Vomiting;Atrial Fibrillation;Tachycardia;Loss Of Consciousness;Wrong Technique In Product Usage Process;Hypoglycaemia;Hyperhidrosis;Heart Rate Increased,Serious,Other Outcomes;Hospitalized,Not Specified,24-OCT-2020,19-NOV-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-NOV-2020,03-NOV-2020,CH,Not Specified,CH-SA-2020SA304019,-,-
18462527,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Abnormal,Non-Serious,Non-Serious,Not Specified,-,18-NOV-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,12-NOV-2020,04-NOV-2020,US,Not Specified,US-SA-2020SA305343,-,-
18496563,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Coronary Artery Occlusion;Blood Glucose Increased;Product Storage Error,Serious,Other Outcomes,Not Specified,2020,16-NOV-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Novolog,09-NOV-2020,12-NOV-2020,US,Not Specified,US-SA-2020SA313611,-,-
18498487,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Dose Omission Issue;Product Storage Error,Non-Serious,Non-Serious,Not Specified,03-NOV-2020,13-NOV-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Novolog,26-MAY-2020,13-NOV-2020,US,Not Specified,US-SA-2020SA138210,-,-
18497099,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Hypoglycaemia;Renal Impairment,Serious,Other Outcomes;Life Threatening,Not Specified,-,12-NOV-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Synjardy,09-NOV-2020,12-NOV-2020,SA,Not Specified,SA-SA-2020SA317524,-,-
18323049,Xultophy 100/3.6;Humalog,Insulin Lispro;Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Liver Function Test Increased;Drug Eruption,Non-Serious,Non-Serious,Male,25-MAY-2020,12-NOV-2020,Expedited,58 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,22-OCT-2020,28-SEP-2020,JP,Not Specified,JP-NOVOPROD-749798,-,-
18289947,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Incorrect Dose Administered By Device;Device Operational Issue;Blood Glucose Increased;Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Not Specified,15-SEP-2020,11-NOV-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,04-NOV-2020,21-SEP-2020,US,Not Specified,US-SA-2020SA255118,-,-
18487915,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Amnesia;Product Dispensing Error,Non-Serious,Non-Serious,Female,-,10-NOV-2020,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,15-JAN-2020,10-NOV-2020,US,Not Specified,US-NOVOPROD-708304,-,-
18487913,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Appetite Disorder;Nausea,Non-Serious,Non-Serious,Female,13-FEB-2020,10-NOV-2020,Non-Expedited,29 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,05-MAR-2020,10-NOV-2020,US,Not Specified,US-NOVOPROD-717832,-,-
18487911,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Weight Decreased;Gastrointestinal Disorder;Drug Ineffective,Non-Serious,Non-Serious,Female,-,10-NOV-2020,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,19-DEC-2019,10-NOV-2020,US,Not Specified,US-NOVOPROD-704512,-,-
18487910,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Vision Blurred;Off Label Use,Non-Serious,Non-Serious,Male,16-DEC-2019,10-NOV-2020,Non-Expedited,75 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,20-DEC-2019,10-NOV-2020,US,Not Specified,US-NOVOPROD-704699,-,-
18487908,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Illness,Non-Serious,Non-Serious,Female,18-DEC-2019,10-NOV-2020,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,18-DEC-2019,10-NOV-2020,US,Not Specified,US-NOVOPROD-704479,-,-
18487907,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Stress;Blood Glucose Abnormal;Eating Disorder,Non-Serious,Non-Serious,Female,-,10-NOV-2020,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,31-DEC-2019,10-NOV-2020,US,Not Specified,US-NOVOPROD-705745,-,-
18487902,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Feeling Abnormal,Non-Serious,Non-Serious,Female,-,10-NOV-2020,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,20-MAR-2020,10-NOV-2020,US,Not Specified,US-NOVOPROD-720718,-,-
18487901,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Vertigo;Gastrointestinal Disorder;Vision Blurred;Facial Pain;Intestinal Obstruction;Expired Product Administered;Vomiting,Non-Serious,Non-Serious,Female,APR-2020,10-NOV-2020,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,05-MAY-2020,10-NOV-2020,US,Not Specified,US-NOVOPROD-727626,-,-
18487900,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Skin Ulcer,Non-Serious,Non-Serious,Male,-,10-NOV-2020,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,08-MAY-2020,10-NOV-2020,US,Not Specified,US-NOVOPROD-728411,-,-
18487899,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Weight Decreased,Non-Serious,Non-Serious,Male,01-SEP-2019,10-NOV-2020,Non-Expedited,61 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,20-DEC-2019,10-NOV-2020,US,Not Specified,US-NOVOPROD-704618,-,-
18487890,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Ill-Defined Disorder,Non-Serious,Non-Serious,Female,-,10-NOV-2020,Non-Expedited,47 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,31-JAN-2020,10-NOV-2020,US,Not Specified,US-NOVOPROD-711500,-,-
18485515,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,10-NOV-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,03-NOV-2020,10-NOV-2020,US,Not Specified,US-SA-2020SA310617,-,-
18485199,Fiasp;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Insulin Aspart,Diabetes Mellitus,Cerebrovascular Accident,Serious,Disabled,Male,-,10-NOV-2020,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,30-OCT-2020,10-NOV-2020,US,Not Specified,US-NOVOPROD-765129,-,-
18485164,Fiasp;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Insulin Aspart,Diabetes Mellitus,Cardiac Failure Congestive,Serious,Disabled,Female,-,10-NOV-2020,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,30-OCT-2020,10-NOV-2020,US,Not Specified,US-NOVOPROD-765110,-,-
17106113,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Product Odour Abnormal;Taste Disorder;Injection Site Discolouration;Nausea;Injection Site Pain;Product Quality Issue,Non-Serious,Non-Serious,Female,JUL-2019,10-NOV-2020,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,27-NOV-2019,03-DEC-2019,US,Not Specified,US-NOVOPROD-686986,-,-
18483664,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Operational Issue;Diabetes Mellitus Inadequate Control,Serious,Other Outcomes,Not Specified,30-OCT-2020,09-NOV-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-OCT-2020,09-NOV-2020,US,Not Specified,US-SA-2020SA308319,-,-
18481423,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Weight Increased,Non-Serious,Non-Serious,Not Specified,-,09-NOV-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,02-NOV-2020,09-NOV-2020,US,Not Specified,US-SA-2020SA310838,-,-
18475281,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Bladder Cancer,Serious,Life Threatening;Other Outcomes,Not Specified,22-JUN-2020,06-NOV-2020,Expedited,56 YR,92 KG,Takeda,Healthcare Professional,Not Specified,-,05-NOV-2020,06-NOV-2020,PT,Not Specified,PT-TAKEDA-2020TEU010590,-,-
18471167,Soliqua 100/33;Prinivil,Lisinopril;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Swelling Face,Serious,Other Outcomes,Not Specified,-,05-NOV-2020,Non-Expedited,Not Specified,Not Specified,Merck,Healthcare Professional,Not Specified,-,02-NOV-2020,05-NOV-2020,US,Not Specified,US-009507513-2011USA000625,-,-
18380141,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Hypertension;Type 2 Diabetes Mellitus,Metabolic Surgery,Serious,Hospitalized,Not Specified,08-JAN-2019,05-NOV-2020,Expedited,60 YR,122 KG,Novo Nordisk,Healthcare Professional,Not Specified,Hydrochlorothiazide\Telmisartan,28-OCT-2020,13-OCT-2020,SI,Not Specified,SI-NOVOPROD-757670,-,-
18464724,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Preparation Error,Non-Serious,Non-Serious,Not Specified,-,04-NOV-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-OCT-2020,04-NOV-2020,US,Not Specified,US-SA-2020SA305339,-,-
18462806,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Fall,Non-Serious,Non-Serious,Not Specified,-,04-NOV-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-OCT-2020,04-NOV-2020,US,Not Specified,US-SA-2020SA305473,-,-
18462028,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Injection Site Erythema;Pruritus;Injection Site Mass,Serious,Other Outcomes,Male,18-SEP-2020,04-NOV-2020,Expedited,63 YR,103 KG,Novo Nordisk,Consumer,Not Specified,Metformin;Atorvastatin;Omeprazole;Nifedipine;Aspirin;Dapagliflozin;Sildenafil;Trulicity,24-OCT-2020,04-NOV-2020,GB,Not Specified,GB-NOVOPROD-762666,-,-
18462026,Xultophy 100/3.6;Novorapid;Spiriva,Tiotropium Bromide Monohydrate;Insulin Aspart;Insulin Degludec\Liraglutide;Tiapride Hydrochloride,Product Used For Unknown Indication;Schizophrenia,Incorrect Route Of Product Administration;Neuroleptic Malignant Syndrome;Death,Serious,Died;Life Threatening,Male,31-JUL-2020,04-NOV-2020,Expedited,58 YR,100 KG,Novo Nordisk,Healthcare Professional,Not Specified,Symbicort;Loxapine Succinate;Tahor;Kardegic;Perindopril Erbumine;Trimeprazine;Albuterol;Effexor;Pantoprazole Sodium;Silodosin,24-OCT-2020,04-NOV-2020,FR,Not Specified,FR-NOVOPROD-762663,-,-
18461603,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Pancreatitis,Serious,Other Outcomes,Not Specified,28-OCT-2020,04-NOV-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,28-OCT-2020,04-NOV-2020,US,Not Specified,US-SA-2020SA304779,-,-
18454783,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Glycosylated Haemoglobin Increased;Visual Impairment;Blood Glucose Increased,Non-Serious,Non-Serious,Not Specified,26-OCT-2020,02-NOV-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin,26-OCT-2020,02-NOV-2020,US,Not Specified,US-SA-2020SA302788,-,-
18454503,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Not Specified,-,02-NOV-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-OCT-2020,02-NOV-2020,US,Not Specified,US-SA-2020SA302778,-,-
18454295,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Circumstance Or Information Capable Of Leading To Medication Error;Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Not Specified,-,02-NOV-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-OCT-2020,02-NOV-2020,US,Not Specified,US-SA-2020SA302633,-,-
18457330,-,Insulin Glargine\Lixisenatide,-,Impaired Gastric Emptying,Serious,Other Outcomes,Not Specified,-,30-OCT-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,23-OCT-2020,30-OCT-2020,RO,Not Specified,RO-SA-2020SA302728,-,-
18444837,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Lactic Acidosis,Serious,Life Threatening;Other Outcomes,Male,20-OCT-2020,30-OCT-2020,Expedited,67 YR,96.7 KG,Takeda,Healthcare Professional,Not Specified,Iodine;Sulfamethoxazole\Trimethoprim;Cilostazol,27-OCT-2020,30-OCT-2020,TW,Not Specified,TW-TAKEDA-2020TJP023531,-,-
18162479,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Tremor;Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Not Specified,-,29-OCT-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,22-OCT-2020,18-AUG-2020,US,Not Specified,US-SA-2020SA215970,-,-
17825148,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Not Specified,-,29-OCT-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,22-OCT-2020,26-MAY-2020,US,Not Specified,US-SA-2020SA131321,-,-
18433680,Spiriva;Xultophy 100/3.6;Novorapid,Insulin Aspart;Insulin Degludec\Liraglutide;Tiotropium Bromide Monohydrate;Tiapride Hydrochloride,Product Used For Unknown Indication;Schizophrenia,Neuroleptic Malignant Syndrome;Pulmonary Embolism,Serious,Other Outcomes;Died;Life Threatening,Male,31-JUL-2020,28-OCT-2020,Expedited,58 YR,100 KG,Boehringer Ingelheim,Healthcare Professional,Not Specified,Sodium Alginate\Sodium Bicarbonate;Trimeprazine;Kardegic;Zopiclone;Perindopril Erbumine;Albuterol Sulfate;Effexor;Silodosin;Pantoprazole Sodium;Tahor;Symbicort;Loxapine,26-OCT-2020,28-OCT-2020,FR,Not Specified,"FR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-057271",-,-
18275246,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Dose Omission Issue;Blood Glucose Increased;Device Issue,Non-Serious,Non-Serious,Not Specified,-,28-OCT-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,21-OCT-2020,17-SEP-2020,US,Not Specified,US-SA-2020SA251734,-,-
18093439,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Injection Site Pain,Non-Serious,Non-Serious,Not Specified,28-JUL-2020,28-OCT-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Metformin,21-OCT-2020,30-JUL-2020,US,Not Specified,US-SA-2020SA198366,-,-
17941440,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 1 Diabetes Mellitus,Blood Glucose Increased;Fibromyalgia;Neuropathy Peripheral;Intentional Product Use Issue,Serious,Other Outcomes,Not Specified,-,28-OCT-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,21-OCT-2020,25-JUN-2020,US,Not Specified,US-SA-2020SA159672,-,-
17885122,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Decreased;Device Leakage;Product Storage Error;Device Breakage,Non-Serious,Non-Serious,Not Specified,-,28-OCT-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,21-OCT-2020,11-JUN-2020,US,Not Specified,US-SA-2020SA149043,-,-
17876699,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Intentional Product Use Issue;Device Operational Issue,Non-Serious,Non-Serious,Not Specified,-,28-OCT-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,21-OCT-2020,09-JUN-2020,US,Not Specified,US-SA-2020SA146211,-,-
17740465,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Intentional Dose Omission;Illness;Sleep Disorder;Blood Glucose Increased,Non-Serious,Non-Serious,Not Specified,APR-2020,28-OCT-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,21-OCT-2020,04-MAY-2020,US,Not Specified,US-SA-2020SA113023,-,-
18432302,-,Insulin Glargine\Lixisenatide,-,Syncope,Serious,Other Outcomes,Not Specified,18-OCT-2020,27-OCT-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-OCT-2020,27-OCT-2020,IL,Not Specified,IL-SA-2020SA298191,-,-
18430340,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Urticaria,Non-Serious,Non-Serious,Not Specified,-,26-OCT-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Trulicity;Tresiba,19-OCT-2020,26-OCT-2020,US,Not Specified,US-SA-2020SA296268,-,-
18429233,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Hip Surgery;Constipation,Serious,Hospitalized,Male,-,26-OCT-2020,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,14-OCT-2020,26-OCT-2020,US,Not Specified,US-NOVOPROD-760533,-,-
18427301,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Preparation Error;Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,26-OCT-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-OCT-2020,26-OCT-2020,US,Not Specified,US-SA-2020SA294382,-,-
18424819,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Not Specified,-,26-OCT-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-OCT-2020,26-OCT-2020,US,Not Specified,US-SA-2020SA295184,-,-
18412944,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,21-OCT-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-OCT-2020,21-OCT-2020,US,Not Specified,US-SA-2020SA294790,-,-
17112668,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Pancreatitis,Serious,Other Outcomes,Female,-,21-OCT-2020,Expedited,59 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Acetaminophen;Metformin Hydrochloride;Tramadol Hydrochloride;Hydroxyzine;Tramadol;Acetaminophen\Opium;Methotrexate;Aripiprazole;Movicol;Venlafaxine;Glycerin\Mineral Oil\Petrolatum;Bisoprolol;Daivobet;Tobradex;Atorvastatin Calcium;Pregabalin;Lormetazepam;Esomeprazole.,25-NOV-2019,04-DEC-2019,FR,Not Specified,FR-NOVOPROD-699725,-,-
18405104,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,20-OCT-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-OCT-2020,20-OCT-2020,US,Not Specified,US-SA-2020SA295212,-,-
18152196,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Device Issue;Device Leakage;Device Failure,Serious,Other Outcomes,Male,07-JUN-2020,20-OCT-2020,30-DAY,70 YR,89 KG,Novo Nordisk,Healthcare Professional,Not Specified,Xigduo Xr,12-OCT-2020,14-AUG-2020,BR,Not Specified,BR-NOVOPROD-734228,-,-
18395555,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Abdominal Pain Upper,Non-Serious,Non-Serious,Not Specified,2020,17-OCT-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,13-OCT-2020,17-OCT-2020,US,Not Specified,US-SA-2020SA286716,-,-
18395353,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Multiple Use Of Single-Use Product,Non-Serious,Non-Serious,Not Specified,-,17-OCT-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-OCT-2020,17-OCT-2020,US,Not Specified,US-SA-2020SA290688,-,-
18395166,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process;Knee Arthroplasty,Non-Serious,Non-Serious,Not Specified,-,16-OCT-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-OCT-2020,16-OCT-2020,US,Not Specified,US-SA-2020SA284889,-,-
18383797,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Intentional Product Misuse;Scratch;Blood Glucose Increased;Condition Aggravated;Pruritus,Non-Serious,Non-Serious,Not Specified,2020,14-OCT-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-OCT-2020,14-OCT-2020,US,Not Specified,US-SA-2020SA279815,-,-
18378335,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Increased,Non-Serious,Non-Serious,Not Specified,06-OCT-2020,13-OCT-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-OCT-2020,13-OCT-2020,US,Not Specified,US-SA-2020SA279620,-,-
18374249,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Urticaria;Rash,Non-Serious,Non-Serious,Not Specified,-,12-OCT-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,05-OCT-2020,12-OCT-2020,US,Not Specified,US-SA-2020SA277976,-,-
18374191,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,-,12-OCT-2020,Non-Expedited,Not Specified,Not Specified,Takeda,Consumer,Not Specified,-,08-OCT-2020,12-OCT-2020,US,Not Specified,US-TAKEDA-2020TUS042249,-,-
18373134,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Urticaria;Rash,Non-Serious,Non-Serious,Not Specified,-,12-OCT-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,05-OCT-2020,12-OCT-2020,US,Not Specified,US-SA-2020SA278008,-,-
16452925,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus;Type 2 Diabetes Mellitus,Dry Skin,Non-Serious,Non-Serious,Not Specified,-,12-OCT-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,05-OCT-2020,19-JUN-2019,US,Not Specified,US-SA-2019SA159597,-,-
18355808,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Cold Sweat;Vomiting;Hyperinsulinaemic Hypoglycaemia;Malaise,Serious,Other Outcomes;Hospitalized,Not Specified,25-AUG-2020,08-OCT-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,01-OCT-2020,07-OCT-2020,IT,Not Specified,IT-SA-2020SA270593,-,-
18353450,Xultophy 100/3.6;Inspra;Xarelto,Rivaroxaban;Amiodarone;Eplerenone;Insulin Degludec\Liraglutide;Atorvastatin;Aspirin\Clopidogrel,Acute Coronary Syndrome;Atrial Fibrillation;Type 2 Diabetes Mellitus,Abdominal Pain;Drug Interaction;Abdominal Distension;Decreased Appetite;Eructation;Hepatic Cytolysis;Nausea,Serious,Other Outcomes,Male,10-JUL-2020,07-OCT-2020,Expedited,57 YR,108 KG,Teva,Healthcare Professional,Not Specified,Ramipril;Bisoprolol Fumarate,29-SEP-2020,07-OCT-2020,FR,Not Specified,FR-TEVA-2020-FR-1835396,-,-
18341469,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Headache;Back Pain,Non-Serious,Non-Serious,Not Specified,-,04-OCT-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,25-SEP-2020,04-OCT-2020,US,Not Specified,US-SA-2020SA265675,-,-
18337008,Xultophy 100/3.6;Xarelto;Inspra,Eplerenone;Rivaroxaban;Aspirin\Clopidogrel;Amiodarone;Atorvastatin Calcium;Insulin Degludec\Liraglutide,Acute Coronary Syndrome;Atrial Fibrillation;Type 2 Diabetes Mellitus,Drug Interaction;Abdominal Distension;Hepatic Cytolysis;Eructation;Nausea;Abdominal Pain;Decreased Appetite,Serious,Other Outcomes,Male,04-JUL-2020,02-OCT-2020,Expedited,57 YR,108 KG,Pfizer,Healthcare Professional,Not Specified,Bisoprolol;Ramipril,28-SEP-2020,02-OCT-2020,FR,Not Specified,FR-PFIZER INC-2020373880,-,-
18336603,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Incorrect Dose Administered By Device;Device Issue;Injection Site Discolouration;Injection Site Injury,Non-Serious,Non-Serious,Not Specified,-,01-OCT-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,25-SEP-2020,01-OCT-2020,US,Not Specified,US-SA-2020SA265384,-,-
18332291,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Hiv Infection;Blood Glucose Increased;Neuropathy Peripheral;Foot Fracture,Serious,Other Outcomes,Not Specified,-,30-SEP-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-SEP-2020,30-SEP-2020,US,Not Specified,US-SA-2020SA263171,-,-
18331326,Inspra;Xultophy 100/3.6;Xarelto,Rivaroxaban;Insulin Degludec\Liraglutide;Aspirin\Clopidogrel;Eplerenone;Amiodarone;Atorvastatin,Acute Coronary Syndrome;Atrial Fibrillation;Type 2 Diabetes Mellitus,Abdominal Pain;Abdominal Distension;Hepatic Cytolysis;Eructation;Drug Interaction;Decreased Appetite;Nausea,Serious,Other Outcomes,Male,10-JUL-2020,30-SEP-2020,Expedited,57 YR,108 KG,Mylan,Healthcare Professional,Not Specified,Ramipril;Bisoprolol,24-SEP-2020,30-SEP-2020,FR,Not Specified,FR-MYLANLABS-2020M1082451,-,-
18315734,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Not Specified,-,26-SEP-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,22-SEP-2020,26-SEP-2020,US,Not Specified,US-SA-2020SA261673,-,-
18314028,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,-,25-SEP-2020,Non-Expedited,Not Specified,Not Specified,Takeda,Consumer,Not Specified,-,23-SEP-2020,25-SEP-2020,US,Not Specified,US-TAKEDA-2020TUS040217,-,-
18311899,Xultophy 100/3.6;Xarelto;Inspra,Eplerenone;Amiodarone;Rivaroxaban;Insulin Degludec\Liraglutide;Atorvastatin Calcium;Aspirin\Clopidogrel,Acute Coronary Syndrome;Atrial Fibrillation;Type 2 Diabetes Mellitus,Drug Interaction;Hepatic Cytolysis;Abdominal Distension;Abdominal Pain;Nausea;Eructation;Decreased Appetite,Serious,Other Outcomes,Male,10-JUL-2020,25-SEP-2020,Expedited,57 YR,108 KG,Accord,Healthcare Professional,Not Specified,Ramipril;Bisoprolol,18-SEP-2020,25-SEP-2020,FR,Not Specified,FR-ACCORD-202692,-,-
18309908,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Anaphylactic Reaction;Hypersensitivity,Serious,Other Outcomes,Not Specified,-,24-SEP-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,10-JUL-2019,24-SEP-2020,US,Not Specified,US-SA-2019SA189364,-,-
18309783,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Drug Ineffective;Hypoglycaemia;Blood Glucose Increased,Non-Serious,Non-Serious,Not Specified,-,24-SEP-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,17-SEP-2020,24-SEP-2020,US,Not Specified,US-SA-2020SA256751,-,-
18308323,-,Insulin Glargine\Lixisenatide,Diabetes Mellitus;Hyperglycaemia,Off Label Use;Gout;Acute Kidney Injury;Dehydration,Serious,Hospitalized;Other Outcomes,Not Specified,-,24-SEP-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Amiodarone;Aspirin;Torsemide;Simvastatin;Tresiba;Trulicity;Novorapid;Atacand,17-SEP-2020,24-SEP-2020,CH,Not Specified,CH-SA-2020SA256774,-,-
18307599,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Hospitalisation,Serious,Hospitalized,Female,-,24-SEP-2020,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,15-SEP-2020,24-SEP-2020,JP,Not Specified,JP-NOVOPROD-754493,-,-
18304545,Xarelto;Inspra;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Amiodarone;Atorvastatin;Eplerenone;Aspirin\Clopidogrel;Rivaroxaban,Acute Coronary Syndrome;Atrial Fibrillation;Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Hepatic Cytolysis;Abdominal Pain;Nausea;Eructation;Abdominal Distension;Decreased Appetite,Serious,Other Outcomes,Male,10-JUL-2020,24-SEP-2020,Expedited,57 YR,108 KG,Aurobindo,Healthcare Professional,Not Specified,Bisoprolol;Ramipril,18-SEP-2020,24-SEP-2020,FR,Not Specified,FR-AUROBINDO-AUR-APL-2020-049214,-,-
18303629,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Not Specified,-,23-SEP-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,16-SEP-2020,23-SEP-2020,US,Not Specified,US-SA-2020SA254625,-,-
18298999,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Presyncope;Circumstance Or Information Capable Of Leading To Medication Error;Blood Glucose Increased,Non-Serious,Non-Serious,Not Specified,15-SEP-2020,22-SEP-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-SEP-2020,22-SEP-2020,US,Not Specified,US-SA-2020SA252052,-,-
18298337,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Myocardial Infarction,Serious,Other Outcomes,Not Specified,-,22-SEP-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,15-SEP-2020,22-SEP-2020,GB,Not Specified,GB-SA-2020SA252658,-,-
18296508,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,-,22-SEP-2020,Non-Expedited,Not Specified,Not Specified,Takeda,Consumer,Not Specified,-,18-SEP-2020,22-SEP-2020,US,Not Specified,US-TAKEDA-2020TUS039653,-,-
18296206,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,22-SEP-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-SEP-2020,22-SEP-2020,US,Not Specified,US-SA-2020SA258341,-,-
18295580,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Dose Omission Issue;Blood Glucose Abnormal;Blood Glucose Increased;Intentional Product Use Issue,Non-Serious,Non-Serious,Not Specified,-,22-SEP-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Levothyroxine,16-SEP-2020,22-SEP-2020,US,Not Specified,US-SA-2020SA255068,-,-
18291355,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 1 Diabetes Mellitus,Glycosylated Haemoglobin Increased;Device Leakage,Non-Serious,Non-Serious,Not Specified,-,21-SEP-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,16-SEP-2020,21-SEP-2020,US,Not Specified,US-SA-2020SA255039,-,-
18290714,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Pancreatitis,Serious,Other Outcomes,Not Specified,-,21-SEP-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,14-SEP-2020,21-SEP-2020,US,Not Specified,US-SA-2020SA250200,-,-
18286339,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Not Specified,16-SEP-2020,20-SEP-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,16-SEP-2020,20-SEP-2020,US,Not Specified,US-SA-2020SA253697,-,-
18285913,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Not Specified,-,19-SEP-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-SEP-2020,19-SEP-2020,US,Not Specified,US-SA-2020SA251198,-,-
18285810,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Fall,Non-Serious,Non-Serious,Not Specified,-,18-SEP-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Humalog,14-SEP-2020,18-SEP-2020,US,Not Specified,US-SA-2020SA250072,-,-
18285251,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Pulmonary Oedema;Hypoglycaemia;Cardiac Failure,Serious,Other Outcomes;Hospitalized,Female,02-SEP-2020,18-SEP-2020,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,09-SEP-2020,18-SEP-2020,IL,Not Specified,IL-NOVOPROD-753106,-,-
18199028,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Therapeutic Response Decreased;Blood Glucose Increased,Non-Serious,Non-Serious,Not Specified,AUG-2020,16-SEP-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-SEP-2020,26-AUG-2020,US,Not Specified,US-SA-2020SA226617,-,-
17432326,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Quality Issue;Blood Glucose Increased,Non-Serious,Non-Serious,Not Specified,2019,15-SEP-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,08-SEP-2020,18-FEB-2020,US,Not Specified,US-SA-2020SA041432,-,-
18255891,Tresiba;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Insulin Degludec,Type 2 Diabetes Mellitus,Cardiac Failure;Blood Glucose Increased;Product Dose Omission Issue,Serious,Hospitalized,Male,-,10-SEP-2020,Expedited,72 YR,112 KG,Novo Nordisk,Healthcare Professional,Not Specified,-,28-AUG-2020,10-SEP-2020,SI,Not Specified,SI-NOVOPROD-750446,-,-
18254594,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,-,10-SEP-2020,Non-Expedited,Not Specified,Not Specified,Takeda,Consumer,Not Specified,-,09-SEP-2020,10-SEP-2020,US,Not Specified,US-TAKEDA-2020TUS038195,-,-
18224065,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Diarrhoea;Drug Ineffective;Eye Pain;Product Communication Issue;Hyperglycaemia;Abdominal Pain Upper;Inflammation,Serious,Other Outcomes,Female,APR-2020,10-SEP-2020,Expedited,56 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,01-SEP-2020,02-SEP-2020,CO,Not Specified,CO-NOVOPROD-725076,-,-
18243654,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,08-SEP-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,04-SEP-2020,08-SEP-2020,US,Not Specified,US-SA-2020SA243581,-,-
18239864,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,17-JUL-2020,08-SEP-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,03-SEP-2020,08-SEP-2020,US,Not Specified,US-SA-2020SA242149,-,-
17509183,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Syncope;Hypotension;Diarrhoea;Vomiting,Serious,Disabled;Hospitalized,Female,25-OCT-2019,08-SEP-2020,Expedited,63 YR,75 KG,Novo Nordisk,Consumer,Not Specified,Allopurinol;Lamivudine;Cholecalciferol;Propafenone;Atorvastatin Calcium;Cellcept;Prednisone;Nebivolol;Ramipril;Nitrofurantoin;Tacrolimus,25-FEB-2020,06-MAR-2020,CZ,Not Specified,CZ-NOVOPROD-714995,-,-
17354380,Xultophy 100/3.6,Insulin Degludec\Liraglutide;Fenofibrate,Diabetes Mellitus;Dyslipidaemia,Pancreatitis;Coma Acidotic,Serious,Hospitalized,Male,07-JAN-2020,08-SEP-2020,Expedited,45 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,27-JAN-2020,31-JAN-2020,FR,Not Specified,FR-NOVOPROD-709495,-,-
17152064,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Acute Myeloid Leukaemia,Serious,Life Threatening,Male,24-DEC-2018,08-SEP-2020,Expedited,67 YR,97 KG,Novo Nordisk,Healthcare Professional,Not Specified,-,05-DEC-2019,13-DEC-2019,SI,Not Specified,SI-NOVOPROD-700584,-,-
18154520,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Injection Site Pain;Wrong Technique In Device Usage Process;Device Operational Issue;Incorrect Dose Administered By Device,Non-Serious,Non-Serious,Not Specified,-,07-SEP-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Toujeo Max,31-AUG-2020,17-AUG-2020,US,Not Specified,US-SA-2020SA205638,-,-
18230199,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Decreased,Non-Serious,Non-Serious,Not Specified,27-AUG-2020,04-SEP-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-AUG-2020,04-SEP-2020,US,Not Specified,US-SA-2020SA232636,-,-
18227949,Soliqua 100/33;Toujeo,Insulin Glargine;Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,28-AUG-2020,03-SEP-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-AUG-2020,03-SEP-2020,US,Not Specified,US-SA-2020SA232632,-,-
18227867,Toujeo;Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Glargine,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,28-AUG-2020,03-SEP-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-AUG-2020,03-SEP-2020,US,Not Specified,US-SA-2020SA232635,-,-
18184631,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Decreased Appetite;Ketoacidosis;Dehydration;Nausea;Pyrexia,Serious,Hospitalized;Other Outcomes,Not Specified,25-JUL-2020,03-SEP-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Amaryl;Dapagliflozin;Lantus;Vildagliptin,31-AUG-2020,24-AUG-2020,JP,Not Specified,JP-SAKK-2020SA219937AA,-,-
18220120,Metformin;Liptruzet,Atorvastatin Calcium\Ezetimibe;Metformin Hydrochloride;Insulin Degludec\Liraglutide;Amlodipine Besylate\Perindopril Arginine;Repaglinide,Diabetes Mellitus;Dyslipidaemia;Hypertension,Acute Kidney Injury;Lactic Acidosis;Acute Coronary Syndrome;Disturbance In Attention,Serious,Life Threatening,Not Specified,20-APR-2018,02-SEP-2020,Expedited,Not Specified,Not Specified,Zydus Pharm,Healthcare Professional,Not Specified,Clopidogrel;Levothyroxine;Pantoprazole,26-MAY-2018,02-SEP-2020,FR,Not Specified,FR-CADILA HEALTHCARE LIMITED-FR-ZYDUS-024244,-,-
18199569,Soliqua 100/33,Insulin Glargine\Lixisenatide,Cataract Operation;Diabetes Mellitus;Diabetes Mellitus Management;Hypertension,Blood Glucose Increased;Product Use Issue,Non-Serious,Non-Serious,Not Specified,06-AUG-2020,02-SEP-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin;Aldactone;Gatifloxacin\Prednisolone Acetate;Micardis Hct,20-AUG-2020,26-AUG-2020,BR,Not Specified,BR-SA-2020SA205385,-,-
18219323,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Multiple Use Of Single-Use Product,Non-Serious,Non-Serious,Not Specified,-,01-SEP-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-AUG-2020,01-SEP-2020,US,Not Specified,US-SA-2020SA231922,-,-
18214299,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Decreased,Non-Serious,Non-Serious,Not Specified,-,31-AUG-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-AUG-2020,31-AUG-2020,US,Not Specified,US-SA-2020SA223464,-,-
18200079,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Urinary Tract Infection;Abdominal Discomfort;Diarrhoea,Non-Serious,Non-Serious,Not Specified,2020,31-AUG-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-AUG-2020,26-AUG-2020,US,Not Specified,US-SA-2020SA220704,-,-
18203250,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Seizure;Product Dose Omission Issue;Blood Glucose Increased,Serious,Hospitalized,Female,14-JUN-2020,27-AUG-2020,Expedited,78 YR,81.65 KG,Novo Nordisk,Consumer,Not Specified,-,18-AUG-2020,27-AUG-2020,US,Not Specified,US-NOVOPROD-748537,-,-
18193830,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,25-AUG-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,24-AUG-2020,25-AUG-2020,US,Not Specified,US-SA-2020SA226472,-,-
18183254,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Not Specified,17-AUG-2020,21-AUG-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,17-AUG-2020,21-AUG-2020,US,Not Specified,US-SA-2020SA217325,-,-
18178108,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Pruritus,Non-Serious,Non-Serious,Not Specified,-,21-AUG-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,17-AUG-2020,21-AUG-2020,US,Not Specified,US-SA-2020SA219302,-,-
17432263,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Device Operational Issue;Blood Glucose Increased,Non-Serious,Non-Serious,Not Specified,-,21-AUG-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,14-AUG-2020,18-FEB-2020,US,Not Specified,US-SA-2020SA035827,-,-
18151361,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Pneumonia,Serious,Hospitalized,Male,-,14-AUG-2020,Expedited,57 YR,105.6 KG,Novo Nordisk,Healthcare Professional,Not Specified,-,06-AUG-2020,14-AUG-2020,JP,Not Specified,JP-NOVOPROD-746474,-,-
18141890,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,12-AUG-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,06-AUG-2020,12-AUG-2020,US,Not Specified,US-SA-2020SA206782,-,-
18140356,Humira;Soliqua 100/33,Insulin Glargine\Lixisenatide;Adalimumab,-,Depression,Non-Serious,Non-Serious,Not Specified,-,12-AUG-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,05-AUG-2020,12-AUG-2020,US,Not Specified,US-SA-2020SA204735,-,-
18139325,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Incorrect Dose Administered By Device;Device Operational Issue;Blood Glucose Abnormal,Non-Serious,Non-Serious,Not Specified,-,12-AUG-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-AUG-2020,12-AUG-2020,US,Not Specified,US-SA-2020SA205421,-,-
18017269,Metformin;Bisoprolol,Metformin Hydrochloride;Bisoprolol\Bisoprolol Fumarate;Empagliflozin\Metformin Hydrochloride;Lisinopril;Aspirin;Atorvastatin;Gliclazide;Ezetimibe;Insulin Degludec\Liraglutide;Torsemide,Blood Cholesterol Abnormal,Weight Decreased;Injury;Hypoglycaemia;Renal Impairment;Arterial Stenosis;Skin Ulcer;Nausea;Osteomyelitis;Urinary Tract Infection;Cellulitis;Dyspepsia;Cardiac Failure;Urosepsis;Impaired Healing;Diabetic Gastroparesis;Gastrooesophageal Reflux Disease;Blood Creatinine Increased;Retinopathy;Anxiety;Selective Eating Disorder,Serious,Hospitalized;Other Outcomes,Female,-,12-AUG-2020,Expedited,53 YR,Not Specified,Merck,Healthcare Professional,Not Specified,-,05-AUG-2020,13-JUL-2020,CH,Not Specified,CH-009507513-2007CHE002280,-,-
18136921,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Not Specified,-,11-AUG-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Sodium,15-JUL-2020,11-AUG-2020,US,Not Specified,US-SA-2020SA186567,-,-
18130866,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus;Hypertension,Nervousness;Cerebrovascular Accident,Serious,Hospitalized,Female,NOV-2019,10-AUG-2020,Expedited,65 YR,66 KG,Novo Nordisk,Consumer,Not Specified,Losartan Potassium;Simvastatin;Aspirin;Hydrochlorothiazide;Metoprolol Succinate,28-JUL-2020,10-AUG-2020,BR,Not Specified,BR-NOVOPROD-744688,-,-
18126905,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Gastrointestinal Disorder,Non-Serious,Non-Serious,Not Specified,-,10-AUG-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,06-AUG-2020,10-AUG-2020,US,Not Specified,US-SA-2020SA206378,-,-
18034278,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Colon Cancer;Limb Discomfort,Serious,Other Outcomes,Not Specified,-,10-AUG-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,03-AUG-2020,16-JUL-2020,US,Not Specified,US-SA-2020SA179769,-,-
17427981,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Cataract;Blood Glucose Increased,Serious,Other Outcomes,Not Specified,-,10-AUG-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,04-AUG-2020,18-FEB-2020,US,Not Specified,US-SA-2020SA041597,-,-
18126482,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,08-AUG-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,03-AUG-2020,08-AUG-2020,US,Not Specified,US-SA-2020SA202515,-,-
18126380,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,08-AUG-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,05-AUG-2020,08-AUG-2020,US,Not Specified,US-SA-2020SA205364,-,-
18121706,-,Gliclazide;Linagliptin;Insulin Glargine\Lixisenatide,Atrial Fibrillation;Dyslipidaemia;Hypertension;Osteoarthritis;Product Used For Unknown Indication;Prophylaxis;Pruritus;Type 2 Diabetes Mellitus,Bradycardia;Acute Kidney Injury,Serious,Hospitalized,Male,-,07-AUG-2020,Expedited,Not Specified,64 KG,Boehringer Ingelheim,Healthcare Professional,Not Specified,Alendronate Sodium;Clobetasol;Rosuvastatin;Terazosin;Digoxin;Perindopril;Warfarin;Atenolol;Ferrous Gluconate,30-JUL-2020,07-AUG-2020,CA,Not Specified,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-039424",-,-
18099462,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Dose Omission Issue,Non-Serious,Non-Serious,Not Specified,29-JUL-2020,06-AUG-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-JUL-2020,31-JUL-2020,US,Not Specified,US-SA-2020SA198648,-,-
18111494,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Not Specified,31-JUL-2020,05-AUG-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,31-JUL-2020,05-AUG-2020,US,Not Specified,US-SA-2020SA200207,-,-
18110544,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Tremor,Non-Serious,Non-Serious,Not Specified,-,04-AUG-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-AUG-2020,04-AUG-2020,US,Not Specified,US-SA-2020SA200597,-,-
18106701,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Pneumonia Influenzal,Serious,Other Outcomes,Female,17-MAR-2020,03-AUG-2020,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,23-JUL-2020,03-AUG-2020,BR,Not Specified,BR-NOVOPROD-743595,-,-
18106661,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Renal Cancer,Serious,Other Outcomes,Male,FEB-2020,03-AUG-2020,Expedited,Not Specified,80 KG,Novo Nordisk,Consumer,Not Specified,Insulin Nos,24-JUL-2020,03-AUG-2020,BR,Not Specified,BR-NOVOPROD-743617,-,-
18104368,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Insomnia;Nightmare,Non-Serious,Non-Serious,Not Specified,-,03-AUG-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-JUL-2020,03-AUG-2020,US,Not Specified,US-SA-2020SA199706,-,-
18094668,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Not Specified,-,31-JUL-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-JUL-2020,31-JUL-2020,US,Not Specified,US-SA-2020SA195857,-,-
18094983,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,30-JUL-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-JUL-2020,30-JUL-2020,US,Not Specified,US-SA-2020SA197466,-,-
18092710,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Not Specified,-,30-JUL-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-JUL-2020,30-JUL-2020,US,Not Specified,US-SA-2020SA197092,-,-
18089865,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Thyroid Cancer,Serious,Other Outcomes,Male,-,29-JUL-2020,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,18-JUL-2020,29-JUL-2020,LB,Not Specified,LB-NOVOPROD-742815,-,-
18088772,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injection Site Haemorrhage,Non-Serious,Non-Serious,Not Specified,23-JUL-2020,29-JUL-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-JUL-2020,29-JUL-2020,US,Not Specified,US-SA-2020SA192966,-,-
18072793,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,23-JUL-2020,27-JUL-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,23-JUL-2020,27-JUL-2020,US,Not Specified,US-SA-2020SA193506,-,-
18072784,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Diarrhoea,Non-Serious,Non-Serious,Not Specified,-,27-JUL-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,17-MAR-2020,27-JUL-2020,US,Not Specified,US-SA-2020SA082485,-,-
18072703,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Not Specified,-,27-JUL-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-JUL-2020,27-JUL-2020,US,Not Specified,US-SA-2020SA189289,-,-
18072678,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injection Site Rash,Non-Serious,Non-Serious,Not Specified,17-JUL-2020,27-JUL-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,17-JUL-2020,27-JUL-2020,US,Not Specified,US-SA-2020SA186864,-,-
17232088,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Not Specified,-,27-JUL-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin,21-JUL-2020,03-JAN-2020,US,Not Specified,US-SA-2020SA000985,-,-
18067720,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,24-JUL-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,20-JUL-2020,24-JUL-2020,US,Not Specified,US-SA-2020SA189245,-,-
18067700,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration;Product Tampering,Non-Serious,Non-Serious,Not Specified,-,24-JUL-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-JUL-2020,24-JUL-2020,US,Not Specified,US-SA-2020SA191309,-,-
18067665,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Not Specified,-,24-JUL-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-JUL-2020,24-JUL-2020,US,Not Specified,US-SA-2020SA191968,-,-
18049801,Trulicity;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Dulaglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration;Vomiting;Blood Pressure Increased;Diarrhoea,Serious,Hospitalized,Female,09-JUL-2020,21-JUL-2020,Expedited,71 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,12-JUL-2020,21-JUL-2020,IL,Not Specified,IL-NOVOPROD-740492,-,-
18049505,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Not Specified,-,21-JUL-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-JUL-2020,21-JUL-2020,US,Not Specified,US-SA-2020SA183883,-,-
18044003,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Malaise,Non-Serious,Non-Serious,Not Specified,-,20-JUL-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-JUL-2020,20-JUL-2020,US,Not Specified,US-SA-2020SA183862,-,-
18037696,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,17-JUL-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,13-JUL-2020,17-JUL-2020,US,Not Specified,US-SA-2020SA184519,-,-
18037683,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Off Label Use;Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,17-JUL-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,13-JUL-2020,17-JUL-2020,US,Not Specified,US-SA-2020SA182409,-,-
18022303,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Adverse Drug Reaction,Serious,Died,Female,-,15-JUL-2020,Expedited,86 YR,Not Specified,Aurobindo,Healthcare Professional,Not Specified,-,24-FEB-2020,15-JUL-2020,US,Not Specified,US-AUROBINDO-AUR-APL-2020-011647,"Gummin DD, Spyker DA, Brooks DE, Beuhler MC, Mowry JB, Rivers LJ et al. 2018 Annual Report of the American Association of Poison Control Centers National Poison Data System (NPDS): 36th Annual Report. Clinical Toxicology. 2019;57(12):1220-1413",-
18024116,Xultophy 100/3.6;Novorapid,Insulin Aspart;Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Hypoglycaemia;Suicide Attempt,Serious,Hospitalized;Life Threatening,Male,-,14-JUL-2020,Expedited,70 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,03-JUL-2020,14-JUL-2020,FR,Not Specified,FR-NOVOPROD-739404,-,-
18020579,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Stomatitis;Tongue Discomfort,Non-Serious,Non-Serious,Not Specified,-,14-JUL-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,09-JUL-2020,14-JUL-2020,US,Not Specified,US-SA-2020SA180959,-,-
18000729,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Hypoacusis;Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Not Specified,-,13-JUL-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-JUL-2020,09-JUL-2020,US,Not Specified,US-SA-2020SA175336,-,-
18005246,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Diarrhoea;Abdominal Pain,Serious,Hospitalized,Female,17-JAN-2020,09-JUL-2020,Expedited,76 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,Clopidogrel Hydrochloride;Lansoprazole;Trulicity;Amlodipine\Ramipril,08-JUL-2020,09-JUL-2020,IT,Not Specified,IT-TAKEDA-2020TEU006229,-,-
17995720,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Intentional Product Use Issue;Glycosylated Haemoglobin Decreased;Product Dose Omission Issue;Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Not Specified,2020,08-JUL-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-JUL-2020,08-JUL-2020,US,Not Specified,US-SA-2020SA173128,-,-
17995700,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Injection Site Pain;Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,08-JUL-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-JUL-2020,08-JUL-2020,US,Not Specified,US-SA-2020SA173139,-,-
17984685,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Not Specified,-,06-JUL-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-JUN-2020,06-JUL-2020,US,Not Specified,US-SA-2020SA171729,-,-
17984529,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Musculoskeletal Discomfort,Non-Serious,Non-Serious,Not Specified,-,06-JUL-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,24-JUN-2020,06-JUL-2020,US,Not Specified,US-SA-2020SA167928,-,-
17979493,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Not Specified,-,03-JUL-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,29-JUN-2020,03-JUL-2020,US,Not Specified,US-SA-2020SA170573,-,-
17979424,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,03-JUL-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,26-JUN-2020,03-JUL-2020,US,Not Specified,US-SA-2020SA168002,-,-
17564813,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Intentional Product Misuse;Pancreatic Disorder;Blood Glucose Increased;Product Use Complaint,Non-Serious,Non-Serious,Not Specified,-,03-JUL-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Humalog,25-JUN-2020,20-MAR-2020,US,Not Specified,US-SA-2020SA071354,-,-
17975783,-,Insulin Glargine\Lixisenatide,-,Nausea;Erectile Dysfunction,Serious,Other Outcomes,Not Specified,-,02-JUL-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,26-JUN-2020,02-JUL-2020,DE,Not Specified,DE-SA-2020SA167925,-,-
17968807,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Tongue Discomfort,Non-Serious,Non-Serious,Not Specified,-,01-JUL-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,26-JUN-2020,01-JUL-2020,US,Not Specified,US-SA-2020SA168231,-,-
17968756,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Dizziness;Asthenia,Non-Serious,Non-Serious,Not Specified,-,01-JUL-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Crestor;Lisinopril;Gabapentin,24-JUN-2020,01-JUL-2020,US,Not Specified,US-SA-2020SA166895,-,-
17968750,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Dizziness;Muscular Weakness,Non-Serious,Non-Serious,Not Specified,-,01-JUL-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,24-JUN-2020,01-JUL-2020,US,Not Specified,US-SA-2020SA166943,-,-
17957923,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Malaise;Arthritis,Non-Serious,Non-Serious,Not Specified,-,29-JUN-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-JUN-2020,29-JUN-2020,US,Not Specified,US-SA-2020SA165016,-,-
17957908,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Multiple Use Of Single-Use Product;Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Not Specified,-,29-JUN-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin,24-JUN-2020,29-JUN-2020,US,Not Specified,US-SA-2020SA165538,-,-
17819874,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Atrial Fibrillation;Hypertension;Type 2 Diabetes Mellitus,Cholecystitis Acute;Bile Duct Stone,Serious,Other Outcomes;Hospitalized,Female,30-MAR-2020,29-JUN-2020,Expedited,87 YR,85 KG,Novo Nordisk,Healthcare Professional,Not Specified,Gliclazide;Sintrom;Irbesartan,15-JUN-2020,24-MAY-2020,CH,Not Specified,CH-NOVOPROD-729019,-,-
17794582,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Faecaloma,Serious,Hospitalized,Female,-,29-JUN-2020,Expedited,54 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,15-JUN-2020,15-MAY-2020,CO,Not Specified,CO-NOVOPROD-727540,-,-
17951246,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Extra Dose Administered;Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Not Specified,-,26-JUN-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,22-JUN-2020,26-JUN-2020,US,Not Specified,US-SA-2020SA164993,-,-
17942099,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Swelling,Non-Serious,Non-Serious,Not Specified,-,25-JUN-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,19-JUN-2020,25-JUN-2020,US,Not Specified,US-SA-2020SA161529,-,-
17940674,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Brain Oedema;Brain Neoplasm Malignant;Visual Impairment,Serious,Died;Other Outcomes,Not Specified,-,25-JUN-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-JUN-2020,25-JUN-2020,US,Not Specified,US-SA-2020SA159358,-,-
17915635,Amlodipine;Xultophy 100/3.6;Kardegic;Fluoxetine;Metformin,Metformin Hydrochloride;Fluoxetine Hydrochloride;Aspirin Dl-Lysine;Pristinamycin;Insulin Degludec\Liraglutide;Atorvastatin;Perindopril;Amlodipine Besylate;Lactulose;Furosemide,Bronchitis;Cerebrovascular Accident;Constipation;Depression;Diabetes Mellitus;Dyslipidaemia;Hypertension;Type 2 Diabetes Mellitus,Vomiting;Dehydration;Hyperkalaemia;Diarrhoea;Acute Kidney Injury;Lactic Acidosis,Serious,Life Threatening,Not Specified,21-FEB-2020,19-JUN-2020,Expedited,Not Specified,Not Specified,Zydus Pharm,Healthcare Professional,Not Specified,-,11-MAR-2020,19-JUN-2020,FR,Not Specified,FR-CADILA HEALTHCARE LIMITED-FR-ZYDUS-048964,-,-
17908125,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Memory Impairment;Extra Dose Administered;Hypoglycaemia,Non-Serious,Non-Serious,Not Specified,12-JUN-2020,17-JUN-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,12-JUN-2020,17-JUN-2020,US,Not Specified,US-SA-2020SA155723,-,-
17900940,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Off Label Use,Non-Serious,Non-Serious,Not Specified,-,16-JUN-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-JUN-2020,16-JUN-2020,US,Not Specified,US-SA-2020SA154093,-,-
17900878,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Swelling Face,Non-Serious,Non-Serious,Not Specified,-,16-JUN-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-JUN-2020,16-JUN-2020,US,Not Specified,US-SA-2020SA151254,-,-
17497270,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Treatment Noncompliance;Diabetic Ketoacidosis,Serious,Hospitalized;Other Outcomes,Not Specified,-,16-JUN-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,09-JUN-2020,04-MAR-2020,US,Not Specified,US-SA-2020SA054028,-,-
17881609,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Temperature Excursion Issue,Non-Serious,Non-Serious,Not Specified,-,10-JUN-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,03-JUN-2020,10-JUN-2020,US,Not Specified,US-SA-2020SA145589,-,-
17879350,Metformin;Competact;Medrol,Methylprednisolone;Metformin Hydrochloride\Pioglitazone Hydrochloride;Metformin Hydrochloride,Diabetes Mellitus;Pneumonitis;Product Used For Unknown Indication,Diabetic Metabolic Decompensation,Serious,Other Outcomes,Female,25-FEB-2020,10-JUN-2020,Expedited,63 YR,Not Specified,Novartis,Healthcare Professional,Not Specified,Clarithromycin;Amlodipine Besylate\Olmesartan Medoxomil;Augmentin;Simvastatin,08-JUN-2020,10-JUN-2020,IT,Not Specified,NVSC2020IT159146,-,-
17876847,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,09-JUN-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,05-JUN-2020,09-JUN-2020,US,Not Specified,US-SA-2020SA147174,-,-
17876706,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Expired Product Administered,Non-Serious,Non-Serious,Not Specified,-,09-JUN-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,02-JUN-2020,09-JUN-2020,US,Not Specified,US-SA-2020SA144616,-,-
17870062,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Not Specified,-,08-JUN-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-MAY-2020,08-JUN-2020,US,Not Specified,US-SA-2020SA145612,-,-
17869914,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Fracture;Accident,Serious,Other Outcomes,Female,-,08-JUN-2020,Expedited,8 DEC,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,26-MAY-2020,08-JUN-2020,JP,Not Specified,JP-NOVOPROD-731463,-,-
17866764,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,05-JUN-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-JUN-2020,05-JUN-2020,US,Not Specified,US-SA-2020SA142679,-,-
17866755,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Product Usage Process,Non-Serious,Non-Serious,Not Specified,-,05-JUN-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-JUN-2020,05-JUN-2020,US,Not Specified,US-SA-2020SA144601,-,-
17866739,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Not Specified,-,05-JUN-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-JUN-2020,05-JUN-2020,US,Not Specified,US-SA-2020SA143056,-,-
17866651,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,05-JUN-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,29-MAY-2020,05-JUN-2020,US,Not Specified,US-SA-2020SA142224,-,-
17866647,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,05-JUN-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-MAY-2020,05-JUN-2020,US,Not Specified,US-SA-2020SA141934,-,-
17860633,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Device Difficult To Use;Injection Site Swelling;Device Operational Issue;Injection Site Haemorrhage,Non-Serious,Non-Serious,Not Specified,-,05-JUN-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,29-MAY-2020,04-JUN-2020,US,Not Specified,US-SA-2020SA141926,-,-
17860665,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Liquid Product Physical Issue;Product Dose Omission Issue;Product Odour Abnormal;Product Quality Issue,Non-Serious,Non-Serious,Not Specified,-,04-JUN-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,29-MAY-2020,04-JUN-2020,US,Not Specified,US-SA-2020SA141866,-,-
17854447,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Rash Pruritic,Non-Serious,Non-Serious,Not Specified,-,03-JUN-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,27-MAY-2020,03-JUN-2020,US,Not Specified,US-SA-2020SA140612,-,-
17850834,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Urine Present;Peripheral Swelling,Non-Serious,Non-Serious,Not Specified,-,02-JUN-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,28-MAY-2020,02-JUN-2020,US,Not Specified,US-SA-2020SA140346,-,-
17850716,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Device Operational Issue;Blood Glucose Decreased,Non-Serious,Non-Serious,Not Specified,-,02-JUN-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-OCT-2019,02-JUN-2020,US,Not Specified,US-SA-2019SA290065,-,-
17846709,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Intentional Product Use Issue;Blood Glucose Abnormal,Non-Serious,Non-Serious,Female,-,01-JUN-2020,Non-Expedited,74 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-MAY-2020,01-JUN-2020,US,Not Specified,US-SA-2020SA137766,-,-
11179461,Pioglitazone Hydrochloride And Metformin Hydrochloride,Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Peripheral Swelling;Product Physical Issue,Non-Serious,Non-Serious,Female,-,29-MAY-2020,Non-Expedited,Not Specified,Not Specified,Teva,Consumer,Not Specified,-,21-MAY-2015,11-JUN-2015,US,Not Specified,US-TEVA-565192USA,-,-
17825053,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Male,-,26-MAY-2020,Non-Expedited,30 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-MAY-2020,26-MAY-2020,US,Not Specified,US-SA-2020SA130317,-,-
17821208,-,Insulin Glargine\Lixisenatide,-,Product Use Issue;Myocardial Infarction,Serious,Other Outcomes,Female,-,25-MAY-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,19-MAY-2020,25-MAY-2020,SE,Not Specified,SE-SA-2020SA131795,-,-
17815945,Pioglitazone And Metformin,Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Drug Ineffective,Non-Serious,Non-Serious,Female,22-MAY-2020,22-MAY-2020,Direct,59 YR,Not Specified,Fda-Ctu,Not Specified,Not Specified,-,-,22-MAY-2020,US,Not Specified,-,-,-
17806394,Fluoxetine;Xultophy 100/3.6;Kardegic;Amlodipine,Amlodipine Besylate;Metformin Hydrochloride;Pristinamycin;Aspirin Dl-Lysine;Perindopril;Insulin Degludec\Liraglutide;Furosemide;Fluoxetine Hydrochloride;Atorvastatin;Lactulose,Bronchitis;Cerebrovascular Accident;Constipation;Depression;Diabetes Mellitus;Dyslipidaemia;Hypertension;Type 2 Diabetes Mellitus,Hyperkalaemia;Dehydration;Vomiting;Diarrhoea;Lactic Acidosis;Acute Kidney Injury,Serious,Life Threatening,Female,21-FEB-2020,20-MAY-2020,Expedited,71 YR,112 KG,Novartis,Healthcare Professional,Not Specified,-,18-MAY-2020,20-MAY-2020,FR,Not Specified,NVSC2020FR136241,-,-
17770839,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Male,-,20-MAY-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-MAY-2020,12-MAY-2020,US,Not Specified,US-SA-2020SA121917,-,-
17801895,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injection Site Discharge;Incorrect Dose Administered By Device,Non-Serious,Non-Serious,Female,-,19-MAY-2020,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-MAY-2020,19-MAY-2020,US,Not Specified,US-SA-2020SA128267,-,-
17801762,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration;Off Label Use,Non-Serious,Non-Serious,Male,-,19-MAY-2020,Non-Expedited,77 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-MAY-2020,19-MAY-2020,US,Not Specified,US-SA-2020SA125846,-,-
17794746,Competact;Metformin;Medrol,Methylprednisolone;Metformin Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Pneumonitis,Diabetic Metabolic Decompensation,Serious,Other Outcomes,Female,25-FEB-2020,16-MAY-2020,Expedited,63 YR,Not Specified,Teva,Healthcare Professional,Not Specified,Augmentin;Clarithromycin;Amlodipine Besylate\Olmesartan Medoxomil;Simvastatin,07-MAY-2020,16-MAY-2020,IT,Not Specified,IT-TEVA-2020-IT-1235077,-,-
17793166,Metformin;Competact;Medrol,Methylprednisolone;Metformin Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Pneumonitis,Diabetic Metabolic Decompensation,Serious,Other Outcomes,Female,25-FEB-2020,15-MAY-2020,Expedited,63 YR,Not Specified,Mylan,Healthcare Professional,Not Specified,Amlodipine Besylate\Olmesartan Medoxomil;Clarithromycin;Simvastatin;Augmentin,09-MAY-2020,15-MAY-2020,IT,Not Specified,IT-MYLANLABS-2020M1047357,-,-
17788849,Medrol;Competact;Metformin,Metformin Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride;Methylprednisolone,Diabetes Mellitus;Pneumonitis;Product Used For Unknown Indication,Diabetic Metabolic Decompensation,Serious,Other Outcomes,Female,25-FEB-2020,15-MAY-2020,Expedited,63 YR,Not Specified,Aurobindo,Healthcare Professional,Not Specified,Simvastatin;Augmentin;Amlodipine Besylate\Olmesartan Medoxomil;Clarithromycin,02-MAY-2020,15-MAY-2020,IT,Not Specified,IT-AUROBINDO-AUR-APL-2020-024053,-,-
17790552,Victoza;Pioglitazone And Metformin,Metformin Hydrochloride\Pioglitazone Hydrochloride;Acipimox;Liraglutide,Hyperlipidaemia;Type 2 Diabetes Mellitus,Jaundice Acholuric,Serious,Hospitalized,Male,18-APR-2020,14-MAY-2020,Expedited,29 YR,85 KG,Novo Nordisk,Healthcare Professional,Not Specified,-,06-MAY-2020,14-MAY-2020,CN,Not Specified,CN-NOVOPROD-727622,-,-
17787505,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Operational Issue;Product Dose Omission Issue;Blood Glucose Increased;Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Female,-,14-MAY-2020,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Humalog,11-MAY-2020,14-MAY-2020,US,Not Specified,US-SA-2020SA123931,-,-
17593531,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Pancreatitis Acute;Pancreatic Neoplasm;Tumour Lysis Syndrome,Serious,Other Outcomes;Hospitalized,Male,07-MAR-2020,14-MAY-2020,Expedited,71 YR,104 KG,Novo Nordisk,Healthcare Professional,Not Specified,Loxoprofen Sodium;Spiriva;Silodosin;Candesartan Cilexetil\Hydrochlorothiazide;Pantoprazole;Corgard;Metformin Hydrochloride;Toviaz;Allopurinol;Kardegic,05-MAY-2020,27-MAR-2020,FR,Not Specified,FR-NOVOPROD-720151,-,-
17766739,Soliqua 100/33,Insulin Glargine\Lixisenatide,Essential Hypertension;Hypercholesterolaemia;Type 2 Diabetes Mellitus,Hypoglycaemia;Swelling Face;Peripheral Swelling,Serious,Other Outcomes,Female,20-APR-2020,11-MAY-2020,Expedited,44 YR,105 KG,Sanofi Aventis,Healthcare Professional,Not Specified,Perindopril Erbumine;Atorvastatin;Cardiomagnyl;Metformin,04-MAY-2020,11-MAY-2020,RU,Not Specified,RU-SA-2020SA116444,-,-
17765574,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Male,-,11-MAY-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,05-MAY-2020,11-MAY-2020,US,Not Specified,US-SA-2020SA119350,-,-
17765561,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Wrong Technique In Device Usage Process;Product Storage Error,Non-Serious,Non-Serious,Male,-,11-MAY-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,06-MAY-2020,11-MAY-2020,US,Not Specified,US-SA-2020SA120593,-,-
17759845,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error;Blood Glucose Decreased,Non-Serious,Non-Serious,Female,-,08-MAY-2020,Non-Expedited,63 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,05-MAY-2020,08-MAY-2020,US,Not Specified,US-SA-2020SA119155,-,-
17759844,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Male,-,08-MAY-2020,Non-Expedited,67 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,05-MAY-2020,08-MAY-2020,US,Not Specified,US-SA-2020SA119180,-,-
17655139,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Dyspnoea;Asthma,Non-Serious,Non-Serious,Male,-,08-MAY-2020,Non-Expedited,55 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-MAY-2020,10-APR-2020,US,Not Specified,US-SA-2020SA091413,-,-
17751503,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Female,-,06-MAY-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-MAY-2020,06-MAY-2020,US,Not Specified,US-SA-2020SA117722,-,-
17745909,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Cholesterol Increased,Non-Serious,Non-Serious,Male,-,05-MAY-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Metformin,28-APR-2020,05-MAY-2020,US,Not Specified,US-SA-2020SA113729,-,-
17740531,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Cholesterol Increased,Non-Serious,Non-Serious,Male,-,04-MAY-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Nystatin;Metformin,28-APR-2020,04-MAY-2020,US,Not Specified,US-SA-2020SA113727,-,-
17729076,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,23-APR-2020,30-APR-2020,Non-Expedited,57 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-APR-2020,30-APR-2020,US,Not Specified,US-SA-2020SA111003,-,-
17729073,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Female,-,30-APR-2020,Non-Expedited,59 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-APR-2020,30-APR-2020,US,Not Specified,US-SA-2020SA112455,-,-
17728280,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Female,-,30-APR-2020,Non-Expedited,62 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,24-APR-2020,30-APR-2020,US,Not Specified,US-SA-2020SA111010,-,-
17723870,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Male,-,29-APR-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-APR-2020,29-APR-2020,US,Not Specified,US-SA-2020SA111405,-,-
17723284,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Female,-,29-APR-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,24-APR-2020,29-APR-2020,US,Not Specified,US-SA-2020SA110053,-,-
17710334,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Drug Ineffective,Non-Serious,Non-Serious,Not Specified,-,27-APR-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-APR-2020,27-APR-2020,US,Not Specified,US-SA-2020SA108195,-,-
17710267,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Incorrect Dose Administered By Device;Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Female,-,27-APR-2020,Non-Expedited,50 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-APR-2020,27-APR-2020,US,Not Specified,US-SA-2020SA104993,-,-
17710225,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration;Product Use Issue,Non-Serious,Non-Serious,Female,-,27-APR-2020,Non-Expedited,80 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-APR-2020,27-APR-2020,US,Not Specified,US-SA-2020SA106913,-,-
17696259,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Visual Impairment;Multiple Use Of Single-Use Product,Non-Serious,Non-Serious,Female,-,27-APR-2020,Non-Expedited,57 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-APR-2020,23-APR-2020,US,Not Specified,US-SA-2020SA101850,-,-
16806572,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process;Hunger,Non-Serious,Non-Serious,Female,-,27-APR-2020,Non-Expedited,55 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-APR-2020,13-SEP-2019,US,Not Specified,US-SA-2019SA252692,-,-
17704743,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus Inadequate Control,Dizziness;Diarrhoea,Non-Serious,Non-Serious,Female,-,24-APR-2020,Non-Expedited,31 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Metformin;Farxiga,17-APR-2020,24-APR-2020,US,Not Specified,US-SA-2020SA103251,-,-
17704713,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Female,-,24-APR-2020,Non-Expedited,50 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,17-APR-2020,24-APR-2020,US,Not Specified,US-SA-2020SA103425,-,-
17685558,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Tremor;Product Storage Error,Non-Serious,Non-Serious,Female,-,20-APR-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,16-APR-2020,20-APR-2020,US,Not Specified,US-SA-2020SA102314,-,-
17685543,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Female,-,20-APR-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,16-APR-2020,20-APR-2020,US,Not Specified,US-SA-2020SA102014,-,-
17685457,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Male,-,20-APR-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-APR-2020,20-APR-2020,US,Not Specified,US-SA-2020SA101847,-,-
17685320,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Male,-,20-APR-2020,Non-Expedited,61 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-APR-2020,20-APR-2020,US,Not Specified,US-SA-2020SA100704,-,-
17685247,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Hypoaesthesia;Muscular Weakness;Circumstance Or Information Capable Of Leading To Medication Error,Non-Serious,Non-Serious,Male,-,20-APR-2020,Non-Expedited,74 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-APR-2020,20-APR-2020,US,Not Specified,US-SA-2020SA098788,-,-
17684203,Soliqua 100/33;Levemir,Insulin Detemir;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Oedema Genital,Serious,Other Outcomes,Female,12-APR-2020,20-APR-2020,Expedited,60 YR,105 KG,Sanofi Aventis,Healthcare Professional,Not Specified,-,15-APR-2020,20-APR-2020,RU,Not Specified,RU-SA-2020SA101300,-,-
17683911,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Pancreatitis,Serious,Other Outcomes,Female,-,20-APR-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,15-APR-2020,20-APR-2020,US,Not Specified,US-SA-2020SA100734,-,-
17124608,-,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Memory Impairment;Product Dose Omission Issue,Non-Serious,Non-Serious,Female,-,20-APR-2020,Non-Expedited,71 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,14-APR-2020,06-DEC-2019,US,Not Specified,US-SA-2019SA337695,-,-
17663600,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Female,-,14-APR-2020,Non-Expedited,57 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-APR-2020,14-APR-2020,US,Not Specified,US-SA-2020SA095735,-,-
17660843,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,13-APR-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-APR-2020,13-APR-2020,US,Not Specified,US-SA-2020SA094597,-,-
17660814,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Dry Throat,Non-Serious,Non-Serious,Female,-,13-APR-2020,Non-Expedited,60 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-APR-2020,13-APR-2020,US,Not Specified,US-SA-2020SA093886,-,-
17608753,Soliqua 100/33,Insulin Glargine\Lixisenatide,Hypertension;Type 2 Diabetes Mellitus,Dizziness;Blood Glucose Fluctuation;Hyperhidrosis;Loss Of Consciousness;Hyperglycaemia;Malaise,Serious,Other Outcomes,Female,MAR-2020,13-APR-2020,Expedited,70 YR,100 KG,Sanofi Aventis,Consumer,Not Specified,Losartan Potassium;Metformin Hydrochloride;Cardiomagnyl;Simvastatin,10-APR-2020,01-APR-2020,RU,Not Specified,RU-SA-2020SA078464,-,-
17658650,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Male,-,12-APR-2020,Non-Expedited,54 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-APR-2020,12-APR-2020,US,Not Specified,US-SA-2020SA093316,-,-
17655318,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Pruritus,Non-Serious,Non-Serious,Female,-,10-APR-2020,Non-Expedited,60 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-APR-2020,10-APR-2020,US,Not Specified,US-SA-2020SA091141,-,-
17655233,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Dose Omission Issue,Non-Serious,Non-Serious,Male,-,10-APR-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-MAR-2020,10-APR-2020,US,Not Specified,US-SA-2020SA088484,-,-
17653689,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Male,-,10-APR-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,03-APR-2020,10-APR-2020,US,Not Specified,US-SA-2020SA089467,-,-
17653666,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 1 Diabetes Mellitus,Headache,Non-Serious,Non-Serious,Male,-,10-APR-2020,Non-Expedited,57 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,02-APR-2020,10-APR-2020,US,Not Specified,US-SA-2020SA089410,-,-
17653622,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Visual Impairment,Non-Serious,Non-Serious,Female,-,10-APR-2020,Non-Expedited,59 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,02-APR-2020,10-APR-2020,US,Not Specified,US-SA-2020SA089434,-,-
17653517,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,10-APR-2020,Non-Expedited,73 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,31-MAR-2020,10-APR-2020,US,Not Specified,US-SA-2020SA088729,-,-
17653270,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Male,-,10-APR-2020,Non-Expedited,74 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-MAR-2020,10-APR-2020,US,Not Specified,US-SA-2020SA089950,-,-
17638474,Soliqua 100/33,Insulin Glargine\Lixisenatide;Hydrochlorothiazide\Irbesartan,-,Vomiting;Renal Impairment,Serious,Hospitalized;Other Outcomes,Male,30-MAR-2020,07-APR-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,30-MAR-2020,07-APR-2020,SA,Not Specified,SA-SA-2020SA081236,-,-
17632958,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Pruritus;Anxiety;Fungal Foot Infection;Tinnitus;Urticaria,Non-Serious,Non-Serious,Female,27-MAR-2020,06-APR-2020,Non-Expedited,56 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Levemir;Novolog,01-APR-2020,06-APR-2020,US,Not Specified,US-SA-2020SA082241,-,-
17622576,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injection Site Bruising;Wrong Technique In Product Usage Process,Non-Serious,Non-Serious,Female,-,03-APR-2020,Non-Expedited,58 YR,77 KG,Sanofi Aventis,Consumer,Not Specified,-,17-MAR-2020,03-APR-2020,US,Not Specified,US-SA-2020SA082296,-,-
17607894,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Drug Intolerance,Non-Serious,Non-Serious,Not Specified,-,31-MAR-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,10-MAR-2020,31-MAR-2020,US,Not Specified,US-SA-2020SA077944,-,-
17602235,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Dose Omission Issue;Diabetic Ketoacidosis;Nausea;Vomiting;Abdominal Pain,Serious,Other Outcomes;Hospitalized,Male,-,31-MAR-2020,Expedited,49 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Invokana,24-MAR-2020,31-MAR-2020,US,Not Specified,US-SA-2020SA077470,-,-
17601621,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 1 Diabetes Mellitus,Vertigo,Serious,Hospitalized,Male,15-JAN-2020,30-MAR-2020,Expedited,84 YR,85 KG,Novo Nordisk,Healthcare Professional,Not Specified,Atorvastatin;Novorapid;Tresiba;Furosemide;Levothyroxine Sodium;Lansoprazole;Kardegic;Janumet;Lercanidipine Hydrochloride;Doliprane,19-MAR-2020,30-MAR-2020,FR,Not Specified,FR-NOVOPROD-719599,-,-
17599563,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Disease Progression;Acne,Serious,Hospitalized,Male,-,30-MAR-2020,Expedited,30 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,20-MAR-2020,30-MAR-2020,US,Not Specified,US-SA-2020SA074406,-,-
17599408,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Bacterial Infection;Fournier's Gangrene,Serious,Other Outcomes,Male,-,30-MAR-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,20-MAR-2020,30-MAR-2020,US,Not Specified,US-SA-2020SA073911,-,-
17593580,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Hepatitis,Serious,Hospitalized,Female,-,27-MAR-2020,Expedited,75 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,19-MAR-2020,27-MAR-2020,BR,Not Specified,BR-NOVOPROD-720323,-,-
17588293,Xultophy 100/3.6;Amlodipine;Metformin;Kardegic;Fluoxetine,Fluoxetine Hydrochloride;Aspirin Dl-Lysine;Metformin Hydrochloride;Amlodipine Besylate;Insulin Degludec\Liraglutide;Atorvastatin;Perindopril;Lactulose;Pristinamycin;Furosemide,Bronchitis;Cerebrovascular Accident;Constipation;Depression;Diabetes Mellitus;Dyslipidaemia;Hypertension;Type 2 Diabetes Mellitus,Lactic Acidosis;Vomiting;Dehydration;Diarrhoea;Acute Kidney Injury;Hyperkalaemia,Serious,Life Threatening,Female,21-FEB-2020,27-MAR-2020,Expedited,71 YR,112 KG,Ranbaxy,Healthcare Professional,Not Specified,-,12-MAR-2020,27-MAR-2020,FR,Not Specified,FR-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-241691,-,-
17586725,Novorapid;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Insulin Aspart,Blood Cholesterol Abnormal;Breast Cancer;Diabetes Mellitus;Feeling Of Relaxation;Hypertension,Skin Discolouration;Breast Cancer,Serious,Other Outcomes,Female,2018,26-MAR-2020,Expedited,Not Specified,100 KG,Novo Nordisk,Consumer,Not Specified,Anastrozole;Pioglitazone Hydrochloride;Spironolactone;Amlodipine Besylate;Simvastatin;Metformin Hydrochloride;Losartan Potassium;Escitalopram Oxalate,16-MAR-2020,26-MAR-2020,BR,Not Specified,BR-NOVOPROD-719550,-,-
17585822,Kardegic;Xultophy 100/3.6;Amlodipine;Metformin;Fluoxetine,Fluoxetine Hydrochloride;Metformin Hydrochloride;Atorvastatin;Amlodipine Besylate;Insulin Degludec\Liraglutide;Aspirin Dl-Lysine;Furosemide;Lactulose;Pristinamycin;Perindopril,Bronchitis;Cerebrovascular Accident;Constipation;Depression;Diabetes Mellitus;Dyslipidaemia;Hypertension;Type 2 Diabetes Mellitus,Hyperkalaemia;Dehydration;Vomiting;Lactic Acidosis;Acute Kidney Injury;Diarrhoea,Serious,Life Threatening,Female,21-FEB-2020,26-MAR-2020,Expedited,71 YR,112 KG,Mylan,Healthcare Professional,Not Specified,-,19-MAR-2020,26-MAR-2020,FR,Not Specified,FR-MYLANLABS-2020M1031989,-,-
17584253,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Respiratory Disorder,Serious,Other Outcomes,Female,-,26-MAR-2020,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,13-MAR-2020,26-MAR-2020,US,Not Specified,US-NOVOPROD-719308,-,-
17578171,Kardegic;Amlodipine;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Atorvastatin;Pristinamycin;Amlodipine Besylate;Fluoxetine Hydrochloride;Perindopril;Lactulose;Furosemide;Aspirin Dl-Lysine;Metformin Hydrochloride,Bronchitis;Cerebrovascular Accident;Constipation;Depression;Diabetes Mellitus;Dyslipidaemia;Hypertension;Type 2 Diabetes Mellitus,Dehydration;Diarrhoea;Lactic Acidosis;Hyperkalaemia;Vomiting;Acute Kidney Injury,Serious,Other Outcomes;Life Threatening,Not Specified,21-FEB-2020,24-MAR-2020,Expedited,Not Specified,Not Specified,Validus,Healthcare Professional,Not Specified,-,12-MAR-2020,24-MAR-2020,FR,Not Specified,FR-VALIDUS PHARMACEUTICALS LLC-FR-2020VAL000209,-,-
17575669,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Hip Arthroplasty,Non-Serious,Non-Serious,Male,-,24-MAR-2020,Non-Expedited,69 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-MAR-2020,24-MAR-2020,US,Not Specified,US-SA-2020SA072627,-,-
17551746,Fluoxetine;Amlodipine;Xultophy 100/3.6;Kardegic;Metformin,Metformin Hydrochloride;Perindopril;Furosemide;Pristinamycin;Aspirin Dl-Lysine;Insulin Degludec\Liraglutide;Lactulose;Amlodipine Besylate;Atorvastatin;Fluoxetine Hydrochloride,Bronchitis;Cerebrovascular Accident;Constipation;Depression;Diabetes Mellitus;Dyslipidaemia;Hypertension;Type 2 Diabetes Mellitus,Diarrhoea;Hyperkalaemia;Dehydration;Acute Kidney Injury;Vomiting;Lactic Acidosis,Serious,Life Threatening,Female,21-FEB-2020,24-MAR-2020,Expedited,71 YR,112 KG,Emd Serono Inc,Healthcare Professional,Not Specified,-,17-MAR-2020,17-MAR-2020,FR,Not Specified,FR-EMD SERONO-E2B_90075773,-,-
17561005,Amlodipine;Xultophy 100/3.6;Fluoxetine;Kardegic,Aspirin Dl-Lysine;Perindopril;Fluoxetine Hydrochloride;Atorvastatin Calcium;Metformin Hydrochloride;Lactulose;Insulin Degludec\Liraglutide;Amlodipine Besylate;Furosemide;Pristinamycin,Bronchitis;Cerebrovascular Accident;Constipation;Depression;Diabetes Mellitus;Dyslipidaemia;Hypertension;Type 2 Diabetes Mellitus,Acute Kidney Injury;Dehydration;Vomiting;Diarrhoea;Lactic Acidosis;Hyperkalaemia,Serious,Life Threatening,Female,21-FEB-2020,19-MAR-2020,Expedited,71 YR,112 KG,Pfizer,Healthcare Professional,Not Specified,-,17-MAR-2020,19-MAR-2020,FR,Not Specified,FR-PFIZER INC-2020116024,-,-
17559725,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injection Site Erythema;Injection Site Pruritus,Non-Serious,Non-Serious,Female,-,19-MAR-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,12-MAR-2020,19-MAR-2020,US,Not Specified,US-SA-2020SA070595,-,-
17436765,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Condition Aggravated;Injection Site Pain;Hypoacusis,Non-Serious,Non-Serious,Male,-,19-MAR-2020,Non-Expedited,79 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-MAR-2020,19-FEB-2020,US,Not Specified,US-SA-2020SA038300,-,-
17555754,Amlodipine;Xultophy 100/3.6;Kardegic,Aspirin Dl-Lysine;Fluoxetine Hydrochloride;Pristinamycin;Metformin Hydrochloride;Atorvastatin;Insulin Degludec\Liraglutide;Furosemide;Amlodipine Besylate;Perindopril;Lactulose,Bronchitis;Cerebrovascular Accident;Constipation;Depression;Diabetes Mellitus;Dyslipidaemia;Hypertension;Type 2 Diabetes Mellitus,Lactic Acidosis;Hyperkalaemia;Vomiting;Diarrhoea;Dehydration;Acute Kidney Injury,Serious,Life Threatening,Female,21-FEB-2020,18-MAR-2020,Expedited,71 YR,112 KG,Bausch And Lomb,Healthcare Professional,Not Specified,-,08-MAR-2020,18-MAR-2020,FR,Not Specified,FR-BAUSCH-BL-2020-007650,-,-
17554078,Xultophy 100/3.6;Kardegic;Amlodipine,Amlodipine Besylate;Aspirin Dl-Lysine;Insulin Degludec\Liraglutide;Fluoxetine Hydrochloride;Atorvastatin;Metformin Hydrochloride;Perindopril;Lactulose;Furosemide;Pristinamycin,Bronchitis;Cerebrovascular Accident;Constipation;Depression;Diabetes Mellitus;Dyslipidaemia;Hypertension;Type 2 Diabetes Mellitus,Acute Kidney Injury;Dehydration;Vomiting;Hyperkalaemia;Lactic Acidosis;Diarrhoea,Serious,Life Threatening,Female,21-FEB-2020,18-MAR-2020,Expedited,71 YR,112 KG,Teva,Healthcare Professional,Not Specified,-,10-MAR-2020,18-MAR-2020,FR,Not Specified,FR-TEVA-2020-FR-1202596,-,-
17553948,Metformin;Xultophy 100/3.6;Kardegic;Fluoxetine;Amlodipine,Amlodipine Besylate;Furosemide;Fluoxetine Hydrochloride;Aspirin Dl-Lysine;Lactulose;Pristinamycin;Insulin Degludec\Liraglutide;Atorvastatin;Metformin Hydrochloride;Perindopril,Bronchitis;Cerebrovascular Accident;Constipation;Depression;Diabetes Mellitus;Dyslipidaemia;Hypertension;Type 2 Diabetes Mellitus,Vomiting;Lactic Acidosis;Acute Kidney Injury;Hyperkalaemia;Dehydration;Diarrhoea,Serious,Life Threatening;Other Outcomes,Female,21-FEB-2020,18-MAR-2020,Expedited,71 YR,112 KG,Aurobindo,Healthcare Professional,Not Specified,-,06-MAR-2020,18-MAR-2020,FR,Not Specified,FR-AUROBINDO-AUR-APL-2020-013200,-,-
16209340,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Operational Issue;Wrong Technique In Device Usage Process;Blood Glucose Decreased,Non-Serious,Non-Serious,Female,-,18-MAR-2020,Non-Expedited,73 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-MAR-2020,17-APR-2019,US,Not Specified,US-SA-2019SA106696,-,-
17553139,Amlodipine;Kardegic;Fluoxetine;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Perindopril;Furosemide;Pristinamycin;Fluoxetine Hydrochloride;Aspirin Dl-Lysine;Amlodipine Besylate;Lactulose;Metformin Hydrochloride;Atorvastatin,Bronchitis;Cerebrovascular Accident;Constipation;Depression;Dyslipidaemia;Hypertension;Type 2 Diabetes Mellitus,Acute Kidney Injury;Dehydration;Lactic Acidosis;Vomiting;Diarrhoea;Hyperkalaemia,Serious,Life Threatening,Female,21-FEB-2020,17-MAR-2020,Expedited,71 YR,112 KG,Novo Nordisk,Healthcare Professional,Not Specified,-,06-MAR-2020,17-MAR-2020,FR,Not Specified,FR-NOVOPROD-717139,-,-
17551303,Metformin;Xultophy 100/3.6;Kardegic;Fluoxetine;Amlodipine,Amlodipine Besylate;Lactulose;Pristinamycin;Fluoxetine Hydrochloride;Perindopril;Atorvastatin Calcium;Furosemide;Aspirin Dl-Lysine;Insulin Degludec\Liraglutide;Metformin Hydrochloride,Bronchitis;Cerebrovascular Accident;Constipation;Depression;Diabetes Mellitus;Dyslipidaemia;Hypertension;Type 2 Diabetes Mellitus,Acute Kidney Injury;Diarrhoea;Vomiting;Lactic Acidosis;Dehydration;Hyperkalaemia,Serious,Life Threatening,Female,21-FEB-2020,17-MAR-2020,Expedited,71 YR,112 KG,Accord,Healthcare Professional,Not Specified,-,06-MAR-2020,17-MAR-2020,FR,Not Specified,FR-ACCORD-175895,-,-
16368904,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Gastrointestinal Hypomotility,Serious,Hospitalized,Male,06-APR-2019,17-MAR-2020,Expedited,55 YR,107 KG,Novo Nordisk,Healthcare Professional,Not Specified,Allopurinol;Indapamide\Perindopril;Aspirin;Atorvastatin;Metformin,15-JAN-2020,29-MAY-2019,HU,Not Specified,HU-NOVOPROD-664225,Dr.Arapovicsné Kiss Krisztina. Unexpected adverse event of a long-acting GLP-1 receptor agonist -decreased gastro-intestinal motility causing clinical symptoms during IDegLira trherapy.A case report. Diabetologica Hungarica. 2019;27(4):263-268,-
17546702,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Wrong Technique In Device Usage Process;Multiple Use Of Single-Use Product,Non-Serious,Non-Serious,Female,-,16-MAR-2020,Non-Expedited,73 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-MAR-2020,16-MAR-2020,US,Not Specified,US-SA-2020SA066285,-,-
17545030,Xultophy 100/3.6;Amlodipine;Kardegic,Aspirin Dl-Lysine;Atorvastatin Calcium;Furosemide;Amlodipine Besylate;Insulin Degludec\Liraglutide;Lactulose;Pristinamycin;Fluoxetine Hydrochloride;Perindopril;Metformin Hydrochloride,Bronchitis;Cerebrovascular Accident;Constipation;Depression;Diabetes Mellitus;Dyslipidaemia;Hypertension;Type 2 Diabetes Mellitus,Dehydration;Acute Kidney Injury;Diarrhoea;Lactic Acidosis;Hyperkalaemia;Vomiting,Serious,Life Threatening,Female,21-FEB-2020,16-MAR-2020,Expedited,71 YR,112 KG,Eli Lilly And Co,Consumer,Not Specified,-,06-MAR-2020,16-MAR-2020,FR,Not Specified,FR-ELI_LILLY_AND_COMPANY-FR202003003918,-,-
17544338,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Breast Cancer Stage Iv;Carcinoid Syndrome,Serious,Other Outcomes,Not Specified,-,16-MAR-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,06-MAR-2020,16-MAR-2020,US,Not Specified,US-SA-2020SA065993,-,-
17544285,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Atrial Fibrillation;Benign Prostatic Hyperplasia;Dyslipidaemia;Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Intestinal Obstruction,Serious,Hospitalized,Male,25-FEB-2020,16-MAR-2020,Expedited,75 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Silodosin;Furosemide;Edoxaban Tosylate;Herbals;Brotizolam;Canagliflozin;Metgluco;Atorvastatin,03-MAR-2020,16-MAR-2020,JP,Not Specified,JP-NOVOPROD-717855,-,-
17540017,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Circumstance Or Information Capable Of Leading To Medication Error,Non-Serious,Non-Serious,Male,-,13-MAR-2020,Non-Expedited,88 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,05-MAR-2020,13-MAR-2020,US,Not Specified,US-SA-2020SA061310,-,-
17534895,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Female,-,12-MAR-2020,Non-Expedited,79 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,05-MAR-2020,12-MAR-2020,US,Not Specified,US-SA-2020SA060952,-,-
17534867,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Female,-,12-MAR-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,05-MAR-2020,12-MAR-2020,US,Not Specified,US-SA-2020SA060964,-,-
17534245,Tresiba;Novorapid;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Insulin Aspart;Insulin Degludec,Benign Prostatic Hyperplasia;Blood Cholesterol Abnormal;Hypertension;Type 2 Diabetes Mellitus,Condition Aggravated;Diabetes Mellitus Inadequate Control;Deafness,Serious,Disabled,Male,FEB-2020,12-MAR-2020,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,Tamsulosin Hydrochloride;Dapagliflozin;Ezetimibe;Losartan,03-MAR-2020,12-MAR-2020,BR,Not Specified,BR-NOVOPROD-717017,-,-
17531665,-,Insulin Glargine\Lixisenatide,-,Malaise;Syncope;Vomiting;Nausea;Intentional Product Misuse,Serious,Other Outcomes,Female,-,12-MAR-2020,Expedited,68 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Lantus,04-MAR-2020,12-MAR-2020,IL,Not Specified,IL-SA-2020SA060568,-,-
17531608,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Injection Site Mass;Injection Site Pain;Injection Site Irritation,Non-Serious,Non-Serious,Not Specified,-,11-MAR-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,04-MAR-2020,11-MAR-2020,US,Not Specified,US-SA-2020SA062388,-,-
17531600,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Rash,Non-Serious,Non-Serious,Male,-,11-MAR-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,04-MAR-2020,11-MAR-2020,US,Not Specified,US-SA-2020SA061097,-,-
17527192,-,Insulin Glargine\Lixisenatide,-,Metastases To Liver;Metastases To Lung;Pancreatic Neoplasm,Serious,Other Outcomes,Female,-,10-MAR-2020,Expedited,63 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,03-MAR-2020,10-MAR-2020,RO,Not Specified,RO-SA-2020SA059126,-,-
17522470,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Migraine;Bone Anchored Hearing Aid Implantation;Visual Impairment;Headache,Non-Serious,Non-Serious,Female,-,10-MAR-2020,Non-Expedited,60 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Novolog,03-MAR-2020,10-MAR-2020,US,Not Specified,US-SA-2020SA059404,-,-
17521781,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Pancreatitis,Serious,Hospitalized;Other Outcomes,Female,-,10-MAR-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,02-MAR-2020,10-MAR-2020,US,Not Specified,US-SA-2020SA058110,-,-
17518368,Jardiance;Soliqua 100/33,Insulin Glargine\Lixisenatide;Empagliflozin,Product Used For Unknown Indication,Renal Failure;Pancreatitis;Blood Triglycerides Abnormal,Serious,Other Outcomes,Male,-,10-MAR-2020,Expedited,Not Specified,Not Specified,Boehringer Ingelheim,Consumer,Not Specified,-,02-MAR-2020,10-MAR-2020,US,Not Specified,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-012695",-,-
17517368,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Female,-,09-MAR-2020,Non-Expedited,68 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,02-MAR-2020,09-MAR-2020,US,Not Specified,US-SA-2020SA057222,-,-
17516682,Xultophy 100/3.6,Insulin Degludec\Liraglutide;Fenofibrate,Diabetes Mellitus;Dyslipidaemia,Pancreatitis;Coma Acidotic,Serious,Hospitalized,Male,07-JAN-2020,09-MAR-2020,Expedited,45 YR,Not Specified,Mylan,Healthcare Professional,Not Specified,-,28-FEB-2020,09-MAR-2020,FR,Not Specified,FR-MYLANLABS-2020M1023662,-,-
16746829,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Cerebrovascular Accident;Movement Disorder;Product Dose Omission Issue;Myocardial Infarction;Blood Glucose Increased;Product Storage Error;Paralysis;Device Operational Issue;Memory Impairment,Serious,Other Outcomes,Female,-,09-MAR-2020,Expedited,67 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,02-MAR-2020,27-AUG-2019,US,Not Specified,US-SA-2019SA228835,-,-
17509489,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Female,-,06-MAR-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-FEB-2020,06-MAR-2020,US,Not Specified,US-SA-2020SA057967,-,-
17509354,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Injection Site Rash,Non-Serious,Non-Serious,Not Specified,-,06-MAR-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Jardiance;Metformin,02-MAR-2020,06-MAR-2020,US,Not Specified,US-SA-2020SA058799,-,-
17505573,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Acute Kidney Injury,Serious,Other Outcomes,Male,-,05-MAR-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,27-FEB-2020,05-MAR-2020,US,Not Specified,US-SA-2020SA054305,-,-
16878730,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injection Site Bruising;Device Operational Issue,Non-Serious,Non-Serious,Female,-,05-MAR-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-FEB-2020,02-OCT-2019,US,Not Specified,US-SA-2019SA270924,-,-
16863879,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injection Site Mass,Non-Serious,Non-Serious,Female,-,05-MAR-2020,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-FEB-2020,27-SEP-2019,US,Not Specified,US-SA-2019SA263970,-,-
17171869,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Device Operational Issue;Product Dose Omission Issue,Non-Serious,Non-Serious,Female,-,04-MAR-2020,Non-Expedited,39 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,25-FEB-2020,18-DEC-2019,US,Not Specified,US-SA-2019SA346465,-,-
16995571,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 1 Diabetes Mellitus,Device Operational Issue;Needle Issue;Injection Site Bruising;Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Female,-,04-MAR-2020,Non-Expedited,83 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-FEB-2020,05-NOV-2019,US,Not Specified,US-SA-2019SA303392,-,-
16878613,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Diabetes Mellitus Inadequate Control;Product Dose Omission Issue;Drug Ineffective,Serious,Other Outcomes,Female,-,04-MAR-2020,Non-Expedited,62 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-FEB-2020,02-OCT-2019,US,Not Specified,US-SA-2019SA263164,-,-
16717700,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Incorrect Dose Administered By Device;Visual Impairment;Hypokinesia;Blood Glucose Increased;Wrong Technique In Device Usage Process;Arthritis;Unevaluable Event;Product Dose Omission Issue;Device Operational Issue;Arthralgia;Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Female,-,04-MAR-2020,Non-Expedited,68 YR,98 KG,Sanofi Aventis,Consumer,Not Specified,-,26-FEB-2020,19-AUG-2019,US,Not Specified,US-SA-2019SA228455,-,-
17491449,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Not Specified,-,03-MAR-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,27-FEB-2020,03-MAR-2020,US,Not Specified,US-SA-2020SA055099,-,-
17491365,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Not Specified,-,03-MAR-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,25-FEB-2020,03-MAR-2020,US,Not Specified,US-SA-2020SA052765,-,-
17491322,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Male,-,03-MAR-2020,Non-Expedited,57 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-FEB-2020,03-MAR-2020,US,Not Specified,US-SA-2020SA055015,-,-
17491281,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Female,-,03-MAR-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-FEB-2020,03-MAR-2020,US,Not Specified,US-SA-2020SA054960,-,-
16869635,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injection Site Pruritus,Non-Serious,Non-Serious,Female,-,03-MAR-2020,Non-Expedited,84 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,25-FEB-2020,30-SEP-2019,US,Not Specified,US-SA-2019SA156933,-,-
17485633,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Female,-,02-MAR-2020,Non-Expedited,60 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,25-FEB-2020,02-MAR-2020,US,Not Specified,US-SA-2020SA053432,-,-
17485576,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Abdominal Pain Upper,Non-Serious,Non-Serious,Male,-,02-MAR-2020,Non-Expedited,68 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,24-FEB-2020,02-MAR-2020,US,Not Specified,US-SA-2020SA051979,-,-
17485559,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Weight Increased,Non-Serious,Non-Serious,Not Specified,-,02-MAR-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,26-FEB-2020,02-MAR-2020,US,Not Specified,US-SA-2020SA053933,-,-
17485532,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Female,-,02-MAR-2020,Non-Expedited,71 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,24-FEB-2020,02-MAR-2020,US,Not Specified,US-SA-2020SA051640,-,-
17482041,Metformin;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Metformin Hydrochloride,Diabetes Mellitus;Product Used For Unknown Indication,Hypoglycaemia;Suicide Attempt,Serious,Hospitalized;Other Outcomes,Male,28-JUL-2018,02-MAR-2020,Expedited,63 YR,80 KG,Novartis,Healthcare Professional,Not Specified,Aldactazine;Ramipril;Allopurinol;Atorvastatin;Urapidil;Lercanidipine,03-OCT-2018,02-MAR-2020,FR,Not Specified,PHHY2018FR120476,-,-
17475229,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Nausea,Non-Serious,Non-Serious,Female,-,28-FEB-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,24-FEB-2020,28-FEB-2020,US,Not Specified,US-SA-2020SA052135,-,-
17475226,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Nausea,Non-Serious,Non-Serious,Female,-,28-FEB-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,24-FEB-2020,28-FEB-2020,US,Not Specified,US-SA-2020SA052155,-,-
17475202,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Triglycerides Decreased,Non-Serious,Non-Serious,Not Specified,-,28-FEB-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,24-FEB-2020,28-FEB-2020,US,Not Specified,US-SA-2020SA051514,-,-
17471412,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Renal Failure,Serious,Other Outcomes,Male,-,28-FEB-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Lantus;Novolog,20-FEB-2020,28-FEB-2020,US,Not Specified,US-SA-2020SA049946,-,-
17315691,Soliqua 100/33,Insulin Glargine\Lixisenatide;Prednisone,Blood Glucose Increased;Gout,Device Use Issue;Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,28-FEB-2020,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Novolog,24-FEB-2020,24-JAN-2020,US,Not Specified,US-SA-2020SA018706,-,-
17469192,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Frustration Tolerance Decreased;Feeling Abnormal;Unevaluable Event;Product Dose Omission Issue;Fatigue,Non-Serious,Non-Serious,Male,-,27-FEB-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Novolog,19-FEB-2020,27-FEB-2020,US,Not Specified,US-SA-2020SA049854,-,-
17469046,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Injection Site Discolouration,Non-Serious,Non-Serious,Not Specified,-,27-FEB-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,20-FEB-2020,27-FEB-2020,US,Not Specified,US-SA-2020SA049448,-,-
17459883,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Peau D'Orange;Injection Site Reaction,Non-Serious,Non-Serious,Female,-,26-FEB-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-FEB-2020,26-FEB-2020,US,Not Specified,US-SA-2020SA048640,-,-
17426397,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus;Hypertension,Neoplasm Progression;Benign Neoplasm,Serious,Other Outcomes,Male,-,26-FEB-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Glifage;Amlodipine;Losartan,19-FEB-2020,17-FEB-2020,BR,Not Specified,BR-SA-2020SA034782,-,-
17458281,Metformin;Soliqua 100/33,Insulin Glargine\Lixisenatide;Repaglinide;Metformin Hydrochloride;Gliclazide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Hypoglycaemia;Hepatitis E,Serious,Other Outcomes,Male,2018,25-FEB-2020,Expedited,50 YR,Not Specified,Novartis,Healthcare Professional,Not Specified,Glimepiride;Insulin Glargine;Insulin Lispro;Pioglitazone,14-FEB-2020,25-FEB-2020,CZ,Not Specified,NVSC2020CZ051250,Vondrakova M. Vondrakova M. Kdy mene muze znamenat i vice aneb Suliqua a spokojenost pacienta se zjednodusenim rezimu. KAZUISTIKY V DIABETOLOGII. 2019;17(3):20-1,-
17451271,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Male,-,24-FEB-2020,Non-Expedited,76 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-FEB-2020,24-FEB-2020,US,Not Specified,US-SA-2020SA046418,-,-
17447210,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Dulaglutide,Diabetes Mellitus,Dermatitis Exfoliative Generalised,Serious,Other Outcomes,Male,01-OCT-2019,21-FEB-2020,Expedited,55 YR,76 KG,Eli Lilly And Co,Healthcare Professional,Not Specified,-,10-FEB-2020,21-FEB-2020,IT,Not Specified,IT-ELI_LILLY_AND_COMPANY-IT202002004576,-,-
17446170,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Rash,Non-Serious,Non-Serious,Female,OCT-2019,21-FEB-2020,Non-Expedited,72 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,14-FEB-2020,21-FEB-2020,US,Not Specified,US-SA-2020SA044786,-,-
17443524,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Cerebrovascular Accident;Hospitalisation,Serious,Hospitalized;Other Outcomes,Male,-,21-FEB-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Metformin,14-FEB-2020,21-FEB-2020,US,Not Specified,US-SA-2020SA042147,-,-
17105357,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injection Site Pain;Acne;Device Operational Issue,Non-Serious,Non-Serious,Female,-,20-FEB-2020,Non-Expedited,65 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-FEB-2020,03-DEC-2019,US,Not Specified,US-SA-2019SA334216,-,-
17436663,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Male,-,19-FEB-2020,Non-Expedited,50 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-FEB-2020,19-FEB-2020,US,Not Specified,US-SA-2020SA041572,-,-
17432187,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,-,18-FEB-2020,Non-Expedited,59 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-FEB-2020,18-FEB-2020,US,Not Specified,US-SA-2020SA039480,-,-
17432139,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Fluctuation,Non-Serious,Non-Serious,Male,-,18-FEB-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-FEB-2020,18-FEB-2020,US,Not Specified,US-SA-2020SA037065,-,-
17431840,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Dulaglutide,Diabetes Mellitus,Dermatitis Exfoliative Generalised,Serious,Other Outcomes,Male,01-OCT-2019,18-FEB-2020,Expedited,55 YR,76 KG,Takeda,Healthcare Professional,Not Specified,-,13-FEB-2020,18-FEB-2020,IT,Not Specified,IT-TAKEDA-2020TEU001782,-,-
15473923,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Breakage;Illness;Device Leakage;Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,18-FEB-2020,Non-Expedited,58 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-FEB-2020,08-OCT-2018,US,Not Specified,US-SA-2018SA272880,-,-
17425413,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Cerebral Infarction,Serious,Died,Female,2020,17-FEB-2020,Expedited,85 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,05-FEB-2020,17-FEB-2020,JP,Not Specified,JP-NOVOPROD-712259,-,-
17419886,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Product Used For Unknown Indication,Bladder Cancer;Abdominal Pain Lower;Cystitis,Serious,Other Outcomes,Male,-,14-FEB-2020,Expedited,44 YR,Not Specified,Takeda,Consumer,Not Specified,Thyroxine,13-OCT-2019,14-FEB-2020,JO,Not Specified,JO-TAKEDA-2019TJP024097,-,-
17415473,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Hypoacusis,Non-Serious,Non-Serious,Male,-,13-FEB-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,06-FEB-2020,13-FEB-2020,US,Not Specified,US-SA-2020SA034512,-,-
17189988,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Abortion Spontaneous;Maternal Exposure During Pregnancy,Serious,Other Outcomes,Female,-,13-FEB-2020,Expedited,Not Specified,95 KG,Novo Nordisk,Healthcare Professional,Not Specified,Glimepiride;Metformin Hydrochloride,03-FEB-2020,23-DEC-2019,FR,Not Specified,FR-NOVOPROD-699895,-,-
17410269,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,12-FEB-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,06-FEB-2020,12-FEB-2020,US,Not Specified,US-SA-2020SA034523,-,-
17055741,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Glomerular Filtration Rate Decreased,Serious,Other Outcomes,Male,NOV-2019,11-FEB-2020,Expedited,80 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,02-FEB-2020,20-NOV-2019,IL,Not Specified,IL-NOVOPROD-697301,-,-
17397227,Xultophy 100/3.6;Metformin,Metformin Hydrochloride;Insulin Degludec\Liraglutide,Diabetes Mellitus,Hypoglycaemia;Suicide Attempt,Serious,Hospitalized,Male,28-JUL-2018,10-FEB-2020,Expedited,63 YR,80 KG,Mylan,Healthcare Professional,Not Specified,Lercanidipine;Urapidil;Ramipril;Aldactazine;Atorvastatin;Allopurinol,05-APR-2019,10-FEB-2020,FR,Not Specified,FR-MYLANLABS-2019M1032901,-,-
17396463,Novolog;Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Aspart,Type 2 Diabetes Mellitus,Cough;Blood Glucose Increased;Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Male,-,10-FEB-2020,Non-Expedited,69 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,31-JAN-2020,10-FEB-2020,US,Not Specified,US-SA-2020SA030585,-,-
17396452,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Glycosylated Haemoglobin Abnormal;Intentional Product Use Issue,Non-Serious,Non-Serious,Female,-,10-FEB-2020,Non-Expedited,52 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,30-JAN-2020,10-FEB-2020,US,Not Specified,US-SA-2020SA028594,-,-
17396373,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Hypoacusis;Wrong Technique In Device Usage Process;Treatment Noncompliance,Non-Serious,Non-Serious,Female,-,10-FEB-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,04-FEB-2020,10-FEB-2020,US,Not Specified,US-SA-2020SA032781,-,-
17396272,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Female,-,10-FEB-2020,Non-Expedited,60 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,03-FEB-2020,10-FEB-2020,US,Not Specified,US-SA-2020SA032768,-,-
17394369,Xultophy 100/3.6,Insulin Degludec\Liraglutide;Fenofibrate,Diabetes Mellitus;Dyslipidaemia,Pancreatitis;Coma Acidotic,Serious,Other Outcomes;Hospitalized,Male,07-JAN-2020,10-FEB-2020,Expedited,45 YR,Not Specified,Aurobindo,Healthcare Professional,Not Specified,-,27-JAN-2020,10-FEB-2020,FR,Not Specified,FR-AUROBINDO-AUR-APL-2020-005693,-,-
17392918,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,-,07-FEB-2020,Non-Expedited,78 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,31-JAN-2020,07-FEB-2020,US,Not Specified,US-SA-2020SA031322,-,-
17390115,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Cervix Carcinoma,Serious,Died,Female,-,07-FEB-2020,Expedited,50 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,28-JAN-2020,07-FEB-2020,JP,Not Specified,JP-NOVOPROD-710539,-,-
17368151,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Arrhythmia;Cardiac Disorder;Hypothyroidism;Type 2 Diabetes Mellitus,Hernia;Prostatomegaly;Calculus Bladder,Serious,Other Outcomes,Male,-,04-FEB-2020,Expedited,Not Specified,110 KG,Novo Nordisk,Consumer,Not Specified,Dapagliflozin;Nifedipine;Cilostazol;Apixaban;Fenofibrate;Losartan Potassium;Levothyroxine Sodium;Pitavastatin Calcium;Propafenone,24-JAN-2020,04-FEB-2020,BR,Not Specified,BR-NOVOPROD-709986,-,-
17366298,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Female,-,04-FEB-2020,Non-Expedited,63 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,06-JAN-2020,04-FEB-2020,US,Not Specified,US-SA-2020SA006316,-,-
13598603,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error;Sleep Disorder;Nausea;Illness;Blood Glucose Increased;Fatigue,Non-Serious,Non-Serious,Female,2017,04-FEB-2020,Non-Expedited,51 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-JAN-2020,31-MAY-2017,US,Not Specified,US-SA-2017SA078192,-,-
17360945,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Female,-,03-FEB-2020,Non-Expedited,23 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-JAN-2020,03-FEB-2020,US,Not Specified,US-SA-2020SA024928,-,-
15902131,Xultophy 100/3.6;Victoza,Liraglutide;Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Medullary Thyroid Cancer;Breast Cancer,Serious,Other Outcomes,Female,NOV-2018,01-FEB-2020,Expedited,69 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,22-JAN-2020,01-FEB-2019,US,Not Specified,US-NOVOPROD-644096,-,-
17355729,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Pruritus,Non-Serious,Non-Serious,Female,-,31-JAN-2020,Non-Expedited,55 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,24-JAN-2020,31-JAN-2020,US,Not Specified,US-SA-2020SA024801,-,-
15553829,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injection Site Pain;Pancreatitis,Serious,Other Outcomes,Female,-,31-JAN-2020,Non-Expedited,56 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,17-DEC-2019,26-OCT-2018,US,Not Specified,US-SA-2018SA292833,-,-
17352198,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Hypotension;Loss Of Consciousness;Diarrhoea,Serious,Other Outcomes,Female,01-JUL-2019,30-JAN-2020,Expedited,76 YR,98 KG,Novo Nordisk,Healthcare Professional,Not Specified,Metformin Hydrochloride;Valsartan;Gliclazide,22-JAN-2020,30-JAN-2020,IT,Not Specified,IT-NOVOPROD-709070,-,-
17349003,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Pruritus,Non-Serious,Non-Serious,Female,-,30-JAN-2020,Non-Expedited,55 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,24-JAN-2020,30-JAN-2020,US,Not Specified,US-SA-2020SA024874,-,-
17345750,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Peritonitis,Serious,Other Outcomes,Female,17-JAN-2020,29-JAN-2020,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,17-JAN-2020,29-JAN-2020,JP,Not Specified,JP-NOVOPROD-708977,-,-
17339664,-,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Gastroenteritis;Nausea;Abdominal Pain,Serious,Hospitalized,Male,-,29-JAN-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,22-JAN-2020,29-JAN-2020,SK,Not Specified,SK-SA-2020SA019577,-,-
17339102,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Use Complaint;Colour Blindness,Non-Serious,Non-Serious,Female,-,29-JAN-2020,Non-Expedited,58 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,22-JAN-2020,29-JAN-2020,US,Not Specified,US-SA-2020SA021601,-,-
17339076,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Prescribed Overdose,Non-Serious,Non-Serious,Male,-,29-JAN-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,22-JAN-2020,29-JAN-2020,US,Not Specified,US-SA-2020SA020855,-,-
17319934,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Diabetic Wound,Serious,Hospitalized;Other Outcomes,Male,-,26-JAN-2020,Expedited,59 YR,67 KG,Novo Nordisk,Consumer,Not Specified,Glifage,16-JAN-2020,26-JAN-2020,BR,Not Specified,BR-NOVOPROD-708277,-,-
17293728,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Weight Increased;Colour Blindness;Glycosylated Haemoglobin Abnormal,Non-Serious,Non-Serious,Male,-,21-JAN-2020,Non-Expedited,67 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,16-JAN-2020,21-JAN-2020,US,Not Specified,US-SA-2020SA016631,-,-
17288383,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Diabetic Neuropathy;Hypoglycaemia;Non-Proliferative Retinopathy,Serious,Other Outcomes,Male,-,20-JAN-2020,Expedited,53 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,14-JAN-2020,20-JAN-2020,RU,Not Specified,RU-SA-2020SA011701,-,-
17286907,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Renal Failure,Serious,Other Outcomes,Female,-,20-JAN-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-JAN-2020,20-JAN-2020,US,Not Specified,US-SA-2020SA011828,-,-
17286903,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Renal Failure,Serious,Other Outcomes,Not Specified,-,20-JAN-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-JAN-2020,20-JAN-2020,US,Not Specified,US-SA-2020SA012865,-,-
17286898,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Renal Failure;Coma,Serious,Other Outcomes,Male,-,20-JAN-2020,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,13-JAN-2020,20-JAN-2020,US,Not Specified,US-SA-2020SA011742,-,-
17285393,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Device Issue;Incorrect Dose Administered By Device,Non-Serious,Non-Serious,Female,-,17-JAN-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-JAN-2020,17-JAN-2020,US,Not Specified,US-SA-2020SA010807,-,-
17285240,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Pancreatic Carcinoma Stage Iv,Serious,Other Outcomes,Male,-,17-JAN-2020,Expedited,60 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,07-JAN-2020,17-JAN-2020,JP,Not Specified,JP-NOVOPROD-706628,-,-
17284520,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Renal Failure;Unresponsive To Stimuli,Serious,Other Outcomes;Hospitalized;Life Threatening,Male,-,17-JAN-2020,Expedited,49 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,13-JAN-2020,17-JAN-2020,US,Not Specified,US-SA-2020SA013984,-,-
16818369,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,15-JAN-2020,Non-Expedited,31 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-JAN-2020,17-SEP-2019,US,Not Specified,US-SA-2018SA054944,-,-
15881871,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Decreased;Blood Glucose Increased;Product Storage Error;Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Male,-,14-JAN-2020,Non-Expedited,73 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin,08-JAN-2020,28-JAN-2019,US,Not Specified,US-SA-2019SA022000,-,-
17117984,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Glycosylated Haemoglobin Increased;Anxiety;Product Storage Error,Non-Serious,Non-Serious,Female,-,13-JAN-2020,Non-Expedited,82 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Lantus,06-JAN-2020,05-DEC-2019,US,Not Specified,US-SA-2019SA335615,-,-
17259343,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Multiple Use Of Single-Use Product,Non-Serious,Non-Serious,Female,-,10-JAN-2020,Non-Expedited,43 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,06-JAN-2020,10-JAN-2020,US,Not Specified,US-SA-2020SA006317,-,-
17253221,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,09-JAN-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,04-JAN-2020,09-JAN-2020,US,Not Specified,US-SA-2020SA006304,-,-
17242638,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Foot Operation,Non-Serious,Non-Serious,Male,-,07-JAN-2020,Non-Expedited,73 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,02-JAN-2020,07-JAN-2020,US,Not Specified,US-SA-2020SA002137,-,-
17241309,Xultophy 100/3.6,Insulin Degludec\Liraglutide;Metformin Hydrochloride,Diabetes Mellitus;Product Used For Unknown Indication,Hypoglycaemia;Suicide Attempt,Serious,Hospitalized,Male,28-JUL-2018,07-JAN-2020,Expedited,63 YR,80 KG,Ranbaxy,Healthcare Professional,Not Specified,Allopurinol;Atorvastatin;Urapidil;Aldactazine;Lercanidipine,08-OCT-2018,07-JAN-2020,FR,Not Specified,FR-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-188442,-,-
17233023,Xultophy 100/3.6,Metformin Hydrochloride;Insulin Degludec\Liraglutide,Diabetes Mellitus,Suicide Attempt;Hypoglycaemia,Serious,Other Outcomes;Hospitalized,Male,28-JUL-2018,03-JAN-2020,Expedited,63 YR,80 KG,Teva,Healthcare Professional,Not Specified,Urapidil;Aldactazine;Lercanidipine;Atorvastatin;Allopurinol,15-OCT-2018,03-JAN-2020,FR,Not Specified,FR-TEVA-2018-FR-966059,-,-
17232045,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Intentional Product Use Issue;Treatment Noncompliance,Non-Serious,Non-Serious,Male,-,03-JAN-2020,Non-Expedited,71 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-DEC-2019,03-JAN-2020,US,Not Specified,US-SA-2019SA362242,-,-
17225407,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Rash;Pruritus;Hypersensitivity,Non-Serious,Non-Serious,Female,-,02-JAN-2020,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-DEC-2019,02-JAN-2020,US,Not Specified,US-SA-2019SA360636,-,-
17219616,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Constipation;Heart Rate Increased;Hospitalisation;Nausea,Serious,Hospitalized,Female,MAY-2019,31-DEC-2019,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,20-DEC-2019,31-DEC-2019,US,Not Specified,US-NOVOPROD-704409,-,-
17216628,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Osteomyelitis;Blood Glucose Increased;Tooth Infection;Influenza;Fungal Infection;Glycosylated Haemoglobin Increased,Serious,Other Outcomes,Female,2019,30-DEC-2019,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,19-DEC-2019,30-DEC-2019,US,Not Specified,US-NOVOPROD-704090,-,-
17215956,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Exposure During Pregnancy,Non-Serious,Non-Serious,Female,-,30-DEC-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,18-DEC-2019,30-DEC-2019,US,Not Specified,US-SA-2019SA353990,-,-
17214874,Soliqua 100/33,Insulin Glargine\Lixisenatide,Blood Glucose,Pancreatic Disorder;Hyperglycaemia,Serious,Hospitalized,Female,2019,30-DEC-2019,Expedited,65 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-DEC-2019,30-DEC-2019,KR,Not Specified,KR-SA-2019SA354386,-,-
16253082,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Productive Cough;Chest Pain;Cough;Respiratory Disorder;Dysuria;Weight Increased;Peripheral Swelling,Non-Serious,Non-Serious,Female,2019,30-DEC-2019,Non-Expedited,84 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin,17-DEC-2019,29-APR-2019,US,Not Specified,US-SA-2019SA114466,-,-
17203955,Soliqua 100/33;Apidra,Insulin Glulisine;Insulin Glargine\Lixisenatide,-,Off Label Use;Cerebrovascular Accident,Serious,Other Outcomes,Not Specified,-,26-DEC-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,17-DEC-2019,26-DEC-2019,RU,Not Specified,RU-SA-2019SA352406,-,-
17192689,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Thyroid Stimulating Hormone Decreased;Alopecia;Nasal Congestion;Blood Glucose Decreased,Non-Serious,Non-Serious,Female,-,23-DEC-2019,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-DEC-2019,23-DEC-2019,US,Not Specified,US-SA-2019SA350895,-,-
17189701,Metformin;Xultophy 100/3.6,Metformin Hydrochloride;Insulin Degludec\Liraglutide,Diabetes Mellitus;Product Used For Unknown Indication,Suicide Attempt;Hypoglycaemia,Serious,Other Outcomes;Hospitalized,Male,28-JUL-2018,23-DEC-2019,Expedited,63 YR,80 KG,Aurobindo,Healthcare Professional,Not Specified,Urapidil;Lercanidipine;Atorvastatin;Allopurinol;Ramipril;Aldactazine,30-SEP-2018,23-DEC-2019,FR,Not Specified,FR-AUROBINDO-AUR-APL-2018-050044,-,-
17185693,Metformin,Metformin Hydrochloride;Insulin Degludec\Liraglutide,Diabetes Mellitus;Product Used For Unknown Indication,Hypoglycaemia;Suicide Attempt,Serious,Hospitalized,Male,28-JUL-2018,20-DEC-2019,Expedited,63 YR,80 KG,Zydus Pharm,Healthcare Professional,Not Specified,Urapidil;Atorvastatin;Lercanidipine;Allopurinol;Althiazide\Spironolactone;Ramipril,28-SEP-2018,20-DEC-2019,FR,Not Specified,FR-ZYDUS-029036,-,-
17172564,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Urticaria;Rash,Non-Serious,Non-Serious,Female,-,19-DEC-2019,Non-Expedited,50 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,11-DEC-2019,19-DEC-2019,US,Not Specified,US-SA-2019SA346504,-,-
17171952,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Intentional Product Use Issue;Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Male,-,18-DEC-2019,Non-Expedited,54 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-DEC-2019,18-DEC-2019,US,Not Specified,US-SA-2019SA345696,-,-
17171884,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Male,-,18-DEC-2019,Non-Expedited,71 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,11-DEC-2019,18-DEC-2019,US,Not Specified,US-SA-2019SA346497,-,-
17169650,Xultophy 100/3.6,Insulin Degludec\Liraglutide;Metformin Hydrochloride,Diabetes Mellitus;Product Used For Unknown Indication,Suicide Attempt;Hypoglycaemia,Serious,Hospitalized,Male,28-JUL-2018,18-DEC-2019,Expedited,63 YR,80 KG,Novo Nordisk,Healthcare Professional,Not Specified,Aldactazine;Ramipril;Atorvastatin;Lercanidipine;Allopurinol;Urapidil,01-OCT-2018,18-DEC-2019,FR,Not Specified,FR-NOVOPROD-625743,-,-
17166130,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Back Disorder;Bedridden,Non-Serious,Non-Serious,Female,-,17-DEC-2019,Non-Expedited,67 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-DEC-2019,17-DEC-2019,US,Not Specified,US-SA-2019SA345038,-,-
17166103,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Injection Site Reaction,Non-Serious,Non-Serious,Female,-,17-DEC-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,10-DEC-2019,17-DEC-2019,US,Not Specified,US-SA-2019SA346492,-,-
17165836,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Vomiting;Hypokalaemia,Serious,Other Outcomes;Hospitalized,Female,07-DEC-2019,17-DEC-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,09-DEC-2019,17-DEC-2019,SA,Not Specified,SA-SA-2019SA342919,-,-
17162618,Xultophy 100/3.6;Metformin,Metformin Hydrochloride;Insulin Degludec\Liraglutide,Diabetes Mellitus;Product Used For Unknown Indication,Hypoglycaemia;Suicide Attempt,Serious,Hospitalized,Male,28-JUL-2018,17-DEC-2019,Expedited,63 YR,80 KG,Emd Serono Inc,Healthcare Professional,Not Specified,Lercanidipine;Aldactazine;Atorvastatin;Urapidil;Allopurinol,01-OCT-2018,17-DEC-2019,FR,Not Specified,FR-EMD SERONO-E2B_90061040,-,-
17160195,Tahor;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Indapamide\Perindopril Erbumine;Furosemide;Polyethylene Glycols;Potassium Chloride;Aspirin;Atorvastatin Calcium,Constipation;Diabetes Mellitus;Hypercholesterolaemia;Hypertension;Hypokalaemia;Oedema;Prophylaxis,Pancreatic Carcinoma,Serious,Life Threatening,Male,JUL-2019,16-DEC-2019,Expedited,74 YR,Not Specified,Mylan,Healthcare Professional,Not Specified,-,06-DEC-2019,16-DEC-2019,FR,Not Specified,FR-MYLANLABS-2019M1122219,-,-
17160123,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Malaise;Device Operational Issue;Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,16-DEC-2019,Non-Expedited,62 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-DEC-2019,16-DEC-2019,US,Not Specified,US-SA-2019SA345657,-,-
17159944,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Female,-,16-DEC-2019,Non-Expedited,52 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-DEC-2019,16-DEC-2019,US,Not Specified,US-SA-2019SA344009,-,-
16942271,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Decreased Appetite;Thrombocytopenic Purpura;Apathy;Blood Glucose Abnormal,Serious,Hospitalized,Female,08-AUG-2019,12-DEC-2019,Expedited,65 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,03-DEC-2019,21-OCT-2019,CO,Not Specified,CO-NOVOPROD-682449,-,-
17142716,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Dry Mouth;Weight Decreased;Syncope;Stomatitis;Cheilitis;Cystitis;Rhinalgia,Serious,Hospitalized;Other Outcomes,Female,SEP-2019,11-DEC-2019,Expedited,80 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,02-DEC-2019,11-DEC-2019,US,Not Specified,US-NOVOPROD-700557,-,-
17141630,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Female,-,11-DEC-2019,Non-Expedited,39 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,04-DEC-2019,11-DEC-2019,US,Not Specified,US-SA-2019SA339546,-,-
17039279,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Hypoglycaemia,Serious,Hospitalized;Life Threatening,Male,20-OCT-2019,11-DEC-2019,Non-Expedited,65 YR,104 KG,Sanofi Aventis,Healthcare Professional,Not Specified,-,05-DEC-2019,15-NOV-2019,US,Not Specified,US-SA-2019SA311965,-,-
17136536,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Female,-,10-DEC-2019,Non-Expedited,64 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,06-DEC-2019,10-DEC-2019,US,Not Specified,US-SA-2019SA341883,-,-
17124815,Metformin,Metformin Hydrochloride;Gliclazide;Insulin Glargine\Lixisenatide;Repaglinide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Hepatitis E;Hypoglycaemia,Serious,Other Outcomes,Male,2018,06-DEC-2019,Expedited,50 YR,Not Specified,Bausch And Lomb,Healthcare Professional,Not Specified,Glimepiride;Insulin Glargine;Pioglitazone;Insulin Lispro,27-NOV-2019,06-DEC-2019,CZ,Not Specified,CZ-BAUSCH-BL-2019-063850,Vondrakova M. Kdy mene muze znamenat i vice aneb Suliqua a spokojenost pacienta se zjednodusenim rezimu. KAZUISTIKY V DIABETOLOGII. 2019;17(3):20-21.,-
17124200,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Pancreatic Carcinoma,Serious,Other Outcomes,Male,-,06-DEC-2019,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,27-NOV-2019,06-DEC-2019,BR,Not Specified,BR-NOVOPROD-699848,-,-
17119562,Metformin,Metformin Hydrochloride;Gliclazide;Insulin Glargine\Lixisenatide;Repaglinide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Hepatitis E;Hypoglycaemia,Serious,Other Outcomes,Male,2018,06-DEC-2019,Expedited,50 YR,Not Specified,Aurobindo,Healthcare Professional,Not Specified,Insulin Lispro;Insulin Glargine;Pioglitazone;Glimepiride,25-NOV-2019,06-DEC-2019,CZ,Not Specified,CZ-AUROBINDO-AUR-APL-2019-103112,Vondrakova M. Kdy mene muze znamenat i vice aneb Suliqua a spokojenost pacienta se zjednodusenim rezimu. KAZUISTIKY V DIABETOLOGII. 2019;17(3):20-21,-
17117999,Fluzone;Fluzone Quadrivalent Nos;Lantus;Soliqua 100/33;Adacel Tdap;Toujeo;Admelog,"Insulin Lispro;Insulin Glargine;Tetanus Toxoid, Reduced Diphtheria Toxoid And Acellular Pertussis Vaccine Adsorbed, Tdap;Insulin Glargine\Lixisenatide;Insulin Glargine;Influenza A Virus A/California/7/2009 X-179a (H1n1) Antigen (Formaldehyde Inactivated)\Influenza A Virus A/Texas/50/2012 X-223a (H3n2) Antigen (Formaldehyde Inactivated)\Influenza B Virus B/Brisbane/60/2008 Antigen (Formaldehyde Inactivated)\Influenza B Virus B/Massachusetts/2/2012 Antigen (Formalde;Influenza A Virus A/California/7/2009 X-179a (H1n1) Antigen (Formaldehyde Inactivated)\Influenza A Virus A/Victoria/210/2009 X-187 (H3n2) Antigen (Formaldehyde Inactivated)\Influenza B Virus B/Brisbane/60/2008 Antigen (Formaldehyde Inactivated)",-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,29-NOV-2019,05-DEC-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,02-DEC-2019,05-DEC-2019,US,Not Specified,US-SA-2019SA336756,-,-
17117974,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Administration Error,Non-Serious,Non-Serious,Male,-,05-DEC-2019,Non-Expedited,62 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,02-DEC-2019,05-DEC-2019,US,Not Specified,US-SA-2019SA335586,-,-
17106115,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Blood Glucose Decreased,Non-Serious,Non-Serious,Male,NOV-2019,03-DEC-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,04-NOV-2019,03-DEC-2019,US,Not Specified,US-NOVOPROD-694705,-,-
17106114,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Drug Ineffective,Non-Serious,Non-Serious,Male,-,03-DEC-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,28-OCT-2019,03-DEC-2019,US,Not Specified,US-NOVOPROD-694417,-,-
17106112,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Blood Glucose Decreased;Incorrect Dose Administered By Device,Non-Serious,Non-Serious,Female,-,03-DEC-2019,Non-Expedited,66 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,27-SEP-2019,03-DEC-2019,US,Not Specified,US-NOVOPROD-688908,-,-
17106110,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Fatigue;Glycosylated Haemoglobin Increased;Asthenia;Tremor,Non-Serious,Non-Serious,Female,MAY-2019,03-DEC-2019,Non-Expedited,62 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,26-AUG-2019,03-DEC-2019,US,Not Specified,US-NOVOPROD-682924,-,-
17106109,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Illness;Asthenia;Blood Glucose Increased,Non-Serious,Non-Serious,Male,SEP-2019,03-DEC-2019,Non-Expedited,76 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,25-SEP-2019,03-DEC-2019,US,Not Specified,US-NOVOPROD-688538,-,-
17106108,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Gastrooesophageal Reflux Disease,Non-Serious,Non-Serious,Female,JUL-2019,03-DEC-2019,Non-Expedited,66 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,30-OCT-2019,03-DEC-2019,US,Not Specified,US-NOVOPROD-694864,-,-
17106107,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Blood Glucose Increased;Body Temperature Increased;Illness;Blood Glucose Decreased,Non-Serious,Non-Serious,Male,08-OCT-2019,03-DEC-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,09-OCT-2019,03-DEC-2019,US,Not Specified,US-NOVOPROD-691070,-,-
17106106,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Blood Glucose Decreased;Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,03-DEC-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,09-SEP-2019,03-DEC-2019,US,Not Specified,US-NOVOPROD-684885,-,-
17106105,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Vomiting;Nausea,Non-Serious,Non-Serious,Female,-,03-DEC-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,28-OCT-2019,03-DEC-2019,US,Not Specified,US-NOVOPROD-694258,-,-
17106104,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Alopecia,Non-Serious,Non-Serious,Female,2019,03-DEC-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,31-OCT-2019,03-DEC-2019,US,Not Specified,US-NOVOPROD-695153,-,-
17106102,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,03-DEC-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,09-SEP-2019,03-DEC-2019,US,Not Specified,US-NOVOPROD-684903,-,-
17106099,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Eructation;Salivary Hypersecretion;Diarrhoea;Abdominal Discomfort,Non-Serious,Non-Serious,Male,25-SEP-2019,03-DEC-2019,Non-Expedited,84 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,30-SEP-2019,03-DEC-2019,US,Not Specified,US-NOVOPROD-689601,-,-
17106097,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 1 Diabetes Mellitus,Dyspepsia;Vomiting;Expired Product Administered,Non-Serious,Non-Serious,Female,OCT-2019,03-DEC-2019,Non-Expedited,72 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,11-NOV-2019,03-DEC-2019,US,Not Specified,US-NOVOPROD-697252,-,-
17105724,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Pancreatic Carcinoma,Serious,Died,Female,-,03-DEC-2019,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,27-NOV-2019,03-DEC-2019,BR,Not Specified,BR-NOVOPROD-699747,-,-
16803166,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Blood Glucose Fluctuation,Non-Serious,Non-Serious,Female,-,03-DEC-2019,Non-Expedited,71 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,21-AUG-2019,13-SEP-2019,US,Not Specified,US-NOVOPROD-680245,-,-
16801994,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Pruritus;Sinus Headache;Diabetes Mellitus Inadequate Control,Non-Serious,Non-Serious,Male,JUN-2019,03-DEC-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,04-SEP-2019,12-SEP-2019,US,Not Specified,US-NOVOPROD-681389,-,-
17101241,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Oropharyngeal Discomfort,Non-Serious,Non-Serious,Female,-,02-DEC-2019,Non-Expedited,78 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-NOV-2019,02-DEC-2019,US,Not Specified,US-SA-2019SA332000,-,-
17101131,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Injection Site Rash;Incorrect Dose Administered By Device;Injection Site Urticaria,Non-Serious,Non-Serious,Female,-,02-DEC-2019,Non-Expedited,61 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,25-NOV-2019,02-DEC-2019,US,Not Specified,US-SA-2019SA329551,-,-
16967901,Metformin;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Metformin Hydrochloride,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Asthenia;Loss Of Consciousness;Vomiting;Syncope,Serious,Other Outcomes,Female,17-SEP-2019,02-DEC-2019,Expedited,51 YR,91 KG,Novo Nordisk,Consumer,Not Specified,Losartan;Atorvastatin;Gemfibrozil;Novorapid;Fluoxetine;Amlodipine,20-NOV-2019,28-OCT-2019,CO,Not Specified,CO-NOVOPROD-689228,-,-
17078006,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Muscle Spasms;Memory Impairment;Constipation;Sleep Disorder,Serious,Other Outcomes,Male,JUL-2019,26-NOV-2019,Expedited,69 YR,83 KG,Novo Nordisk,Consumer,Not Specified,Gliclazide;Metformin Hydrochloride,18-NOV-2019,26-NOV-2019,FR,Not Specified,FR-NOVOPROD-697283,-,-
17077996,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Pancreatic Carcinoma,Serious,Other Outcomes,Male,-,26-NOV-2019,Expedited,73 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,18-NOV-2019,26-NOV-2019,IL,Not Specified,IL-NOVOPROD-697941,-,-
16359015,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Dose Omission Issue;Device Leakage;Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,26-NOV-2019,Non-Expedited,60 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-NOV-2019,27-MAY-2019,US,Not Specified,US-SA-2019SA137082,-,-
16339627,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injection Site Erythema;Injection Site Haemorrhage;Injection Site Swelling;Injury Associated With Device,Non-Serious,Non-Serious,Female,-,26-NOV-2019,Non-Expedited,58 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-NOV-2019,21-MAY-2019,US,Not Specified,US-SA-2019SA137069,-,-
17067090,Metformin,Metformin Hydrochloride;Repaglinide;Insulin Glargine\Lixisenatide;Gliclazide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Hypoglycaemia;Hepatitis E,Serious,Other Outcomes,Male,2018,22-NOV-2019,Expedited,50 YR,Not Specified,Mylan,Healthcare Professional,Not Specified,Insulin Glargine;Pioglitazone;Insulin Lispro;Glimepiride,18-NOV-2019,22-NOV-2019,CZ,Not Specified,CZ-MYLANLABS-2019M1112361,Vondrakova M. Kdy mene muze znamenat i vice aneb Suliqua a spokojenost pacienta se zjednodusenim rezimu. KAZUISTIKY V DIABETOLOGII. 2019;17(3):20-21,-
17061138,Toujeo;Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Glargine,-,Diarrhoea,Non-Serious,Non-Serious,Not Specified,-,21-NOV-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,14-NOV-2019,21-NOV-2019,US,Not Specified,US-SA-2019SA320395,-,-
17061126,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Decreased,Non-Serious,Non-Serious,Female,-,21-NOV-2019,Non-Expedited,67 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-NOV-2019,21-NOV-2019,US,Not Specified,US-SA-2019SA321500,-,-
16811555,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Operational Issue;Incorrect Dose Administered By Device;Injection Site Reaction;Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Female,-,21-NOV-2019,Non-Expedited,49 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-NOV-2019,16-SEP-2019,US,Not Specified,US-SA-2019SA255632,-,-
16644736,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 1 Diabetes Mellitus,Incorrect Dose Administered By Device;Exposure Via Skin Contact;Device Issue;Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,21-NOV-2019,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-NOV-2019,29-JUL-2019,US,Not Specified,US-SA-2019SA200623,-,-
16547777,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Injection Site Haemorrhage;Incorrect Dose Administered;Blood Glucose Increased;Injection Site Bruising;Injection Site Discolouration,Non-Serious,Non-Serious,Female,-,21-NOV-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-NOV-2019,09-JUL-2019,US,Not Specified,US-SA-2019SA180840,-,-
16315214,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Incorrect Dose Administered By Device;Diabetes Mellitus Inadequate Control;Device Operational Issue,Serious,Other Outcomes,Male,-,20-NOV-2019,Non-Expedited,77 YR,77 KG,Sanofi Aventis,Consumer,Not Specified,-,15-NOV-2019,15-MAY-2019,US,Not Specified,US-SA-2019SA106283,-,-
17045941,Soliqua 100/33;Jardiance,Empagliflozin;Insulin Glargine\Lixisenatide,Product Used For Unknown Indication,Overweight;Weight Decreased,Non-Serious,Non-Serious,Not Specified,-,19-NOV-2019,Non-Expedited,Not Specified,Not Specified,Boehringer Ingelheim,Consumer,Not Specified,-,12-NOV-2019,19-NOV-2019,US,Not Specified,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-113636",-,-
17044991,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Female,-,18-NOV-2019,Non-Expedited,48 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-NOV-2019,18-NOV-2019,US,Not Specified,US-SA-2019SA315056,-,-
17042019,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Hepatic Neoplasm,Serious,Other Outcomes,Male,-,18-NOV-2019,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,07-NOV-2019,18-NOV-2019,FR,Not Specified,FR-NOVOPROD-695732,-,-
16452783,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injection Site Scab,Non-Serious,Non-Serious,Female,-,18-NOV-2019,Non-Expedited,76 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-NOV-2019,19-JUN-2019,US,Not Specified,US-SA-2019SA137107,-,-
17040700,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Hepatic Neoplasm,Serious,Other Outcomes,Male,-,17-NOV-2019,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,07-NOV-2019,17-NOV-2019,FR,Not Specified,FR-NOVOPROD-695707,-,-
17039397,Soliqua 100/33,Insulin Glargine\Lixisenatide;Metformin Hydrochloride,Type 2 Diabetes Mellitus,Hypoglycaemia,Non-Serious,Non-Serious,Not Specified,-,15-NOV-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,08-NOV-2019,15-NOV-2019,US,Not Specified,US-SA-2019SA316280,-,-
17039379,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment;Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Female,-,15-NOV-2019,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-NOV-2019,15-NOV-2019,US,Not Specified,US-SA-2019SA315463,-,-
17039214,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Erythema;Pruritus,Non-Serious,Non-Serious,Male,-,15-NOV-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,06-NOV-2019,15-NOV-2019,US,Not Specified,US-SA-2019SA312911,-,-
16065257,-,Insulin Glargine\Lixisenatide,-,Glycosylated Haemoglobin Decreased;Intentional Product Misuse;Inappropriate Schedule Of Product Administration;Injection Site Pain;Feeling Abnormal;Blood Glucose Increased,Serious,Other Outcomes,Male,-,15-NOV-2019,Expedited,73 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,06-MAR-2019,13-MAR-2019,US,Not Specified,US-SA-2019SA066077,-,-
17033312,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error;Product Dose Omission Issue,Non-Serious,Non-Serious,Female,-,14-NOV-2019,Non-Expedited,61 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-FEB-2019,14-NOV-2019,US,Not Specified,US-SA-2019SA047635,-,-
17033280,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Hypoacusis,Non-Serious,Non-Serious,Male,-,14-NOV-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-NOV-2019,14-NOV-2019,US,Not Specified,US-SA-2019SA316388,-,-
16685458,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Abdominal Pain;Drug Ineffective,Non-Serious,Non-Serious,Female,-,14-NOV-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,05-NOV-2019,09-AUG-2019,US,Not Specified,US-SA-2019SA211554,-,-
17010626,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Product Usage Process,Non-Serious,Non-Serious,Male,-,08-NOV-2019,Non-Expedited,62 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-NOV-2019,08-NOV-2019,US,Not Specified,US-SA-2019SA307805,-,-
16905377,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Diabetes Mellitus Inadequate Control;Blood Glucose Increased,Serious,Other Outcomes,Female,-,07-NOV-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-OCT-2019,10-OCT-2019,US,Not Specified,US-SA-2019SA276626,-,-
15111060,-,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Product Dose Omission Issue,Non-Serious,Non-Serious,Female,-,05-NOV-2019,Non-Expedited,51 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Atorvastatin;Glimepiride;Metformin,24-OCT-2019,05-JUL-2018,US,Not Specified,US-SA-2018SA174780,-,-
16990956,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Increased,Non-Serious,Non-Serious,Not Specified,-,04-NOV-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,28-OCT-2019,04-NOV-2019,US,Not Specified,US-SA-2019SA303351,-,-
16990908,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Fatigue;Anaemia;Product Storage Error,Non-Serious,Non-Serious,Female,-,04-NOV-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-OCT-2019,04-NOV-2019,US,Not Specified,US-SA-2019SA301001,-,-
16990889,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Female,-,04-NOV-2019,Non-Expedited,53 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-OCT-2019,04-NOV-2019,US,Not Specified,US-SA-2019SA300693,-,-
16406867,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Hypertension;Type 2 Diabetes Mellitus,Eye Haemorrhage;Retinal Detachment;Eye Disorder;Upper Limb Fracture;Bone Pain;Condition Aggravated;Weight Decreased;Hypoglycaemic Unconsciousness;Diabetic Retinopathy,Serious,Other Outcomes,Female,MAR-2019,31-OCT-2019,Expedited,57 YR,58 KG,Novo Nordisk,Consumer,Not Specified,Enalapril Maleate;Metformin;Gliclazide,17-OCT-2019,07-JUN-2019,BR,Not Specified,BR-NOVOPROD-665861,-,-
16910041,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Muscle Spasms;Pancreatitis Acute;Nausea;Vomiting;Gastrooesophageal Reflux Disease;Lipase Decreased;Dehydration;Drug Intolerance,Serious,Hospitalized;Other Outcomes,Male,07-OCT-2019,30-OCT-2019,Expedited,57 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,22-OCT-2019,11-OCT-2019,LB,Not Specified,LB-NOVOPROD-689138,-,-
16957100,Amaryl,Glimepiride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Hypoglycaemia;Hyporesponsive To Stimuli,Serious,Other Outcomes,Male,25-JUL-2019,24-OCT-2019,Expedited,89 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Cyproterone Acetate;Losartan;Eliquis;Isoptin,17-OCT-2019,24-OCT-2019,IT,Not Specified,IT-SA-2019SA289645,-,-
16953355,Jardiance;Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Rosuvastatin;Irbesartan;Alogliptin Benzoate;Empagliflozin;Febuxostat,Dyslipidaemia;Hypertension;Hyperuricaemia;Type 2 Diabetes Mellitus,Hydrocephalus,Serious,Hospitalized;Other Outcomes,Male,JUL-2019,23-OCT-2019,Expedited,61 YR,Not Specified,Astrazeneca,Healthcare Professional,Not Specified,-,15-OCT-2019,23-OCT-2019,GR,Not Specified,GR-ASTRAZENECA-2019SF46271,-,-
16944786,Amaryl,Glimepiride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Hyporesponsive To Stimuli;Hypoglycaemia,Serious,Other Outcomes,Male,25-JUL-2019,22-OCT-2019,Expedited,89 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,Isoptin;Eliquis;Losartan;Cyproterone Acetate,17-OCT-2019,22-OCT-2019,IT,Not Specified,IT-TAKEDA-2019TEU012395,-,-
16944167,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Eye Operation,Serious,Other Outcomes,Male,-,22-OCT-2019,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,10-OCT-2019,22-OCT-2019,US,Not Specified,US-NOVOPROD-690810,-,-
16943121,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Pseudocyst;Pancreatitis Acute,Serious,Hospitalized,Male,07-SEP-2019,21-OCT-2019,Expedited,76 YR,80 KG,Novo Nordisk,Healthcare Professional,Not Specified,Aspirin;Bisoprolol;Ezetimibe\Simvastatin;Glucophage;Cytotec,10-OCT-2019,21-OCT-2019,IT,Not Specified,IT-NOVOPROD-689883,-,-
16942290,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Female,-,21-OCT-2019,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-OCT-2019,21-OCT-2019,US,Not Specified,US-SA-2019SA290285,-,-
16941218,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Seizure,Serious,Died;Other Outcomes,Female,-,21-OCT-2019,Expedited,38 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-OCT-2019,21-OCT-2019,US,Not Specified,US-SA-2019SA288723,-,-
16937044,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Cardiac Failure;Respiratory Failure,Serious,Hospitalized;Other Outcomes,Male,27-SEP-2019,18-OCT-2019,Expedited,65 YR,108 KG,Takeda,Healthcare Professional,Not Specified,Victoza,17-OCT-2019,18-OCT-2019,IT,Not Specified,IT-TAKEDA-2019TEU012394,-,-
16934968,Jardiance;Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Empagliflozin;Irbesartan;Febuxostat;Rosuvastatin Calcium;Alogliptin Benzoate,Dyslipidaemia;Hypertension;Hyperuricaemia;Type 2 Diabetes Mellitus,Hydrocephalus,Serious,Hospitalized;Other Outcomes,Male,JUL-2019,18-OCT-2019,Expedited,61 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,-,16-OCT-2019,18-OCT-2019,GR,Not Specified,GR-TAKEDA-2019TEU012275,-,-
16926680,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Abdominal Distension,Non-Serious,Non-Serious,Female,-,16-OCT-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,09-OCT-2019,16-OCT-2019,US,Not Specified,US-SA-2019SA283949,-,-
16911993,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Incorrect Dose Administered By Device,Non-Serious,Non-Serious,Male,-,14-OCT-2019,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-OCT-2019,14-OCT-2019,US,Not Specified,US-SA-2019SA282172,-,-
16911884,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Cholelithiasis,Non-Serious,Non-Serious,Female,-,14-OCT-2019,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,03-OCT-2019,14-OCT-2019,US,Not Specified,US-SA-2019SA278070,-,-
16867060,Jardiance;Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Irbesartan;Rosuvastatin;Febuxostat;Empagliflozin;Alogliptin Benzoate,Dyslipidaemia;Hypertension;Hyperuricaemia;Type 2 Diabetes Mellitus,Hydrocephalus,Serious,Hospitalized;Other Outcomes,Male,JUL-2019,10-OCT-2019,Expedited,61 YR,Not Specified,Boehringer Ingelheim,Healthcare Professional,Not Specified,-,03-OCT-2019,30-SEP-2019,GR,Not Specified,"GR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-104665",-,-
16891216,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Issue;Blood Glucose Abnormal,Non-Serious,Non-Serious,Male,-,07-OCT-2019,Non-Expedited,77 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin,02-OCT-2019,07-OCT-2019,US,Not Specified,US-SA-2019SA276632,-,-
16891195,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Weight Decreased;Product Storage Error,Non-Serious,Non-Serious,Female,-,07-OCT-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-OCT-2019,07-OCT-2019,US,Not Specified,US-SA-2019SA274551,-,-
16886577,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error;Product Use Issue,Non-Serious,Non-Serious,Female,-,04-OCT-2019,Non-Expedited,40 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-OCT-2019,04-OCT-2019,US,Not Specified,US-SA-2019SA274558,-,-
16883220,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,04-OCT-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,27-SEP-2019,04-OCT-2019,US,Not Specified,US-SA-2019SA272345,-,-
16882598,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Condition Aggravated;Product Dose Omission Issue;Pre-Existing Disease,Serious,Hospitalized,Female,-,03-OCT-2019,Expedited,58 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,23-SEP-2019,03-OCT-2019,RU,Not Specified,IL-NOVOPROD-687859,-,-
16869639,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Abnormal;Glycosylated Haemoglobin Abnormal;Device Operational Issue,Non-Serious,Non-Serious,Male,-,30-SEP-2019,Non-Expedited,35 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,24-SEP-2019,30-SEP-2019,US,Not Specified,US-SA-2019SA268542,-,-
16852242,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Female,-,25-SEP-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,17-SEP-2019,25-SEP-2019,US,Not Specified,US-SA-2019SA261661,-,-
16850022,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Mental Disorder;Glycosylated Haemoglobin Increased,Serious,Hospitalized;Other Outcomes,Female,-,25-SEP-2019,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,15-SEP-2019,25-SEP-2019,IL,Not Specified,IL-NOVOPROD-686047,-,-
16844915,Toujeo;Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Insulin Glargine,Diabetes Mellitus,Hypoglycaemia;Confusional State,Serious,Other Outcomes,Male,09-AUG-2019,24-SEP-2019,Expedited,52 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,-,20-SEP-2019,24-SEP-2019,IT,Not Specified,IT-TAKEDA-2019TEU011196,-,-
16765883,-,Insulin Glargine\Lixisenatide,-,Feeling Abnormal;Asthenia;Adverse Drug Reaction;Presyncope;Depressed Level Of Consciousness,Serious,Other Outcomes,Male,20-AUG-2019,23-SEP-2019,Expedited,70 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Atorvastatin;Aspirin;Losartan,16-SEP-2019,03-SEP-2019,IL,Not Specified,IL-SA-2019SA240468,-,-
16835017,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Female,-,20-SEP-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Jardiance;Metformin,17-JUL-2019,20-SEP-2019,US,Not Specified,US-SA-2019SA196544,-,-
16828385,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Injection Site Reaction,Non-Serious,Non-Serious,Female,-,19-SEP-2019,Non-Expedited,61 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,13-SEP-2019,19-SEP-2019,US,Not Specified,US-SA-2019SA259045,-,-
16801813,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Device Operational Issue;Injection Site Haemorrhage;Product Contamination With Body Fluid,Non-Serious,Non-Serious,Male,-,18-SEP-2019,Non-Expedited,57 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-SEP-2019,12-SEP-2019,US,Not Specified,US-SA-2019SA252120,-,-
16818455,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Decreased;Hyperhidrosis;Tremor;Wrong Technique In Product Usage Process,Non-Serious,Non-Serious,Male,-,17-SEP-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,11-SEP-2019,17-SEP-2019,US,Not Specified,US-SA-2019SA257011,-,-
16818448,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Contusion,Non-Serious,Non-Serious,Female,-,17-SEP-2019,Non-Expedited,79 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,11-SEP-2019,17-SEP-2019,US,Not Specified,US-SA-2019SA256992,-,-
16818357,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,-,17-SEP-2019,Non-Expedited,56 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-SEP-2019,17-SEP-2019,US,Not Specified,US-SA-2019SA254311,-,-
16818353,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Hypersensitivity,Non-Serious,Non-Serious,Not Specified,-,17-SEP-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,10-SEP-2019,17-SEP-2019,US,Not Specified,US-SA-2019SA253425,-,-
16811557,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Oedema;Glycosylated Haemoglobin Increased;Aspartate Aminotransferase Increased;Alanine Aminotransferase Increased;Nausea,Non-Serious,Non-Serious,Male,-,16-SEP-2019,Non-Expedited,54 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Metformin Hydrochloride,10-SEP-2019,16-SEP-2019,US,Not Specified,US-SA-2019SA254714,-,-
16811528,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Anaphylactic Reaction,Serious,Hospitalized,Male,-,16-SEP-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,09-SEP-2019,16-SEP-2019,US,Not Specified,US-SA-2019SA253692,-,-
16811511,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Male,-,16-SEP-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-SEP-2019,16-SEP-2019,US,Not Specified,US-SA-2019SA254353,-,-
16803171,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Weight Increased;Nausea;Drug Ineffective;Dizziness;Blood Glucose Increased;Increased Appetite,Non-Serious,Non-Serious,Male,JUL-2019,13-SEP-2019,Non-Expedited,81 YR,185 KG,Novo Nordisk,Consumer,Not Specified,-,30-JUL-2019,13-SEP-2019,US,Not Specified,US-NOVOPROD-677854,-,-
16803169,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Rash;Urticaria,Non-Serious,Non-Serious,Male,JUL-2019,13-SEP-2019,Non-Expedited,60 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,23-JUL-2019,13-SEP-2019,US,Not Specified,US-NOVOPROD-676335,-,-
16803165,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Circumstance Or Information Capable Of Leading To Medication Error,Non-Serious,Non-Serious,Female,-,13-SEP-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,30-JUL-2019,13-SEP-2019,US,Not Specified,US-NOVOPROD-679190,-,-
16803155,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Liquid Product Physical Issue;Incorrect Product Administration Duration;Blood Glucose Increased,Non-Serious,Non-Serious,Female,2019,13-SEP-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,Novolog,21-JUN-2019,13-SEP-2019,US,Not Specified,US-NOVOPROD-670472,-,-
16803154,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Circumstance Or Information Capable Of Leading To Medication Error,Non-Serious,Non-Serious,Female,-,13-SEP-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,19-JUN-2019,13-SEP-2019,US,Not Specified,US-NOVOPROD-669849,-,-
16803152,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Blood Glucose Increased;Incorrect Dose Administered;Injection Site Discharge,Non-Serious,Non-Serious,Female,JUN-2019,13-SEP-2019,Non-Expedited,61 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,12-JUN-2019,13-SEP-2019,US,Not Specified,US-NOVOPROD-668236,-,-
16803151,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Upper Respiratory Tract Infection;Bronchitis,Non-Serious,Non-Serious,Female,DEC-2018,13-SEP-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,06-JUN-2019,13-SEP-2019,US,Not Specified,US-NOVOPROD-667830,-,-
16803149,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Product Intolerance;Feeling Abnormal,Non-Serious,Non-Serious,Male,-,13-SEP-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,31-MAY-2019,13-SEP-2019,US,Not Specified,US-NOVOPROD-666459,-,-
16420773,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Food Poisoning;Abdominal Pain Upper,Non-Serious,Non-Serious,Female,12-APR-2019,13-SEP-2019,Non-Expedited,87 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,06-JUN-2019,12-JUN-2019,US,Not Specified,US-NOVOPROD-659246,-,-
16802318,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Female,-,12-SEP-2019,Non-Expedited,39 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,03-SEP-2019,12-SEP-2019,US,Not Specified,US-SA-2019SA248880,-,-
16802000,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Nausea;Product Dose Omission Issue,Non-Serious,Non-Serious,Female,-,12-SEP-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,13-JUN-2019,12-SEP-2019,US,Not Specified,US-NOVOPROD-668263,-,-
16801999,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Glycosylated Haemoglobin Increased;Blood Glucose Increased;Product Prescribing Error,Non-Serious,Non-Serious,Female,AUG-2018,12-SEP-2019,Non-Expedited,63 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,Glimepiride;Metformin Hydrochloride,12-AUG-2019,12-SEP-2019,US,Not Specified,US-NOVOPROD-680099,-,-
16801998,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Nausea;Flatulence;Urticaria,Non-Serious,Non-Serious,Female,FEB-2019,12-SEP-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,23-MAY-2019,12-SEP-2019,US,Not Specified,US-NOVOPROD-665401,-,-
16801997,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Male,01-AUG-2019,12-SEP-2019,Non-Expedited,72 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,05-AUG-2019,12-SEP-2019,US,Not Specified,US-NOVOPROD-679087,-,-
16801996,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Nausea,Non-Serious,Non-Serious,Female,-,12-SEP-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,19-JUN-2019,12-SEP-2019,US,Not Specified,US-NOVOPROD-669820,-,-
16801995,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Alopecia,Non-Serious,Non-Serious,Female,MAY-2019,12-SEP-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,20-JUN-2019,12-SEP-2019,US,Not Specified,US-NOVOPROD-670234,-,-
16801993,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Nausea;Blood Glucose Increased;Blood Glucose Decreased,Non-Serious,Non-Serious,Female,18-JUL-2019,12-SEP-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,31-JUL-2019,12-SEP-2019,US,Not Specified,US-NOVOPROD-678195,-,-
16801991,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Product Quality Issue;Drug Ineffective,Non-Serious,Non-Serious,Female,JUN-2019,12-SEP-2019,Non-Expedited,51 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,28-JUN-2019,12-SEP-2019,US,Not Specified,US-NOVOPROD-671533,-,-
16420794,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Product Label Confusion;Wrong Technique In Product Usage Process;Incorrect Dose Administered;Blood Glucose Fluctuation,Non-Serious,Non-Serious,Male,-,12-SEP-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,17-JUN-2019,12-JUN-2019,US,Not Specified,US-NOVOPROD-663192,-,-
16420772,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Injection Site Reaction;Injection Site Bruising,Non-Serious,Non-Serious,Not Specified,MAY-2019,12-SEP-2019,Non-Expedited,89 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,23-JUL-2019,12-JUN-2019,US,Not Specified,US-NOVOPROD-663349,-,-
14984035,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Latent Autoimmune Diabetes In Adults,Diarrhoea;Off Label Use;Depression;Abdominal Pain Upper,Non-Serious,Non-Serious,Female,30-NOV-2017,12-SEP-2019,Non-Expedited,58 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,15-JUL-2019,07-JUN-2018,US,Not Specified,US-NOVOPROD-588795,-,-
16796393,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Hypoacusis,Non-Serious,Non-Serious,Male,-,11-SEP-2019,Non-Expedited,74 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,03-SEP-2019,11-SEP-2019,US,Not Specified,US-SA-2019SA247199,-,-
16793942,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Gallbladder Disorder;Pancreatitis Acute,Serious,Other Outcomes,Female,-,11-SEP-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,03-SEP-2019,11-SEP-2019,US,Not Specified,US-SA-2019SA249361,-,-
16709832,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Dose Omission Issue;Illness,Serious,Hospitalized,Female,-,11-SEP-2019,Expedited,58 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,04-SEP-2019,16-AUG-2019,US,Not Specified,US-SA-2019SA222086,-,-
16791540,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Urticaria,Serious,Other Outcomes,Female,10-SEP-2019,10-SEP-2019,Direct,51 YR,98.55 KG,Fda-Ctu,Healthcare Professional,Health Professional,-,-,10-SEP-2019,US,Y,-,-,-
16790632,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Amnesia,Serious,Other Outcomes,Female,22-SEP-2017,10-SEP-2019,Expedited,52 YR,80 KG,Novo Nordisk,Consumer,Not Specified,-,30-AUG-2019,10-SEP-2019,SE,Not Specified,SE-NOVOPROD-682898,-,-
16782681,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Hypertension;Product Dose Omission Issue,Non-Serious,Non-Serious,Male,28-AUG-2019,06-SEP-2019,Non-Expedited,60 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Xigduo Xr,28-AUG-2019,06-SEP-2019,US,Not Specified,US-SA-2019SA244483,-,-
16782613,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Nausea,Non-Serious,Non-Serious,Female,-,06-SEP-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,29-AUG-2019,06-SEP-2019,US,Not Specified,US-SA-2019SA246487,-,-
16781458,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error;Weight Decreased,Non-Serious,Non-Serious,Male,-,06-SEP-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-AUG-2019,06-SEP-2019,US,Not Specified,US-SA-2019SA242328,-,-
16781446,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Wrong Technique In Device Usage Process;Product Dose Omission Issue,Non-Serious,Non-Serious,Female,-,06-SEP-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-AUG-2019,06-SEP-2019,US,Not Specified,US-SA-2019SA242352,-,-
16781436,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Rash,Non-Serious,Non-Serious,Not Specified,-,06-SEP-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,28-AUG-2019,06-SEP-2019,US,Not Specified,US-SA-2019SA243535,-,-
16778793,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Male,-,06-SEP-2019,Non-Expedited,63 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-AUG-2019,06-SEP-2019,US,Not Specified,US-SA-2019SA240348,-,-
16778790,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Hypoglycaemia,Non-Serious,Non-Serious,Male,-,06-SEP-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,23-AUG-2019,06-SEP-2019,US,Not Specified,US-SA-2019SA239359,-,-
16768836,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,03-SEP-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,23-AUG-2019,03-SEP-2019,US,Not Specified,US-SA-2019SA239091,-,-
16768759,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Injection Site Pain;Device Operational Issue,Non-Serious,Non-Serious,Male,-,03-SEP-2019,Non-Expedited,74 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,22-AUG-2019,03-SEP-2019,US,Not Specified,US-SA-2019SA239559,-,-
16765890,-,Insulin Glargine\Lixisenatide,-,Cholelithiasis;Abdominal Pain Upper;Pancreatitis;Jaundice,Serious,Hospitalized;Other Outcomes,Male,-,03-SEP-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,22-AUG-2019,03-SEP-2019,IL,Not Specified,IL-SA-2019SA238391,-,-
16765591,Soliqua 100/33,Insulin Glargine\Lixisenatide,Angina Pectoris;Blood Cholesterol;Blood Pressure Measurement;Diabetes Mellitus;Stent Placement;Type 2 Diabetes Mellitus;Varicose Vein,Spinal Deformity;Skin Discolouration;Stent Placement;Spinal Pain;Product Storage Error,Serious,Hospitalized,Female,JAN-2019,03-SEP-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Cilostazol;Diosmin\Hesperidin;Manivasc;Vytorin;Ivabradine;Dapagliflozin;Metformin;Monocordil;Etilefrine Hydrochloride;Pioglitazone Hydrochloride;Lasix,26-JUN-2019,03-SEP-2019,BR,Not Specified,BR-SA-2019SA175721,-,-
16761752,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Cortisol Decreased;Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,30-AUG-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,21-AUG-2019,30-AUG-2019,US,Not Specified,US-SA-2019SA236177,-,-
16761591,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,30-AUG-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,16-AUG-2019,30-AUG-2019,US,Not Specified,US-SA-2019SA234424,-,-
15259935,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process;Visual Impairment,Non-Serious,Non-Serious,Female,-,30-AUG-2019,Non-Expedited,61 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-AUG-2019,09-AUG-2018,US,Not Specified,US-SA-2018SA217098,-,-
16757092,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Dehydration;Speech Disorder;Dry Mouth;Viral Infection,Serious,Hospitalized,Female,20-JUN-2019,29-AUG-2019,Expedited,67 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,20-JUN-2019,29-AUG-2019,CO,Not Specified,CO-NOVOPROD-669412,-,-
16675713,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Hypoglycaemia;Pancreatic Carcinoma,Serious,Other Outcomes,Female,-,29-AUG-2019,Expedited,78 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,20-AUG-2019,06-AUG-2019,GR,Not Specified,GR-NOVOPROD-676329,-,-
16752362,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Cardiac Failure,Serious,Hospitalized;Other Outcomes,Male,-,28-AUG-2019,Expedited,76 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Metformin;Insulin Nos,19-AUG-2019,28-AUG-2019,BR,Not Specified,BR-NOVOPROD-681278,-,-
16752019,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Myocardial Infarction;Product Storage Error;Surgery,Serious,Other Outcomes;Hospitalized,Male,13-AUG-2019,28-AUG-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,20-AUG-2019,28-AUG-2019,US,Not Specified,US-SA-2019SA234841,-,-
16747019,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,27-AUG-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,20-AUG-2019,27-AUG-2019,US,Not Specified,US-SA-2019SA235447,-,-
16742932,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Musculoskeletal Discomfort;Arthropathy;Back Disorder;Chest Discomfort;Arthritis;Procedural Pain;Dry Throat;Wrong Technique In Device Usage Process;Cough,Serious,Other Outcomes,Male,-,27-AUG-2019,Expedited,79 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-AUG-2019,27-AUG-2019,US,Not Specified,US-SA-2019SA224524,-,-
16727367,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Operational Issue;Incorrect Dose Administered By Device,Non-Serious,Non-Serious,Female,-,27-AUG-2019,Non-Expedited,80 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-AUG-2019,22-AUG-2019,US,Not Specified,US-SA-2019SA228710,-,-
16564910,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Gastric Haemorrhage;Haemoglobin Decreased;Gastric Polyps,Serious,Hospitalized,Female,07-JUL-2019,27-AUG-2019,Expedited,80 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-JUL-2019,12-JUL-2019,IL,Not Specified,IL-SA-2019SA185548,-,-
15602706,Soliqua 100/33;Lantus,Insulin Glargine;Levothyroxine Sodium;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Headache;Blood Glucose Abnormal;Hypertension;Device Defective,Non-Serious,Non-Serious,Female,-,27-AUG-2019,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Janumet,06-DEC-2018,09-NOV-2018,US,Not Specified,US-SA-2018SA307014,-,-
16739963,Januvia;Soliqua 100/33,Insulin Glargine\Lixisenatide;Sitagliptin Phosphate,-,Blood Glucose Abnormal;Blood Pressure Fluctuation;Headache,Non-Serious,Non-Serious,Female,-,26-AUG-2019,Non-Expedited,Not Specified,Not Specified,Merck,Consumer,Not Specified,-,15-AUG-2019,26-AUG-2019,US,Not Specified,US-009507513-1908USA006859,-,-
16928710,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Loss Of Consciousness;Product Substitution Issue;Hypoglycaemia,Serious,Hospitalized;Life Threatening,Male,21-NOV-2018,23-AUG-2019,Direct,71 YR,Not Specified,Fda-Ctu,Healthcare Professional,Health Professional,-,-,23-AUG-2019,US,Not Specified,-,-,-
16731597,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Off Label Use,Non-Serious,Non-Serious,Female,-,22-AUG-2019,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,16-AUG-2019,22-AUG-2019,US,Not Specified,US-SA-2019SA231782,-,-
16731568,Soliqua 100/33,Insulin Glargine\Lixisenatide;Glipizide;Metformin Hydrochloride,Type 2 Diabetes Mellitus,Burning Sensation;Blood Glucose Increased;Blood Glucose Decreased,Non-Serious,Non-Serious,Female,-,22-AUG-2019,Non-Expedited,57 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,16-AUG-2019,22-AUG-2019,US,Not Specified,US-SA-2019SA234119,-,-
16728670,Xultophy 100/3.6,Insulin Degludec\Liraglutide;Potassium Chloride;Indapamide\Perindopril;Polyethylene Glycols;Aspirin;Furosemide;Atorvastatin Calcium,Constipation;Diabetes Mellitus;Hypercholesterolaemia;Hypertension;Hypokalaemia;Oedema;Prophylaxis,Pancreatic Carcinoma,Serious,Life Threatening,Not Specified,JUL-2019,22-AUG-2019,Expedited,Not Specified,Not Specified,Validus,Healthcare Professional,Not Specified,-,07-AUG-2019,22-AUG-2019,FR,Not Specified,FR-VALIDUS PHARMACEUTICALS LLC-FR-2019VAL000403,-,-
16727389,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Female,-,22-AUG-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-AUG-2019,22-AUG-2019,US,Not Specified,US-SA-2019SA228905,-,-
16711421,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Product Usage Process;Diabetes Mellitus Inadequate Control;Weight Decreased;Sleep Disorder;Conjunctivitis;Inappropriate Schedule Of Product Administration;Device Issue;Circumstance Or Information Capable Of Leading To Medication Error;Feeling Abnormal;Blood Glucose Increased;Dehydration,Serious,Other Outcomes,Female,-,22-AUG-2019,Non-Expedited,56 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,06-AUG-2019,16-AUG-2019,US,Not Specified,US-SA-2019SA217951,-,-
16726725,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Nausea;Heart Rate Increased;Chest Pain;Dehydration;Abdominal Pain,Serious,Other Outcomes,Male,23-JUL-2019,21-AUG-2019,Expedited,40 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Metformin,13-AUG-2019,21-AUG-2019,US,Not Specified,US-NOVOPROD-679971,-,-
16711647,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Headache,Non-Serious,Non-Serious,Female,-,16-AUG-2019,Non-Expedited,45 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Januvia,09-AUG-2019,16-AUG-2019,US,Not Specified,US-SA-2019SA221675,-,-
16711621,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Vision Blurred;Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Female,-,16-AUG-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,08-AUG-2019,16-AUG-2019,US,Not Specified,US-SA-2019SA221539,-,-
16710569,Xultophy 100/3.6;Tahor,Atorvastatin Calcium;Aspirin;Furosemide;Insulin Degludec\Liraglutide;Indapamide\Perindopril Arginine;Polyethylene Glycols;Potassium Chloride,Constipation;Diabetes Mellitus;Hypercholesterolaemia;Hypertension;Hypokalaemia;Oedema;Prophylaxis,Pancreatic Carcinoma,Serious,Life Threatening;Other Outcomes,Male,JUL-2019,16-AUG-2019,Expedited,74 YR,Not Specified,Pfizer,Healthcare Professional,Not Specified,-,12-AUG-2019,16-AUG-2019,FR,Not Specified,FR-PFIZER INC-2019346729,-,-
16704771,Afrezza;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Insulin Human,Product Used For Unknown Indication,Taste Disorder;Decreased Appetite,Non-Serious,Non-Serious,Female,-,14-AUG-2019,Non-Expedited,Not Specified,Not Specified,Mannkind,Healthcare Professional,Not Specified,-,09-JUL-2018,14-AUG-2019,US,Not Specified,US-MANNKIND CORPORATION-2018MK000172,-,-
16631118,Xultophy 100/3.6;Novolog,Insulin Aspart;Insulin Degludec\Liraglutide,Diabetes Mellitus,Coronary Artery Bypass;Disability;Foot Operation;Skin Ulcer;Foot Deformity,Serious,Other Outcomes;Disabled,Male,JAN-2017,13-AUG-2019,Expedited,56 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,02-AUG-2019,25-JUL-2019,US,Not Specified,US-NOVOPROD-674502,-,-
16694830,Xultophy 100/3.6;Tahor,Atorvastatin Calcium;Insulin Degludec\Liraglutide;Aspirin;Polyethylene Glycols;Indapamide\Perindopril Arginine;Furosemide;Potassium Chloride,Constipation;Hypercholesterolaemia;Hypertension;Hypokalaemia;Oedema;Prophylaxis;Type 2 Diabetes Mellitus,Pancreatic Carcinoma,Serious,Life Threatening,Male,JUL-2019,12-AUG-2019,Expedited,74 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,02-AUG-2019,12-AUG-2019,FR,Not Specified,FR-NOVOPROD-677321,-,-
16694826,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Oral Candidiasis,Serious,Other Outcomes,Female,2019,12-AUG-2019,Expedited,65 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,01-AUG-2019,12-AUG-2019,US,Not Specified,US-NOVOPROD-678309,-,-
16694111,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Incorrect Dose Administered By Product,Non-Serious,Non-Serious,Female,-,12-AUG-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,05-AUG-2019,12-AUG-2019,US,Not Specified,US-SA-2019SA209065,-,-
16685763,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Incorrect Dose Administered By Device;Device Operational Issue,Non-Serious,Non-Serious,Female,-,09-AUG-2019,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,02-AUG-2019,09-AUG-2019,US,Not Specified,US-SA-2019SA213703,-,-
16685568,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Female,-,09-AUG-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-JUL-2019,09-AUG-2019,US,Not Specified,US-SA-2019SA211626,-,-
16685446,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Decreased;Blood Glucose Increased;Intentional Product Use Issue,Non-Serious,Non-Serious,Female,-,09-AUG-2019,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,31-JUL-2019,09-AUG-2019,US,Not Specified,US-SA-2019SA211542,-,-
16684269,Soliqua 100/33;Jardiance,Empagliflozin;Metformin Hydrochloride;Insulin Glargine\Lixisenatide,Product Used For Unknown Indication,Weight Decreased,Non-Serious,Non-Serious,Not Specified,-,08-AUG-2019,Non-Expedited,Not Specified,Not Specified,Bristol Myers Squibb,Consumer,Not Specified,-,26-JUL-2019,08-AUG-2019,US,Not Specified,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-074366,-,-
16680056,-,Insulin Glargine\Lixisenatide,Hypertension;Sleep Disorder;Type 2 Diabetes Mellitus,Visual Impairment;Muscular Weakness;Stress;Wrong Technique In Product Usage Process;Insomnia;Wrong Dose;Hypoglycaemic Unconsciousness;Syncope;Dysarthria;Muscle Rigidity,Serious,Hospitalized;Other Outcomes,Female,26-JUL-2019,07-AUG-2019,Expedited,50 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Alprazolam;Losartan,31-JUL-2019,07-AUG-2019,CO,Not Specified,CO-SA-2019SA211801,-,-
16679019,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Product Usage Process;Blood Glucose Increased;Device Operational Issue,Non-Serious,Non-Serious,Male,-,07-AUG-2019,Non-Expedited,60 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-JUL-2019,07-AUG-2019,US,Not Specified,US-SA-2019SA209711,-,-
16674893,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Urticaria,Non-Serious,Non-Serious,Female,-,06-AUG-2019,Non-Expedited,35 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,26-JUL-2019,06-AUG-2019,US,Not Specified,US-SA-2019SA206042,-,-
16674520,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Glycosylated Haemoglobin Increased;Wrong Device Used;Dysstasia;Palpitations;Dyspnoea;Blood Glucose Decreased;Cataract,Serious,Other Outcomes,Female,-,06-AUG-2019,Expedited,70 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Glimepiride,18-JUL-2019,06-AUG-2019,US,Not Specified,US-SA-2019SA198318,-,-
16560424,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Male,-,06-AUG-2019,Non-Expedited,89 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-JUL-2019,11-JUL-2019,US,Not Specified,US-SA-2019SA183724,-,-
16406864,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Malaise;Headache;Device Failure;Device Defective;Blood Glucose Increased,Serious,Life Threatening,Female,-,05-AUG-2019,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,29-JUL-2019,07-JUN-2019,BR,Not Specified,BR-NOVOPROD-666180,-,-
16657396,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Dose Omission Issue;Product Storage Error,Non-Serious,Non-Serious,Male,-,01-AUG-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,25-JUL-2019,01-AUG-2019,US,Not Specified,US-SA-2019SA205069,-,-
16654179,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,31-JUL-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,23-JUL-2019,31-JUL-2019,US,Not Specified,US-SA-2019SA203036,-,-
16654055,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Urinary Tract Infection,Serious,Other Outcomes,Female,-,31-JUL-2019,Expedited,80 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,25-JUL-2019,31-JUL-2019,IL,Not Specified,IL-NOVOPROD-676318,-,-
16653946,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Bladder Irritation;Blood Glucose Increased;Cystitis Noninfective;Bladder Disorder,Serious,Disabled,Female,-,31-JUL-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,25-JUL-2019,31-JUL-2019,US,Not Specified,US-SA-2019SA205381,-,-
16647556,-,Insulin Glargine\Lixisenatide,Blood Cholesterol;Blood Pressure Measurement;Type 2 Diabetes Mellitus,Vision Blurred;Abdominal Pain;Chest Discomfort;Injection Site Pain;Asthenia;Diarrhoea;Blindness,Serious,Other Outcomes,Male,20-JAN-2019,30-JUL-2019,Expedited,67 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Enalapril Maleate;Simvastatin,21-JAN-2019,30-JUL-2019,IL,Not Specified,IL-SA-2019SA019781,-,-
16644978,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Intentional Product Use Issue,Non-Serious,Non-Serious,Female,-,29-JUL-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,24-JUL-2019,29-JUL-2019,US,Not Specified,US-SA-2019SA205036,-,-
16644939,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Decreased;Needle Issue,Non-Serious,Non-Serious,Female,-,29-JUL-2019,Non-Expedited,60 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,22-JUL-2019,29-JUL-2019,US,Not Specified,US-SA-2019SA203081,-,-
16644692,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Visual Impairment;Hypoacusis,Non-Serious,Non-Serious,Female,-,29-JUL-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-JUL-2019,29-JUL-2019,US,Not Specified,US-SA-2019SA198231,-,-
16159634,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus;Type 2 Diabetes Mellitus,Needle Issue;Arthropathy;Device Issue;Circumstance Or Information Capable Of Leading To Medication Error,Non-Serious,Non-Serious,Female,-,29-JUL-2019,Non-Expedited,62 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-JUL-2019,04-APR-2019,US,Not Specified,US-SA-2019SA092332,-,-
16628037,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Infection,Serious,Hospitalized,Male,-,24-JUL-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,18-JUL-2019,24-JUL-2019,US,Not Specified,US-SA-2019SA197568,-,-
16627059,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Female,-,24-JUL-2019,Non-Expedited,57 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-JUL-2019,24-JUL-2019,US,Not Specified,US-SA-2019SA198966,-,-
16626997,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Male,-,24-JUL-2019,Non-Expedited,45 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-JUL-2019,24-JUL-2019,US,Not Specified,US-SA-2019SA198408,-,-
16626895,Toujeo;Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Glargine,Type 2 Diabetes Mellitus,Eye Disorder,Non-Serious,Non-Serious,Female,-,24-JUL-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,17-JUL-2019,24-JUL-2019,US,Not Specified,US-SA-2019SA198800,-,-
16221469,-,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Diabetic Foot,Serious,Other Outcomes;Hospitalized,Male,-,24-JUL-2019,Expedited,58 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-JUL-2019,22-APR-2019,KR,Not Specified,KR-SA-2019SA103877,-,-
16505484,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Musculoskeletal Discomfort;Stress;Blood Glucose Increased;Depression,Non-Serious,Non-Serious,Female,15-JUL-2019,22-JUL-2019,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-JUL-2019,01-JUL-2019,US,Not Specified,US-SA-2019SA172020,-,-
16599253,-,Insulin Glargine\Lixisenatide;Insulin Glargine,Diabetes Mellitus,Tuberculosis;Hyperglycaemia;Limb Discomfort;Vomiting;Illness,Serious,Other Outcomes,Male,2018,19-JUL-2019,Expedited,81 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,22-MAR-2019,19-JUL-2019,KR,Not Specified,KR-SA-2019SA081747,-,-
16598963,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,19-JUL-2019,Non-Expedited,56 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-JUL-2019,19-JUL-2019,US,Not Specified,US-SA-2019SA191030,-,-
16410602,-,Insulin Glargine\Lixisenatide;Insulin Glargine,Diabetes Mellitus,Hypoaesthesia;Myalgia;Hypoglycaemia;Pain In Extremity;Inappropriate Schedule Of Product Administration;Injection Site Erythema;Cerebrovascular Stenosis;Diplopia;Muscular Weakness;Tremor;Hyperglycaemia;Headache;Product Storage Error;Palpitations,Serious,Other Outcomes,Female,MAR-2019,18-JUL-2019,Expedited,61 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-JUL-2019,10-JUN-2019,KR,Not Specified,KR-SA-2019SA106041,-,-
16587202,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 1 Diabetes Mellitus,Injection Site Pain;Incorrect Dose Administered By Device;Inappropriate Schedule Of Product Administration;Device Operational Issue,Non-Serious,Non-Serious,Male,-,17-JUL-2019,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Humalog,12-JUL-2019,17-JUL-2019,US,Not Specified,US-SA-2019SA191781,-,-
16586441,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Gait Disturbance;Arthralgia;Paraesthesia,Serious,Other Outcomes,Male,01-MAY-2019,17-JUL-2019,Expedited,56 YR,80 KG,Novo Nordisk,Healthcare Professional,Not Specified,-,08-JUL-2019,17-JUL-2019,FR,Not Specified,FR-NOVOPROD-672191,-,-
16580188,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Model For End Stage Liver Disease Score Abnormal;Hepatic Cirrhosis,Serious,Other Outcomes,Not Specified,-,16-JUL-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,09-JUL-2019,16-JUL-2019,US,Not Specified,US-SA-2019SA186937,-,-
16572670,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,-,15-JUL-2019,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-JUL-2019,15-JUL-2019,US,Not Specified,US-SA-2019SA186206,-,-
16572666,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Malaise;Device Operational Issue;Product Dose Omission Issue,Non-Serious,Non-Serious,Female,-,15-JUL-2019,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-JUL-2019,15-JUL-2019,US,Not Specified,US-SA-2019SA186895,-,-
16572562,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 1 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Male,-,15-JUL-2019,Non-Expedited,50 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,02-JUL-2019,15-JUL-2019,US,Not Specified,US-SA-2019SA181021,-,-
16567884,Novolog;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Insulin Aspart,Product Used For Unknown Indication,Constipation;Dysphonia;Dysphagia;Blood Glucose Increased;Gait Inability;Dyspnoea;Abdominal Pain Upper;Glycosylated Haemoglobin Increased,Serious,Other Outcomes,Female,-,12-JUL-2019,Expedited,65 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,05-JUL-2019,12-JUL-2019,US,Not Specified,US-NOVOPROD-672332,-,-
16566944,Novorapid;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Insulin Aspart,Type 2 Diabetes Mellitus,Nephrolithiasis;Hyperglycaemia,Serious,Hospitalized;Other Outcomes,Male,JUN-2019,12-JUL-2019,Expedited,71 YR,120 KG,Novo Nordisk,Consumer,Not Specified,Glifage,01-JUL-2019,12-JUL-2019,BR,Not Specified,BR-NOVOPROD-671834,-,-
16550631,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Pancreatic Carcinoma,Serious,Other Outcomes,Not Specified,-,10-JUL-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-JUN-2019,10-JUL-2019,US,Not Specified,US-SA-2019SA179259,-,-
16547814,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Off Label Use,Non-Serious,Non-Serious,Female,-,09-JUL-2019,Non-Expedited,47 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,01-JUL-2019,09-JUL-2019,US,Not Specified,US-SA-2019SA180275,-,-
16541370,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Atrial Fibrillation;Hypertension;Obesity;Type 2 Diabetes Mellitus,Hypoglycaemia,Serious,Hospitalized,Male,04-FEB-2019,08-JUL-2019,Expedited,67 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,Bisoprolol Fumarate;Atorvastatin;Pradaxa;Amlodipine\Indapamide\Perindopril;Furosemide,04-JUL-2019,08-JUL-2019,IT,Not Specified,IT-TAKEDA-2019TEU007851,-,-
16540178,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Neoplasm Malignant,Serious,Other Outcomes,Female,-,08-JUL-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-JUN-2019,08-JUL-2019,US,Not Specified,US-SA-2019SA178177,-,-
16540003,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Hepatic Steatosis;Hepatitis;Glycosylated Haemoglobin Increased,Serious,Hospitalized,Male,-,08-JUL-2019,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,25-JUN-2019,08-JUL-2019,FR,Not Specified,FR-NOVOPROD-670470,-,-
16538067,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Pruritus;Eye Infection,Non-Serious,Non-Serious,Female,-,08-JUL-2019,Non-Expedited,49 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,25-JUN-2019,08-JUL-2019,US,Not Specified,US-SA-2019SA174815,-,-
16538034,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Pruritus,Non-Serious,Non-Serious,Female,-,08-JUL-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,24-JUN-2019,08-JUL-2019,US,Not Specified,US-SA-2019SA174996,-,-
16537959,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Male,-,08-JUL-2019,Non-Expedited,53 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,24-JUN-2019,08-JUL-2019,US,Not Specified,US-SA-2019SA175440,-,-
16537953,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,08-JUL-2019,Non-Expedited,73 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-JUN-2019,08-JUL-2019,US,Not Specified,US-SA-2019SA177687,-,-
16501163,-,Insulin Glargine\Lixisenatide,-,Weight Decreased;Intentional Dose Omission;Pancreatitis,Serious,Other Outcomes;Hospitalized,Male,-,08-JUL-2019,Expedited,55 YR,85 KG,Sanofi Aventis,Consumer,Not Specified,-,01-JUL-2019,01-JUL-2019,BR,Not Specified,BR-SA-2019SA176781,-,-
15579277,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Dose Omission Issue;Illness;Device Operational Issue,Non-Serious,Non-Serious,Female,-,08-JUL-2019,Non-Expedited,62 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-JUN-2019,02-NOV-2018,US,Not Specified,US-SA-2018SA300634,-,-
16527476,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Nausea,Non-Serious,Non-Serious,Female,-,03-JUL-2019,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-JUN-2019,03-JUL-2019,US,Not Specified,US-SA-2019SA172517,-,-
16480343,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Diabetic Microangiopathy;Myocardial Ischaemia;Vomiting;Nausea;Hyperglycaemia;Hyperlipidaemia;Drug Ineffective;Asthma;Haemodynamic Instability;Discomfort,Non-Serious,Non-Serious,Female,-,03-JUL-2019,Expedited,63 YR,70 KG,Novo Nordisk,Healthcare Professional,Not Specified,-,25-JUN-2019,26-JUN-2019,SK,Not Specified,SK-NOVOPROD-664878,-,-
15062082,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Transitional Cell Carcinoma,Serious,Other Outcomes,Not Specified,NOV-2013,28-JUN-2019,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,-,21-JUN-2019,25-JUN-2018,US,Not Specified,US-TAKEDA-2018TUS020541,-,-
16485626,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Injection Site Pain,Non-Serious,Non-Serious,Female,-,27-JUN-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,18-JUN-2019,27-JUN-2019,US,Not Specified,US-SA-2019SA169123,-,-
16462490,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Pancreatitis,Serious,Hospitalized;Other Outcomes,Not Specified,-,27-JUN-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,13-JUN-2019,21-JUN-2019,HK,Not Specified,HK-SA-2019SA163000,-,-
15949924,Invokana;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Canagliflozin,Type 2 Diabetes Mellitus,Intervertebral Disc Degeneration;Pancreatitis;Diabetes Mellitus Inadequate Control;Hyperlipidaemia;Hepatic Enzyme Increased;Dermatitis;Post Herpetic Neuralgia,Serious,Other Outcomes,Female,2017,27-JUN-2019,Expedited,50 YR,Not Specified,Johnson And Johnson,Healthcare Professional,Not Specified,Cymbalta;Clobetasol;Norco;Senna;Gabapentin;Lantus;Simvastatin;Metformin;Voltaren;Ativan;Celexa,12-JUN-2019,12-FEB-2019,US,Not Specified,US-JNJFOC-20190210546,-,-
15976373,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Fall;Product Use Issue;Contusion,Serious,Hospitalized,Male,03-JAN-2019,25-JUN-2019,Expedited,76 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Insulin Degludec;Victoza,16-JUN-2019,18-FEB-2019,IL,Not Specified,IL-SA-2019SA039478,-,-
16471273,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Abdominal Pain Upper;Vomiting,Non-Serious,Non-Serious,Female,-,24-JUN-2019,Non-Expedited,78 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-JUN-2019,24-JUN-2019,US,Not Specified,US-SA-2019SA165216,-,-
16469447,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,24-JUN-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-JUN-2019,24-JUN-2019,US,Not Specified,US-SA-2019SA165103,-,-
16469411,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Liver Function Test Increased,Non-Serious,Non-Serious,Not Specified,-,24-JUN-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,12-JUN-2019,24-JUN-2019,US,Not Specified,US-SA-2019SA163693,-,-
16469285,Soliqua 100/33,Insulin Glargine\Lixisenatide;Metformin Hydrochloride,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,24-JUN-2019,Non-Expedited,46 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-JUN-2019,24-JUN-2019,US,Not Specified,US-SA-2019SA162367,-,-
16100441,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Abdominal Pain,Serious,Hospitalized,Not Specified,-,24-JUN-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,13-MAR-2019,21-MAR-2019,US,Not Specified,US-SA-2019SA074014,-,-
16457513,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Back Pain;Cardiovascular Event Prophylaxis;Diabetes Mellitus;Hypertension;Hypothyroidism;Insomnia;Macular Degeneration;Multiple Allergies;Supplementation Therapy,Bronchitis;Cough,Non-Serious,Non-Serious,Female,-,20-JUN-2019,Non-Expedited,75 YR,83.45 KG,Takeda,Consumer,Not Specified,Lexapro;Aspirin;Zyrtec;Melatonin;Losartan;Vitamins;Calcium;Levothyroxine;Tizanidine,11-JUN-2019,20-JUN-2019,US,Not Specified,US-TAKEDA-2019TUS037449,-,-
16452918,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Nausea,Non-Serious,Non-Serious,Male,-,19-JUN-2019,Non-Expedited,64 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,10-JUN-2019,19-JUN-2019,US,Not Specified,US-SA-2019SA159613,-,-
16452889,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Increased;Product Dose Omission Issue,Non-Serious,Non-Serious,Female,-,19-JUN-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-JUN-2019,19-JUN-2019,US,Not Specified,US-SA-2019SA158710,-,-
16452850,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Male,-,19-JUN-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,06-JUN-2019,19-JUN-2019,US,Not Specified,US-SA-2019SA157454,-,-
16439139,Viagra;Vivitrol;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Sildenafil Citrate;Naltrexone,Alcoholism;Erectile Dysfunction;Type 2 Diabetes Mellitus,Injection Site Pain;Premature Ejaculation;Injection Site Reaction;Nausea;Influenza;Injection Site Abscess;Blood Thyroid Stimulating Hormone Decreased;Swelling;Headache;Glycosylated Haemoglobin Increased;Alcohol Use;Erectile Dysfunction;Vomiting;Stress;Productive Cough;Tenderness;Injection Site Swelling;Injection Site Inflammation;Injection Site Infection;Injection Site Haemorrhage;Blood Glucose Increased;Injection Site Cellulitis;Drug Ineffective,Serious,Hospitalized,Male,NOV-2015,17-JUN-2019,Expedited,44 YR,107.9 KG,Pfizer,Healthcare Professional,Not Specified,Omeprazole;Invokana;Zoloft;Stendra;Zetia;Gliclazide;Cialis;Bystolic;Singulair;Trulicity;Antabuse;Androgel;Nasonex,03-JUN-2019,17-JUN-2019,US,Not Specified,US-PFIZER INC-2019248166,-,-
15312511,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injection Site Pain;Injection Site Swelling,Non-Serious,Non-Serious,Male,-,17-JUN-2019,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,16-AUG-2018,23-AUG-2018,US,Not Specified,US-SA-2018SA230335,-,-
16266308,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Product Storage Error;Drug Ineffective;Blood Glucose Increased;Urinary Tract Infection;Dehydration,Serious,Other Outcomes,Female,2019,14-JUN-2019,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,05-JUN-2019,02-MAY-2019,US,Not Specified,US-NOVOPROD-659727,-,-
16266307,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Sciatica;Glycosylated Haemoglobin Increased,Serious,Other Outcomes,Male,FEB-2019,14-JUN-2019,Expedited,83 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,06-JUN-2019,02-MAY-2019,US,Not Specified,US-NOVOPROD-659983,-,-
16428031,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Operational Issue;Incorrect Dose Administered By Device;Injection Site Pain,Non-Serious,Non-Serious,Female,-,13-JUN-2019,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,06-JUN-2019,13-JUN-2019,US,Not Specified,US-SA-2019SA158573,-,-
16428013,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Dizziness;Inflammation;Somnolence;Nasal Congestion;Injection Site Pruritus;Headache;Injection Site Erythema;Heart Rate Increased,Non-Serious,Non-Serious,Female,-,13-JUN-2019,Non-Expedited,52 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,06-JUN-2019,13-JUN-2019,US,Not Specified,US-SA-2019SA158578,-,-
16426421,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Fall;Spinal Fracture,Serious,Other Outcomes;Hospitalized,Female,-,13-JUN-2019,Expedited,79 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,04-JUN-2019,13-JUN-2019,IL,Not Specified,IL-NOVOPROD-666811,-,-
16207525,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Hospitalisation;Abdominal Pain Upper;Nausea,Serious,Other Outcomes;Hospitalized,Female,08-APR-2019,13-JUN-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Metformin,07-JUN-2019,17-APR-2019,RO,Not Specified,RO-SA-2019SA103128,-,-
16422801,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Decreased;Intentional Product Use Issue,Non-Serious,Non-Serious,Female,-,12-JUN-2019,Non-Expedited,55 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,05-JUN-2019,12-JUN-2019,US,Not Specified,US-SA-2019SA156998,-,-
16420792,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Dyspepsia,Non-Serious,Non-Serious,Female,-,12-JUN-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,25-APR-2019,12-JUN-2019,US,Not Specified,US-NOVOPROD-660544,-,-
16420790,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,12-JUN-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,20-MAR-2019,12-JUN-2019,US,Not Specified,US-NOVOPROD-654221,-,-
16420789,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Rash,Non-Serious,Non-Serious,Male,-,12-JUN-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,28-FEB-2019,12-JUN-2019,US,Not Specified,US-NOVOPROD-649989,-,-
16420788,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Weight Increased,Non-Serious,Non-Serious,Female,2019,12-JUN-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,26-MAR-2019,12-JUN-2019,US,Not Specified,US-NOVOPROD-655439,-,-
16420786,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Nausea,Non-Serious,Non-Serious,Female,-,12-JUN-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,06-MAY-2019,12-JUN-2019,US,Not Specified,US-NOVOPROD-662534,-,-
16420785,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Diabetes Mellitus Inadequate Control;Hyperhidrosis,Non-Serious,Non-Serious,Female,APR-2019,12-JUN-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,12-APR-2019,12-JUN-2019,US,Not Specified,US-NOVOPROD-658479,-,-
16420784,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus;Hypertension;Product Used For Unknown Indication,Blood Glucose Increased;Drug Ineffective,Non-Serious,Non-Serious,Male,-,12-JUN-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,Propranolol Hydrochloride;Metformin;Novolog,07-MAR-2019,12-JUN-2019,US,Not Specified,US-NOVOPROD-652089,-,-
16420780,Metformin;Xultophy 100/3.6;Farxiga,Dapagliflozin Propanediol;Insulin Degludec\Liraglutide;Metformin Hydrochloride,Product Used For Unknown Indication,Blood Glucose Decreased,Non-Serious,Non-Serious,Male,-,12-JUN-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,27-MAR-2019,12-JUN-2019,US,Not Specified,US-NOVOPROD-655684,-,-
16420779,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Blood Glucose Increased,Non-Serious,Non-Serious,Female,10-APR-2019,12-JUN-2019,Non-Expedited,54 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,09-MAY-2019,12-JUN-2019,US,Not Specified,US-NOVOPROD-663190,-,-
16420778,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Tremor;Hyperhidrosis,Non-Serious,Non-Serious,Female,-,12-JUN-2019,Non-Expedited,Not Specified,107.94 KG,Novo Nordisk,Consumer,Not Specified,-,23-MAR-2019,12-JUN-2019,US,Not Specified,US-NOVOPROD-655229,-,-
16420775,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Papillary Thyroid Cancer,Serious,Other Outcomes,Female,-,12-JUN-2019,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,09-APR-2019,12-JUN-2019,US,Not Specified,US-NOVOPROD-657604,-,-
16420774,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Injection Site Pain,Non-Serious,Non-Serious,Female,-,12-JUN-2019,Non-Expedited,63 YR,107.94 KG,Novo Nordisk,Consumer,Not Specified,-,28-MAR-2019,12-JUN-2019,US,Not Specified,US-NOVOPROD-655863,-,-
16420771,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Nausea;Abdominal Distension;Dizziness;Influenza Like Illness;Malaise;Abdominal Pain Upper,Non-Serious,Non-Serious,Female,27-MAR-2019,12-JUN-2019,Non-Expedited,65 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,29-MAR-2019,12-JUN-2019,US,Not Specified,US-NOVOPROD-656122,-,-
16420769,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Wrong Technique In Product Usage Process,Non-Serious,Non-Serious,Female,-,12-JUN-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,17-APR-2019,12-JUN-2019,US,Not Specified,US-NOVOPROD-659276,-,-
16420768,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Peripheral Swelling,Non-Serious,Non-Serious,Female,FEB-2019,12-JUN-2019,Non-Expedited,79 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,26-MAR-2019,12-JUN-2019,US,Not Specified,US-NOVOPROD-655451,-,-
16420767,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Nausea;Abdominal Discomfort;Abdominal Pain Upper;Pancreatic Enzymes Abnormal;Nervousness,Non-Serious,Non-Serious,Male,AUG-2018,12-JUN-2019,Non-Expedited,79 YR,78.01 KG,Novo Nordisk,Consumer,Not Specified,-,01-APR-2019,12-JUN-2019,US,Not Specified,US-NOVOPROD-656400,-,-
16420766,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Circumstance Or Information Capable Of Leading To Medication Error,Non-Serious,Non-Serious,Female,-,12-JUN-2019,Non-Expedited,79 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,08-MAR-2019,12-JUN-2019,US,Not Specified,US-NOVOPROD-654936,-,-
16420765,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Blood Glucose Increased;Weight Increased,Non-Serious,Non-Serious,Female,-,12-JUN-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,25-MAR-2019,12-JUN-2019,US,Not Specified,US-NOVOPROD-654705,-,-
16420763,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Extra Dose Administered,Non-Serious,Non-Serious,Male,-,12-JUN-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,28-FEB-2019,12-JUN-2019,US,Not Specified,US-NOVOPROD-650263,-,-
16420762,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Product Prescribing Error,Non-Serious,Non-Serious,Male,OCT-2018,12-JUN-2019,Non-Expedited,82 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,23-APR-2019,12-JUN-2019,US,Not Specified,US-NOVOPROD-660211,-,-
16420755,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Headache;Dizziness;Dyspnoea;Nausea,Non-Serious,Non-Serious,Female,MAY-2019,12-JUN-2019,Non-Expedited,71 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,13-MAY-2019,12-JUN-2019,US,Not Specified,US-NOVOPROD-663362,-,-
16420754,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Male,2017,12-JUN-2019,Non-Expedited,55 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,Glimepiride;Jardiance,19-APR-2019,12-JUN-2019,US,Not Specified,US-NOVOPROD-659757,-,-
16420752,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Weight Decreased,Non-Serious,Non-Serious,Male,-,12-JUN-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,03-APR-2019,12-JUN-2019,US,Not Specified,US-NOVOPROD-656954,-,-
16420751,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Tooth Loss,Non-Serious,Non-Serious,Female,-,12-JUN-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,22-MAR-2019,12-JUN-2019,US,Not Specified,US-NOVOPROD-654438,-,-
16420750,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Injection Site Pruritus;Injection Site Erythema,Non-Serious,Non-Serious,Female,04-APR-2019,12-JUN-2019,Non-Expedited,77 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,22-APR-2019,12-JUN-2019,US,Not Specified,US-NOVOPROD-659951,-,-
16415702,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Female,-,11-JUN-2019,Non-Expedited,58 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,03-JUN-2019,11-JUN-2019,US,Not Specified,US-SA-2019SA155324,-,-
16413766,-,Insulin Glargine\Lixisenatide,Chronic Kidney Disease;Type 2 Diabetes Mellitus,Pancreatic Carcinoma;Renal Disorder;Glycosylated Haemoglobin Increased,Serious,Other Outcomes,Male,JUN-2017,11-JUN-2019,Expedited,83 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,04-JUN-2019,11-JUN-2019,US,Not Specified,US-SA-2019SA155107,-,-
16399722,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Product Odour Abnormal;Product Storage Error,Non-Serious,Non-Serious,Female,-,06-JUN-2019,Non-Expedited,51 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,30-MAY-2019,06-JUN-2019,US,Not Specified,US-SA-2019SA151085,-,-
16399196,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Unevaluable Event;Left Ventricular Failure;Coronary Artery Disease;Weight Decreased;Dyslipidaemia,Serious,Other Outcomes,Male,-,06-JUN-2019,Expedited,61 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Metformin;Jardiance,29-MAY-2019,06-JUN-2019,US,Not Specified,US-SA-2019SA152304,-,-
16390561,Soliqua 100/33;Toujeo,Insulin Glargine;Insulin Glargine\Lixisenatide,-,Inappropriate Schedule Of Product Administration;Hyperglycaemia;Weight Decreased;Renal Failure,Serious,Hospitalized,Female,27-MAY-2019,04-JUN-2019,Expedited,53 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Metformin,27-MAY-2019,04-JUN-2019,RU,Not Specified,RU-SA-2019SA148337,-,-
16383698,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error;Product Dose Omission Issue;Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,03-JUN-2019,Non-Expedited,59 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,24-MAY-2019,03-JUN-2019,US,Not Specified,US-SA-2019SA146018,-,-
16382037,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Hyperglycaemia;Pancreatitis Acute,Serious,Hospitalized,Male,01-MAY-2019,03-JUN-2019,Expedited,53 YR,123 KG,Sanofi Aventis,Healthcare Professional,Not Specified,-,28-MAY-2019,03-JUN-2019,MX,Not Specified,MX-SA-2019SA148397,-,-
16379735,Xultophy 100/3.6;Vivitrol,Naltrexone;Insulin Degludec\Liraglutide,Alcoholism;Hyperlipidaemia;Hypertension;Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Headache;Productive Cough;Vomiting;Premature Ejaculation;Injection Site Abscess;Blood Thyroid Stimulating Hormone Decreased;Blood Glucose Increased;Influenza;Nausea;Glycosylated Haemoglobin Decreased;Erectile Dysfunction,Serious,Hospitalized,Male,2018,31-MAY-2019,Expedited,44 YR,107.96 KG,Novo Nordisk,Healthcare Professional,Not Specified,Bystolic;Omeprazole;Zoloft;Invokana;Loratadine;Zetia;Singulair;Nasonex;Antabuse;Androgel,21-MAY-2019,31-MAY-2019,US,Not Specified,US-NOVOPROD-665263,-,-
16375100,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Syncope;Hypoglycaemia,Serious,Hospitalized;Other Outcomes,Male,-,31-MAY-2019,Expedited,70 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,22-MAY-2019,31-MAY-2019,US,Not Specified,US-SA-2019SA143081,-,-
16373628,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Hypoglycaemia,Non-Serious,Non-Serious,Male,-,30-MAY-2019,Non-Expedited,91 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,22-MAY-2019,30-MAY-2019,US,Not Specified,US-SA-2019SA146005,-,-
16371427,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Taste Disorder;Nausea,Serious,Hospitalized,Female,-,30-MAY-2019,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,17-MAY-2019,30-MAY-2019,SE,Not Specified,SE-NOVOPROD-663564,-,-
16367099,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injection Site Pain,Non-Serious,Non-Serious,Male,-,29-MAY-2019,Non-Expedited,85 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,20-MAY-2019,29-MAY-2019,US,Not Specified,US-SA-2019SA142776,-,-
16366036,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus Inadequate Control;Glycosylated Haemoglobin,Hypoglycaemic Unconsciousness;Hypoglycaemia,Serious,Hospitalized,Female,-,29-MAY-2019,Expedited,35 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,22-MAY-2019,29-MAY-2019,US,Not Specified,US-SA-2019SA143190,-,-
16359234,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Injection Site Reaction,Non-Serious,Non-Serious,Not Specified,-,27-MAY-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,21-MAY-2019,27-MAY-2019,US,Not Specified,US-SA-2019SA140659,-,-
16359227,Soliqua 100/33,Insulin Glargine\Lixisenatide,Abscess,Urticaria;Diabetes Mellitus Inadequate Control,Serious,Other Outcomes,Female,18-MAY-2019,27-MAY-2019,Non-Expedited,50 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Keflex,20-MAY-2019,27-MAY-2019,US,Not Specified,US-SA-2019SA140011,-,-
16155128,-,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Asthenia;Dizziness;Hypokalaemia,Serious,Other Outcomes;Hospitalized,Female,10-MAR-2019,27-MAY-2019,Expedited,48 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,20-MAY-2019,03-APR-2019,PH,Not Specified,PH-SA-2019SA079950,-,-
16015877,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Nausea;Pancreatitis;Abdominal Pain;Malaise,Serious,Other Outcomes,Male,-,27-MAY-2019,Expedited,60 YR,122.01 KG,Sanofi Aventis,Healthcare Professional,Not Specified,-,20-MAY-2019,28-FEB-2019,US,Not Specified,US-SA-2019SA050905,-,-
16353517,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Drug Dependence;Alcoholism,Serious,Other Outcomes,Male,-,24-MAY-2019,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,15-MAY-2019,24-MAY-2019,US,Not Specified,US-NOVOPROD-663762,-,-
16349022,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Jaundice;Pancreatitis;Hepatic Failure,Serious,Other Outcomes,Female,2019,23-MAY-2019,Expedited,59 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,14-MAY-2019,23-MAY-2019,US,Not Specified,US-NOVOPROD-663299,-,-
15967067,-,Insulin Glargine\Lixisenatide,-,Condition Aggravated;Diarrhoea;Blood Glucose Fluctuation;Gait Disturbance;Neuropathy Peripheral,Serious,Other Outcomes,Male,19-DEC-2018,21-MAY-2019,Expedited,64 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-MAY-2019,15-FEB-2019,IL,Not Specified,IL-SA-2019SA038441,-,-
16323664,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Disability,Serious,Disabled,Female,-,17-MAY-2019,Expedited,58 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,09-MAY-2019,17-MAY-2019,US,Not Specified,US-SA-2019SA133256,-,-
16196921,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Road Traffic Accident;Dyspepsia;Blood Glucose Abnormal;Nausea;General Physical Health Deterioration,Non-Serious,Non-Serious,Female,MAR-2019,17-MAY-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-APR-2019,15-APR-2019,KR,Not Specified,KR-SA-2019SA101843,-,-
16321443,-,Insulin Glargine\Lixisenatide,-,Constipation;Haematochezia,Serious,Other Outcomes,Female,18-MAR-2019,16-MAY-2019,Expedited,43 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,05-APR-2019,16-MAY-2019,PH,Not Specified,PH-SA-2019SA095920,-,-
16313196,Apidra;Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Glulisine,Type 2 Diabetes Mellitus,Incorrect Dose Administered By Device;Cardiac Disorder;Device Issue,Serious,Hospitalized,Female,-,15-MAY-2019,Expedited,71 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,09-MAY-2019,15-MAY-2019,US,Not Specified,US-SA-2019SA132242,-,-
16284908,Xultophy 100/3.6,Insulin Degludec\Liraglutide;Amiodarone Hydrochloride,Type 2 Diabetes Mellitus,Cardio-Respiratory Arrest;Influenza;Dyspnoea;Interstitial Lung Disease,Serious,Hospitalized;Died,Male,28-DEC-2018,15-MAY-2019,Expedited,75 YR,88 KG,Pfizer,Healthcare Professional,Not Specified,Novorapid,12-MAY-2019,08-MAY-2019,SI,Not Specified,SI-PFIZER INC-2019195936,-,-
16307863,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Rectal Haemorrhage,Serious,Other Outcomes,Female,-,14-MAY-2019,Expedited,58 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,09-MAY-2019,14-MAY-2019,US,Not Specified,US-SA-2019SA129888,-,-
16257132,Vivitrol;Xultophy 100/3.6;Viagra,Sildenafil Citrate;Insulin Degludec\Liraglutide;Naltrexone,Alcoholism;Erectile Dysfunction;Hypertension;Premature Ejaculation;Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Blood Glucose Increased;Blood Thyroid Stimulating Hormone Decreased;Injection Site Reaction;Headache;Nausea;Influenza;Injection Site Infection;Injection Site Swelling;Productive Cough;Injection Site Pain;Injection Site Inflammation;Alcohol Use;Premature Ejaculation;Erectile Dysfunction;Glycosylated Haemoglobin Increased;Vomiting;Injection Site Abscess;Injection Site Cellulitis,Serious,Other Outcomes;Hospitalized,Male,APR-2019,13-MAY-2019,Expedited,44 YR,107.94 KG,Alkermes,Healthcare Professional,Not Specified,Zetia;Nasonex;Androgel;Antabuse;Invokana;Cialis;Singulair;Claritin;Zoloft;Bystolic;Stendra;Protonix,08-MAY-2019,30-APR-2019,US,Not Specified,US-ALKERMES INC.-ALK-2019-002279,-,-
14946261,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Drug Ineffective,Non-Serious,Non-Serious,Not Specified,-,13-MAY-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,17-MAY-2018,29-MAY-2018,US,Not Specified,US-SA-2018SA142681,-,-
16300419,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Polypectomy;Diarrhoea;Diverticulitis,Serious,Other Outcomes,Female,-,10-MAY-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,06-MAY-2019,10-MAY-2019,US,Not Specified,US-SA-2019SA125832,-,-
15894400,-,Lisinopril;Insulin Glargine\Lixisenatide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Arrhythmia;Malaise;Palpitations;Fatigue;Atrial Fibrillation;Product Dose Omission Issue;Cough,Serious,Hospitalized;Other Outcomes,Female,-,10-MAY-2019,Expedited,81 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Eliquis;Propafenone;Toprol Xl,03-MAY-2019,31-JAN-2019,US,Not Specified,US-SAKK-2019SA021988AA,-,-
16295581,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Bronchitis;Product Storage Error;Incorrect Dose Administered By Device;Device Operational Issue,Non-Serious,Non-Serious,Female,-,09-MAY-2019,Non-Expedited,79 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Ozempic,01-MAY-2019,09-MAY-2019,US,Not Specified,US-SA-2019SA122009,-,-
16288003,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Cataract,Serious,Other Outcomes,Female,-,08-MAY-2019,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,Glifage,29-APR-2019,08-MAY-2019,BR,Not Specified,BR-NOVOPROD-660940,-,-
16283573,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Female,-,07-MAY-2019,Non-Expedited,68 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-APR-2019,07-MAY-2019,US,Not Specified,US-SA-2019SA120911,-,-
16283450,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Increased;Device Operational Issue,Non-Serious,Non-Serious,Female,-,07-MAY-2019,Non-Expedited,71 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-APR-2019,07-MAY-2019,US,Not Specified,US-SA-2019SA102024,-,-
16062556,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Product Dose Omission Issue;Device Operational Issue;Product Contamination With Body Fluid,Non-Serious,Non-Serious,Female,-,07-MAY-2019,Non-Expedited,55 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,07-MAR-2019,12-MAR-2019,US,Not Specified,US-SA-2019SA066297,-,-
16142091,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 1 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,06-MAY-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-APR-2019,01-APR-2019,US,Not Specified,US-SA-2019SA081046,-,-
16078251,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 1 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,06-MAY-2019,Non-Expedited,45 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-APR-2019,15-MAR-2019,US,Not Specified,US-SA-2019SA066803,-,-
16029247,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Fluctuation;Device Operational Issue,Non-Serious,Non-Serious,Female,-,06-MAY-2019,Non-Expedited,68 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-APR-2019,04-MAR-2019,US,Not Specified,US-SA-2019SA056498,-,-
16002475,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Death,Serious,Died,Male,17-FEB-2019,03-MAY-2019,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,26-APR-2019,25-FEB-2019,BR,Not Specified,BR-NOVOPROD-648631,-,-
16266866,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Pain In Extremity;Burning Sensation;Peripheral Swelling,Non-Serious,Non-Serious,Female,-,02-MAY-2019,Non-Expedited,54 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Victoza,24-APR-2019,02-MAY-2019,US,Not Specified,US-SA-2019SA117498,-,-
16266464,-,Insulin Glargine\Lixisenatide,-,Diabetic Coma,Serious,Other Outcomes,Female,-,02-MAY-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,25-APR-2019,02-MAY-2019,US,Not Specified,US-SA-2019SA118787,-,-
16266299,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Hospice Care,Serious,Other Outcomes,Male,-,02-MAY-2019,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,23-APR-2019,02-MAY-2019,US,Not Specified,US-NOVOPROD-659749,-,-
16069428,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injection Site Pain,Non-Serious,Non-Serious,Male,-,02-MAY-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin,26-APR-2019,13-MAR-2019,US,Not Specified,US-SA-2019SA066815,-,-
16062467,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Abnormal;Blood Pressure Abnormal;Device Operational Issue,Non-Serious,Non-Serious,Female,-,02-MAY-2019,Non-Expedited,79 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-APR-2019,12-MAR-2019,US,Not Specified,US-SA-2019SA066352,-,-
16261606,-,Insulin Glargine\Lixisenatide,-,Hernia,Serious,Other Outcomes,Male,22-MAR-2019,01-MAY-2019,Expedited,57 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,24-APR-2019,01-MAY-2019,US,Not Specified,US-SA-2019SA116215,-,-
16253128,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Rhinorrhoea;Drug Hypersensitivity;Cough;Condition Aggravated;Oropharyngeal Pain,Non-Serious,Non-Serious,Male,-,01-MAY-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,24-APR-2019,29-APR-2019,US,Not Specified,US-SA-2019SA114598,-,-
16253297,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Increased;Abdominal Distension,Non-Serious,Non-Serious,Female,-,29-APR-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,24-APR-2019,29-APR-2019,US,Not Specified,US-SA-2019SA116188,-,-
16253190,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error;Constipation,Non-Serious,Non-Serious,Male,-,29-APR-2019,Non-Expedited,61 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,24-APR-2019,29-APR-2019,US,Not Specified,US-SA-2019SA116189,-,-
16253121,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,29-APR-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Januvia;Glimepiride;Metformin,22-APR-2019,29-APR-2019,US,Not Specified,US-SA-2019SA114573,-,-
16072188,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,29-APR-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-APR-2019,14-MAR-2019,US,Not Specified,US-SA-2019SA069160,-,-
15917694,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Pancreatitis;Nausea;Abdominal Pain;Lipase Increased;Blood Glucose Increased,Serious,Other Outcomes,Male,03-AUG-2018,29-APR-2019,Expedited,63 YR,237 KG,Sanofi Aventis,Healthcare Professional,Not Specified,Victoza,23-APR-2019,05-FEB-2019,US,Not Specified,US-SA-2019SA026703,-,-
16239244,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Drug Ineffective;Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,25-APR-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Glimepiride;Metformin;Januvia,22-APR-2019,25-APR-2019,US,Not Specified,US-SA-2019SA114138,-,-
16238987,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Burning Sensation,Non-Serious,Non-Serious,Female,-,25-APR-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,18-APR-2019,25-APR-2019,US,Not Specified,US-SA-2019SA111468,-,-
16214012,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Pancreatic Carcinoma,Serious,Other Outcomes,Male,20-MAR-2019,18-APR-2019,Expedited,70 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Fenofibrate\Simvastatin;Gliclazide;Amlodipine Besylate\Indapamide\Perindopril Arginine;Metformin Hydrochloride;Glycopyrronium\Indacaterol,11-APR-2019,18-APR-2019,SI,Not Specified,SI-NOVOPROD-657699,-,-
16200184,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Rash,Non-Serious,Non-Serious,Not Specified,-,15-APR-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,10-APR-2019,15-APR-2019,US,Not Specified,US-SA-2019SA103575,-,-
16200123,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Male,-,15-APR-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,10-APR-2019,15-APR-2019,US,Not Specified,US-SA-2019SA103578,-,-
16197323,-,Insulin Glargine\Lixisenatide;Insulin Glargine,Type 2 Diabetes Mellitus,Dizziness;Cardiac Disorder,Serious,Hospitalized,Male,-,15-APR-2019,Expedited,Not Specified,69 KG,Sanofi Aventis,Consumer,Not Specified,-,03-APR-2019,15-APR-2019,BR,Not Specified,BR-SA-2019SA094932,-,-
16195639,-,Insulin Glargine\Lixisenatide,-,Blood Glucose Abnormal;Intensive Care,Serious,Other Outcomes,Female,25-SEP-2018,15-APR-2019,Expedited,64 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-SEP-2018,15-APR-2019,IL,Not Specified,IL-SA-2018SA271264,-,-
15933861,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injection Site Swelling;Injection Site Reaction;Injection Site Warmth,Non-Serious,Non-Serious,Female,-,15-APR-2019,Non-Expedited,50 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-APR-2019,07-FEB-2019,US,Not Specified,US-SA-2019SA028260,-,-
16192602,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Abdominal Pain,Non-Serious,Non-Serious,Female,-,12-APR-2019,Non-Expedited,60 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,09-APR-2019,12-APR-2019,US,Not Specified,US-SA-2019SA102025,-,-
16192262,Jardiance;Soliqua 100/33,Insulin Glargine\Lixisenatide;Empagliflozin,Blood Glucose;Product Used For Unknown Indication,Oral Fungal Infection;Tongue Disorder;Pruritus;Hypersensitivity;Urticaria;Genital Infection,Non-Serious,Non-Serious,Female,-,12-APR-2019,Non-Expedited,Not Specified,Not Specified,Boehringer Ingelheim,Consumer,Not Specified,-,05-APR-2019,12-APR-2019,US,Not Specified,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-016098",-,-
16189348,-,Insulin Glargine\Lixisenatide,Diabetes Mellitus;Gout;Heart Rate Irregular;Thrombosis Prophylaxis;Type 2 Diabetes Mellitus,Loss Of Consciousness;Glycosylated Haemoglobin Increased;Hypoglycaemia;Balance Disorder,Serious,Other Outcomes,Male,FEB-2019,12-APR-2019,Expedited,82 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Torsemide;Pradaxa;Tamsulosin;Metoprolol;Febuxostat;Linagliptin;Spironolactone;Metformin,12-MAR-2019,12-APR-2019,EE,Not Specified,EE-SA-2019SA068661,-,-
16187572,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Cardiac Disorder;Dyspnoea,Serious,Life Threatening,Male,-,12-APR-2019,Expedited,55 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,05-APR-2019,12-APR-2019,PH,Not Specified,PH-SA-2019SA101514,-,-
15954107,-,Insulin Glargine\Lixisenatide,Diabetes Mellitus;Infarction,Vomiting;Asthenia;Retching;Choking;Malaise;Dysphagia;Nausea;Abdominal Discomfort,Serious,Other Outcomes,Female,2019,12-APR-2019,Expedited,66 YR,80.4 KG,Sanofi Aventis,Consumer,Not Specified,Glifage;Aspirin;Jardiance,03-APR-2019,13-FEB-2019,BR,Not Specified,BR-SA-2019SA036351,-,-
15387097,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 1 Diabetes Mellitus;Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,12-APR-2019,Non-Expedited,83 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-APR-2019,14-SEP-2018,US,Not Specified,US-SA-2018SA248300,-,-
16176420,Soliqua 100/33,Insulin Glargine\Lixisenatide;Investigational Product,Type 2 Diabetes Mellitus,Movement Disorder;Hypoglycaemia;Cerebrovascular Accident,Serious,Other Outcomes,Male,MAR-2018,09-APR-2019,Expedited,69 YR,87 KG,Sanofi Aventis,Consumer,Not Specified,-,02-APR-2019,09-APR-2019,MX,Not Specified,MX-SA-2019SA093431,-,-
16173105,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Colitis Ulcerative;Coronary Artery Disease;Gastrooesophageal Reflux Disease;Type 2 Diabetes Mellitus,Abnormal Faeces;Colitis Ulcerative,Serious,Other Outcomes,Male,-,09-APR-2019,Expedited,73 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Metformin;Plavix;Metoprolol Tartrate;Dapagliflozin;Lipitor;Pentasa;Nexium,29-MAR-2019,09-APR-2019,NO,Not Specified,NO-NOVOPROD-655379,-,-
16165467,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Diabetes Mellitus Inadequate Control;Hepatic Cirrhosis,Serious,Other Outcomes,Male,2018,05-APR-2019,Expedited,61 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,27-MAR-2019,05-APR-2019,US,Not Specified,US-NOVOPROD-654989,-,-
16164135,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Hypersensitivity;Pruritus;Fungal Infection,Non-Serious,Non-Serious,Female,-,05-APR-2019,Non-Expedited,65 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,02-APR-2019,05-APR-2019,US,Not Specified,US-SA-2019SA092307,-,-
16163833,Soliqua 100/33,Insulin Glargine\Lixisenatide;Investigational Product,-,Hepatic Steatosis;Kidney Infection,Serious,Other Outcomes,Male,-,05-APR-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-APR-2019,05-APR-2019,MX,Not Specified,MX-SA-2019SA091969,-,-
16152295,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Abdominal Tenderness;Injection Site Pruritus;Product Storage Error,Non-Serious,Non-Serious,Female,-,04-APR-2019,Non-Expedited,62 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-APR-2019,03-APR-2019,US,Not Specified,US-SA-2019SA063608,-,-
16119655,Soliqua 100/33,Insulin Glargine\Lixisenatide,Blood Cholesterol;Type 2 Diabetes Mellitus,Condition Aggravated;Injection Site Pain;Injection Site Mass;Pain;Injection Site Erythema;Injection Site Pruritus,Serious,Hospitalized;Other Outcomes,Female,16-MAR-2019,04-APR-2019,Expedited,56 YR,92 KG,Sanofi Aventis,Healthcare Professional,Not Specified,Metformin;Jardiance;Atorvastatin,22-MAR-2019,26-MAR-2019,BR,Not Specified,BR-SA-2019SA080791,-,-
15736509,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Glycosylated Haemoglobin Increased;Cerebral Infarction,Serious,Hospitalized;Other Outcomes,Female,28-NOV-2018,04-APR-2019,Expedited,52 YR,83 KG,Novo Nordisk,Healthcare Professional,Not Specified,Glimepiride;Bisoprolol;Metformin Hydrochloride;Tramadol;Nitrofurantoin;Amlodipine;Rosuvastatin;Hydrochlorothiazide;Medroxyprogesterone;Lisinopril;Omeprazole,25-MAR-2019,18-DEC-2018,NL,Not Specified,NL-NOVOPROD-637565,-,-
16116161,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Infarction;Cerebrovascular Accident;Blood Glucose Abnormal;Intentional Product Use Issue,Serious,Other Outcomes,Female,17-MAR-2019,03-APR-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-APR-2019,26-MAR-2019,BR,Not Specified,BR-SA-2019SA079321,-,-
15730459,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Peripheral Swelling;Rash;Expired Product Administered;Skin Discolouration,Non-Serious,Non-Serious,Female,-,03-APR-2019,Non-Expedited,75 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,29-MAR-2019,17-DEC-2018,US,Not Specified,US-SA-2018SA339324,-,-
16150960,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Renal Impairment;Anaemia,Serious,Other Outcomes,Female,-,02-APR-2019,Non-Expedited,65 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,29-MAR-2019,02-APR-2019,US,Not Specified,US-SA-2019SA090337,-,-
16143488,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Pancreatitis;Diabetes Mellitus Inadequate Control,Serious,Hospitalized;Other Outcomes,Female,-,01-APR-2019,Expedited,26 YR,85 KG,Sanofi Aventis,Healthcare Professional,Not Specified,Amaryl;Janumet;Jardiance,27-MAR-2019,01-APR-2019,SA,Not Specified,SA-SA-2019SA089190,-,-
16142478,Soliqua 100/33,Insulin Glargine\Lixisenatide;Investigational Product,-,Bronchiolitis,Serious,Other Outcomes,Female,-,01-APR-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,25-MAR-2019,01-APR-2019,MX,Not Specified,MX-SA-2019SA083881,-,-
16142271,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Urticaria,Non-Serious,Non-Serious,Female,-,01-APR-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,26-MAR-2019,01-APR-2019,US,Not Specified,US-SA-2019SA087085,-,-
16142270,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Malaise;Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,01-APR-2019,Non-Expedited,58 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-MAR-2019,01-APR-2019,US,Not Specified,US-SA-2019SA086746,-,-
16142238,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Female,-,01-APR-2019,Non-Expedited,52 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-MAR-2019,01-APR-2019,US,Not Specified,US-SA-2019SA086043,-,-
16142226,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Diarrhoea,Non-Serious,Non-Serious,Male,-,01-APR-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,26-MAR-2019,01-APR-2019,US,Not Specified,US-SA-2019SA086863,-,-
16138703,Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Glargine,Type 2 Diabetes Mellitus,Metastases To Liver,Serious,Other Outcomes;Hospitalized,Female,-,01-APR-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,25-MAR-2019,01-APR-2019,BR,Not Specified,BR-SA-2019SA085477,-,-
16137352,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Male,-,01-APR-2019,Non-Expedited,80 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-MAR-2019,01-APR-2019,US,Not Specified,US-SA-2019SA083774,-,-
16137292,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Colour Blindness,Non-Serious,Non-Serious,Male,-,01-APR-2019,Non-Expedited,62 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,25-MAR-2019,01-APR-2019,US,Not Specified,US-SA-2019SA085373,-,-
16131100,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Myalgia;Laryngeal Oedema,Serious,Life Threatening,Female,FEB-2019,01-APR-2019,Expedited,65 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Indapamide;Amlodipine Besylate;Atacand;Euthyrox;Bisoprolol Fumarate,25-MAR-2019,28-MAR-2019,RO,Not Specified,RO-SA-2019SA080005,-,-
16265911,Tresiba;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Insulin Degludec,-,Product Dispensing Error,Non-Serious,Non-Serious,Not Specified,-,29-MAR-2019,Direct,Not Specified,Not Specified,Fda-Ctu,Not Specified,Not Specified,-,-,29-MAR-2019,US,Not Specified,-,-,-
16135270,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Intentional Underdose;Nausea;Vomiting;Blood Glucose Increased;Weight Decreased;Decreased Appetite;Diarrhoea,Non-Serious,Non-Serious,Male,-,29-MAR-2019,Non-Expedited,42 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-MAR-2019,29-MAR-2019,US,Not Specified,US-SA-2019SA081047,-,-
16132908,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 1 Diabetes Mellitus,Device Operational Issue,Non-Serious,Non-Serious,Female,-,29-MAR-2019,Non-Expedited,72 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-FEB-2019,29-MAR-2019,US,Not Specified,US-SA-2019SA047174,-,-
15957501,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Fear;Asthenia;Swelling;Throat Tightness;Hyperhidrosis;Somnolence;Brain Fog;Tension Headache;Mental Disorder;Vision Blurred;Taste Disorder;Panic Reaction;Dizziness;Vertigo;Chest Discomfort,Non-Serious,Non-Serious,Not Specified,-,29-MAR-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-MAR-2019,13-FEB-2019,US,Not Specified,US-SA-2019SA036608,-,-
16128895,Xultophy 100/3.6;Victoza,Liraglutide;Insulin Degludec\Liraglutide,Diabetes Mellitus,Graves' Disease;Back Pain,Serious,Other Outcomes,Female,-,28-MAR-2019,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,19-MAR-2019,28-MAR-2019,US,Not Specified,US-NOVOPROD-653987,-,-
16128891,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Adenocarcinoma Pancreas,Serious,Life Threatening,Male,JAN-2019,28-MAR-2019,Expedited,67 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,21-MAR-2019,28-MAR-2019,FR,Not Specified,FR-NOVOPROD-653603,-,-
15997118,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Product Storage Error;Injection Site Discharge;Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,27-MAR-2019,Non-Expedited,63 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-MAR-2019,22-FEB-2019,US,Not Specified,US-SA-2019SA042132,-,-
15710649,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Optic Disc Disorder;Glycosylated Haemoglobin Increased;Optic Neuritis;Optic Neuropathy,Serious,Hospitalized,Male,-,27-MAR-2019,Expedited,61 YR,83 KG,Novo Nordisk,Healthcare Professional,Not Specified,-,20-MAR-2019,11-DEC-2018,SI,Not Specified,SI-NOVOPROD-636823,-,-
13598625,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Decreased;Influenza,Non-Serious,Non-Serious,Female,18-MAY-2017,27-MAR-2019,Non-Expedited,54 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-MAR-2019,31-MAY-2017,US,Not Specified,US-SA-2017SA095110,-,-
16118416,Soliqua 100/33,Insulin Glargine\Lixisenatide,Blood Glucose,Hypoglycaemia,Non-Serious,Non-Serious,Male,-,26-MAR-2019,Non-Expedited,83 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,19-MAR-2019,26-MAR-2019,US,Not Specified,US-SA-2019SA078673,-,-
16116179,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Operational Issue;Product Dose Omission Issue,Non-Serious,Non-Serious,Male,-,26-MAR-2019,Non-Expedited,57 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-MAR-2019,26-MAR-2019,US,Not Specified,US-SA-2019SA077142,-,-
16116137,-,Insulin Glargine\Lixisenatide,-,Hypoglycaemia;Cerebrovascular Accident;Product Use Issue,Serious,Hospitalized,Female,07-NOV-2018,26-MAR-2019,Expedited,80 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Toujeo,08-NOV-2018,26-MAR-2019,IL,Not Specified,IL-SA-2018SA310705,-,-
16116123,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Nasopharyngitis,Non-Serious,Non-Serious,Female,-,26-MAR-2019,Non-Expedited,58 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-MAR-2019,26-MAR-2019,US,Not Specified,US-SA-2019SA077166,-,-
16113829,-,Insulin Glargine\Lixisenatide,-,Mental Disorder;Weight Decreased;Hyperglycaemia,Serious,Other Outcomes,Male,18-MAR-2019,25-MAR-2019,Expedited,62 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-MAR-2019,25-MAR-2019,US,Not Specified,US-SA-2019SA078563,-,-
16111829,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Issue,Non-Serious,Non-Serious,Male,-,25-MAR-2019,Non-Expedited,71 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,18-MAR-2019,25-MAR-2019,US,Not Specified,US-SA-2019SA077122,-,-
16111828,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Weight Increased;Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,25-MAR-2019,Non-Expedited,73 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Humalog,18-MAR-2019,25-MAR-2019,US,Not Specified,US-SA-2019SA077107,-,-
16109758,Solostar,Device;Insulin Glargine\Lixisenatide,-,Diabetic Retinal Oedema;Weight Fluctuation;Renal Disorder;Neuropathy Peripheral;Glycosylated Haemoglobin Abnormal,Serious,Other Outcomes,Not Specified,-,25-MAR-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-MAR-2019,25-MAR-2019,US,Not Specified,US-SA-2019SA076574,-,-
16055957,Solostar,Device;Insulin Glargine\Lixisenatide,-,Visual Impairment;Eye Disorder;Retinal Degeneration,Serious,Other Outcomes,Male,-,22-MAR-2019,Expedited,82 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Novorapid,17-MAR-2019,11-MAR-2019,IL,Not Specified,IL-SA-2019SA062253,-,-
15695062,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Chronic Kidney Disease;Renal Injury,Serious,Other Outcomes,Female,29-OCT-2018,22-MAR-2019,Expedited,64 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Losartan;Verapamil;Hydrochlorothiazide\Triamterene;Prednisone,13-MAR-2019,06-DEC-2018,US,Not Specified,US-NOVOPROD-634115,-,-
16100929,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Urticaria,Non-Serious,Non-Serious,Female,-,21-MAR-2019,Non-Expedited,55 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,13-MAR-2019,21-MAR-2019,US,Not Specified,US-SA-2019SA072847,-,-
16090088,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Pruritus,Non-Serious,Non-Serious,Female,-,19-MAR-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,13-MAR-2019,19-MAR-2019,US,Not Specified,US-SA-2019SA072711,-,-
16048358,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Condition Aggravated;Pancreatitis;Abdominal Pain Upper;Pain;Decreased Appetite;Nausea,Serious,Other Outcomes,Female,FEB-2019,19-MAR-2019,Expedited,67 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Metformin;Atorvastatin Calcium,14-MAR-2019,07-MAR-2019,RU,Not Specified,RU-SA-2019SA060965,-,-
16085468,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Metastases To Liver;Metastases To Stomach;Metastases To Lung,Serious,Other Outcomes;Hospitalized,Female,-,18-MAR-2019,Expedited,70 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,07-MAR-2019,18-MAR-2019,IL,Not Specified,IL-NOVOPROD-651701,-,-
16082943,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Nausea;Drug Intolerance,Non-Serious,Non-Serious,Not Specified,-,18-MAR-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,08-MAR-2019,18-MAR-2019,US,Not Specified,US-SA-2019SA069129,-,-
15993695,Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Weight Decreased,Non-Serious,Non-Serious,Female,-,15-MAR-2019,Expedited,Not Specified,83 KG,Sanofi Aventis,Healthcare Professional,Not Specified,-,12-MAR-2019,22-FEB-2019,BR,Not Specified,BR-SA-2019SA044693,-,-
15886061,Ozempic;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Semaglutide,Body Mass Index Increased;Glycosylated Haemoglobin Increased;Product Used For Unknown Indication,Hepatic Enzyme Increased,Serious,Other Outcomes,Female,2018,15-MAR-2019,Expedited,54 YR,105.22 KG,Novo Nordisk,Healthcare Professional,Not Specified,Aspirin;Metformin Hydrochloride;Vitamin D3;Magnesium;Losartan;Claritin;Humira;Nature-Throid,05-MAR-2019,29-JAN-2019,US,Not Specified,US-NOVOPROD-643103,-,-
16073406,Solostar,Device;Insulin Glargine\Lixisenatide,-,Product Dose Omission Issue;Decreased Appetite;Influenza;Blood Glucose Increased;Dehydration,Serious,Hospitalized,Male,-,14-MAR-2019,Expedited,58 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,05-FEB-2019,14-MAR-2019,IL,Not Specified,IL-SA-2019SA035228,-,-
16072225,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Injection Site Pain,Non-Serious,Non-Serious,Male,-,14-MAR-2019,Non-Expedited,54 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,11-MAR-2019,14-MAR-2019,US,Not Specified,US-SA-2019SA069161,-,-
16072197,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Weight Decreased,Non-Serious,Non-Serious,Male,-,14-MAR-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,11-MAR-2019,14-MAR-2019,US,Not Specified,US-SA-2019SA070856,-,-
16069450,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Vomiting;Nausea,Non-Serious,Non-Serious,Female,-,13-MAR-2019,Non-Expedited,82 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,05-MAR-2019,13-MAR-2019,US,Not Specified,US-SA-2019SA063401,-,-
16069426,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Weight Increased;Injection Site Pruritus,Non-Serious,Non-Serious,Female,-,13-MAR-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Humulin Nos;Jentadueto,09-MAR-2019,13-MAR-2019,US,Not Specified,US-SA-2019SA066845,-,-
16067089,Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error;Abdominal Discomfort;Incorrect Route Of Product Administration;Haemorrhage,Serious,Other Outcomes,Male,-,13-MAR-2019,Expedited,Not Specified,92 KG,Sanofi Aventis,Consumer,Not Specified,-,07-MAR-2019,13-MAR-2019,BR,Not Specified,BR-SA-2019SA066261,-,-
16063138,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Nausea;Vomiting,Serious,Hospitalized,Female,-,12-MAR-2019,Non-Expedited,82 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Lantus,05-MAR-2019,12-MAR-2019,US,Not Specified,US-SA-2019SA063154,-,-
16062719,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Muscle Discomfort;Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Male,2016,12-MAR-2019,Non-Expedited,69 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,Jardiance,02-JAN-2019,12-MAR-2019,US,Not Specified,US-NOVOPROD-641008,-,-
16062718,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Pancreatitis,Serious,Other Outcomes,Male,-,12-MAR-2019,Expedited,45 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,24-JAN-2019,12-MAR-2019,US,Not Specified,US-NOVOPROD-644469,-,-
16062716,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Blood Glucose Increased;Device Breakage;Intentional Product Use Issue,Non-Serious,Non-Serious,Female,-,12-MAR-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,27-DEC-2018,12-MAR-2019,US,Not Specified,US-NOVOPROD-640494,-,-
16062715,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Blood Glucose Increased,Non-Serious,Non-Serious,Male,FEB-2019,12-MAR-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,11-FEB-2019,12-MAR-2019,US,Not Specified,US-NOVOPROD-646876,-,-
16062714,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Product Use Issue,Non-Serious,Non-Serious,Female,-,12-MAR-2019,Non-Expedited,84 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,24-JAN-2019,12-MAR-2019,US,Not Specified,US-NOVOPROD-644481,-,-
16062713,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Blood Glucose Decreased;Off Label Use,Non-Serious,Non-Serious,Male,-,12-MAR-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,13-NOV-2018,12-MAR-2019,US,Not Specified,US-NOVOPROD-632881,-,-
16062711,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Product Storage Error;Blood Glucose Increased,Non-Serious,Non-Serious,Female,04-JAN-2019,12-MAR-2019,Non-Expedited,59 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,18-JAN-2019,12-MAR-2019,US,Not Specified,US-NOVOPROD-643291,-,-
16062710,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Diarrhoea,Non-Serious,Non-Serious,Male,NOV-2018,12-MAR-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,07-DEC-2018,12-MAR-2019,US,Not Specified,US-NOVOPROD-637511,-,-
16062709,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Device Malfunction;Blood Glucose Increased,Non-Serious,Non-Serious,Male,NOV-2018,12-MAR-2019,Non-Expedited,44 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,04-DEC-2018,12-MAR-2019,US,Not Specified,US-NOVOPROD-637518,-,-
16062708,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Arthralgia;Product Dispensing Error;Swelling Face;Swelling;Pain In Extremity,Non-Serious,Non-Serious,Female,2018,12-MAR-2019,Non-Expedited,58 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,29-NOV-2018,12-MAR-2019,US,Not Specified,US-NOVOPROD-635955,-,-
16062707,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Dysarthria,Non-Serious,Non-Serious,Male,OCT-2018,12-MAR-2019,Non-Expedited,56 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Gabapentin,15-JAN-2019,12-MAR-2019,US,Not Specified,US-NOVOPROD-642642,-,-
16062705,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Extra Dose Administered,Non-Serious,Non-Serious,Female,10-DEC-2018,12-MAR-2019,Non-Expedited,61 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,10-DEC-2018,12-MAR-2019,US,Not Specified,US-NOVOPROD-637825,-,-
16062704,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Female,06-SEP-2018,12-MAR-2019,Non-Expedited,60 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,06-DEC-2018,12-MAR-2019,US,Not Specified,US-NOVOPROD-637501,-,-
16062703,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Weight Decreased;Hypophagia;Glycosylated Haemoglobin Decreased;Pre-Existing Condition Improved;Taste Disorder,Non-Serious,Non-Serious,Male,2018,12-MAR-2019,Non-Expedited,Not Specified,102.49 KG,Novo Nordisk,Consumer,Not Specified,-,17-DEC-2018,12-MAR-2019,US,Not Specified,US-NOVOPROD-639424,-,-
16062702,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Wrong Technique In Product Usage Process,Non-Serious,Non-Serious,Male,-,12-MAR-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,14-DEC-2018,12-MAR-2019,US,Not Specified,US-NOVOPROD-638795,-,-
16062700,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Product Dispensing Error,Non-Serious,Non-Serious,Male,19-FEB-2019,12-MAR-2019,Non-Expedited,74 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,19-FEB-2019,12-MAR-2019,US,Not Specified,US-NOVOPROD-648545,-,-
16062699,Xultophy 100/3.6;Invokana,Canagliflozin;Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Abdominal Discomfort;Blood Glucose Increased,Non-Serious,Non-Serious,Male,11-DEC-2018,12-MAR-2019,Non-Expedited,71 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,17-DEC-2018,12-MAR-2019,US,Not Specified,US-NOVOPROD-639381,-,-
16062698,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Diarrhoea;Gastrointestinal Disorder,Non-Serious,Non-Serious,Not Specified,-,12-MAR-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,03-JAN-2019,12-MAR-2019,US,Not Specified,US-NOVOPROD-642213,-,-
16062697,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Device Failure;Injection Site Pain,Non-Serious,Non-Serious,Female,NOV-2018,12-MAR-2019,Non-Expedited,61 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,03-DEC-2018,12-MAR-2019,US,Not Specified,US-NOVOPROD-637005,-,-
16062695,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Abdominal Discomfort;Diarrhoea,Non-Serious,Non-Serious,Male,2018,12-MAR-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,29-NOV-2018,12-MAR-2019,US,Not Specified,US-NOVOPROD-635956,-,-
16062694,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 1 Diabetes Mellitus,Blood Glucose Increased;Product Use In Unapproved Indication;Blood Glucose Decreased,Non-Serious,Non-Serious,Female,2018,12-MAR-2019,Non-Expedited,67 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,Humalog,26-DEC-2018,12-MAR-2019,US,Not Specified,US-NOVOPROD-640251,-,-
16062693,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Weight Decreased,Non-Serious,Non-Serious,Female,AUG-2018,12-MAR-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,14-JAN-2019,12-MAR-2019,US,Not Specified,US-NOVOPROD-643061,-,-
16062692,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Blood Glucose Decreased,Non-Serious,Non-Serious,Male,OCT-2018,12-MAR-2019,Non-Expedited,69 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,07-JAN-2019,12-MAR-2019,US,Not Specified,US-NOVOPROD-641576,-,-
15697379,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Incorrect Dose Administered,Non-Serious,Non-Serious,Male,OCT-2018,12-MAR-2019,Non-Expedited,51 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,26-NOV-2018,07-DEC-2018,US,Not Specified,US-NOVOPROD-629785,-,-
15695116,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Exposure During Pregnancy,Non-Serious,Non-Serious,Female,-,12-MAR-2019,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,26-NOV-2018,06-DEC-2018,US,Not Specified,US-NOVOPROD-620648,-,-
15695098,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Vomiting;Diarrhoea,Non-Serious,Non-Serious,Male,23-AUG-2018,12-MAR-2019,Non-Expedited,62 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,11-JAN-2019,06-DEC-2018,US,Not Specified,US-NOVOPROD-623644,-,-
16057397,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Eye Swelling;Mouth Swelling;Angioedema;Anaphylactic Shock,Serious,Other Outcomes,Female,-,11-MAR-2019,Non-Expedited,40 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,28-FEB-2019,11-MAR-2019,US,Not Specified,US-SA-2019SA060754,-,-
15953877,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Hypertension;Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Rash;Eosinophilia;Asthma,Non-Serious,Non-Serious,Female,28-DEC-2018,11-MAR-2019,Expedited,58 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Indapamide\Perindopril;Metformin Hydrochloride,28-FEB-2019,12-FEB-2019,FR,Not Specified,FR-NOVOPROD-645917,-,-
16037274,Solostar,Device;Insulin Glargine\Lixisenatide;Insulin Glulisine,Type 2 Diabetes Mellitus,Seizure;Feeling Abnormal,Serious,Hospitalized,Female,25-FEB-2019,08-MAR-2019,Expedited,59 YR,87 KG,Sanofi Aventis,Consumer,Not Specified,-,25-FEB-2019,05-MAR-2019,BR,Not Specified,BR-SA-2019SA053422,-,-
16048876,Solostar,Device;Insulin Glargine\Lixisenatide,-,Cerebrovascular Accident,Serious,Other Outcomes,Female,-,07-MAR-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,01-MAR-2019,07-MAR-2019,US,Not Specified,US-SA-2019SA061181,-,-
16048748,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Rash Pruritic;Chapped Lips,Non-Serious,Non-Serious,Female,-,07-MAR-2019,Non-Expedited,36 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,02-MAR-2019,07-MAR-2019,US,Not Specified,US-SA-2019SA062914,-,-
16048531,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Dysphonia,Non-Serious,Non-Serious,Male,-,07-MAR-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,27-FEB-2019,07-MAR-2019,US,Not Specified,US-SA-2019SA059646,-,-
16047179,Xultophy 100/3.6;Invokana,Canagliflozin;Insulin Degludec\Liraglutide,Anxiety;Constipation;Depression;Dermatitis;Pain;Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Hepatic Enzyme Increased;Herpes Zoster,Serious,Other Outcomes,Female,NOV-2018,07-MAR-2019,Expedited,50 YR,104.76 KG,Novo Nordisk,Healthcare Professional,Not Specified,Ativan;Lantus;Senna Alexandrina Whole;Ibuprofen;Metformin;Simvastatin;Cymbalta;Celexa;Clobetasol;Norco,16-JAN-2019,07-MAR-2019,US,Not Specified,US-NOVOPROD-643253,-,-
16046591,Solostar,Device;Insulin Glargine\Lixisenatide,Cardiac Disorder,Blood Glucose Decreased;Weight Decreased;Decreased Appetite,Serious,Other Outcomes,Male,07-FEB-2019,07-MAR-2019,Expedited,55 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Flecainide,21-FEB-2019,07-MAR-2019,US,Not Specified,US-SA-2019SA054857,-,-
16045271,Solostar,Device;Insulin Glargine\Lixisenatide,-,Coronary Artery Disease,Serious,Hospitalized,Male,20-FEB-2019,07-MAR-2019,Expedited,68 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-FEB-2019,07-MAR-2019,IL,Not Specified,IL-SA-2019SA041472,-,-
16043889,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,06-MAR-2019,Non-Expedited,77 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,25-FEB-2019,06-MAR-2019,US,Not Specified,US-SA-2019SA056368,-,-
16043878,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Device Issue;Product Dose Omission Issue,Non-Serious,Non-Serious,Female,-,06-MAR-2019,Non-Expedited,45 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-FEB-2019,06-MAR-2019,US,Not Specified,US-SA-2019SA056632,-,-
16043836,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Menstruation Irregular;Incorrect Dose Administered By Device;Device Operational Issue,Non-Serious,Non-Serious,Female,-,06-MAR-2019,Non-Expedited,45 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-FEB-2019,06-MAR-2019,US,Not Specified,US-SA-2019SA055735,-,-
16043830,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Dose Omission Issue,Non-Serious,Non-Serious,Male,-,06-MAR-2019,Non-Expedited,57 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-FEB-2019,06-MAR-2019,US,Not Specified,US-SA-2019SA053142,-,-
15398115,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Nausea;Loss Of Consciousness;Dysgeusia;Blood Glucose Increased,Serious,Other Outcomes,Male,-,06-MAR-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,18-FEB-2019,18-SEP-2018,US,Not Specified,US-SA-2018SA252241,-,-
16035577,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Pancreatic Carcinoma,Serious,Other Outcomes,Female,-,05-MAR-2019,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,22-FEB-2019,05-MAR-2019,HU,Not Specified,HU-NOVOPROD-649210,-,-
16035474,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Inappropriate Schedule Of Product Administration;Blood Glucose Increased,Non-Serious,Non-Serious,Not Specified,-,05-MAR-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,22-FEB-2019,05-MAR-2019,US,Not Specified,US-SA-2019SA054831,-,-
16035221,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Expired Product Administered,Non-Serious,Non-Serious,Female,-,05-MAR-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-FEB-2019,05-MAR-2019,US,Not Specified,US-SA-2019SA054753,-,-
16031325,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Dizziness;Product Use Complaint,Non-Serious,Non-Serious,Female,-,04-MAR-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-FEB-2019,04-MAR-2019,US,Not Specified,US-SA-2019SA059778,-,-
16028248,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Hyperglycaemia;Drug Ineffective;Arrhythmia;Blood Glucose Fluctuation,Serious,Hospitalized,Male,-,04-MAR-2019,Expedited,Not Specified,95 KG,Sanofi Aventis,Consumer,Not Specified,Metformin;Metoprolol Succinate;Simvastatin,13-FEB-2019,04-MAR-2019,BR,Not Specified,BR-SA-2019SA044229,-,-
15766720,Solostar,Device;Insulin Glargine\Lixisenatide,-,Glycosylated Haemoglobin Increased;Surgery;Dementia;Cataract Operation;Joint Injury;Hearing Disability;Weight Decreased,Serious,Other Outcomes,Male,17-DEC-2018,04-MAR-2019,Expedited,66 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin;Trulicity;Linagliptin,25-FEB-2019,27-DEC-2018,US,Not Specified,US-SA-2018SA393431,-,-
16025111,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Blood Glucose Fluctuation;Expired Product Administered,Non-Serious,Non-Serious,Female,-,01-MAR-2019,Non-Expedited,72 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-FEB-2019,01-MAR-2019,US,Not Specified,US-SA-2019SA056633,-,-
16025082,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Diabetes Mellitus,No Adverse Event,Non-Serious,Non-Serious,Male,-,01-MAR-2019,Non-Expedited,61 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,21-FEB-2019,01-MAR-2019,US,Not Specified,US-SA-2019SA055747,-,-
16024980,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Device Leakage;Device Operational Issue;Inappropriate Schedule Of Product Administration;Product Administration Error,Non-Serious,Non-Serious,Female,-,01-MAR-2019,Non-Expedited,61 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-FEB-2019,01-MAR-2019,US,Not Specified,US-SA-2019SA052237,-,-
16022084,Soliqua 100/33;Solostar,Insulin Glargine\Lixisenatide;Device;Investigational Product,-,Hypertension;Hypoaesthesia;Neuropathy Peripheral;Pruritus,Serious,Other Outcomes,Female,-,01-MAR-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-FEB-2019,01-MAR-2019,MX,Not Specified,MX-SA-2019SA052189,-,-
16012587,Solostar,Device;Insulin Glargine\Lixisenatide,-,Pneumonia;Blood Glucose Increased,Serious,Other Outcomes,Female,-,27-FEB-2019,Expedited,56 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-FEB-2019,27-FEB-2019,IL,Not Specified,IL-SA-2019SA052410,-,-
16012389,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Cardiomegaly;Obesity;Death,Serious,Died,Male,-,27-FEB-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,22-FEB-2019,27-FEB-2019,US,Not Specified,US-SA-2019SA054837,-,-
16009783,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Diabetes Mellitus,Extra Dose Administered;Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,27-FEB-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin;Farxiga,19-FEB-2019,27-FEB-2019,US,Not Specified,US-SA-2019SA049732,-,-
13925563,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Diabetes Mellitus,Injection Site Oedema;Drug Ineffective;Injection Site Pruritus,Non-Serious,Non-Serious,Male,-,27-FEB-2019,Non-Expedited,54 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,18-FEB-2019,31-AUG-2017,US,Not Specified,US-SA-2017SA137135,-,-
16003970,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Glycosylated Haemoglobin Increased;Red Blood Cell Sedimentation Rate Abnormal;Inflammation;Weight Increased;Diabetic Metabolic Decompensation,Serious,Hospitalized;Other Outcomes,Male,07-JAN-2019,26-FEB-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Metformin;.Alpha.-Lipoic Acid;Pentoxifylline,14-FEB-2019,26-FEB-2019,RO,Not Specified,RO-SA-2019SA044960,-,-
16003942,Solostar,Device;Insulin Glargine\Lixisenatide,Diabetes Mellitus,Brain Neoplasm,Serious,Other Outcomes,Female,-,26-FEB-2019,Expedited,50 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-FEB-2019,26-FEB-2019,US,Not Specified,US-SA-2019SA048781,-,-
16002688,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,25-FEB-2019,Non-Expedited,64 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-FEB-2019,25-FEB-2019,US,Not Specified,US-SA-2019SA045837,-,-
16002687,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Operational Issue;Nasopharyngitis;Product Dose Omission Issue;Cough,Non-Serious,Non-Serious,Female,-,25-FEB-2019,Non-Expedited,52 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-FEB-2019,25-FEB-2019,US,Not Specified,US-SA-2019SA045826,-,-
16002682,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Expired Device Used;Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,25-FEB-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-FEB-2019,25-FEB-2019,US,Not Specified,US-SA-2019SA045838,-,-
15997751,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,22-FEB-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-FEB-2019,22-FEB-2019,US,Not Specified,US-SA-2019SA044315,-,-
15997076,Solostar,Device;Insulin Glargine\Lixisenatide,-,Anxiety;Nervousness;Decreased Appetite;Nasopharyngitis;Hypoglycaemia;Wound;Wound Infection,Serious,Hospitalized;Other Outcomes,Male,01-FEB-2017,22-FEB-2019,Expedited,41 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-FEB-2019,22-FEB-2019,US,Not Specified,US-SA-2019SA047351,-,-
15993776,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Storage Error,Non-Serious,Non-Serious,Not Specified,-,22-FEB-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-FEB-2019,22-FEB-2019,US,Not Specified,US-SA-2019SA041197,-,-
15993737,Soliqua 100/33,Insulin Glargine\Lixisenatide;Investigational Product,-,Malaise,Serious,Hospitalized,Female,-,22-FEB-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-FEB-2019,22-FEB-2019,MX,Not Specified,MX-SA-2019SA045129,-,-
15961885,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Operational Issue;Incorrect Dose Administered By Device;Device Breakage,Non-Serious,Non-Serious,Male,-,22-FEB-2019,Non-Expedited,55 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-FEB-2019,14-FEB-2019,US,Not Specified,US-SA-2018SA310232,-,-
15647566,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Expired Product Administered;Product Dose Omission Issue,Non-Serious,Non-Serious,Female,-,22-FEB-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-NOV-2018,22-NOV-2018,US,Not Specified,US-SA-2018SA315921,-,-
15690853,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Diabetes Mellitus,Nervousness;Blood Glucose Increased;Product Dose Omission Issue,Non-Serious,Non-Serious,Female,-,19-FEB-2019,Non-Expedited,47 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-FEB-2019,05-DEC-2018,US,Not Specified,US-SA-2018SA326761,-,-
15974385,Solostar,Device;Insulin Glulisine;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Neck Pain;Hypoglycaemia;Diabetic Metabolic Decompensation;Back Pain,Serious,Hospitalized,Male,10-JAN-2019,18-FEB-2019,Expedited,42 YR,103 KG,Sanofi Aventis,Healthcare Professional,Not Specified,-,08-FEB-2019,18-FEB-2019,BR,Not Specified,BR-SA-2019SA040931,-,-
15967207,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Injection Site Reaction,Non-Serious,Non-Serious,Female,-,15-FEB-2019,Non-Expedited,45 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,07-FEB-2019,15-FEB-2019,US,Not Specified,US-SA-2019SA039714,-,-
15827336,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Condition Aggravated;Glare;Retinal Oedema,Serious,Other Outcomes,Female,-,15-FEB-2019,Non-Expedited,67 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-JAN-2019,15-JAN-2019,US,Not Specified,US-SA-2019SA008173,-,-
15813131,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,15-FEB-2019,Non-Expedited,65 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,04-JAN-2019,11-JAN-2019,US,Not Specified,US-SA-2019SA005733,-,-
15781418,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Anxiety;Lack Of Injection Site Rotation;Product Administration Error;Tremor;Confusional State;Hyperhidrosis;Wrong Technique In Product Usage Process;Hypoglycaemia;Vision Blurred,Non-Serious,Non-Serious,Male,-,15-FEB-2019,Non-Expedited,61 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Methotrexate;Victoza,08-FEB-2019,02-JAN-2019,US,Not Specified,US-SA-2018SA396063,-,-
15771869,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Blood Glucose Abnormal,Non-Serious,Non-Serious,Female,-,15-FEB-2019,Non-Expedited,51 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-DEC-2018,28-DEC-2018,US,Not Specified,US-SA-2018SA393411,-,-
15619246,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Odour Abnormal,Non-Serious,Non-Serious,Not Specified,-,15-FEB-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,06-NOV-2018,14-NOV-2018,US,Not Specified,US-SA-2018SA308774,-,-
15106741,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Tremor;Drug Ineffective;Hyperglycaemia,Non-Serious,Non-Serious,Male,-,15-FEB-2019,Non-Expedited,73 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,06-FEB-2019,04-JUL-2018,US,Not Specified,US-SA-2018SA176189,-,-
15584492,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Device Operational Issue,Non-Serious,Non-Serious,Male,-,14-FEB-2019,Non-Expedited,73 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,29-OCT-2018,05-NOV-2018,US,Not Specified,US-SA-2018SA300660,-,-
15957743,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Hypoaesthesia,Non-Serious,Non-Serious,Female,-,13-FEB-2019,Non-Expedited,68 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,06-FEB-2019,13-FEB-2019,US,Not Specified,US-SA-2019SA039724,-,-
15957495,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Expired Product Administered,Non-Serious,Non-Serious,Male,-,13-FEB-2019,Non-Expedited,83 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,04-FEB-2019,13-FEB-2019,US,Not Specified,US-SA-2019SA035696,-,-
15794128,Solostar,Device;Insulin Glargine\Lixisenatide,Diabetes Mellitus,Facial Paresis;Blood Glucose Fluctuation,Serious,Hospitalized,Female,DEC-2018,13-FEB-2019,Expedited,61 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,31-JAN-2019,07-JAN-2019,KR,Not Specified,KR-SA-2019SA001662,-,-
15487882,Soliqua 100/33;Lantus;Solostar,Device;Insulin Glargine;Insulin Glargine\Lixisenatide,-,Hypotension,Non-Serious,Non-Serious,Female,-,12-FEB-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Lisinopril,29-JAN-2019,11-OCT-2018,US,Not Specified,US-SA-2018SA276502,-,-
15945361,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device;Metformin Hydrochloride,Type 2 Diabetes Mellitus,Blood Glucose Increased;Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Female,-,11-FEB-2019,Non-Expedited,67 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-FEB-2019,11-FEB-2019,US,Not Specified,US-SA-2019SA033985,-,-
15945344,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Gait Disturbance,Non-Serious,Non-Serious,Male,-,11-FEB-2019,Non-Expedited,58 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,31-JAN-2019,11-FEB-2019,US,Not Specified,US-SA-2019SA031319,-,-
15482498,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Device Issue;Product Dose Omission Issue,Non-Serious,Non-Serious,Female,-,08-FEB-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,02-OCT-2018,10-OCT-2018,US,Not Specified,US-SA-2018SA275828,-,-
15403889,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Decreased Appetite;Wrong Technique In Product Usage Process,Non-Serious,Non-Serious,Female,-,08-FEB-2019,Non-Expedited,46 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,29-JAN-2019,19-SEP-2018,US,Not Specified,US-SA-2018SA254268,-,-
15932033,-,Insulin Glargine\Lixisenatide,-,Visual Impairment;Diabetes Mellitus,Serious,Other Outcomes,Female,-,07-FEB-2019,Expedited,Not Specified,48 KG,Sanofi Aventis,Consumer,Not Specified,-,25-JAN-2019,07-FEB-2019,BR,Not Specified,BR-SA-2019SA025921,-,-
15931240,Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Glargine,Type 2 Diabetes Mellitus,Cerebrovascular Accident,Serious,Other Outcomes,Male,-,07-FEB-2019,Expedited,Not Specified,108 KG,Sanofi Aventis,Consumer,Not Specified,-,29-JAN-2019,07-FEB-2019,BR,Not Specified,BR-SA-2019SA029032,-,-
15918439,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,-,05-FEB-2019,Non-Expedited,65 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-JAN-2019,05-FEB-2019,US,Not Specified,US-SA-2019SA027234,-,-
15918415,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Lipase Increased,Non-Serious,Non-Serious,Not Specified,-,05-FEB-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,28-JAN-2019,05-FEB-2019,US,Not Specified,US-SA-2019SA027585,-,-
15918383,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Glomerular Filtration Rate Decreased,Non-Serious,Non-Serious,Female,-,05-FEB-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,28-JAN-2019,05-FEB-2019,US,Not Specified,US-SA-2019SA027226,-,-
15918180,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Asthenia;Unevaluable Event;Wound;Eating Disorder;Speech Disorder;Vomiting;Central Obesity;Diarrhoea,Serious,Hospitalized,Male,-,05-FEB-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-JAN-2019,05-FEB-2019,BR,Not Specified,BR-SA-2019SA027385,-,-
15918156,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Aneurysm,Serious,Other Outcomes,Male,-,05-FEB-2019,Expedited,Not Specified,74 KG,Sanofi Aventis,Consumer,Not Specified,-,28-JAN-2019,05-FEB-2019,BR,Not Specified,BR-SA-2019SA027023,-,-
15917590,-,Insulin Glargine\Lixisenatide,-,Product Dose Omission Issue;Intentional Product Misuse;Pneumonia;Blood Glucose Abnormal,Serious,Hospitalized,Female,-,05-FEB-2019,Expedited,71 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,04-SEP-2018,05-FEB-2019,IL,Not Specified,IL-SA-2018SA250908,-,-
15851167,Xultophy 100/3.6;Victoza;Metformin;Levemir,Insulin Detemir;Metformin Hydrochloride;Liraglutide;Furosemide;Insulin Degludec\Liraglutide;Acarbose;Ezetimibe\Simvastatin;Ramipril;Aspirin,Diabetes Mellitus;Product Used For Unknown Indication,Diabetic Metabolic Decompensation;Therapeutic Product Effect Incomplete;Ischaemic Cardiomyopathy,Serious,Other Outcomes,Not Specified,2018,05-FEB-2019,Expedited,Not Specified,Not Specified,Aurobindo,Healthcare Professional,Not Specified,Liraglutide,21-JAN-2019,22-JAN-2019,IT,Not Specified,IT-AUROBINDO-AUR-APL-2019-001567,-,-
15907507,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Odour Abnormal;Device Leakage,Non-Serious,Non-Serious,Female,-,04-FEB-2019,Non-Expedited,45 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,28-JAN-2019,04-FEB-2019,US,Not Specified,US-SA-2019SA026778,-,-
15906424,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Hypoglycaemia,Non-Serious,Non-Serious,Female,-,04-FEB-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,24-JAN-2019,04-FEB-2019,US,Not Specified,US-SA-2019SA024002,-,-
15906302,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Pruritus;Blister;Skin Burning Sensation;General Physical Health Deterioration;Hypersensitivity;Peripheral Swelling;Rash Papular,Serious,Other Outcomes,Male,17-JAN-2019,04-FEB-2019,Expedited,55 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Aspirin;Metformin Hydrochloride;Ramipril;Crestor;Bisoprolol Fumarate,23-JAN-2019,04-FEB-2019,RO,Not Specified,RO-SAKK-2019SA022360AA,-,-
15906301,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Anaphylactic Shock,Serious,Other Outcomes,Female,06-DEC-2018,04-FEB-2019,Expedited,68 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Metformin;Benfotiamine,23-JAN-2019,04-FEB-2019,RO,Not Specified,RO-SAKK-2019SA021202AA,-,-
15804877,Victoza;Xultophy 100/3.6;Levemir,Insulin Detemir;Insulin Degludec\Liraglutide;Liraglutide;Ezetimibe\Simvastatin;Metformin Hydrochloride;Aspirin;Furosemide;Acarbose;Ramipril,Diabetes Mellitus;Product Used For Unknown Indication,Ischaemic Cardiomyopathy;Diabetic Metabolic Decompensation,Serious,Other Outcomes,Male,2018,04-FEB-2019,Expedited,59 YR,119 KG,Bristol Myers Squibb,Healthcare Professional,Not Specified,-,23-JAN-2019,09-JAN-2019,IT,Not Specified,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-001357,-,-
15895310,Levemir;Victoza;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Insulin Detemir;Liraglutide;Acarbose;Furosemide;Aspirin;Ezetimibe\Simvastatin;Metformin Hydrochloride;Ramipril,Diabetes Mellitus;Product Used For Unknown Indication,Tachyphylaxis;Diabetic Metabolic Decompensation;Therapeutic Product Effect Incomplete,Serious,Other Outcomes,Male,2018,31-JAN-2019,Expedited,59 YR,119.5 KG,Merck,Healthcare Professional,Not Specified,Liraglutide,10-JAN-2019,31-JAN-2019,IT,Not Specified,IT-009507513-1901ITA003625,-,-
15894041,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Hepatic Enzyme Increased,Serious,Other Outcomes,Not Specified,-,31-JAN-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Diabex,21-JAN-2019,31-JAN-2019,KR,Not Specified,KR-SAKK-2019SA020090AA,-,-
15890725,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Dose Omission Issue,Non-Serious,Non-Serious,Not Specified,-,30-JAN-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-JAN-2019,30-JAN-2019,US,Not Specified,US-SA-2019SA020056,-,-
15889326,-,Insulin Glargine;Insulin Glargine\Lixisenatide,-,Off Label Use;Diabetic Ketoacidosis;Blood Glucose Increased;Epididymitis,Serious,Other Outcomes;Hospitalized,Male,-,30-JAN-2019,Expedited,34 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,22-JAN-2019,30-JAN-2019,US,Not Specified,US-SAKK-2019SA023636AA,-,-
15883534,Soliqua 100/33,Insulin Glargine\Lixisenatide;Investigational Product,-,Malaise,Serious,Hospitalized,Male,-,29-JAN-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-JAN-2019,29-JAN-2019,MX,Not Specified,MX-SAKK-2019SA019867AA,-,-
15883529,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Hepatic Enzyme Increased,Serious,Other Outcomes,Not Specified,-,29-JAN-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Diabex,21-JAN-2019,29-JAN-2019,KR,Not Specified,KR-SA-2019SA020073,-,-
15882937,-,Insulin Glargine\Lixisenatide,-,Disease Progression,Serious,Hospitalized,Male,-,29-JAN-2019,Expedited,79 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-JAN-2019,29-JAN-2019,IL,Not Specified,IL-SA-2019SA019887,-,-
15881501,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Injection Site Urticaria,Non-Serious,Non-Serious,Female,-,28-JAN-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,17-JAN-2019,28-JAN-2019,US,Not Specified,US-SA-2019SA017235,-,-
15880453,Xultophy 100/3.6;Novorapid,Insulin Aspart;Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Cerebrovascular Accident,Serious,Hospitalized,Female,-,28-JAN-2019,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,16-JAN-2019,28-JAN-2019,BR,Not Specified,BR-NOVOPROD-643677,-,-
15879846,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Pruritus;Urticaria,Serious,Hospitalized,Male,18-NOV-2018,28-JAN-2019,Expedited,43 YR,112 KG,Novo Nordisk,Healthcare Professional,Not Specified,Metformin Hydrochloride,16-JAN-2019,28-JAN-2019,IT,Not Specified,IT-NOVOPROD-642660,-,-
15877876,-,Insulin Glargine\Lixisenatide,-,Blood Glucose Abnormal;Feeling Abnormal;Memory Impairment;Impaired Gastric Emptying;Therapeutic Response Unexpected,Serious,Other Outcomes,Male,-,28-JAN-2019,Expedited,53 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,17-JAN-2019,28-JAN-2019,US,Not Specified,US-SA-2019SA019287,-,-
15858618,-,Insulin Glargine\Lixisenatide,-,Hypoglycaemia;Depressed Level Of Consciousness;Blood Glucose Increased;Feeling Abnormal;Nervousness;Nausea;Abnormal Behaviour;Dizziness,Serious,Other Outcomes,Male,11-APR-2018,23-JAN-2019,Expedited,52 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin,11-OCT-2018,23-JAN-2019,US,Not Specified,US-SAKK-2018SA285811AA,-,-
15675633,-,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Chest Injury;Dyspepsia;Blood Glucose Increased;Hyperglycaemia;Fall;Injection Site Pain;Dizziness Postural;Gastrooesophageal Reflux Disease;Muscle Spasms;Fracture;Non-Cardiac Chest Pain,Serious,Other Outcomes,Female,2018,23-JAN-2019,Expedited,83 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-JAN-2019,30-NOV-2018,KR,Not Specified,KR-SA-2018SA281951,-,-
15852127,-,Insulin Glargine\Lixisenatide,-,Myocardial Infarction,Serious,Other Outcomes,Female,14-JAN-2019,22-JAN-2019,Expedited,50 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-JAN-2019,22-JAN-2019,IL,Not Specified,IL-SA-2019SA013167,-,-
15852104,-,Insulin Glargine\Lixisenatide,-,Blood Glucose Increased;Pneumonia,Serious,Hospitalized,Male,01-JAN-2018,22-JAN-2019,Expedited,63 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-JAN-2019,22-JAN-2019,US,Not Specified,US-SA-2019SA013704,-,-
15710827,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Decreased;Malaise;Diarrhoea;Feeling Abnormal;Abdominal Discomfort;Headache;Nausea;Hunger,Non-Serious,Non-Serious,Male,-,22-JAN-2019,Non-Expedited,55 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-JAN-2019,11-DEC-2018,US,Not Specified,US-SA-2018SA335244,-,-
15850034,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Hypersensitivity;Nausea;Abdominal Discomfort;Diarrhoea;Pruritus,Non-Serious,Non-Serious,Female,-,21-JAN-2019,Non-Expedited,51 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,11-JAN-2019,21-JAN-2019,US,Not Specified,US-SA-2019SA010653,-,-
15849290,-,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Cyst;Diarrhoea;Glucose Urine;Malaise;Abdominal Pain;Disease Progression;Nausea;Nephrolithiasis;Dysuria,Serious,Other Outcomes,Female,-,21-JAN-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin,14-JAN-2019,21-JAN-2019,IL,Not Specified,IL-SA-2019SA013105,-,-
15844192,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Rash;Hypersensitivity,Non-Serious,Non-Serious,Female,-,18-JAN-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,10-JAN-2019,18-JAN-2019,US,Not Specified,US-SA-2019SA010790,-,-
15844178,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Abdominal Discomfort;Pruritus;Hypersensitivity,Non-Serious,Non-Serious,Female,-,18-JAN-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-JAN-2019,18-JAN-2019,US,Not Specified,US-SA-2019SA012840,-,-
15768063,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Hypersensitivity;Respiratory Disorder;Dyspnoea;Peripheral Swelling;Paraesthesia,Serious,Other Outcomes,Male,-,18-JAN-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,07-JAN-2019,27-DEC-2018,CH,Not Specified,CH-SA-2018SA390006,-,-
15827348,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Intentional Product Use Issue;Nausea;Vomiting,Non-Serious,Non-Serious,Female,-,15-JAN-2019,Non-Expedited,65 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,09-JAN-2019,15-JAN-2019,US,Not Specified,US-SA-2019SA009583,-,-
15822938,-,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Abdominal Pain Upper;Abdominal Distension;Ejection Fraction Decreased;Hypersensitivity;Heart Rate Decreased;Glycosylated Haemoglobin Decreased;Expired Product Administered;Weight Increased;Urticaria;Abdominal Discomfort,Serious,Other Outcomes;Hospitalized,Female,-,14-JAN-2019,Expedited,62 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-JAN-2019,14-JAN-2019,US,Not Specified,US-SA-2019SA008832,-,-
15820756,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Abdominal Pain Lower;Diarrhoea,Non-Serious,Non-Serious,Male,-,14-JAN-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-JAN-2019,14-JAN-2019,US,Not Specified,US-SA-2019SA008138,-,-
15820723,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Male,-,14-JAN-2019,Non-Expedited,69 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-JAN-2019,14-JAN-2019,US,Not Specified,US-SA-2019SA007277,-,-
15681231,-,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Injection Site Pain;Rib Fracture;Hyperglycaemia,Serious,Hospitalized,Male,NOV-2018,14-JAN-2019,Expedited,57 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-DEC-2018,03-DEC-2018,KR,Not Specified,KR-SAKK-2018SA323004AA,-,-
15814884,Xultophy 100/3.6,Ramipril;Insulin Degludec\Liraglutide;Furosemide,Hypertension;Oedema;Type 2 Diabetes Mellitus,Tongue Oedema;Renal Tubular Necrosis,Serious,Hospitalized,Male,22-JAN-2018,11-JAN-2019,Expedited,62 YR,94 KG,Accord,Healthcare Professional,Not Specified,Metformin;Bisoprolol Fumarate;Kardegic,01-JAN-2019,11-JAN-2019,FR,Not Specified,FR-ACCORD-101223,-,-
15812646,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Pancreatitis,Serious,Other Outcomes,Female,-,11-JAN-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,03-JAN-2019,11-JAN-2019,US,Not Specified,US-SA-2019SA005996,-,-
15807717,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Pancreatic Neoplasm,Serious,Other Outcomes,Male,-,10-JAN-2019,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,07-JAN-2019,10-JAN-2019,IL,Not Specified,IL-NOVOPROD-641365,-,-
15807572,Competact;Victoza,Liraglutide;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Abdominal Pain;Drug-Induced Liver Injury;Jaundice,Serious,Other Outcomes,Male,02-DEC-2018,10-JAN-2019,Expedited,58 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,04-JAN-2019,10-JAN-2019,IT,Not Specified,IT-NOVOPROD-641059,-,-
15804643,Competact;Victoza,Liraglutide;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Jaundice;Drug-Induced Liver Injury;Abdominal Pain,Serious,Other Outcomes,Male,02-DEC-2018,09-JAN-2019,Expedited,58 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,-,07-JAN-2019,09-JAN-2019,IT,Not Specified,IT-TAKEDA-2019TEU000169,-,-
15798332,-,Insulin Glargine\Lixisenatide,-,Blood Glucose Increased;Vascular Graft,Serious,Other Outcomes,Female,24-DEC-2018,08-JAN-2019,Expedited,52 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Humalog,02-JAN-2019,08-JAN-2019,US,Not Specified,US-SA-2019SA003159,-,-
15795231,Xultophy 100/3.6,Insulin Degludec\Liraglutide;Pravastatin,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Stress;Rash Pruritic;Diarrhoea;Pyrexia;Skin Haemorrhage;Dyspnoea;Migraine;Eye Swelling;Swelling Face;Blood Glucose Increased,Serious,Hospitalized,Female,DEC-2018,07-JAN-2019,Expedited,58 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,27-DEC-2018,07-JAN-2019,US,Not Specified,US-NOVOPROD-640425,-,-
15794011,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Sleep Terror,Non-Serious,Non-Serious,Male,-,07-JAN-2019,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,02-JAN-2019,07-JAN-2019,US,Not Specified,US-SA-2019SA002364,-,-
15790178,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Operational Issue,Non-Serious,Non-Serious,Female,-,04-JAN-2019,Non-Expedited,64 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,31-DEC-2018,04-JAN-2019,US,Not Specified,US-SA-2019SA000945,-,-
15790163,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Abnormal;Product Physical Issue;Device Operational Issue,Non-Serious,Non-Serious,Male,-,04-JAN-2019,Non-Expedited,53 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-DEC-2018,04-JAN-2019,US,Not Specified,US-SA-2019SA000679,-,-
15607264,-,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Abdominal Pain Upper,Serious,Hospitalized,Female,11-SEP-2018,04-JAN-2019,Expedited,71 YR,66 KG,Novo Nordisk,Healthcare Professional,Not Specified,Metformin;Gliclazide,21-DEC-2018,12-NOV-2018,CN,Not Specified,CN-NOVOPROD-630695,-,-
15787354,-,Insulin Glargine\Lixisenatide,Abdominal Discomfort;Hypertension;Hypothyroidism;Type 2 Diabetes Mellitus,Weight Decreased;Erysipelas;Pyrexia;Liver Disorder;Illness;Vision Blurred;Muscle Spasms;Malaise,Serious,Other Outcomes,Female,-,03-JAN-2019,Expedited,67 YR,95 KG,Sanofi Aventis,Consumer,Not Specified,Apidra;Amlodipine;Omeprazole;Levothyroxine,13-DEC-2018,03-JAN-2019,BR,Not Specified,BR-SA-2018SA387402,-,-
15785783,Soliqua 100/33,Insulin Glargine\Lixisenatide,Arteriosclerosis;Diabetes Mellitus;Hypertension,Tongue Cancer Recurrent;Hyperglycaemia;Off Label Use,Serious,Other Outcomes,Male,SEP-2018,03-JAN-2019,Expedited,63 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Livalo;Hydrochlorothiazide\Telmisartan,19-NOV-2018,03-JAN-2019,KR,Not Specified,KR-SA-2018SA319104,-,-
15783481,-,Insulin Glargine\Lixisenatide,Diabetes Mellitus;Hypertension;Type 2 Diabetes Mellitus,Metabolic Surgery;Product Storage Error;Nail Bed Bleeding;Nail Operation;Weight Decreased,Serious,Other Outcomes,Male,JUN-2018,02-JAN-2019,Expedited,59 YR,108 KG,Sanofi Aventis,Consumer,Not Specified,Aspirin;Glifage;Losartan Potassium,19-DEC-2018,02-JAN-2019,BR,Not Specified,BR-SA-2018SA393429,-,-
15781341,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Weight Decreased;Product Dose Omission Issue,Non-Serious,Non-Serious,Male,-,02-JAN-2019,Non-Expedited,65 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-DEC-2018,02-JAN-2019,US,Not Specified,US-SA-2018SA396572,-,-
15740954,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Night Blindness;Product Storage Error;Tremor;Blood Glucose Fluctuation;Hypoglycaemia;Asthenia;Arrhythmia;Abdominal Pain Upper;Injection Site Pain;Illness;Product Use Issue,Serious,Other Outcomes,Female,17-OCT-2018,02-JAN-2019,Expedited,48 YR,62 KG,Sanofi Aventis,Consumer,Not Specified,-,13-DEC-2018,19-DEC-2018,BR,Not Specified,BR-SA-2018SA340396,-,-
15603033,Soliqua 100/33,Insulin Glargine\Lixisenatide,Product Used For Unknown Indication,Vomiting,Non-Serious,Non-Serious,Female,31-OCT-2018,02-JAN-2019,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,01-NOV-2018,09-NOV-2018,RO,Not Specified,RO-SA-2018SA304488,-,-
14694209,-,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Diarrhoea,Serious,Hospitalized,Male,10-MAR-2018,31-DEC-2018,Expedited,63 YR,74 KG,Novo Nordisk,Healthcare Professional,Not Specified,Metformin Hydrochloride;Humulin Nos;Insulin Glargine Recombinant;Levemir,21-DEC-2018,29-MAR-2018,CN,Not Specified,CN-NOVOPROD-591920,-,-
15772575,Soliqua 100/33;Toujeo;Apidra,Insulin Glulisine;Insulin Glargine;Insulin Glargine\Lixisenatide,Blood Glucose;Diabetes Mellitus Management,Off Label Use;Drug Ineffective,Non-Serious,Non-Serious,Female,-,28-DEC-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,19-DEC-2018,28-DEC-2018,US,Not Specified,US-SA-2018SA394847,-,-
15771871,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Drug Ineffective,Non-Serious,Non-Serious,Male,-,28-DEC-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,19-DEC-2018,28-DEC-2018,US,Not Specified,US-SA-2018SA393424,-,-
15771176,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Intentional Dose Omission;Intentional Product Misuse;Product Storage Error;Injection Site Pain;Wrong Product Administered;Weight Increased;Starvation;Blood Glucose Increased,Serious,Other Outcomes,Female,18-NOV-2018,28-DEC-2018,Expedited,70 YR,69 KG,Sanofi Aventis,Consumer,Not Specified,Glifage;Dapagliflozin,26-OCT-2018,28-DEC-2018,BR,Not Specified,BR-SA-2018SA299277,-,-
15765394,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Device Operational Issue,Non-Serious,Non-Serious,Female,-,28-DEC-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-DEC-2018,27-DEC-2018,US,Not Specified,US-SA-2018SA392510,-,-
15767083,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Pancreatic Neuroendocrine Tumour,Serious,Other Outcomes,Female,-,27-DEC-2018,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Tresiba,22-NOV-2018,27-DEC-2018,FR,Not Specified,FR-NOVOPROD-639974,-,-
15690841,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment;Blood Glucose Increased;Inability To Afford Medication;Blood Glucose Decreased;Intentional Product Use Issue,Serious,Other Outcomes,Male,-,27-DEC-2018,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,14-DEC-2018,05-DEC-2018,US,Not Specified,US-SA-2018SA325693,-,-
15651494,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Operational Issue;Device Delivery System Issue,Non-Serious,Non-Serious,Female,-,27-DEC-2018,Non-Expedited,68 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-NOV-2018,23-NOV-2018,US,Not Specified,US-SA-2018SA320837,-,-
15752356,Trulicity;Metformin;Ferinject;Tresiba;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Insulin Degludec;Ferric Carboxymaltose;Metformin Hydrochloride;Dulaglutide,-,Exposure During Pregnancy;Pre-Eclampsia,Serious,Other Outcomes,Female,06-JAN-2018,21-DEC-2018,Expedited,34 YR,Not Specified,American Regent,Healthcare Professional,Not Specified,Lantus,18-DEC-2018,21-DEC-2018,CH,Not Specified,CH-LPDUSPRD-20182419,-,-
15752349,Metformin;Xultophy 100/3.6;Ferinject;Trulicity;Tresiba,Insulin Degludec;Dulaglutide;Ferric Carboxymaltose;Insulin Degludec\Liraglutide;Metformin Hydrochloride,-,Premature Baby;Foetal Exposure During Pregnancy,Serious,Other Outcomes,Male,06-JAN-2018,21-DEC-2018,Expedited,0 YR,2.71 KG,American Regent,Healthcare Professional,Not Specified,Lantus,20-DEC-2018,21-DEC-2018,CH,Not Specified,CH-LPDUSPRD-20182436,-,-
15746504,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Male,-,21-DEC-2018,Non-Expedited,62 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-DEC-2018,20-DEC-2018,US,Not Specified,US-SA-2018SA343925,-,-
15746496,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Device Operational Issue;Product Use Complaint,Non-Serious,Non-Serious,Male,-,21-DEC-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-DEC-2018,20-DEC-2018,US,Not Specified,US-SA-2018SA344198,-,-
15744343,Metformin;Tresiba;Ferinject;Trulicity;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Dulaglutide;Insulin Degludec;Ferric Carboxymaltose;Metformin Hydrochloride,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Premature Baby;Foetal Exposure During Pregnancy,Serious,Other Outcomes,Not Specified,-,20-DEC-2018,Expedited,Not Specified,2.71 KG,Eli Lilly And Co,Healthcare Professional,Not Specified,Lantus,10-DEC-2018,20-DEC-2018,CH,Not Specified,CH-ELI_LILLY_AND_COMPANY-CH201812005883,-,-
15744340,Tresiba;Ferinject;Trulicity;Xultophy 100/3.6;Metformin,Metformin Hydrochloride;Insulin Degludec\Liraglutide;Dulaglutide;Ferric Carboxymaltose;Insulin Degludec,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Pre-Eclampsia;Maternal Exposure During Pregnancy,Serious,Other Outcomes,Female,-,20-DEC-2018,Expedited,Not Specified,2.71 KG,Eli Lilly And Co,Healthcare Professional,Not Specified,Lantus,10-DEC-2018,20-DEC-2018,CH,Not Specified,CH-ELI_LILLY_AND_COMPANY-CH201812005941,-,-
15741547,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Incorrect Dose Administered;Device Operational Issue,Non-Serious,Non-Serious,Male,-,20-DEC-2018,Non-Expedited,61 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-DEC-2018,19-DEC-2018,US,Not Specified,US-SA-2018SA344601,-,-
15741509,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error;Device Breakage,Non-Serious,Non-Serious,Female,-,20-DEC-2018,Non-Expedited,62 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-DEC-2018,19-DEC-2018,US,Not Specified,US-SA-2018SA344451,-,-
15741825,Trulicity;Ferinject;Tresiba;Metformin;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Metformin Hydrochloride;Insulin Degludec;Ferric Carboxymaltose;Dulaglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Foetal Exposure During Pregnancy;Premature Baby,Serious,Other Outcomes,Male,23-DEC-2017,19-DEC-2018,Expedited,Not Specified,2.71 KG,Novo Nordisk,Healthcare Professional,Not Specified,Lantus,10-DEC-2018,19-DEC-2018,CH,Not Specified,CH-NOVOPROD-637919,-,-
15736511,Xultophy 100/3.6;Metformin;Ferinject;Trulicity;Tresiba,Insulin Degludec;Dulaglutide;Ferric Carboxymaltose;Metformin Hydrochloride;Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Off Label Use;Premature Delivery;Pre-Eclampsia;Exposure During Pregnancy,Serious,Other Outcomes,Female,16-FEB-2018,18-DEC-2018,Expedited,35 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Lantus,10-DEC-2018,18-DEC-2018,CH,Not Specified,CH-NOVOPROD-637850,-,-
15731018,Xultophy 100/3.6,Insulin Degludec\Liraglutide;Drospirenone\Ethinyl Estradiol;Dapagliflozin;Cyproterone,Product Used For Unknown Indication,Drug-Induced Liver Injury,Serious,Other Outcomes,Female,07-DEC-2018,17-DEC-2018,Expedited,30 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,09-DEC-2018,17-DEC-2018,BR,Not Specified,BR-NOVOPROD-638160,-,-
15730616,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Device Operational Issue,Non-Serious,Non-Serious,Male,-,17-DEC-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-DEC-2018,17-DEC-2018,US,Not Specified,US-SA-2018SA339805,-,-
15723522,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Pancreatitis Chronic;Lipase Increased;Pancreatitis Acute,Serious,Disabled;Hospitalized,Male,-,14-DEC-2018,Non-Expedited,73 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,07-DEC-2018,14-DEC-2018,US,Not Specified,US-SA-2018SA339315,-,-
15723444,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Constipation,Non-Serious,Non-Serious,Not Specified,-,14-DEC-2018,Non-Expedited,49 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,07-DEC-2018,14-DEC-2018,US,Not Specified,US-SA-2018SA339522,-,-
15722333,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Arrhythmia,Serious,Other Outcomes,Female,-,14-DEC-2018,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,05-DEC-2018,14-DEC-2018,BR,Not Specified,BR-NOVOPROD-637280,-,-
15574878,Soliqua 100/33,Insulin Glargine\Lixisenatide,Product Used For Unknown Indication,Muscle Spasms,Non-Serious,Non-Serious,Male,25-APR-2018,12-DEC-2018,Non-Expedited,56 YR,102.5 KG,Sanofi Aventis,Healthcare Professional,Not Specified,-,03-DEC-2018,01-NOV-2018,US,Not Specified,US-SA-2018SA300649,-,-
15710688,-,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Abdominal Pain Upper;Diarrhoea;Pancreatitis,Serious,Hospitalized,Male,-,11-DEC-2018,Expedited,56 YR,110 KG,Sanofi Aventis,Healthcare Professional,Not Specified,Metformin;Toujeo,28-NOV-2018,11-DEC-2018,NL,Not Specified,NL-SAKK-2018SA328376AA,-,-
15561857,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Issue;Blood Glucose Abnormal,Non-Serious,Non-Serious,Male,-,10-DEC-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-NOV-2018,29-OCT-2018,US,Not Specified,US-SA-2018SA259845,-,-
15697408,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Nausea,Non-Serious,Non-Serious,Male,-,07-DEC-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,19-NOV-2018,07-DEC-2018,US,Not Specified,US-NOVOPROD-634355,-,-
15697388,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Neck Mass;Arthralgia,Non-Serious,Non-Serious,Female,-,07-DEC-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,29-OCT-2018,07-DEC-2018,US,Not Specified,US-NOVOPROD-630172,-,-
15695115,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Hypoaesthesia,Non-Serious,Non-Serious,Female,SEP-2018,06-DEC-2018,Non-Expedited,71 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,11-SEP-2018,06-DEC-2018,US,Not Specified,US-NOVOPROD-621454,-,-
15695114,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Vomiting;Expired Product Administered,Non-Serious,Non-Serious,Male,-,06-DEC-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,07-SEP-2018,06-DEC-2018,US,Not Specified,US-NOVOPROD-621655,-,-
15695112,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Inappropriate Schedule Of Product Administration;Blood Glucose Increased;Weight Decreased;Decreased Appetite,Non-Serious,Non-Serious,Female,-,06-DEC-2018,Non-Expedited,51 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,26-SEP-2018,06-DEC-2018,US,Not Specified,US-NOVOPROD-624154,-,-
15695101,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Injection Site Urticaria,Non-Serious,Non-Serious,Male,-,06-DEC-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,27-SEP-2018,06-DEC-2018,US,Not Specified,US-NOVOPROD-624421,-,-
15695100,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Injection Site Urticaria,Non-Serious,Non-Serious,Male,-,06-DEC-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,27-SEP-2018,06-DEC-2018,US,Not Specified,US-NOVOPROD-624422,-,-
15695099,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Depressed Mood;Chromaturia;Diarrhoea;Abdominal Discomfort;Somnolence;Rash Pruritic;Fatigue,Non-Serious,Non-Serious,Female,29-JUL-2018,06-DEC-2018,Non-Expedited,64 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,18-SEP-2018,06-DEC-2018,US,Not Specified,US-NOVOPROD-622828,-,-
15695095,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Nausea;Blood Glucose Increased;Discomfort;Decreased Appetite,Non-Serious,Non-Serious,Male,SEP-2018,06-DEC-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,01-OCT-2018,06-DEC-2018,US,Not Specified,US-NOVOPROD-625041,-,-
15695079,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Nasopharyngitis,Non-Serious,Non-Serious,Female,OCT-2018,06-DEC-2018,Non-Expedited,68 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,24-OCT-2018,06-DEC-2018,US,Not Specified,US-NOVOPROD-629480,-,-
15695078,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Accidental Underdose,Non-Serious,Non-Serious,Female,-,06-DEC-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,08-OCT-2018,06-DEC-2018,US,Not Specified,US-NOVOPROD-626898,-,-
15695077,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Expired Product Administered;Blood Glucose Increased,Non-Serious,Non-Serious,Female,OCT-2018,06-DEC-2018,Non-Expedited,71 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,17-OCT-2018,06-DEC-2018,US,Not Specified,US-NOVOPROD-627919,-,-
15695076,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Hyperhidrosis;Confusional State;Dizziness;Decreased Appetite;Nausea,Non-Serious,Non-Serious,Female,22-OCT-2018,06-DEC-2018,Non-Expedited,63 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,22-OCT-2018,06-DEC-2018,US,Not Specified,US-NOVOPROD-628912,-,-
15695075,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Diarrhoea,Non-Serious,Non-Serious,Female,05-OCT-2018,06-DEC-2018,Non-Expedited,52 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,10-OCT-2018,06-DEC-2018,US,Not Specified,US-NOVOPROD-627207,-,-
15695074,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Therapeutic Response Delayed;Diabetes Mellitus Inadequate Control,Non-Serious,Non-Serious,Male,-,06-DEC-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,01-OCT-2018,06-DEC-2018,US,Not Specified,US-NOVOPROD-624783,-,-
15695073,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Glycosylated Haemoglobin Increased;Blood Glucose Increased,Non-Serious,Non-Serious,Male,2018,06-DEC-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,15-OCT-2018,06-DEC-2018,US,Not Specified,US-NOVOPROD-627920,-,-
15695072,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Nausea,Non-Serious,Non-Serious,Female,-,06-DEC-2018,Non-Expedited,33 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,31-AUG-2018,06-DEC-2018,US,Not Specified,US-NOVOPROD-619940,-,-
15695071,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Nausea;Malaise,Non-Serious,Non-Serious,Male,-,06-DEC-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,12-NOV-2018,06-DEC-2018,US,Not Specified,US-NOVOPROD-633535,-,-
15695070,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Circumstance Or Information Capable Of Leading To Medication Error,Non-Serious,Non-Serious,Female,-,06-DEC-2018,Non-Expedited,73 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,06-SEP-2018,06-DEC-2018,US,Not Specified,US-NOVOPROD-620358,-,-
15695061,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Nausea,Non-Serious,Non-Serious,Male,-,06-DEC-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,08-NOV-2018,06-DEC-2018,US,Not Specified,US-NOVOPROD-632140,-,-
15695060,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Diarrhoea,Non-Serious,Non-Serious,Female,2017,06-DEC-2018,Non-Expedited,64 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,24-AUG-2018,06-DEC-2018,US,Not Specified,US-NOVOPROD-618729,-,-
15358703,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Pruritus;Nausea,Non-Serious,Non-Serious,Female,JUN-2018,06-DEC-2018,Non-Expedited,62 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,18-SEP-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-617190,-,-
15358700,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Dizziness;Nausea;Decreased Appetite,Non-Serious,Non-Serious,Male,2018,06-DEC-2018,Non-Expedited,47 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,11-SEP-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-615769,-,-
15358688,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Rash,Non-Serious,Non-Serious,Female,06-JUN-2018,06-DEC-2018,Non-Expedited,45 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,06-SEP-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-614701,-,-
15358687,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Blood Glucose Decreased,Non-Serious,Non-Serious,Female,03-AUG-2018,06-DEC-2018,Non-Expedited,72 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,10-SEP-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-615464,-,-
15358685,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Expired Product Administered;Blood Glucose Increased,Non-Serious,Non-Serious,Female,13-JUL-2018,06-DEC-2018,Non-Expedited,58 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,28-AUG-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-612711,-,-
15358684,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Drug Ineffective;Blood Glucose Increased,Non-Serious,Non-Serious,Male,JUN-2018,06-DEC-2018,Non-Expedited,73 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,Novolog,04-OCT-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-612494,-,-
15248366,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Dose Omission Issue;Hypoacusis;Tremor;Memory Impairment;Injection Site Haemorrhage;Incorrect Dose Administered,Non-Serious,Non-Serious,Male,-,06-DEC-2018,Non-Expedited,78 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-NOV-2018,07-AUG-2018,US,Not Specified,US-SA-2018SA207230,-,-
15691742,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Thyroid Neoplasm,Serious,Other Outcomes,Female,-,05-DEC-2018,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,26-NOV-2018,05-DEC-2018,US,Not Specified,US-NOVOPROD-635134,-,-
15690821,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Packaging Quantity Issue;Blood Glucose Increased;Intentional Product Use Issue,Non-Serious,Non-Serious,Male,-,05-DEC-2018,Non-Expedited,65 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-NOV-2018,05-DEC-2018,US,Not Specified,US-SA-2018SA325711,-,-
15690303,-,Insulin Glargine\Lixisenatide,-,Dyspnoea;Limb Operation;Off Label Use;Weight Decreased;Glycosylated Haemoglobin Increased,Serious,Other Outcomes,Male,01-APR-2018,05-DEC-2018,Expedited,57 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-SEP-2018,05-DEC-2018,US,Not Specified,US-SAKK-2018SA266159AA,-,-
14905397,-,Insulin Glargine;Insulin Glargine\Lixisenatide,Diabetes Mellitus;Type 2 Diabetes Mellitus,Oxygen Saturation Decreased;Tremor;Cataract;Memory Impairment;Hypoacusis;Glycosylated Haemoglobin Increased,Serious,Other Outcomes,Male,2017,05-DEC-2018,Expedited,78 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-NOV-2018,17-MAY-2018,US,Not Specified,US-SA-2018SA001089,-,-
15685979,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Hypoglycaemia,Non-Serious,Non-Serious,Male,-,04-DEC-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-NOV-2018,04-DEC-2018,US,Not Specified,US-SA-2018SA326777,-,-
15633802,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Loss Of Consciousness,Serious,Other Outcomes,Male,29-SEP-2018,03-DEC-2018,Non-Expedited,78 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,13-NOV-2018,19-NOV-2018,US,Not Specified,US-SA-2018SA315916,-,-
15468693,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Fluctuation;Depressed Mood;Diabetic Coma;Blood Glucose Abnormal;Abdominal Pain;Swelling;Weight Decreased;Blood Glucose Increased;Malaise;Drug Ineffective;Hyperglycaemia;Intentional Product Misuse,Serious,Other Outcomes,Female,23-AUG-2018,03-DEC-2018,Expedited,64 YR,64 KG,Sanofi Aventis,Consumer,Not Specified,-,22-NOV-2018,05-OCT-2018,BR,Not Specified,BR-SAKK-2018SA244639AA,-,-
15665073,Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injection Site Pain;Blood Glucose Increased;Nausea;Impaired Gastric Emptying;Feeding Disorder,Serious,Other Outcomes,Female,29-JAN-2018,30-NOV-2018,Expedited,57 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-MAY-2018,28-NOV-2018,US,Not Specified,US-SA-2018SA054954,-,-
14279861,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Erysipelas;Hypertension;Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Hypoglycaemia;Acute Kidney Injury;Tubulointerstitial Nephritis;Abdominal Pain;Blood Glucose Fluctuation,Serious,Hospitalized;Other Outcomes,Female,02-OCT-2017,30-NOV-2018,Expedited,57 YR,145 KG,Novo Nordisk,Healthcare Professional,Not Specified,Insulin Human;Metformin Hydrochloride;Flucloxacillin;Crestor;Enalapril;Cholecalciferol;Hydrochlorothiazide;Rosuvastatin,23-NOV-2018,12-DEC-2017,NL,Not Specified,NL-NOVOPROD-575953,M.F. Schmitz et.al. Reversible acute kidney failure induced by liraglutide. Annual Meeting of the Netherlands Association of Internal Medicine. 2018;30,-
15673227,Novolin R;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Insulin Human,Diabetes Mellitus;Hypothyroidism;Product Used For Unknown Indication,Postoperative Wound Infection,Serious,Other Outcomes,Female,2018,29-NOV-2018,Expedited,Not Specified,88 KG,Novo Nordisk,Consumer,Not Specified,Furosemide;Jardiance;Levothyroxine,19-NOV-2018,29-NOV-2018,BR,Not Specified,BR-NOVOPROD-634853,-,-
15670598,-,Insulin Glargine\Lixisenatide,Blood Cholesterol Increased;Diabetes Mellitus;Type 2 Diabetes Mellitus,Positive Airway Pressure Therapy;Extra Dose Administered;Cyst;Back Pain;Blood Glucose Increased;Decreased Appetite;Product Administered At Inappropriate Site;Depression;Overweight,Serious,Other Outcomes,Male,MAY-2018,29-NOV-2018,Expedited,62 YR,106 KG,Sanofi Aventis,Consumer,Not Specified,Pravastatin;Synthroid;Fenofibrate;Metformin;Enalapril,14-MAY-2018,29-NOV-2018,US,Not Specified,US-SAKK-2018SA138426AA,-,-
15670596,Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Glargine,Diabetes Mellitus,Drug Ineffective;Pancreatitis,Serious,Other Outcomes,Male,-,29-NOV-2018,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Toujeo,27-JUL-2018,29-NOV-2018,US,Not Specified,US-SA-2018SA209939,-,-
15670216,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Decreased;Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,29-NOV-2018,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-NOV-2018,29-NOV-2018,US,Not Specified,US-SA-2018SA324964,-,-
15670203,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Quality Issue,Serious,Other Outcomes,Female,-,29-NOV-2018,Non-Expedited,63 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-JUL-2018,29-NOV-2018,US,Not Specified,US-SA-2018SA192087,-,-
15111301,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Pancreatitis,Serious,Other Outcomes,Not Specified,-,29-NOV-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,05-JUN-2018,05-JUL-2018,US,Not Specified,US-SA-2018SA177757,-,-
14955550,Soliqua 100/33,Insulin Glargine\Lixisenatide,Product Used For Unknown Indication,Rash,Non-Serious,Non-Serious,Not Specified,-,29-NOV-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,25-MAY-2018,31-MAY-2018,US,Not Specified,US-SA-2018SA145555,-,-
14946312,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Product Use Issue;Headache;Blood Glucose Decreased;Abdominal Pain;Diarrhoea;Dyspepsia,Non-Serious,Non-Serious,Female,14-MAY-2018,29-NOV-2018,Non-Expedited,84 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Insulin Nos;Warfarin;Simvastatin,15-JUN-2018,29-MAY-2018,US,Not Specified,US-SA-2018SA144281,-,-
15663081,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Glycosylated Haemoglobin Increased;Hypoglycaemia,Non-Serious,Non-Serious,Female,31-OCT-2018,27-NOV-2018,Non-Expedited,63 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,21-NOV-2018,27-NOV-2018,US,Not Specified,US-SA-2018SA322697,-,-
15659030,-,Insulin Glargine\Lixisenatide,Diabetes Mellitus;Type 2 Diabetes Mellitus,Malaise;Headache;Hypoglycaemia;Distractibility;Fatigue;Loss Of Consciousness;Vomiting;Product Use Issue;Dyspepsia,Serious,Other Outcomes,Female,10-SEP-2018,27-NOV-2018,Expedited,62 YR,72 KG,Sanofi Aventis,Consumer,Not Specified,Januvia;Novorapid,20-SEP-2018,27-NOV-2018,BR,Not Specified,BR-SA-2018SA265434,-,-
15366219,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Myocardial Infarction,Serious,Other Outcomes,Male,26-JUN-2017,27-NOV-2018,Expedited,51 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-AUG-2018,10-SEP-2018,US,Not Specified,US-SA-2018SA244005,-,-
15657988,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Myocardial Infarction,Serious,Hospitalized,Male,-,26-NOV-2018,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,14-NOV-2018,26-NOV-2018,US,Not Specified,US-SA-2018SA316419,-,-
15653163,Novolog;Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Aspart,Product Used For Unknown Indication,Ill-Defined Disorder;Cervical Radiculopathy,Non-Serious,Non-Serious,Female,-,23-NOV-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,30-AUG-2018,23-NOV-2018,US,Not Specified,US-NOVOPROD-619602,-,-
15653028,Novolog;Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Aspart,Product Used For Unknown Indication,Blood Glucose Increased;Malaise,Non-Serious,Non-Serious,Male,-,23-NOV-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,07-JUN-2018,23-NOV-2018,US,Not Specified,US-NOVOPROD-605439,-,-
15647558,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Injection Site Discharge,Non-Serious,Non-Serious,Male,-,22-NOV-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,13-NOV-2018,22-NOV-2018,US,Not Specified,US-SA-2018SA315928,-,-
15647550,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Rash,Non-Serious,Non-Serious,Not Specified,-,22-NOV-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,14-NOV-2018,22-NOV-2018,US,Not Specified,US-SA-2018SA317036,-,-
15644121,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Blood Triglycerides Increased;Abdominal Pain Upper,Serious,Other Outcomes,Female,2018,21-NOV-2018,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,13-NOV-2018,21-NOV-2018,US,Not Specified,US-NOVOPROD-632882,-,-
15643236,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Wrong Technique In Product Usage Process;Device Issue,Non-Serious,Non-Serious,Female,-,21-NOV-2018,Non-Expedited,59 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-NOV-2018,21-NOV-2018,US,Not Specified,US-SA-2018SA314494,-,-
15643213,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Therapeutic Response Decreased,Non-Serious,Non-Serious,Not Specified,-,21-NOV-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,14-NOV-2018,21-NOV-2018,US,Not Specified,US-SA-2018SA317051,-,-
15640700,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Dose Omission Issue;Pain;Product Storage Error;Hypoglycaemic Seizure;Injection Site Swelling;Burning Sensation;Injection Site Mass;Weight Decreased;Hypoglycaemia,Serious,Other Outcomes;Hospitalized,Female,11-JAN-2017,20-NOV-2018,Expedited,55 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-MAY-2018,20-NOV-2018,US,Not Specified,US-SA-2018SA146257,-,-
15633825,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Increased,Non-Serious,Non-Serious,Not Specified,-,19-NOV-2018,Non-Expedited,59 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Janumet;Basaglar,13-NOV-2018,19-NOV-2018,US,Not Specified,US-SA-2018SA315588,-,-
15633426,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Urine Output Decreased;Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,19-NOV-2018,Non-Expedited,68 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-NOV-2018,19-NOV-2018,US,Not Specified,US-SA-2018SA311536,-,-
15626252,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Nausea,Non-Serious,Non-Serious,Male,-,16-NOV-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,08-NOV-2018,16-NOV-2018,US,Not Specified,US-SA-2018SA311535,-,-
15061685,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Multiple Organ Dysfunction Syndrome;Metastatic Carcinoma Of The Bladder,Serious,Other Outcomes;Died,Not Specified,DEC-2017,16-NOV-2018,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,-,09-NOV-2018,25-JUN-2018,US,Not Specified,US-TAKEDA-2018TUS020542,-,-
15622257,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Neuropathy Peripheral,Serious,Other Outcomes,Male,-,15-NOV-2018,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,08-AUG-2018,15-NOV-2018,GB,Not Specified,GB-NOVOPROD-632520,-,-
15621272,-,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Inappropriate Schedule Of Product Administration;Hypoglycaemia;Cystitis,Serious,Hospitalized,Female,27-SEP-2018,15-NOV-2018,Expedited,69 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,06-NOV-2018,15-NOV-2018,KR,Not Specified,KR-SAKK-2018SA307668AA,-,-
15619201,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Eye Disorder;Visual Impairment;Retinopathy;Blood Glucose Increased,Serious,Other Outcomes,Male,2017,14-NOV-2018,Non-Expedited,29 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,06-NOV-2018,14-NOV-2018,US,Not Specified,US-SA-2018SA307618,-,-
15616967,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Pancreatic Carcinoma,Serious,Died,Male,-,14-NOV-2018,Expedited,64 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,08-NOV-2018,14-NOV-2018,IL,Not Specified,IL-NOVOPROD-631761,-,-
15612045,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Off Label Use;Device Issue,Non-Serious,Non-Serious,Female,-,13-NOV-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,06-NOV-2018,13-NOV-2018,US,Not Specified,US-SA-2018SA309113,-,-
15594789,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Female,-,13-NOV-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-OCT-2018,06-NOV-2018,US,Not Specified,US-SA-2018SA302322,-,-
15608770,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Anaphylactic Reaction,Serious,Other Outcomes,Female,-,12-NOV-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,02-NOV-2018,12-NOV-2018,US,Not Specified,US-SA-2018SA307634,-,-
15596143,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,07-NOV-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,01-NOV-2018,07-NOV-2018,US,Not Specified,US-SA-2018SA305280,-,-
15594669,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Needle Issue;Chest Pain;Device Operational Issue;Product Storage Error;Pain In Extremity;Fatigue,Non-Serious,Non-Serious,Male,-,06-NOV-2018,Non-Expedited,49 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-OCT-2018,06-NOV-2018,US,Not Specified,US-SA-2018SA302389,-,-
15585832,Soliqua 100/33;Lantus,Insulin Glargine;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Quality Issue;Cataract Operation;Product Dose Omission Issue,Serious,Other Outcomes,Male,08-OCT-2017,05-NOV-2018,Expedited,75 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,24-OCT-2018,05-NOV-2018,US,Not Specified,US-SAKK-2018SA296653AA,-,-
15584491,Soliqua 100/33;Lantus;Toujeo,Insulin Glargine;Insulin Glargine;Insulin Glargine\Lixisenatide,-,Pain;Burning Sensation,Non-Serious,Non-Serious,Not Specified,-,05-NOV-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-OCT-2018,05-NOV-2018,US,Not Specified,US-SA-2018SA302266,-,-
15584450,Lantus;Toujeo;Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Glargine;Insulin Glargine,-,Pain;Injection Site Pain,Non-Serious,Non-Serious,Not Specified,-,05-NOV-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-OCT-2018,05-NOV-2018,US,Not Specified,US-SA-2018SA302432,-,-
15579393,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Loss Of Consciousness;Laryngitis;Dyspnoea;Anaphylactic Shock;Pruritus,Serious,Hospitalized;Life Threatening,Male,-,02-NOV-2018,Expedited,61 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Influenza Virus Vaccine,24-OCT-2018,02-NOV-2018,IL,Not Specified,IL-SAKK-2018SA297673AA,-,-
15565213,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Operational Issue;Incorrect Dose Administered;Device Issue,Non-Serious,Non-Serious,Female,-,30-OCT-2018,Non-Expedited,53 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-OCT-2018,30-OCT-2018,US,Not Specified,US-SA-2018SA296470,-,-
15565180,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Incorrect Dose Administered By Device;Device Operational Issue,Non-Serious,Non-Serious,Male,-,30-OCT-2018,Non-Expedited,69 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,22-OCT-2018,30-OCT-2018,US,Not Specified,US-SA-2018SA294523,-,-
15565156,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Off Label Use;Device Issue;Vision Blurred,Non-Serious,Non-Serious,Male,-,30-OCT-2018,Non-Expedited,67 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,22-OCT-2018,30-OCT-2018,US,Not Specified,US-SA-2018SA294425,-,-
15561968,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Abdominal Distension;Paraesthesia;Back Pain;Neuralgia,Non-Serious,Non-Serious,Male,-,29-OCT-2018,Non-Expedited,49 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-OCT-2018,29-OCT-2018,US,Not Specified,US-SA-2018SA296467,-,-
15561901,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Fluctuation,Non-Serious,Non-Serious,Female,-,29-OCT-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-OCT-2018,29-OCT-2018,US,Not Specified,US-SA-2018SA296469,-,-
15561856,Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Lispro,Type 2 Diabetes Mellitus,Product Prescribing Error;Therapeutic Response Decreased;Hyperglycaemia,Non-Serious,Non-Serious,Female,-,29-OCT-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,22-OCT-2018,29-OCT-2018,US,Not Specified,US-SA-2018SA294501,-,-
15285413,-,Insulin Glargine;Metformin Hydrochloride;Glimepiride;Insulin Glargine\Lixisenatide,Adjuvant Therapy;Dyslipidaemia;Hypertension;Hypothyroidism;Meniere's Disease;Neuropathy Peripheral;Prophylaxis;Type 2 Diabetes Mellitus,Invasive Ductal Breast Carcinoma,Serious,Other Outcomes,Female,25-MAY-2018,29-OCT-2018,Expedited,86 YR,76 KG,Sanofi Aventis,Healthcare Professional,Not Specified,Fish Oil;Clidinium;Atenolol;Chlorthalidone;Ecotrin;Toujeo;Levothyroxine;Chlordiazepoxide;Melatonin;Atorvastatin;Meclizine Hydrochloride;Metanx,16-OCT-2018,16-AUG-2018,US,Not Specified,US-SA-2018SA177479,-,-
15555823,Soliqua 100/33,Insulin Glargine\Lixisenatide;Lisinopril,Type 2 Diabetes Mellitus,Swelling Face,Serious,Other Outcomes,Not Specified,-,26-OCT-2018,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,18-OCT-2018,26-OCT-2018,US,Not Specified,US-SA-2018SA291266,-,-
15468508,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Device Operational Issue;Incorrect Dose Administered,Non-Serious,Non-Serious,Male,-,26-OCT-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,24-SEP-2018,05-OCT-2018,US,Not Specified,US-SA-2018SA266032,-,-
15102674,-,Insulin Glargine\Lixisenatide,-,Brain Fog;Intentional Dose Omission;Contusion;Weight Increased;Injection Site Pain;Drug Ineffective;Thermal Burn;Thyroid Disorder;Fatigue,Non-Serious,Non-Serious,Female,23-AUG-2018,26-OCT-2018,Non-Expedited,64 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-OCT-2018,03-JUL-2018,US,Not Specified,US-SA-2018SA170422,-,-
15550627,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Glomerular Filtration Rate Decreased;Blood Urea Increased,Non-Serious,Non-Serious,Female,-,25-OCT-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,19-OCT-2018,25-OCT-2018,US,Not Specified,US-SA-2018SA293900,-,-
15508292,-,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Atrioventricular Block;Myocardial Infarction,Serious,Hospitalized;Other Outcomes,Male,03-SEP-2018,24-OCT-2018,Expedited,76 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-OCT-2018,16-OCT-2018,US,Not Specified,US-SA-2018SA281854,-,-
15402933,-,Insulin Glargine\Lixisenatide;Investigational Product,Type 2 Diabetes Mellitus,Dementia;Device Colour Issue,Serious,Other Outcomes,Female,-,23-OCT-2018,Expedited,77 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Hydralazine;Furosemide;Glipizide;Sucralfate;Plavix;Escitalopram;Atorvastatin,12-OCT-2018,19-SEP-2018,US,Not Specified,US-SA-2018SA252223,-,-
15538751,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,22-OCT-2018,Non-Expedited,52 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Novolog,16-OCT-2018,22-OCT-2018,US,Not Specified,US-SA-2018SA290648,-,-
15529132,Repatha;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Evolocumab,Hypercholesterolaemia;Product Used For Unknown Indication,Weight Decreased;Rash Papular;Off Label Use,Non-Serious,Non-Serious,Male,SEP-2018,18-OCT-2018,Non-Expedited,69 YR,Not Specified,Amgen,Consumer,Not Specified,-,12-SEP-2018,18-OCT-2018,US,Not Specified,US-AMGEN-USASL2018128048,-,-
15526970,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Illness,Non-Serious,Non-Serious,Male,-,18-OCT-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-OCT-2018,18-OCT-2018,US,Not Specified,US-SA-2018SA287196,-,-
15358672,Tresiba;Levemir;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Insulin Detemir;Insulin Degludec,Type 2 Diabetes Mellitus,Peripheral Swelling,Non-Serious,Non-Serious,Female,JUN-2018,18-OCT-2018,Non-Expedited,69 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,11-JUL-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-611209,-,-
15522736,Tresiba;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Insulin Degludec,Product Used For Unknown Indication,Blood Glucose Increased;Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Female,-,17-OCT-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,11-SEP-2018,17-OCT-2018,US,Not Specified,US-NOVOPROD-621989,-,-
15518987,Soliqua 100/33;Repatha,Evolocumab;Insulin Glargine\Lixisenatide,Myocardial Ischaemia;Product Used For Unknown Indication;Type V Hyperlipidaemia,Tremor,Non-Serious,Non-Serious,Male,-,17-OCT-2018,Non-Expedited,60 YR,Not Specified,Amgen,Consumer,Not Specified,-,11-JUL-2018,17-OCT-2018,US,Not Specified,US-AMGEN-USASL2018095987,-,-
15518774,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Hypoglycaemia;Rash,Non-Serious,Non-Serious,Female,-,17-OCT-2018,Non-Expedited,46 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,15-OCT-2018,17-OCT-2018,US,Not Specified,US-SA-2018SA287594,-,-
15518751,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Wrong Schedule,Non-Serious,Non-Serious,Female,-,17-OCT-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-OCT-2018,17-OCT-2018,US,Not Specified,US-SA-2018SA285792,-,-
15518702,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Injection Site Pain,Non-Serious,Non-Serious,Male,-,17-OCT-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-OCT-2018,17-OCT-2018,US,Not Specified,US-SA-2018SA286129,-,-
15517809,Xultophy 100/3.6;Coveram;Metformin;Liptruzet,Atorvastatin Calcium\Ezetimibe;Metformin Hydrochloride;Repaglinide;Amlodipine\Perindopril;Insulin Degludec\Liraglutide,Diabetes Mellitus;Dyslipidaemia;Hypertension;Product Used For Unknown Indication,Lactic Acidosis;Disturbance In Attention;Acute Kidney Injury;Acute Coronary Syndrome,Serious,Life Threatening;Other Outcomes,Male,20-APR-2018,17-OCT-2018,Expedited,79 YR,95 KG,Mylan,Healthcare Professional,Not Specified,Pantoprazole;Clopidogrel Hydrochloride;Levothyroxine,15-OCT-2018,17-OCT-2018,FR,Not Specified,FR-MYLANLABS-2018M1077804,-,-
15508230,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 1 Diabetes Mellitus,Blood Glucose Fluctuation;Dysphagia;Dry Throat;Dry Mouth;Blood Glucose Abnormal,Non-Serious,Non-Serious,Female,-,16-OCT-2018,Non-Expedited,80 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Zolpidem Tartrate;Celebrex;Novolog,11-OCT-2018,16-OCT-2018,US,Not Specified,US-SA-2018SA286130,-,-
15508056,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Unevaluable Event,Non-Serious,Non-Serious,Female,-,16-OCT-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-OCT-2018,16-OCT-2018,US,Not Specified,US-SA-2018SA286121,-,-
15507666,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Diarrhoea;Eructation;Flatulence,Non-Serious,Non-Serious,Female,-,16-OCT-2018,Non-Expedited,51 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-OCT-2018,16-OCT-2018,US,Not Specified,US-SA-2018SA284843,-,-
15504915,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Dose Omission Issue,Non-Serious,Non-Serious,Male,-,16-OCT-2018,Non-Expedited,82 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,09-OCT-2018,16-OCT-2018,US,Not Specified,US-SA-2018SA282030,-,-
15504854,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Anaphylactic Reaction;Rash,Serious,Other Outcomes;Hospitalized,Male,-,16-OCT-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,08-OCT-2018,16-OCT-2018,US,Not Specified,US-SA-2018SA280127,-,-
15504635,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Dose Omission Issue,Non-Serious,Non-Serious,Male,-,16-OCT-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,05-OCT-2018,16-OCT-2018,US,Not Specified,US-SA-2018SA279928,-,-
15461135,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Asthenia;Hypertension,Serious,Hospitalized,Female,-,12-OCT-2018,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,07-OCT-2018,03-OCT-2018,IL,Not Specified,IL-NOVOPROD-624234,-,-
15274917,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injection Site Pain;Vitreous Floaters,Non-Serious,Non-Serious,Male,03-AUG-2018,12-OCT-2018,Non-Expedited,59 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-OCT-2018,14-AUG-2018,US,Not Specified,US-SA-2018SA220395,-,-
15248348,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Incorrect Dose Administered,Non-Serious,Non-Serious,Female,-,11-OCT-2018,Non-Expedited,61 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,04-OCT-2018,07-AUG-2018,US,Not Specified,US-SA-2018SA213199,-,-
15244044,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,11-OCT-2018,Non-Expedited,71 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,04-OCT-2018,06-AUG-2018,US,Not Specified,US-SA-2018SA212463,-,-
15482874,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Increased,Non-Serious,Non-Serious,Not Specified,-,10-OCT-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,04-OCT-2018,10-OCT-2018,US,Not Specified,US-SA-2018SA279942,-,-
15482562,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,10-OCT-2018,Non-Expedited,76 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,05-MAY-2018,10-OCT-2018,US,Not Specified,US-SA-2018SA132420,-,-
15482501,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Expired Product Administered;Underdose,Non-Serious,Non-Serious,Female,-,10-OCT-2018,Non-Expedited,76 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,02-OCT-2018,10-OCT-2018,US,Not Specified,US-SA-2018SA275903,-,-
15482381,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Condition Aggravated;Autoimmune Pancytopenia;Immune Thrombocytopenia,Serious,Other Outcomes,Male,2018,10-OCT-2018,Expedited,78 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Lisinopril,28-SEP-2018,10-OCT-2018,US,Not Specified,US-NOVOPROD-625287,-,-
15481039,Metact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Anaemia,Non-Serious,Non-Serious,Not Specified,-,10-OCT-2018,Expedited,Not Specified,Not Specified,Teva,Healthcare Professional,Not Specified,Aspirin,16-JAN-2018,10-OCT-2018,JP,Not Specified,JP-TEVA-2018-JP-000181J,-,-
15321265,Soliqua 100/33;Lantus Solostar,Insulin Glargine;Insulin Glargine\Lixisenatide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Drug Ineffective;Device Issue;Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,10-OCT-2018,Non-Expedited,61 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,04-OCT-2018,27-AUG-2018,US,Not Specified,US-SA-2018SA238400,-,-
15230725,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injection Site Haemorrhage;Injection Site Mass;Device Issue;Injection Site Bruising,Non-Serious,Non-Serious,Female,-,10-OCT-2018,Non-Expedited,60 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,04-OCT-2018,02-AUG-2018,US,Not Specified,US-SA-2018SA207266,-,-
15474219,Soliqua 100/33,Insulin Glargine\Lixisenatide;Lisinopril,-,Blood Pressure Decreased,Non-Serious,Non-Serious,Female,-,08-OCT-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,03-OCT-2018,08-OCT-2018,US,Not Specified,US-SA-2018SA276496,-,-
15474190,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Nausea;Vomiting;Biliary Colic;Blood Triglycerides Increased;Abdominal Pain Upper;Diarrhoea;Lipase Increased,Non-Serious,Non-Serious,Female,-,08-OCT-2018,Non-Expedited,54 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,03-OCT-2018,08-OCT-2018,US,Not Specified,US-SA-2018SA276489,-,-
15474172,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Hypoacusis,Non-Serious,Non-Serious,Male,-,08-OCT-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,02-OCT-2018,08-OCT-2018,US,Not Specified,US-SA-2018SA275901,-,-
15467957,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Gastric Disorder;Gastrointestinal Disorder,Non-Serious,Non-Serious,Female,-,05-OCT-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,27-SEP-2018,05-OCT-2018,US,Not Specified,US-SA-2018SA273959,-,-
15467937,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Drug Ineffective,Non-Serious,Non-Serious,Not Specified,-,05-OCT-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-SEP-2018,05-OCT-2018,US,Not Specified,US-SA-2018SA274370,-,-
15390891,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Decreased;Blood Glucose Increased;Abdominal Pain Upper;Expired Product Administered;Dyspepsia;Fatigue,Non-Serious,Non-Serious,Male,-,05-OCT-2018,Non-Expedited,72 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin,24-SEP-2018,17-SEP-2018,US,Not Specified,US-SA-2018SA256011,-,-
15477961,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Nausea;Myalgia;Pyrexia;Weight Decreased;Chills;Abdominal Pain Upper;Lipase Increased;Abdominal Pain;Vomiting;Economic Problem;Hyperhidrosis,Serious,Hospitalized,Female,20-AUG-2018,02-OCT-2018,Direct,54 YR,74.7 KG,Fda-Ctu,Consumer,Consumer,Janumet;Crestor,-,02-OCT-2018,US,Y,-,-,Yes
15457058,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Use Issue,Non-Serious,Non-Serious,Male,-,02-OCT-2018,Non-Expedited,76 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-SEP-2018,02-OCT-2018,US,Not Specified,US-SA-2018SA267372,-,-
15456129,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Antinuclear Antibody Positive,Non-Serious,Non-Serious,Not Specified,-,02-OCT-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,20-SEP-2018,02-OCT-2018,US,Not Specified,US-SA-2018SA266216,-,-
15452487,Soliqua 100/33,Insulin Glargine\Lixisenatide,Hyperglycaemia,Vomiting;Pruritus;Dyspnoea;Hypersensitivity,Serious,Hospitalized;Life Threatening,Male,19-SEP-2018,01-OCT-2018,Expedited,62 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,25-SEP-2018,01-OCT-2018,US,Not Specified,US-SA-2018SA269837,-,-
15450724,Novolog;Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Aspart,Product Used For Unknown Indication,Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,01-OCT-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-SEP-2018,01-OCT-2018,US,Not Specified,US-SA-2018SA271049,-,-
15444492,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Increased;Device Leakage,Non-Serious,Non-Serious,Female,-,28-SEP-2018,Non-Expedited,49 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,19-SEP-2018,28-SEP-2018,US,Not Specified,US-SA-2018SA266225,-,-
15358679,Xultophy 100/3.6;Ozempic,Semaglutide;Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Vulvovaginal Discomfort;Tremor,Non-Serious,Non-Serious,Female,03-JUL-2018,28-SEP-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,05-JUL-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-610025,-,-
15437278,Soliqua 100/33;Humalog;Tresiba,Insulin Degludec;Insulin Lispro;Insulin Glargine\Lixisenatide,Product Used For Unknown Indication,Cerebrovascular Accident,Serious,Other Outcomes,Female,JAN-2018,27-SEP-2018,Expedited,62 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,17-SEP-2018,27-SEP-2018,US,Not Specified,US-NOVOPROD-622672,-,-
15431746,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Fluctuation;Intentional Product Misuse;Hypoglycaemia;Drug Ineffective;Abdominal Pain Upper;Neuropathy Peripheral,Serious,Other Outcomes,Male,07-JUN-2018,26-SEP-2018,Expedited,63 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin;Novolog,14-JUN-2018,26-SEP-2018,US,Not Specified,US-SA-2018SA191872,-,-
15431549,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Injection Site Rash;Dyspnoea,Non-Serious,Non-Serious,Female,-,26-SEP-2018,Non-Expedited,60 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,19-SEP-2018,26-SEP-2018,US,Not Specified,US-SA-2018SA266170,-,-
15431548,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Dyspnoea;Injection Site Rash,Non-Serious,Non-Serious,Female,-,26-SEP-2018,Non-Expedited,60 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,19-SEP-2018,26-SEP-2018,US,Not Specified,US-SA-2018SA266171,-,-
15431520,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Injection Site Rash,Non-Serious,Non-Serious,Female,-,26-SEP-2018,Non-Expedited,40 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,19-SEP-2018,26-SEP-2018,US,Not Specified,US-SA-2018SA266197,-,-
15431384,Humalog;Soliqua 100/33;Tresiba,Insulin Degludec;Insulin Glargine\Lixisenatide;Insulin Lispro,Product Used For Unknown Indication,Cerebrovascular Accident;Blood Glucose Abnormal;Glycosylated Haemoglobin Increased;Goitre,Serious,Other Outcomes,Female,-,26-SEP-2018,Expedited,Not Specified,Not Specified,Eli Lilly And Co,Consumer,Not Specified,-,18-SEP-2018,26-SEP-2018,US,Not Specified,US-ELI_LILLY_AND_COMPANY-US201809008459,-,-
15190811,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Knee Operation;Pain;Arthritis;Cellulitis;Malaise;Weight Decreased;Limb Injury;Mobility Decreased;Blood Glucose Increased;Drug Ineffective,Serious,Hospitalized,Male,09-JUN-2018,26-SEP-2018,Expedited,58 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Toujeo;Metformin,11-SEP-2018,24-JUL-2018,US,Not Specified,US-SAKK-2018SA162281AA,-,-
15418938,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Weight Increased,Non-Serious,Non-Serious,Female,-,24-SEP-2018,Non-Expedited,55 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,18-SEP-2018,24-SEP-2018,US,Not Specified,US-SA-2018SA264488,-,-
15418519,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Arthralgia,Non-Serious,Non-Serious,Female,-,24-SEP-2018,Non-Expedited,68 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,17-SEP-2018,24-SEP-2018,US,Not Specified,US-SA-2018SA261685,-,-
15418471,Soliqua 100/33,Insulin Glargine\Lixisenatide,Product Used For Unknown Indication,Diarrhoea;Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,24-SEP-2018,Non-Expedited,79 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,06-SEP-2018,24-SEP-2018,US,Not Specified,US-SA-2018SA254286,-,-
15312513,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injection Site Pain,Non-Serious,Non-Serious,Male,-,24-SEP-2018,Non-Expedited,50 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,12-SEP-2018,23-AUG-2018,US,Not Specified,US-SA-2018SA230338,-,-
15407185,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Use Issue,Non-Serious,Non-Serious,Female,05-SEP-2018,21-SEP-2018,Non-Expedited,76 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,05-SEP-2018,20-SEP-2018,US,Not Specified,US-SA-2018SA252688,-,-
15409049,-,Insulin Glargine\Lixisenatide,-,Toe Amputation;Peripheral Swelling;Product Dispensing Error;Cellulitis;Pain In Extremity;Localised Infection,Serious,Other Outcomes,Female,-,20-SEP-2018,Expedited,62 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-JUN-2017,20-SEP-2018,US,Not Specified,US-SA-2018SA238471,-,-
15408572,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Hepatic Enzyme Increased;Cholelithiasis,Serious,Other Outcomes,Male,-,20-SEP-2018,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,11-SEP-2018,20-SEP-2018,US,Not Specified,US-SA-2018SA258089,-,-
15397021,Soliqua 100/33,Insulin Glargine\Lixisenatide,Product Used For Unknown Indication,Nausea;Decreased Appetite,Non-Serious,Non-Serious,Female,-,18-SEP-2018,Non-Expedited,73 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,12-SEP-2018,18-SEP-2018,US,Not Specified,US-SA-2018SA259888,-,-
15396496,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Pain;Spinal Stenosis;Spinal Fusion Surgery;Rheumatoid Arthritis,Serious,Other Outcomes,Female,03-FEB-2017,18-SEP-2018,Expedited,60 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,22-AUG-2018,18-SEP-2018,US,Not Specified,US-SA-2018SA239223,-,-
15396487,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Joint Arthroplasty;Neuropathy Peripheral;Cholelithiasis;Weight Decreased;Haemoglobin Decreased,Serious,Other Outcomes,Male,2017,18-SEP-2018,Expedited,61 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin,11-DEC-2017,18-SEP-2018,US,Not Specified,US-SA-2017SA268428,-,-
15390923,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Visual Impairment;Device Operational Issue,Non-Serious,Non-Serious,Female,-,17-SEP-2018,Non-Expedited,63 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-SEP-2018,17-SEP-2018,US,Not Specified,US-SA-2018SA258347,-,-
15390888,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Not Specified,-,17-SEP-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-SEP-2018,17-SEP-2018,US,Not Specified,US-SA-2018SA258397,-,-
15390867,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment;Device Operational Issue,Non-Serious,Non-Serious,Male,-,17-SEP-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-SEP-2018,17-SEP-2018,US,Not Specified,US-SA-2018SA256019,-,-
15312492,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus;Gastrooesophageal Reflux Disease;Pollakiuria,Nausea;Abdominal Discomfort;Vomiting,Non-Serious,Non-Serious,Male,13-APR-2018,17-SEP-2018,Non-Expedited,70 YR,79.38 KG,Sanofi Aventis,Consumer,Not Specified,Nexium I.V.;Proscar;Metformin Hydrochloride;Cialis,04-SEP-2018,23-AUG-2018,US,Not Specified,US-SA-2018SA226162,-,-
15120732,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Ill-Defined Disorder;Blood Glucose Abnormal;Device Operational Issue,Non-Serious,Non-Serious,Male,-,17-SEP-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,16-AUG-2018,09-JUL-2018,US,Not Specified,US-SA-2018SA155735,-,-
14989105,Coveram;Xultophy 100/3.6;Liptruzet,Atorvastatin Calcium\Ezetimibe;Metformin Hydrochloride;Repaglinide;Insulin Degludec\Liraglutide;Amlodipine\Perindopril,Diabetes Mellitus;Dyslipidaemia;Hypertension;Product Used For Unknown Indication,Lactic Acidosis;Disturbance In Attention;Acute Kidney Injury;Acute Coronary Syndrome,Serious,Other Outcomes;Life Threatening,Male,20-APR-2018,17-SEP-2018,Expedited,79 YR,95 KG,Bristol Myers Squibb,Healthcare Professional,Not Specified,Levothyroxine;Clopidogrel;Pantoprazole,05-SEP-2018,08-JUN-2018,FR,Not Specified,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-051589,-,-
14824704,-,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Bronchitis;Helicobacter Gastritis,Serious,Hospitalized,Female,12-MAR-2018,17-SEP-2018,Expedited,60 YR,92 KG,Novo Nordisk,Healthcare Professional,Not Specified,Gliclazide;Metformin Hydrochloride;Dapagliflozin,06-SEP-2018,29-APR-2018,ZA,Not Specified,ZA-NOVOPROD-595552,-,-
15386600,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Weight Decreased;Nervousness;Blood Glucose Decreased;Neuropathy Peripheral;Abdominal Discomfort;Dizziness;Nausea;Migraine;Decreased Appetite;Injection Site Pain;Glycosylated Haemoglobin Abnormal;Fatigue;Feeling Drunk;Anxiety,Serious,Other Outcomes,Female,20-MAY-2018,14-SEP-2018,Expedited,28 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,31-MAY-2018,14-SEP-2018,US,Not Specified,US-SA-2018SA166095,-,-
15330492,Lantus;Toujeo;Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Glargine;Insulin Glargine;Insulin Glargine,Diabetes Mellitus;Hypoglycaemia,Hypoglycaemia;Medication Error;Somnolence;Tooth Fracture;Retinal Detachment,Serious,Other Outcomes,Male,JUL-2017,13-SEP-2018,Expedited,73 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,03-SEP-2018,29-AUG-2018,KR,Not Specified,KR-SA-2018SA216994,-,-
15371515,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Gastrointestinal Haemorrhage;Abdominal Pain,Serious,Other Outcomes,Female,-,11-SEP-2018,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,30-AUG-2018,11-SEP-2018,US,Not Specified,US-SA-2018SA246285,-,-
15370618,Soliqua 100/33,Insulin Glargine\Lixisenatide,Product Used For Unknown Indication,Fall,Serious,Hospitalized,Female,-,11-SEP-2018,Expedited,87 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,31-AUG-2018,11-SEP-2018,US,Not Specified,US-SA-2018SA247232,-,-
15366265,Basaglar;Lantus;Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Glargine;Insulin Glargine,Diabetes Mellitus;Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,10-SEP-2018,Non-Expedited,48 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,24-AUG-2018,10-SEP-2018,US,Not Specified,US-SA-2018SA241218,-,-
15306918,Soliqua 100/33,Insulin Glargine\Lixisenatide;Metformin Hydrochloride,Type 2 Diabetes Mellitus,Blood Glucose Increased;Pruritus;Incorrect Route Of Product Administration;Abdominal Pain Upper;Muscle Spasms;Urine Odour Abnormal;Wrong Technique In Device Usage Process,Non-Serious,Non-Serious,Female,-,07-SEP-2018,Non-Expedited,79 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Humalog,20-AUG-2018,22-AUG-2018,US,Not Specified,US-SA-2018SA226138,-,-
14984116,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Eructation;Flatulence;Vomiting;Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Female,2018,07-SEP-2018,Non-Expedited,67 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,21-JUN-2018,07-JUN-2018,US,Not Specified,US-NOVOPROD-601758,-,-
14984115,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Device Failure,Non-Serious,Non-Serious,Male,01-MAY-2018,07-SEP-2018,Non-Expedited,70 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,26-JUN-2018,07-JUN-2018,US,Not Specified,US-NOVOPROD-600029,-,-
14984113,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Therapy Non-Responder;Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,07-SEP-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,18-JUL-2018,07-JUN-2018,US,Not Specified,US-NOVOPROD-600084,-,-
14984110,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Device Failure,Non-Serious,Non-Serious,Female,20-APR-2018,07-SEP-2018,Non-Expedited,46 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Metformin,14-JUN-2018,07-JUN-2018,US,Not Specified,US-NOVOPROD-599775,-,-
14984109,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus Management,Lipase Increased;Back Pain,Non-Serious,Non-Serious,Female,02-MAY-2018,07-SEP-2018,Non-Expedited,48 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,22-JUN-2018,07-JUN-2018,US,Not Specified,US-NOVOPROD-600824,-,-
14984083,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Pancreatitis Acute,Serious,Hospitalized,Male,15-APR-2018,07-SEP-2018,Non-Expedited,46 YR,177.78 KG,Novo Nordisk,Healthcare Professional,Not Specified,-,27-JUN-2018,07-JUN-2018,US,Not Specified,US-NOVOPROD-597692,-,-
15358709,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Dysphagia,Non-Serious,Non-Serious,Female,-,06-SEP-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,14-AUG-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-617704,-,-
15358708,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Latent Autoimmune Diabetes In Adults,Therapeutic Product Effect Increased;Drug Ineffective;Blood Glucose Increased;Off Label Use;Blood Glucose Decreased,Non-Serious,Non-Serious,Female,2018,06-SEP-2018,Non-Expedited,60 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,14-AUG-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-617193,-,-
15358706,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,06-SEP-2018,Non-Expedited,66 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,Novolog,09-AUG-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-616915,-,-
15358705,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Drug Intolerance,Non-Serious,Non-Serious,Male,-,06-SEP-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,09-AUG-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-616518,-,-
15358704,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Product Complaint;Blood Glucose Fluctuation;Injection Site Pain,Non-Serious,Non-Serious,Male,2018,06-SEP-2018,Non-Expedited,82 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,13-AUG-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-617155,-,-
15358702,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Rash,Non-Serious,Non-Serious,Male,-,06-SEP-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,09-AUG-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-616517,-,-
15358701,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Dysphagia,Non-Serious,Non-Serious,Female,-,06-SEP-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,06-AUG-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-615999,-,-
15358694,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Device Leakage;Blood Glucose Increased,Non-Serious,Non-Serious,Female,09-JUL-2018,06-SEP-2018,Non-Expedited,53 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,17-JUL-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-611606,-,-
15358693,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Drug Hypersensitivity;Nausea,Non-Serious,Non-Serious,Female,2018,06-SEP-2018,Non-Expedited,75 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,02-JUL-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-609738,-,-
15358689,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Blood Thyroid Stimulating Hormone Increased,Non-Serious,Non-Serious,Female,-,06-SEP-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,19-JUL-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-612712,-,-
15358683,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Pancreatitis;Dyspepsia,Serious,Hospitalized,Male,20-JUL-2018,06-SEP-2018,Non-Expedited,37 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,30-JUL-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-613909,-,-
15358682,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Pancreatitis,Serious,Other Outcomes,Not Specified,-,06-SEP-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,25-JUL-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-613661,-,-
15358681,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Blood Glucose Increased,Non-Serious,Non-Serious,Female,07-MAY-2018,06-SEP-2018,Non-Expedited,65 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,18-JUN-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-608538,-,-
15358680,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Blood Glucose Decreased,Serious,Other Outcomes,Female,-,06-SEP-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,09-JUL-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-610268,-,-
15358676,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Serious,Other Outcomes,Female,12-JUL-2018,06-SEP-2018,Non-Expedited,69 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,Glipizide,16-JUL-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-611388,-,-
15358675,Xultophy 100/3.6;Afrezza,Insulin Human;Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Decreased Appetite;Taste Disorder,Non-Serious,Non-Serious,Female,-,06-SEP-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,25-JUN-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-608268,-,-
15358674,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Injection Site Discharge;Injury Associated With Device,Non-Serious,Non-Serious,Male,-,06-SEP-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,16-JUL-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-612216,-,-
15358673,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Vomiting;Nausea;Abdominal Discomfort,Non-Serious,Non-Serious,Female,-,06-SEP-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,16-JUL-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-611639,-,-
15358671,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,06-SEP-2018,Non-Expedited,60 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,21-JUN-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-607647,-,-
15358670,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Rash,Non-Serious,Non-Serious,Female,07-MAY-2018,06-SEP-2018,Non-Expedited,70 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,22-MAY-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-602207,-,-
15358669,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Blood Glucose Increased;Drug Ineffective,Non-Serious,Non-Serious,Male,-,06-SEP-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,11-JUN-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-606279,-,-
15358668,Xultophy 100/3.6,Insulin Degludec\Liraglutide;Glimepiride,Product Used For Unknown Indication,Blood Glucose Decreased,Non-Serious,Non-Serious,Female,2018,06-SEP-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,31-MAY-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-605101,-,-
15358667,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Gastritis,Serious,Hospitalized,Female,2018,06-SEP-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,07-JUN-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-605105,-,-
15358666,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,06-SEP-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,08-JUN-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-605870,-,-
15358665,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Blood Glucose Fluctuation;Vomiting;Product Quality Issue;Back Pain;Malaise,Non-Serious,Non-Serious,Male,12-JUN-2018,06-SEP-2018,Non-Expedited,55 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,15-JUN-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-606963,-,-
15358664,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Pain In Extremity;Hypoaesthesia;Burning Sensation,Non-Serious,Non-Serious,Female,-,06-SEP-2018,Non-Expedited,57 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,01-JUN-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-604134,-,-
15358663,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Peripheral Swelling;Dizziness;Cough;Joint Swelling;Oropharyngeal Pain,Non-Serious,Non-Serious,Female,20-MAY-2018,06-SEP-2018,Non-Expedited,71 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,01-JUN-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-603846,-,-
15358662,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Hypoglycaemia,Non-Serious,Non-Serious,Female,2017,06-SEP-2018,Non-Expedited,46 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,23-MAY-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-602489,-,-
15358661,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Nausea;Vomiting;Angioedema;Headache,Serious,Other Outcomes,Female,25-APR-2018,06-SEP-2018,Non-Expedited,69 YR,78.91 KG,Novo Nordisk,Healthcare Professional,Not Specified,Lisinopril,07-JUN-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-605104,-,-
15358660,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Device Breakage,Non-Serious,Non-Serious,Male,28-MAY-2018,06-SEP-2018,Non-Expedited,60 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,06-JUN-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-605314,-,-
15358659,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Injection Site Pain,Non-Serious,Non-Serious,Male,-,06-SEP-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,22-JUN-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-607905,-,-
15358653,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Circumstance Or Information Capable Of Leading To Medication Error,Non-Serious,Non-Serious,Female,-,06-SEP-2018,Non-Expedited,58 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,23-MAY-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-603192,-,-
15358652,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Diarrhoea,Non-Serious,Non-Serious,Male,-,06-SEP-2018,Non-Expedited,57 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,29-MAY-2018,06-SEP-2018,US,Not Specified,US-NOVOPROD-603562,-,-
15357632,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Issue;Product Dose Omission Issue;Device Operational Issue,Non-Serious,Non-Serious,Female,-,06-SEP-2018,Non-Expedited,42 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin,24-AUG-2018,06-SEP-2018,US,Not Specified,US-SA-2018SA241475,-,-
15357605,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Operational Issue;Product Dose Omission Issue,Non-Serious,Non-Serious,Female,-,06-SEP-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,22-AUG-2018,06-SEP-2018,US,Not Specified,US-SA-2018SA236896,-,-
15357437,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Suicide Attempt,Intentional Overdose;Suicide Attempt;Hypoglycaemia,Serious,Other Outcomes;Hospitalized,Male,22-JUL-2018,06-SEP-2018,Expedited,62 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Acetaminophen\Codeine Phosphate;Atorvastatin;Metformin Hydrochloride;Aldactazine;Urapidil;Allopurinol;Lercanidipine,28-AUG-2018,06-SEP-2018,FR,Not Specified,FR-NOVOPROD-619134,-,-
15356858,Soliqua 100/33,Insulin Glargine\Lixisenatide,Product Used For Unknown Indication,Headache,Non-Serious,Non-Serious,Male,-,06-SEP-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,30-AUG-2018,06-SEP-2018,US,Not Specified,US-SA-2018SA247638,-,-
15356756,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Drug Ineffective;Ear Infection;Diabetes Mellitus Inadequate Control;Blood Glucose Increased;Illness,Serious,Other Outcomes,Female,-,06-SEP-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-AUG-2018,06-SEP-2018,US,Not Specified,US-SAKK-2018SA247026AA,-,-
15352690,Soliqua 100/33,Insulin Glargine\Lixisenatide,Product Used For Unknown Indication,Headache,Non-Serious,Non-Serious,Male,-,05-SEP-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,30-AUG-2018,05-SEP-2018,US,Not Specified,US-SA-2018SA247603,-,-
15347307,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Sleep Apnoea Syndrome,Non-Serious,Non-Serious,Female,-,04-SEP-2018,Non-Expedited,53 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-AUG-2018,04-SEP-2018,US,Not Specified,US-SA-2018SA246323,-,-
15347254,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error;Incorrect Dose Administered;Product Dose Omission Issue,Non-Serious,Non-Serious,Female,-,04-SEP-2018,Non-Expedited,37 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin,20-AUG-2018,04-SEP-2018,US,Not Specified,US-SA-2018SA234815,-,-
15322226,-,Insulin Glargine\Lixisenatide,Blood Glucose Increased;Blood Pressure Measurement;Type 2 Diabetes Mellitus,Blood Calcium Increased;Therapeutic Response Decreased;Blood Glucose Increased;Compression Fracture;Osteoporosis;Vision Blurred;Dizziness;Pain;Nephrolithiasis,Serious,Other Outcomes,Male,25-APR-2018,04-SEP-2018,Expedited,63 YR,99 KG,Sanofi Aventis,Consumer,Not Specified,Lisinopril;Aspirin;Metformin;Glimepiride;Cobamamide;Vitamin D3;Lantus,20-AUG-2018,27-AUG-2018,US,Not Specified,US-SA-2018SA124765,-,-
15059807,Soliqua 100/33,Insulin Glargine\Lixisenatide,Product Used For Unknown Indication,Blood Glucose Increased;Abdominal Pain Upper,Serious,Hospitalized,Female,09-JUN-2018,04-SEP-2018,Expedited,67 YR,102 KG,Sanofi Aventis,Consumer,Not Specified,Tresiba,20-AUG-2018,25-JUN-2018,US,Not Specified,US-SA-2018SA166608,-,-
15344417,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Headache;Pruritus;Nasopharyngitis;Hypersensitivity,Non-Serious,Non-Serious,Female,-,03-SEP-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Levemir,16-AUG-2018,03-SEP-2018,US,Not Specified,US-SA-2018SA234657,-,-
15334725,-,Insulin Glargine\Lixisenatide;Gabapentin,Neuropathy Peripheral,Neuropathy Peripheral;Diverticulitis,Serious,Other Outcomes,Female,23-MAY-2017,30-AUG-2018,Expedited,58 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-MAY-2017,30-AUG-2018,US,Not Specified,US-SA-2018SA236973,-,-
15330497,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Pharyngitis Streptococcal;Inappropriate Schedule Of Product Administration;Influenza Like Illness;Blood Glucose Decreased;Loss Of Consciousness,Serious,Other Outcomes,Male,30-MAY-2018,29-AUG-2018,Expedited,58 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-MAY-2018,29-AUG-2018,US,Not Specified,US-SA-2018SA161713,-,-
15106591,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Pruritus;Drug Ineffective;Pain,Non-Serious,Non-Serious,Female,-,29-AUG-2018,Non-Expedited,51 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-JUL-2018,04-JUL-2018,US,Not Specified,US-SA-2018SA170443,-,-
15327606,-,Insulin Glargine\Lixisenatide;Insulin Glargine,Type 2 Diabetes Mellitus,Drug Ineffective;Blood Glucose Fluctuation;Diabetic Metabolic Decompensation;Blood Glucose Increased;Blood Glucose Decreased;Product Prescribing Error;Hypoglycaemia,Serious,Other Outcomes,Male,04-JUL-2013,28-AUG-2018,Expedited,59 YR,68 KG,Sanofi Aventis,Consumer,Not Specified,-,04-JUL-2018,28-AUG-2018,BR,Not Specified,BR-SA-2018SA184872,-,-
15326308,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Device Delivery System Issue,Serious,Other Outcomes,Male,-,28-AUG-2018,Non-Expedited,69 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-AUG-2018,28-AUG-2018,US,Not Specified,US-SA-2018SA225274,-,-
15317221,Ozempic;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Semaglutide,Product Used For Unknown Indication,Neoplasm Malignant,Serious,Other Outcomes,Not Specified,-,24-AUG-2018,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,15-AUG-2018,24-AUG-2018,US,Not Specified,US-NOVOPROD-617196,-,-
15312508,Soliqua 100/33,Insulin Glargine\Lixisenatide,Product Used For Unknown Indication,Injection Site Haemorrhage,Non-Serious,Non-Serious,Female,-,23-AUG-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,16-AUG-2018,23-AUG-2018,US,Not Specified,US-SA-2018SA230193,-,-
15310661,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Taste Disorder;Pancreatitis;Decreased Appetite;Nausea;Ketoacidosis;Device Delivery System Issue,Serious,Other Outcomes,Female,06-AUG-2018,23-AUG-2018,Expedited,50 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,06-AUG-2018,23-AUG-2018,US,Not Specified,US-SA-2018SA219094,-,-
15181133,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Blood Cholesterol Increased;Hypertension;Type 2 Diabetes Mellitus,Mesenteric Vein Thrombosis;Pancreatic Carcinoma Stage Iv;Cough;Portal Vein Thrombosis;Pyrexia,Serious,Other Outcomes,Male,25-JUN-2018,23-AUG-2018,Expedited,59 YR,107.94 KG,Novo Nordisk,Healthcare Professional,Not Specified,Metformin;Tricor;Pravachol;Lisinopril,14-AUG-2018,23-JUL-2018,US,Not Specified,US-NOVOPROD-610945,-,-
15308521,Xultophy 100/3.6,Insulin Degludec\Liraglutide;Insulin Human,Product Used For Unknown Indication,Diabetic Ketoacidosis,Serious,Hospitalized,Female,29-JUL-2018,22-AUG-2018,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,14-AUG-2018,22-AUG-2018,BR,Not Specified,BR-NOVOPROD-617266,-,-
15306917,Soliqua 100/33,Insulin Glargine\Lixisenatide,Product Used For Unknown Indication,Peripheral Swelling;Swelling Face;Pruritus,Non-Serious,Non-Serious,Not Specified,-,22-AUG-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,13-AUG-2018,22-AUG-2018,US,Not Specified,US-SA-2018SA227257,-,-
15306413,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,22-AUG-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-AUG-2018,22-AUG-2018,US,Not Specified,US-SA-2018SA229715,-,-
15301552,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injection Site Pruritus,Non-Serious,Non-Serious,Female,-,21-AUG-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-AUG-2018,21-AUG-2018,US,Not Specified,US-SA-2018SA229722,-,-
15301491,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Injection Site Nodule;Injection Site Haemorrhage;Injury Associated With Device,Non-Serious,Non-Serious,Female,-,21-AUG-2018,Non-Expedited,55 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-AUG-2018,21-AUG-2018,US,Not Specified,US-SA-2018SA227258,-,-
15301455,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Storage Error,Non-Serious,Non-Serious,Female,-,21-AUG-2018,Non-Expedited,38 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-AUG-2018,21-AUG-2018,US,Not Specified,US-SA-2018SA224979,-,-
15289208,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Rotator Cuff Repair;Sciatica;Toe Operation;Umbilical Hernia Repair;Appendicectomy;Spondylolisthesis;Cholecystectomy;Polyarthritis,Serious,Other Outcomes,Male,-,17-AUG-2018,Expedited,31 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,03-AUG-2018,17-AUG-2018,US,Not Specified,US-SA-2018SA218118,-,-
15286438,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Vision Blurred,Non-Serious,Non-Serious,Female,-,16-AUG-2018,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-AUG-2018,16-AUG-2018,US,Not Specified,US-SA-2018SA224998,-,-
15283719,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Drug Ineffective,Non-Serious,Non-Serious,Male,-,16-AUG-2018,Non-Expedited,54 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,09-AUG-2018,16-AUG-2018,US,Not Specified,US-SA-2018SA224960,-,-
15283683,Soliqua 100/33;Lantus,Insulin Glargine;Insulin Glargine\Lixisenatide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,16-AUG-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-AUG-2018,16-AUG-2018,US,Not Specified,US-SA-2018SA218215,-,-
15281285,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Palpitations;Abdominal Pain Upper;Nausea;Abdominal Distension,Serious,Hospitalized,Male,FEB-2018,15-AUG-2018,Expedited,50 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,06-AUG-2018,15-AUG-2018,FR,Not Specified,FR-NOVOPROD-616048,-,-
15278120,-,Insulin Glargine\Lixisenatide,-,Renal Failure,Serious,Other Outcomes,Not Specified,-,14-AUG-2018,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-JUN-2018,14-AUG-2018,US,Not Specified,US-SAKK-2018SA191213AA,-,-
15274866,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Weight Decreased;Blood Glucose Abnormal;Decreased Appetite,Non-Serious,Non-Serious,Female,-,14-AUG-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,31-JUL-2018,14-AUG-2018,US,Not Specified,US-SA-2018SA210710,-,-
15270851,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Use Issue;Injection Site Pain,Non-Serious,Non-Serious,Female,-,13-AUG-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,08-AUG-2018,13-AUG-2018,US,Not Specified,US-SA-2018SA220585,-,-
15270743,Lantus;Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Glargine,Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,13-AUG-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-AUG-2018,13-AUG-2018,US,Not Specified,US-SA-2018SA218222,-,-
15266706,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Swelling,Non-Serious,Non-Serious,Female,-,10-AUG-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,06-AUG-2018,10-AUG-2018,US,Not Specified,US-SA-2018SA219535,-,-
15263940,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus;Product Used For Unknown Indication,Labelled Drug-Drug Interaction Issue,Non-Serious,Non-Serious,Male,-,10-AUG-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Tresiba,06-AUG-2018,10-AUG-2018,US,Not Specified,US-SA-2018SA217076,-,-
15263930,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Abdominal Pain Upper;Stress;Diarrhoea,Non-Serious,Non-Serious,Female,-,10-AUG-2018,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,04-AUG-2018,10-AUG-2018,US,Not Specified,US-SA-2018SA218137,-,-
15023154,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Pancreatic Carcinoma;Blood Glucose Abnormal,Serious,Other Outcomes,Female,-,10-AUG-2018,Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,30-MAY-2018,18-JUN-2018,US,Not Specified,US-SA-2018SA147431,-,-
15255021,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Poor Quality Sleep;Blood Glucose Increased;Decreased Appetite;Pruritus;Abdominal Discomfort;Stress,Serious,Other Outcomes,Female,11-JUN-2018,08-AUG-2018,Expedited,39 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-JUN-2018,08-AUG-2018,US,Not Specified,US-SAKK-2018SA167756AA,-,-
15251365,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Tremor;Product Dose Omission Issue;Blood Glucose Increased;Vision Blurred,Non-Serious,Non-Serious,Male,-,08-AUG-2018,Non-Expedited,49 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-JUL-2018,07-AUG-2018,US,Not Specified,US-SA-2018SA209069,-,-
15251178,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Impaired Gastric Emptying,Serious,Other Outcomes,Female,14-FEB-2018,07-AUG-2018,Expedited,56 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-MAY-2018,07-AUG-2018,US,Not Specified,US-SA-2018SA167810,-,-
15248392,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Rash;Lip Swelling,Serious,Hospitalized,Female,-,07-AUG-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,31-JUL-2018,07-AUG-2018,US,Not Specified,US-SA-2018SA211743,-,-
15248332,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Off Label Use,Non-Serious,Non-Serious,Male,-,07-AUG-2018,Non-Expedited,52 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-JUL-2018,07-AUG-2018,US,Not Specified,US-SA-2018SA207908,-,-
15246458,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Decreased;Head Discomfort;Accident,Serious,Other Outcomes,Male,-,06-AUG-2018,Expedited,64 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-JUL-2018,06-AUG-2018,US,Not Specified,US-SA-2018SA207972,-,-
15244018,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Hypoglycaemia,Non-Serious,Non-Serious,Female,-,06-AUG-2018,Non-Expedited,57 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-JUL-2018,06-AUG-2018,US,Not Specified,US-SA-2018SA211984,-,-
15243981,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Issue;Injection Site Discomfort;Injection Site Pain,Non-Serious,Non-Serious,Female,-,06-AUG-2018,Non-Expedited,65 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,31-JUL-2018,06-AUG-2018,US,Not Specified,US-SA-2018SA212472,-,-
15238640,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Pancreatitis Acute,Serious,Other Outcomes;Hospitalized,Not Specified,-,03-AUG-2018,Expedited,50 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,26-JUN-2018,03-AUG-2018,US,Not Specified,US-SAKK-2018SA176387AA,-,-
15237077,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Pruritus,Non-Serious,Non-Serious,Female,-,03-AUG-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-JUL-2018,03-AUG-2018,US,Not Specified,US-SA-2018SA208966,-,-
15236910,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Drug Ineffective,Non-Serious,Non-Serious,Female,-,03-AUG-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,27-JUL-2018,03-AUG-2018,US,Not Specified,US-SA-2018SA207913,-,-
15230723,Synjardy;Soliqua 100/33,Insulin Glargine\Lixisenatide;Empagliflozin\Metformin Hydrochloride,-,Gout,Non-Serious,Non-Serious,Male,-,02-AUG-2018,Non-Expedited,40 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,27-JUL-2018,02-AUG-2018,US,Not Specified,US-SA-2018SA208372,-,-
15230679,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Adverse Event,Non-Serious,Non-Serious,Male,-,02-AUG-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,25-JUL-2018,02-AUG-2018,US,Not Specified,US-SA-2018SA206356,-,-
14826069,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Road Traffic Accident;Surgery;Upper Limb Fracture;Ankle Fracture,Serious,Other Outcomes;Hospitalized,Male,10-APR-2018,02-AUG-2018,Expedited,50 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,22-JUL-2018,30-APR-2018,IL,Not Specified,IL-NOVOPROD-596474,-,-
15228298,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Breast Enlargement,Non-Serious,Non-Serious,Male,-,01-AUG-2018,Non-Expedited,68 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Amlodipine,17-JUL-2018,01-AUG-2018,US,Not Specified,US-SA-2018SA198060,-,-
15226822,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Glycosylated Haemoglobin Increased;Blood Glucose Increased;Dysphagia;Feeling Abnormal;Thyroid Disorder;Arthralgia;Dyspepsia;Intentional Product Misuse;Product Dose Omission Issue;Gastrooesophageal Reflux Disease;Oesophageal Stenosis;Hiatus Hernia;Diarrhoea,Serious,Other Outcomes,Female,2018,01-AUG-2018,Expedited,44 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin,21-FEB-2018,01-AUG-2018,US,Not Specified,US-SA-2018SA056404,-,-
15226711,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Headache,Non-Serious,Non-Serious,Female,-,01-AUG-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,24-JUL-2018,01-AUG-2018,US,Not Specified,US-SA-2018SA205782,-,-
15226565,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Male,-,01-AUG-2018,Non-Expedited,73 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,16-JUL-2018,01-AUG-2018,US,Not Specified,US-SA-2018SA197174,-,-
15226564,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Weight Increased,Non-Serious,Non-Serious,Male,-,01-AUG-2018,Non-Expedited,64 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,17-JUL-2018,01-AUG-2018,US,Not Specified,US-SA-2018SA198044,-,-
15226494,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Injection Site Swelling,Non-Serious,Non-Serious,Female,-,01-AUG-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,17-JUL-2018,01-AUG-2018,US,Not Specified,US-SA-2018SA198078,-,-
15226390,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Movement Disorder;Abdominal Pain;Decreased Appetite,Serious,Other Outcomes,Female,19-JAN-2018,01-AUG-2018,Expedited,60 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,13-MAR-2018,01-AUG-2018,FR,Not Specified,FR-NOVOPROD-591676,-,-
15067833,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Dose Omission Issue;Coronary Artery Bypass;Blood Glucose Decreased,Serious,Hospitalized;Other Outcomes,Male,07-JUN-2018,01-AUG-2018,Expedited,64 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-JUL-2018,26-JUN-2018,US,Not Specified,US-SA-2018SA134259,-,-
14940257,Amaryl,Glimepiride;Investigational Product;Insulin Glargine\Lixisenatide;Lixisenatide,Atrial Fibrillation;Dyslipidaemia;Hypertension;Hyperuricaemia;Insomnia;Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Pulmonary Alveolar Haemorrhage;Cardiac Failure Congestive,Serious,Life Threatening;Died;Hospitalized,Female,12-APR-2017,01-AUG-2018,Expedited,71 YR,67 KG,Sanofi Aventis,Healthcare Professional,Not Specified,Allopurinol;Amlodipine Besylate;Atenolol;Rosuvastatin Calcium;Crestor;Metformin Hydrochloride;Etizolam;Warfarin Potassium,19-JUL-2018,25-MAY-2018,JP,Not Specified,JP-SA-2017SA075740,-,-
14472001,Trulicity;Soliqua 100/33;Toujeo;Humalog,Insulin Lispro;Insulin Glargine;Insulin Glargine\Lixisenatide;Dulaglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Nausea;Blood Glucose Increased;Glycosylated Haemoglobin Increased;Blood Glucose Fluctuation,Non-Serious,Non-Serious,Male,-,31-JUL-2018,Non-Expedited,Not Specified,Not Specified,Eli Lilly And Co,Consumer,Not Specified,-,16-JUL-2018,31-JAN-2018,US,Not Specified,US-ELI_LILLY_AND_COMPANY-US201801012032,-,-
15216968,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Blood Creatine Phosphokinase Increased,Serious,Other Outcomes,Female,-,30-JUL-2018,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Simvastatin;Ciprofibrate,23-JUL-2018,30-JUL-2018,BR,Not Specified,BR-NOVOPROD-613024,-,-
15215258,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Issue;Blood Glucose Increased,Non-Serious,Non-Serious,Female,10-APR-2018,30-JUL-2018,Non-Expedited,47 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-APR-2018,30-JUL-2018,US,Not Specified,US-SA-2018SA107152,-,-
15214971,Trulicity;Humalog;Soliqua 100/33;Toujeo,Insulin Glargine;Insulin Glargine\Lixisenatide;Insulin Lispro;Dulaglutide,Product Used For Unknown Indication,Blood Glucose Increased;Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Male,-,30-JUL-2018,Non-Expedited,Not Specified,Not Specified,Eli Lilly And Co,Consumer,Not Specified,-,23-JUL-2018,30-JUL-2018,US,Not Specified,US-ELI_LILLY_AND_COMPANY-US201807010852,-,-
15214001,Soliqua 100/33,Insulin Glargine\Lixisenatide,Product Used For Unknown Indication,Constipation,Non-Serious,Non-Serious,Female,-,30-JUL-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,18-JUL-2018,30-JUL-2018,US,Not Specified,US-SA-2018SA200564,-,-
15213942,Soliqua 100/33,Insulin Glargine\Lixisenatide,Product Used For Unknown Indication,Arthralgia,Non-Serious,Non-Serious,Male,-,30-JUL-2018,Non-Expedited,88 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,16-JUL-2018,30-JUL-2018,US,Not Specified,US-SA-2018SA197184,-,-
15213796,Soliqua 100/33,Insulin Glargine\Lixisenatide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Pruritus,Non-Serious,Non-Serious,Male,-,30-JUL-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Benadryl,05-JUL-2018,30-JUL-2018,US,Not Specified,US-SA-2018SA187746,-,-
15210395,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Pancreatitis,Serious,Other Outcomes,Male,-,27-JUL-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,21-JUN-2018,27-JUL-2018,US,Not Specified,US-SAKK-2018SA170517AA,-,-
15209397,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Headache;Dyspepsia,Non-Serious,Non-Serious,Male,-,27-JUL-2018,Non-Expedited,65 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-JUL-2018,27-JUL-2018,US,Not Specified,US-SA-2018SA192815,-,-
15204725,Xultophy 100/3.6;Metformin;Coveram;Liptruzet,Atorvastatin Calcium\Ezetimibe;Repaglinide;Amlodipine\Perindopril;Metformin Hydrochloride;Insulin Degludec\Liraglutide,Diabetes Mellitus;Dyslipidaemia;Hypertension;Product Used For Unknown Indication,Acute Kidney Injury;Disturbance In Attention;Lactic Acidosis;Acute Coronary Syndrome,Serious,Life Threatening,Male,20-APR-2018,26-JUL-2018,Expedited,79 YR,95 KG,Sandoz,Healthcare Professional,Not Specified,Clopidogrel;Levothyroxine;Pantoprazole,22-JUL-2018,26-JUL-2018,FR,Not Specified,PHHY2018FR055817,-,-
15194988,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Diarrhoea,Non-Serious,Non-Serious,Not Specified,-,25-JUL-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,10-JUL-2018,25-JUL-2018,US,Not Specified,US-SA-2018SA191275,-,-
15194980,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Not Specified,-,25-JUL-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,06-JUL-2018,25-JUL-2018,US,Not Specified,US-SA-2018SA187859,-,-
15194958,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Device Malfunction;Incorrect Dose Administered,Non-Serious,Non-Serious,Male,-,25-JUL-2018,Non-Expedited,45 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,06-JUL-2018,25-JUL-2018,US,Not Specified,US-SA-2018SA188193,-,-
15182862,Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Glargine,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,23-JUL-2018,Non-Expedited,65 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-JUL-2018,23-JUL-2018,US,Not Specified,US-SA-2018SA192953,-,-
15181231,Soliqua 100/33;Lantus Solostar,Insulin Glargine;Insulin Glargine\Lixisenatide,-,Blood Glucose Fluctuation,Non-Serious,Non-Serious,Male,-,23-JUL-2018,Non-Expedited,68 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-JUL-2018,23-JUL-2018,US,Not Specified,US-SA-2018SA191184,-,-
15180205,-,Investigational Product;Insulin Glargine;Insulin Glargine\Lixisenatide,Benign Prostatic Hyperplasia;Dyslipidaemia;Hypertension;Hypertonic Bladder;Lumbar Hernia;Musculoskeletal Stiffness;Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Angina Pectoris;Aneurysm,Serious,Hospitalized,Male,24-APR-2018,23-JUL-2018,Expedited,59 YR,78 KG,Sanofi Aventis,Healthcare Professional,Not Specified,Candesartan Cilexetil;Loxoprofen Sodium;Naftopidil;Metgluco;Atorvastatin Calcium;Imidafenacin,24-APR-2018,23-JUL-2018,JP,Not Specified,JP-SA-2018SA120408,-,-
15173025,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Injection Site Reaction,Non-Serious,Non-Serious,Female,-,20-JUL-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,21-JUN-2018,20-JUL-2018,US,Not Specified,US-SA-2018SA175692,-,-
15173012,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Nausea,Non-Serious,Non-Serious,Not Specified,-,20-JUL-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,05-JUN-2018,20-JUL-2018,US,Not Specified,US-SA-2018SA177756,-,-
15167890,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Vasculitis,Serious,Other Outcomes;Hospitalized,Male,-,19-JUL-2018,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,19-JUN-2018,19-JUL-2018,GR,Not Specified,GR-NOVOPROD-608219,-,-
15167244,Soliqua 100/33,Insulin Glargine\Lixisenatide,Product Used For Unknown Indication,Drug Ineffective,Non-Serious,Non-Serious,Not Specified,-,19-JUL-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-JUN-2018,19-JUL-2018,US,Not Specified,US-SA-2018SA190814,-,-
15166082,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Extra Dose Administered,Non-Serious,Non-Serious,Not Specified,12-JUN-2018,19-JUL-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,12-JUN-2018,19-JUL-2018,US,Not Specified,US-SA-2018SA190841,-,-
15153746,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Drug Ineffective,Non-Serious,Non-Serious,Not Specified,-,17-JUL-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,12-JUN-2018,17-JUL-2018,US,Not Specified,US-SA-2018SA190870,-,-
15151012,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Rosacea,Non-Serious,Non-Serious,Female,-,16-JUL-2018,Non-Expedited,50 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,02-JUL-2018,16-JUL-2018,US,Not Specified,US-SA-2018SA181449,-,-
15036717,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Pustular Psoriasis,Serious,Other Outcomes,Male,MAY-2018,16-JUL-2018,Expedited,66 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,02-JUL-2018,20-JUN-2018,US,Not Specified,US-NOVOPROD-606123,-,-
15144994,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Administration Site Bruise;Blood Glucose Decreased;Blood Glucose Increased;Weight Increased;Diarrhoea;Tremor;Gastric Ph Decreased,Serious,Other Outcomes,Female,-,13-JUL-2018,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,29-JUN-2018,13-JUL-2018,US,Not Specified,US-SA-2018SA182221,-,-
15140771,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Urine Analysis Abnormal;Hospitalisation;Nasopharyngitis;Oropharyngeal Pain;Hyperglycaemia;Weight Decreased;Asthenia;Dyspepsia;Urine Abnormality;Medication Error;Dizziness;Sneezing,Serious,Hospitalized,Female,APR-2018,13-JUL-2018,Expedited,52 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,11-APR-2018,13-JUL-2018,KR,Not Specified,KR-SA-2018SA107463,-,-
15140076,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Unevaluable Event,Non-Serious,Non-Serious,Male,-,13-JUL-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-MAY-2018,13-JUL-2018,US,Not Specified,US-SA-2018SA150675,-,-
15140029,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Prescribed Underdose,Non-Serious,Non-Serious,Not Specified,-,13-JUL-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,23-JUN-2018,13-JUL-2018,US,Not Specified,US-SA-2018SA174636,-,-
15136280,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment;Blood Glucose Increased;Drug Ineffective,Non-Serious,Non-Serious,Male,-,12-JUL-2018,Non-Expedited,62 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-JUN-2018,12-JUL-2018,US,Not Specified,US-SA-2018SA178139,-,-
15131253,-,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Dyspepsia;Dizziness;Dyspnoea,Serious,Other Outcomes,Male,-,11-JUL-2018,Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,20-JUN-2018,11-JUL-2018,US,Not Specified,US-SAKK-2018SA170886AA,-,-
15129741,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Injection Site Pain,Non-Serious,Non-Serious,Male,-,11-JUL-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,26-JUN-2018,11-JUL-2018,US,Not Specified,US-SA-2018SA178307,-,-
15129710,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Decreased,Non-Serious,Non-Serious,Male,-,11-JUL-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,27-JUN-2018,11-JUL-2018,US,Not Specified,US-SA-2018SA178311,-,-
15106484,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Hyperglycaemia;Diarrhoea,Non-Serious,Non-Serious,Male,-,11-JUL-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,04-JUN-2018,04-JUL-2018,US,Not Specified,US-SA-2018SA152268,-,-
15120797,Soliqua 100/33,Insulin Glargine\Lixisenatide,Product Used For Unknown Indication,Drug Hypersensitivity;Rash,Non-Serious,Non-Serious,Female,-,09-JUL-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,07-JUN-2018,09-JUL-2018,US,Not Specified,US-SA-2018SA178115,-,-
15120780,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Pancreatic Disorder,Non-Serious,Non-Serious,Not Specified,-,09-JUL-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,06-JUN-2018,09-JUL-2018,US,Not Specified,US-SA-2018SA174342,-,-
15120772,Soliqua 100/33,Insulin Glargine\Lixisenatide,Product Used For Unknown Indication,Injury Associated With Device,Non-Serious,Non-Serious,Female,-,09-JUL-2018,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,04-JUN-2018,09-JUL-2018,US,Not Specified,US-SA-2018SA166278,-,-
15120724,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Therapeutic Product Effect Incomplete;Blood Glucose Fluctuation;Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Female,-,09-JUL-2018,Non-Expedited,61 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-MAY-2018,09-JUL-2018,US,Not Specified,US-SA-2018SA161997,-,-
15120704,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Incorrect Dose Administered;Device Malfunction;Needle Issue,Non-Serious,Non-Serious,Male,-,09-JUL-2018,Non-Expedited,53 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,17-MAY-2018,09-JUL-2018,US,Not Specified,US-SA-2018SA159612,-,-
14852607,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Vomiting;Vertigo;Asthenia;Impaired Driving Ability;Pruritus;Blister;Nausea;Decreased Appetite,Serious,Other Outcomes,Female,-,09-JUL-2018,Expedited,68 YR,73 KG,Novo Nordisk,Healthcare Professional,Not Specified,Ezetimibe;Metformin Hydrochloride,27-JUN-2018,07-MAY-2018,IT,Not Specified,IT-NOVOPROD-597548,-,-
15114930,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,06-JUL-2018,Non-Expedited,55 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,01-JUN-2018,06-JUL-2018,US,Not Specified,US-SA-2018SA164293,-,-
15114921,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Quality Issue,Non-Serious,Non-Serious,Not Specified,31-MAY-2018,06-JUL-2018,Non-Expedited,66 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,31-MAY-2018,06-JUL-2018,US,Not Specified,US-SA-2018SA164304,-,-
14946402,Soliqua 100/33;Solostar;Toujeo,Insulin Glargine;Device;Insulin Glargine\Lixisenatide,Diabetes Mellitus,Wrong Product Administered;Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Male,2018,06-JUL-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,18-JUN-2018,29-MAY-2018,US,Not Specified,US-SA-2018SA099265,-,-
15111054,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Off Label Use,Non-Serious,Non-Serious,Male,-,05-JUL-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,21-JUN-2018,05-JUL-2018,US,Not Specified,US-SA-2018SA172658,-,-
15110860,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,05-JUL-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-MAY-2018,05-JUL-2018,US,Not Specified,US-SA-2018SA155745,-,-
15110825,Soliqua 100/33,Insulin Glargine\Lixisenatide,Hyperglycaemia,Hypoglycaemia,Non-Serious,Non-Serious,Female,-,05-JUL-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,16-MAY-2018,05-JUL-2018,US,Not Specified,US-SA-2018SA161942,-,-
15106817,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Diabetic Ketoacidosis,Serious,Other Outcomes,Not Specified,-,04-JUL-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,24-JUN-2018,04-JUL-2018,US,Not Specified,US-SA-2018SA173344,-,-
15106576,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Blood Glucose Increased;Malaise;Device Issue,Non-Serious,Non-Serious,Female,17-APR-2018,04-JUL-2018,Non-Expedited,58 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,17-APR-2018,04-JUL-2018,US,Not Specified,US-SA-2018SA113834,-,-
15106569,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Hyperglycaemia;Device Issue,Non-Serious,Non-Serious,Male,2018,04-JUL-2018,Non-Expedited,88 YR,77 KG,Sanofi Aventis,Consumer,Not Specified,-,23-APR-2018,04-JUL-2018,US,Not Specified,US-SA-2018SA118655,-,-
15106537,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Rash,Non-Serious,Non-Serious,Male,16-MAY-2018,04-JUL-2018,Non-Expedited,54 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,29-MAY-2018,04-JUL-2018,US,Not Specified,US-SA-2018SA146745,-,-
15106495,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Decreased;Nerve Injury;Food Craving;Blood Glucose Increased;Weight Increased;Peripheral Swelling;Dry Mouth,Non-Serious,Non-Serious,Female,-,04-JUL-2018,Non-Expedited,60 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Humalog;Lantus;Metformin,13-APR-2018,04-JUL-2018,US,Not Specified,US-SA-2018SA111405,-,-
15102728,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 1 Diabetes Mellitus,Ill-Defined Disorder,Non-Serious,Non-Serious,Female,-,03-JUL-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-JUN-2018,03-JUL-2018,US,Not Specified,US-SA-2018SA170811,-,-
15102696,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Weight Increased,Non-Serious,Non-Serious,Female,-,03-JUL-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,15-JUN-2018,03-JUL-2018,US,Not Specified,US-SA-2018SA170444,-,-
15102602,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Dose Omission Issue,Non-Serious,Non-Serious,Male,11-JUN-2018,03-JUL-2018,Non-Expedited,70 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-JUN-2018,03-JUL-2018,US,Not Specified,US-SA-2018SA165764,-,-
15102582,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Dose Omission Issue,Non-Serious,Non-Serious,Female,-,03-JUL-2018,Non-Expedited,62 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,13-JUN-2018,03-JUL-2018,US,Not Specified,US-SA-2018SA171999,-,-
15089142,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Nausea;Vomiting;Dizziness;Diarrhoea;Headache;Illness,Non-Serious,Non-Serious,Not Specified,-,29-JUN-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,13-JUN-2018,29-JUN-2018,US,Not Specified,US-SA-2018SA171984,-,-
15089133,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Drug Ineffective,Non-Serious,Non-Serious,Not Specified,-,29-JUN-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,-,13-JUN-2018,29-JUN-2018,US,Not Specified,US-SA-2018SA171956,-,-
15089108,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Back Pain,Non-Serious,Non-Serious,Male,-,29-JUN-2018,Non-Expedited,41 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,12-JUN-2018,29-JUN-2018,US,Not Specified,US-SA-2018SA165848,-,-
14391917,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Genitourinary Tract Neoplasm,Serious,Hospitalized,Male,30-SEP-2017,29-JUN-2018,Expedited,73 YR,66 KG,Takeda,Healthcare Professional,Not Specified,-,27-JUN-2018,16-JAN-2018,IT,Not Specified,IT-TAKEDA-2018TEU000164,-,-
15084320,Xultophy 100/3.6;Coveram;Liptruzet,Atorvastatin Calcium\Ezetimibe;Amlodipine\Perindopril;Metformin Hydrochloride;Repaglinide;Insulin Degludec\Liraglutide,Diabetes Mellitus;Dyslipidaemia;Hypertension,Acute Coronary Syndrome;Lactic Acidosis;Acute Kidney Injury;Disturbance In Attention,Serious,Life Threatening,Male,20-APR-2018,28-JUN-2018,Expedited,79 YR,95 KG,Teva,Healthcare Professional,Not Specified,Levothyroxine;Pantoprazole;Clopidogrel Hydrochloride,21-JUN-2018,28-JUN-2018,FR,Not Specified,FR-TEVA-2018-FR-913432,-,-
15075758,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Device Breakage,Non-Serious,Non-Serious,Female,-,27-JUN-2018,Non-Expedited,52 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,08-JUN-2018,27-JUN-2018,US,Not Specified,US-SA-2018SA164574,-,-
15067789,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Benign Prostatic Hyperplasia;Diabetes Mellitus;Hypertension;Type 2 Diabetes Mellitus,Rash;Joint Swelling,Non-Serious,Non-Serious,Male,21-FEB-2018,26-JUN-2018,Non-Expedited,55 YR,80.73 KG,Sanofi Aventis,Healthcare Professional,Not Specified,Toujeo;Metformin;Losartan;Cialis;Tamsulosin,23-APR-2018,26-JUN-2018,US,Not Specified,US-SA-2018SA120685,-,-
15061872,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Supraventricular Extrasystoles,Serious,Other Outcomes,Male,2018,25-JUN-2018,Expedited,52 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,14-JUN-2018,25-JUN-2018,US,Not Specified,US-NOVOPROD-606542,-,-
15061734,Actoplus Met;Actos,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,2016,25-JUN-2018,Non-Expedited,Not Specified,Not Specified,Takeda,Consumer,Not Specified,-,20-JUN-2018,25-JUN-2018,US,Not Specified,US-TAKEDA-2018TUS020439,-,-
15059803,Soliqua 100/33;Lantus,Insulin Glargine;Insulin Glargine\Lixisenatide,Diabetes Mellitus,Nausea;Fluid Retention,Non-Serious,Non-Serious,Female,-,25-JUN-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,07-JUN-2018,25-JUN-2018,US,Not Specified,US-SA-2018SA164246,-,-
15037110,-,Insulin Nos;Insulin Aspart;Insulin Lispro;Insulin Glulisine;Insulin Human;Investigational Product;Insulin Glargine\Lixisenatide,Type 1 Diabetes Mellitus,Alanine Aminotransferase Increased,Serious,Other Outcomes,Female,27-DEC-2017,20-JUN-2018,Expedited,14 YR,58 KG,Sanofi Aventis,Healthcare Professional,Not Specified,-,29-DEC-2017,20-JUN-2018,CL,Not Specified,CL-SA-2018SA000328,-,-
15029566,-,Insulin Glargine\Lixisenatide;Metformin Hydrochloride,Cholelithiasis;Hyperlipidaemia;Hypertension;Hyperuricaemia;Prophylaxis;Type 2 Diabetes Mellitus,Cardiac Failure,Serious,Hospitalized,Female,22-JAN-2018,19-JUN-2018,Expedited,73 YR,101 KG,Sanofi Aventis,Healthcare Professional,Not Specified,Allopurinol;Eliquis;Ciprofibrate;Repatha;Bezafibrate;Enalapril Maleate\Lercanidipine Hydrochloride;Cephalexin;Bisoprolol Fumarate;Herbals;Amiodarone Hydrochloride;Cymbalta,23-JAN-2018,19-JUN-2018,IL,Not Specified,IL-SA-2018SA019406,-,-
15028967,Xultophy 100/3.6,Insulin Degludec\Liraglutide;Furosemide;Ramipril,Hypertension;Oedema;Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Renal Tubular Necrosis,Serious,Hospitalized,Male,22-JAN-2018,19-JUN-2018,Expedited,62 YR,94 KG,Mylan,Healthcare Professional,Not Specified,Bisoprolol Fumarate;Kardegic;Metformin Hydrochloride,06-JUN-2018,19-JUN-2018,FR,Not Specified,FR-MYLANLABS-2018M1040056,-,-
15026753,Metformin;Coveram;Xultophy 100/3.6;Liptruzet,Atorvastatin Calcium\Ezetimibe;Insulin Degludec\Liraglutide;Amlodipine\Perindopril;Repaglinide;Metformin Hydrochloride,Diabetes Mellitus;Dyslipidaemia;Hypertension;Product Used For Unknown Indication,Lactic Acidosis;Acute Kidney Injury;Disturbance In Attention;Acute Coronary Syndrome,Serious,Hospitalized,Male,20-APR-2018,18-JUN-2018,Expedited,79 YR,95 KG,Ranbaxy,Healthcare Professional,Not Specified,Clopidogrel;Levothyroxine;Pantoprazole,04-JUN-2018,18-JUN-2018,FR,Not Specified,FR-SUN PHARMACEUTICAL INDUSTRIES LTD-2018R1-175949,-,-
15023157,Soliqua 100/33,Insulin Glargine\Lixisenatide,Product Used For Unknown Indication,Renal Pain,Serious,Other Outcomes,Male,30-MAY-2018,18-JUN-2018,Expedited,53 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,30-MAY-2018,18-JUN-2018,US,Not Specified,US-SAKK-2018SA150623AA,-,-
15010783,Coveram;Xultophy 100/3.6;Metformin;Liptruzet,Atorvastatin Calcium\Ezetimibe;Metformin Hydrochloride;Insulin Degludec\Liraglutide;Amlodipine\Perindopril;Repaglinide,Diabetes Mellitus;Dyslipidaemia;Hypertension,Acute Coronary Syndrome;Acute Kidney Injury;Lactic Acidosis;Disturbance In Attention,Serious,Life Threatening,Male,20-APR-2018,14-JUN-2018,Expedited,79 YR,95 KG,Merck,Healthcare Professional,Not Specified,Pantoprazole;Clopidogrel;Levothyroxine,08-JUN-2018,14-JUN-2018,FR,Not Specified,FR-009507513-1806FRA004208,-,-
14997390,Metformin;Coveram;Liptruzet;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Atorvastatin Calcium\Ezetimibe;Amlodipine\Perindopril;Repaglinide;Metformin Hydrochloride,Dyslipidaemia;Hypertension;Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Disturbance In Attention;Acute Kidney Injury;Acute Coronary Syndrome;Lactic Acidosis,Serious,Life Threatening,Not Specified,20-APR-2018,11-JUN-2018,Expedited,Not Specified,Not Specified,Marina Biotech,Healthcare Professional,Not Specified,Levothyroxine;Clopidogrel;Pantoprazole,28-MAY-2018,11-JUN-2018,FR,Not Specified,"FR-MARINA BIOTECH, INC.-2018MARINA000515",-,-
14992626,Xultophy 100/3.6;Liptruzet;Metformin;Coveram,Amlodipine\Perindopril;Metformin Hydrochloride;Atorvastatin Calcium\Ezetimibe;Insulin Degludec\Liraglutide;Repaglinide,Diabetes Mellitus;Dyslipidaemia;Hypertension;Product Used For Unknown Indication,Acute Coronary Syndrome;Lactic Acidosis;Disturbance In Attention;Acute Kidney Injury,Serious,Life Threatening,Male,20-APR-2018,09-JUN-2018,Expedited,79 YR,95 KG,Aurobindo,Healthcare Professional,Not Specified,Levothyroxine;Clopidogrel Hydrochloride;Pantoprazole,27-MAY-2018,09-JUN-2018,FR,Not Specified,FR-AUROBINDO-AUR-APL-2018-029869,-,-
14984114,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Dizziness;Rhinorrhoea;Nausea,Non-Serious,Non-Serious,Male,11-MAY-2018,07-JUN-2018,Non-Expedited,64 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,14-MAY-2018,07-JUN-2018,US,Not Specified,US-NOVOPROD-601042,-,-
14984103,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Pancreatitis,Serious,Hospitalized,Male,-,07-JUN-2018,Non-Expedited,58 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,25-APR-2018,07-JUN-2018,US,Not Specified,US-NOVOPROD-597920,-,-
14984102,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Dizziness;Constipation,Non-Serious,Non-Serious,Female,2018,07-JUN-2018,Non-Expedited,74 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,19-APR-2018,07-JUN-2018,US,Not Specified,US-NOVOPROD-596822,-,-
14984091,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Blood Glucose Increased;Wrong Technique In Product Usage Process,Non-Serious,Non-Serious,Male,-,07-JUN-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,30-APR-2018,07-JUN-2018,US,Not Specified,US-NOVOPROD-598672,-,-
14984087,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Flatulence;Abdominal Distension,Non-Serious,Non-Serious,Male,-,07-JUN-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,25-APR-2018,07-JUN-2018,US,Not Specified,US-NOVOPROD-597918,-,-
14984086,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Injection Site Bruising;Device Malfunction,Non-Serious,Non-Serious,Female,APR-2018,07-JUN-2018,Non-Expedited,53 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,20-APR-2018,07-JUN-2018,US,Not Specified,US-NOVOPROD-597190,-,-
14984085,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,16-APR-2018,07-JUN-2018,Non-Expedited,54 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,19-APR-2018,07-JUN-2018,US,Not Specified,US-NOVOPROD-596823,-,-
14984084,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Circumstance Or Information Capable Of Leading To Medication Error,Non-Serious,Non-Serious,Male,-,07-JUN-2018,Non-Expedited,41 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,19-APR-2018,07-JUN-2018,US,Not Specified,US-NOVOPROD-597162,-,-
14984079,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Glycosylated Haemoglobin Increased;Treatment Noncompliance;Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,07-JUN-2018,Non-Expedited,49 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,09-MAR-2018,07-JUN-2018,US,Not Specified,US-NOVOPROD-590847,-,-
14984078,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Blood Glucose Increased,Back Pain;Night Sweats,Non-Serious,Non-Serious,Female,-,07-JUN-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,30-MAR-2018,07-JUN-2018,US,Not Specified,US-NOVOPROD-593559,-,-
14984077,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Blood Glucose Increased,Non-Serious,Non-Serious,Male,14-MAR-2018,07-JUN-2018,Non-Expedited,48 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,15-MAR-2018,07-JUN-2018,US,Not Specified,US-NOVOPROD-591364,-,-
14984076,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Peripheral Coldness;Nasopharyngitis,Non-Serious,Non-Serious,Male,MAR-2018,07-JUN-2018,Non-Expedited,81 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,13-MAR-2018,07-JUN-2018,US,Not Specified,US-NOVOPROD-590659,-,-
14984075,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Herpes Zoster,Non-Serious,Non-Serious,Male,MAR-2018,07-JUN-2018,Non-Expedited,63 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,04-APR-2018,07-JUN-2018,US,Not Specified,US-NOVOPROD-594338,-,-
14984074,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Fluid Retention;Type 2 Diabetes Mellitus,Malaise;Diabetes Mellitus Inadequate Control,Non-Serious,Non-Serious,Female,-,07-JUN-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,Lasix,26-MAR-2018,07-JUN-2018,US,Not Specified,US-NOVOPROD-592504,-,-
14984073,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Product Quality Issue;Blood Glucose Increased,Non-Serious,Non-Serious,Female,16-MAR-2018,07-JUN-2018,Non-Expedited,50 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Novolog,19-MAR-2018,07-JUN-2018,US,Not Specified,US-NOVOPROD-591847,-,-
14984072,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Nausea;Flatulence;Diarrhoea;Decreased Appetite;Off Label Use,Non-Serious,Non-Serious,Female,23-MAR-2018,07-JUN-2018,Non-Expedited,64 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,26-MAR-2018,07-JUN-2018,US,Not Specified,US-NOVOPROD-592730,-,-
14984071,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Rash,Non-Serious,Non-Serious,Female,FEB-2018,07-JUN-2018,Non-Expedited,72 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,19-APR-2018,07-JUN-2018,US,Not Specified,US-NOVOPROD-596821,-,-
14984070,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Rash,Non-Serious,Non-Serious,Female,NOV-2017,07-JUN-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,11-APR-2018,07-JUN-2018,US,Not Specified,US-NOVOPROD-595705,-,-
14984069,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Product Prescribing Error,Non-Serious,Non-Serious,Female,-,07-JUN-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,26-MAR-2018,07-JUN-2018,US,Not Specified,US-NOVOPROD-592708,-,-
14984068,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Pancreatitis,Serious,Other Outcomes,Male,13-MAR-2018,07-JUN-2018,Non-Expedited,50 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Lantus,28-MAR-2018,07-JUN-2018,US,Not Specified,US-NOVOPROD-593220,-,-
14984065,Novolog;Humalog;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Insulin Lispro;Insulin Aspart,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,29-MAR-2018,07-JUN-2018,Non-Expedited,76 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,30-MAR-2018,07-JUN-2018,US,Not Specified,US-NOVOPROD-593691,-,-
14984041,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Male,FEB-2018,07-JUN-2018,Non-Expedited,65 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,05-MAR-2018,07-JUN-2018,US,Not Specified,US-NOVOPROD-589161,-,-
14984040,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Wrong Technique In Product Usage Process,Non-Serious,Non-Serious,Male,01-MAR-2018,07-JUN-2018,Non-Expedited,82 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,12-MAR-2018,07-JUN-2018,US,Not Specified,US-NOVOPROD-590414,-,-
14984039,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Injection Site Discomfort,Non-Serious,Non-Serious,Female,DEC-2017,07-JUN-2018,Non-Expedited,56 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,13-MAR-2018,07-JUN-2018,US,Not Specified,US-NOVOPROD-590656,-,-
14984038,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Weight Decreased;Abdominal Discomfort,Non-Serious,Non-Serious,Male,NOV-2017,07-JUN-2018,Non-Expedited,75 YR,98.87 KG,Novo Nordisk,Consumer,Not Specified,-,05-MAR-2018,07-JUN-2018,US,Not Specified,US-NOVOPROD-589257,-,-
14984037,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Nausea;Product Storage Error;Renal Disorder;Diarrhoea;Blood Glucose Increased;Incorrect Product Administration Duration,Non-Serious,Non-Serious,Female,FEB-2018,07-JUN-2018,Non-Expedited,48 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,28-FEB-2018,07-JUN-2018,US,Not Specified,US-NOVOPROD-588347,-,-
14984036,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Pancreatitis,Serious,Other Outcomes,Male,-,07-JUN-2018,Non-Expedited,52 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,02-MAR-2018,07-JUN-2018,US,Not Specified,US-NOVOPROD-589004,-,-
14984031,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus Inadequate Control;Hyperlipidaemia;Hypertension;Product Used For Unknown Indication,Nausea;Vomiting;Cholelithiasis,Serious,Hospitalized,Female,FEB-2018,07-JUN-2018,Non-Expedited,81 YR,61.86 KG,Novo Nordisk,Healthcare Professional,Not Specified,Clopidogrel;Aspirin;Metoprolol Succinate;Crestor;Citalopram,07-MAR-2018,07-JUN-2018,US,Not Specified,US-NOVOPROD-589650,-,-
14984030,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Drug Ineffective,Non-Serious,Non-Serious,Male,09-FEB-2018,07-JUN-2018,Non-Expedited,85 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,27-FEB-2018,07-JUN-2018,US,Not Specified,US-NOVOPROD-588340,-,-
14635919,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Influenza;Feeding Disorder;Asthenia,Non-Serious,Non-Serious,Female,27-DEC-2017,07-JUN-2018,Non-Expedited,66 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,09-MAR-2018,14-MAR-2018,US,Not Specified,US-NOVOPROD-583553,-,-
14635871,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Wrong Technique In Product Usage Process,Non-Serious,Non-Serious,Female,17-NOV-2017,07-JUN-2018,Non-Expedited,63 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,09-MAR-2018,14-MAR-2018,US,Not Specified,US-NOVOPROD-574702,-,-
14635861,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Extra Dose Administered,Non-Serious,Non-Serious,Female,16-DEC-2017,07-JUN-2018,Non-Expedited,70 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,09-MAR-2018,14-MAR-2018,US,Not Specified,US-NOVOPROD-577913,-,-
14252283,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus;Diabetes Mellitus Management,Nausea;Gastrooesophageal Reflux Disease,Non-Serious,Non-Serious,Female,26-OCT-2017,07-JUN-2018,Non-Expedited,55 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,09-MAR-2018,05-DEC-2017,US,Not Specified,US-NOVOPROD-572006,-,-
14976582,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Vomiting;Nausea,Non-Serious,Non-Serious,Male,2018,05-JUN-2018,Non-Expedited,82 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,21-MAY-2018,05-JUN-2018,US,Not Specified,US-SA-2018SA143235,-,-
14973413,Liptruzet;Coveram;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Metformin Hydrochloride;Amlodipine\Perindopril;Atorvastatin Calcium\Ezetimibe;Repaglinide,Dyslipidaemia;Hypertension;Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Blood Glucose Increased;Acute Coronary Syndrome;Lactic Acidosis;Acute Kidney Injury;Disturbance In Attention,Serious,Life Threatening,Male,20-APR-2018,05-JUN-2018,Expedited,79 YR,95 KG,Novo Nordisk,Healthcare Professional,Not Specified,Levothyroxine;Pantoprazole;Clopidogrel Hydrochloride,28-MAY-2018,05-JUN-2018,FR,Not Specified,FR-NOVOPROD-603457,-,-
14969288,Xultophy 100/3.6;Coveram;Liptruzet,Atorvastatin Calcium\Ezetimibe;Metformin Hydrochloride;Repaglinide;Amlodipine\Perindopril;Insulin Degludec\Liraglutide,Diabetes Mellitus;Dyslipidaemia;Hypertension;Product Used For Unknown Indication,Disturbance In Attention;Acute Kidney Injury;Lactic Acidosis;Acute Coronary Syndrome,Serious,Life Threatening,Male,20-APR-2018,04-JUN-2018,Expedited,79 YR,95 KG,Bausch And Lomb,Healthcare Professional,Not Specified,Levothyroxine;Pantoprazole;Clopidogrel Hydrochloride,29-MAY-2018,04-JUN-2018,FR,Not Specified,FR-BAUSCH-BL-2018-015700,-,-
14957801,Invokana;Victoza;Lantus;Metformin;Humalog,Insulin Lispro;Metformin Hydrochloride;Insulin Glargine;Liraglutide;Metformin Hydrochloride\Pioglitazone Hydrochloride;Canagliflozin,Diabetes Mellitus;Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Metatarsal Excision;Diabetic Foot;Acute Kidney Injury;Osteomyelitis,Serious,Hospitalized,Male,JUL-2014,31-MAY-2018,Expedited,55 YR,Not Specified,Janssen,Healthcare Professional,Not Specified,-,24-MAY-2018,31-MAY-2018,US,Not Specified,US-JNJFOC-20180538965,-,-
14957482,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Diabetic Ketoacidosis,Serious,Other Outcomes,Male,-,31-MAY-2018,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,17-MAY-2018,31-MAY-2018,US,Not Specified,US-NOVOPROD-601496,-,-
14948184,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Eye Haemorrhage,Serious,Other Outcomes,Female,MAY-2018,29-MAY-2018,Expedited,64 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,18-MAY-2018,29-MAY-2018,US,Not Specified,US-NOVOPROD-601733,-,-
14946339,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Decreased,Non-Serious,Non-Serious,Female,-,29-MAY-2018,Non-Expedited,Not Specified,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin Hydrochloride,21-MAY-2018,29-MAY-2018,US,Not Specified,US-SA-2018SA143303,-,-
14945956,Pioglitazone And Metformin Hydrocholride,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Product Dispensing Error;Blood Glucose Increased;Drug Ineffective,Non-Serious,Non-Serious,Not Specified,-,29-MAY-2018,Non-Expedited,Not Specified,Not Specified,Macleods,Consumer,Not Specified,-,09-MAR-2018,29-MAY-2018,US,Not Specified,US-MACLEODS PHARMACEUTICALS US LTD-MAC2018011484,-,-
14943837,Xultophy 100/3.6,Insulin Degludec\Liraglutide;Furosemide;Ramipril,Hypertension;Oedema;Type 2 Diabetes Mellitus,Renal Tubular Necrosis,Serious,Hospitalized,Male,22-JAN-2018,28-MAY-2018,Expedited,62 YR,94 KG,Teva,Healthcare Professional,Not Specified,Kardegic;Bisoprolol Fumarate;Metformin Hydrochloride,24-MAY-2018,28-MAY-2018,FR,Not Specified,FR-TEVA-2018-FR-898430,-,-
14939316,-,Pioglitazone Hydrochloride;Metformin Hydrochloride;Insulin Glargine\Lixisenatide,Coronary Artery Disease;Hypercholesterolaemia;Hypertension;Type 2 Diabetes Mellitus;Urinary Retention,Basal Cell Carcinoma,Serious,Other Outcomes,Male,17-FEB-2017,25-MAY-2018,Non-Expedited,75 YR,84 KG,Sanofi Aventis,Healthcare Professional,Not Specified,Aspirin;Amlodipine;Dipyridamole;Flomax;Lisinopril;Atenolol;Atorvastatin,19-JUL-2017,25-MAY-2018,US,Not Specified,US-SA-2017SA135434,-,-
14681824,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Jaundice,Serious,Hospitalized,Male,16-MAR-2018,22-MAY-2018,Expedited,Not Specified,88 KG,Novo Nordisk,Healthcare Professional,Not Specified,Aspirin;Lipitor;Lasix;Metformin;Glucophage,11-MAY-2018,26-MAR-2018,GR,Not Specified,GR-NOVOPROD-591631,-,-
14892173,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Haematochezia;Vision Blurred;Blood Urine Present;Back Pain;Headache,Serious,Other Outcomes,Female,19-APR-2018,21-MAY-2018,Expedited,57 YR,88.89 KG,Novo Nordisk,Healthcare Professional,Not Specified,-,08-MAY-2018,14-MAY-2018,US,Not Specified,US-NOVOPROD-599408,-,-
14898409,Solostar;Toujeo;Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Glargine;Device,Diabetes Mellitus,Injection Site Erythema;Rash;Blood Glucose Abnormal,Non-Serious,Non-Serious,Male,-,17-MAY-2018,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,22-MAR-2018,15-MAY-2018,US,Not Specified,US-SA-2018SA089250,-,-
14898107,Humalog;Toujeo;Xultophy 100/3.6;Solostar;Jardiance,Empagliflozin;Device;Insulin Degludec\Liraglutide;Insulin Glargine;Insulin Lispro,-,Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Not Specified,-,17-MAY-2018,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,28-OCT-2017,15-MAY-2018,US,Not Specified,US-SA-2018SA025532,-,-
14898741,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Anaphylactic Reaction,Serious,Hospitalized,Female,-,15-MAY-2018,Expedited,56 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,-,10-MAY-2018,15-MAY-2018,US,Not Specified,US-SA-2018SA135728,-,-
14879068,Toujeo;Farxiga;Xultophy 100/3.6;Humalog;Apidra,Insulin Glulisine;Insulin Lispro;Lixisenatide;Insulin Degludec\Liraglutide;Dapagliflozin Propanediol;Insulin Glargine,-,Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Female,-,15-MAY-2018,Non-Expedited,60 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,Vildagliptin;Novolog;Victoza;Invokana;Tresiba,22-OCT-2017,11-MAY-2018,US,Not Specified,US-SA-2018SA043523,-,-
10243845,Soliqua 100/33;Solostar;Lantus Solostar,Insulin Glargine;Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Vascular Graft;Blood Glucose Fluctuation;Weight Increased;Peripheral Vascular Disorder,Serious,Hospitalized,Male,-,12-MAY-2018,Expedited,60 YR,Not Specified,Aventis,Consumer,Not Specified,-,07-MAY-2018,18-JUN-2014,US,Not Specified,US-SA-2014SA076137,-,-
14876405,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Death;Dizziness,Serious,Died,Male,-,10-MAY-2018,Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,27-APR-2018,10-MAY-2018,US,Not Specified,US-SA-2018SA124323,-,-
14802470,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus;Weight Control,Pneumonia,Serious,Hospitalized,Female,-,24-APR-2018,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,13-APR-2018,24-APR-2018,BR,Not Specified,BR-NOVOPROD-596005,-,-
14787899,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Bladder Cancer,Serious,Other Outcomes,Not Specified,-,22-APR-2018,Non-Expedited,Not Specified,Not Specified,Teva,Consumer,Not Specified,-,10-APR-2018,22-APR-2018,US,Not Specified,US-TEVA-2018-US-882114,-,-
14787173,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Vomiting;Irritable Bowel Syndrome,Serious,Hospitalized,Male,-,21-APR-2018,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,11-APR-2018,21-APR-2018,IL,Not Specified,IL-NOVOPROD-595519,-,-
14689495,Xultophy 100/3.6,Insulin Degludec\Liraglutide;Ramipril;Furosemide,Hypertension;Oedema;Type 2 Diabetes Mellitus,Renal Tubular Necrosis,Serious,Other Outcomes;Hospitalized,Male,22-JAN-2018,04-APR-2018,Expedited,62 YR,Not Specified,Pfizer,Healthcare Professional,Not Specified,Bisoprolol Fumarate;Kardegic;Metformin,29-MAR-2018,28-MAR-2018,FR,Not Specified,FR-PFIZER INC-2018126361,-,-
14709274,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Cardiac Failure Congestive;Blood Glucose Increased,Serious,Other Outcomes,Female,-,03-APR-2018,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,26-MAR-2018,03-APR-2018,US,Not Specified,US-NOVOPROD-592699,-,-
14707369,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Blood Glucose Fluctuation;Drug Ineffective,Non-Serious,Non-Serious,Male,-,03-APR-2018,Non-Expedited,Not Specified,67.12 KG,Aurobindo,Consumer,Not Specified,-,11-JUL-2017,03-APR-2018,US,Not Specified,US-AUROBINDO-AUR-APU-2017-37301,-,-
14701898,Xultophy 100/3.6,Insulin Degludec\Liraglutide;Furosemide;Ramipril,Hypertension;Oedema;Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Renal Tubular Necrosis,Serious,Other Outcomes;Hospitalized,Male,22-JAN-2018,31-MAR-2018,Expedited,62 YR,94 KG,Aurobindo,Healthcare Professional,Not Specified,Bisoprolol Fumarate;Metformin Hydrochloride;Kardegic,20-MAR-2018,31-MAR-2018,FR,Not Specified,FR-AUROBINDO-AUR-APL-2018-017046,-,-
14699395,Xultophy 100/3.6,Insulin Degludec\Liraglutide;Furosemide;Ramipril,Hypertension;Oedema;Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Renal Tubular Necrosis,Serious,Hospitalized,Male,22-JAN-2018,30-MAR-2018,Expedited,62 YR,Not Specified,Validus,Healthcare Professional,Not Specified,Kardegic;Metformin;Bisoprolol Fumarate,20-MAR-2018,30-MAR-2018,FR,Not Specified,FR-VALIDUS PHARMACEUTICALS LLC-FR-2018VAL000576,-,-
14699336,Xultophy 100/3.6,Insulin Degludec\Liraglutide;Ramipril;Furosemide,Hypertension;Oedema;Type 2 Diabetes Mellitus,Renal Tubular Necrosis,Serious,Hospitalized,Male,22-JAN-2018,30-MAR-2018,Expedited,62 YR,94 KG,Novo Nordisk,Healthcare Professional,Not Specified,Kardegic;Metformin;Bisoprolol Fumarate,20-MAR-2018,30-MAR-2018,FR,Not Specified,FR-NOVOPROD-592072,-,-
14679563,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Muscular Weakness,Serious,Other Outcomes;Disabled,Male,-,26-MAR-2018,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Metformin,13-MAR-2018,26-MAR-2018,HU,Not Specified,HU-NOVOPROD-590466,-,-
14659774,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Retinopathy,Serious,Other Outcomes,Female,-,20-MAR-2018,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,09-MAR-2018,20-MAR-2018,GB,Not Specified,GB-NOVOPROD-590272,-,-
14650164,Bydureon;Xultophy 100/3.6;Victoza,Liraglutide;Insulin Degludec\Liraglutide;Exenatide,Type 2 Diabetes Mellitus,Malignant Peritoneal Neoplasm;Pancreatic Carcinoma,Serious,Hospitalized;Life Threatening,Female,JAN-2018,16-MAR-2018,Expedited,71 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,06-MAR-2018,16-MAR-2018,CH,Not Specified,CH-NOVOPROD-589507,-,-
14635921,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Injection Site Pain,Non-Serious,Non-Serious,Male,JAN-2018,14-MAR-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,18-JAN-2018,14-MAR-2018,US,Not Specified,US-NOVOPROD-582219,-,-
14635920,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Male,17-JAN-2018,14-MAR-2018,Non-Expedited,56 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,19-JAN-2018,14-MAR-2018,US,Not Specified,US-NOVOPROD-582484,-,-
14635918,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Tinnitus,Non-Serious,Non-Serious,Female,JAN-2018,14-MAR-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,31-JAN-2018,14-MAR-2018,US,Not Specified,US-NOVOPROD-584212,-,-
14635917,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Swelling Face,Non-Serious,Non-Serious,Female,NOV-2017,14-MAR-2018,Non-Expedited,55 YR,73.92 KG,Novo Nordisk,Healthcare Professional,Not Specified,-,03-JAN-2018,14-MAR-2018,US,Not Specified,US-NOVOPROD-580045,-,-
14635916,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Male,06-JAN-2018,14-MAR-2018,Non-Expedited,85 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,23-JAN-2018,14-MAR-2018,US,Not Specified,US-NOVOPROD-582888,-,-
14635915,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Tinnitus;Blood Glucose Increased;Dizziness,Non-Serious,Non-Serious,Female,JAN-2018,14-MAR-2018,Non-Expedited,62 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Stelara,31-JAN-2018,14-MAR-2018,US,Not Specified,US-NOVOPROD-584161,-,-
14635914,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Vomiting,Non-Serious,Non-Serious,Female,26-JAN-2018,14-MAR-2018,Non-Expedited,69 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,29-JAN-2018,14-MAR-2018,US,Not Specified,US-NOVOPROD-583757,-,-
14635913,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Vomiting;Nausea,Non-Serious,Non-Serious,Male,24-JAN-2018,14-MAR-2018,Non-Expedited,72 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,25-JAN-2018,14-MAR-2018,US,Not Specified,US-NOVOPROD-583376,-,-
14635912,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Pancreatitis,Serious,Other Outcomes,Not Specified,-,14-MAR-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,22-JAN-2018,14-MAR-2018,US,Not Specified,US-NOVOPROD-582674,-,-
14635911,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Abdominal Pain,Non-Serious,Non-Serious,Female,-,14-MAR-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,20-FEB-2018,14-MAR-2018,US,Not Specified,US-NOVOPROD-587460,-,-
14635910,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,14-MAR-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,07-FEB-2018,14-MAR-2018,US,Not Specified,US-NOVOPROD-585296,-,-
14635909,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Pancreatitis,Serious,Other Outcomes,Not Specified,-,14-MAR-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,22-JAN-2018,14-MAR-2018,US,Not Specified,US-NOVOPROD-582675,-,-
14635908,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Device Malfunction,Non-Serious,Non-Serious,Female,05-JAN-2018,14-MAR-2018,Non-Expedited,71 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,05-JAN-2018,14-MAR-2018,US,Not Specified,US-NOVOPROD-580739,-,-
14635907,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Product Storage Error;Blood Glucose Increased,Serious,Other Outcomes,Female,-,14-MAR-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,05-JAN-2018,14-MAR-2018,US,Not Specified,US-NOVOPROD-580428,-,-
14635906,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Pruritus,Non-Serious,Non-Serious,Male,DEC-2017,14-MAR-2018,Non-Expedited,75 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,01-FEB-2018,14-MAR-2018,US,Not Specified,US-NOVOPROD-584356,-,-
14635903,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Malaise,Non-Serious,Non-Serious,Female,03-FEB-2018,14-MAR-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,10-FEB-2018,14-MAR-2018,US,Not Specified,US-NOVOPROD-585707,-,-
14635873,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Gastrooesophageal Reflux Disease;Dyspepsia,Non-Serious,Non-Serious,Female,11-DEC-2017,14-MAR-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,13-DEC-2017,14-MAR-2018,US,Not Specified,US-NOVOPROD-577539,-,-
14635872,Xultophy 100/3.6;Victoza,Liraglutide;Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Off Label Use;Blood Glucose Increased,Non-Serious,Non-Serious,Male,2017,14-MAR-2018,Non-Expedited,76 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,14-DEC-2017,14-MAR-2018,US,Not Specified,US-NOVOPROD-577723,-,-
14635870,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Vomiting;Blood Glucose Decreased;Nausea;Diarrhoea;Taste Disorder;Weight Increased,Non-Serious,Non-Serious,Female,2017,14-MAR-2018,Non-Expedited,69 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,Metformin;Humalog,12-DEC-2017,14-MAR-2018,US,Not Specified,US-NOVOPROD-577523,-,-
14635862,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Product Odour Abnormal;Device Breakage;Device Leakage,Non-Serious,Non-Serious,Female,03-DEC-2017,14-MAR-2018,Non-Expedited,60 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,04-DEC-2017,14-MAR-2018,US,Not Specified,US-NOVOPROD-576240,-,-
14635860,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Malaise,Non-Serious,Non-Serious,Female,-,14-MAR-2018,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,28-DEC-2017,14-MAR-2018,US,Not Specified,US-NOVOPROD-579559,-,-
14252291,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Injection Site Haemorrhage;Vomiting;Electric Shock Sensation;Urinary Incontinence;Blood Glucose Increased;Blood Glucose Decreased,Non-Serious,Non-Serious,Female,11-NOV-2017,14-MAR-2018,Non-Expedited,48 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,01-DEC-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-572822,-,-
14252282,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Oropharyngeal Pain;Urticaria;Nausea;Pruritus;Constipation;Muscle Spasms,Non-Serious,Non-Serious,Female,OCT-2017,14-MAR-2018,Non-Expedited,77 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,Influenza Virus Vaccine,30-NOV-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-571217,-,-
14252277,Xultophy 100/3.6,Insulin Degludec\Liraglutide;Atenolol,Tachycardia;Type 2 Diabetes Mellitus,Blood Pressure Increased;Erythema;Heart Rate Increased;Blood Glucose Increased,Non-Serious,Non-Serious,Female,04-NOV-2017,14-MAR-2018,Non-Expedited,55 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,20-DEC-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-572798,-,-
14252269,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Injection Site Erythema;Skin Reaction,Non-Serious,Non-Serious,Female,NOV-2017,14-MAR-2018,Non-Expedited,53 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,26-JAN-2018,05-DEC-2017,US,Not Specified,US-NOVOPROD-573394,-,-
13960813,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Diabetes Mellitus Inadequate Control;Off Label Use,Non-Serious,Non-Serious,Male,JUN-2017,14-MAR-2018,Non-Expedited,74 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,21-NOV-2017,12-SEP-2017,US,Not Specified,US-NOVOPROD-551569,-,-
14625278,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Retinopathy,Serious,Disabled,Female,-,12-MAR-2018,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,01-MAR-2018,12-MAR-2018,SE,Not Specified,SE-NOVOPROD-588612,-,-
14613619,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Off Label Use;Blood Glucose Decreased;Weight Decreased;Nausea,Serious,Other Outcomes,Female,22-FEB-2018,08-MAR-2018,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,22-FEB-2018,08-MAR-2018,IL,Not Specified,IL-NOVOPROD-587776,-,-
14613587,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Nausea;Breath Odour;Off Label Use,Serious,Disabled,Female,11-NOV-2017,08-MAR-2018,Expedited,45 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Ramipril;Humalog;Bisoprolol Fumarate,27-FEB-2018,08-MAR-2018,SI,Not Specified,SI-NOVOPROD-588457,-,-
14605336,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus;Insomnia;Type 2 Diabetes Mellitus,Vertigo;Diarrhoea;Muscle Atrophy;Anal Incontinence;Blood Glucose Decreased;Aphasia,Serious,Other Outcomes,Female,09-MAY-2017,06-MAR-2018,Expedited,60 YR,78 KG,Novo Nordisk,Healthcare Professional,Not Specified,Zolpidem;Glimepiride;Metformin Pamoate,15-SEP-2017,06-MAR-2018,FR,Not Specified,FR-NOVOPROD-564935,-,-
14598251,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Unevaluable Event;Insomnia;Muscle Disorder,Non-Serious,Non-Serious,Male,2018,05-MAR-2018,Non-Expedited,64 YR,Not Specified,Aventis,Consumer,Not Specified,Lantus Solostar,19-FEB-2018,05-MAR-2018,US,Not Specified,US-SA-2018SA050550,-,-
14598250,Soliqua 100/33;Metformin;Solostar,Device;Metformin Hydrochloride;Insulin Glargine\Lixisenatide;Glimepiride,-,Product Dose Omission Issue,Non-Serious,Non-Serious,Female,-,05-MAR-2018,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,18-FEB-2018,05-MAR-2018,US,Not Specified,US-SA-2018SA050026,-,-
14598249,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Rash,Non-Serious,Non-Serious,Male,-,05-MAR-2018,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Solostar,16-FEB-2018,05-MAR-2018,US,Not Specified,US-SA-2018SA049883,-,-
14590742,Trulicity;Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Dulaglutide,Product Used For Unknown Indication,Diabetes Mellitus;Ketoacidosis;Metabolic Disorder;Angiopathy;Diabetic Hyperglycaemic Coma;Blood Glucose Increased;Glomerular Filtration Rate Decreased,Serious,Hospitalized;Other Outcomes;Life Threatening;Died,Male,22-JAN-2018,02-MAR-2018,Expedited,68 YR,Not Specified,Eli Lilly And Co,Healthcare Professional,Not Specified,Gliclazide;Metformin,23-FEB-2018,02-MAR-2018,HU,Not Specified,HU-ELI_LILLY_AND_COMPANY-HU201802011084,-,-
14579365,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Device Issue;Blister;Leg Amputation;Blood Glucose Increased,Serious,Other Outcomes,Female,-,02-MAR-2018,Expedited,75 YR,Not Specified,Aventis,Consumer,Not Specified,-,19-FEB-2018,27-FEB-2018,US,Not Specified,US-SA-2018SA050004,-,-
14505329,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Blood Iron Decreased;Dyslipidaemia;Gastrooesophageal Reflux Disease;Glaucoma;Gout;Hyperchlorhydria;Hypertension;Hypothyroidism;Renal Failure;Thrombosis Prophylaxis;Type 2 Diabetes Mellitus;Vitamin D Deficiency,Blood Creatinine Increased,Serious,Other Outcomes,Female,13-DEC-2017,02-MAR-2018,Expedited,63 YR,157 KG,Novo Nordisk,Healthcare Professional,Not Specified,Maalox Antacid;Izba;Levothyroxine Sodium;Ezetimibe\Simvastatin;Hydrochlorothiazide\Olmesartan Medoxomil;Calcifediol;Lansoprazole;Lasix;Febuxostat;Omega-3-Acid Ethyl Esters;Cardura;Clopidogrel,01-FEB-2018,08-FEB-2018,IT,Not Specified,IT-NOVOPROD-584502,-,-
14579364,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Nausea,Non-Serious,Non-Serious,Female,-,27-FEB-2018,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,14-FEB-2018,27-FEB-2018,US,Not Specified,US-SA-2018SA044756,-,-
14579363,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Injection Site Reaction,Non-Serious,Non-Serious,Female,-,27-FEB-2018,Non-Expedited,50 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,-,14-FEB-2018,27-FEB-2018,US,Not Specified,US-SA-2018SA044752,-,-
14579362,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Heart Rate Increased;Blood Pressure Increased,Non-Serious,Non-Serious,Female,FEB-2018,27-FEB-2018,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,14-FEB-2018,27-FEB-2018,US,Not Specified,US-SA-2018SA044248,-,-
14579361,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Issue;Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,27-FEB-2018,Non-Expedited,63 YR,Not Specified,Aventis,Consumer,Not Specified,Novolog;Lantus,11-FEB-2018,27-FEB-2018,US,Not Specified,US-SA-2018SA041897,-,-
14579360,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Blood Glucose Increased,Non-Serious,Non-Serious,Not Specified,-,27-FEB-2018,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,17-NOV-2017,27-FEB-2018,US,Not Specified,US-SA-2018SA041895,-,-
14579359,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Blood Glucose Increased;Device Issue,Non-Serious,Non-Serious,Not Specified,-,27-FEB-2018,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,09-FEB-2018,27-FEB-2018,US,Not Specified,US-SA-2018SA040931,-,-
14579358,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,27-FEB-2018,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,02-FEB-2018,27-FEB-2018,US,Not Specified,US-SA-2018SA037095,-,-
14579357,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Increased;Drug Ineffective,Non-Serious,Non-Serious,Female,-,27-FEB-2018,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,Bydureon,05-FEB-2018,27-FEB-2018,US,Not Specified,US-SA-2018SA034843,-,-
14579356,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Abdominal Pain Upper,Non-Serious,Non-Serious,Female,05-FEB-2018,27-FEB-2018,Non-Expedited,72 YR,Not Specified,Aventis,Consumer,Not Specified,Lantus,05-FEB-2018,27-FEB-2018,US,Not Specified,US-SA-2018SA034834,-,-
14579355,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Feeling Abnormal,Non-Serious,Non-Serious,Male,-,27-FEB-2018,Non-Expedited,56 YR,Not Specified,Aventis,Consumer,Not Specified,-,05-FEB-2018,27-FEB-2018,US,Not Specified,US-SA-2018SA034830,-,-
14579354,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Use In Unapproved Indication,Non-Serious,Non-Serious,Female,-,27-FEB-2018,Non-Expedited,73 YR,Not Specified,Aventis,Consumer,Not Specified,-,02-FEB-2018,27-FEB-2018,US,Not Specified,US-SA-2018SA032975,-,-
14579353,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Dizziness,Non-Serious,Non-Serious,Male,-,27-FEB-2018,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,01-FEB-2018,27-FEB-2018,US,Not Specified,US-SA-2018SA032961,-,-
14579352,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Influenza;Product Storage Error,Non-Serious,Non-Serious,Male,-,27-FEB-2018,Non-Expedited,59 YR,Not Specified,Aventis,Consumer,Not Specified,-,01-FEB-2018,27-FEB-2018,US,Not Specified,US-SA-2018SA030592,-,-
14579351,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Not Specified,-,27-FEB-2018,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,29-JAN-2018,27-FEB-2018,US,Not Specified,US-SA-2018SA028470,-,-
14579350,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Eye Discharge,Non-Serious,Non-Serious,Male,-,27-FEB-2018,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,30-JAN-2018,27-FEB-2018,US,Not Specified,US-SA-2018SA026559,-,-
14579349,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Blood Glucose Increased;Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Male,-,27-FEB-2018,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,23-JAN-2018,27-FEB-2018,US,Not Specified,US-SA-2018SA025963,-,-
14579348,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injection Site Swelling;Injury Associated With Device;Injection Site Discolouration;Injection Site Pain,Non-Serious,Non-Serious,Male,23-JAN-2018,27-FEB-2018,Non-Expedited,63 YR,90.71 KG,Aventis,Consumer,Not Specified,-,25-JAN-2018,27-FEB-2018,US,Not Specified,US-SA-2018SA025870,-,-
14579347,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Abdominal Pain Upper,Non-Serious,Non-Serious,Not Specified,-,27-FEB-2018,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,15-JAN-2018,27-FEB-2018,US,Not Specified,US-SA-2018SA015175,-,-
14579346,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Nasopharyngitis;Cough;Eye Disorder,Non-Serious,Non-Serious,Female,DEC-2017,27-FEB-2018,Non-Expedited,45 YR,Not Specified,Aventis,Consumer,Not Specified,-,15-JAN-2018,27-FEB-2018,US,Not Specified,US-SA-2018SA013510,-,-
14579345,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Decreased Appetite,Non-Serious,Non-Serious,Female,-,27-FEB-2018,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,15-JAN-2018,27-FEB-2018,US,Not Specified,US-SA-2018SA013480,-,-
14579344,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Device Issue;Injection Site Bruising;Weight Increased,Non-Serious,Non-Serious,Female,-,27-FEB-2018,Non-Expedited,67 YR,Not Specified,Aventis,Consumer,Not Specified,-,13-JAN-2018,27-FEB-2018,US,Not Specified,US-SA-2018SA012638,-,-
14579343,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Product Dose Omission Issue,Non-Serious,Non-Serious,Female,10-JAN-2018,27-FEB-2018,Non-Expedited,65 YR,Not Specified,Aventis,Consumer,Not Specified,Lantus Solostar;Januvia;Novolog;Solostar,11-JAN-2018,27-FEB-2018,US,Not Specified,US-SA-2018SA012165,-,-
14579342,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Product Dose Omission Issue,Non-Serious,Non-Serious,Female,-,27-FEB-2018,Non-Expedited,65 YR,Not Specified,Aventis,Consumer,Not Specified,Lantus Solostar;Novolog;Januvia,11-JAN-2018,27-FEB-2018,US,Not Specified,US-SA-2018SA012159,-,-
14579341,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Pancreatitis Acute,Serious,Hospitalized,Male,-,27-FEB-2018,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,11-JAN-2018,27-FEB-2018,US,Not Specified,US-SA-2018SA011521,-,-
14579340,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Injection Site Pain;Injection Site Swelling,Non-Serious,Non-Serious,Not Specified,-,27-FEB-2018,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,11-JAN-2018,27-FEB-2018,US,Not Specified,US-SA-2018SA011504,-,-
14579339,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Injection Site Erythema;Injection Site Pain;Hernia;Product Storage Error;Blood Glucose Decreased;Product Use Issue;Nausea;Blood Glucose Increased;Diarrhoea,Non-Serious,Non-Serious,Female,DEC-2017,27-FEB-2018,Non-Expedited,68 YR,Not Specified,Aventis,Consumer,Not Specified,Glucotrol Xl;Glucophage Xr,10-JAN-2018,27-FEB-2018,US,Not Specified,US-SA-2018SA011024,-,-
14579338,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Muscle Spasms,Non-Serious,Non-Serious,Male,2017,27-FEB-2018,Non-Expedited,39 YR,Not Specified,Aventis,Consumer,Not Specified,-,05-JAN-2018,27-FEB-2018,US,Not Specified,US-SA-2018SA007589,-,-
14579337,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Nausea,Non-Serious,Non-Serious,Male,-,27-FEB-2018,Non-Expedited,64 YR,Not Specified,Aventis,Consumer,Not Specified,-,03-JAN-2018,27-FEB-2018,US,Not Specified,US-SA-2018SA005116,-,-
14579336,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Injection Site Erythema,Non-Serious,Non-Serious,Not Specified,-,27-FEB-2018,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,28-DEC-2017,27-FEB-2018,US,Not Specified,US-SA-2018SA002417,-,-
14579335,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Injection Site Bruising,Non-Serious,Non-Serious,Female,-,27-FEB-2018,Non-Expedited,49 YR,Not Specified,Aventis,Consumer,Not Specified,-,27-DEC-2017,27-FEB-2018,US,Not Specified,US-SA-2018SA000007,-,-
14579334,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Product Dose Omission Issue;Blood Glucose Decreased;Blood Glucose Increased;Inappropriate Schedule Of Product Administration,Non-Serious,Non-Serious,Not Specified,-,27-FEB-2018,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,18-DEC-2017,27-FEB-2018,US,Not Specified,US-SA-2017SA261798,-,-
14579333,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Product Use Issue;Blood Glucose Decreased;Heart Rate Decreased;Hyperhidrosis,Non-Serious,Non-Serious,Female,17-DEC-2017,27-FEB-2018,Non-Expedited,59 YR,Not Specified,Aventis,Consumer,Not Specified,-,18-DEC-2017,27-FEB-2018,US,Not Specified,US-SA-2017SA260696,-,-
14579332,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Off Label Use;Hypotension;Unevaluable Event,Non-Serious,Non-Serious,Female,15-DEC-2017,27-FEB-2018,Non-Expedited,60 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,-,15-DEC-2017,27-FEB-2018,US,Not Specified,US-SA-2017SA258568,-,-
14579331,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Glycosylated Haemoglobin Increased;Drug Ineffective,Non-Serious,Non-Serious,Not Specified,-,27-FEB-2018,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,14-DEC-2017,27-FEB-2018,US,Not Specified,US-SA-2017SA258040,-,-
14579330,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Diabetes Mellitus,Weight Increased;Oedema Peripheral,Non-Serious,Non-Serious,Female,-,27-FEB-2018,Non-Expedited,62 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,Actos;Trulicity,14-DEC-2017,27-FEB-2018,US,Not Specified,US-SA-2017SA257739,-,-
14579329,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Drug Ineffective,Non-Serious,Non-Serious,Male,-,27-FEB-2018,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,08-DEC-2017,27-FEB-2018,US,Not Specified,US-SA-2017SA254541,-,-
14579328,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Headache;Vomiting;Oropharyngeal Pain;Nausea;Blood Glucose Abnormal,Non-Serious,Non-Serious,Male,-,27-FEB-2018,Non-Expedited,62 YR,Not Specified,Aventis,Consumer,Not Specified,-,11-DEC-2017,27-FEB-2018,US,Not Specified,US-SA-2017SA254521,-,-
14579327,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Diarrhoea,Non-Serious,Non-Serious,Female,2017,27-FEB-2018,Non-Expedited,58 YR,Not Specified,Aventis,Consumer,Not Specified,-,07-DEC-2017,27-FEB-2018,US,Not Specified,US-SA-2017SA251855,-,-
14579326,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Diabetes Mellitus,Back Pain;Urinary Tract Infection,Non-Serious,Non-Serious,Female,21-NOV-2017,27-FEB-2018,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,06-DEC-2017,27-FEB-2018,US,Not Specified,US-SA-2017SA250653,-,-
14579325,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Visual Impairment,Non-Serious,Non-Serious,Female,-,27-FEB-2018,Non-Expedited,60 YR,Not Specified,Aventis,Consumer,Not Specified,-,04-DEC-2017,27-FEB-2018,US,Not Specified,US-SA-2017SA246928,-,-
14579324,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Pain In Extremity,Non-Serious,Non-Serious,Male,-,27-FEB-2018,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,04-DEC-2017,27-FEB-2018,US,Not Specified,US-SA-2017SA246906,-,-
14579323,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,27-FEB-2018,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,04-DEC-2017,27-FEB-2018,US,Not Specified,US-SA-2017SA246773,-,-
14579322,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Drug Intolerance,Non-Serious,Non-Serious,Female,-,27-FEB-2018,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,04-DEC-2017,27-FEB-2018,US,Not Specified,US-SA-2017SA246766,-,-
14579321,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Hypoglycaemia;Nausea,Non-Serious,Non-Serious,Female,11-OCT-2017,27-FEB-2018,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,05-DEC-2017,27-FEB-2018,US,Not Specified,US-SA-2017SA246376,-,-
14579320,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Rash;Pruritus;Burning Sensation,Non-Serious,Non-Serious,Male,-,27-FEB-2018,Non-Expedited,63 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,Lantus,01-DEC-2017,27-FEB-2018,US,Not Specified,US-SA-2017SA244891,-,-
14579319,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Nausea;Headache,Non-Serious,Non-Serious,Female,NOV-2017,27-FEB-2018,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,30-NOV-2017,27-FEB-2018,US,Not Specified,US-SA-2017SA244851,-,-
14579318,Actos;Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Swelling;Fluid Retention;Hyperglycaemia;Infection;Erythema;Rash,Non-Serious,Non-Serious,Female,2017,27-FEB-2018,Non-Expedited,56 YR,Not Specified,Aventis,Consumer,Not Specified,-,30-NOV-2017,27-FEB-2018,US,Not Specified,US-SA-2017SA244820,-,-
14579317,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Diabetes Mellitus,Rash,Non-Serious,Non-Serious,Female,-,27-FEB-2018,Non-Expedited,63 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,-,29-NOV-2017,27-FEB-2018,US,Not Specified,US-SA-2017SA243465,-,-
14579316,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Drug Ineffective;Blood Glucose Abnormal,Non-Serious,Non-Serious,Female,-,27-FEB-2018,Non-Expedited,63 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,-,29-NOV-2017,27-FEB-2018,US,Not Specified,US-SA-2017SA243294,-,-
14579315,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Blood Glucose Decreased;Product Use Issue;Blood Glucose Increased,Non-Serious,Non-Serious,Male,2017,27-FEB-2018,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,25-NOV-2017,27-FEB-2018,US,Not Specified,US-SA-2017SA239723,-,-
14579130,Metformin;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Metformin Hydrochloride;Gliclazide,-,Hypoglycaemic Coma;Product Administration Error,Serious,Hospitalized,Female,DEC-2017,27-FEB-2018,Expedited,84 YR,Not Specified,Teva,Healthcare Professional,Not Specified,Metoprolol Succinate;Torsemide;Atorvastatin;Estazolam;Aspirin;Euthyrox,13-FEB-2018,27-FEB-2018,CH,Not Specified,CH-TEVA-2018-CH-861295,-,-
14238985,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Pain Threshold Decreased,Non-Serious,Non-Serious,Male,-,27-FEB-2018,Non-Expedited,61 YR,Not Specified,Aventis,Consumer,Not Specified,Humalog;Novolog,23-JAN-2018,30-NOV-2017,US,Not Specified,US-SA-2017SA229051,-,-
14238981,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Diabetes Mellitus;Hyperlipidaemia;Hypothyroidism,Vomiting Projectile;Nausea,Non-Serious,Non-Serious,Male,03-NOV-2017,27-FEB-2018,Non-Expedited,67 YR,84.82 KG,Aventis,Healthcare Professional,Not Specified,Simvastatin;Actos;Metformin;Levothyroxine,08-JAN-2018,30-NOV-2017,US,Not Specified,US-SA-2017SA224705,-,-
14238976,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Diabetes Mellitus;Thyroid Disorder,Depression;Weight Increased,Non-Serious,Non-Serious,Female,2017,27-FEB-2018,Non-Expedited,73 YR,56.7 KG,Aventis,Consumer,Not Specified,Qvar;Furosemide;Vitamins;Proair Hfa;Pantoprazole Sodium;Ciprofloxacin;Bystolic;Synthroid;Ranitidine;Gabapentin;Atorvastatin;Ipratropium;Losartan;Azelastine.;Latanoprost,19-DEC-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA221159,-,-
14238969,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Balance Disorder;Diabetes Mellitus;Gastric Disorder,Incorrect Route Of Product Administration;Hypoglycaemic Seizure;Hypoglycaemia,Serious,Other Outcomes,Not Specified,21-OCT-2017,27-FEB-2018,Non-Expedited,57 YR,90.71 KG,Aventis,Healthcare Professional,Not Specified,Sertraline;Lialda;Azathioprine;Omeprazole;Metformin,23-JAN-2018,30-NOV-2017,US,Not Specified,US-SA-2017SA216852,-,-
14238965,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Rhinorrhoea;Nasopharyngitis,Non-Serious,Non-Serious,Female,2017,27-FEB-2018,Non-Expedited,59 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,Farxiga;Levothyroxine;Humalog;Lisinopril;Metformin,22-NOV-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA208673,-,-
14238960,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Weight Decreased;Herpes Zoster;Device Issue;Blood Glucose Abnormal,Non-Serious,Non-Serious,Female,-,27-FEB-2018,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,08-DEC-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA207359,-,-
14238958,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Product Use Issue;Blood Glucose Increased,Non-Serious,Non-Serious,Male,2017,27-FEB-2018,Non-Expedited,68 YR,Not Specified,Aventis,Consumer,Not Specified,-,01-JAN-2018,30-NOV-2017,US,Not Specified,US-SA-2017SA206301,-,-
14238956,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Drug Ineffective,Non-Serious,Non-Serious,Female,OCT-2017,27-FEB-2018,Non-Expedited,50 YR,Not Specified,Aventis,Consumer,Not Specified,-,05-DEC-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA206294,-,-
14238940,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Rash;Injection Site Rash,Non-Serious,Non-Serious,Female,16-AUG-2017,27-FEB-2018,Non-Expedited,51 YR,Not Specified,Aventis,Consumer,Not Specified,-,16-DEC-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA179006,-,-
14238932,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Diabetes Mellitus,Blood Glucose Increased;Headache;Blood Glucose Decreased;Abdominal Distension;Blood Pressure Decreased;Blood Glucose Abnormal,Non-Serious,Non-Serious,Female,-,27-FEB-2018,Non-Expedited,53 YR,Not Specified,Aventis,Consumer,Not Specified,Xultophy 100/3.6,28-NOV-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA168781,-,-
14238928,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Anxiety;Depression;Diabetes Mellitus;Essential Tremor;Thyroid Disorder;Type 2 Diabetes Mellitus,Wrong Technique In Product Usage Process;Device Use Issue,Non-Serious,Non-Serious,Female,AUG-2017,27-FEB-2018,Non-Expedited,62 YR,79.38 KG,Aventis,Consumer,Not Specified,Primidone;Metformin;Crestor;Invokana;Propranolol;Levothyroxine;Lorazepam;Duloxetine,21-NOV-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA166981,-,-
14238914,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Fatigue;Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,27-FEB-2018,Non-Expedited,62 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,-,21-NOV-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA162864,-,-
14574272,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Malaise;Diabetic Ketoacidosis,Serious,Other Outcomes,Male,25-OCT-2017,26-FEB-2018,Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,12-FEB-2018,26-FEB-2018,US,Not Specified,US-SA-2018SA048211,-,-
14557561,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Tongue Disorder;Injection Site Vesicles;Injection Site Pruritus;Nasal Discomfort;Feeling Abnormal;Burning Sensation;Dyspnoea;Tremor;Scratch,Serious,Life Threatening,Female,2018,21-FEB-2018,Expedited,65 YR,Not Specified,Aventis,Consumer,Not Specified,-,10-FEB-2018,21-FEB-2018,US,Not Specified,US-SA-2018SA040257,-,-
13865694,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Cardiomyopathy;Diabetes Mellitus,Acidosis,Serious,Hospitalized,Female,28-JUL-2017,20-FEB-2018,Expedited,63 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,Lasix,15-FEB-2018,14-AUG-2017,IT,Not Specified,IT-TAKEDA-2017TEU003431,-,-
14521488,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Euglycaemic Diabetic Ketoacidosis,Serious,Hospitalized,Female,-,12-FEB-2018,Expedited,63 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,Jardiance,01-FEB-2018,12-FEB-2018,US,Not Specified,US-SA-2018SA030264,-,-
14511982,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Loss Of Consciousness,Serious,Other Outcomes,Male,-,09-FEB-2018,Expedited,75 YR,Not Specified,Aventis,Consumer,Not Specified,-,29-JAN-2018,09-FEB-2018,US,Not Specified,US-SA-2018SA028335,-,-
14506571,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Diabetic Ketoacidosis,Serious,Hospitalized,Female,-,08-FEB-2018,Expedited,47 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,Invokana,01-FEB-2018,08-FEB-2018,US,Not Specified,US-SA-2018SA030276,-,-
14447082,Xultophy 100/3.6,Insulin Degludec\Liraglutide;Indapamide\Perindopril Erbumine,Diabetes Mellitus;Hypertension,Lip Oedema;Tongue Oedema,Serious,Hospitalized,Female,18-OCT-2017,26-JAN-2018,Expedited,64 YR,121 KG,Novo Nordisk,Healthcare Professional,Not Specified,Metformin Hydrochloride;Kardegic;Tahor,18-JAN-2018,26-JAN-2018,FR,Not Specified,FR-NOVOPROD-582310,-,-
14446606,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Leukoplakia Oral,Serious,Other Outcomes,Female,-,26-JAN-2018,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,17-JAN-2018,26-JAN-2018,US,Not Specified,US-NOVOPROD-581673,-,-
14417600,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Lung Neoplasm Malignant,Serious,Other Outcomes,Female,-,22-JAN-2018,Expedited,55 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Metformin Hydrochloride,10-JAN-2018,22-JAN-2018,SI,Not Specified,SI-NOVOPROD-580837,-,-
14413616,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Intervertebral Disc Operation,Serious,Other Outcomes,Male,05-JAN-2018,19-JAN-2018,Expedited,75 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,11-JAN-2018,19-JAN-2018,US,Not Specified,US-NOVOPROD-581156,-,-
14413512,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Cholangiocarcinoma,Serious,Hospitalized,Female,-,19-JAN-2018,Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,11-JAN-2018,19-JAN-2018,CH,Not Specified,CH-NOVOPROD-581010,-,-
14411124,Invokana;Toujeo;Xultophy 100/3.6;Novolog;Humalog Mix75/25;Byetta,Exenatide;Insulin Lispro;Insulin Aspart;Insulin Degludec\Liraglutide;Insulin Glargine;Canagliflozin;Linagliptin,Product Used For Unknown Indication,Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Not Specified,-,19-JAN-2018,Non-Expedited,Not Specified,Not Specified,Janssen,Healthcare Professional,Not Specified,-,28-NOV-2017,19-JAN-2018,US,Not Specified,US-JNJFOC-20171134491,-,-
14410951,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Lung Neoplasm Malignant,Serious,Other Outcomes,Male,-,19-JAN-2018,Expedited,62 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Metformin Hydrochloride;Gliclazide,10-JAN-2018,19-JAN-2018,SI,Not Specified,SI-NOVOPROD-580812,-,-
14219390,Invokamet;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Canagliflozin\Metformin Hydrochloride,Product Used For Unknown Indication,Hypoglycaemia,Non-Serious,Non-Serious,Female,-,19-JAN-2018,Non-Expedited,64 YR,Not Specified,Janssen,Healthcare Professional,Not Specified,-,13-NOV-2017,23-NOV-2017,US,Not Specified,US-JNJFOC-20171101552,-,-
14385944,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Distributive Shock,Serious,Hospitalized,Male,06-JAN-2018,18-JAN-2018,Expedited,75 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,-,12-JAN-2018,15-JAN-2018,IT,Not Specified,IT-TAKEDA-2018TEU000194,-,-
14238975,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Blood Glucose Increased;Dementia;Headache;Decreased Appetite;Weight Decreased;Speech Disorder;Road Traffic Accident;Sensory Loss;Myocardial Infarction;Cerebrovascular Accident,Serious,Hospitalized;Life Threatening,Male,10-DEC-2017,05-JAN-2018,Expedited,55 YR,Not Specified,Aventis,Consumer,Not Specified,-,14-DEC-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA221137,-,-
14345685,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Rash Maculo-Papular;Pruritus,Serious,Hospitalized,Female,JUN-2017,03-JAN-2018,Expedited,63 YR,89 KG,Novo Nordisk,Healthcare Professional,Not Specified,Metformin Hydrochloride;Gliclazide;Potassium Chloride;Indapamide\Perindopril;Tahor;Esomeprazole Magnesium,22-DEC-2017,03-JAN-2018,FR,Not Specified,FR-NOVOPROD-579214,-,-
14343176,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Acute Kidney Injury;Cardiac Failure Congestive;Oedema,Serious,Hospitalized,Male,24-DEC-2017,29-DEC-2017,Direct,56 YR,Not Specified,Fda-Ctu,Healthcare Professional,Health Professional,Sotalol;Zolpidem,-,29-DEC-2017,US,Not Specified,-,-,-
14329107,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Pressure Increased;Headache,Serious,Hospitalized,Male,OCT-2017,27-DEC-2017,Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,18-DEC-2017,27-DEC-2017,NL,Not Specified,NL-SA-2017SA260223,-,-
13467387,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Off Label Use;Weight Decreased;Blood Glucose Increased;Therapy Change;Weight Increased;Glycosylated Haemoglobin Increased,Serious,Hospitalized,Male,OCT-2016,27-DEC-2017,Expedited,61 YR,123 KG,Novo Nordisk,Healthcare Professional,Not Specified,Zolpidem;Metformin Hydrochloride;Indapamide\Perindopril Erbumine;Amlodipine Besylate;Apidra;Gliclazide;Cymbalta,14-DEC-2017,21-APR-2017,FR,Not Specified,FR-NOVOPROD-541169,-,-
14298923,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Cataract,Serious,Disabled,Female,01-AUG-2017,16-DEC-2017,Direct,49 YR,87.75 KG,Fda-Ctu,Consumer,Consumer,Pravastatin;Losartan;Aspirin;Excedrin;Amlodipine,-,16-DEC-2017,US,Not Specified,-,-,Yes
14284791,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Dyspnoea,Serious,Other Outcomes,Male,-,14-DEC-2017,Expedited,42 YR,121 KG,Novo Nordisk,Healthcare Professional,Not Specified,Metformin,05-DEC-2017,14-DEC-2017,GB,Not Specified,GB-NOVOPROD-576197,-,-
13882600,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Hypersensitivity;Prophylaxis;Type 2 Diabetes Mellitus,Feeling Hot;Palpitations;Blood Magnesium Decreased;Confusional State;Hyperhidrosis;Device Use Issue;Dizziness;Arrhythmia;Incoherent;Fatigue;Headache;Blood Potassium Decreased;Presyncope;Asthenia;Hypoglycaemia,Serious,Other Outcomes,Female,04-JUL-2017,12-DEC-2017,Expedited,37 YR,98.42 KG,Aventis,Consumer,Not Specified,Valtrex;Klonopin;Maxzide;Amaryl;Prinivil;Lexapro;Glucophage Xr;Lisinopril;Zyrtec;Pataday;Invokana;Zestril;Magnesium Citrate,30-NOV-2017,18-AUG-2017,US,Not Specified,US-SA-2017SA148539,-,-
14253113,Humalog;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Insulin Lispro,Product Used For Unknown Indication,Product Dispensing Error,Non-Serious,Non-Serious,Female,-,06-DEC-2017,Non-Expedited,Not Specified,Not Specified,Eli Lilly And Co,Consumer,Not Specified,Toujeo,27-NOV-2017,06-DEC-2017,US,Not Specified,US-ELI_LILLY_AND_COMPANY-US201711012249,-,-
14252306,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Abdominal Pain Upper,Non-Serious,Non-Serious,Female,-,05-DEC-2017,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,20-NOV-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-574027,-,-
14252296,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,20-NOV-2017,05-DEC-2017,Non-Expedited,50 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,20-NOV-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-574305,-,-
14252290,Humalog;Xultophy 100/3.6;Farxiga;Levemir,Insulin Detemir;Dapagliflozin Propanediol;Insulin Degludec\Liraglutide;Albiglutide;Insulin Lispro,Type 2 Diabetes Mellitus,Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Male,-,05-DEC-2017,Non-Expedited,60 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,03-NOV-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-572153,-,-
14252284,Novolog Mix 70/30;Tresiba;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Insulin Degludec;Insulin Aspart,Type 2 Diabetes Mellitus,Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Male,-,05-DEC-2017,Non-Expedited,41 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,02-NOV-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-571972,-,-
14252281,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Diarrhoea,Non-Serious,Non-Serious,Female,05-NOV-2017,05-DEC-2017,Non-Expedited,79 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,06-NOV-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-571656,-,-
14252279,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Abdominal Pain,Non-Serious,Non-Serious,Female,-,05-DEC-2017,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,07-NOV-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-572177,-,-
14252276,Humalog Mix75/25;Toujeo;Xultophy 100/3.6;Invokana;Byetta;Novolog;Tradjenta,Linagliptin;Insulin Aspart;Exenatide;Canagliflozin;Insulin Degludec\Liraglutide;Insulin Glargine;Insulin Lispro,Type 2 Diabetes Mellitus,Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Male,-,05-DEC-2017,Non-Expedited,52 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,02-NOV-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-571942,-,-
14252275,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Blood Glucose Increased,Chest Pain;Nausea,Serious,Other Outcomes,Female,11-NOV-2017,05-DEC-2017,Non-Expedited,53 YR,105.21 KG,Novo Nordisk,Healthcare Professional,Not Specified,-,13-NOV-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-573077,-,-
14252272,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Dizziness;Nausea;Abdominal Pain Upper,Non-Serious,Non-Serious,Female,2017,05-DEC-2017,Non-Expedited,64 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,08-NOV-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-572374,-,-
14252266,Xultophy 100/3.6;Humalog Mix75/25;Humalog;Januvia;Farxiga;Levemir,Insulin Detemir;Dapagliflozin Propanediol;Sitagliptin Phosphate;Insulin Lispro;Insulin Lispro;Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Male,-,05-DEC-2017,Non-Expedited,55 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Victoza,13-OCT-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-568858,-,-
14252264,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Hypoglycaemia,Non-Serious,Non-Serious,Male,-,05-DEC-2017,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,26-OCT-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-570611,-,-
14252263,Novolog;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Insulin Aspart,Type 1 Diabetes Mellitus,Hypoglycaemia,Non-Serious,Non-Serious,Male,27-OCT-2017,05-DEC-2017,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,27-OCT-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-570941,-,-
14252261,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Pancreatitis,Serious,Other Outcomes,Female,-,05-DEC-2017,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,01-NOV-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-570880,-,-
14252255,Trulicity;Humalog Mix75/25;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Insulin Lispro;Dulaglutide;Insulin Nos;Linagliptin,Type 2 Diabetes Mellitus,Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Female,-,05-DEC-2017,Non-Expedited,67 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,18-OCT-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-569648,-,-
14252254,Humalog Mix75/25;Apidra;Toujeo;Xultophy 100/3.6;Farxiga,Dapagliflozin Propanediol;Insulin Degludec\Liraglutide;Insulin Glargine;Lixisenatide;Insulin Glulisine;Insulin Lispro,Type 2 Diabetes Mellitus,Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Male,-,05-DEC-2017,Non-Expedited,60 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,13-OCT-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-568604,-,-
14252253,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Blood Glucose Increased;Incorrect Dose Administered,Non-Serious,Non-Serious,Female,OCT-2017,05-DEC-2017,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,23-OCT-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-570339,-,-
14252252,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 1 Diabetes Mellitus,Product Use In Unapproved Indication,Non-Serious,Non-Serious,Male,-,05-DEC-2017,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,Novolog,27-OCT-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-570942,-,-
14252251,Xultophy 100/3.6;Humalog;Jardiance;Toujeo,Insulin Glargine;Empagliflozin;Linagliptin;Insulin Lispro;Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Female,-,05-DEC-2017,Non-Expedited,46 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,18-OCT-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-569638,-,-
14252250,Xultophy 100/3.6;Tradjenta;Metformin,Metformin Hydrochloride;Linagliptin;Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Female,-,05-DEC-2017,Non-Expedited,55 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,23-OCT-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-570039,-,-
14252249,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Lipase Increased,Non-Serious,Non-Serious,Male,-,05-DEC-2017,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,05-OCT-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-567649,-,-
14252248,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,2017,05-DEC-2017,Non-Expedited,73 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,04-OCT-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-568372,-,-
14252247,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Peripheral Swelling,Non-Serious,Non-Serious,Male,-,05-DEC-2017,Non-Expedited,50 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,13-OCT-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-568871,-,-
14252246,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Headache;Feeling Abnormal;Fungal Infection;Rhinorrhoea;Dizziness;Blood Glucose Decreased;Brain Fog;Hot Flush,Non-Serious,Non-Serious,Female,OCT-2017,05-DEC-2017,Non-Expedited,67 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,Glipizide,23-OCT-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-570311,-,-
14252244,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Pancreatitis,Serious,Other Outcomes,Male,SEP-2017,05-DEC-2017,Non-Expedited,52 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,11-SEP-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-563239,-,-
14252231,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Nightmare,Non-Serious,Non-Serious,Male,-,05-DEC-2017,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,22-SEP-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-565541,-,-
14252229,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Visual Field Defect,Non-Serious,Non-Serious,Male,-,05-DEC-2017,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,20-SEP-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-564831,-,-
14252222,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Hypersensitivity,Non-Serious,Non-Serious,Male,-,05-DEC-2017,Non-Expedited,37 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,22-SEP-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-565838,-,-
14252219,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Dizziness,Non-Serious,Non-Serious,Female,-,05-DEC-2017,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,22-AUG-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-561142,-,-
14252218,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 1 Diabetes Mellitus,Device Leakage;Blood Glucose Increased,Non-Serious,Non-Serious,Female,SEP-2017,05-DEC-2017,Non-Expedited,60 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,04-OCT-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-567422,-,-
14252217,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Urticaria,Non-Serious,Non-Serious,Male,20-SEP-2017,05-DEC-2017,Non-Expedited,34 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Metformin,20-SEP-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-565395,-,-
14252216,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Tachycardia,Non-Serious,Non-Serious,Female,-,05-DEC-2017,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,14-SEP-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-564453,-,-
14252215,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Injection Site Pruritus;Arthralgia;Headache,Non-Serious,Non-Serious,Female,SEP-2017,05-DEC-2017,Non-Expedited,70 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,26-SEP-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-566258,-,-
14252214,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Hyperglycaemia;Feeling Abnormal;Drug Dose Titration Not Performed,Non-Serious,Non-Serious,Female,-,05-DEC-2017,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,01-SEP-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-562823,-,-
14252213,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Blood Glucose Fluctuation,Non-Serious,Non-Serious,Male,-,05-DEC-2017,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,22-AUG-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-561104,-,-
14252212,Invokamet;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Canagliflozin\Metformin Hydrochloride,Diabetes Mellitus,Hypoglycaemia,Non-Serious,Non-Serious,Female,06-JUL-2017,05-DEC-2017,Non-Expedited,64 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,19-SEP-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-565044,-,-
14252211,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Nausea,Non-Serious,Non-Serious,Female,-,05-DEC-2017,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,20-SEP-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-565580,-,-
14252208,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Arthralgia,Non-Serious,Non-Serious,Male,25-AUG-2017,05-DEC-2017,Non-Expedited,47 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,28-AUG-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-561901,-,-
14252207,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Hyperhidrosis,Non-Serious,Non-Serious,Male,-,05-DEC-2017,Non-Expedited,45 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,29-AUG-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-562231,-,-
14252206,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Drug Intolerance;Hypoglycaemia,Non-Serious,Non-Serious,Male,-,05-DEC-2017,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,28-AUG-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-561909,-,-
14252198,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Product Use Issue,Non-Serious,Non-Serious,Female,-,05-DEC-2017,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,01-SEP-2017,05-DEC-2017,US,Not Specified,US-NOVOPROD-562779,-,-
13960841,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Diarrhoea;Abdominal Pain,Non-Serious,Non-Serious,Male,09-JUL-2017,05-DEC-2017,Non-Expedited,61 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,06-SEP-2017,12-SEP-2017,US,Not Specified,US-NOVOPROD-556406,-,-
14137582,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Obesity,Serious,Died,Female,2017,03-DEC-2017,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,21-NOV-2017,27-OCT-2017,US,Not Specified,US-NOVOPROD-569058,-,-
14238997,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Blood Glucose Increased;Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Female,-,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,16-NOV-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA231473,-,-
14238992,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide;Atorvastatin,-,Rash Pruritic,Non-Serious,Non-Serious,Male,-,30-NOV-2017,Non-Expedited,70 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,Lantus,17-NOV-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA232388,-,-
14238990,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Dysgeusia;Malaise;Abdominal Pain Upper;Hyperhidrosis;Retching;Back Pain;Blood Glucose Increased;Nausea,Non-Serious,Non-Serious,Male,17-NOV-2017,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,17-NOV-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA232368,-,-
14238989,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Dysgeusia;Vision Blurred,Non-Serious,Non-Serious,Female,NOV-2017,30-NOV-2017,Non-Expedited,71 YR,Not Specified,Aventis,Consumer,Not Specified,Humalog,17-NOV-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA232222,-,-
14238988,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Pancreatitis,Serious,Other Outcomes,Not Specified,-,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,16-NOV-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA231184,-,-
14238986,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Blood Glucose Increased;Vomiting;Nausea;Headache,Non-Serious,Non-Serious,Female,-,30-NOV-2017,Non-Expedited,70 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,-,15-NOV-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA230085,-,-
14238984,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Injection Site Urticaria;Injection Site Rash,Non-Serious,Non-Serious,Male,-,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,14-NOV-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA228989,-,-
14238983,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Decreased Appetite;Blood Glucose Increased,Non-Serious,Non-Serious,Female,NOV-2017,30-NOV-2017,Non-Expedited,59 YR,Not Specified,Aventis,Consumer,Not Specified,Metformin;Glimepiride,10-NOV-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA225738,-,-
14238980,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Abdominal Discomfort;Nausea,Non-Serious,Non-Serious,Male,-,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,09-NOV-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA224675,-,-
14238979,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Decreased Appetite;Nausea;Illness;Vomiting,Non-Serious,Non-Serious,Female,2017,30-NOV-2017,Non-Expedited,45 YR,Not Specified,Aventis,Consumer,Not Specified,Solostar;Toujeo,10-NOV-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA223723,-,-
14238978,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Tremor;Blood Glucose Fluctuation,Non-Serious,Non-Serious,Female,-,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,07-NOV-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA222631,-,-
14238974,Soliqua 100/33;Solostar,Insulin Glargine\Lixisenatide;Device,-,Cough;Nasopharyngitis,Non-Serious,Non-Serious,Female,-,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,06-NOV-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA221100,-,-
14238973,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Injection Site Reaction,Non-Serious,Non-Serious,Not Specified,-,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,31-OCT-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA220197,-,-
14238971,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Injection Site Pain,Non-Serious,Non-Serious,Female,-,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,02-NOV-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA217690,-,-
14238970,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Dizziness;Fatigue;Nausea,Non-Serious,Non-Serious,Male,-,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Levemir,31-OCT-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA217089,-,-
14238968,Soliqua 100/33;Solostar,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Rash Pruritic,Non-Serious,Non-Serious,Female,-,30-NOV-2017,Non-Expedited,66 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,Lantus;Novolog,31-OCT-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA215641,-,-
14238966,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Unevaluable Event,Non-Serious,Non-Serious,Not Specified,-,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,18-OCT-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA211157,-,-
14238964,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Injection Site Urticaria,Non-Serious,Non-Serious,Female,-,30-NOV-2017,Non-Expedited,50 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,-,24-OCT-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA208636,-,-
14238963,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Drug Ineffective;Blood Glucose Increased;Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Male,2017,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,21-OCT-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA208030,-,-
14238961,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Incorrect Dose Administered,Serious,Other Outcomes,Female,-,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Trulicity,19-OCT-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA207365,-,-
14238959,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Rash,Non-Serious,Non-Serious,Male,-,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,Toujeo,13-OCT-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA207356,-,-
14238955,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Headache;Vomiting;Abdominal Discomfort,Non-Serious,Non-Serious,Female,2017,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,18-OCT-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA205751,-,-
14238954,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Gastrointestinal Disorder,Non-Serious,Non-Serious,Not Specified,-,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,10-OCT-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA204180,-,-
14238952,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Abdominal Distension,Non-Serious,Non-Serious,Female,-,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,11-OCT-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA201166,-,-
14238951,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Use Issue,Non-Serious,Non-Serious,Female,2016,30-NOV-2017,Non-Expedited,63 YR,Not Specified,Aventis,Consumer,Not Specified,-,10-OCT-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA199589,-,-
14238950,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Diabetes Mellitus,Gastrointestinal Disorder,Non-Serious,Non-Serious,Male,-,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,09-OCT-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA198977,-,-
14238949,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Blood Glucose Increased;Device Use Issue,Non-Serious,Non-Serious,Female,2017,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,09-OCT-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA198628,-,-
14238947,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Device Issue;Blood Glucose Increased,Non-Serious,Non-Serious,Female,2017,30-NOV-2017,Non-Expedited,65 YR,Not Specified,Aventis,Consumer,Not Specified,-,09-OCT-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA198624,-,-
14238946,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Diabetes Mellitus,Abdominal Pain Upper;Vomiting;Polyuria;Nausea;Urinary Tract Infection,Non-Serious,Non-Serious,Female,AUG-2017,30-NOV-2017,Non-Expedited,63 YR,Not Specified,Aventis,Consumer,Not Specified,-,02-OCT-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA193985,-,-
14238945,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Confusional State;Aphasia;Feeling Abnormal,Non-Serious,Non-Serious,Female,2017,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,Humalog,02-OCT-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA193249,-,-
14238944,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Injection Site Haemorrhage;Injection Site Swelling,Non-Serious,Non-Serious,Not Specified,-,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,22-SEP-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA184665,-,-
14238942,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Arthralgia;Blood Glucose Increased,Non-Serious,Non-Serious,Female,SEP-2017,30-NOV-2017,Non-Expedited,65 YR,Not Specified,Aventis,Consumer,Not Specified,Lantus Solostar;Solostar,22-SEP-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA184520,-,-
14238941,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Constipation;Nausea;Blood Glucose Abnormal;Illness,Non-Serious,Non-Serious,Female,-,30-NOV-2017,Non-Expedited,62 YR,Not Specified,Aventis,Consumer,Not Specified,Toujeo;Solostar,21-SEP-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA181764,-,-
14238939,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Hypoglycaemia,Non-Serious,Non-Serious,Female,-,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,Toujeo;Solostar,19-SEP-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA178713,-,-
14238937,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Drug Hypersensitivity;Eye Swelling,Non-Serious,Non-Serious,Male,-,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,14-SEP-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA174213,-,-
14238936,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Injection Site Irritation,Non-Serious,Non-Serious,Female,11-SEP-2017,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,11-SEP-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA172323,-,-
14238935,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Product Dose Omission Issue;Cough,Non-Serious,Non-Serious,Female,-,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,10-SEP-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA170196,-,-
14238933,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Diabetes Mellitus,Blood Glucose Decreased,Non-Serious,Non-Serious,Not Specified,-,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,06-SEP-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA168783,-,-
14238931,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Diabetes Mellitus Management,Glomerular Filtration Rate Decreased;Blood Creatinine Increased,Non-Serious,Non-Serious,Female,-,30-NOV-2017,Non-Expedited,60 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,-,05-SEP-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA168336,-,-
14238930,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Diabetes Mellitus,Nausea;Diarrhoea,Non-Serious,Non-Serious,Female,-,30-NOV-2017,Non-Expedited,78 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,-,05-SEP-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA167860,-,-
14238927,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Glycosylated Haemoglobin;Type 2 Diabetes Mellitus,Nerve Block;Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,30-NOV-2017,Non-Expedited,66 YR,Not Specified,Aventis,Consumer,Not Specified,-,01-SEP-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA165774,-,-
14238926,Novolog;Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device;Insulin Aspart,-,Weight Increased;Blood Glucose Increased;Constipation,Non-Serious,Non-Serious,Not Specified,JAN-2017,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,27-AUG-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA164910,-,-
14238925,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Drug Ineffective,Non-Serious,Non-Serious,Female,31-AUG-2017,30-NOV-2017,Non-Expedited,64 YR,Not Specified,Aventis,Consumer,Not Specified,-,31-AUG-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA164899,-,-
14238923,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Abdominal Pain Upper,Non-Serious,Non-Serious,Male,-,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,30-AUG-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA164894,-,-
14238922,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Hypersensitivity;Lip Swelling;Swollen Tongue;Swelling Face,Non-Serious,Non-Serious,Female,-,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,27-AUG-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA164887,-,-
14238921,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Injection Site Reaction,Non-Serious,Non-Serious,Female,-,30-NOV-2017,Non-Expedited,38 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,-,30-AUG-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA164868,-,-
14238919,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Lipase Increased;Pancreatitis;Amylase Increased,Serious,Hospitalized,Not Specified,-,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,31-AUG-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA164652,-,-
14238918,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Not Specified,-,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,30-AUG-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA163766,-,-
14238917,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Vision Blurred,Non-Serious,Non-Serious,Female,-,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,30-AUG-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA163746,-,-
14238916,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Decreased,Serious,Other Outcomes,Female,-,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,30-AUG-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA163740,-,-
14238913,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Product Dose Omission Issue,Non-Serious,Non-Serious,Female,-,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,29-AUG-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA162849,-,-
14238912,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Joint Swelling,Non-Serious,Non-Serious,Female,-,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,29-AUG-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA162809,-,-
14238911,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Injection Site Nodule;Injection Site Swelling,Non-Serious,Non-Serious,Male,AUG-2017,30-NOV-2017,Non-Expedited,78 YR,69.4 KG,Aventis,Healthcare Professional,Not Specified,-,29-AUG-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA162789,-,-
14238909,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Bacterial Infection;Fungal Infection;Urinary Tract Infection;Rash,Non-Serious,Non-Serious,Female,-,30-NOV-2017,Non-Expedited,56 YR,Not Specified,Aventis,Consumer,Not Specified,-,29-AUG-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA162765,-,-
14238908,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Rash,Non-Serious,Non-Serious,Female,2017,30-NOV-2017,Non-Expedited,67 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,Lantus,25-AUG-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA161723,-,-
14238907,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Gastrointestinal Disorder,Non-Serious,Non-Serious,Not Specified,-,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,25-AUG-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA161679,-,-
14238906,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,AUG-2017,30-NOV-2017,Non-Expedited,85 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,Humalog;Lantus;Victoza,25-AUG-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA161655,-,-
14238904,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injection Site Pain,Non-Serious,Non-Serious,Male,-,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Device\Insulin Nos,22-AUG-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA158489,-,-
14238903,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Hypoglycaemia,Serious,Hospitalized,Male,-,30-NOV-2017,Non-Expedited,46 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,Metformin,22-AUG-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA157157,-,-
14238902,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Rash;Gait Disturbance,Non-Serious,Non-Serious,Male,-,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,21-AUG-2017,30-NOV-2017,US,Not Specified,US-SA-2017SA156563,-,-
13925585,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Injection Site Pruritus;Blood Glucose Decreased,Non-Serious,Non-Serious,Male,-,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,06-SEP-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA157475,-,-
13925566,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Hyperglycaemia;Hypoaesthesia Eye;Hypoaesthesia Oral;Hypoaesthesia;Paraesthesia;Paraesthesia Oral,Non-Serious,Non-Serious,Male,24-JUL-2017,30-NOV-2017,Non-Expedited,62 YR,Not Specified,Aventis,Consumer,Not Specified,-,18-OCT-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA139509,-,-
13925536,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Diabetes Mellitus,Drug Ineffective;Blood Glucose Increased,Serious,Hospitalized,Female,14-JUN-2017,30-NOV-2017,Non-Expedited,Not Specified,98 KG,Aventis,Consumer,Not Specified,Lantus Solostar;Solostar,22-SEP-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA109214,-,-
13598623,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Diabetes Mellitus,Abdominal Pain,Non-Serious,Non-Serious,Male,-,30-NOV-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,28-SEP-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA093589,-,-
14076550,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Blood Pressure Abnormal,Serious,Hospitalized,Male,-,29-NOV-2017,Expedited,58 YR,93 KG,Novo Nordisk,Healthcare Professional,Not Specified,Lacidipine;Aspirin Plus C;Perindopril;Glucophage;Isosorbide Mononitrate;Gliclazide;Bisoprolol Fumarate;Crestor,17-NOV-2017,11-OCT-2017,SI,Not Specified,SI-NOVOPROD-566758,-,-
14215902,Toujeo;Xultophy 100/3.6;Jardiance,Empagliflozin;Insulin Degludec\Liraglutide;Insulin Lispro;Insulin Glargine;Linagliptin,Product Used For Unknown Indication,Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Not Specified,-,22-NOV-2017,Non-Expedited,Not Specified,Not Specified,Eli Lilly And Co,Healthcare Professional,Not Specified,-,17-NOV-2017,22-NOV-2017,US,Not Specified,US-ELI_LILLY_AND_COMPANY-US201711008818,-,-
14208539,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Blood Glucose Increased,Drug Ineffective;Diarrhoea,Non-Serious,Non-Serious,Female,-,21-NOV-2017,Non-Expedited,Not Specified,Not Specified,Takeda,Consumer,Not Specified,-,15-NOV-2017,21-NOV-2017,US,Not Specified,US-TAKEDA-2017TUS024143,-,-
14074429,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Thrombocytopenia;Platelet Adhesiveness,Serious,Other Outcomes,Male,OCT-2017,16-NOV-2017,Expedited,68 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,-,08-NOV-2017,11-OCT-2017,IL,Not Specified,IL-TAKEDA-2017TEU004304,-,-
14192050,Xultophy 100/3.6;Levemir;Metformin;Humalog;Novolog;Farxiga;Victoza;Invokana;Tresiba,Insulin Degludec;Canagliflozin;Linagliptin;Liraglutide;Dapagliflozin Propanediol;Insulin Aspart;Insulin Lispro;Metformin Hydrochloride;Insulin Detemir;Insulin Degludec\Liraglutide;Albiglutide,Product Used For Unknown Indication,Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Not Specified,-,15-NOV-2017,Non-Expedited,Not Specified,Not Specified,Eli Lilly And Co,Healthcare Professional,Not Specified,-,13-NOV-2017,15-NOV-2017,US,Not Specified,US-ELI_LILLY_AND_COMPANY-US201711005694,-,-
14189533,Byetta;Toujeo;Invokana;Novolog;Humalog Mix75/25;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Insulin Lispro;Insulin Aspart;Canagliflozin;Insulin Glargine;Exenatide;Linagliptin,Product Used For Unknown Indication,Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Not Specified,-,15-NOV-2017,Non-Expedited,Not Specified,Not Specified,Eli Lilly And Co,Healthcare Professional,Not Specified,-,13-NOV-2017,15-NOV-2017,US,Not Specified,US-ELI_LILLY_AND_COMPANY-US201711005481,-,-
14184383,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Abdominal Pain;Pancreatitis,Serious,Hospitalized,Not Specified,-,13-NOV-2017,Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,31-OCT-2017,13-NOV-2017,US,Not Specified,US-SA-2017SA216843,-,-
14073635,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Thrombocytopenia;Platelet Adhesiveness,Serious,Other Outcomes,Male,OCT-2017,13-NOV-2017,Expedited,68 YR,Not Specified,Teva,Healthcare Professional,Not Specified,-,08-NOV-2017,11-OCT-2017,IL,Not Specified,IL-TEVA-812827ACC,-,-
14174559,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Weight Increased;Pneumonia;Hepatic Enzyme Increased;Alopecia,Serious,Other Outcomes,Female,-,09-NOV-2017,Expedited,82 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,31-OCT-2017,09-NOV-2017,US,Not Specified,US-NOVOPROD-571190,-,-
13993108,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Glimepiride,Diabetes Mellitus,Agitation;Hypoglycaemia;Confusional State;Product Use Issue,Serious,Hospitalized,Male,29-JUN-2017,08-NOV-2017,Expedited,85 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,Hydrochlorothiazide\Valsartan;Bicalutamide;Aspirin,02-NOV-2017,20-SEP-2017,IT,Not Specified,IT-SA-2017SA171520,-,-
14160287,Xultophy 100/3.6;Levemir;Victoza;Januvia;Farxiga;Humalog;Humalog Mix75/25,Insulin Lispro;Insulin Lispro;Dapagliflozin Propanediol;Sitagliptin Phosphate;Liraglutide;Insulin Detemir;Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Male,-,06-NOV-2017,Non-Expedited,55 YR,Not Specified,Merck,Healthcare Professional,Not Specified,-,23-OCT-2017,06-NOV-2017,US,Not Specified,US-009507513-1710USA012206,-,-
13997610,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Glimepiride,Diabetes Mellitus,Confusional State;Agitation;Hypoglycaemia,Serious,Hospitalized,Male,29-JUN-2017,06-NOV-2017,Expedited,85 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,Hydrochlorothiazide\Valsartan;Aspirin;Bicalutamide,02-NOV-2017,21-SEP-2017,IT,Not Specified,IT-TAKEDA-2017TEU003957,-,-
14158913,Humalog Mix75/25;Xultophy 100/3.6;Trulicity,Dulaglutide;Linagliptin;Insulin Degludec\Liraglutide;Insulin Lispro,Product Used For Unknown Indication,Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Female,-,03-NOV-2017,Non-Expedited,67 YR,Not Specified,Eli Lilly And Co,Healthcare Professional,Not Specified,-,31-OCT-2017,03-NOV-2017,US,Not Specified,US-ELI_LILLY_AND_COMPANY-US201711000443,-,-
14155057,Toujeo;Jardiance;Humalog;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Linagliptin;Insulin Lispro;Empagliflozin;Insulin Glargine,Product Used For Unknown Indication,Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Not Specified,-,03-NOV-2017,Non-Expedited,Not Specified,Not Specified,Eli Lilly And Co,Healthcare Professional,Not Specified,-,31-OCT-2017,03-NOV-2017,US,Not Specified,US-ELI_LILLY_AND_COMPANY-US201711000542,-,-
14095574,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Glycosylated Haemoglobin Increased;Hypoglycaemia;Epilepsy;Laboratory Test Abnormal;Rheumatic Disorder;Muscle Tightness;Pineal Gland Cyst;Back Pain,Serious,Hospitalized,Female,2017,03-NOV-2017,Expedited,54 YR,115 KG,Aventis,Healthcare Professional,Not Specified,Simvastatin,23-OCT-2017,16-OCT-2017,NL,Not Specified,NL-SA-2017SA193169,-,-
14132156,Farxiga;Toujeo;Humalog Mix75/25;Xultophy 100/3.6;Apidra,Insulin Glulisine;Insulin Degludec\Liraglutide;Lixisenatide;Insulin Lispro;Insulin Glargine;Dapagliflozin Propanediol,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Male,-,27-OCT-2017,Non-Expedited,60 YR,Not Specified,Eli Lilly And Co,Healthcare Professional,Not Specified,-,23-OCT-2017,27-OCT-2017,US,Not Specified,US-ELI_LILLY_AND_COMPANY-US201710009296,-,-
14125848,Levemir;Humalog Mix75/25;Humalog;Victoza;Januvia;Farxiga;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Dapagliflozin Propanediol;Sitagliptin Phosphate;Liraglutide;Insulin Lispro;Insulin Lispro;Insulin Detemir,Type 2 Diabetes Mellitus,Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Male,-,25-OCT-2017,Non-Expedited,55 YR,Not Specified,Eli Lilly And Co,Healthcare Professional,Not Specified,-,23-OCT-2017,25-OCT-2017,US,Not Specified,US-ELI_LILLY_AND_COMPANY-US201710009533,-,-
14115530,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Pathological Fracture,Serious,Other Outcomes,Female,-,23-OCT-2017,Expedited,79 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,10-OCT-2017,23-OCT-2017,GR,Not Specified,GR-NOVOPROD-568658,-,-
14076395,Competact;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Blood Cholesterol Abnormal;Blood Triglycerides Abnormal;Diabetes Mellitus;Glycosylated Haemoglobin Increased;Hypertension;Hypothyroidism;Product Used For Unknown Indication,Arrhythmia;Malaise;Hypoaesthesia;Hypoglycaemia,Serious,Other Outcomes,Female,-,23-OCT-2017,Expedited,65 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,Nebivolol;Valsartan;Lercanidipine;Janumet;Glimepiride;Simvastatin;Fenofibrate,16-OCT-2017,11-OCT-2017,PT,Not Specified,PT-TAKEDA-2017TJP021321,-,-
14075447,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Thrombocytopenia,Serious,Other Outcomes,Male,JUN-2015,11-OCT-2017,Expedited,59 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,-,02-OCT-2017,11-OCT-2017,IL,Not Specified,IL-TAKEDA-2017TEU004306,-,-
14073652,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Thrombocytopenia,Serious,Other Outcomes,Male,JUN-2015,11-OCT-2017,Expedited,59 YR,Not Specified,Teva,Healthcare Professional,Not Specified,-,02-OCT-2017,11-OCT-2017,IL,Not Specified,IL-TEVA-812821ACC,-,-
14061758,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Urinary Incontinence,Non-Serious,Non-Serious,Male,-,09-OCT-2017,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,-,27-SEP-2017,09-OCT-2017,US,Not Specified,US-TAKEDA-2017TUS020274,-,-
14048119,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Impaired Gastric Emptying,Serious,Hospitalized,Male,-,05-OCT-2017,Expedited,49 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,Lantus,21-SEP-2017,05-OCT-2017,US,Not Specified,US-SA-2017SA181846,-,-
14037408,Soliqua 100/33;Synjardy,Empagliflozin\Metformin Hydrochloride;Insulin Glargine\Lixisenatide,Diabetes Mellitus,Diabetic Ketoacidosis;Vomiting,Serious,Hospitalized,Female,02-OCT-2017,03-OCT-2017,Direct,60 YR,91 KG,Fda-Ctu,Healthcare Professional,Health Professional,-,-,03-OCT-2017,US,Not Specified,-,-,-
14035405,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Diabetes Mellitus Inadequate Control;Pneumonia,Serious,Hospitalized,Female,-,03-OCT-2017,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,27-SEP-2017,03-OCT-2017,US,Not Specified,US-NOVOPROD-565842,-,-
14016716,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Dizziness,Serious,Hospitalized,Male,SEP-2017,27-SEP-2017,Expedited,75 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,19-SEP-2017,27-SEP-2017,US,Not Specified,US-NOVOPROD-564597,-,-
13833578,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Cardiopulmonary Failure;Drug Titration Error,Serious,Died,Male,-,27-SEP-2017,Expedited,53 YR,200 KG,Novo Nordisk,Healthcare Professional,Not Specified,Ramipril;Atorvastatin Calcium;Cordarone;Bisoprolol Fumarate;Spironolactone;Metformin Hydrochloride;Aspirin,18-SEP-2017,04-AUG-2017,CZ,Not Specified,CZ-NOVOPROD-555742,-,-
14013357,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Dehydration,Serious,Hospitalized,Female,-,26-SEP-2017,Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Lantus,15-SEP-2017,26-SEP-2017,US,Not Specified,US-SA-2017SA174111,-,-
13927551,Metformin;Lyrica;Haldol;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Lithium Carbonate;Haloperidol;Pregabalin;Hydrochlorothiazide\Irbesartan;Metformin Hydrochloride,Bipolar Disorder;Diabetic Neuropathy;Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Toxicity To Various Agents;Urinary Tract Infection;Metabolic Acidosis;Delirium;Hyperphosphataemia;Hyperkalaemia;Diarrhoea;Sinus Bradycardia;Hypothyroidism;Acute Kidney Injury,Serious,Hospitalized,Female,JUL-2017,13-SEP-2017,Expedited,73 YR,75 KG,Novo Nordisk,Healthcare Professional,Not Specified,Nexium;Atorvastatin;Calcium\Vitamin D;Aspirin,07-SEP-2017,01-SEP-2017,CH,Not Specified,CH-NOVOPROD-561045,-,-
13960850,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Peripheral Swelling;Joint Stiffness;Joint Swelling,Non-Serious,Non-Serious,Male,-,12-SEP-2017,Non-Expedited,70 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,02-AUG-2017,12-SEP-2017,US,Not Specified,US-NOVOPROD-558098,-,-
13960849,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Injection Site Rash,Non-Serious,Non-Serious,Female,-,12-SEP-2017,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,16-AUG-2017,12-SEP-2017,US,Not Specified,US-NOVOPROD-560352,-,-
13960848,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Abdominal Pain;Diarrhoea,Non-Serious,Non-Serious,Male,-,12-SEP-2017,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,14-AUG-2017,12-SEP-2017,US,Not Specified,US-NOVOPROD-559978,-,-
13960847,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Dizziness;Insomnia;Hyperhidrosis;Blood Glucose Increased;Pollakiuria;Tremor;Headache;Somnolence,Non-Serious,Non-Serious,Male,AUG-2017,12-SEP-2017,Non-Expedited,60 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,04-AUG-2017,12-SEP-2017,US,Not Specified,US-NOVOPROD-558537,-,-
13960846,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Balance Disorder;Visual Impairment;Headache,Non-Serious,Non-Serious,Male,03-AUG-2017,12-SEP-2017,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,17-AUG-2017,12-SEP-2017,US,Not Specified,US-NOVOPROD-560361,-,-
13960845,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Fixed Eruption,Non-Serious,Non-Serious,Female,-,12-SEP-2017,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,02-AUG-2017,12-SEP-2017,US,Not Specified,US-NOVOPROD-558110,-,-
13960842,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Nausea;Abdominal Pain,Non-Serious,Non-Serious,Male,JUL-2017,12-SEP-2017,Non-Expedited,69 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,31-JUL-2017,12-SEP-2017,US,Not Specified,US-NOVOPROD-557770,-,-
13960840,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Oedema Peripheral,Non-Serious,Non-Serious,Female,-,12-SEP-2017,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,14-JUL-2017,12-SEP-2017,US,Not Specified,US-NOVOPROD-555246,-,-
13960839,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,12-SEP-2017,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,06-JUL-2017,12-SEP-2017,US,Not Specified,US-NOVOPROD-553860,-,-
13960838,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Abdominal Discomfort;Injection Site Haemorrhage;Injection Site Pain,Non-Serious,Non-Serious,Female,-,12-SEP-2017,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,25-JUL-2017,12-SEP-2017,US,Not Specified,US-NOVOPROD-556790,-,-
13960837,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Peripheral Swelling,Non-Serious,Non-Serious,Male,-,12-SEP-2017,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,13-JUL-2017,12-SEP-2017,US,Not Specified,US-NOVOPROD-555057,-,-
13960836,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Blister;Acne;Swelling Face;Rash,Non-Serious,Non-Serious,Female,-,12-SEP-2017,Non-Expedited,60 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,22-JUN-2017,12-SEP-2017,US,Not Specified,US-NOVOPROD-552157,-,-
13960830,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Vulvovaginal Swelling;Swelling;Mouth Swelling,Non-Serious,Non-Serious,Female,-,12-SEP-2017,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,12-JUL-2017,12-SEP-2017,US,Not Specified,US-NOVOPROD-554807,-,-
13960829,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Malaise,Non-Serious,Non-Serious,Male,-,12-SEP-2017,Non-Expedited,59 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,11-JUL-2017,12-SEP-2017,US,Not Specified,US-NOVOPROD-554648,-,-
13960828,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Oedema Peripheral,Non-Serious,Non-Serious,Female,-,12-SEP-2017,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,14-JUL-2017,12-SEP-2017,US,Not Specified,US-NOVOPROD-555247,-,-
13960827,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Feeling Hot;Erythema;Paraesthesia;Flushing,Non-Serious,Non-Serious,Female,-,12-SEP-2017,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,17-JUL-2017,12-SEP-2017,US,Not Specified,US-NOVOPROD-555487,-,-
13960824,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Abdominal Discomfort,Non-Serious,Non-Serious,Male,2017,12-SEP-2017,Non-Expedited,70 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,05-JUN-2017,12-SEP-2017,US,Not Specified,US-NOVOPROD-549389,-,-
13960823,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Blood Glucose Fluctuation,Non-Serious,Non-Serious,Female,2017,12-SEP-2017,Non-Expedited,66 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,07-JUL-2017,12-SEP-2017,US,Not Specified,US-NOVOPROD-554068,-,-
13960812,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Nausea,Non-Serious,Non-Serious,Female,JUN-2017,12-SEP-2017,Non-Expedited,51 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,02-JUN-2017,12-SEP-2017,US,Not Specified,US-NOVOPROD-549261,-,-
13960811,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,12-SEP-2017,Non-Expedited,50 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,03-JUN-2017,12-SEP-2017,US,Not Specified,US-NOVOPROD-549427,-,-
13960810,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Diarrhoea,Non-Serious,Non-Serious,Male,09-JUN-2017,12-SEP-2017,Non-Expedited,44 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,19-JUN-2017,12-SEP-2017,US,Not Specified,US-NOVOPROD-551570,-,-
13960809,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Blood Glucose Decreased,Non-Serious,Non-Serious,Female,-,12-SEP-2017,Non-Expedited,Not Specified,Not Specified,Novo Nordisk,Consumer,Not Specified,-,20-JUN-2017,12-SEP-2017,US,Not Specified,US-NOVOPROD-551806,-,-
13925584,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Furuncle,Non-Serious,Non-Serious,Not Specified,-,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,17-AUG-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA155832,Somersworth,-
13925583,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Therapeutic Response Decreased,Non-Serious,Non-Serious,Female,-,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Lantus,18-AUG-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA155769,-,-
13925582,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Abdominal Discomfort,Non-Serious,Non-Serious,Not Specified,-,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,15-AUG-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA153076,-,-
13925581,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Diabetes Mellitus,"Hallucination, Visual",Non-Serious,Non-Serious,Female,-,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Solostar;Toujeo,15-AUG-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA153071,-,-
13925580,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Blood Glucose Decreased,Non-Serious,Non-Serious,Female,-,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,15-AUG-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA152782,-,-
13925579,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Product Use Issue,Non-Serious,Non-Serious,Not Specified,-,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,14-AUG-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA152096,-,-
13925578,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Drug Ineffective;Blood Glucose Fluctuation,Non-Serious,Non-Serious,Male,-,31-AUG-2017,Non-Expedited,67 YR,Not Specified,Aventis,Consumer,Not Specified,Lantus;Metformin,14-AUG-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA152079,-,-
13925577,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Diabetes Mellitus,Extra Dose Administered,Non-Serious,Non-Serious,Male,-,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,13-AUG-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA150979,-,-
13925576,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Diarrhoea,Non-Serious,Non-Serious,Female,-,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,08-AUG-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA150423,-,-
13925575,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Blood Glucose Increased,Non-Serious,Non-Serious,Female,10-AUG-2017,31-AUG-2017,Non-Expedited,36 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,Prednisone;Protonix;Plaquenil;Metformin;Meloxicam,10-AUG-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA150314,-,-
13925574,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Vomiting,Non-Serious,Non-Serious,Female,-,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,09-AUG-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA149018,-,-
13925573,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Rash,Non-Serious,Non-Serious,Male,JUL-2017,31-AUG-2017,Non-Expedited,64 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,-,07-AUG-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA148120,-,-
13925572,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Diabetes Mellitus,Pruritus;Urticaria;Mass;Nausea,Non-Serious,Non-Serious,Female,JUN-2017,31-AUG-2017,Non-Expedited,58 YR,Not Specified,Aventis,Consumer,Not Specified,Aspirin;Isosorbide;Pantoprazole;Rosuvastatin;Diltiazem;Lisinopril;Metformin,07-AUG-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA148043,-,-
13925571,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Arthralgia,Non-Serious,Non-Serious,Not Specified,-,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Solostar,07-AUG-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA147738,-,-
13925570,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Diabetes Mellitus,Rash,Non-Serious,Non-Serious,Male,-,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,03-AUG-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA145905,-,-
13925569,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Dysuria;Palpitations;Blood Glucose Increased;Abdominal Pain Upper;Malaise;Feeling Abnormal,Non-Serious,Non-Serious,Female,-,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Lantus;Victoza,01-AUG-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA143850,-,-
13925568,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Diarrhoea,Non-Serious,Non-Serious,Female,-,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,29-JUL-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA143321,-,-
13925567,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Headache,Non-Serious,Non-Serious,Female,-,31-AUG-2017,Non-Expedited,59 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,Solostar,28-JUL-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA141245,-,-
13925565,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Gastrointestinal Disorder,Non-Serious,Non-Serious,Not Specified,-,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Solostar,20-JUL-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA137326,-,-
13925564,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Injection Site Reaction,Non-Serious,Non-Serious,Not Specified,-,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,Solostar,20-JUL-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA137154,-,-
13925562,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Injection Site Discomfort;Rash Pruritic;Urticaria,Non-Serious,Non-Serious,Female,-,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Solostar,21-JUL-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA136922,-,-
13925561,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Vomiting,Non-Serious,Non-Serious,Female,-,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Solostar,19-JUL-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA135683,-,-
13925560,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Ill-Defined Disorder,Non-Serious,Non-Serious,Male,-,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Solostar,19-JUL-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA135682,-,-
13925559,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Injection Site Pruritus;Injection Site Rash,Non-Serious,Non-Serious,Not Specified,-,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Solostar,18-JUL-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA135625,-,-
13925558,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Pruritus;Swelling,Non-Serious,Non-Serious,Female,2017,31-AUG-2017,Non-Expedited,82 YR,Not Specified,Aventis,Consumer,Not Specified,Solostar,14-JUL-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA132488,-,-
13925557,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Urticaria,Non-Serious,Non-Serious,Female,JUL-2017,31-AUG-2017,Non-Expedited,75 YR,Not Specified,Aventis,Consumer,Not Specified,Solostar,13-JUL-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA132473,-,-
13925556,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Blood Cholesterol Increased;Hypertension;Type 2 Diabetes Mellitus,Nausea;Diarrhoea;Product Use Issue,Non-Serious,Non-Serious,Female,25-MAY-2017,31-AUG-2017,Non-Expedited,73 YR,82.1 KG,Aventis,Healthcare Professional,Not Specified,Simvastatin;Metformin;Lisinopril,14-JUL-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA132464,-,-
13925555,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Drug Hypersensitivity,Non-Serious,Non-Serious,Male,-,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Solostar,11-JUL-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA128008,-,-
13925554,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Abnormal;Incorrect Dose Administered,Non-Serious,Non-Serious,Male,2017,31-AUG-2017,Non-Expedited,52 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,Solostar,11-JUL-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA127608,-,-
13925553,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Product Use Issue;Blood Glucose Increased;Device Issue,Non-Serious,Non-Serious,Male,2017,31-AUG-2017,Non-Expedited,58 YR,Not Specified,Aventis,Consumer,Not Specified,-,07-JUL-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA125279,-,-
13925552,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Use Issue,Non-Serious,Non-Serious,Female,JUN-2017,31-AUG-2017,Non-Expedited,48 YR,Not Specified,Aventis,Consumer,Not Specified,Solostar,30-JUN-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA120711,-,-
13925551,Apidra Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Glulisine,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Solostar,29-JUN-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA119741,-,-
13925550,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Urticaria;Pruritus;Palpitations;Dyspnoea;Chest Pain,Non-Serious,Non-Serious,Female,2017,31-AUG-2017,Non-Expedited,31 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,Solostar;Diclofenac;Lidocaine,28-JUN-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA118151,-,-
13925549,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,2017,31-AUG-2017,Non-Expedited,55 YR,Not Specified,Aventis,Consumer,Not Specified,Solostar,27-JUN-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA117486,-,-
13925548,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Blood Glucose Increased;Incorrect Dose Administered;Device Issue,Non-Serious,Non-Serious,Male,2017,31-AUG-2017,Non-Expedited,57 YR,Not Specified,Aventis,Consumer,Not Specified,-,24-JUN-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA117125,-,-
13925547,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Not Specified,JUN-2017,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Solostar,26-JUN-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA117058,-,-
13925546,Metformin;Soliqua 100/33,Insulin Glargine\Lixisenatide;Metformin Hydrochloride,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,Solostar,19-JUN-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA112739,-,-
13925545,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 1 Diabetes Mellitus,Influenza Like Illness;Hot Flush;Nausea;Extra Dose Administered;Device Use Issue,Non-Serious,Non-Serious,Female,18-JUN-2017,31-AUG-2017,Non-Expedited,40 YR,Not Specified,Aventis,Consumer,Not Specified,-,19-JUN-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA112724,-,-
13925544,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Fluctuation;Nausea,Non-Serious,Non-Serious,Male,JUN-2017,31-AUG-2017,Non-Expedited,60 YR,Not Specified,Aventis,Consumer,Not Specified,Levemir;Metformin;Solostar;Farxiga,19-JUN-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA112692,-,-
13925543,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Weight Increased,Non-Serious,Non-Serious,Not Specified,-,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Solostar,15-JUN-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA112420,-,-
13925542,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Weight Increased,Non-Serious,Non-Serious,Not Specified,-,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Solostar,15-JUN-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA112415,-,-
13925541,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Incorrect Dose Administered;Sinusitis,Non-Serious,Non-Serious,Female,2017,31-AUG-2017,Non-Expedited,45 YR,Not Specified,Aventis,Consumer,Not Specified,Solostar,17-JUN-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA111711,-,-
13925540,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,2017,31-AUG-2017,Non-Expedited,64 YR,Not Specified,Aventis,Consumer,Not Specified,Toujeo;Victoza;Solostar,16-JUN-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA111629,-,-
13925539,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Weight Increased,Non-Serious,Non-Serious,Not Specified,-,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Solostar,15-JUN-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA110248,-,-
13925538,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Weight Increased,Non-Serious,Non-Serious,Not Specified,-,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,Solostar,13-JUN-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA109442,-,-
13925537,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Increased;Product Use Issue,Non-Serious,Non-Serious,Female,13-JUN-2017,31-AUG-2017,Non-Expedited,34 YR,131.08 KG,Aventis,Healthcare Professional,Not Specified,Ferrous Sulfate;Epipen;Ativan;Solostar,13-JUN-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA109426,-,-
13925535,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Somnolence;Product Use Issue;Product Storage Error;Blood Glucose Increased,Non-Serious,Non-Serious,Male,JUN-2017,31-AUG-2017,Non-Expedited,46 YR,Not Specified,Aventis,Consumer,Not Specified,Solostar;Metformin,13-JUN-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA109211,-,-
13925534,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Nausea;Extra Dose Administered,Non-Serious,Non-Serious,Female,12-JUN-2017,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,Lantus Solostar;Solostar,12-JUN-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA108895,-,-
13925533,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Injection Site Rash,Non-Serious,Non-Serious,Not Specified,-,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Solostar,09-JUN-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA107351,-,-
13925532,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Glycosylated Haemoglobin Increased,Non-Serious,Non-Serious,Not Specified,-,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Solostar,06-JUN-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA104440,-,-
13925531,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Constipation,Non-Serious,Non-Serious,Male,2017,31-AUG-2017,Non-Expedited,68 YR,Not Specified,Aventis,Consumer,Not Specified,Solostar,06-JUN-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA103814,-,-
13925530,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Hypoglycaemia;Nausea;Dehydration,Serious,Hospitalized,Female,-,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Solostar,06-JUN-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA103747,-,-
13925529,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Drug Ineffective;Blood Glucose Increased;Nausea,Non-Serious,Non-Serious,Male,2017,31-AUG-2017,Non-Expedited,65 YR,Not Specified,Aventis,Consumer,Not Specified,Lantus;Novolog;Solostar,31-MAY-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA103587,-,-
13925528,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Gastrointestinal Disorder,Non-Serious,Non-Serious,Not Specified,-,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Solostar,01-JUN-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA101874,-,-
13925527,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injection Site Pain;Injection Site Mass;Device Issue;Injection Site Haemorrhage,Non-Serious,Non-Serious,Male,2017,31-AUG-2017,Non-Expedited,74 YR,Not Specified,Aventis,Consumer,Not Specified,Levemir,02-JUN-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA101871,-,-
13925526,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Injection Site Reaction;Injection Site Inflammation,Non-Serious,Non-Serious,Female,-,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Solostar,01-JUN-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA101868,-,-
13925525,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Gastrointestinal Disorder,Non-Serious,Non-Serious,Not Specified,-,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Solostar,01-JUN-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA101771,-,-
13925524,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Diabetes Mellitus,Device Use Issue;Burning Sensation;Rash Pruritic;Erythema;Incorrect Dose Administered,Non-Serious,Non-Serious,Male,APR-2017,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,31-MAY-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA100203,-,-
13925523,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,31-AUG-2017,Non-Expedited,65 YR,Not Specified,Aventis,Consumer,Not Specified,Lantus Solostar;Solostar,25-MAY-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA097972,-,-
13925522,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Nausea,Non-Serious,Non-Serious,Female,-,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Solostar,24-MAY-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA096594,-,-
13925521,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Increased;Drug Ineffective;Vomiting;Nausea,Non-Serious,Non-Serious,Male,-,31-AUG-2017,Non-Expedited,65 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,Solostar,22-MAY-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA095857,-,-
13925520,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Pancreatitis,Serious,Other Outcomes,Not Specified,-,31-AUG-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Solostar,22-MAY-2017,31-AUG-2017,US,Not Specified,US-SA-2017SA095421,-,-
13598618,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Device Use Issue;Blood Glucose Increased;Inappropriate Schedule Of Product Administration;Off Label Use,Non-Serious,Non-Serious,Male,MAY-2017,31-AUG-2017,Non-Expedited,56 YR,Not Specified,Aventis,Consumer,Not Specified,Solostar;Victoza;Toujeo;Novolog,29-JUN-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA091274,-,-
13921212,Haldol;Xultophy 100/3.6;Lyrica,Pregabalin;Lithium;Insulin Degludec\Liraglutide;Haloperidol;Metformin Hydrochloride;Hydrochlorothiazide\Irbesartan,Bipolar Disorder;Diabetic Neuropathy;Hypertension;Type 2 Diabetes Mellitus,Delirium;Sinus Bradycardia;Hyperphosphataemia;Hyperkalaemia;Drug Interaction;Diarrhoea;Hypothyroidism;Metabolic Acidosis;Toxicity To Various Agents;Acute Kidney Injury,Serious,Hospitalized,Female,JUL-2017,30-AUG-2017,Expedited,73 YR,75 KG,Janssen,Healthcare Professional,Not Specified,Vitamin D2;Aspirin;Calcium;Atorvastatin;Nexium,22-AUG-2017,30-AUG-2017,CH,Not Specified,CH-JNJFOC-20170819969,-,-
13857637,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Jaundice,Serious,Hospitalized,Female,01-JUL-2017,30-AUG-2017,Expedited,58 YR,98 KG,Novo Nordisk,Healthcare Professional,Not Specified,Metformin,21-AUG-2017,11-AUG-2017,HU,Not Specified,HU-NOVOPROD-557636,-,-
13910902,Haldol;Lyrica;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Metformin Hydrochloride;Hydrochlorothiazide\Irbesartan;Pregabalin;Lithium Carbonate;Haloperidol,Bipolar Disorder;Diabetic Neuropathy;Hypertension;Type 2 Diabetes Mellitus,Sinus Bradycardia;Hyperphosphataemia;Hyperkalaemia;Anaemia;Diarrhoea;Acute Kidney Injury;Confusional State;Toxicity To Various Agents;Metabolic Acidosis;Delirium;Escherichia Urinary Tract Infection;Hypothyroidism;Blood Glucose Decreased;Drug Interaction,Serious,Other Outcomes;Hospitalized,Female,JUL-2017,28-AUG-2017,Expedited,73 YR,75 KG,Pfizer,Healthcare Professional,Not Specified,Atorvastatin;Aspirin;Nexium;Vitamins;Calcium,22-AUG-2017,28-AUG-2017,CH,Not Specified,CH-PFIZER INC-2017365672,-,-
13903247,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,-,Dizziness;Anxiety,Serious,Hospitalized,Female,-,24-AUG-2017,Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,15-AUG-2017,24-AUG-2017,US,Not Specified,US-SA-2017SA152753,-,-
13869737,Xultophy 100/3.6;Victoza;Apidra;Lantus;Bydureon;Trulicity,Dulaglutide;Exenatide;Insulin Glargine;Insulin Glulisine;Liraglutide;Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Hepatitis Acute;Pancreatic Carcinoma;Lipase Increased,Serious,Hospitalized,Male,01-MAR-2017,23-AUG-2017,Expedited,69 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Aspirin\Clopidogrel;Amlodipine Besylate;Metformin;Levothyroxine;Bisoprolol Fumarate\Hydrochlorothiazide;Esomeprazole Magnesium;Ezetimibe;Spironolactone;Crestor;Rasilez;Glyburide;Gliclazide,14-AUG-2017,15-AUG-2017,FR,Not Specified,FR-NOVOPROD-557998,-,-
13861453,Xultophy 100/3.6;Bydureon;Trulicity;Lantus;Victoza;Apidra,Insulin Glulisine;Liraglutide;Insulin Glargine;Dulaglutide;Exenatide;Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Hepatitis Acute;Lipase Increased;Pancreatic Carcinoma,Serious,Hospitalized,Male,01-MAR-2017,23-AUG-2017,Expedited,69 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,Ezetimibe;Esomeprazole;Bisoprolol Fumarate\Hydrochlorothiazide;Levothyroxine;Aspirin\Clopidogrel;Amlodipine Besylate;Crestor;Spironolactone;Rasilez;Metformin;Gliclazide,16-AUG-2017,11-AUG-2017,FR,Not Specified,FR-SA-2017SA145284,-,-
13882581,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,-,Ulcer,Serious,Hospitalized,Male,-,18-AUG-2017,Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,08-AUG-2017,18-AUG-2017,US,Not Specified,US-SA-2017SA148057,-,-
13860031,Victoza;Xultophy 100/3.6;Lantus;Apidra;Bydureon;Trulicity,Dulaglutide;Exenatide;Insulin Glulisine;Insulin Glargine;Insulin Degludec\Liraglutide;Liraglutide,Type 2 Diabetes Mellitus,Pancreatic Carcinoma;Hepatitis Acute;Lipase Increased,Serious,Hospitalized,Male,01-MAR-2017,11-AUG-2017,Expedited,25284 DAY,Not Specified,Astrazeneca,Healthcare Professional,Not Specified,Spironolactone;Rasilez;Amlodipine Besylate;Aspirin\Clopidogrel;Metformin Hydrochloride;Levothyroxine;Bisoprolol Fumarate\Hydrochlorothiazide;Crestor;Esomeprazole;Ezetimibe,04-AUG-2017,11-AUG-2017,FR,Not Specified,FR-ASTRAZENECA-2017SE80759,-,-
13855939,Trulicity;Apidra;Xultophy 100/3.6;Lantus,Insulin Glargine;Insulin Degludec\Liraglutide;Insulin Glulisine;Dulaglutide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Pancreatic Carcinoma;Hepatic Cytolysis;Pancreatic Disorder;Biliary Tract Disorder;Lipase Increased;Cholestasis;Pancreatic Cyst;Hepatitis,Serious,Hospitalized,Male,01-MAR-2017,10-AUG-2017,Expedited,69 YR,Not Specified,Eli Lilly And Co,Healthcare Professional,Not Specified,Esomeprazole Magnesium;Bisoprolol Fumarate\Hydrochlorothiazide;Spironolactone;Ezetimibe;Rasilez;Amlodipine Besylate;Levothyroxine;Metformin Hydrochloride;Crestor;Aspirin\Clopidogrel,08-AUG-2017,10-AUG-2017,FR,Not Specified,FR-ELI_LILLY_AND_COMPANY-FR201708002936,-,-
13800327,Xultophy 100/3.6;Victoza,Liraglutide;Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Pancreatic Carcinoma Metastatic;Pancreatitis Chronic,Serious,Hospitalized,Female,19-JUL-2017,08-AUG-2017,Expedited,66 YR,89 KG,Novo Nordisk,Healthcare Professional,Not Specified,Metformin Hydrochloride;Gliclazide,28-JUL-2017,27-JUL-2017,HU,Not Specified,HU-NOVOPROD-555125,-,-
13665688,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Small Cell Lung Cancer,Serious,Other Outcomes,Male,JUN-2017,04-AUG-2017,Expedited,55 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,28-JUL-2017,19-JUN-2017,SI,Not Specified,SI-NOVOPROD-549095,-,-
13822748,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Osteomyelitis;Blood Glucose Abnormal;Pain In Extremity,Serious,Hospitalized,Female,2017,01-AUG-2017,Expedited,64 YR,Not Specified,Aventis,Consumer,Not Specified,Solostar;Novolog,18-JUL-2017,01-AUG-2017,US,Not Specified,US-SA-2017SA133587,-,-
13801865,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Myocardial Infarction,Serious,Died,Male,-,27-JUL-2017,Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Solostar,21-JUL-2017,27-JUL-2017,US,Not Specified,US-SA-2017SA136929,-,-
13255896,Invokana;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Canagliflozin,Type 2 Diabetes Mellitus,Small Intestinal Haemorrhage;Syncope;Blood Glucose Increased;Diverticulum;Diabetic Ketoacidosis,Serious,Hospitalized;Life Threatening,Male,29-DEC-2016,27-JUL-2017,Expedited,67 YR,90 KG,Novo Nordisk,Consumer,Not Specified,Metformin;Thyroxine;Gliclazide;Captopril,20-JUL-2017,21-FEB-2017,GB,Not Specified,GB-NOVOPROD-531532,-,-
13700788,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Cholelithiasis;Pancreatitis Acute;Pancreatic Pseudocyst,Serious,Hospitalized,Female,28-MAR-2017,26-JUL-2017,Expedited,34 YR,99 KG,Novo Nordisk,Healthcare Professional,Not Specified,Ferrous Sulfate;Metformin,19-JUL-2017,29-JUN-2017,GB,Not Specified,GB-NOVOPROD-551034,-,-
13776800,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Angina Pectoris;Gastric Disorder;Hypercholesterolaemia;Hypertension;Type 2 Diabetes Mellitus,Abdominal Pain;Fluid Intake Reduced;Acute Kidney Injury;Nausea,Serious,Hospitalized,Female,02-JUL-2017,21-JUL-2017,Expedited,59 YR,76 KG,Novo Nordisk,Healthcare Professional,Not Specified,Ticagrelor;Ivabradine;Carbaspirin;Furosemide;Metformin Hydrochloride;Irbesartan;Calcium Carbonate;Albuterol Sulfate;Beclomethasone Dipropionate;Pantoprazole Sodium;Ferrous Fumarate;Mometasone;Atorvastatin,13-JUL-2017,21-JUL-2017,NL,Not Specified,NL-NOVOPROD-554194,-,-
13226702,Invokana;Xultophy 100/3.6,Insulin Degludec\Liraglutide;Canagliflozin,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Diverticulum;Small Intestinal Haemorrhage;Blood Glucose Increased;Diabetic Ketoacidosis;Syncope,Serious,Life Threatening;Hospitalized,Male,29-DEC-2016,21-JUL-2017,Expedited,67 YR,90 KG,Janssen,Consumer,Not Specified,Metformin;Thyroxine;Gliclazide;Captopril,20-JUL-2017,13-FEB-2017,GB,Not Specified,GB-JNJFOC-20170211023,-,-
13298138,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Transitional Cell Carcinoma,Serious,Other Outcomes,Not Specified,01-MAY-2015,20-JUL-2017,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Glucotrol;Avandia;Januvia,12-JUL-2017,06-MAR-2017,US,Not Specified,US-TAKEDA-2017TUS004673,-,-
13760240,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Gastrointestinal Carcinoma,Serious,Other Outcomes,Female,-,17-JUL-2017,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,04-JUL-2017,17-JUL-2017,NL,Not Specified,NL-NOVOPROD-553076,-,-
13760236,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Diabetes Mellitus,Dry Skin;Blister;Myocardial Infarction,Serious,Died,Female,-,17-JUL-2017,Expedited,69 YR,130 KG,Novo Nordisk,Healthcare Professional,Not Specified,-,29-MAY-2017,17-JUL-2017,CH,Not Specified,CH-NOVOPROD-548519,-,-
13746141,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Myalgia,Non-Serious,Non-Serious,Female,05-JUL-2017,12-JUL-2017,Direct,45 YR,94.05 KG,Fda-Ctu,Healthcare Professional,Health Professional,Atorvastatin;Vitamin B12;Hydrochlorothiazide\Lisinopril;Levothyroxine;Vitamin D3;Metformin,-,12-JUL-2017,US,Not Specified,-,-,-
13550213,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Latent Autoimmune Diabetes In Adults,Off Label Use;Diabetic Ketoacidosis;Malaise,Serious,Hospitalized,Female,-,09-JUL-2017,Expedited,69 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,28-JUN-2017,16-MAY-2017,NL,Not Specified,NL-NOVOPROD-544174,-,-
13598576,Soliqua 100/33,Insulin Glargine\Lixisenatide;Furosemide,Type 2 Diabetes Mellitus,Erythema;Dermatitis Bullous,Serious,Other Outcomes,Male,01-FEB-2017,06-JUL-2017,Expedited,53 YR,116.57 KG,Aventis,Healthcare Professional,Not Specified,Metformin;Clopidogrel;Simvastatin;Actos;Hydrochlorothiazide,22-JUN-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA044009,-,-
13718358,Soliqua 100/33,Insulin Glargine\Lixisenatide;Furosemide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Erythema;Dermatitis Bullous,Serious,Other Outcomes,Not Specified,01-FEB-2017,05-JUL-2017,Expedited,Not Specified,Not Specified,Validus,Healthcare Professional,Not Specified,Metformin;Actos;Hydrochlorothiazide;Simvastatin;Clopidogrel,22-JUN-2017,05-JUL-2017,US,Not Specified,US-VALIDUS PHARMACEUTICALS LLC-US-2017VAL001003,-,-
13674686,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Cardiac Flutter,Serious,Other Outcomes,Female,2017,21-JUN-2017,Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Solostar,14-JUN-2017,21-JUN-2017,US,Not Specified,US-SA-2017SA109428,-,-
13665834,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Oedema Peripheral;Respiratory Failure,Serious,Hospitalized;Other Outcomes,Female,-,19-JUN-2017,Expedited,55 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,-,12-JUN-2017,19-JUN-2017,GR,Not Specified,GR-TAKEDA-2017TJP012953,-,-
13665832,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Hospitalisation,Serious,Hospitalized,Female,-,19-JUN-2017,Expedited,42 YR,Not Specified,Takeda,Consumer,Not Specified,-,01-JUN-2017,19-JUN-2017,MX,Not Specified,MX-TAKEDA-2017TJP012399,-,-
13630447,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,08-JUN-2017,Non-Expedited,61 YR,Not Specified,Novo Nordisk,Consumer,Not Specified,-,08-MAY-2017,08-JUN-2017,US,Not Specified,US-NOVOPROD-545338,-,-
13617027,Lantus Solostar,Insulin Glargine;Metformin Hydrochloride\Pioglitazone Hydrochloride;Glyburide,Diabetes Mellitus,Dyspnoea,Non-Serious,Non-Serious,Not Specified,-,06-JUN-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,Solostar,10-AUG-2016,06-JUN-2017,US,Not Specified,US-SA-2016SA147940,-,-
13537764,Metformin;Amlodipine,Amlodipine Besylate;Liraglutide;Ramipril;Ezetimibe\Simvastatin;Atorvastatin;Dapagliflozin;Insulin Degludec;Metformin Hydrochloride;Metformin Hydrochloride\Sitagliptin Phosphate;Exenatide;Repaglinide;Metformin Hydrochloride\Pioglitazone Hydrochloride;Nebivolol,Dyslipidaemia;Hypertension;Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Diabetes Mellitus Inadequate Control,Serious,Other Outcomes,Male,-,02-JUN-2017,Expedited,66 YR,83 KG,Bausch And Lomb,Healthcare Professional,Not Specified,-,22-MAY-2017,11-MAY-2017,IT,Not Specified,IT-BAUSCH-BL-2017-014621,-,-
13603063,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Potassium Decreased;Vomiting;Dehydration,Serious,Hospitalized,Female,-,01-JUN-2017,Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,23-MAY-2017,01-JUN-2017,US,Not Specified,US-SA-2017SA096476,-,-
13505346,Metformin;Novatrex (Methotrexate);Plaquenil;Clopidogrel;Xultophy 100/3.6;Amlodipine;Utibron Neohaler,Glycopyrrolate\Indacaterol Maleate;Irbesartan;Amlodipine Besylate;Insulin Degludec\Liraglutide;Folic Acid;Clopidogrel Bisulfate;Hydroxychloroquine Sulfate;Methotrexate Sodium;Allopurinol;Metformin Hydrochloride,Chronic Obstructive Pulmonary Disease;Hypertension;Product Used For Unknown Indication;Rheumatoid Arthritis;Type 2 Diabetes Mellitus;Vitamin B Complex Deficiency,Neutropenia,Serious,Hospitalized,Not Specified,-,01-JUN-2017,Expedited,Not Specified,Not Specified,Sunovion,Consumer,Not Specified,"Prevenar;Pneumococcal Vaccine, Polyvalent 23;Movicol",19-MAY-2017,02-MAY-2017,FR,Not Specified,US-SUNOVION-2017SUN001829,-,-
13598624,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Diabetes Mellitus,Device Issue;Malaise,Non-Serious,Non-Serious,Female,-,31-MAY-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,17-MAY-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA093630,-,-
13598622,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Back Pain,Non-Serious,Non-Serious,Not Specified,-,31-MAY-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,17-MAY-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA093555,-,-
13598620,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Injection Site Rash,Non-Serious,Non-Serious,Male,-,31-MAY-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,17-MAY-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA093513,-,-
13598619,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Palpitations,Non-Serious,Non-Serious,Female,MAY-2017,31-MAY-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,16-MAY-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA091836,-,-
13598617,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Hyperhidrosis;Abdominal Discomfort;Appetite Disorder;Diarrhoea;Blood Glucose Increased;Nausea;Feeling Abnormal,Non-Serious,Non-Serious,Female,2017,31-MAY-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,Amlodipine;Meloxicam;Gabapentin;Victoza;Solostar;Naltrexone;Novolog;Zoloft;Lantus;Atenolol,15-MAY-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA089732,-,-
13598616,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Injection Site Reaction,Non-Serious,Non-Serious,Not Specified,-,31-MAY-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Solostar,11-MAY-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA088536,-,-
13598614,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 1 Diabetes Mellitus,Product Dose Omission Issue;Device Issue;Blood Glucose Increased,Non-Serious,Non-Serious,Male,2017,31-MAY-2017,Non-Expedited,52 YR,Not Specified,Aventis,Consumer,Not Specified,-,08-MAY-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA085165,-,-
13598613,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Not Specified,-,31-MAY-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Solostar,06-MAY-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA084490,-,-
13598612,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Headache;Dizziness;Diarrhoea;Nausea,Non-Serious,Non-Serious,Female,-,31-MAY-2017,Non-Expedited,70 YR,Not Specified,Aventis,Consumer,Not Specified,-,06-MAY-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA084480,-,-
13598611,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Injection Site Reaction,Non-Serious,Non-Serious,Not Specified,-,31-MAY-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,Solostar,04-MAY-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA084426,-,-
13598610,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Diarrhoea,Non-Serious,Non-Serious,Male,-,31-MAY-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,03-MAY-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA083481,-,-
13598608,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Fluid Retention;Limb Discomfort,Non-Serious,Non-Serious,Not Specified,-,31-MAY-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Solostar,03-MAY-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA083429,-,-
13598607,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Nausea,Non-Serious,Non-Serious,Not Specified,-,31-MAY-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Solostar,02-MAY-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA082145,-,-
13598606,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Injection Site Erythema,Non-Serious,Non-Serious,Female,-,31-MAY-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,01-MAY-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA081694,-,-
13598605,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Pruritus,Non-Serious,Non-Serious,Male,-,31-MAY-2017,Non-Expedited,63 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,Solostar,01-MAY-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA081636,-,-
13598604,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Constipation,Non-Serious,Non-Serious,Male,-,31-MAY-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,Solostar,27-APR-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA080699,-,-
13598601,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Weight Decreased;Binge Eating,Non-Serious,Non-Serious,Female,APR-2017,31-MAY-2017,Non-Expedited,53 YR,Not Specified,Aventis,Consumer,Not Specified,Solostar;Toujeo,21-APR-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA078101,-,-
13598600,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Abnormal,Non-Serious,Non-Serious,Male,2017,31-MAY-2017,Non-Expedited,66 YR,Not Specified,Aventis,Consumer,Not Specified,-,22-APR-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA075663,-,-
13598599,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Gastrointestinal Disorder,Non-Serious,Non-Serious,Female,APR-2017,31-MAY-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Trulicity,21-APR-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA075072,-,-
13598598,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Hyperglycaemia,Non-Serious,Non-Serious,Not Specified,APR-2017,31-MAY-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,21-APR-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA075050,-,-
13598597,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Injection Site Swelling,Non-Serious,Non-Serious,Female,-,31-MAY-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,31-MAR-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA073565,-,-
13598595,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Injection Site Pruritus;Injection Site Granuloma;Injection Site Pain,Non-Serious,Non-Serious,Female,2017,31-MAY-2017,Non-Expedited,39 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,-,18-APR-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA072341,-,-
13598594,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injection Site Erythema,Non-Serious,Non-Serious,Male,2017,31-MAY-2017,Non-Expedited,46 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,-,12-APR-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA068420,-,-
13598593,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Swelling Face;Urticaria,Non-Serious,Non-Serious,Male,-,31-MAY-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,10-APR-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA066711,-,-
13598592,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Gastrointestinal Disorder;Illness,Non-Serious,Non-Serious,Female,-,31-MAY-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,29-MAR-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA057137,-,-
13598591,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Injection Site Pruritus;Injection Site Bruising,Non-Serious,Non-Serious,Male,-,31-MAY-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Tanzeum,29-MAR-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA057118,-,-
13598589,Toujeo;Soliqua 100/33,Insulin Glargine\Lixisenatide;Insulin Glargine,Type 2 Diabetes Mellitus,Hypoglycaemia,Non-Serious,Non-Serious,Female,-,31-MAY-2017,Non-Expedited,40 YR,Not Specified,Aventis,Consumer,Not Specified,Trulicity;Solostar,29-MAR-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA057087,-,-
13598588,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Injection Site Reaction,Non-Serious,Non-Serious,Female,-,31-MAY-2017,Non-Expedited,52 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,-,28-MAR-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA056484,-,-
13598587,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Urticaria,Non-Serious,Non-Serious,Female,-,31-MAY-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,28-MAR-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA056323,-,-
13598586,Soliqua 100/33;Solostar,Device;Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Product Use Issue;Injection Site Induration;Injection Site Discharge;Device Issue,Non-Serious,Non-Serious,Male,-,31-MAY-2017,Non-Expedited,63 YR,Not Specified,Aventis,Consumer,Not Specified,-,28-MAR-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA056317,-,-
13598585,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Weight Increased,Non-Serious,Non-Serious,Not Specified,-,31-MAY-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,22-MAR-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA050103,-,-
13598584,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Dizziness;Rhinorrhoea;Dyspnoea;Oropharyngeal Pain;Nasal Dryness;Nasal Congestion,Non-Serious,Non-Serious,Male,-,31-MAY-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,20-MAR-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA050065,-,-
13598582,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Pruritus,Non-Serious,Non-Serious,Female,-,31-MAY-2017,Non-Expedited,67 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,-,20-MAR-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA049365,-,-
13598581,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Weight Increased,Non-Serious,Non-Serious,Male,-,31-MAY-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,17-MAR-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA047965,-,-
13598580,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Rash Pruritic;Rash,Non-Serious,Non-Serious,Female,2017,31-MAY-2017,Non-Expedited,54 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,-,15-MAR-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA046392,-,-
13598579,Solostar;Soliqua 100/33,Insulin Glargine\Lixisenatide;Device,Type 2 Diabetes Mellitus,Device Issue;Wrong Technique In Product Usage Process;Intentional Product Misuse,Non-Serious,Non-Serious,Female,-,31-MAY-2017,Non-Expedited,61 YR,Not Specified,Aventis,Consumer,Not Specified,-,06-MAR-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA044045,-,-
13598578,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Vomiting;Nausea,Non-Serious,Non-Serious,Female,-,31-MAY-2017,Non-Expedited,62 YR,Not Specified,Aventis,Consumer,Not Specified,Lantus,13-MAR-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA044039,-,-
13598575,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Dizziness;Nausea;Headache;Vision Blurred,Non-Serious,Non-Serious,Female,-,31-MAY-2017,Non-Expedited,62 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,-,10-MAR-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA043344,-,-
13598574,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Heart Rate Increased;Feeling Jittery;Blood Glucose Increased;Heart Rate Decreased,Non-Serious,Non-Serious,Female,11-MAR-2017,31-MAY-2017,Non-Expedited,58 YR,Not Specified,Aventis,Consumer,Not Specified,Metformin;Glimepiride,12-MAR-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA041917,-,-
13598573,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Fluctuation;Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,31-MAY-2017,Non-Expedited,56 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,-,09-MAR-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA041881,-,-
13598572,Soliqua 100/33,Insulin Glargine\Lixisenatide,Blood Uric Acid Increased;Hypertension;Type 2 Diabetes Mellitus,Constipation,Non-Serious,Non-Serious,Male,06-MAR-2017,31-MAY-2017,Non-Expedited,63 YR,88.4 KG,Aventis,Consumer,Not Specified,Solostar;Trulicity;Quinapril;Probenecid;Toujeo,08-MAR-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA041074,-,-
13598570,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Diarrhoea;Flatulence;Blood Glucose Abnormal,Non-Serious,Non-Serious,Female,-,31-MAY-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,06-MAR-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA040909,-,-
13598569,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Blood Glucose Decreased,Non-Serious,Non-Serious,Female,-,31-MAY-2017,Non-Expedited,70 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,Lantus;Lithium,07-MAR-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA040855,-,-
13598568,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,31-MAY-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,07-MAR-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA040840,-,-
13598567,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Nausea,Non-Serious,Non-Serious,Male,-,31-MAY-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,02-MAR-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA040255,-,-
13598565,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus;Sialoadenitis,Back Pain;Hypoaesthesia;Heart Rate Increased;Neuropathy Peripheral;Blood Pressure Systolic Increased;Tongue Discomfort;Pain In Extremity,Non-Serious,Non-Serious,Female,06-FEB-2017,31-MAY-2017,Non-Expedited,63 YR,106.14 KG,Aventis,Healthcare Professional,Not Specified,Metformin;Glipizide;Cephalexin;Victoza;Pioglitazone,03-MAR-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA038106,-,-
13598564,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Hypoglycaemia;Nausea,Non-Serious,Non-Serious,Male,-,31-MAY-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,01-MAR-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA037799,-,-
13598563,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Dizziness,Non-Serious,Non-Serious,Female,-,31-MAY-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,Toujeo;Solostar,01-MAR-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA037783,-,-
13598562,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Injection Site Erythema;Injection Site Rash,Non-Serious,Non-Serious,Male,-,31-MAY-2017,Non-Expedited,61 YR,Not Specified,Aventis,Consumer,Not Specified,-,23-FEB-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA034125,-,-
13598561,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Blood Glucose Increased,Non-Serious,Non-Serious,Female,-,31-MAY-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Lantus,22-FEB-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA032325,-,-
13598559,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Presyncope,Non-Serious,Non-Serious,Male,FEB-2017,31-MAY-2017,Non-Expedited,51 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,Lantus,21-FEB-2017,31-MAY-2017,US,Not Specified,US-SA-2017SA031868,-,-
13266123,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Decreased;Hypersensitivity,Serious,Hospitalized,Female,-,31-MAY-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Solostar;Lantus,28-APR-2017,23-FEB-2017,US,Not Specified,US-SA-2017SA028695,-,-
13502216,Metformin;Plaquenil;Clopidogrel;Xultophy 100/3.6;Novatrex (Methotrexate);Amlodipine,Amlodipine Besylate;Allopurinol;Methotrexate Sodium;Insulin Degludec\Liraglutide;Glycopyrronium\Indacaterol;Clopidogrel Bisulfate;Hydroxychloroquine Sulfate;Folic Acid;Metformin Hydrochloride;Irbesartan,Chronic Obstructive Pulmonary Disease;Hypertension;Product Used For Unknown Indication;Rheumatoid Arthritis;Type 2 Diabetes Mellitus;Vitamin B Complex Deficiency,Neutropenia,Serious,Hospitalized,Female,15-FEB-2017,30-MAY-2017,Expedited,82 YR,Not Specified,Concordia,Healthcare Professional,Not Specified,-,17-MAY-2017,02-MAY-2017,FR,Not Specified,FR-CONCORDIA PHARMACEUTICALS INC.-GSH201704-002615,-,-
13285591,Competact;Metformin,Metformin Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Cardiovascular Disorder;Thirst;Intentional Product Misuse;Lactic Acidosis;Vomiting;Anuria;Renal Failure,Serious,Other Outcomes;Life Threatening,Male,19-FEB-2017,30-MAY-2017,Expedited,78 YR,75 KG,Takeda,Healthcare Professional,Not Specified,-,25-MAY-2017,02-MAR-2017,IT,Not Specified,IT-TAKEDA-2017TEU000815,-,-
13495698,Clopidogrel;Xultophy 100/3.6;Amlodipine;Plaquenil;Novatrex (Methotrexate),Methotrexate Sodium;Folic Acid;Hydroxychloroquine Sulfate;Amlodipine Besylate;Glycopyrronium\Indacaterol;Insulin Degludec\Liraglutide;Clopidogrel Bisulfate;Irbesartan;Allopurinol;Metformin Hydrochloride,Chronic Obstructive Pulmonary Disease;Hypertension;Product Used For Unknown Indication;Rheumatoid Arthritis;Type 2 Diabetes Mellitus;Vitamin B Complex Deficiency,Neutropenia,Serious,Hospitalized,Female,15-FEB-2017,25-MAY-2017,Expedited,82 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Victoza;Piperacillin Sodium\Tazobactam Sodium,17-MAY-2017,28-APR-2017,FR,Not Specified,FR-NOVOPROD-542089,-,-
13576987,Amlodipine;Metformin;Novatrex (Methotrexate);Xultophy 100/3.6;Clopidogrel;Plaquenil,Hydroxychloroquine Sulfate;Glycopyrronium\Indacaterol;Folic Acid;Clopidogrel Bisulfate;Allopurinol;Irbesartan;Methotrexate Sodium;Insulin Degludec\Liraglutide;Metformin Hydrochloride;Amlodipine Besylate,Chronic Obstructive Pulmonary Disease;Hypertension;Rheumatoid Arthritis;Type 2 Diabetes Mellitus;Vitamin B Complex Deficiency,Neutropenia;Myelodysplastic Syndrome,Serious,Hospitalized,Female,15-FEB-2017,24-MAY-2017,Expedited,82 YR,Not Specified,Pfizer,Healthcare Professional,Not Specified,Victoza,18-APR-2017,24-MAY-2017,FR,Not Specified,FR-PFIZER INC-2017171782,-,-
13468659,-,Repaglinide;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Diabetes Mellitus Inadequate Control;Gravitational Oedema,Serious,Other Outcomes,Male,OCT-2014,11-MAY-2017,Expedited,66 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Nebivolol;Atorvastatin;Ramipril;Liraglutide;Amlodipine Besylate,10-MAY-2017,21-APR-2017,IT,Not Specified,IT-TAKEDA-2017TEU001639,Gravina G.. Uso di exenatide monosettimanale in un paziente con diabete mellito tipo 2 con controllo glicemico scadente (8.3%). Media. 2017;17:32-3,-
13456364,Halcion,Triazolam;Insulin Degludec\Liraglutide,Insomnia;Type 2 Diabetes Mellitus,Irritability;Hip Fracture;Road Traffic Accident,Serious,Hospitalized,Male,26-MAR-2017,28-APR-2017,Expedited,55 YR,88 KG,Pfizer,Healthcare Professional,Not Specified,Metformin Hydrochloride;Triazolam;Voglibose;Mitiglinide;Insulin Degludec;Repaglinide,24-APR-2017,18-APR-2017,JP,Not Specified,JP-PFIZER INC-2017161448,-,-
13167669,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Losartan Potassium,Product Used For Unknown Indication,Urticaria;Erythema;Skin Exfoliation,Serious,Hospitalized,Female,01-NOV-2016,18-APR-2017,Expedited,71 YR,112 KG,Takeda,Healthcare Professional,Not Specified,-,12-APR-2017,31-JAN-2017,IT,Not Specified,IT-TAKEDA-2017TEU000301,-,-
13152744,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Losartan Potassium,-,Urticaria;Skin Exfoliation;Erythema,Serious,Hospitalized,Female,01-NOV-2016,14-APR-2017,Expedited,71 YR,112 KG,Merck,Healthcare Professional,Not Specified,-,12-APR-2017,25-JAN-2017,IT,Not Specified,IT-009507513-1701ITA011436,-,-
13313262,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Atrial Fibrillation,Serious,Hospitalized,Male,-,11-APR-2017,Expedited,66 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,Lantus,04-APR-2017,09-MAR-2017,US,Not Specified,US-SA-2017SA038078,-,-
13040276,-,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Abdominal Pain;Gastritis;Diarrhoea;Gastrooesophageal Reflux Disease;Vomiting;Irritable Bowel Syndrome;Nausea,Serious,Hospitalized,Female,23-APR-2016,31-MAR-2017,Expedited,48 YR,124 KG,Novo Nordisk,Healthcare Professional,Not Specified,Metformin,22-MAR-2017,19-DEC-2016,ZA,Not Specified,ZA-NOVOPROD-498964,-,-
13351617,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Prednisone,Breast Inflammation;Diabetes Mellitus,Blood Pressure Systolic Increased;Glycosuria;Drug Interaction;Hyperglycaemia,Serious,Other Outcomes,Female,18-APR-2016,30-MAR-2017,Expedited,62 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,-,27-MAR-2017,20-MAR-2017,IT,Not Specified,IT-TAKEDA-2017TEU001149,-,-
13342964,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Haematuria,Serious,Other Outcomes,Female,03-FEB-2015,16-MAR-2017,Expedited,62 YR,90 KG,Takeda,Consumer,Not Specified,Aspirin;Lipitor;Victoza;Levothyroxine,13-MAR-2017,16-MAR-2017,GR,Not Specified,GR-TAKEDA-2017TEU001089,-,-
13341904,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Hypertension;Hypercholesterolaemia,Serious,Other Outcomes,Female,24-FEB-2017,16-MAR-2017,Expedited,65 YR,86 KG,Novo Nordisk,Healthcare Professional,Not Specified,Ramipril;Atorvastatin;Naproxen;Amlodipine;Acetaminophen;Ferrous Gluconate;Clotrimazole;Dihydrocodeine;Zinc Oxide;Furosemide;Atenolol;Metformin;Tresiba;Diclofenac Sodium;Omeprazole,08-MAR-2017,16-MAR-2017,GB,Not Specified,GB-NOVOPROD-535408,-,-
13299377,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Hypersensitivity;Throat Tightness,Serious,Hospitalized,Female,15-FEB-2017,06-MAR-2017,Expedited,42 YR,Not Specified,Aventis,Consumer,Not Specified,Victoza;Toujeo;Solostar,23-FEB-2017,06-MAR-2017,US,Not Specified,US-SA-2017SA033767,-,-
13299277,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Asthenia,Non-Serious,Non-Serious,Male,FEB-2017,06-MAR-2017,Non-Expedited,45 YR,Not Specified,Aventis,Consumer,Not Specified,Androgel;Viagra,19-FEB-2017,06-MAR-2017,US,Not Specified,US-SA-2017SA031082,-,-
13299276,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Dysgeusia,Non-Serious,Non-Serious,Male,2017,06-MAR-2017,Non-Expedited,71 YR,Not Specified,Aventis,Consumer,Not Specified,Lantus,20-FEB-2017,06-MAR-2017,US,Not Specified,US-SA-2017SA030883,-,-
13299275,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Syncope;Anxiety,Non-Serious,Non-Serious,Not Specified,-,06-MAR-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,17-FEB-2017,06-MAR-2017,US,Not Specified,US-SA-2017SA030667,-,-
13299274,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Nausea,Non-Serious,Non-Serious,Female,-,06-MAR-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,15-FEB-2017,06-MAR-2017,US,Not Specified,US-SA-2017SA028596,-,-
13299273,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Product Use Issue,Non-Serious,Non-Serious,Female,-,06-MAR-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,09-FEB-2017,06-MAR-2017,US,Not Specified,US-SA-2017SA025808,-,-
13299272,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Nausea;Vision Blurred,Non-Serious,Non-Serious,Female,-,06-MAR-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,-,10-FEB-2017,06-MAR-2017,US,Not Specified,US-SA-2017SA025765,-,-
13299271,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Product Use Issue,Non-Serious,Non-Serious,Not Specified,-,06-MAR-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,09-FEB-2017,06-MAR-2017,US,Not Specified,US-SA-2017SA025646,-,-
13299270,Soliqua 100/33,Insulin Glargine\Lixisenatide,Type 2 Diabetes Mellitus,Cough;Dyspnoea;Intentional Product Misuse;Nausea;Blood Glucose Increased;Rhinorrhoea,Non-Serious,Non-Serious,Female,FEB-2017,06-MAR-2017,Non-Expedited,63 YR,Not Specified,Aventis,Consumer,Not Specified,-,12-FEB-2017,06-MAR-2017,US,Not Specified,US-SA-2017SA025645,-,-
13299269,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Injection Site Rash,Non-Serious,Non-Serious,Female,JAN-2017,06-MAR-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,-,01-FEB-2017,06-MAR-2017,US,Not Specified,US-SA-2017SA020401,-,-
13299268,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Injection Site Swelling;Injection Site Discharge;Injection Site Reaction;Injection Site Pruritus,Non-Serious,Non-Serious,Male,-,06-MAR-2017,Non-Expedited,50 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,-,01-FEB-2017,06-MAR-2017,US,Not Specified,US-SA-2017SA019826,-,-
13299267,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Blood Glucose Increased,Non-Serious,Non-Serious,Male,JAN-2017,06-MAR-2017,Non-Expedited,Not Specified,Not Specified,Aventis,Consumer,Not Specified,Lantus,29-JAN-2017,06-MAR-2017,US,Not Specified,US-SA-2017SA017252,-,-
13299266,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Injection Site Urticaria,Non-Serious,Non-Serious,Female,-,06-MAR-2017,Non-Expedited,55 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,-,25-JAN-2017,06-MAR-2017,US,Not Specified,US-SA-2017SA014714,-,-
13299265,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Injection Site Pruritus;Injection Site Pain;Injection Site Erythema;Injection Site Rash,Non-Serious,Non-Serious,Female,20-JAN-2017,06-MAR-2017,Non-Expedited,60 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,-,23-JAN-2017,06-MAR-2017,US,Not Specified,US-SA-2017SA014700,-,-
13299264,Soliqua 100/33,Insulin Glargine\Lixisenatide,Diabetes Mellitus,Urticaria,Non-Serious,Non-Serious,Female,JAN-2017,06-MAR-2017,Non-Expedited,55 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,-,19-JAN-2017,06-MAR-2017,US,Not Specified,US-SA-2017SA011712,-,-
13298198,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Product Used For Unknown Indication,Spleen Disorder;Lower Respiratory Tract Infection,Serious,Died;Hospitalized,Male,-,06-MAR-2017,Expedited,57 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,24-FEB-2017,06-MAR-2017,GB,Not Specified,GB-NOVOPROD-533671,-,-
13287072,Metact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Gastric Cancer,Serious,Other Outcomes;Hospitalized,Male,30-SEP-2016,02-MAR-2017,Expedited,75 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,Amlodipine Besylate,21-FEB-2017,02-MAR-2017,JP,Not Specified,JP-TAKEDA-2017TJP003795,-,-
13231330,Soliqua 100/33,Insulin Glargine\Lixisenatide,-,Hypersensitivity;Urticaria;Throat Tightness,Serious,Hospitalized,Female,JAN-2017,14-FEB-2017,Expedited,Not Specified,Not Specified,Aventis,Healthcare Professional,Not Specified,Lantus,02-FEB-2017,14-FEB-2017,US,Not Specified,US-SA-2017SA021042,-,-
13031662,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Hypertension;Type 2 Diabetes Mellitus,Eye Haemorrhage;Blood Glucose Increased,Serious,Other Outcomes,Male,27-OCT-2016,14-FEB-2017,Expedited,68 YR,105 KG,Novo Nordisk,Healthcare Professional,Not Specified,Tahor;Urapidil;Kardegic;Hydrochlorothiazide\Potassium Chloride;Acebutolol;Metformin Hydrochloride;Coveram,03-FEB-2017,15-DEC-2016,FR,Not Specified,FR-NOVOPROD-523021,-,-
13101719,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Anticoagulant Therapy;Blood Cholesterol Increased;Type 2 Diabetes Mellitus,Pulmonary Oedema,Serious,Hospitalized,Male,20-DEC-2016,31-JAN-2017,Expedited,70 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,Aspirin;Lescol,23-JAN-2017,10-JAN-2017,GR,Not Specified,GR-TAKEDA-2017TJP000443,-,-
13156074,Valium;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Diazepam,Depression;Diabetes Mellitus;Hypertension;Insomnia;Product Used For Unknown Indication,Hepatic Enzyme Increased,Non-Serious,Non-Serious,Male,DEC-2009,26-JAN-2017,Non-Expedited,62 YR,72.6 KG,Roche,Consumer,Not Specified,Diovan;Nitrazepam;Nuvigil;Amlodipine;Effexor,05-MAR-2010,26-JAN-2017,US,Not Specified,US-ROCHE-690932,-,-
12947473,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Mass,Serious,Hospitalized,Male,-,10-JAN-2017,Expedited,Not Specified,Not Specified,Takeda,Consumer,Not Specified,-,04-JAN-2017,16-NOV-2016,DE,Not Specified,DE-TAKEDA-2016TEU005641,-,-
13076248,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Type 2 Diabetes Mellitus,Guillain-Barre Syndrome,Serious,Hospitalized,Male,05-NOV-2016,30-DEC-2016,Expedited,57 YR,120 KG,Novo Nordisk,Healthcare Professional,Not Specified,Januvia;Lantus;Aspirin;Metformin,20-DEC-2016,30-DEC-2016,CH,Not Specified,CH-NOVOPROD-524432,-,-
13021439,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Ramipril;Ibuprofen;Amoxicillin,Drug Abuse,Sopor;Drug Abuse;Crying,Serious,Hospitalized,Male,10-MAR-2014,29-DEC-2016,Expedited,65 YR,Not Specified,Ranbaxy,Healthcare Professional,Not Specified,-,15-DEC-2016,13-DEC-2016,IT,Not Specified,IT-SUN PHARMACEUTICAL INDUSTRIES LTD-2016RR-129064,-,-
13019498,Competact,Ibuprofen;Metformin Hydrochloride\Pioglitazone Hydrochloride;Ramipril;Amoxicillin,Drug Abuse,Drug Abuse;Alcohol Abuse;Partial Seizures;Crying;Sopor,Serious,Hospitalized,Male,10-MAR-2014,28-DEC-2016,Expedited,65 YR,Not Specified,Teva,Healthcare Professional,Not Specified,-,16-DEC-2016,12-DEC-2016,IT,Not Specified,IT-TEVA-717824ACC,-,-
13007488,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Amoxicillin;Ramipril;Ibuprofen,Drug Abuse,Sopor;Drug Abuse;Crying,Serious,Hospitalized,Male,10-MAR-2014,27-DEC-2016,Expedited,65 YR,Not Specified,Sandoz,Healthcare Professional,Not Specified,-,15-DEC-2016,07-DEC-2016,IT,Not Specified,PHHY2016IT165732,-,-
12994341,Competact;Amoxicillin Trihydrate,Amoxicillin;Ibuprofen;Metformin Hydrochloride\Pioglitazone Hydrochloride;Ramipril,Drug Abuse,Sopor;Drug Abuse;Crying,Serious,Hospitalized,Male,10-MAR-2014,27-DEC-2016,Expedited,65 YR,Not Specified,Pfizer,Healthcare Professional,Not Specified,-,15-DEC-2016,02-DEC-2016,IT,Not Specified,IT-PFIZER INC-2016555894,-,-
12997457,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Ibuprofen;Alcohol;Amoxicillin;Ramipril,Alcohol Abuse;Drug Abuse,Drug Abuse;Sopor;Crying,Serious,Hospitalized,Male,10-MAR-2014,26-DEC-2016,Expedited,65 YR,Not Specified,Johnson And Johnson,Healthcare Professional,Not Specified,-,15-DEC-2016,05-DEC-2016,IT,Not Specified,IT-JNJFOC-20161129392,-,-
13007349,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Amoxicillin;Ibuprofen;Ramipril,Product Used For Unknown Indication,Sopor;Crying;Drug Abuse,Serious,Hospitalized,Not Specified,10-MAR-2014,23-DEC-2016,Expedited,Not Specified,Not Specified,Mylan,Healthcare Professional,Not Specified,-,16-DEC-2016,07-DEC-2016,IT,Not Specified,IT-MYLANLABS-2016M1053292,-,-
12998617,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Ibuprofen;Amoxicillin;Ramipril,Drug Abuse,Sopor;Drug Abuse;Crying,Serious,Hospitalized,Male,10-MAR-2014,21-DEC-2016,Expedited,65 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,-,15-DEC-2016,05-DEC-2016,IT,Not Specified,IT-TAKEDA-2016TEU005962,-,-
13037082,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Arthritis;Diabetes Mellitus,Therapeutic Product Effect Decreased;Bronchitis,Serious,Other Outcomes,Not Specified,2016,16-DEC-2016,Expedited,Not Specified,Not Specified,Mylan,Consumer,Not Specified,Prednisone,02-DEC-2016,16-DEC-2016,US,Not Specified,US-MYLANLABS-2016M1053462,-,-
13027577,Xultophy 100/3.6,Insulin Degludec\Liraglutide,Atrial Fibrillation;Diabetes Mellitus;Duodenal Ulcer;Hypertension;Myocardial Infarction;Overweight;Type 2 Diabetes Mellitus,Myocardial Infarction,Serious,Hospitalized;Died,Male,30-OCT-2016,14-DEC-2016,Expedited,75 YR,99.2 KG,Novo Nordisk,Healthcare Professional,Not Specified,Bisoprolol;Metformin;Amlodipine;Terazosin;Gliclazide;Atorvastatin;Omeprazole;Indapamide;Perindopril Erbumine;Aspirin,22-NOV-2016,14-DEC-2016,GB,Not Specified,GB-NOVOPROD-520780,-,-
12963114,Metact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Constipation;Dementia With Lewy Bodies;Diabetes Mellitus;Hypertension,Generalised Oedema;Cardiac Failure,Serious,Other Outcomes,Female,DEC-2015,09-DEC-2016,Expedited,79 YR,42 KG,Takeda,Healthcare Professional,Not Specified,Voglibose;Donepezil Hydrochloride;Magnesium Oxide;Carbidopa\Levodopa;Valproate Sodium;Imidapril Hydrochloride,30-NOV-2016,22-NOV-2016,JP,Not Specified,JP-TAKEDA-2016TJP024788,-,-
13001085,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Ibuprofen;Amoxicillin;Ramipril,Product Used For Unknown Indication,Sopor;Drug Abuse;Crying,Serious,Hospitalized,Male,10-MAR-2014,06-DEC-2016,Expedited,65 YR,Not Specified,Aurobindo,Healthcare Professional,Not Specified,-,28-NOV-2016,06-DEC-2016,IT,Not Specified,IT-AUROBINDO-AUR-APL-2016-15027,-,-
12965274,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Glimepiride,Diabetes Mellitus,Sopor;Hypoglycaemia,Serious,Other Outcomes,Male,19-OCT-2016,22-NOV-2016,Expedited,77 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,Deursil;Sinemet;Cymbalta,17-NOV-2016,22-NOV-2016,IT,Not Specified,IT-SA-2016SA212805,-,-
12963610,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Glimepiride,Diabetes Mellitus,Sopor;Hypoglycaemia,Serious,Other Outcomes,Male,19-OCT-2016,22-NOV-2016,Expedited,77 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,Sinemet;Cymbalta;Deursil,17-NOV-2016,22-NOV-2016,IT,Not Specified,IT-TAKEDA-2016TEU005792,-,-
11937447,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Linagliptin;Glyburide,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Hypoglycaemia;Drug Interaction,Serious,Hospitalized,Male,19-DEC-2015,16-NOV-2016,Expedited,81 YR,Not Specified,Boehringer Ingelheim,Healthcare Professional,Not Specified,Cyanocobalamin;Mirabegron;Micardis;Quetiapine;Lorazepam;Alprazolam;Aclidinium Bromide;Calcifediol;Herbals\Saw Palmetto,14-NOV-2016,21-JAN-2016,ES,Not Specified,"ES-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-02583ES",-,-
12887487,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Lethargy;Vitamin B12 Deficiency;Decreased Appetite;Fatigue;Depression;Coordination Abnormal,Serious,Other Outcomes,Male,12-MAY-2016,26-OCT-2016,Expedited,72 YR,88 KG,Takeda,Consumer,Not Specified,Quinapril;Allopurinol;Bendroflumethiazide;Aspirin;Amlodipine;Atorvastatin;Atenolol,21-OCT-2016,26-OCT-2016,GB,Not Specified,GB-TAKEDA-2016TEU005365,-,-
12836757,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Anxiety Disorder;Essential Hypertension;Type 2 Diabetes Mellitus,Vision Blurred;Cataract,Serious,Other Outcomes,Male,MAY-2016,11-OCT-2016,Expedited,71 YR,105 KG,Takeda,Healthcare Professional,Not Specified,Normabel;Lescol Xl;Amlodipine Besylate\Indapamide\Perindopril Arginine;Humulin N;Victoza;Tamsulosin Hydrochloride,07-OCT-2016,11-OCT-2016,HR,Not Specified,HR-TAKEDA-2016TEU005147,-,-
12708692,Trulicity;Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Dulaglutide,Blood Glucose Increased,Postprandial Hypoglycaemia;Syncope;Off Label Use,Serious,Life Threatening,Female,JUL-2016,19-SEP-2016,Expedited,71 YR,Not Specified,Eli Lilly And Co,Healthcare Professional,Not Specified,Moxonidine;Levothyroxine Sodium;Hydrochlorothiazide\Lisinopril;Metoprolol Tartrate;Atorvastatin,13-SEP-2016,01-SEP-2016,AT,Not Specified,AT-ELI_LILLY_AND_COMPANY-AT201608012979,-,-
12736815,-,Metformin Hydrochloride\Pioglitazone Hydrochloride;Insulin Nos,Diabetes Mellitus,Diarrhoea;Blood Glucose Decreased;Wrong Technique In Product Usage Process;Abdominal Pain Upper;Abdominal Discomfort,Non-Serious,Non-Serious,Female,2016,13-SEP-2016,Non-Expedited,Not Specified,90.8 KG,Teva,Consumer,Not Specified,-,08-AUG-2016,13-SEP-2016,US,Not Specified,US-TEVA-685791USA,-,-
12519378,Humalog Mix75/25;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Glipizide;Insulin Lispro,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Hypoglycaemia;Tremor;Blood Glucose Increased;Blood Glucose Decreased;Weight Decreased,Serious,Other Outcomes,Male,DEC-2015,12-SEP-2016,Non-Expedited,Not Specified,Not Specified,Eli Lilly And Co,Healthcare Professional,Not Specified,Lexapro;Desonide;Androgel;Synthroid;Claritin;Fluocinonide;Ultracet;Lipitor;Mometasone Furoate;Metformin Hydrochloride;Lopressor;Norvasc;Aspirin;Actos;Nystatin\Triamcinolone;Nexium;Enalapril Maleate;Astepro;Wellbutrin,31-AUG-2016,30-JUN-2016,US,Not Specified,US-ELI_LILLY_AND_COMPANY-US201606009301,-,-
12624487,Actos;Metact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Diabetes Mellitus;Hypertension;Thrombosis Prophylaxis,Bladder Neoplasm,Serious,Hospitalized,Male,28-JUL-2016,18-AUG-2016,Expedited,67 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,Glucobay;Carvedilol;Januvia;Teneligliptin;Metgluco;Aspirin;Miglitol;Amaryl;Adalat,09-AUG-2016,05-AUG-2016,JP,Not Specified,JP-TAKEDA-2016TJP015950,-,-
12611642,Actoplus Met Xr,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Micturition Urgency;Bladder Cancer;Chromaturia;Pollakiuria,Serious,Other Outcomes,Not Specified,-,01-AUG-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,-,07-NOV-2012,01-AUG-2016,US,Not Specified,US-TAKEDA-TPA2012A09038,-,-
11511706,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer;Death,Serious,Died;Other Outcomes,Not Specified,21-JAN-2007,27-JUL-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Januvia,21-JUL-2016,15-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A07361,-,-
11498455,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Transitional Cell Carcinoma;Death,Serious,Died;Other Outcomes,Not Specified,14-MAY-2009,25-JUL-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Diabeta;Humalog;Januvia;Metformin;Lantus;Glucophage,19-JUL-2016,11-SEP-2015,US,Not Specified,US-TAKEDA-TPA2011A08758,-,-
12554886,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Death;Bladder Cancer,Serious,Other Outcomes;Died,Not Specified,25-MAY-2012,13-JUL-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Avandia;Metformin,10-MAY-2013,13-JUL-2016,US,Not Specified,US-TAKEDA-TPA2013A03610,-,-
12537796,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Blood Glucose Increased,Non-Serious,Non-Serious,Not Specified,-,07-JUL-2016,Non-Expedited,Not Specified,Not Specified,Takeda,Consumer,Not Specified,-,27-JUN-2016,07-JUL-2016,US,Not Specified,US-TAKEDA-2016TUS011311,-,-
12529311,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,-,05-JUL-2016,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Amaryl;Metformin;Glucophage,18-JAN-2014,05-JUL-2016,US,Not Specified,US-TAKEDA-2014TUS000398,-,-
12197762,Eliquis;Onglyza;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Enalapril Maleate;Bromocriptine;Saxagliptin Hydrochloride;Apixaban;Metoprolol;Aspirin,Anxiety;Product Used For Unknown Indication;Weight Increased,Swelling;Pneumonia;Atrial Fibrillation,Serious,Hospitalized,Female,-,05-JUL-2016,Expedited,Not Specified,Not Specified,Aurobindo,Consumer,Not Specified,Ziprasidone;Lorazepam,21-JUN-2016,22-MAR-2016,US,Not Specified,US-AUROBINDO-AUR-APL-2016-03895,-,-
12369739,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Metformin Hydrochloride,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Dialysis;Hypercreatininaemia;Lactic Acidosis,Serious,Life Threatening;Other Outcomes,Male,29-FEB-2016,29-JUN-2016,Expedited,76 YR,Not Specified,Bristol Myers Squibb,Healthcare Professional,Not Specified,Trazodone Hydrochloride;Calcifediol;Gabapentin,17-JUN-2016,16-MAY-2016,IT,Not Specified,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-035596,-,-
12497360,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Death;Bladder Cancer,Serious,Other Outcomes;Died,Not Specified,SEP-2011,24-JUN-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Levemir;Novolog;Glucophage,26-NOV-2012,24-JUN-2016,US,Not Specified,US-TAKEDA-TPA2012A09507,-,-
12477551,Actoplus Met;Onglyza;Eliquis;Depakote,Divalproex Sodium;Ziprasidone;Lithium;Thiothixene;Enalapril Maleate;Omega-3-Acid Ethyl Esters;Bromocriptine;Apixaban;Simvastatin;Saxagliptin Hydrochloride;Metoprolol;Metformin Hydrochloride\Pioglitazone Hydrochloride;Aspirin,Product Used For Unknown Indication,Atrial Fibrillation;Pneumonia;Weight Increased;Peripheral Swelling;Weight Decreased,Serious,Other Outcomes;Hospitalized,Female,-,17-JUN-2016,Expedited,Not Specified,Not Specified,Sandoz,Consumer,Not Specified,Lorazepam,28-JAN-2016,17-JUN-2016,US,Not Specified,PHHY2016US077181,-,-
12324928,Competact;Metformin,Metformin Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride;Metformin Hydrochloride,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Lactic Acidosis;Hypercreatininaemia,Serious,Life Threatening;Other Outcomes,Not Specified,29-FEB-2016,17-JUN-2016,Expedited,Not Specified,Not Specified,Mylan,Healthcare Professional,Not Specified,Calcifediol;Trazodone Hydrochloride;Gabapentin,14-JUN-2016,02-MAY-2016,IT,Not Specified,IT-MYLANLABS-2016M1018143,-,-
11511528,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Death;Bladder Cancer,Serious,Other Outcomes;Died,Not Specified,20-MAY-2011,10-JUN-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin,03-JUN-2016,15-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A06390,-,-
12454903,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Abdominal Distension;Intraocular Pressure Increased,Non-Serious,Non-Serious,Male,-,09-JUN-2016,Direct,73 YR,235 LB,-,Consumer,Consumer,Ramipril,-,09-JUN-2016,Not Specified,Not Specified,-,-,-
12449374,Actos;Actoplus Met Xr,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer Recurrent;Death,Serious,Died;Other Outcomes,Not Specified,09-AUG-2010,08-JUN-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Avandia;Lantus;Glucophage;Diabeta;Metformin,23-JUL-2013,08-JUN-2016,US,Not Specified,US-TAKEDA-TPA2013A07154,-,-
12434450,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Death;Bladder Cancer,Serious,Died;Other Outcomes,Not Specified,2011,03-JUN-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Diabeta;Januvia,23-APR-2013,03-JUN-2016,US,Not Specified,US-TAKEDA-TPA2013A03002,-,-
11530200,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Prostate Cancer;Bladder Cancer;Death,Serious,Died;Other Outcomes,Not Specified,2006,02-JUN-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Januvia;Amaryl;Metformin;Glucophage,26-MAY-2016,21-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A05263,-,-
12421670,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Died;Other Outcomes,Not Specified,APR-2012,31-MAY-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Glucotrol;Glucophage,24-APR-2014,31-MAY-2016,US,Not Specified,US-TAKEDA-2014TUS003293,-,-
11498475,Actos;Actoplus Met Xr,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer;Death,Serious,Died;Other Outcomes,Not Specified,MAY-2011,31-MAY-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Fortamet;Janumet,23-MAY-2016,11-SEP-2015,US,Not Specified,US-TAKEDA-TPA2011A08742,-,-
12400168,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Haematuria;Bladder Cancer;Urinary Tract Infection;Death;Bladder Papilloma,Serious,Other Outcomes;Died,Not Specified,18-MAY-2010,24-MAY-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Glucophage;Byetta;Metformin;Amaryl;Januvia;Lantus,09-MAR-2012,24-MAY-2016,US,Not Specified,US-TAKEDA-TPA2012A01318,-,-
12390516,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Death;Bladder Cancer,Serious,Other Outcomes;Died,Not Specified,2009,20-MAY-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin,12-MAR-2012,20-MAY-2016,US,Not Specified,US-TAKEDA-TPA2012A01366,-,-
11618431,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Blood Glucose Increased;Myocardial Infarction;Blood Pressure Increased;Off Label Use;Kidney Infection,Serious,Died;Hospitalized;Other Outcomes,Male,07-NOV-2015,16-MAY-2016,Expedited,66 YR,64 KG,Takeda,Consumer,Not Specified,-,29-SEP-2015,12-OCT-2015,MX,Not Specified,MX-TAKEDA-2015TJP018775,-,-
12349228,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer;Death,Serious,Died;Other Outcomes,Not Specified,13-OCT-2009,09-MAY-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Glucophage;Starlix;Januvia;Prandin;Metformin,03-MAY-2013,09-MAY-2016,US,Not Specified,US-TAKEDA-TPA2013A03282,-,-
12349223,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Death;Bladder Cancer,Serious,Died;Other Outcomes,Not Specified,DEC-2008,09-MAY-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Lantus;Novolog;Metformin;Avandia,05-JUN-2012,09-MAY-2016,US,Not Specified,US-TAKEDA-TPA2012A03427,-,-
12343569,Actoplus Met;Onglyza;Eliquis;Depakote,Divalproex Sodium;Omega-3-Acid Ethyl Esters;Aspirin;Apixaban;Simvastatin;Thiothixene;Bromocriptine;Saxagliptin Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride;Metoprolol Tartrate;Lithium;Ziprasidone;Enalapril Maleate,Anxiety;Product Used For Unknown Indication,Weight Increased;Atrial Fibrillation;Pneumonia;Weight Decreased;Peripheral Swelling,Serious,Hospitalized,Not Specified,-,06-MAY-2016,Expedited,Not Specified,Not Specified,Validus,Consumer,Not Specified,Lorazepam,28-JAN-2016,06-MAY-2016,US,Not Specified,US-VALIDUS PHARMACEUTICALS LLC-US-2016VAL000411,-,-
12316028,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Metastases To Lymph Nodes;Bladder Cancer;Death,Serious,Other Outcomes;Died,Not Specified,05-APR-2007,28-APR-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Avandia;Novolog;Diabeta;Glyburide\Metformin;Glucotrol;Metformin,22-JUL-2013,28-APR-2016,US,Not Specified,US-TAKEDA-TPA2013A07032,-,-
12302142,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Dyspnoea;Gout;Muscle Spasms;Product Used For Unknown Indication;Swelling;Wheezing,Drug Hypersensitivity,Non-Serious,Non-Serious,Male,-,25-APR-2016,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Albuterol;Aldactone;Metolazone;Cyanocobalamin;K-Dur;Glycolax;Selenium;Hydralazine;Imdur;Torsemide;Docusate Sodium;Glucotrol;Meloxicam;Baclofen;Acetaminophen\Oxycodone Hydrochloride\Oxycodone Terephthalate;Carvedilol;Eliquis;Lyrica;Diclofenac Sodium;Allopurinol;Colchicine;Hawthorn Leaf With Flower;Lisinopril,15-APR-2016,25-APR-2016,US,Not Specified,US-TAKEDA-2016TUS006769,-,-
12300993,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer;Death,Serious,Died;Other Outcomes,Not Specified,14-JUL-2006,25-APR-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Insulin Nos;Januvia,11-JUN-2012,25-APR-2016,US,Not Specified,US-TAKEDA-TPA2012A03692,-,-
12287886,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Death;Bladder Cancer,Serious,Other Outcomes;Died,Not Specified,06-OCT-2010,20-APR-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Amaryl,20-SEP-2012,20-APR-2016,US,Not Specified,US-TAKEDA-TPA2012A07250,-,-
12287885,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Death;Bladder Cancer,Serious,Other Outcomes;Died,Not Specified,NOV-2011,20-APR-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Januvia;Metformin,05-JUN-2012,20-APR-2016,US,Not Specified,US-TAKEDA-TPA2012A03412,-,-
11456693,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Death;Bladder Cancer,Serious,Other Outcomes;Died,Not Specified,MAR-2013,18-APR-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Byetta;Lantus,12-APR-2016,03-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS004884,-,-
12273456,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Death;Bladder Cancer,Serious,Died;Other Outcomes,Not Specified,NOV-2008,15-APR-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Amaryl;Januvia,01-FEB-2013,15-APR-2016,US,Not Specified,US-TAKEDA-TPA2013A01267,-,-
12269489,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer;Death,Serious,Other Outcomes;Died,Not Specified,10-AUG-2012,14-APR-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,-,05-JUN-2013,14-APR-2016,US,Not Specified,US-TAKEDA-TPA2013A04736,-,-
12269465,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Death;Bladder Cancer;Haematuria,Serious,Died;Other Outcomes,Not Specified,17-AUG-2010,14-APR-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,-,04-JAN-2013,14-APR-2016,US,Not Specified,US-TAKEDA-TPA2012A09939,-,-
12224957,Lantus;Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Insulin Glargine,Diabetes Mellitus,Hypoglycaemia;Sopor;Hyperhidrosis;Medication Error,Serious,Other Outcomes,Male,01-APR-2013,11-APR-2016,Expedited,79 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,Ramipril;Irbesartan;Lansoprazole;Nebivolol Hydrochloride;Ascriptin,04-APR-2016,31-MAR-2016,IT,Not Specified,IT-TAKEDA-2016TEU002177,-,-
12161655,Eliquis;Zocor;Actoplus Met;Onglyza,Saxagliptin Hydrochloride;Bromocriptine;Metformin Hydrochloride\Pioglitazone Hydrochloride;Enalapril Maleate;Simvastatin;Apixaban;Metoprolol Tartrate;Aspirin,Anxiety,Atrial Fibrillation;Weight Decreased;Peripheral Swelling;Inflammation;Pneumonia,Serious,Other Outcomes;Hospitalized,Female,-,11-APR-2016,Expedited,Not Specified,Not Specified,Merck,Consumer,Not Specified,Lorazepam;Ziprasidone,05-APR-2016,09-MAR-2016,US,Not Specified,US-009507513-1603USA002835,-,-
12235213,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Death;Bladder Cancer,Serious,Died;Other Outcomes,Not Specified,JUL-2011,04-APR-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Januvia;Byetta;Amaryl,26-JUN-2013,04-APR-2016,US,Not Specified,US-TAKEDA-TPA2013A05873,-,-
12202835,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Death;Bladder Cancer,Serious,Other Outcomes;Died,Not Specified,SEP-2012,22-MAR-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin,23-APR-2013,22-MAR-2016,US,Not Specified,US-TAKEDA-TPA2013A03032,-,-
12194414,Onglyza;Actoplus Met;Eliquis,Apixaban;Metformin Hydrochloride\Pioglitazone Hydrochloride;Bromocriptine;Saxagliptin Hydrochloride;Aspirin;Metoprolol;Enalapril Maleate;Simvastatin,Anxiety;Product Used For Unknown Indication;Weight Increased,Atrial Fibrillation;Peripheral Swelling;Pneumonia,Serious,Hospitalized;Life Threatening;Other Outcomes,Female,-,21-MAR-2016,Expedited,Not Specified,Not Specified,Hospira,Consumer,Not Specified,Ziprasidone;Lorazepam,07-MAR-2016,21-MAR-2016,US,Not Specified,US-HOSPIRA-3219728,-,-
12192741,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,JUN-2015,18-MAR-2016,Non-Expedited,Not Specified,Not Specified,Takeda,Consumer,Not Specified,-,11-MAR-2016,18-MAR-2016,US,Not Specified,US-TAKEDA-2016TUS004410,-,-
12190614,Actoplus Met;Eliquis;Depakote;Onglyza,Saxagliptin Hydrochloride;Apixaban;Divalproex Sodium;Bromocriptine;Lorazepam;Metformin Hydrochloride\Pioglitazone Hydrochloride;Enalapril;Metoprolol;Simvastatin;Aspirin;Lithium;Thiothixene,Product Used For Unknown Indication,Pneumonia;Inflammation;Atrial Fibrillation;Weight Decreased;Weight Increased,Serious,Other Outcomes;Hospitalized,Female,-,18-MAR-2016,Expedited,Not Specified,Not Specified,Ranbaxy,Consumer,Not Specified,-,03-MAR-2016,18-MAR-2016,US,Not Specified,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2016US-113422,-,-
11459811,Actos;Actoplus Met,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Death;Bladder Cancer,Serious,Other Outcomes;Died,Not Specified,07-FEB-2008,18-MAR-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Avandia;Glucotrol,11-MAR-2016,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS006997,-,-
12188903,Actoplus Met;Eliquis;Onglyza,Metoprolol Tartrate;Saxagliptin Hydrochloride;Simvastatin;Apixaban;Enalapril Maleate;Metformin Hydrochloride\Pioglitazone Hydrochloride;Bromocriptine;Aspirin,Anxiety,Peripheral Swelling;Pneumonia;Atrial Fibrillation,Serious,Other Outcomes;Hospitalized,Female,-,17-MAR-2016,Expedited,Not Specified,Not Specified,Ipca,Consumer,Not Specified,Lorazepam;Ziprasidone,03-MAR-2016,17-MAR-2016,US,Not Specified,US-IPCA LABORATORIES LIMITED-IPC201603-000336,-,-
12186691,Onglyza;Actoplus Met;Eliquis,Apixaban;Bromocriptine;Enalapril Maleate;Simvastatin;Metformin Hydrochloride\Pioglitazone Hydrochloride;Saxagliptin Hydrochloride;Metoprolol Tartrate;Aspirin,Anxiety;Product Used For Unknown Indication;Weight Increased,Atrial Fibrillation;Swelling;Pneumonia,Serious,Hospitalized;Other Outcomes,Female,-,17-MAR-2016,Expedited,Not Specified,Not Specified,Bristol Myers Squibb,Consumer,Not Specified,Lorazepam;Ziprasidone,07-MAR-2016,17-MAR-2016,US,Not Specified,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-018277,-,-
11456198,Actoplus Met Xr;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer;Death,Serious,Died;Other Outcomes,Not Specified,28-MAR-2012,17-MAR-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Glucophage;Metformin,10-MAR-2016,03-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS001972,-,-
12185629,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer Recurrent;Death,Serious,Died;Other Outcomes,Not Specified,08-FEB-2007,16-MAR-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin,20-JUN-2013,16-MAR-2016,US,Not Specified,US-TAKEDA-TPA2013A05611,-,-
12181166,Depakote;Eliquis;Actoplus Met;Onglyza,Saxagliptin Hydrochloride;Lorazepam;Metformin Hydrochloride\Pioglitazone Hydrochloride;Aspirin;Simvastatin;Thiothixene;Ziprasidone;Enalapril;Lithium;Apixaban;Bromocriptine;Divalproex Sodium;Metoprolol Tartrate,Product Used For Unknown Indication,Inflammation;Weight Fluctuation;Peripheral Swelling;Atrial Fibrillation;Pneumonia,Serious,Hospitalized,Female,-,15-MAR-2016,Expedited,Not Specified,Not Specified,Takeda,Consumer,Not Specified,-,07-MAR-2016,15-MAR-2016,US,Not Specified,US-TAKEDA-2016TUS004220,-,-
12174003,Eliquis;Onglyza;Depakote;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Metoprolol Tartrate;Aspirin;Simvastatin;Divalproex Sodium;Thiothixene;Apixaban;Saxagliptin Hydrochloride;Lithium;Enalapril Maleate;Bromocriptine,Anxiety;Product Used For Unknown Indication;Weight Decreased,Atrial Fibrillation;Weight Increased;Peripheral Swelling;Pneumonia,Serious,Hospitalized;Other Outcomes,Female,-,14-MAR-2016,Expedited,Not Specified,Not Specified,Bausch And Lomb,Consumer,Not Specified,Ziprasidone;Lorazepam,07-MAR-2016,14-MAR-2016,US,Not Specified,US-BAUSCH-BL-2016-005938,-,-
11530268,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Death;Bladder Cancer,Serious,Died;Other Outcomes,Not Specified,19-JUL-2011,03-MAR-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Glucophage;Glucotrol;Metformin Hydrochloride;Avandia;Levemir,25-FEB-2016,21-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A05118,-,-
12139085,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer Recurrent;Death,Serious,Other Outcomes;Died,Not Specified,2010,02-MAR-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Novolog;Metformin;Janumet;Humulin N,22-OCT-2012,02-MAR-2016,US,Not Specified,US-TAKEDA-TPA2012A08525,-,-
12138619,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Death;Bladder Cancer,Serious,Died;Other Outcomes,Not Specified,JUL-2012,02-MAR-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin,17-SEP-2012,02-MAR-2016,US,Not Specified,US-TAKEDA-TPA2012A07009,-,-
12122411,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Death;Bladder Cancer;Ureteric Cancer,Serious,Died;Other Outcomes,Not Specified,24-SEP-2010,26-FEB-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin,06-SEP-2012,26-FEB-2016,US,Not Specified,US-TAKEDA-TPA2012A06509,-,-
11523521,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Functional Gastrointestinal Disorder;Back Pain;Metastatic Carcinoma Of The Bladder;Pollakiuria;Weight Decreased;Abdominal Pain Lower;Micturition Urgency;Decreased Appetite;Metastases To Liver;Metastases To Bone;Dysuria;Blood Urine Present,Serious,Died;Other Outcomes,Not Specified,04-MAR-2011,24-FEB-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,-,16-FEB-2016,18-SEP-2015,US,Not Specified,US-TAKEDA-TPA2011A08274,-,-
11884903,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes;Died,Male,-,19-FEB-2016,Expedited,Not Specified,Not Specified,Takeda,Consumer,Not Specified,-,12-FEB-2016,04-JAN-2016,DE,Not Specified,DE-TAKEDA-2015TEU011105,-,-
12089079,Competact;Crestor,Rosuvastatin Calcium;Furosemide;Fluindione;Allopurinol;Metformin Hydrochloride\Pioglitazone Hydrochloride;Bisoprolol Fumarate;Perindopril;Nitroglycerin,Product Used For Unknown Indication,Acute Kidney Injury;Lactic Acidosis;Hyperkalaemia;Aspartate Aminotransferase Increased;Septic Shock;Hypotension;Pallor;Alanine Aminotransferase Increased;Disorientation;Tachypnoea;Diarrhoea;Hyperthermia;Asthenia;Abdominal Pain,Serious,Hospitalized;Died;Life Threatening,Not Specified,07-SEP-2009,18-FEB-2016,Expedited,Not Specified,Not Specified,Symplmed Pharmaceuticals,Healthcare Professional,Not Specified,-,26-NOV-2009,18-FEB-2016,FR,Not Specified,FR-SYMPLMED PHARMACEUTICALS-2009SYMPLMED000144,-,-
12062431,Actos;Actoplus Met Xr,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Death;Bladder Cancer,Serious,Other Outcomes;Died,Not Specified,JUL-2008,10-FEB-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin,03-AUG-2012,10-FEB-2016,US,Not Specified,US-TAKEDA-TPA2012A05676,-,-
12047244,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Death;Bladder Cancer,Serious,Died;Other Outcomes,Not Specified,JUN-2012,08-FEB-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,-,07-SEP-2013,08-FEB-2016,US,Not Specified,US-TAKEDA-2013TUS000361,-,-
12017065,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer;Death,Serious,Other Outcomes;Died,Not Specified,APR-2008,05-FEB-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Glucophage;Metformin,31-OCT-2012,05-FEB-2016,US,Not Specified,US-TAKEDA-TPA2012A08846,-,-
12017055,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer;Death,Serious,Other Outcomes;Died,Not Specified,16-NOV-2012,05-FEB-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Avandamet;Glucophage;Metformin,10-OCT-2013,05-FEB-2016,US,Not Specified,US-TAKEDA-2013TUS001316,-,-
11456262,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer;Death,Serious,Other Outcomes;Died,Not Specified,20-NOV-2009,05-FEB-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Glucotrol;Humalog,29-JAN-2016,03-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS001118,-,-
11511598,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Death;Bladder Cancer Stage Ii,Serious,Other Outcomes;Died,Not Specified,27-NOV-2010,29-JAN-2016,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Januvia;Avandia;Byetta,21-JAN-2016,15-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A06735,-,-
11930490,Amaryl;Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Glimepiride,Type 2 Diabetes Mellitus,Hypoglycaemic Coma,Serious,Hospitalized;Other Outcomes,Female,21-OCT-2014,28-JAN-2016,Expedited,69 YR,75 KG,Takeda,Healthcare Professional,Not Specified,Tapazole;Aspirin;Folic Acid;Flecainide;Ramipril;Coumadin;Enoxaparin Sodium;Simvastatin;Fentanyl;Ferrous Sulfate,25-JAN-2016,20-JAN-2016,IT,Not Specified,IT-TAKEDA-2016TEU000338,-,-
11920885,Competact;Levemir,Insulin Detemir;Gliclazide;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Hypoglycaemia;Anaemia Vitamin B12 Deficiency,Serious,Hospitalized,Female,16-DEC-2014,15-JAN-2016,Expedited,76 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Lasix;Benserazide Hydrochloride\Levodopa;Cardura;Levothyroxine Sodium;Enalapril Maleate,07-JAN-2016,15-JAN-2016,IT,Not Specified,IT-NOVOPROD-476423,-,-
11909790,Levemir;Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Gliclazide;Insulin Detemir,Type 2 Diabetes Mellitus,Speech Disorder;Anaemia Vitamin B12 Deficiency;Hypoglycaemia;Vertigo,Serious,Hospitalized,Female,16-DEC-2014,15-JAN-2016,Expedited,76 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,Lasix;Cardura;Enalapril Maleate;Levothyroxine Sodium;Benserazide Hydrochloride\Levodopa,12-JAN-2016,12-JAN-2016,IT,Not Specified,IT-TAKEDA-2016TEU000129,-,-
11514317,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer;Death,Serious,Other Outcomes;Died,Not Specified,08-NOV-2011,28-DEC-2015,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Levemir;Lantus;Byetta;Amaryl;Novolog,17-DEC-2015,16-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A07533,-,-
11868181,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer;Death,Serious,Died;Other Outcomes,Not Specified,04-MAR-2011,24-DEC-2015,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin,26-JUN-2013,24-DEC-2015,US,Not Specified,US-TAKEDA-TPA2013A06013,-,-
11866235,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer Recurrent;Death,Serious,Died;Other Outcomes,Not Specified,28-NOV-2007,23-DEC-2015,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Diabeta;Novolin Nos;Metformin;Avandia,15-JAN-2013,23-DEC-2015,US,Not Specified,US-TAKEDA-TPA2013A00805,-,-
11790238,Lantus;Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Insulin Glargine,-,Sopor;Vomiting;Suicide Attempt;Drug Abuse,Serious,Hospitalized;Life Threatening,Female,06-MAR-2015,23-DEC-2015,Expedited,49 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,-,18-DEC-2015,01-DEC-2015,IT,Not Specified,IT-SA-2015SA195873,-,-
11786328,Lantus;Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Insulin Glargine,Suicide Attempt,Vomiting;Drug Abuse;Sopor,Serious,Life Threatening,Female,06-MAR-2015,22-DEC-2015,Expedited,49 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,-,18-DEC-2015,30-NOV-2015,IT,Not Specified,IT-TAKEDA-2015TEU009899,-,-
11660520,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Lixisenatide,Diabetes Mellitus;Type 2 Diabetes Mellitus,Hypoglycaemia;Palpitations;Medication Error,Serious,Other Outcomes,Male,05-MAR-2014,21-DEC-2015,Expedited,75 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,Enalapril Maleate\Lercanidipine Hydrochloride,15-DEC-2015,26-OCT-2015,IT,Not Specified,IT-TAKEDA-2015TEU008896,-,-
11853488,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Death;Bladder Cancer,Serious,Died;Other Outcomes,Not Specified,APR-2009,18-DEC-2015,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Amaryl,07-JUN-2013,18-DEC-2015,US,Not Specified,US-TAKEDA-TPA2013A04979,-,-
11466686,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Death;Bladder Cancer,Serious,Died;Other Outcomes,Not Specified,08-MAY-2014,17-DEC-2015,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Glucophage;Glucotrol;Metformin,09-DEC-2015,07-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS014797,-,-
11833878,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Death;Bladder Cancer,Serious,Other Outcomes;Died,Not Specified,JUN-2011,14-DEC-2015,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Glucotrol,25-OCT-2011,14-DEC-2015,US,Not Specified,US-TAKEDA-TPA2011A07032,-,-
11379351,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Hepatic Steatosis,Tachycardia;Hypertension;Nervousness;Fear;Anxiety;Off Label Use;Blepharospasm;Paraesthesia;Agitation,Non-Serious,Non-Serious,Male,16-APR-2015,04-DEC-2015,Expedited,25 YR,Not Specified,Takeda,Consumer,Not Specified,-,20-NOV-2015,13-AUG-2015,MX,Not Specified,MX-TAKEDA-2015TJP014929,-,-
11662191,Amaryl;Competact;Metformin,Metformin Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride;Glimepiride,Asthma;Diabetes Mellitus,Dizziness;Headache;Asthenia;Medication Error;Confusional State;Dysstasia;Gait Disturbance;Hypoglycaemia,Serious,Hospitalized,Female,25-JUN-2012,02-DEC-2015,Expedited,80 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,Ranitidine;Theophylline;Ramipril,17-NOV-2015,26-OCT-2015,IT,Not Specified,IT-TAKEDA-2015TEU008884,-,-
11616401,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Product Used For Unknown Indication,Cardiac Failure;Myocardial Infarction;Bladder Hypertrophy;Cerebrovascular Accident,Serious,Other Outcomes,Not Specified,-,26-OCT-2015,Expedited,Not Specified,Not Specified,Takeda,Consumer,Not Specified,-,19-OCT-2015,09-OCT-2015,US,Not Specified,US-TAKEDA-2015TUS013546,-,-
11655029,Januvia;Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Repaglinide;Sitagliptin Phosphate,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Hypoglycaemia,Serious,Hospitalized,Male,17-MAY-2012,23-OCT-2015,Expedited,74 YR,Not Specified,Actavis,Healthcare Professional,Not Specified,Olmesartan Medoxomil;Ramipril,14-OCT-2015,23-OCT-2015,IT,Not Specified,IT-ACTAVIS-2015-22368,-,-
11460968,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,16-DEC-2012,20-OCT-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Januvia,13-OCT-2015,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS009639,-,-
11636372,Competact;Januvia,Sitagliptin Phosphate;Metformin Hydrochloride\Pioglitazone Hydrochloride;Repaglinide,Type 2 Diabetes Mellitus,Hypoglycaemia,Serious,Hospitalized,Male,17-MAY-2012,16-OCT-2015,Expedited,74 YR,Not Specified,Merck,Healthcare Professional,Not Specified,Olmesartan Medoxomil;Ramipril,14-OCT-2015,16-OCT-2015,IT,Not Specified,IT-009507513-1510ITA006920,-,-
11475091,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Transitional Cell Carcinoma,Serious,Other Outcomes,Not Specified,19-AUG-2014,15-OCT-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Bydureon;Amaryl;Glucophage;Avandia;Januvia;Metformin;Fortamet;Glumetza,06-OCT-2015,08-SEP-2015,US,Not Specified,US-TAKEDA-2015TUS002968,-,-
11518531,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Died;Other Outcomes,Not Specified,13-AUG-2012,12-OCT-2015,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Januvia,05-OCT-2015,17-SEP-2015,US,Not Specified,US-TAKEDA-2015TUS001252,-,-
11475008,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,JUL-2010,12-OCT-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Amaryl,05-OCT-2015,08-SEP-2015,US,Not Specified,US-TAKEDA-2015TUS002685,-,-
11537097,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,APR-2011,22-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Januvia;Metformin;Levemir;Lantus;Avandia,31-JAN-2013,22-SEP-2015,US,Not Specified,US-TAKEDA-TPA2011A05710,-,-
11532507,Metact;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Dyslipidaemia,Bladder Cancer,Serious,Other Outcomes;Life Threatening,Male,-,21-SEP-2015,Non-Expedited,67 YR,57.6 KG,Takeda,Healthcare Professional,Not Specified,Metgluco;Nesina;Metformin Hydrochloride;Livalo,15-JUN-2015,21-SEP-2015,JP,Not Specified,JP-TAKEDA-2015TJP010984AA,-,-
11532401,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Hypertension;Cerebral Infarction;Cardiac Failure,Serious,Died;Other Outcomes,Not Specified,-,21-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,-,18-JUL-2013,21-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A06917,-,-
11532196,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes;Died,Not Specified,FEB-2012,21-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Lantus;Metformin;Glucotrol;Avandia,19-JUL-2013,21-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A06934,-,-
11532168,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Urinary Tract Infection;Bladder Cancer,Serious,Other Outcomes,Not Specified,JAN-2010,21-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Levemir;Byetta,31-JUL-2013,21-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A07335,-,-
11532073,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer Recurrent,Serious,Other Outcomes,Not Specified,2007,21-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Avandia;Glucophage;Lantus;Metformin;Amaryl,12-JUL-2013,21-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A06840,-,-
11531672,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer;Cardiac Failure Congestive;Death,Serious,Other Outcomes;Died,Not Specified,16-APR-2007,21-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Amaryl;Glucophage;Metformin;Lantus;Januvia,26-JUN-2013,21-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A06140,-,-
11531621,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,01-MAY-2013,21-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Amaryl,26-JUN-2013,21-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A06177,-,-
11531618,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Dysfunction;Bladder Cancer,Serious,Other Outcomes;Died,Not Specified,2009,21-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Onglyza,21-JUN-2013,21-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A05914,-,-
11531457,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes;Died,Not Specified,AUG-2009,21-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Glucophage;Avandia,21-JUN-2013,21-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A05757,-,-
11530512,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Died;Other Outcomes,Not Specified,MAR-2011,21-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Lantus;Humalog;Metformin,07-JUN-2013,21-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A04840,-,-
11530493,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer;Metastases To Bone,Serious,Other Outcomes,Not Specified,14-AUG-2012,21-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Glucotrol,18-MAR-2013,21-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A02223,-,-
11530256,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,2012,21-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Glucotrol;Metformin,17-MAY-2013,21-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A03931,-,-
11526139,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,20-DEC-2009,18-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin,14-DEC-2012,18-SEP-2015,US,Not Specified,US-TAKEDA-TPA2012A11223,-,-
11526126,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Weight Fluctuation;Prostate Cancer,Serious,Other Outcomes,Not Specified,-,18-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,-,20-DEC-2012,18-SEP-2015,US,Not Specified,US-TAKEDA-TPA2012A10412,-,-
11526114,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Weight Fluctuation;Prostate Cancer;Hypoaesthesia,Serious,Other Outcomes,Not Specified,-,18-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,-,08-NOV-2012,18-SEP-2015,US,Not Specified,US-TAKEDA-TPA2012A09097,-,-
11526095,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,02-DEC-2011,18-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin,10-SEP-2012,18-SEP-2015,US,Not Specified,US-TAKEDA-TPA2012A06707,-,-
11526088,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Renal Embolism;Bladder Cancer,Serious,Other Outcomes,Not Specified,15-APR-2010,18-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Glipizide,17-SEP-2012,18-SEP-2015,US,Not Specified,US-TAKEDA-TPA2012A07032,-,-
11526073,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,MAY-2011,18-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Amaryl;Glucophage,10-JUL-2012,18-SEP-2015,US,Not Specified,US-TAKEDA-TPA2012A04657,-,-
11526067,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Transitional Cell Carcinoma,Serious,Other Outcomes,Not Specified,11-NOV-2011,18-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Janumet,19-JUL-2012,18-SEP-2015,US,Not Specified,US-TAKEDA-TPA2012A05157,-,-
11525944,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Transitional Cell Carcinoma Metastatic;Hyponatraemia,Serious,Died;Other Outcomes,Not Specified,JUL-2011,18-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,-,04-MAY-2012,18-SEP-2015,US,Not Specified,US-TAKEDA-TPA2012A02644,-,-
11525528,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Haematuria;Bladder Cancer,Serious,Other Outcomes,Not Specified,OCT-2009,18-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Zocor;Glucophage;Lisinopril;Metformin Hydrochloride;Janumet,11-JAN-2012,18-SEP-2015,US,Not Specified,US-TAKEDA-TPA2012A00260,-,-
11525527,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,MAR-2010,18-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Glucophage;Glucotrol;Levemir,02-FEB-2012,18-SEP-2015,US,Not Specified,US-TAKEDA-TPA2012A00623,-,-
11525522,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,DEC-2000,18-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Januvia,28-MAR-2012,18-SEP-2015,US,Not Specified,US-TAKEDA-TPA2012A01737,-,-
11525521,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,11-MAY-2007,18-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,-,05-APR-2012,18-SEP-2015,US,Not Specified,US-TAKEDA-TPA2012A01922,-,-
11523903,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Death;Bladder Cancer,Serious,Died;Other Outcomes,Not Specified,27-OCT-2009,18-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Glucophage;Novolog;Metformin,23-DEC-2011,18-SEP-2015,US,Not Specified,US-TAKEDA-TPA2011A08754,-,-
11521588,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer;Death,Serious,Other Outcomes;Died,Not Specified,22-APR-2006,18-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Lantus;Metformin;Avandia;Glucovance;Glucotrol;Starlix;Amaryl,09-SEP-2011,18-SEP-2015,US,Not Specified,US-TAKEDA-TPA2011A05644,-,-
10867713,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Cystitis,Serious,Other Outcomes,Not Specified,2007,18-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Glucophage;Amaryl;Glucotrol;Humalog,17-APR-2015,25-FEB-2015,US,Not Specified,US-TAKEDA-TPA2012A01859,-,-
11518571,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Disabled;Other Outcomes,Male,24-FEB-2015,17-SEP-2015,Non-Expedited,74 YR,77 KG,Takeda,Healthcare Professional,Not Specified,-,15-MAY-2015,17-SEP-2015,IT,Not Specified,IT-TAKEDA-2015TEU004236,-,-
11518491,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Metastases To Prostate;Bladder Transitional Cell Carcinoma Metastatic,Serious,Other Outcomes,Not Specified,AUG-2013,17-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Glucophage;Avandia;Glucotrol;Januvia,16-JAN-2015,17-SEP-2015,US,Not Specified,US-TAKEDA-2015TUS000590,-,-
11516982,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Renal Cancer;Bladder Cancer,Serious,Other Outcomes;Died,Not Specified,OCT-2013,17-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin,09-DEC-2014,17-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS013907,-,-
11516932,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Urinary Tract Infection;Bladder Transitional Cell Carcinoma;Bladder Squamous Cell Carcinoma Stage Unspecified,Serious,Died;Other Outcomes,Not Specified,2009,17-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Glucotrol;Glucophage;Metformin;Amaryl;Januvia,08-NOV-2014,17-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS011188,-,-
11516913,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Prostate Cancer,Serious,Other Outcomes,Not Specified,12-MAY-2010,17-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Glucotrol,05-DEC-2014,17-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS013855,-,-
11516900,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer;Renal Cancer,Serious,Other Outcomes,Not Specified,DEC-2012,17-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin,23-OCT-2014,17-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS010444,-,-
11516026,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer;Cystitis;Urinary Incontinence;Loss Of Personal Independence In Daily Activities,Serious,Other Outcomes,Not Specified,-,17-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Amaryl;Metformin;Avandia,03-JUN-2014,17-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS004524,-,-
11514358,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,2014,16-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Amaryl,17-JUN-2014,16-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS004882,-,-
11514356,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,10-JUN-2011,16-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Glucophage;Lantus;Amaryl;Metformin;Byetta;Humalog,15-OCT-2014,16-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A07712,-,-
11514345,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,30-JAN-2009,16-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin,06-AUG-2013,16-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A07495,-,-
11514344,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,2011,16-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Glucotrol;Janumet,20-AUG-2013,16-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A07767,-,-
11514340,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,11-AUG-2010,16-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Glucophage;Glucotrol;Metformin,02-OCT-2014,16-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A07749,-,-
11514327,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,15-AUG-2011,16-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Glucotrol;Januvia,01-OCT-2014,16-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A07747,-,-
11514325,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,02-NOV-2011,16-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Januvia;Glucophage;Janumet;Amaryl,01-OCT-2014,16-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A07708,-,-
11511986,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Therapeutic Product Effect Decreased,Non-Serious,Non-Serious,Female,-,16-SEP-2015,Non-Expedited,Not Specified,Not Specified,Teva,Consumer,Not Specified,-,08-JUN-2015,16-SEP-2015,US,Not Specified,US-TEVA-569594USA,-,-
11511710,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,01-SEP-2009,15-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Avandia;Metformin;Humulin Nos,06-AUG-2013,15-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A07459,-,-
11511682,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,03-JUL-2012,15-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Avandamet;Glucotrol;Metformin;Amaryl,06-AUG-2013,15-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A07453,-,-
11511673,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,03-AUG-2011,15-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Janumet;Avandamet,06-AUG-2013,15-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A07481,-,-
11511667,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,19-DEC-2011,15-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Avandia;Janumet;Januvia,30-JUL-2013,15-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A07322,-,-
11511666,Actos;Actoplus Met,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,06-MAR-2012,15-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Lantus;Glucophage;Glucotrol,06-AUG-2013,15-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A07455,-,-
11511659,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,SEP-2004,15-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Lantus;Metformin;Amaryl;Glucotrol;Januvia,23-JUL-2013,15-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A07189,-,-
11511632,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,APR-2008,15-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Lantus;Metformin;Januvia;Humalog;Glucophage,19-JUL-2013,15-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A06959,-,-
11511619,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,08-JUN-2005,15-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Lantus;Metformin;Novolog;Amaryl;Avandia;Glucophage;Glucotrol,30-JUL-2013,15-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A07311,-,-
11511618,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,01-JUL-2011,15-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Amaryl;Byetta;Metformin,30-JUL-2013,15-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A07282,-,-
11511607,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,SEP-2012,15-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Amaryl;Glucotrol;Lovaza;Metformin;Avandia,12-JUL-2013,15-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A06809,-,-
11511561,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,03-AUG-2010,15-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Glucotrol,05-JUL-2013,15-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A06505,-,-
11511541,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,18-SEP-2009,15-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Avandamet;Janumet;Metformin,03-JUL-2013,15-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A06403,-,-
11511537,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,03-OCT-2011,15-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Lantus;Avandia;Avandamet;Humalog,03-JUL-2013,15-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A06362,-,-
11511000,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,26-AUG-2006,15-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin,26-JUN-2013,15-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A06107,-,-
11510988,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Transitional Cell Carcinoma Stage I,Serious,Other Outcomes,Not Specified,AUG-2008,15-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Glucotrol,26-JUN-2013,15-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A06146,-,-
11510923,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,14-OCT-2008,15-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Lantus;Phenacetin;Glucotrol,26-JUN-2013,15-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A06180,-,-
11510921,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Transitional Cell Carcinoma,Serious,Other Outcomes,Not Specified,20-APR-2012,15-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Glucophage;Glucotrol;Januvia;Amaryl;Metformin;Levemir;Lantus,26-JUN-2013,15-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A06214,-,-
11510911,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,28-SEP-2009,15-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Glucophage;Glucotrol;Metformin;Humalog;Precose;Lantus;Byetta;Januvia,26-JUN-2013,15-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A06154,-,-
11510869,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,JAN-2012,15-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Lantus;Lantus Solostar;Glucotrol;Metformin,26-JUN-2013,15-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A06174,-,-
11504196,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,30-APR-2009,14-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Amaryl,24-JUN-2013,14-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A05969,-,-
11504156,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,09-AUG-2012,14-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Januvia;Starlix;Glucotrol;Metformin,14-JUN-2013,14-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A05323,-,-
11503837,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,25-APR-2011,14-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Avandia;Metformin;Victoza;Byetta;Starlix,24-MAY-2013,14-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A04148,-,-
11503829,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,MAR-2013,14-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Lantus;Januvia;Levemir;Novolin Nos;Avandia,07-JUN-2013,14-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A04876,-,-
11503812,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,28-FEB-2012,14-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Glucophage,13-MAR-2013,14-SEP-2015,US,Not Specified,US-TAKEDA-TPA2013A02113,-,-
11503364,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,JUL-2011,14-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin,14-DEC-2012,14-SEP-2015,US,Not Specified,US-TAKEDA-TPA2012A11337,-,-
11503353,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,02-MAY-2011,14-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin,31-OCT-2012,14-SEP-2015,US,Not Specified,US-TAKEDA-TPA2012A08852,-,-
11503337,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,01-APR-2008,14-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Glucophage;Metformin,14-DEC-2012,14-SEP-2015,US,Not Specified,US-TAKEDA-TPA2012A10823,-,-
11503231,Actoplus Met Xr;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Transitional Cell Carcinoma,Serious,Other Outcomes,Not Specified,30-JAN-2012,14-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Glucovance;Levemir,05-DEC-2012,14-SEP-2015,US,Not Specified,US-TAKEDA-TPA2012A09707,-,-
11502984,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Transitional Cell Carcinoma,Serious,Other Outcomes,Not Specified,AUG-2011,14-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Byetta;Januvia,14-DEC-2012,14-SEP-2015,US,Not Specified,US-TAKEDA-TPA2012A11669,-,-
11502876,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,13-JUL-2011,14-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Glucophage;Januvia;Novolog;Metformin;Levemir;Avandia,17-SEP-2012,14-SEP-2015,US,Not Specified,US-TAKEDA-TPA2012A07033,-,-
11502833,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,03-DEC-2011,14-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Januvia;Metformin,10-DEC-2012,14-SEP-2015,US,Not Specified,US-TAKEDA-TPA2012A09824,-,-
11502359,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,01-MAY-2008,14-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Januvia;Lantus;Amaryl;Metformin;Insulin Lispro;Byetta;Glucotrol,30-NOV-2012,14-SEP-2015,US,Not Specified,US-TAKEDA-TPA2012A09574,-,-
11501784,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,24-JUN-2009,14-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Lantus;Byetta;Novolog;Humulin R,06-JUN-2012,14-SEP-2015,US,Not Specified,US-TAKEDA-TPA2012A03538,-,-
11501744,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,03-FEB-2010,14-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin,19-JUL-2012,14-SEP-2015,US,Not Specified,US-TAKEDA-TPA2012A04399,-,-
11501723,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,30-MAR-2011,14-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,-,06-JUN-2012,14-SEP-2015,US,Not Specified,US-TAKEDA-TPA2012A03524,-,-
11498468,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,04-AUG-2009,11-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Glucophage;Avandia;Metformin,23-DEC-2011,11-SEP-2015,US,Not Specified,US-TAKEDA-TPA2011A08723,-,-
11498445,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer Stage Iii,Serious,Other Outcomes,Not Specified,22-DEC-2010,11-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Glucotrol;Metformin,21-DEC-2011,11-SEP-2015,US,Not Specified,US-TAKEDA-TPA2011A08683,-,-
11498434,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,11-JAN-2011,11-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Januvia;Amaryl;Levemir;Metformin;Byetta,14-NOV-2011,11-SEP-2015,US,Not Specified,US-TAKEDA-TPA2011A07644,-,-
11497916,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,01-JUN-2013,11-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Amaryl;Januvia;Metformin,30-APR-2015,11-SEP-2015,US,Not Specified,US-TAKEDA-2015TUS005903,-,-
11497768,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,15-JAN-2013,11-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Avandamet,24-APR-2015,11-SEP-2015,US,Not Specified,US-TAKEDA-2015TUS005510,-,-
11488317,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,2006,09-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Lantus;Glucophage;Lisinopril;Metformin;Simvastatin;Humalog,10-MAR-2015,09-SEP-2015,US,Not Specified,US-TAKEDA-2015TUS003080,-,-
11487659,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,-,09-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Consumer,Not Specified,-,09-MAR-2015,09-SEP-2015,US,Not Specified,US-TAKEDA-2015TUS003056,-,-
11480437,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,2012,09-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Januvia;Avandamet,26-MAR-2015,09-SEP-2015,US,Not Specified,US-TAKEDA-2015TUS003818,-,-
11469220,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,30-SEP-2011,08-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Amaryl;Metformin,10-FEB-2015,08-SEP-2015,US,Not Specified,US-TAKEDA-2015TUS001560,-,-
11469210,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,-,08-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Januvia;Amaryl;Avandaryl;Metformin Hydrochloride;Apidra;Lantus,12-FEB-2015,08-SEP-2015,US,Not Specified,US-TAKEDA-2015TUS001688,-,-
11468614,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Transitional Cell Carcinoma,Serious,Other Outcomes,Not Specified,15-JUL-2013,08-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Glucophage;Metformin;Glucotrol;Victoza;Byetta,16-JAN-2015,08-SEP-2015,US,Not Specified,US-TAKEDA-2015TUS000591,-,-
11466683,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,15-AUG-2014,07-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Byetta;Metformin,24-DEC-2014,07-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS014816,-,-
11466619,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,30-JUL-2012,07-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Glucotrol;Glucophage;Metformin;Novolog,08-DEC-2014,07-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS013759,-,-
11466578,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,JUN-2014,07-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Amaryl;Metformin,05-DEC-2014,07-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS013678,-,-
11466554,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,JAN-2011,07-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,-,02-DEC-2014,07-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS013362,-,-
11466461,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,JAN-2014,07-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Avandia;Glucophage;Glucotrol;Metformin;Byetta,27-NOV-2014,07-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS012691,-,-
11466332,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Product Prescribing Error,Non-Serious,Non-Serious,Not Specified,-,07-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,-,19-NOV-2014,07-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS012561,-,-
11466108,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,MAR-2014,07-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Starlix,30-OCT-2014,07-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS010583,-,-
11466100,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,05-MAR-2013,07-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Victoza;Apidra;Invokana;Metformin;Glucotrol;Lantus,12-NOV-2014,07-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS011307,-,-
11466066,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,OCT-2013,07-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Amaryl,08-NOV-2014,07-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS011186,-,-
11466056,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,JAN-2013,07-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Janumet;Januvia;Metformin,30-OCT-2014,07-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS010745,-,-
11466050,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,29-SEP-2014,07-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Lantus;Symlin;Metformin,23-OCT-2014,07-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS010439,-,-
11466031,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,MAY-2014,07-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,-,07-NOV-2014,07-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS011193,-,-
11465803,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,30-AUG-2007,07-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Avandia;Glucotrol;Metformin;Glucophage,24-OCT-2014,07-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS010651,-,-
11461017,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,2005,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Micronase;Glucophage;Lantus;Metformin,08-OCT-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS009715,-,-
11461016,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,11-JUL-2013,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Januvia;Glucotrol;Metformin,14-OCT-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS009930,-,-
11461012,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,05-APR-2013,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Avandia;Rezulin;Januvia;Glucophage;Humalog;Metformin,14-OCT-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS009928,-,-
11460998,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,01-MAR-2013,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Januvia,08-OCT-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS009748,-,-
11460997,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,09-DEC-2010,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Avandia;Glucotrol;Metformin,03-OCT-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS009690,-,-
11460981,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,MAY-2013,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin,27-SEP-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS009286,-,-
11460970,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,DEC-2012,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Januvia;Metformin,30-SEP-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS009337,-,-
11460925,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,15-MAR-2004,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Glucophage;Byetta;Metformin;Amaryl,25-SEP-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS009191,-,-
11460898,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,20-MAR-2014,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Glucotrol;Amaryl;Januvia;Starlix;Glucophage;Metformin,25-SEP-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS009192,-,-
11460890,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,03-SEP-2009,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin,22-SEP-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS009090,-,-
11460871,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,AUG-2012,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Novolog;Glucotrol;Levemir;Humalog;Glucophage;Byetta;Lantus;Metformin;Avandia;Amaryl,17-SEP-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS008790,-,-
11460752,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,21-AUG-2013,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Glucotrol,11-SEP-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS008617,-,-
11460600,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,13-DEC-2010,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Amaryl;Metformin,29-AUG-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS008036,-,-
11460547,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Transitional Cell Carcinoma,Serious,Other Outcomes,Not Specified,-,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,-,29-AUG-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS008195,-,-
11460336,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,2011,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Januvia,27-AUG-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS007861,-,-
11460127,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,18-OCT-2013,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Amaryl;Glucophage,21-AUG-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS007601,-,-
11460126,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Transitional Cell Carcinoma,Serious,Other Outcomes,Not Specified,OCT-2013,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Glucotrol;Amaryl;Levemir;Metformin,24-AUG-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS007681,-,-
11460079,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,-,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,-,15-AUG-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS007490,-,-
11459822,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,SEP-2003,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Amaryl;Januvia,30-JUL-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS006986,-,-
11459793,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,03-JAN-2005,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Januvia;Janumet;Nisoldipine,30-JUL-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS006999,-,-
11459784,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,19-NOV-2013,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Avandia;Avandamet;Metformin;Victoza;Fortamet;Amaryl;Levemir,30-JUL-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS006966,-,-
11459767,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,29-APR-2013,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin,06-AUG-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS007153,-,-
11459747,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Blood Glucose Increased,Non-Serious,Non-Serious,Male,-,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Consumer,Not Specified,-,04-AUG-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS007237,-,-
11459669,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,02-FEB-2005,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Glucovance;Victoza;Januvia;Amaryl,30-JUL-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS006806,-,-
11459357,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,JAN-2013,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Glucophage;Metformin,11-JUL-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS005786,-,-
11459351,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,JUN-2013,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Humalog;Levemir;Metformin,17-JUL-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS006327,-,-
11459350,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,19-MAR-2013,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Januvia;Glucotrol;Metformin,17-JUL-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS006306,-,-
11459241,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,22-AUG-2008,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin,17-JUL-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS006338,-,-
11459200,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,12-FEB-2013,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin,16-JUL-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS006321,-,-
11459197,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,30-SEP-2013,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Amaryl;Fortamet;Metformin,10-JUL-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS005746,-,-
11459135,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,09-OCT-2013,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Januvia;Levemir;Amaryl;Novolog;Avandia;Byetta,04-JUL-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS005605,-,-
11458927,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,OCT-2013,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Humalog;Januvia;Glucophage,09-JUL-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS005453,-,-
11458839,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,21-SEP-2009,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Victoza;Apidra;Metformin;Glucophage;Lantus;Byetta,09-JUL-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS005456,-,-
11458838,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,10-MAY-2013,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Lantus;Glucophage;Avandia;Humalog;Januvia;Metformin,09-JUL-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS005433,-,-
11458749,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,AUG-2013,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin,02-JUL-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS005495,-,-
11458487,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,13-JUL-2012,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin,09-JUL-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS005360,-,-
11458486,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,12-JUN-2013,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Avandia;Amaryl;Metformin,09-JUL-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS005368,-,-
11458385,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,SEP-2013,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Lantus;Humalog;Glucotrol;Novolog;Metformin,25-JUL-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS005370,-,-
11458379,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,16-SEP-2013,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Lantus,26-JUN-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS005206,-,-
11458360,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,04-DEC-2012,04-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Glucophage;Metformin,26-JUN-2014,04-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS005208,-,-
11456707,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,01-AUG-2012,03-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Lantus;Glucophage;Januvia;Metformin,05-JUN-2014,03-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS004514,-,-
11456703,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,MAY-2013,03-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Avandamet;Avandia;Metformin;Glucotrol,23-JUN-2014,03-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS005024,-,-
11456702,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,2012,03-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Lantus;Metformin,17-JUN-2014,03-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS004877,-,-
11456700,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,24-JAN-2012,03-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Glucotrol;Metformin,21-JUN-2014,03-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS005022,-,-
11456679,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,2012,03-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Glucophage;Amaryl,20-JUN-2014,03-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS004980,-,-
11456654,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,AUG-2001,03-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Humalog;Glucotrol,23-JUN-2014,03-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS005056,-,-
11456648,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,JUN-2012,03-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Glucotrol;Bydureon;Byetta,07-MAY-2014,03-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS003654,-,-
11456635,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,14-JUL-2011,03-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Avandia;Lantus;Metformin,05-JUN-2014,03-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS004513,-,-
11456617,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Transitional Cell Carcinoma,Serious,Other Outcomes,Not Specified,OCT-2012,03-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,-,01-MAY-2014,03-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS003554,-,-
11456613,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,MAY-2013,03-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Lantus;Metformin;Starlix,30-APR-2014,03-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS003343,-,-
11456610,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,23-APR-2013,03-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Starlix;Metformin;Byetta;Amaryl;Victoza;Humalog;Invokana;Cycloset;Lantus,23-MAY-2014,03-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS004147,-,-
11456512,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,11-DEC-2012,03-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Levemir;Glucotrol;Metformin,19-MAR-2014,03-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS002108,-,-
11456509,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,23-NOV-2011,03-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Avandamet;Metformin,19-MAR-2014,03-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS002070,-,-
11456505,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,18-MAY-2012,03-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Janumet;Amaryl;Byetta;Januvia;Glucophage;Victoza,19-MAR-2014,03-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS002032,-,-
11456496,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,05-AUG-2005,03-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Amaryl;Humalog;Glucovance;Glucophage;Januvia,19-MAR-2014,03-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS002076,-,-
11456492,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,16-APR-2011,03-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Januvia;Metformin,19-MAR-2014,03-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS002087,-,-
11456487,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,02-JAN-2013,03-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin,19-MAR-2014,03-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS002073,-,-
11456481,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,16-AUG-2011,03-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Cycloset;Amaryl;Avandia;Januvia;Lantus;Victoza;Metformin,19-MAR-2014,03-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS002067,-,-
11456467,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,19-MAR-2012,03-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Glucophage;Metformin,19-MAR-2014,03-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS002124,-,-
11456454,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,23-MAR-2011,03-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Glucotrol;Avandia;Canagliflozin;Januvia,19-MAR-2014,03-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS002028,-,-
11456442,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,03-JUL-2008,03-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin,19-MAR-2014,03-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS002029,-,-
11456275,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,03-AUG-2012,03-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin,15-FEB-2014,03-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS001142,-,-
11456268,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,10-AUG-2012,03-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Amaryl;Micronase;Lantus;Novolin Nos;Metformin;Glucophage;Byetta,15-FEB-2014,03-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS001101,-,-
11456174,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,11-NOV-2012,03-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,-,19-MAR-2014,03-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS001983,-,-
11456158,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,21-MAR-2011,03-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin,09-FEB-2014,03-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS000923,-,-
11456151,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,01-MAY-2011,03-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Glucophage;Glucovance;Metformin;Lantus;Avandia,09-FEB-2014,03-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS000921,-,-
11455746,Actos;Actoplus Met,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,02-MAR-2010,03-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Januvia;Metformin,24-JAN-2014,03-SEP-2015,US,Not Specified,US-TAKEDA-2014TUS000569,-,-
11455736,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,22-DEC-2012,03-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Januvia;Metformin,24-DEC-2013,03-SEP-2015,US,Not Specified,US-TAKEDA-2013TUS003349,-,-
11455729,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,28-SEP-2010,03-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Glucophage;Metformin;Glucotrol;Starlix;Januvia;Avandia;Byetta;Humalog,18-OCT-2013,03-SEP-2015,US,Not Specified,US-TAKEDA-2013TUS001509,-,-
11455546,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,27-OCT-2010,03-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Avandamet;Januvia;Avandia;Glucotrol,05-DEC-2013,03-SEP-2015,US,Not Specified,US-TAKEDA-2013TUS002873,-,-
11455515,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,OCT-2011,03-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Januvia,18-SEP-2013,03-SEP-2015,US,Not Specified,US-TAKEDA-2013TUS000696,-,-
11455503,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,2005,03-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Avandia;Glucophage;Metformin,30-AUG-2013,03-SEP-2015,US,Not Specified,US-TAKEDA-2013TUS000056,-,-
11455491,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,AUG-2011,03-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Lantus;Metformin;Fortamet;Glucophage;Avandia;Novolog,18-SEP-2013,03-SEP-2015,US,Not Specified,US-TAKEDA-2013TUS000660,-,-
11455483,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Not Specified,2011,03-SEP-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Metformin;Glucotrol;Lantus,10-OCT-2013,03-SEP-2015,US,Not Specified,US-TAKEDA-2013TUS001455,-,-
11288948,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Peripheral Swelling,Non-Serious,Non-Serious,Female,-,21-JUL-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Consumer,Not Specified,-,21-MAY-2015,21-JUL-2015,US,Not Specified,US-TAKEDA-2015TUS006918,-,-
10955453,Glucophage;Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Metformin Hydrochloride,Diabetes Mellitus;Product Used For Unknown Indication,Kidney Infection;Lactic Acidosis,Serious,Life Threatening,Female,08-MAR-2015,13-JUL-2015,Expedited,73 YR,Not Specified,Bristol Myers Squibb,Healthcare Professional,Not Specified,Coumadin;Lasix;Olmesartan Medoxomil,03-JUL-2015,26-MAR-2015,IT,Not Specified,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-017129,-,-
10913421,Competact;Glucophage,Metformin Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Lactic Acidosis;Kidney Infection,Serious,Life Threatening,Female,08-MAR-2015,03-JUL-2015,Expedited,73 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,Olmesartan Medoxomil;Coumadin;Lasix,02-JUL-2015,13-MAR-2015,IT,Not Specified,IT-TAKEDA-2015TEU002283,-,-
11184579,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Therapeutic Product Effect Variable,Non-Serious,Non-Serious,Female,-,11-JUN-2015,Direct,64 YR,Not Specified,-,Healthcare Professional,Health Professional,-,-,11-JUN-2015,Not Specified,Not Specified,-,-,-
10941693,Glipizide Xl;Januvia;Invokana,Canagliflozin;Sitagliptin Phosphate;Metformin Hydrochloride\Pioglitazone Hydrochloride;Glipizide,Hypercholesterolaemia;Hypertension;Type 2 Diabetes Mellitus,Blood Creatinine Increased;Renal Impairment,Serious,Other Outcomes,Male,2014,24-MAY-2015,Non-Expedited,Not Specified,77.11 KG,Janssen,Healthcare Professional,Not Specified,Crestor;Hydrochlorothiazide;Irbesartan;Nitrostat;Carvedilol,11-AUG-2014,22-MAR-2015,US,Not Specified,US-JNJFOC-20140711645,-,-
11038358,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Glyburide\Metformin Hydrochloride,Hypertension;Type 2 Diabetes Mellitus,Hyperkalaemia;Drug Abuse;Lactic Acidosis;Acute Kidney Injury,Serious,Life Threatening;Other Outcomes,Male,10-MAR-2015,12-MAY-2015,Expedited,66 YR,65 KG,Takeda,Healthcare Professional,Not Specified,Hydrochlorothiazide\Losartan Potassium,07-MAY-2015,16-APR-2015,IT,Not Specified,IT-TAKEDA-2015TEU003311,-,-
10990237,Actoplus Met;Uloric,Febuxostat;Metformin Hydrochloride\Pioglitazone Hydrochloride;Allopurinol,-,Bladder Cancer;Liver Disorder;Fatigue;Weight Decreased,Serious,Other Outcomes;Required Intervention,Male,08-MAY-2013,26-FEB-2015,Non-Expedited,64 YR,238 LB,Takeda,Not Specified,"Consumer,Health Professional",Lisinopril;Metformin Hydrochloride;Januvia;Norco,09-MAY-2013,26-FEB-2015,Not Specified,Not Specified,TPA2012A06142,-,-
10989982,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Male,JAN-2012,26-FEB-2015,Non-Expedited,52 YR,Not Specified,Takeda,Healthcare Professional,Health Professional,Metformin;Glimepiride;Aspirin;Lescol;Diovan,12-APR-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A01288,-,-
10989977,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Male,OCT-2010,26-FEB-2015,Non-Expedited,55 YR,165 LB,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Lantus;Avandia;Januvia;Novolog;Metformin Hydrochloride,12-OCT-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A05601,-,-
10989969,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Male,JUL-2012,26-FEB-2015,Non-Expedited,57 YR,240 LB,Takeda,Healthcare Professional,"Consumer,Health Professional",Metformin,25-OCT-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A07009,-,-
10979227,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Male,NOV-2013,26-FEB-2015,Non-Expedited,62 YR,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,10-JUN-2014,26-FEB-2015,Not Specified,Not Specified,2014TUS004758,-,-
10979193,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Male,MAY-2009,26-FEB-2015,Non-Expedited,64 YR,Not Specified,Takeda,Not Specified,"Company Representative ,Consumer,Health Professional",Onglyza;Glucotrol;Avandaryl;Metformin,02-AUG-2013,26-FEB-2015,Not Specified,Not Specified,TPA2013A05471,-,-
10976727,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Male,-,26-FEB-2015,Non-Expedited,69 YR,70.7 KG,Takeda,Healthcare Professional,Health Professional,Avandia,30-DEC-2013,26-FEB-2015,Not Specified,Not Specified,2013TUS002593,-,-
10976718,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Male,06-MAR-2012,26-FEB-2015,Non-Expedited,88 YR,102.9 KG,Takeda,Healthcare Professional,Health Professional,Glucophage;Glucotrol;Metformin;Lantus,12-AUG-2014,26-FEB-2015,Not Specified,Not Specified,TPA2013A7455,-,-
10976712,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Female,03-AUG-2011,26-FEB-2015,Non-Expedited,66 YR,95.2 KG,Takeda,Healthcare Professional,Health Professional,-,28-AUG-2014,26-FEB-2015,Not Specified,Not Specified,TPA2013A07481,-,-
10974310,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Female,NOV-2006,26-FEB-2015,Non-Expedited,64 YR,118.8 KG,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Metformin;Januvia;Lantus;Avandia;Glucophage,08-AUG-2013,26-FEB-2015,Not Specified,Not Specified,TPA2013A03437,-,-
10964441,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Male,15-NOV-2010,26-FEB-2015,Non-Expedited,67 YR,205 LB,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Atorvastatin Calcium;Valsartan;Glimepiride;Omeprazole;Aspirin;Sitagliptin Phosphate,25-JUL-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A01494,-,-
10960201,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Female,MAY-2006,26-FEB-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Consumer,"Consumer,Health Professional",-,11-APR-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A02033,-,-
10960200,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes;Required Intervention,Not Specified,-,26-FEB-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Consumer,Consumer,-,19-JUL-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A04386,-,-
10960196,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Non-Serious,Non-Serious,Not Specified,-,26-FEB-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Consumer,"Company Representative ,Consumer",-,19-JUL-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A04385,-,-
10957154,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Male,02-APR-2010,26-FEB-2015,Non-Expedited,65 YR,285 LB,Takeda,Not Specified,"Company Representative ,Consumer,Health Professional",Glucophage;Metformin Hydrochloride;Allopurinol;Aspirin,25-OCT-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A03418,-,-
10957141,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Bladder Cancer;Blood Urine Present;Urinary Tract Pain,Serious,Required Intervention;Hospitalized;Other Outcomes,Male,JAN-2010,26-FEB-2015,Non-Expedited,70 YR,155 LB,Takeda,Consumer,"Consumer,Health Professional",Novolog;Levemir;Lisinopril;Crestor,26-JUN-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A03302,-,-
10957137,Metformin;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Metformin Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer;Bladder Transitional Cell Carcinoma Recurrent;Bladder Transitional Cell Carcinoma,Serious,Required Intervention;Other Outcomes,Male,12-JUN-2009,26-FEB-2015,Non-Expedited,72 YR,225 LB,Takeda,Not Specified,"Company Representative ,Consumer,Health Professional",Glucotrol;Lantus,15-NOV-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A02972,-,-
10957132,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes;Required Intervention,Male,MAR-2012,26-FEB-2015,Non-Expedited,66 YR,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,16-MAY-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A02927,-,-
10957123,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer;Haematuria,Serious,Other Outcomes;Required Intervention,Male,JAN-2011,26-FEB-2015,Non-Expedited,69 YR,183 LB,Takeda,Not Specified,"Company Representative ,Health Professional",-,30-MAY-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A02390,-,-
10957110,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Bladder Neoplasm,Serious,Required Intervention;Other Outcomes,Male,-,26-FEB-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Not Specified,"Company Representative ,Health Professional",-,04-APR-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A01965,-,-
10957098,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Hip Fracture;Oedema Peripheral;Blood Glucose Increased;Drug Ineffective,Serious,Hospitalized,Female,NOV-2011,26-FEB-2015,Non-Expedited,83 YR,180 LB,Takeda,Consumer,Consumer,-,02-APR-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A01837,-,-
10957088,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Male,MAY-2011,26-FEB-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Consumer,"Company Representative ,Consumer",-,29-MAR-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A01761,-,-
10956929,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer;Urinary Tract Infection;Cystitis,Serious,Other Outcomes;Required Intervention,Female,23-JUN-2011,26-FEB-2015,Non-Expedited,Not Specified,260 LB,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Glucotrol;Metformin,02-AUG-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A01638,-,-
10956795,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Male,08-NOV-2011,26-FEB-2015,Non-Expedited,72 YR,81.6 KG,Takeda,Healthcare Professional,Health Professional,Amaryl;Prandin;Novolog;Byetta;Levemir;Metformin;Lantus,28-AUG-2014,26-FEB-2015,Not Specified,Not Specified,TPA2013A07533,-,-
10956236,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Non-Serious,Non-Serious,Male,07-APR-2010,26-FEB-2015,Non-Expedited,71 YR,214 LB,Takeda,Consumer,"Company Representative ,Consumer",Glucotrol;Amaryl;Byetta;Metformin;Avandia,22-OCT-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A08583,-,-
10956235,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer Recurrent,Serious,Required Intervention;Other Outcomes,Male,2010,26-FEB-2015,Non-Expedited,79 YR,147 LB,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Metformin;Novolog;Janumet,27-NOV-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A08525,-,-
10956229,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes;Required Intervention,Male,29-JUN-2010,26-FEB-2015,Non-Expedited,62 YR,301 LB,Takeda,Not Specified,"Company Representative ,Consumer,Health Professional",Amaryl,04-JAN-2013,26-FEB-2015,Not Specified,Not Specified,TPA2012A08092,-,-
10956221,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Male,12-SEP-2011,26-FEB-2015,Non-Expedited,58 YR,205 LB,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,07-JAN-2013,26-FEB-2015,Not Specified,Not Specified,TPA2012A07686,-,-
10956206,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Male,06-OCT-2010,26-FEB-2015,Non-Expedited,72 YR,280 LB,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Metformin;Amaryl,11-JAN-2013,26-FEB-2015,Not Specified,Not Specified,TPA2012A07250,-,-
10956196,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes;Required Intervention,Male,AUG-2010,26-FEB-2015,Non-Expedited,67 YR,195 LB,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Metformin;Janumet,08-JAN-2013,26-FEB-2015,Not Specified,Not Specified,TPA2012A06902,-,-
10956187,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Male,2009,26-FEB-2015,Non-Expedited,73 YR,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Glucotrol;Metformin,14-NOV-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A04725,-,-
10956174,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes;Required Intervention,Male,18-DEC-2008,26-FEB-2015,Non-Expedited,66 YR,190 LB,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Glucotrol,02-NOV-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A04681,-,-
10956166,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes;Required Intervention,Male,MAY-2011,26-FEB-2015,Non-Expedited,67 YR,260 LB,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Glucophage;Amaryl,14-NOV-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A04657,-,-
10956159,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Male,19-JUN-2008,26-FEB-2015,Non-Expedited,65 YR,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Metformin,23-JUL-2013,26-FEB-2015,Not Specified,Not Specified,TPA2013A03668,-,-
10956155,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Male,MAY-2009,26-FEB-2015,Non-Expedited,75 YR,200 LB,Takeda,Not Specified,"Company Representative ,Consumer,Health Professional",Prandin;Diabeta;Metformin;Glucophage;Avandia;Januvia;Byetta;Glucotrol,25-JUL-2013,26-FEB-2015,Not Specified,Not Specified,TPA2013A03387,-,-
10956150,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes;Required Intervention,Female,JUL-2009,26-FEB-2015,Non-Expedited,62 YR,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Metformin;Januvia,07-JUN-2013,26-FEB-2015,Not Specified,Not Specified,TPA2013A02958,-,-
10956142,Actoplus Met;Glucotrol;Actos,Pioglitazone Hydrochloride;Glipizide;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Transitional Cell Carcinoma,Serious,Required Intervention;Other Outcomes,Male,03-JAN-2011,26-FEB-2015,Non-Expedited,68 YR,173.5 LB,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Metformin;Starlix,05-JUN-2013,26-FEB-2015,Not Specified,Not Specified,TPA2013A01816,-,-
10956129,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Male,NOV-2007,26-FEB-2015,Non-Expedited,63 YR,Not Specified,Takeda,Not Specified,"Company Representative ,Consumer,Health Professional",Metformin;Avandia,24-JUL-2013,26-FEB-2015,Not Specified,Not Specified,TPA2013A01687,-,-
10956121,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes;Required Intervention,Male,AUG-2011,26-FEB-2015,Non-Expedited,73 YR,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Metformin;Glucophage,12-FEB-2013,26-FEB-2015,Not Specified,Not Specified,TPA2013A01497,-,-
10956112,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes;Required Intervention,Male,16-FEB-2012,26-FEB-2015,Non-Expedited,62 YR,220 LB,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Amaryl;Metformin;Janumet;Lantus,31-JAN-2013,26-FEB-2015,Not Specified,Not Specified,TPA2013A01200,-,-
10956102,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes;Required Intervention,Male,02-MAR-2011,26-FEB-2015,Non-Expedited,72 YR,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Januvia;Metformin Hydrochloride,04-MAR-2013,26-FEB-2015,Not Specified,Not Specified,TPA2013A01194,-,-
10956095,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer Stage Iii,Serious,Required Intervention;Other Outcomes,Male,FEB-2011,26-FEB-2015,Non-Expedited,68 YR,Not Specified,Takeda,Not Specified,"Company Representative ,Consumer,Health Professional",Metformin Hydrochloride;Avandia,04-MAR-2013,26-FEB-2015,Not Specified,Not Specified,TPA2013A01172,-,-
10956086,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes;Required Intervention,Male,04-JAN-2012,26-FEB-2015,Non-Expedited,69 YR,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",Metformin,26-FEB-2013,26-FEB-2015,Not Specified,Not Specified,TPA2013A01066,-,-
10956031,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer Recurrent,Serious,Required Intervention;Other Outcomes,Male,28-NOV-2007,26-FEB-2015,Non-Expedited,59 YR,173 LB,Takeda,Healthcare Professional,"Company Representative ,Health Professional",Diabeta;Avandia;Metformin,22-APR-2013,26-FEB-2015,Not Specified,Not Specified,TPA2013A00805,-,-
10956015,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes;Required Intervention,Female,03-AUG-2009,26-FEB-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Not Specified,"Company Representative ,Consumer",-,08-JAN-2013,26-FEB-2015,Not Specified,Not Specified,TPA2012A00698,-,-
10956007,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Male,MAY-2012,26-FEB-2015,Non-Expedited,63 YR,Not Specified,Takeda,Not Specified,"Company Representative ,Consumer,Health Professional",Metformin;Januvia,03-APR-2013,26-FEB-2015,Not Specified,Not Specified,TPA2012A09990,-,-
10955965,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Male,AUG-2011,26-FEB-2015,Non-Expedited,63 YR,216 LB,Takeda,Not Specified,"Company Representative ,Consumer,Health Professional",Metformin;Januvia;Amaryl,29-JAN-2013,26-FEB-2015,Not Specified,Not Specified,TPA2012A09676,-,-
10955947,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Female,29-DEC-2011,26-FEB-2015,Non-Expedited,50 YR,225 LB,Takeda,Not Specified,"Company Representative ,Consumer,Health Professional",-,28-NOV-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A09552,-,-
10955943,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Female,08-MAY-2008,26-FEB-2015,Non-Expedited,66 YR,240 LB,Takeda,Not Specified,"Company Representative ,Consumer,Health Professional",Novolog;Levemir;Glipizide;Glucophage;Byetta,03-JAN-2013,26-FEB-2015,Not Specified,Not Specified,TPA2012A09362,-,-
10955929,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Transitional Cell Carcinoma,Serious,Other Outcomes;Required Intervention,Male,04-DEC-2007,26-FEB-2015,Non-Expedited,60 YR,225 LB,Takeda,Not Specified,"Company Representative ,Consumer,Health Professional",Metformin;Glipizide;Glucophage,03-JAN-2013,26-FEB-2015,Not Specified,Not Specified,TPA2012A09355,-,-
10955920,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Female,23-FEB-2007,26-FEB-2015,Non-Expedited,57 YR,252 LB,Takeda,Not Specified,"Company Representative ,Consumer,Health Professional",Glucophage;Metformin;Janumet,31-DEC-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A09272,-,-
10955911,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Male,02-JUL-2010,26-FEB-2015,Non-Expedited,65 YR,240 LB,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Metformin;Lantus,26-DEC-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A09174,-,-
10955903,Metformin;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Metformin Hydrochloride,-,Urinary Tract Infection;Bladder Cancer,Serious,Required Intervention;Other Outcomes,Female,NOV-2010,26-FEB-2015,Non-Expedited,50 YR,248 LB,Takeda,Healthcare Professional,"Company Representative ,Health Professional",Amaryl;Glucophage,05-NOV-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A08964,-,-
10955869,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes;Required Intervention,Male,07-APR-2009,26-FEB-2015,Non-Expedited,47 YR,190 LB,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Glucophage;Amaryl;Metformin,19-OCT-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A03779,-,-
10955862,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes;Required Intervention,Male,14-JUL-2006,26-FEB-2015,Non-Expedited,63 YR,200 LB,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Metformin;Januvia;Insulin Nos,31-OCT-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A03692,-,-
10955808,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes;Required Intervention,Male,NOV-2011,26-FEB-2015,Non-Expedited,55 YR,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Metformin;Januvia,01-NOV-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A03412,-,-
10955766,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer Recurrent,Serious,Other Outcomes;Required Intervention,Male,08-JAN-2008,26-FEB-2015,Non-Expedited,56 YR,290 LB,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Januvia;Metformin;Lantus;Byetta,06-NOV-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A02948,-,-
10955742,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Male,01-NOV-2010,26-FEB-2015,Non-Expedited,54 YR,265 LB,Takeda,Healthcare Professional,Health Professional,Amaryl;Metformin;Januvia,15-NOV-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A01815,-,-
10955734,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Male,03-MAR-2011,26-FEB-2015,Non-Expedited,60 YR,190 LB,Takeda,Not Specified,"Company Representative ,Consumer,Health Professional",Diabeta;Metformin,01-NOV-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A01411,-,-
10955728,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes;Required Intervention,Male,2009,26-FEB-2015,Non-Expedited,72 YR,Not Specified,Takeda,Not Specified,"Company Representative ,Consumer,Health Professional",Metformin,01-NOV-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A01366,-,-
10954774,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Urinary Tract Infection;Haematuria;Bladder Papilloma;Bladder Cancer,Serious,Other Outcomes;Required Intervention,Male,JUN-2010,26-FEB-2015,Non-Expedited,71 YR,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Metformin;Glucophage;Byetta;Lantus;Januvia;Amaryl,25-JUL-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A01318,-,-
10953974,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Male,13-NOV-2009,26-FEB-2015,Non-Expedited,65 YR,205 LB,Takeda,Not Specified,"Company Representative ,Consumer,Health Professional",-,31-OCT-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A05216,-,-
10951086,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Oedema Peripheral,Serious,Hospitalized,Female,-,26-FEB-2015,Non-Expedited,9 DEC,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,30-JAN-2009,26-FEB-2015,Not Specified,Not Specified,TPA2009A00169,-,-
10951061,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Upper Limb Fracture,Serious,Hospitalized,Female,28-JUL-2010,26-FEB-2015,Non-Expedited,52 YR,230 LB,Takeda,Not Specified,Consumer,Simvastatin;Cozaar;Tricor;Neurontin;Prozac;Tenormin,16-AUG-2010,26-FEB-2015,Not Specified,Not Specified,TPA2010A04531,-,-
10951057,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Cardiac Failure Congestive,Serious,Hospitalized,Not Specified,-,26-FEB-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,04-MAY-2010,26-FEB-2015,Not Specified,Not Specified,TPA2010A02616,-,-
10951053,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Hypothermia;Shock;Lactic Acidosis;Hypotension,Serious,Life Threatening;Hospitalized,Male,01-FEB-2010,26-FEB-2015,Non-Expedited,72 YR,152 LB,Takeda,Healthcare Professional,"Company Representative ,Health Professional",Aspirin;Diovan;Avodart,04-MAY-2010,26-FEB-2015,Not Specified,Not Specified,TPA2010A00666,-,-
10951052,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Cardiac Failure Congestive,Serious,Required Intervention;Other Outcomes,Female,-,26-FEB-2015,Non-Expedited,70 YR,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,10-DEC-2009,26-FEB-2015,Not Specified,Not Specified,TPA2009A04154,-,-
10951049,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Upper Limb Fracture,Serious,Other Outcomes;Required Intervention,Female,20-AUG-2009,26-FEB-2015,Non-Expedited,51 YR,216 LB,Takeda,Consumer,Consumer,Lisinopril;Simvastatin;Atenolol,20-OCT-2009,26-FEB-2015,Not Specified,Not Specified,TPA2009A03326,-,-
10951042,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes;Required Intervention,Female,13-FEB-2012,26-FEB-2015,Non-Expedited,74 YR,205 LB,Takeda,Healthcare Professional,"Consumer,Health Professional",Amaryl,17-JUL-2013,26-FEB-2015,Not Specified,Not Specified,TPA2013A04437,-,-
10951041,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes;Required Intervention,Male,24-MAY-2012,26-FEB-2015,Non-Expedited,77 YR,165 LB,Takeda,Not Specified,"Company Representative ,Consumer,Health Professional",Metformin;Avandia;Glucophage;Januvia,16-JUL-2013,26-FEB-2015,Not Specified,Not Specified,TPA2013A04131,-,-
10951036,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes;Died,Female,NOV-2010,26-FEB-2015,Non-Expedited,69 YR,Not Specified,Takeda,Not Specified,"Company Representative ,Consumer,Health Professional",Metformin,20-APR-2013,26-FEB-2015,Not Specified,Not Specified,TPA2013A02962,-,-
10951032,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer Recurrent,Serious,Required Intervention;Other Outcomes;Died,Male,MAY-2008,26-FEB-2015,Non-Expedited,64 YR,180 LB,Takeda,Not Specified,"Company Representative ,Consumer,Health Professional",Avandia;Amaryl;Metformin,18-JUN-2013,26-FEB-2015,Not Specified,Not Specified,TPA2013A02026,-,-
10951018,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Pollakiuria;Micturition Urgency;Chromaturia,Serious,Required Intervention;Other Outcomes,Male,-,26-FEB-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Not Specified,"Company Representative ,Consumer,Health Professional",-,07-NOV-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A09038,-,-
10951002,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Died;Other Outcomes;Required Intervention,Female,MAY-2010,26-FEB-2015,Non-Expedited,56 YR,105 LB,Takeda,Not Specified,"Company Representative ,Consumer,Health Professional",-,13-NOV-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A02355,-,-
10950980,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Male,01-MAY-2009,26-FEB-2015,Non-Expedited,58 YR,180 LB,Takeda,Not Specified,"Company Representative ,Consumer,Health Professional",Byetta;Lantus;Metformin;Amaryl;Avandia;Humalog,26-JUL-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A05016,-,-
10950964,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Depression;Urinary Retention;Bladder Cancer,Serious,Required Intervention;Other Outcomes,Male,11-FEB-2008,26-FEB-2015,Non-Expedited,63 YR,Not Specified,Takeda,Not Specified,"Company Representative ,Consumer,Health Professional",Glimepiride;Lisinopril;Glyburide;Insulin Glargine;Exenatide,31-JUL-2012,26-FEB-2015,Not Specified,Not Specified,TPA2012A03481,-,-
10950357,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes;Required Intervention,Female,30-JUL-2012,26-FEB-2015,Non-Expedited,74 YR,120 LB,Takeda,Healthcare Professional,"Company Representative ,Health Professional",Avandia;Metformin,24-JUL-2013,26-FEB-2015,Not Specified,Not Specified,TPA2013A04880,-,-
10950344,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes;Required Intervention,Male,20-FEB-2009,26-FEB-2015,Non-Expedited,80 YR,162 LB,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Januvia;Lantus;Amaryl;Metformin;Prandin,17-JUL-2013,26-FEB-2015,Not Specified,Not Specified,TPA2013A04618,-,-
10950320,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Cardiac Failure Congestive;Cerebrovascular Accident,Serious,Hospitalized;Required Intervention;Other Outcomes,Male,2009,26-FEB-2015,Non-Expedited,57 YR,Not Specified,Takeda,Healthcare Professional,Health Professional,Lantus;Diltiazem,28-AUG-2009,26-FEB-2015,Not Specified,Not Specified,TPA2009A02525,-,-
10950310,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Cardiac Failure Congestive,Serious,Required Intervention;Other Outcomes,Male,APR-2008,26-FEB-2015,Non-Expedited,69 YR,Not Specified,Takeda,Healthcare Professional,Health Professional,Metformin;Humalog;Lantus;Glipizide;Iron;Novolog,10-APR-2009,26-FEB-2015,Not Specified,Not Specified,TPA2009A00582,-,-
10950297,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Vomiting;Gastroenteritis Viral;Loss Of Consciousness;Hypoglycaemia,Serious,Hospitalized,Female,-,26-FEB-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",Lantus,25-MAR-2009,26-FEB-2015,Not Specified,Not Specified,TPA2009A00486,-,-
8942395,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Weight Abnormal;Hypoaesthesia;Prostate Cancer,Serious,Required Intervention;Other Outcomes,Male,-,26-FEB-2015,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",-,08-NOV-2012,21-NOV-2012,Not Specified,Not Specified,TPA2012A09097,-,-
8859045,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Died;Required Intervention;Other Outcomes,Female,29-MAR-2010,26-FEB-2015,Non-Expedited,53 YR,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Metformin,05-NOV-2012,23-OCT-2012,Not Specified,Not Specified,TPA2012A07997,-,-
8851653,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Urinary Tract Infection;Renal Cancer,Serious,Required Intervention;Other Outcomes,Female,OCT-2008,26-FEB-2015,Non-Expedited,53 YR,170 LB,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Metformin;Diabeta,12-NOV-2012,17-OCT-2012,Not Specified,Not Specified,TPA2012A07922,-,-
8326736,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Died;Required Intervention;Other Outcomes,Male,14-NOV-2010,26-FEB-2015,Non-Expedited,68 YR,Not Specified,Takeda,Not Specified,"Company Representative ,Consumer,Health Professional",Onglyza;Avandia;Metformin,07-SEP-2012,29-DEC-2011,Not Specified,Not Specified,TPA2011A08476,-,-
8292395,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Pulmonary Oedema;Bladder Transitional Cell Carcinoma;Haematuria;Abdominal Pain,Serious,Required Intervention;Hospitalized;Other Outcomes,Female,11-NOV-2010,26-FEB-2015,Non-Expedited,79 YR,180 LB,Takeda,Healthcare Professional,"Company Representative ,Health Professional",Norvasc;Amlodipine;Metformin;Keflex;Elavil;Timolol;Glyburide,14-MAR-2012,09-DEC-2011,Not Specified,Not Specified,TPA2011A08079,-,-
8283853,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Male,03-JAN-2008,26-FEB-2015,Non-Expedited,50 YR,230 LB,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Metformin;Byetta,31-OCT-2012,05-DEC-2011,Not Specified,Not Specified,TPA2011A07869,-,-
8249136,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes;Required Intervention,Female,2009,26-FEB-2015,Non-Expedited,80 YR,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Glucotrol;Avandia;Metformin;Glucophage,16-JAN-2013,14-NOV-2011,Not Specified,Not Specified,TPA2011A07233,-,-
8243080,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Male,JUN-2011,26-FEB-2015,Non-Expedited,72 YR,240 LB,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Metformin,07-SEP-2012,08-NOV-2011,Not Specified,Not Specified,TPA2011A07032,-,-
8215346,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes;Required Intervention,Male,MAY-2011,26-FEB-2015,Non-Expedited,72 YR,180 LB,Takeda,Not Specified,"Company Representative ,Consumer,Health Professional",Metformin;Avandia,04-SEP-2012,24-OCT-2011,Not Specified,Not Specified,TPA2011A06584,-,-
8168288,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes;Required Intervention,Male,APR-2011,26-FEB-2015,Non-Expedited,70 YR,Not Specified,Takeda,Not Specified,"Company Representative ,Consumer,Health Professional",Levemir;Avandia;Metformin;Januvia,31-JAN-2013,26-SEP-2011,Not Specified,Not Specified,TPA2011A05710,-,-
8161774,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Dysuria;Haematuria;Bladder Cancer Recurrent;Pollakiuria;Bladder Cancer;Abdominal Discomfort;Urinary Tract Infection;Bladder Transitional Cell Carcinoma,Serious,Hospitalized;Other Outcomes;Required Intervention,Male,MAY-2009,26-FEB-2015,Non-Expedited,68 YR,112.3 KG,Takeda,Not Specified,"Company Representative ,Consumer,Health Professional",Cytoxan;Amaryl;Metformin Hydrochloride,26-SEP-2012,21-SEP-2011,Not Specified,Not Specified,TPA2011A05763,-,-
8097076,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer Recurrent;Bladder Cancer,Serious,Required Intervention;Other Outcomes,Male,JUN-2008,26-FEB-2015,Non-Expedited,43 YR,Not Specified,Takeda,Not Specified,"Company Representative ,Consumer,Health Professional",Levemir;Glucophage;Glucotrol;Metformin,05-NOV-2012,09-AUG-2011,Not Specified,Not Specified,TPA2011A04416,-,-
8062398,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Transitional Cell Carcinoma;Nephrolithiasis;Haematuria;Renal Cyst,Serious,Required Intervention;Other Outcomes,Female,28-MAR-2011,26-FEB-2015,Non-Expedited,82 YR,115 LB,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Fish Oil;Zocor,03-MAY-2012,20-JUL-2011,Not Specified,Not Specified,TPA2011A03775,-,-
10358360,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Diabetes Mellitus,Benign Prostatic Hyperplasia,Non-Serious,Non-Serious,Male,-,16-FEB-2015,Expedited,71 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,-,23-JAN-2015,01-AUG-2014,MX,Not Specified,MX-TAKEDA-2014TJP010061,-,-
10774626,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Diabetes Mellitus Inadequate Control;Bladder Cancer,Serious,Other Outcomes,Male,17-SEP-2012,09-FEB-2015,Expedited,75 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,-,19-JAN-2015,09-FEB-2015,FI,Not Specified,FI-TAKEDA-2015TJP001496,-,-
10358358,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Diabetes Mellitus Management,Prostate Cancer,Serious,Other Outcomes,Male,-,04-FEB-2015,Expedited,75 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,-,23-JAN-2015,01-AUG-2014,MX,Not Specified,MX-TAKEDA-2014TJP010052,-,-
10621459,Pioglitazone Hydrochloride And Metformin Hydrochloride,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Tremor;Dyspnoea;Insomnia,Serious,Hospitalized,Male,-,03-DEC-2014,Expedited,Not Specified,Not Specified,Aurobindo,Consumer,Not Specified,-,01-DEC-2014,03-DEC-2014,US,Not Specified,US-AUROBINDO-AUR-APU-2014-12719,-,-
10622231,Actoplus Met;Starlix,Nateglinide;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus Inadequate Control,Diarrhoea;Rash;Skin Infection;Product Substitution Issue,Serious,Other Outcomes,Female,-,01-DEC-2014,Direct,Not Specified,178 LB,-,Healthcare Professional,Health Professional,-,-,01-DEC-2014,Not Specified,Not Specified,-,-,-
10587149,Amaryl;Competact;Lantus,Insulin Glargine;Metformin Hydrochloride\Pioglitazone Hydrochloride;Glimepiride,Diabetes Mellitus,Hypoglycaemia,Serious,Hospitalized,Male,14-SEP-2014,17-NOV-2014,Expedited,85 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,Rosuvastatin;Bisoprolol,10-NOV-2014,17-NOV-2014,IT,Not Specified,IT-SA-2014SA155316,-,-
10528101,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Melanocytic Naevus,Serious,Other Outcomes,Male,-,20-OCT-2014,Expedited,Not Specified,Not Specified,Takeda,Consumer,Not Specified,-,15-OCT-2014,20-OCT-2014,IT,Not Specified,IT-TAKEDA-2014TEU009047,-,-
10412051,Januvia;Glipizide Xl;Invokana,Canagliflozin;Glipizide;Sitagliptin Phosphate;Metformin Hydrochloride\Pioglitazone Hydrochloride,Hypercholesterolaemia;Hypertension;Type 2 Diabetes Mellitus,Blood Creatinine Increased;Renal Impairment,Serious,Other Outcomes,Male,2014,27-AUG-2014,Expedited,Not Specified,77.98 KG,Merck,Healthcare Professional,Not Specified,Irbesartan;Carvedilol;Nitrostat;Hydrochlorothiazide;Crestor,22-AUG-2014,27-AUG-2014,US,Not Specified,US-009507513-1408USA013778,-,-
10344881,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Carotidynia;Diabetes Mellitus;Hypercholesterolaemia,Pain;Fracture,Serious,Other Outcomes,Female,01-MAR-2014,26-AUG-2014,Expedited,68 YR,58 KG,Takeda,Healthcare Professional,Not Specified,Aspirin Dl-Lysine,18-AUG-2014,28-JUL-2014,IT,Not Specified,IT-TAKEDA-2014TEU006399,-,-
10365967,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Myalgia;Product Substitution Issue;Diarrhoea;Nausea;Headache,Serious,Other Outcomes,Male,04-AUG-2014,05-AUG-2014,Direct,56 YR,205 LB,-,Consumer,Consumer,-,-,05-AUG-2014,Not Specified,Not Specified,-,-,-
10353736,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Product Used For Unknown Indication,Prostate Cancer,Serious,Other Outcomes,Male,-,31-JUL-2014,Expedited,75 YR,Not Specified,Eli Lilly And Co,Healthcare Professional,Not Specified,-,24-JUL-2014,31-JUL-2014,MX,Not Specified,MX-ELI_LILLY_AND_COMPANY-MX201407011221,-,-
10353731,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Product Used For Unknown Indication,Prostate Cancer,Serious,Other Outcomes,Male,-,31-JUL-2014,Expedited,71 YR,Not Specified,Eli Lilly And Co,Healthcare Professional,Not Specified,-,24-JUL-2014,31-JUL-2014,MX,Not Specified,MX-ELI_LILLY_AND_COMPANY-MX201407011200,-,-
10274080,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Papilloma,Serious,Other Outcomes,Male,-,17-JUL-2014,Expedited,63 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,Gliclazide;Carvedilol;Atorvastatin;Clopidogrel,08-JUL-2014,02-JUL-2014,GR,Not Specified,GR-TAKEDA-2014TJP008607,-,-
10276096,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Coronary Artery Disease;Type 2 Diabetes Mellitus,Bladder Papilloma,Serious,Other Outcomes,Male,-,03-JUL-2014,Expedited,63 YR,Not Specified,Eli Lilly And Co,Healthcare Professional,Not Specified,Carvedilol;Clopidogrel;Atorvastatin;Gliclazide,26-JUN-2014,03-JUL-2014,GR,Not Specified,GR-ELI_LILLY_AND_COMPANY-GR201406009517,-,-
9889095,Actos;Metact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Diabetes Mellitus;Hyperlipidaemia;Hypertension,Bladder Cancer,Serious,Other Outcomes;Life Threatening,Male,20-DEC-2013,17-JUN-2014,Expedited,64 YR,85.7 KG,Takeda,Healthcare Professional,Not Specified,Glyburide;Metformin Hydrochloride;Exforge;Amlodipine Besylate\Telmisartan;Lipitor;Icosapent Ethyl;Micardis;Amlodipine Besylate;Diovan;Calblock,03-JUN-2014,11-FEB-2014,JP,Not Specified,JP-TAKEDA-2014TJP001343,-,-
10072072,Competact;Metformin,Metformin Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride;Furosemide;Ramipril,Diabetes Mellitus;Myocardial Ischaemia,Myocardial Ischaemia;Lactic Acidosis;Acute Kidney Injury;Drug Interaction;Dialysis,Serious,Life Threatening;Hospitalized;Other Outcomes,Male,03-FEB-2014,04-JUN-2014,Expedited,64 YR,110 KG,Aurobindo,Healthcare Professional,"Health Professional ,Foreign",Carvedilol;Simvastatin;Levemir;Aspirin,20-MAY-2014,09-APR-2014,Not Specified,Not Specified,AUR-APL-2014-04208,-,-
10209882,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Hyperphagia;Jaundice,Serious,Other Outcomes,Male,-,02-JUN-2014,Expedited,42 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,-,20-MAY-2014,02-JUN-2014,MX,Not Specified,MX-TAKEDA-2014TJP006175,-,-
10059272,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Ramipril;Metformin Hydrochloride;Furosemide,Diabetes Mellitus;Myocardial Ischaemia,Acute Kidney Injury;Drug Interaction;Blood Creatinine Increased;Lactic Acidosis,Serious,Life Threatening;Hospitalized;Other Outcomes,Male,03-FEB-2014,28-MAY-2014,Expedited,64 YR,110 KG,Pfizer,Healthcare Professional,Not Specified,Aspirin;Simvastatin;Carvedilol;Levemir,20-MAY-2014,04-APR-2014,IT,Not Specified,IT-PFIZER INC-2014092164,-,-
10058317,Metformin;Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Ramipril;Metformin Hydrochloride;Furosemide,Diabetes Mellitus;Myocardial Ischaemia,Lactic Acidosis;Drug Interaction;Acute Kidney Injury,Serious,Life Threatening;Hospitalized,Male,03-FEB-2014,28-MAY-2014,Expedited,64 YR,110 KG,Aventis,Healthcare Professional,Not Specified,Carvedilol;Aspirin;Simvastatin;Levemir,21-MAY-2014,04-APR-2014,IT,Not Specified,IT-SA-2014SA041163,-,-
10053126,Metformin;Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Metformin Hydrochloride;Ramipril;Furosemide,Diabetes Mellitus;Myocardial Ischaemia,Lactic Acidosis;Acute Kidney Injury,Serious,Hospitalized;Other Outcomes;Life Threatening,Male,03-FEB-2014,23-MAY-2014,Expedited,64 YR,110 KG,Takeda,Healthcare Professional,Not Specified,Carvedilol;Levemir;Simvastatin;Aspirin,21-MAY-2014,02-APR-2014,IT,Not Specified,IT-TAKEDA-2014TEU002704,-,-
10165439,Actoplus Met;Bydureon;Levemir,Insulin Detemir;Exenatide;Metformin Hydrochloride\Pioglitazone Hydrochloride;Insulin Nos,Diabetes Mellitus;Type 2 Diabetes Mellitus,Injection Site Haemorrhage;Injection Site Bruising;Drug Ineffective;Injection Site Pain,Non-Serious,Non-Serious,Male,2013,10-MAY-2014,Non-Expedited,51 YR,197.73 KG,Bristol Myers Squibb,Consumer,Not Specified,-,19-NOV-2013,10-MAY-2014,US,Not Specified,US-BRISTOL-MYERS SQUIBB COMPANY-19837376,-,-
10150399,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Dehydration;Diarrhoea,Serious,Hospitalized,Male,-,02-MAY-2014,Expedited,50 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,-,25-APR-2014,02-MAY-2014,MX,Not Specified,MX-TAKEDA-2014TJP005567,-,-
10150393,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Diarrhoea;Dehydration,Serious,Hospitalized,Female,-,02-MAY-2014,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,-,25-APR-2014,02-MAY-2014,MX,Not Specified,MX-TAKEDA-2014TJP005548,-,-
10080850,Metformin;Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Ramipril;Furosemide;Metformin Hydrochloride,Diabetes Mellitus;Myocardial Ischaemia;Product Used For Unknown Indication,Lactic Acidosis;Acute Kidney Injury;Drug Interaction,Serious,Life Threatening,Male,03-FEB-2014,16-APR-2014,Expedited,64 YR,110 KG,Teva,Healthcare Professional,Not Specified,Levemir;Aspirin;Carvedilol,01-APR-2014,16-APR-2014,IT,Not Specified,IT-TEVA-473324ISR,-,-
10079706,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Ramipril;Metformin Hydrochloride;Furosemide,Diabetes Mellitus;Myocardial Ischaemia;Product Used For Unknown Indication,Drug Interaction;Lactic Acidosis;Acute Kidney Injury,Serious,Life Threatening,Male,03-FEB-2014,15-APR-2014,Expedited,64 YR,110 KG,Watson,Healthcare Professional,Not Specified,Carvedilol;Aspirin;Simvastatin;Levemir,01-APR-2014,15-APR-2014,IT,Not Specified,IT-WATSON-2014-07314,-,-
10077177,Metformin;Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Ramipril;Metformin Hydrochloride;Furosemide,Diabetes Mellitus;Myocardial Ischaemia;Product Used For Unknown Indication,Acute Kidney Injury;Lactic Acidosis;Drug Interaction,Serious,Life Threatening,Male,03-FEB-2014,14-APR-2014,Expedited,64 YR,110 KG,Mylan,Healthcare Professional,Not Specified,Aspirin;Simvastatin;Levemir;Carvedilol,01-APR-2014,14-APR-2014,IT,Not Specified,IT-MYLANLABS-2014S1007811,-,-
10071192,Competact;Metformin,Metformin Hydrochloride;Ramipril;Metformin Hydrochloride\Pioglitazone Hydrochloride;Furosemide,Diabetes Mellitus;Myocardial Ischaemia,Lactic Acidosis;Acute Kidney Injury,Serious,Life Threatening,Male,03-FEB-2014,10-APR-2014,Expedited,Not Specified,Not Specified,Sandoz,Healthcare Professional,Not Specified,Carvedilol;Simvastatin;Aspirin;Levemir,01-APR-2014,10-APR-2014,IT,Not Specified,PHHY2014IT040281,-,-
10071035,Moduretic 5-50,Amiloride Hydrochloride\Hydrochlorothiazide;Repaglinide;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Hypertension;Product Used For Unknown Indication,Malaise;Hypoglycaemia;Hyponatraemia,Serious,Other Outcomes,Female,08-FEB-2014,10-APR-2014,Expedited,76 YR,Not Specified,Actavis,Healthcare Professional,Not Specified,Calcium Carbonate\Vitamin D;Plavix;Perindopril Erbumine,27-MAR-2014,10-APR-2014,IT,Not Specified,IT-ACTAVIS-2014-06847,-,-
9839224,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Cardiac Failure;Septic Shock;Pneumonia,Serious,Other Outcomes;Died,Female,29-DEC-2013,09-APR-2014,Expedited,87 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,-,01-APR-2014,23-JAN-2014,MX,Not Specified,MX-TAKEDA-2014TJP000732,-,-
10063509,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Septic Shock;Cardiac Failure;Pneumonia,Serious,Died,Female,29-DEC-2013,07-APR-2014,Expedited,87 YR,Not Specified,Eli Lilly And Co,Healthcare Professional,Not Specified,-,01-APR-2014,07-APR-2014,MX,Not Specified,MX-ELI_LILLY_AND_COMPANY-MX201401006581,-,-
10055626,Metformin;Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Metformin Hydrochloride;Ramipril;Furosemide,Diabetes Mellitus;Myocardial Ischaemia;Product Used For Unknown Indication,Lactic Acidosis;Drug Interaction;Acute Kidney Injury,Serious,Life Threatening;Other Outcomes,Male,03-FEB-2014,03-APR-2014,Expedited,64 YR,110 KG,Dr Reddys,Healthcare Professional,Not Specified,Aspirin;Simvastatin;Carvedilol,31-MAR-2014,03-APR-2014,IT,Not Specified,IT-DRREDDYS-GER/ITL/14/0039344,-,-
9916683,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Anaphylactic Reaction;Rash,Serious,Other Outcomes,Male,JAN-2014,05-MAR-2014,Expedited,67 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,Amlodipine,25-FEB-2014,21-FEB-2014,GR,Not Specified,GR-TAKEDA-2014TJP001684,-,-
9915144,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Hypertension;Type 2 Diabetes Mellitus,Anaphylactic Reaction;Rash,Serious,Other Outcomes,Male,JAN-2014,28-FEB-2014,Expedited,67 YR,Not Specified,Eli Lilly And Co,Healthcare Professional,Not Specified,Amlodipine,25-FEB-2014,20-FEB-2014,GR,Not Specified,GR-ELI_LILLY_AND_COMPANY-GR201402004560,-,-
9833147,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Stomatitis;Dry Mouth;Lip Infection,Non-Serious,Non-Serious,Not Specified,2013,30-JAN-2014,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,-,23-JAN-2014,21-JAN-2014,GR,Not Specified,GR-TAKEDA-2014TJP000579,-,-
9822864,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Dry Mouth;Stomatitis;Lip Infection,Non-Serious,Non-Serious,Male,2013,30-JAN-2014,Expedited,65 YR,Not Specified,Eli Lilly And Co,Healthcare Professional,Not Specified,-,23-JAN-2014,16-JAN-2014,GR,Not Specified,GR-ELI_LILLY_AND_COMPANY-GR201401003867,-,-
9781609,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Death,Serious,Died,Not Specified,27-NOV-2013,24-DEC-2013,Expedited,Not Specified,Not Specified,Takeda,Consumer,Not Specified,-,17-DEC-2013,24-DEC-2013,MX,Not Specified,MX-TAKEDA-2013TJP003968,-,-
9730162,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Muscle Contusion;Nephrotic Syndrome,Serious,Disabled,Female,30-MAY-2012,04-DEC-2013,Expedited,65 YR,104 KG,Takeda,Healthcare Professional,Not Specified,Apidra;Amlodipine Besylate\Telmisartan;Crestor,28-NOV-2013,04-DEC-2013,JP,Not Specified,JP-TAKEDA-2013TJP000109,-,-
9729844,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Sinus Tachycardia;Type 2 Diabetes Mellitus,Hypertensive Encephalopathy,Serious,Other Outcomes,Female,14-MAR-2013,04-DEC-2013,Expedited,61 YR,68 KG,Takeda,Healthcare Professional,Not Specified,Humalog;Atenolol;Diphenidol Hydrochloride;Lipitor;Januvia;Unspecified Ingredient,28-NOV-2013,04-DEC-2013,JP,Not Specified,JP-TAKEDA-2013TJP000470,-,-
9684650,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Heat Illness,Serious,Hospitalized,Male,25-JUL-2013,29-NOV-2013,Expedited,63 YR,74 KG,Takeda,Healthcare Professional,Not Specified,Calblock;Allopurinol;Zetia;Pravastatin Sodium;Omeprazole,22-NOV-2013,12-NOV-2013,JP,Not Specified,JP-TAKEDA-2013TJP002647,-,-
9668247,Pioglitazone Hydrochloride And Metformin Hydrochloride,Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Loss Of Consciousness,Serious,Other Outcomes,Not Specified,-,26-NOV-2013,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Foreign",-,21-NOV-2013,04-NOV-2013,JP,Not Specified,JP-TAKEDA-2013TJP002395,-,-
9611621,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Glimepiride,Diabetes Mellitus;Giant Cell Arteritis,Hypoglycaemic Coma;Bradyphrenia;Hyperhidrosis,Serious,Hospitalized;Other Outcomes,Female,28-AUG-2013,21-NOV-2013,Expedited,89 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,Aspirin;Lorazepam;Omeprazole;Prednisone,15-NOV-2013,10-OCT-2013,IT,Not Specified,IT-TAKEDA-2013TEU001018,-,-
9608626,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Cerebrovascular Accident,Serious,Other Outcomes,Not Specified,-,11-NOV-2013,Expedited,Not Specified,Not Specified,Takeda,Consumer,Not Specified,-,31-OCT-2013,09-OCT-2013,MX,Not Specified,MX-TAKEDA-2013TJP001546,-,-
9676452,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Weight Increased;Pruritus;Visual Impairment;Schizophrenia;Swelling Face,Serious,Other Outcomes,Not Specified,-,07-NOV-2013,Expedited,Not Specified,Not Specified,Takeda,Consumer,Not Specified,-,30-OCT-2013,07-NOV-2013,ES,Not Specified,ES-TAKEDA-2013TJP002466,-,-
9669671,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Weight Increased;Swelling Face;Visual Impairment;Schizophrenia;Pruritus,Serious,Other Outcomes,Female,-,05-NOV-2013,Expedited,65 YR,Not Specified,Eli Lilly And Co,Consumer,Not Specified,-,30-OCT-2013,05-NOV-2013,ES,Not Specified,ES-ELI_LILLY_AND_COMPANY-ES201310010504,-,-
9554023,-,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone,-,Renal Disorder,Serious,Hospitalized,Not Specified,-,05-NOV-2013,Expedited,Not Specified,Not Specified,Takeda,Consumer,Not Specified,-,25-OCT-2013,25-SEP-2013,MX,Not Specified,MX-TAKEDA-2013TJP001082,-,-
9636172,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Death,Serious,Died,Not Specified,-,21-OCT-2013,Expedited,Not Specified,Not Specified,Takeda,Consumer,Not Specified,Linagliptin,14-OCT-2013,21-OCT-2013,MX,Not Specified,MX-TAKEDA-2013TJP001916,-,-
9628030,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Linagliptin\Metformin Hydrochloride,-,Death,Serious,Died,Male,-,16-OCT-2013,Expedited,Not Specified,Not Specified,Boehringer Ingelheim,Consumer,Not Specified,-,14-OCT-2013,16-OCT-2013,MX,Not Specified,"MX-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2013-BI-32715MX",-,-
9611098,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Breast Cancer,Serious,Other Outcomes;Life Threatening;Hospitalized,Female,14-SEP-2012,09-OCT-2013,Expedited,73 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,Miglitol;Lansoprazole;Calblock;Nesina;Simvastatin;Cholecalciferol;Azelnidipine\Olmesartan Medoxomil;Indapamide,03-OCT-2013,09-OCT-2013,JP,Not Specified,JP-TAKEDA-TCI2013A06009,-,-
9610680,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Acute Myocardial Infarction,Serious,Other Outcomes;Hospitalized;Life Threatening,Female,21-SEP-2012,09-OCT-2013,Expedited,79 YR,39 KG,Takeda,Healthcare Professional,Not Specified,Voglibose;Unisia;Bisoprolol Fumarate;Mitiglinide,08-JUL-2013,09-OCT-2013,JP,Not Specified,JP-TAKEDA-TCI2013A04071,-,-
9520210,Humalog,Insulin Lispro;Metformin Hydrochloride\Pioglitazone Hydrochloride,Blood Glucose;Diabetes Mellitus,Drug Ineffective;Hypoglycaemic Unconsciousness;Hyperglycaemia,Serious,Other Outcomes,Not Specified,-,09-OCT-2013,Expedited,Not Specified,Not Specified,Takeda,Consumer,Not Specified,Lantus,06-SEP-2013,12-SEP-2013,MX,Not Specified,MX-TAKEDA-2013TJP000530,-,-
9604927,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Hypertension;Type 2 Diabetes Mellitus,Hypercreatininaemia;Diarrhoea;Lactic Acidosis;Renal Failure;Abdominal Pain;Pyrexia;Cystitis,Serious,Hospitalized;Other Outcomes;Life Threatening,Not Specified,2012,08-OCT-2013,Expedited,Not Specified,Not Specified,Takeda,Consumer,Not Specified,Norvasc,01-OCT-2013,08-OCT-2013,IT,Not Specified,IT-TAKEDA-2013TEU000865,-,-
9604097,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Hypoglycaemia,Serious,Hospitalized,Not Specified,28-AUG-2013,08-OCT-2013,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Levofloxacin;Barnidipine Hydrochloride;Ramipril,04-SEP-2013,08-OCT-2013,IT,Not Specified,IT-TAKEDA-2013TEU000276,-,-
9562697,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Nephrolithiasis,Serious,Hospitalized,Female,JUN-2012,27-SEP-2013,Expedited,50 YR,71 KG,Takeda,Healthcare Professional,Not Specified,Voglibose;Metgluco,25-SEP-2013,27-SEP-2013,JP,Not Specified,JP-TAKEDA-2013TJP000361,-,-
9562353,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Hypoglycaemia;Acute Kidney Injury;Lactic Acidosis,Serious,Life Threatening;Other Outcomes,Not Specified,17-JUL-2013,27-SEP-2013,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Tramadol Hydrochloride;Tenormin;Nadroparin Calcium;Atorvastatin;Irbesartan;Deponit;Lasix;Omeprazole Sodium;Domperidone;Acetaminophen\Codeine Phosphate,19-SEP-2013,27-SEP-2013,IT,Not Specified,IT-TAKEDA-TIF2013A00123,-,-
9552331,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Transitional Cell Carcinoma;Albuminuria,Serious,Other Outcomes,Not Specified,MAY-2009,25-SEP-2013,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,Amlodipine Besylate;Metformin;Ciprofibrate;Metformin\Sitagliptin;Glimepiride;Sotalol,05-SEP-2013,25-SEP-2013,FR,Not Specified,FR-TAKEDA-LTI2011A00170,-,-
9542709,Pioglitazone Hydrochloride And Metformin Hydrochloride,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Thyroid Cancer,Serious,Other Outcomes,Male,06-NOV-2012,23-SEP-2013,Expedited,64 YR,103 KG,Takeda,Healthcare Professional,Not Specified,Amlodipine Besylate,30-AUG-2013,23-SEP-2013,JP,Not Specified,JP-TAKEDA-TCI2013A04707,-,-
9531910,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Atrial Fibrillation,Serious,Other Outcomes,Not Specified,-,18-SEP-2013,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Not Specified,-,09-SEP-2013,18-SEP-2013,US,Not Specified,US-TAKEDA-2013TUS000543,-,-
9456217,Pioglitazone Hydrochloride And Metformin Hydrochloride,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Thyroid Cancer,Serious,Required Intervention,Male,06-NOV-2012,08-AUG-2013,Expedited,64 YR,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Study,Foreign",-,30-JUL-2013,08-AUG-2013,Not Specified,Not Specified,TCI2013A04707,-,-
9447513,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Diabetic Ketoacidosis;Hypoaesthesia;Dizziness;Anger;Limb Discomfort,Serious,Hospitalized;Required Intervention,Male,14-JUL-2013,05-AUG-2013,Expedited,Not Specified,Not Specified,Takeda,Not Specified,"Study,Foreign",-,22-JUL-2013,05-AUG-2013,Not Specified,Not Specified,THQ2013A05695,-,-
9435388,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Tramadol Hydrochloride,Type 2 Diabetes Mellitus,Haemodialysis;Hypoglycaemia;Acute Kidney Injury;Lactic Acidosis,Serious,Life Threatening,Female,17-JUL-2013,02-AUG-2013,Expedited,64 YR,Not Specified,Takeda,Not Specified,"Other,Health Professional ,Foreign",Lasix,26-JUL-2013,30-JUL-2013,Not Specified,Not Specified,TIF2013A00123,-,-
9437311,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Death,Serious,Died,Male,MAY-2013,31-JUL-2013,Expedited,74 YR,Not Specified,Takeda,Not Specified,"Study,Foreign",-,16-JUL-2013,31-JUL-2013,Not Specified,Not Specified,THQ2013A05564,-,-
9432956,Bactrim;Actoplus Met;Lipitor;Zocor,Simvastatin;Losartan;Clarithromycin;Ciprofloxacin;Sulfamethoxazole;Atorvastatin Calcium;Azithromycin Anhydrous;Metformin Hydrochloride\Pioglitazone Hydrochloride;Sulfamethoxazole\Trimethoprim;Lisinopril,-,Drug Hypersensitivity,Non-Serious,Non-Serious,Female,-,31-JUL-2013,Non-Expedited,54 YR,Not Specified,Pfizer,Healthcare Professional,Not Specified,-,26-JUL-2013,31-JUL-2013,US,Not Specified,US-PFIZER INC-2013221024,-,-
9416337,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Abdominal Pain Upper;Dizziness;Nausea;Blood Glucose Increased;Dehydration;Feeding Disorder;Lactic Acidosis,Serious,Other Outcomes;Hospitalized,Female,13-JUN-2013,18-JUL-2013,Expedited,Not Specified,Not Specified,Takeda,Consumer,Consumer,-,15-JUL-2013,18-JUL-2013,Not Specified,Not Specified,TPA2013A05382,-,-
9340830,Competact;Pantozol,Pantoprazole Sodium;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Prophylaxis,Chronic Kidney Disease;Vitamin B12 Deficiency;Vomiting;Renal Tubular Necrosis;Diarrhoea;Gait Disturbance;Lactic Acidosis;Fall;Metabolic Acidosis;Chondrocalcinosis;Blood Glucose Decreased;Blood Potassium Increased;Acute Kidney Injury;Tubulointerstitial Nephritis,Serious,Hospitalized,Female,2013,28-JUN-2013,Expedited,73 YR,Not Specified,Takeda,Not Specified,"Other,Health Professional ,Foreign",Oxazepam;Simvastatin,21-JUN-2013,05-JUN-2013,Not Specified,Not Specified,TPG2013A00611,-,-
9326454,Pantozol;Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pantoprazole Sodium,Depression;Diabetes Mellitus;Prophylaxis,Fall;Lactic Acidosis;Vitamin B12 Deficiency;Blood Creatinine Increased;Diarrhoea;Vomiting;Chronic Kidney Disease;Blood Potassium Increased,Serious,Hospitalized,Female,26-APR-2013,28-JUN-2013,Expedited,73 YR,Not Specified,Pfizer,Healthcare Professional,Not Specified,Oxazepam;Xanax;Simvastatin;Venlafaxine Hydrochloride;Candesartan Cilexetil And Hydrochlorothiazide;Phenprocoumon,21-JUN-2013,04-JUN-2013,CH,Not Specified,CH-PFIZER INC-2013167178,-,-
9357238,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Bladder Transitional Cell Carcinoma,Serious,Required Intervention;Other Outcomes,Male,-,20-JUN-2013,Expedited,65 YR,Not Specified,Takeda,Healthcare Professional,Health Professional,Celebrex;Colcrys;Aspirin,07-JUN-2013,17-JUN-2013,Not Specified,Not Specified,TPA2013A05006,-,-
9360836,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Pancreatic Carcinoma,Serious,Other Outcomes;Died;Required Intervention,Not Specified,-,18-JUN-2013,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Foreign",-,04-JUN-2013,18-JUN-2013,Not Specified,Not Specified,THQ2013A04500,-,-
9332000,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Vulval Cancer,Serious,Hospitalized,Female,02-JAN-2013,03-JUN-2013,Expedited,56 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",Enalapril,27-MAY-2013,03-JUN-2013,Not Specified,Not Specified,TPG2013A00613,-,-
9303855,Competact;Avelox;Rivotril,Clonazepam;Moxifloxacin Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride;Aspirin;Trimebutine;Phenytoin Sodium;Paroxetine Hydrochloride;Colchicine;Omeprazole,Asphyxia;Gastric Disorder;Nervousness;Pain,Dehydration,Serious,Hospitalized,Male,27-APR-2013,22-MAY-2013,Expedited,77 YR,Not Specified,Ucb,Consumer,Not Specified,-,07-MAY-2013,22-MAY-2013,MX,Not Specified,MX-UCBSA-086711,-,-
9294208,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Blood Glucose Increased;Product Substitution Issue;Therapy Non-Responder,Serious,Other Outcomes,Female,29-JAN-2008,16-MAY-2013,Direct,55 YR,157 LB,-,Healthcare Professional,Health Professional,-,-,16-MAY-2013,Not Specified,Not Specified,-,-,-
9293110,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes;Required Intervention;Died,Male,AUG-2007,14-MAY-2013,Expedited,55 YR,160 LB,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Januvia;Lantus;Metformin;Starlix,08-MAY-2013,14-MAY-2013,Not Specified,Not Specified,TPA2013A03460,-,-
9288425,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Urinary Tract Obstruction;Transitional Cell Carcinoma;Metastases To Lymph Nodes;Hydronephrosis,Serious,Hospitalized;Disabled;Life Threatening,Female,27-MAR-2013,13-MAY-2013,Direct,63 YR,70.3 KG,-,Healthcare Professional,Health Professional,Lisinopril;Simvastatin;Sitagliptin,-,13-MAY-2013,Not Specified,Not Specified,-,-,-
9412087,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Glimepiride,Diabetes Mellitus,Pancreatitis Acute,Serious,Hospitalized,Female,15-MAR-2013,10-MAY-2013,Expedited,71 YR,Not Specified,Takeda,Not Specified,"Other,Health Professional ,Foreign",Iron;Simvastatin;Lantus,02-MAY-2013,10-APR-2013,IT,Not Specified,TIF2013A00057,-,-
9224651,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Glimepiride,Diabetes Mellitus,Pancreatitis Acute,Serious,Hospitalized,Female,15-MAR-2013,08-MAY-2013,Expedited,71 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,Iron;Lantus;Simvastatin;Folic Acid,03-MAY-2013,11-APR-2013,IT,Not Specified,IT-SANOFI-AVENTIS-2013SA035884,-,-
8085547,Victoza;Pioglitazone Hydrochloride And Metformin Hydrochloride;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride;Liraglutide,Type 2 Diabetes Mellitus,Dehydration;Hypoglycaemia;Heart Rate Increased;Oedema Peripheral;Vomiting;Nausea;Decreased Appetite;Pleural Effusion;Hypophagia,Serious,Hospitalized,Female,FEB-2011,05-APR-2013,Expedited,77 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Study,Foreign",Levofloxacin;Metformin Hydrochloride;Clarithromycin;Amaryl;Rifadin,29-MAR-2013,22-JUL-2011,Not Specified,Not Specified,TCI2011A03972,-,-
9189342,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Metastases To Bone;Bladder Cancer,Serious,Other Outcomes;Required Intervention,Male,2007,26-MAR-2013,Expedited,48 YR,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",-,19-MAR-2013,22-MAR-2013,Not Specified,Not Specified,TPA2013A02222,-,-
9015537,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Died;Other Outcomes,Male,06-NOV-2007,25-MAR-2013,Expedited,80 YR,170 LB,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",-,19-MAR-2013,02-JAN-2013,Not Specified,Not Specified,TPA2012A11835,-,-
9167801,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Death,Serious,Died,Male,-,14-MAR-2013,Expedited,55 YR,Not Specified,Takeda,Not Specified,"Other,Study",-,08-MAR-2013,14-MAR-2013,Not Specified,Not Specified,TPA2013A02047,-,-
9012278,Metact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Respiratory Failure,Serious,Died,Female,24-JUN-2011,05-MAR-2013,Expedited,78 YR,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Study,Foreign",-,19-FEB-2013,31-DEC-2012,Not Specified,Not Specified,TCI2012A07286,-,-
9148555,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Drug-Induced Liver Injury,Serious,Other Outcomes,Male,01-JAN-2011,28-FEB-2013,Direct,63 YR,238 LB,-,Not Specified,Not Specified,-,-,28-FEB-2013,Not Specified,Not Specified,-,-,-
9162547,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Male,2008,21-FEB-2013,Expedited,63 YR,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",-,12-FEB-2013,21-FEB-2013,Not Specified,Not Specified,TPA2012A12126,-,-
9158174,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Erectile Dysfunction,Serious,Other Outcomes,Male,-,20-FEB-2013,Expedited,49 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",Glucophage,06-FEB-2013,23-JAN-2013,Not Specified,Not Specified,THQ2013A00817,-,-
9103370,Celebrex;Actoplus Met;Neurontin,Gabapentin;Metformin Hydrochloride\Pioglitazone Hydrochloride;Celecoxib,Arthritis;Blood Cholesterol Abnormal;Blood Pressure Abnormal;Burning Sensation;Diabetes Mellitus,Pain;Drug Ineffective,Non-Serious,Non-Serious,Male,2012,19-FEB-2013,Non-Expedited,57 YR,132 KG,Pfizer,Consumer,Not Specified,Lisinopril;Metformin;Bystolic,13-FEB-2013,19-FEB-2013,US,Not Specified,US-PFIZER INC-2013060424,-,-
9026635,Metact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Interstitial Lung Disease,Serious,Disabled,Male,07-NOV-2012,11-FEB-2013,Expedited,67 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",Lipitor,30-JAN-2013,07-JAN-2013,Not Specified,Not Specified,TCI2012A07551,-,-
8233395,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes;Required Intervention;Hospitalized,Male,21-SEP-2011,11-FEB-2013,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",-,31-JAN-2013,01-NOV-2011,Not Specified,Not Specified,TPA2011A06805,-,-
8844577,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Colon Cancer;Bladder Cancer,Serious,Other Outcomes,Female,-,05-FEB-2013,Expedited,54 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",-,21-JAN-2013,12-OCT-2012,Not Specified,Not Specified,THQ2012A08927,-,-
9095496,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Hyperglycaemia,Haematochezia;Abdominal Pain Lower,Serious,Other Outcomes,Male,01-MAR-2011,24-JAN-2013,Expedited,55 YR,Not Specified,Takeda,Not Specified,"Other,Foreign",-,16-JAN-2013,24-JAN-2013,Not Specified,Not Specified,TIF2013A00010,-,-
9041026,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes;Hospitalized;Life Threatening;Disabled,Male,27-APR-2011,23-JAN-2013,Direct,74 YR,180 LB,-,Healthcare Professional,Not Specified,-,-,23-JAN-2013,Not Specified,Not Specified,-,-,-
9041308,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Dysuria;Transitional Cell Carcinoma;Urinary Tract Obstruction,Serious,Other Outcomes;Required Intervention,Male,08-JUL-2011,14-JAN-2013,Expedited,46 YR,290 LB,Takeda,Not Specified,"Company Representative ,Consumer,Health Professional",Glipizide;Metformin,07-JAN-2013,14-JAN-2013,Not Specified,Not Specified,TPA2013A00649,-,-
9034702,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Non-Serious,Non-Serious,Male,2010,11-JAN-2013,Expedited,64 YR,176 LB,Takeda,Not Specified,Not Specified,Metformin,07-JAN-2013,11-JAN-2013,Not Specified,Not Specified,TPA2012A06472,-,-
9034666,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Male,17-AUG-2010,11-JAN-2013,Expedited,67 YR,220 LB,Takeda,Not Specified,"Company Representative ,Consumer,Health Professional",-,04-JAN-2013,11-JAN-2013,Not Specified,Not Specified,TPA2012A09939,-,-
8170734,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Bladder Transitional Cell Carcinoma,Serious,Hospitalized;Other Outcomes,Male,-,28-DEC-2012,Expedited,44 YR,Not Specified,Takeda,Not Specified,"Other,Health Professional ,Foreign",Insulin Glargine;Glimepiride;Bupropion Hydrochloride;Metformin Hydrochloride;Cloxazolam;Sertraline Hydrochloride,18-DEC-2012,14-SEP-2011,Not Specified,Not Specified,THQ2011A05419,-,-
9012149,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Prostate Cancer;Weight Fluctuation,Serious,Other Outcomes;Required Intervention,Male,-,27-DEC-2012,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Health Professional,-,20-DEC-2012,27-DEC-2012,Not Specified,Not Specified,TPA2012A10412,-,-
8844704,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Died;Required Intervention;Other Outcomes,Male,-,26-DEC-2012,Expedited,60 YR,240 LB,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Glucotrol;Metformin,18-DEC-2012,12-OCT-2012,Not Specified,Not Specified,TPA2012A07628,-,-
8971417,Januvia;Competact;Metformin,Metformin Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride;Sitagliptin Phosphate,Hiv Infection;Type 1 Diabetes Mellitus,Acute Myocardial Infarction;Arteriosclerosis Coronary Artery;Off Label Use,Serious,Hospitalized,Male,16-MAR-2009,18-DEC-2012,Expedited,46 YR,Not Specified,Merck,Healthcare Professional,Not Specified,Viramune;Truvada,04-DEC-2012,18-DEC-2012,FR,Not Specified,FR-MERCK-1212FRA005072,-,-
8969465,Januvia;Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Sitagliptin Phosphate,Type 1 Diabetes Mellitus,Congenital Musculoskeletal Disorder Of Skull;Foetal Exposure During Pregnancy;Neural Tube Defect,Serious,Congenital Anomaly;Died;Other Outcomes,Not Specified,2009,18-DEC-2012,Expedited,Not Specified,Not Specified,Merck,Healthcare Professional,Not Specified,Insulin Human;Novorapid,04-DEC-2012,18-DEC-2012,FR,Not Specified,FR-009507513-1010FRA00081B1,-,-
8170739,Januvia;Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Sitagliptin Phosphate;Gliclazide,Type 2 Diabetes Mellitus,Bladder Neoplasm;Oedema Peripheral;Haematuria,Serious,Other Outcomes;Life Threatening,Male,SEP-2010,18-DEC-2012,Expedited,68 YR,75 KG,Merck,Healthcare Professional,Not Specified,-,04-DEC-2012,26-SEP-2011,FR,Not Specified,FR-MERCK-1109FRA00079,-,-
7649701,Competact;Januvia,Sitagliptin Phosphate;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 1 Diabetes Mellitus,Exposure During Pregnancy;Off Label Use;Abortion Induced,Serious,Other Outcomes,Female,04-DEC-2009,18-DEC-2012,Expedited,35 YR,Not Specified,Merck,Healthcare Professional,Not Specified,Insulin Human;Novorapid,04-DEC-2012,29-OCT-2010,FR,Not Specified,FR-MERCK-1010FRA00081,-,-
8948113,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Insulin-Requiring Type 2 Diabetes Mellitus,Haematuria,Serious,Other Outcomes,Male,26-NOV-2012,27-NOV-2012,Expedited,62 YR,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Foreign",-,12-NOV-2012,27-NOV-2012,Not Specified,Not Specified,TIF2012A00085,-,-
8918536,Lisinopril And Hydrochlorothiazide;Nexium;Crestor;Tylenol;Actoplus Met Xr;Cymbalta,Duloxetine Hydrochloride;Glimepiride;Metformin Hydrochloride\Pioglitazone Hydrochloride;Acetaminophen;Rosuvastatin Calcium;Esomeprazole Magnesium;Metoprolol Tartrate;Hydrochlorothiazide\Lisinopril;Aspirin,Nausea;Pain,Fatigue;Dyspnoea;Obesity;Urinary Incontinence;Pain In Extremity;Drug Hypersensitivity;Depression;Essential Hypertension;Diabetes Mellitus Inadequate Control;Abdominal Pain;Dyslipidaemia;Cholecystitis;Diabetic Neuropathy;Testicular Failure,Non-Serious,Non-Serious,Male,-,20-NOV-2012,Non-Expedited,51 YR,Not Specified,Astrazeneca,Consumer,Not Specified,.Alpha.-Lipoic Acid;Depo-Testosterone;Victoza;Pravachol;Lantus;Vitamin B12;Fluvax;Tricor;Zofran Odt;Celebrex;Fish Oil,19-MAR-2012,20-NOV-2012,US,Not Specified,US-ASTRAZENECA-2012SE18866,-,-
8932563,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Hepatic Cancer;Malaise;Fatigue,Serious,Died,Male,FEB-2012,19-NOV-2012,Expedited,76 YR,200 LB,Takeda,Consumer,"Consumer,Study",-,05-NOV-2012,19-NOV-2012,Not Specified,Not Specified,TPA2012A08953,-,-
8892175,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Knee Arthroplasty;Cataract Operation,Serious,Required Intervention;Other Outcomes,Female,-,31-OCT-2012,Expedited,Not Specified,Not Specified,Takeda,Consumer,Consumer,-,15-OCT-2012,31-OCT-2012,Not Specified,Not Specified,TPA2012A08257,-,-
8861261,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Product Commingling;Product Packaging Issue,Non-Serious,Non-Serious,Male,-,25-OCT-2012,Direct,Not Specified,290 LB,-,Consumer,Not Specified,-,-,25-OCT-2012,Not Specified,Not Specified,-,-,-
8817952,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Anaemia;Colon Cancer;Cervix Carcinoma Stage Iv,Serious,Other Outcomes,Female,-,22-OCT-2012,Expedited,54 YR,Not Specified,Eli Lilly And Co,Healthcare Professional,Not Specified,-,16-OCT-2012,01-OCT-2012,MX,Not Specified,MX-ELI_LILLY_AND_COMPANY-MX201209008303,-,-
8856282,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,-,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Male,DEC-2010,19-OCT-2012,Expedited,69 YR,206 LB,Takeda,Healthcare Professional,"Company Representative ,Health Professional",Amaryl;Synthroid;Glimepiride;Losartan;Januvia;Coumadin;Lipitor;Levothyroxine,04-OCT-2012,19-OCT-2012,Not Specified,Not Specified,TPA2012A07573,-,-
8856198,Avastin;Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Bevacizumab,Diabetes Mellitus;Malignant Melanoma,Ejection Fraction Decreased;Fatigue;Left Ventricular Dysfunction;Dyspnoea Exertional,Serious,Other Outcomes,Female,03-MAY-2012,19-OCT-2012,Expedited,78 YR,Not Specified,Takeda,Not Specified,"Other,Health Professional ,Study,Foreign",Gliclazide;Ezetimibe;Verapamil;Losartan,10-OCT-2012,19-OCT-2012,Not Specified,Not Specified,TUK2012A00274,-,-
8839689,Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Bladder Cancer,Serious,Died,Male,11-OCT-2011,12-OCT-2012,Direct,86 YR,Not Specified,-,Not Specified,Not Specified,-,-,12-OCT-2012,Not Specified,Not Specified,-,-,-
8756048,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Cardiac Failure Congestive;Renal Failure;Bladder Cancer,Serious,Other Outcomes;Required Intervention,Female,JUL-2007,10-OCT-2012,Expedited,59 YR,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Metformin;Januvia;Avandia,07-AUG-2012,13-AUG-2012,Not Specified,Not Specified,TPA2012A03424,-,-
8822248,Tricor;Januvia;Lipitor;Aciphex;Zoloft;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Sertraline Hydrochloride;Rabeprazole Sodium;Atorvastatin Calcium;Sitagliptin Phosphate;Fenofibrate,Diabetes Mellitus,Hypersomnia,Non-Serious,Non-Serious,Female,-,03-OCT-2012,Non-Expedited,62 YR,96.6 KG,Pfizer,Consumer,Not Specified,Insulin Nos,27-SEP-2012,03-OCT-2012,US,Not Specified,US-PFIZER INC-2012241178,-,-
8804615,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Hospitalized,Male,18-AUG-2012,24-SEP-2012,Expedited,62 YR,Not Specified,Abbott,Healthcare Professional,Not Specified,Simvastatin,12-SEP-2012,24-SEP-2012,AT,Not Specified,AT-ABBOTT-12P-009-0977196-00,-,-
8804612,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Glimepiride\Pioglitazone Hydrochloride,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Bladder Cancer;Drug Intolerance,Serious,Hospitalized;Disabled;Life Threatening,Male,17-FEB-2012,24-SEP-2012,Expedited,67 YR,Not Specified,Abbott,Healthcare Professional,Not Specified,Quinapril Hydrochloride;Nebivolol Hydrochloride;Hydrochlorothiazide\Quinapril Hydrochloride;Simvastatin,12-SEP-2012,24-SEP-2012,AT,Not Specified,AT-ABBOTT-12P-009-0978422-00,-,-
8791255,Avandamet;Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Metformin Hydrochloride\Rosiglitazone Maleate,Diabetes Mellitus,Haemoglobin Decreased;Normocytic Anaemia,Serious,Required Intervention;Life Threatening,Female,2005,11-SEP-2012,Expedited,63 YR,Not Specified,Takeda,Not Specified,Foreign,-,28-AUG-2012,11-SEP-2012,Not Specified,Not Specified,TUK2012A00241,-,-
8764233,Metformin;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Metformin Hydrochloride,Bladder Cancer;Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes;Required Intervention;Died,Male,2008,28-AUG-2012,Expedited,67 YR,195 LB,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Glimepiride;Amaryl,09-AUG-2012,28-AUG-2012,Not Specified,Not Specified,TPA2012A04267,-,-
8387750,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Transitional Cell Carcinoma,Serious,Required Intervention;Other Outcomes,Male,OCT-2009,10-AUG-2012,Expedited,52 YR,182 LB,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Metformin Hydrochloride;Janumet,26-JUL-2012,20-JAN-2012,Not Specified,Not Specified,TPA2012A00260,-,-
8682017,Metact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Rhabdomyolysis;Myalgia,Serious,Other Outcomes,Female,18-APR-2012,24-JUL-2012,Expedited,69 YR,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Foreign",Amaryl;Januvia,10-JUL-2012,06-JUL-2012,Not Specified,Not Specified,TCI2012A03345,-,-
8309963,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Retinal Vein Thrombosis;Disease Recurrence,Serious,Other Outcomes,Male,JUN-2010,19-JUL-2012,Expedited,42 MTH,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",Victoza;Allopurinol;Xalatan;Atorvastatin;Repaglinide,04-JUL-2012,15-DEC-2011,Not Specified,Not Specified,TPG2011A03219,-,-
8735128,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Metabolic Surgery,Serious,Hospitalized,Female,-,07-JUL-2012,Expedited,Not Specified,Not Specified,Takeda,Not Specified,Health Professional,-,23-JUL-2012,07-JUL-2012,Not Specified,Not Specified,TPA2012A05074,-,-
8339751,Metact;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Urine Cytology Abnormal;Bladder Transitional Cell Carcinoma,Serious,Hospitalized,Male,OCT-2011,29-JUN-2012,Expedited,75 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",Carvedilol,15-JUN-2012,09-JAN-2012,Not Specified,Not Specified,TCI2011A06871,-,-
8639691,Januvia,Sitagliptin Phosphate;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Oedema Peripheral;Drug Interaction,Serious,Other Outcomes,Female,01-MAY-2011,27-JUN-2012,Expedited,71 YR,Not Specified,Merck,Healthcare Professional,Health Professional,-,25-JUN-2012,27-JUN-2012,ES,Not Specified,ES-MERCK-1206ESP00032,-,-
8621934,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Hypersensitivity,Serious,Hospitalized,Male,-,19-JUN-2012,Expedited,45 YR,Not Specified,Eli Lilly And Co,Healthcare Professional,Health Professional,-,12-JUN-2012,19-JUN-2012,MX,Not Specified,MX-ELI_LILLY_AND_COMPANY-MX201206004623,-,-
8623163,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Trisomy 21;Maternal Drugs Affecting Foetus,Serious,Congenital Anomaly,Not Specified,07-NOV-2011,07-JUN-2012,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Health Professional,-,22-MAY-2012,07-JUN-2012,Not Specified,Not Specified,TPA2012A03066,-,-
8578473,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Hospitalized,Male,11-APR-2012,22-MAY-2012,Direct,75 YR,204 LB,-,Consumer,Not Specified,-,-,22-MAY-2012,Not Specified,Not Specified,-,-,-
8573346,Onglyza,Saxagliptin Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Oedema Peripheral,Non-Serious,Non-Serious,Female,-,22-MAY-2012,Non-Expedited,72 YR,Not Specified,Bristol Myers Squibb,Consumer,Not Specified,-,09-FEB-2012,22-MAY-2012,US,Not Specified,US-BRISTOL-MYERS SQUIBB COMPANY-16391393,-,-
8501413,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Metastases To Lymph Nodes;Lymphadenopathy,Serious,Hospitalized;Disabled,Male,MAR-2012,01-MAY-2012,Expedited,60 YR,194.6 LB,Takeda,Healthcare Professional,Health Professional,Tricor;Pristiq Extended-Release;Lotrel,26-MAR-2012,04-APR-2012,Not Specified,Not Specified,TPA2012A01578,-,-
8320537,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Renal Failure;Haematuria;Malnutrition;Bladder Cancer;Drug Intolerance;Dialysis;Septic Shock;Metastases To Liver;Urinary Tract Infection;Post Procedural Complication;Metastases To Lung,Serious,Hospitalized;Died,Male,OCT-2010,12-APR-2012,Expedited,65 YR,Not Specified,Takeda,Healthcare Professional,"Other,Health Professional ,Foreign",-,29-MAR-2012,22-DEC-2011,Not Specified,Not Specified,LTI2011A00324,-,-
8506623,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Supraventricular Tachycardia;Pericarditis,Serious,Other Outcomes,Male,-,06-APR-2012,Expedited,52 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",Metformin Hydrochloride;Losartan Potassium,22-MAR-2012,06-APR-2012,Not Specified,Not Specified,THQ2012A02196,-,-
8493429,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Male,19-MAR-2012,04-APR-2012,Direct,75 YR,103.87 KG,-,Healthcare Professional,Health Professional,-,-,04-APR-2012,US,Not Specified,-,-,-
8493426,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Male,19-MAR-2012,04-APR-2012,Direct,75 YR,103.87 KG,-,Healthcare Professional,Health Professional,-,-,04-APR-2012,US,Not Specified,-,-,-
8494885,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Blood Urine Present;Bladder Cancer,Serious,Other Outcomes,Male,-,29-MAR-2012,Expedited,59 YR,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,13-MAR-2012,29-MAR-2012,Not Specified,Not Specified,TPA2012A00902,-,-
8112265,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Intestinal Fistula Infection;Bladder Transitional Cell Carcinoma Stage Iii,Serious,Life Threatening;Hospitalized;Other Outcomes,Male,19-MAY-2010,27-MAR-2012,Expedited,68 YR,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Foreign",Metformin Hydrochloride;Plavix;Atorvastatin Calcium;Repaglinide;Valsartan;Sectral,13-MAR-2012,19-AUG-2011,Not Specified,Not Specified,LTI2011A00242,-,-
8024932,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Lung Disorder;Urethral Polyp;Bladder Neoplasm;General Physical Health Deterioration;Pleurisy,Serious,Hospitalized;Died,Male,07-APR-2011,27-MAR-2012,Expedited,83 YR,Not Specified,Takeda,Healthcare Professional,"Other,Health Professional ,Foreign",Fenofibrate;Esomeprazole Magnesium;Levothyroxine Sodium,12-MAR-2012,21-JUN-2011,Not Specified,Not Specified,LTI2011A00144,-,-
8487694,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Supraventricular Tachycardia,Serious,Other Outcomes,Male,-,23-MAR-2012,Expedited,52 YR,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Foreign",Metformin Hydrochloride,07-MAR-2012,23-MAR-2012,Not Specified,Not Specified,THQ2011A02196,-,-
8429110,Januvia;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Sitagliptin Phosphate,Type 2 Diabetes Mellitus,Renal Disorder;Small Intestinal Obstruction;Umbilical Hernia;Volvulus;Blood Glucose Abnormal;Chronic Kidney Disease,Serious,Other Outcomes,Female,01-JAN-2011,23-MAR-2012,Expedited,64 YR,Not Specified,Merck,Healthcare Professional,Health Professional,Oxybutynin.;Furosemide;Procardia;Insulin Nos;Nortriptyline;Tramadol Hydrochloride;Lisinopril,19-MAR-2012,27-FEB-2012,US,Not Specified,US-MERCK-1202USA03149,-,-
8417703,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Transitional Cell Carcinoma Recurrent,Serious,Hospitalized,Male,MAY-2011,20-MAR-2012,Expedited,61 YR,Not Specified,Takeda,Not Specified,"Other,Health Professional ,Foreign",Indapamide;Omeprazole Sodium;Crestor;Plavix;Nitroglycerin;Vastarel;Metoprolol,05-MAR-2012,07-FEB-2012,Not Specified,Not Specified,LTI2012A00031,-,-
8470087,-,Flutamide;Metformin Hydrochloride\Pioglitazone Hydrochloride,Depression;Diabetes Mellitus,Stress Fracture;Osteopenia;Foot Fracture,Serious,Required Intervention,Female,-,14-MAR-2012,Expedited,58 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",Ezetimibe And Simvastatin,28-FEB-2012,14-MAR-2012,Not Specified,Not Specified,TPG2012A00210,-,-
8464035,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Bladder Adenocarcinoma Stage Unspecified,Serious,Hospitalized,Male,04-JAN-2012,09-MAR-2012,Expedited,79 YR,Not Specified,Takeda,Healthcare Professional,"Other,Health Professional ,Foreign",Coumadin;Norvasc,23-FEB-2012,09-MAR-2012,Not Specified,Not Specified,TIF2012A00007,-,-
8458741,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Bladder Cancer,Serious,Other Outcomes;Required Intervention;Died,Male,-,06-MAR-2012,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,28-FEB-2012,06-MAR-2012,Not Specified,Not Specified,TPA2012A01110,-,-
8248718,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Transitional Cell Carcinoma,Serious,Other Outcomes;Required Intervention,Male,APR-2011,24-FEB-2012,Expedited,85 YR,140.5 LB,Takeda,Healthcare Professional,Health Professional,Exforge;Iron;Vitamin C;Diovan;Lipitor;Alprazolam;Plavix;Metoprolol Tartrate,13-FEB-2012,14-NOV-2011,Not Specified,Not Specified,TPA2011A07280,-,-
8438554,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Male,31-DEC-2007,22-FEB-2012,Expedited,59 YR,Not Specified,Takeda,Consumer,"Company Representative ,Consumer",-,13-FEB-2012,22-FEB-2012,Not Specified,Not Specified,TPA2012A00796,-,-
8438497,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Male,30-JUN-2010,22-FEB-2012,Expedited,72 YR,Not Specified,Takeda,Consumer,"Company Representative ,Consumer",-,13-FEB-2012,22-FEB-2012,Not Specified,Not Specified,TPA2012A00795,-,-
8278384,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Hospitalized;Required Intervention;Other Outcomes,Male,-,16-FEB-2012,Expedited,61 YR,268 LB,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,07-FEB-2012,01-DEC-2011,Not Specified,Not Specified,TPA2011A07834,-,-
8428854,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Male,OCT-2011,15-FEB-2012,Expedited,70 YR,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",Glyburide;Metformin Hydrochloride;Lovastatin;Ibuprofen;Hydrochlorothiazide;Lortab;Flomax;Enalapril,06-FEB-2012,15-FEB-2012,Not Specified,Not Specified,TPA2012A00667,-,-
8410497,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Transitional Cell Carcinoma;Haematuria,Serious,Other Outcomes;Hospitalized,Male,-,06-FEB-2012,Expedited,74 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",Aspirin;Losartan Potassium;Glimepiride;Atorvastatin,18-JAN-2012,06-FEB-2012,Not Specified,Not Specified,THQ2012A00344,-,-
8409896,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Eye Disorder;Effusion,Serious,Other Outcomes,Female,OCT-2011,03-FEB-2012,Expedited,54 YR,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Foreign",Simvastatin,24-JAN-2012,03-FEB-2012,Not Specified,Not Specified,TPG2012A00086,-,-
8258375,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Transitional Cell Carcinoma;Prostate Cancer,Serious,Disabled;Hospitalized;Life Threatening,Male,15-MAR-2011,01-FEB-2012,Expedited,66 YR,Not Specified,Takeda,Not Specified,"Other,Health Professional ,Foreign",Amlodipine;Candesartan Cilexetil;Carvedilol;Dihydralazine Sulfate,17-JAN-2012,14-NOV-2011,Not Specified,Not Specified,TPG2011A02984,-,-
8400100,Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Transitional Cell Carcinoma Stage Ii,Serious,Hospitalized,Male,JUN-2011,31-JAN-2012,Expedited,63 YR,Not Specified,Takeda,Not Specified,"Other,Health Professional ,Foreign",Isoptin,17-JAN-2012,31-JAN-2012,Not Specified,Not Specified,LTI2012A00018,-,-
8400913,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,-,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Male,-,30-JAN-2012,Expedited,32 YR,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,17-JAN-2012,30-JAN-2012,Not Specified,Not Specified,TPA2012A00359,-,-
8345026,Actos;Vioxx;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Unspecified Ingredient;Rofecoxib;Pioglitazone Hydrochloride,Diabetes Mellitus Management,Bone Disorder;Memory Impairment;Ischaemic Stroke;Myocardial Infarction;Road Traffic Accident;Panic Disorder;Depression;Impaired Healing;Gastrointestinal Disorder;Bone Density Decreased;Arthralgia;Intervertebral Disc Degeneration;Urinary Tract Infection;Attention Deficit Hyperactivity Disorder;Cardiac Valve Disease,Serious,Other Outcomes;Required Intervention,Male,02-APR-2011,25-JAN-2012,Expedited,50 YR,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Prilosec;Cephalexin;Cialis;Vytorin;Lipitor;Mobic;Aciphex;Glumetza;Celebrex;Viagra;Prozac;Glucophage;Naproxen;Pristiq Extended-Release;Paxil;Cymbalta;Metformin Hydrochloride;Simvastatin;Fortamet;Glipizide;Nexium;Aspirin;Glucotrol Xl;Cyclobenzaprine Hydrochloride;Cozaar;Claritin-D 12 Hour;Parecoxib Sodium,13-JAN-2012,10-JAN-2012,Not Specified,Not Specified,TPA2011A08815,-,-
8218050,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes;Died,Not Specified,2010,20-JAN-2012,Expedited,56 YR,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,10-JAN-2012,21-OCT-2011,Not Specified,Not Specified,TPA2011A06564,-,-
8393250,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Insulin Resistance;Type 2 Diabetes Mellitus,Retinal Vein Occlusion,Serious,Other Outcomes,Male,JUN-2010,17-JAN-2012,Expedited,42 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",Lantus;Allopurinol;Atorvastatin;Victoza,11-JAN-2012,17-JAN-2012,Not Specified,Not Specified,TPO2011A03219,-,-
8375373,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer;Abdominal Pain,Serious,Other Outcomes;Required Intervention,Male,-,17-JAN-2012,Expedited,79 YR,227 LB,Takeda,Consumer,Consumer,-,09-JAN-2012,17-JAN-2012,Not Specified,Not Specified,TPA2012A00166,-,-
8373592,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Ulcer;Body Height Decreased;Blood Pressure Decreased;Weight Decreased;Mantle Cell Lymphoma Stage Iv;Loss Of Consciousness;Rib Fracture,Serious,Other Outcomes;Required Intervention,Male,17-DEC-2010,17-JAN-2012,Expedited,47 YR,286 LB,Takeda,Healthcare Professional,Health Professional,Pravastatin;Coreg;Potassium Chloride;Ambien;Digoxin;Celebrex;Aspirin;Plavix;Lasix;Dexilant,09-JAN-2012,17-JAN-2012,Not Specified,Not Specified,TPA2012A00201,-,-
8322466,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention,Male,17-MAY-2011,23-DEC-2011,Expedited,69 YR,Not Specified,Takeda,Healthcare Professional,"Other,Health Professional ,Foreign",-,12-DEC-2011,23-DEC-2011,Not Specified,Not Specified,THQ2011A08346,-,-
8315412,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Neoplasm Surgery,Serious,Hospitalized,Female,18-AUG-2011,20-DEC-2011,Expedited,70 YR,Not Specified,Takeda,Not Specified,"Other,Health Professional ,Foreign",-,09-DEC-2011,20-DEC-2011,Not Specified,Not Specified,LTI2011A00314,-,-
8298956,Actoplus Met;Crestor,Rosuvastatin Calcium;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Hypercholesterolaemia;Hypertension;Type 1 Diabetes Mellitus,Extrasystoles;Headache,Non-Serious,Non-Serious,Female,01-NOV-2010,19-DEC-2011,Non-Expedited,73 YR,Not Specified,Astrazeneca,Consumer,Not Specified,Metoprolol;Metformin Hydrochloride;Lipitor,13-DEC-2010,19-DEC-2011,US,Not Specified,US-ASTRAZENECA-2010SE58833,-,-
8306788,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Renal Cell Carcinoma;Bladder Cancer,Serious,Other Outcomes;Required Intervention,Female,-,15-DEC-2011,Expedited,7 DEC,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,02-DEC-2011,15-DEC-2011,Not Specified,Not Specified,TPA2011A08168,-,-
8298396,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Cholelithiasis;Procedural Site Reaction;Post Procedural Complication;Infection;Abdominal Hernia,Serious,Hospitalized,Male,2011,12-DEC-2011,Expedited,69 YR,180 LB,Takeda,Consumer,Consumer,Naproxen;Flomax;Fluticasone Propionate;Lisinopril;Vicodin,30-NOV-2011,12-DEC-2011,Not Specified,Not Specified,TPA2011A08099,-,-
8154411,Lantus,Insulin Glargine;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Haemoglobin Decreased;Blood Glucose Increased,Non-Serious,Non-Serious,Not Specified,-,17-NOV-2011,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Foreign",Atacand;Bricanyl;Simvastatin;Pulmicort Flexhaler;Levothyroxine Sodium,02-NOV-2011,13-SEP-2011,Not Specified,Not Specified,THQ2011A05416,-,-
8216899,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes;Required Intervention,Male,07-FEB-2006,15-NOV-2011,Expedited,73 YR,208.5 LB,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,04-NOV-2011,21-OCT-2011,Not Specified,Not Specified,TPA2011A06621,-,-
8235078,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Insulin Resistance,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Male,2007,14-NOV-2011,Expedited,52 YR,260 LB,Takeda,Consumer,"Consumer,Health Professional",-,02-NOV-2011,31-OCT-2011,Not Specified,Not Specified,TPA2011A06808,-,-
8243663,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Transitional Cell Carcinoma,Serious,Hospitalized,Male,JUN-2010,09-NOV-2011,Expedited,63 YR,Not Specified,Takeda,Healthcare Professional,"Other,Health Professional ,Foreign",Aspirin,26-OCT-2011,09-NOV-2011,Not Specified,Not Specified,TIF2011A00125,-,-
8182925,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Transitional Cell Carcinoma,Serious,Hospitalized,Male,25-AUG-2010,04-NOV-2011,Expedited,60 YR,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",Gliclazide;Pravastatin;Tricor,24-OCT-2011,05-OCT-2011,Not Specified,Not Specified,TPA2011A06037,-,-
8238694,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Urinary Tract Infection;Bladder Cancer;Oedema;Sepsis,Serious,Hospitalized;Other Outcomes;Required Intervention,Female,08-JUN-2010,03-NOV-2011,Expedited,64 YR,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",Multi-Vitamin;Vitamin D3;Synthroid;Folic Acid;Lantus;Avonex;Methotrexate;Topiramate;Neurontin;Dimethyl Sulfone;Citalopram Hydrobromide;Macrobid,20-OCT-2011,03-NOV-2011,Not Specified,Not Specified,TPA2011A06951,-,-
8222364,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Hospitalized,Female,SEP-2011,26-OCT-2011,Expedited,76 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",-,10-OCT-2011,26-OCT-2011,Not Specified,Not Specified,THQ2011A06518,-,-
8199112,Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Hospitalized,Male,-,17-OCT-2011,Expedited,Not Specified,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",-,30-SEP-2011,17-OCT-2011,Not Specified,Not Specified,THQ2011A06301,-,-
8202850,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer;Weight Increased,Serious,Hospitalized,Male,2011,14-OCT-2011,Expedited,51 YR,195 LB,Takeda,Healthcare Professional,"Consumer,Health Professional",Xanax,06-OCT-2011,14-OCT-2011,Not Specified,Not Specified,TPA2011A06346,-,-
8041073,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Transitional Cell Carcinoma;Haematuria,Serious,Life Threatening;Hospitalized;Other Outcomes,Male,14-MAY-2009,12-OCT-2011,Expedited,69 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",-,28-SEP-2011,05-JUL-2011,Not Specified,Not Specified,LTI2011A00170,-,-
8184999,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Male,MAR-2011,06-OCT-2011,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Foreign",-,21-SEP-2011,06-OCT-2011,Not Specified,Not Specified,THQ2011A05884,-,-
8065374,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Transitional Cell Carcinoma,Serious,Other Outcomes,Male,08-JAN-2011,06-OCT-2011,Expedited,67 YR,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Foreign",Lansoprazole;Caduet;Valsartan And Hydrochlorothiazide,23-SEP-2011,13-JUL-2011,Not Specified,Not Specified,LTI2011A00185,-,-
8013307,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Pulmonary Fibrosis;Lymphadenopathy Mediastinal,Serious,Hospitalized;Died,Male,2009,05-OCT-2011,Expedited,62 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",Perindopril Erbumine;Atorvastatin Calcium;Diltiazem Hydrochloride;Aspirin,22-SEP-2011,19-APR-2011,Not Specified,Not Specified,LTI2011A00077,-,-
8182174,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Female,-,04-OCT-2011,Expedited,62 YR,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,19-SEP-2011,04-OCT-2011,Not Specified,Not Specified,TPA2011A05936,-,-
8162255,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Acute Kidney Injury;Flatulence;Nephropathy,Serious,Other Outcomes;Hospitalized,Male,-,30-SEP-2011,Expedited,57 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",Actos;Glucophage,15-SEP-2011,21-SEP-2011,Not Specified,Not Specified,THQ2011A05662,-,-
8109211,Metact;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Hospitalized;Life Threatening,Female,19-APR-2011,29-SEP-2011,Expedited,78 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",Metformin Hydrochloride;Rasilez;Norvasc;Candesartan Cilexetil,16-SEP-2011,17-AUG-2011,Not Specified,Not Specified,TCI2011A04298,-,-
8057200,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Blood Glucose Increased,Bladder Transitional Cell Carcinoma,Serious,Required Intervention;Other Outcomes,Male,SEP-2008,29-SEP-2011,Expedited,66 YR,306 LB,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,15-SEP-2011,13-JUL-2011,Not Specified,Not Specified,TPA2011A03640,-,-
8041070,Januvia,Sitagliptin Phosphate;Metformin Hydrochloride\Pioglitazone Hydrochloride;Gliclazide,Type 2 Diabetes Mellitus,Oedema Peripheral;Bladder Cancer Stage Ii,Serious,Life Threatening;Other Outcomes,Male,02-OCT-2010,29-SEP-2011,Expedited,68 YR,Not Specified,Takeda,Healthcare Professional,"Other,Health Professional ,Foreign",-,16-SEP-2011,05-JUL-2011,Not Specified,Not Specified,LTI2011A00173,-,-
8083284,Metformin,Metformin Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride;Metformin Hydrochloride\Rosiglitazone Maleate,Diabetes Mellitus;Diabetes Mellitus Inadequate Control,Mitral Valve Incompetence;Cardiac Failure;Coronary Artery Stenosis;Myocardial Ischaemia,Serious,Hospitalized;Life Threatening,Male,07-JUN-2011,27-SEP-2011,Expedited,74 YR,Not Specified,Takeda,Healthcare Professional,"Other,Health Professional ,Foreign",Simvastatin,13-SEP-2011,29-JUL-2011,Not Specified,Not Specified,TIF2011A00106,-,-
8170556,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Haematuria;Bladder Transitional Cell Carcinoma,Serious,Hospitalized,Male,JUN-2010,22-SEP-2011,Expedited,63 YR,Not Specified,Takeda,Healthcare Professional,"Other,Health Professional",-,15-SEP-2011,22-SEP-2011,Not Specified,Not Specified,TIP2011A00125,-,-
8001468,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Transitional Cell Carcinoma,Serious,Life Threatening;Required Intervention,Male,29-APR-2011,16-SEP-2011,Expedited,66 YR,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Foreign",Gliclazide,06-SEP-2011,03-JUN-2011,Not Specified,Not Specified,LTI2011A00126,-,-
8159230,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Blood Urine Present,Serious,Required Intervention,Male,-,12-SEP-2011,Expedited,60 YR,Not Specified,Takeda,Not Specified,"Other,Health Professional ,Foreign",Ezetimibe;Rasilez;Cymbalta;Lantus;Onglyza;Amlodipine Besylate;Apidra,29-AUG-2011,12-SEP-2011,Not Specified,Not Specified,TUK2011A00128,-,-
8142220,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes;Required Intervention,Male,2011,08-SEP-2011,Expedited,7 DEC,216 LB,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,30-AUG-2011,08-SEP-2011,Not Specified,Not Specified,TPA2011A05202,-,-
8142006,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Bladder Cancer,Serious,Other Outcomes;Required Intervention,Female,-,08-SEP-2011,Expedited,75 YR,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,24-AUG-2011,08-SEP-2011,Not Specified,Not Specified,TPA2011A05200,-,-
8114170,Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Cystitis;Bladder Cancer;Metastases To Retroperitoneum,Serious,Hospitalized;Disabled,Female,14-JUN-2011,07-SEP-2011,Expedited,72 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",Prednisone;Amlodipine;Opipramol;Levothyroxine Sodium;Simvastatin;Doxycycline Hydrochloride;Ibuprofen;Trental;Sulfamethoxazole\Trimethoprim;Diazepam;Insulin Nos;Clobutinol;Pantozol;Prednisolone;Ciprofloxacin,23-AUG-2011,18-AUG-2011,Not Specified,Not Specified,TPG2011A02252,-,-
8114198,Actoplus Met;Cymbalta,Duloxetine Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride;Gabapentin,Diabetic Neuropathy;Type 2 Diabetes Mellitus,Drug Interaction;Bedridden;Dehydration;Loss Of Consciousness;Limb Crushing Injury;Diabetes Mellitus Inadequate Control;Weight Decreased;Ankle Fracture;Hallucination;Lower Limb Fracture,Serious,Hospitalized;Disabled;Other Outcomes,Male,15-MAR-2011,31-AUG-2011,Expedited,Not Specified,Not Specified,Pfizer,Consumer,Not Specified,-,25-AUG-2011,31-AUG-2011,US,Not Specified,US-PFIZER INC-2011198187,-,-
8126356,-,Aspirin;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Condition Aggravated;Haematuria;Bladder Cancer,Serious,Hospitalized,Male,MAY-2008,26-AUG-2011,Expedited,52 YR,Not Specified,Takeda,Healthcare Professional,"Other,Health Professional ,Foreign",Ezetimibe And Simvastatin,15-AUG-2011,26-AUG-2011,Not Specified,Not Specified,TPG2011A02362,-,-
8123448,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Thyroid Neoplasm;Swelling,Serious,Other Outcomes;Required Intervention,Female,19-JUL-2011,25-AUG-2011,Expedited,70 YR,240 LB,Takeda,Consumer,Consumer,Levothyroxine Sodium,16-AUG-2011,25-AUG-2011,Not Specified,Not Specified,TPA2011A04970,-,-
8118404,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes;Required Intervention,Male,MAY-2011,25-AUG-2011,Expedited,64 YR,337 LB,Takeda,Healthcare Professional,"Company Representative ,Health Professional",Ibuprofen;Januvia;Zovirax;Norvasc;Folic Acid;Aspirin;Fenofibrate;Simvastatin,18-AUG-2011,23-AUG-2011,Not Specified,Not Specified,TPA2011A04849,-,-
8054144,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Atrioventricular Block,Serious,Died,Male,JUN-2011,25-AUG-2011,Expedited,0 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",-,09-AUG-2011,05-JUL-2011,Not Specified,Not Specified,THQ2011A03125,-,-
8115553,Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Metastases To Liver;Bladder Adenocarcinoma Stage Unspecified;Constipation;Metastases To Lung;Haematuria,Serious,Life Threatening,Male,FEB-2011,22-AUG-2011,Expedited,65 YR,Not Specified,Takeda,Healthcare Professional,"Other,Health Professional ,Foreign",-,08-AUG-2011,22-AUG-2011,Not Specified,Not Specified,LTI2011A00239,-,-
8048263,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus Inadequate Control,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Female,15-APR-2011,17-AUG-2011,Expedited,73 YR,168 LB,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,04-AUG-2011,05-JUL-2011,Not Specified,Not Specified,TPA2011A03244,-,-
8106844,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Repaglinide;Irbesartan;Celiprolol Hydrochloride;Simvastatin;Aspirin,Product Used For Unknown Indication,Bladder Transitional Cell Carcinoma Stage I,Serious,Hospitalized;Other Outcomes,Male,26-JUN-2009,16-AUG-2011,Expedited,64 YR,Not Specified,Aurobindo,Healthcare Professional,"Health Professional ,Foreign",-,03-AUG-2011,16-AUG-2011,Not Specified,Not Specified,AUR-APL-2011-04604,-,-
8106419,Celectol,Celiprolol Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride;Irbesartan;Simvastatin;Aspirin;Repaglinide,Type 2 Diabetes Mellitus,Bladder Neoplasm;Haematuria,Serious,Hospitalized,Male,26-JUN-2009,16-AUG-2011,Expedited,64 YR,Not Specified,Takeda,Healthcare Professional,"Other,Health Professional ,Foreign",-,03-AUG-2011,16-AUG-2011,Not Specified,Not Specified,LTI2011A00235,-,-
8101263,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer;Urinary Bladder Polyp;Haematuria,Serious,Required Intervention,Male,24-MAR-2011,12-AUG-2011,Expedited,69 YR,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Foreign",Cozaar;Zocor;Kardegic;Nebivolol Hydrochloride,28-JUL-2011,12-AUG-2011,Not Specified,Not Specified,LTI2011A00096,-,-
8088110,Celectol,Celiprolol Hydrochloride;Simvastatin;Metformin Hydrochloride\Pioglitazone Hydrochloride;Aspirin;Repaglinide;Irbesartan,Type 2 Diabetes Mellitus,Bladder Neoplasm;Bladder Transitional Cell Carcinoma Stage Iii,Serious,Hospitalized,Not Specified,26-JUN-2009,12-AUG-2011,Expedited,Not Specified,Not Specified,Novo Nordisk,Healthcare Professional,Health Professional,-,04-AUG-2011,12-AUG-2011,FR,Not Specified,FR-NOVOPROD-333189,-,-
8095013,Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Weight Increased;Headache;Eyelid Oedema;Blood Urine Present;Visual Impairment;Insomnia;Abdominal Distension,Serious,Hospitalized;Other Outcomes,Female,MAR-2010,09-AUG-2011,Expedited,37 YR,Not Specified,Takeda,Not Specified,Foreign,-,01-AUG-2011,09-AUG-2011,Not Specified,Not Specified,LTI2011A00221,-,-
8080745,Celectol,Celiprolol Hydrochloride;Irbesartan;Metformin Hydrochloride\Pioglitazone Hydrochloride;Repaglinide;Simvastatin;Aspirin,-,Bladder Neoplasm,Serious,Hospitalized,Male,26-JUN-2009,08-AUG-2011,Expedited,64 YR,Not Specified,Bristol Myers Squibb,Consumer,Not Specified,-,03-AUG-2011,08-AUG-2011,FR,Not Specified,FR-BRISTOL-MYERS SQUIBB COMPANY-15949670,-,-
8076216,Actoplus Met;Niaspan,Niacin;Metformin Hydrochloride\Pioglitazone Hydrochloride,Blood Cholesterol Increased;Product Used For Unknown Indication,Tremor;Diarrhoea;Dizziness;Blood Glucose Decreased;Fatigue,Non-Serious,Non-Serious,Male,25-JAN-2011,06-AUG-2011,Non-Expedited,45 YR,Not Specified,Abbott,Consumer,Not Specified,-,31-JAN-2011,06-AUG-2011,US,Not Specified,US-ABBOTT-11P-163-0701429-00,-,-
8059764,Multi-Vitamin;Actoplus Met,"Metformin Hydrochloride\Pioglitazone Hydrochloride;.Alpha.-Tocopherol Acetate, Dl-\Ascorbic Acid\Cyanocobalamin\Fluoride Ion\Folic Acid\Niacin\Pyridoxine\Riboflavin\Thiamine\Vitamin A\Vitamin D",Glucose Tolerance Impaired,Oropharyngeal Pain;Oedema Peripheral;Headache;Pulmonary Embolism;Deep Vein Thrombosis,Serious,Died,Male,2011,04-AUG-2011,Expedited,34 YR,378 LB,-,Healthcare Professional,"Company Representative ,Health Professional",Norvasc;Depo-Testosterone;Ergocalciferol;Altace,20-JUL-2011,15-JUL-2011,Not Specified,Not Specified,TPA2011A02064,-,-
7986910,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Fall;Humerus Fracture,Serious,Hospitalized,Female,03-APR-2011,29-JUL-2011,Expedited,67 YR,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Foreign",Pravastatin;Olmesartan Medoxomil,15-JUL-2011,23-MAY-2011,Not Specified,Not Specified,TPG2011A00951,-,-
8079832,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Treatment Noncompliance;Bladder Cancer,Serious,Required Intervention,Female,DEC-2009,28-JUL-2011,Expedited,Not Specified,Not Specified,Takeda,Consumer,"Company Representative ,Consumer",Lisinopril;Singulair,15-JUL-2011,28-JUL-2011,Not Specified,Not Specified,TPA2011A03930,-,-
8054966,Avandamet,Metformin Hydrochloride\Rosiglitazone Maleate;Metformin Hydrochloride\Pioglitazone Hydrochloride;Repaglinide,Diabetes Mellitus,Myocardial Ischaemia;Cardiac Failure,Serious,Life Threatening,Male,07-JUN-2011,26-JUL-2011,Expedited,74 YR,Not Specified,Glaxosmithkline,Healthcare Professional,Health Professional,Simvastatin,19-JUL-2011,26-JUL-2011,IT,Not Specified,IT-GLAXOSMITHKLINE-B0735074A,-,-
8054951,Avandamet,Metformin Hydrochloride\Rosiglitazone Maleate;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Haematuria;Papillary Tumour Of Renal Pelvis,Serious,Life Threatening,Male,01-JAN-2008,26-JUL-2011,Expedited,61 YR,Not Specified,Glaxosmithkline,Healthcare Professional,Health Professional,-,18-JUL-2011,26-JUL-2011,FR,Not Specified,FR-GLAXOSMITHKLINE-B0733497A,-,-
8070544,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Bcg Vaccine,Bladder Cancer;Type 2 Diabetes Mellitus,"Dizziness;Influenza Like Illness;Weight Decreased;Bladder Cancer Stage 0, With Cancer In Situ",Serious,Required Intervention;Other Outcomes,Female,-,22-JUL-2011,Expedited,59 YR,130 LB,Takeda,Healthcare Professional,"Consumer,Health Professional",Vytorin;Actonel;Multi-Vitamin;Venlafaxine;Ramipril,18-JUL-2011,22-JUL-2011,Not Specified,Not Specified,TPA2011A03754,-,-
8066041,Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Transitional Cell Carcinoma,Serious,Hospitalized,Male,APR-2011,22-JUL-2011,Expedited,72 YR,Not Specified,Takeda,Not Specified,"Other,Health Professional ,Foreign",Allopurinol;Glucovance;Levothyroxine Sodium,11-JUL-2011,22-JUL-2011,Not Specified,Not Specified,LTI2011A00196,-,-
8039527,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Transitional Cell Carcinoma;Urinary Bladder Polyp,Serious,Other Outcomes,Male,06-APR-2011,21-JUL-2011,Expedited,59 YR,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Foreign",Irbesartan;Aldactone;Gliclazide;Aspirin;Urapidil;Furosemide;Omeprazole Sodium;Potassium Chloride;Kerlone,07-JUL-2011,30-JUN-2011,Not Specified,Not Specified,LTI2011A00161,-,-
8051862,Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Transitional Cell Carcinoma;Haematuria,Serious,Required Intervention;Other Outcomes,Male,05-FEB-2011,19-JUL-2011,Expedited,59 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",Tenormin;Crestor;Aspirin;Ramipril;Amaryl,04-JUL-2011,12-JUL-2011,Not Specified,Not Specified,LTI2011A00182,-,-
8059424,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Dyspepsia;Abdominal Pain Upper,Serious,Other Outcomes,Female,MAY-2011,18-JUL-2011,Expedited,Not Specified,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",Glimepiride;Exforge;Nexium,01-JUL-2011,18-JUL-2011,Not Specified,Not Specified,THQ2011A03487,-,-
8041067,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Drug Hypersensitivity,Serious,Other Outcomes,Female,31-MAY-2011,18-JUL-2011,Expedited,45 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",-,01-JUL-2011,05-JUL-2011,Not Specified,Not Specified,THQ2011A03124,-,-
8054200,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Bladder Neoplasm,Serious,Other Outcomes;Required Intervention,Male,APR-2011,12-JUL-2011,Expedited,58 YR,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,28-JUN-2011,12-JUL-2011,Not Specified,Not Specified,TPA2011A03637,-,-
8051945,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Adenocarcinoma Stage Unspecified,Serious,Other Outcomes;Life Threatening,Male,27-JUN-2011,12-JUL-2011,Expedited,61 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",Simvastatin;Fenofibrate;Perindopril Erbumine;Haloperidol;Nebivolol Hydrochloride;Sulpiride;Cipralex,27-JUN-2011,12-JUL-2011,Not Specified,Not Specified,ERD2011A00235,-,-
8049188,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes;Required Intervention,Male,-,11-JUL-2011,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,24-JUN-2011,11-JUL-2011,Not Specified,Not Specified,TPA2011A03456,-,-
8049536,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Transitional Cell Carcinoma Stage I,Serious,Other Outcomes,Male,17-FEB-2011,08-JUL-2011,Expedited,71 YR,Not Specified,Takeda,Not Specified,"Other,Health Professional ,Foreign",Omeprazole;Crestor;Propranolol;Aspirin,04-JUL-2011,08-JUL-2011,Not Specified,Not Specified,LTI2011A00158,-,-
8047609,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Male,2008,08-JUL-2011,Expedited,63 YR,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,23-JUN-2011,08-JUL-2011,Not Specified,Not Specified,TPA2011A03405,-,-
8044957,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Male,2010,07-JUL-2011,Expedited,73 YR,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",Coreg;Nasonex;Diovan Hct;Aspirin;Tamsulosin Hydrochloride;Lipitor;Norvasc,21-JUN-2011,07-JUL-2011,Not Specified,Not Specified,TPA2011A03332,-,-
7991615,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Prostate Cancer;Bladder Transitional Cell Carcinoma;Urinary Tract Infection,Serious,Other Outcomes;Required Intervention,Male,APR-2011,05-JUL-2011,Expedited,59 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",Aspirin;Crestor,20-JUN-2011,26-MAY-2011,Not Specified,Not Specified,LTI2011A00121,-,-
8039685,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Haematuria;Transitional Cell Carcinoma,Serious,Required Intervention,Male,27-NOV-2009,30-JUN-2011,Expedited,62 YR,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Foreign",-,15-JUN-2011,30-JUN-2011,Not Specified,Not Specified,LTI2011A00162,-,-
8018800,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Hospitalized;Required Intervention;Life Threatening,Male,11-MAR-2011,29-JUN-2011,Expedited,65 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",-,14-JUN-2011,16-JUN-2011,Not Specified,Not Specified,LTI2011A00141,-,-
7950704,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Transitional Cell Carcinoma;Diverticulum Intestinal,Serious,Life Threatening;Hospitalized,Male,07-MAR-2011,29-JUN-2011,Expedited,71 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",Glyburide;Crestor,15-JUN-2011,29-APR-2011,Not Specified,Not Specified,LTI2011A00099,-,-
7999303,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Acute Pulmonary Oedema;Abdominal Distension;Cholelithiasis;Aortic Stenosis;Cardiac Failure,Serious,Hospitalized,Female,APR-2011,24-JUN-2011,Expedited,80 YR,Not Specified,Takeda,Not Specified,"Other,Health Professional ,Foreign",-,09-JUN-2011,02-JUN-2011,Not Specified,Not Specified,LTI2011A00127,-,-
8024976,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Transitional Cell Carcinoma,Serious,Life Threatening,Male,30-APR-2010,21-JUN-2011,Expedited,66 YR,Not Specified,Takeda,Not Specified,"Other,Health Professional ,Foreign",Valsartan;Metformin Hydrochloride;Atorvastatin Calcium,06-JUN-2011,21-JUN-2011,Not Specified,Not Specified,LTI2011A00146,-,-
8018808,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Male,2009,16-JUN-2011,Expedited,80 YR,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Foreign",-,01-JUN-2011,16-JUN-2011,Not Specified,Not Specified,LTI2011A00139,-,-
8001527,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Prostate Cancer Metastatic;Metastases To Urinary Tract;Bladder Transitional Cell Carcinoma,Serious,Other Outcomes;Hospitalized,Male,2010,15-JUN-2011,Expedited,67 YR,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Foreign",Aspirin,31-MAY-2011,27-MAY-2011,Not Specified,Not Specified,LTI2011A00124,-,-
8007564,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Myocardial Infarction,Serious,Hospitalized,Male,20-MAY-2011,09-JUN-2011,Expedited,54 YR,282 LB,Takeda,Not Specified,"Company Representative ,Health Professional",Simvastatin;Glyburide,26-MAY-2011,09-JUN-2011,Not Specified,Not Specified,TPA2011A02709,-,-
8007557,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Latanoprost,Glaucoma;Type 2 Diabetes Mellitus,Weight Increased;Intraocular Pressure Increased,Serious,Required Intervention;Other Outcomes,Female,2011,09-JUN-2011,Expedited,61 YR,182 LB,Takeda,Not Specified,Consumer,Metformin Hydrochloride;Lisinopril And Hydrochlorothiazide;Norvasc,01-JUN-2011,09-JUN-2011,Not Specified,Not Specified,TPA2011A02770,-,-
7994181,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Oedema Peripheral;Weight Increased;Depression;Joint Range Of Motion Decreased;Muscular Weakness;Sleep Disorder;Lethargy;Muscle Spasms;Myalgia,Serious,Other Outcomes,Female,03-JUN-2011,08-JUN-2011,Direct,49 YR,326 LB,-,Healthcare Professional,Health Professional,-,-,08-JUN-2011,Not Specified,Not Specified,-,-,-
7888752,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Chest Pain;Urticaria,Serious,Hospitalized,Female,27-FEB-2011,08-JUN-2011,Expedited,62 YR,Not Specified,Takeda,Healthcare Professional,"Other,Health Professional ,Foreign",Hydrochlorothiazide\Olmesartan Medoxomil;Vytorin,25-MAY-2011,15-MAR-2011,Not Specified,Not Specified,TIF2011A00050,-,-
7994303,Avandamet,Metformin Hydrochloride\Rosiglitazone Maleate;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Haematuria;Bladder Cancer,Serious,Other Outcomes;Required Intervention;Life Threatening,Male,MAY-2008,25-MAY-2011,Expedited,64 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",-,17-MAY-2011,25-MAY-2011,Not Specified,Not Specified,LIT2011A00105,-,-
7991889,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Weight Increased;Myocardial Infarction;Alopecia;Dyspnoea,Serious,Required Intervention,Female,2009,24-MAY-2011,Expedited,76 YR,Not Specified,Takeda,Not Specified,Foreign,Glucophage;Gliclazide,10-MAY-2011,24-MAY-2011,Not Specified,Not Specified,LTI2011A00118,-,-
8170725,Lisinopril And Hydrochlorothiazide,Hydrochlorothiazide\Lisinopril;Metformin Hydrochloride\Pioglitazone Hydrochloride;Latanoprost,Glaucoma;Hypertension;Type 2 Diabetes Mellitus,Weight Increased;Intraocular Pressure Increased;Drug Ineffective,Serious,Other Outcomes,Female,01-JAN-2011,23-MAY-2011,Expedited,60 YR,82.54 KG,Pfizer,Consumer,Not Specified,Metformin Hydrochloride;Metoprolol;Norvasc,16-MAY-2011,23-MAY-2011,US,Not Specified,US-PFIZER INC-2011106587,-,-
7985789,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Haematuria;Bladder Transitional Cell Carcinoma,Serious,Hospitalized;Other Outcomes,Male,20-NOV-2009,19-MAY-2011,Expedited,72 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",Indapamide;Ramipril;Sectral;Plavix;Ezetimibe And Simvastatin,03-MAY-2011,18-FEB-2011,Not Specified,Not Specified,LTI2011A00035,-,-
7977995,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Male,2010,13-MAY-2011,Expedited,64 YR,Not Specified,Takeda,Not Specified,Foreign,-,28-APR-2011,13-MAY-2011,Not Specified,Not Specified,LTI2011A00105,-,-
7969896,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Lactic Acidosis,Serious,Died,Male,-,13-MAY-2011,Expedited,4 DEC,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,29-APR-2011,13-MAY-2011,Not Specified,Not Specified,TPA2011A01958,-,-
7965189,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer,Serious,Other Outcomes,Male,2008,11-MAY-2011,Expedited,Not Specified,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",-,29-APR-2011,11-MAY-2011,Not Specified,Not Specified,LTI2011A00104,-,-
7931338,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Death,Serious,Died,Female,-,13-APR-2011,Expedited,62 YR,Not Specified,Takeda,Not Specified,Health Professional,-,11-APR-2011,13-APR-2011,Not Specified,Not Specified,TPA2011A00748,-,-
7929582,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Hypertension;Condition Aggravated,Serious,Other Outcomes;Required Intervention,Female,02-MAR-2011,13-APR-2011,Expedited,63 YR,Not Specified,Takeda,Not Specified,"Other,Health Professional ,Foreign",Clomipramine Hydrochloride;Captopril;Escitalopram Oxalate;Rabeprazole Sodium,30-MAR-2011,13-APR-2011,Not Specified,Not Specified,ERD2011A00133,-,-
7919762,Byetta;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Glipizide;Exenatide;Metformin Hydrochloride;Sitagliptin,Type 2 Diabetes Mellitus,Chronic Obstructive Pulmonary Disease;Condition Aggravated;Bronchitis Chronic;Visual Acuity Reduced;Weight Increased;Asthma;Pneumonia;Diabetes Mellitus Inadequate Control;Presyncope;Uterine Leiomyoma,Serious,Required Intervention;Other Outcomes,Female,JUL-2009,06-APR-2011,Expedited,56 YR,89.8 KG,Takeda,Consumer,Consumer,-,25-MAR-2011,06-APR-2011,Not Specified,Not Specified,TPA2011A01242,-,-
7916304,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus Management,Oedema Peripheral;Oedema;Pulmonary Oedema;Cardiac Failure Congestive,Serious,Required Intervention;Life Threatening;Hospitalized;Other Outcomes,Female,03-FEB-2011,15-MAR-2011,Direct,50 YR,347 LB,-,Consumer,Not Specified,-,-,15-MAR-2011,Not Specified,Not Specified,-,-,-
7840726,Lisinopril And Hydrochlorothiazide;Salicylate;Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Salicylic Acid;Hydrochlorothiazide\Lisinopril;Alcohol;Hydrochlorothiazide;Atenolol;Ibuprofen;Acetaminophen\Diphenhydramine;Diphenhydramine,Product Used For Unknown Indication,Completed Suicide,Serious,Died,Female,-,04-MAR-2011,Expedited,44 YR,Not Specified,Ranbaxy,Healthcare Professional,Health Professional,-,22-FEB-2011,04-MAR-2011,US,Not Specified,US-RANBAXY-2011US-42465,"Bronstein AC., et al. 2009 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 27th Annual Report. Clinical Toxicology (2010). 2010; 48; 979-1178",-
7916299,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Condition Aggravated;Hyperhidrosis;Hypervolaemia;Cardiac Failure Congestive,Serious,Hospitalized,Male,21-FEB-2011,25-FEB-2011,Direct,65 YR,219 LB,-,Healthcare Professional,Health Professional,Klor-Con;Simvastatin;Carvedilol;Lisinopril;Aspirin;Torsemide,-,25-FEB-2011,Not Specified,Not Specified,-,-,-
7802427,Lisinopril And Hydrochlorothiazide,Hydrochlorothiazide\Lisinopril;Hydrochlorothiazide;Diphenhydramine;Ibuprofen;Acetaminophen\Diphenhydramine Hydrochloride;Atenolol;Metformin Hydrochloride\Pioglitazone Hydrochloride;Alcohol;Unspecified Ingredient,-,Completed Suicide,Serious,Died,Female,-,08-FEB-2011,Expedited,44 YR,Not Specified,Novartis,Healthcare Professional,Health Professional,-,31-JAN-2011,07-FEB-2011,US,Not Specified,CHPA2011US01847,"BRONSTEIN AC, SPYKER DA, CANTILENA LR, GREEN JL, RUMACK BH, GIFFIN SL. 2009 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 27th Annual Report. Clinical Toxicology. 2010;48:979-1178",-
7839265,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Glomerular Filtration Rate Decreased,Serious,Required Intervention;Other Outcomes,Female,-,07-FEB-2011,Expedited,64 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",Amlodipine;Simvastatin;Aspirin;Losartan;Atenolol,28-JAN-2011,07-FEB-2011,Not Specified,Not Specified,TUK2011A00010,-,-
7838575,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Benign Prostatic Hyperplasia,Serious,Hospitalized,Male,JAN-2011,07-FEB-2011,Expedited,60 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",Atorvastatin Calcium;Lovaza;Nifedipine;Nicorandil;Pentoxifylline;Sarpogrelate Hydrochloride,25-JAN-2011,04-FEB-2011,Not Specified,Not Specified,THQ2011A00243,-,-
7819133,Competact;Lisinopril And Hydrochlorothiazide,Hydrochlorothiazide\Lisinopril;Ibuprofen;Alcohol;Metformin Hydrochloride\Pioglitazone Hydrochloride;Hydrochlorothiazide;Atenolol;Acetaminophen\Diphenhydramine;Aspirin;Diphenhydramine,-,Toxicity To Various Agents;Completed Suicide,Serious,Died,Female,-,26-JAN-2011,Expedited,44 YR,Not Specified,Aurobindo,Healthcare Professional,"Other,Health Professional ,Literature",-,31-DEC-2010,26-JAN-2011,Not Specified,Not Specified,AUR-APL-2011-00167,-,-
7755522,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride;Acetaminophen\Diphenhydramine;Ibuprofen;Atenolol;Diphenhydramine;Alcohol;Hydrochlorothiazide\Lisinopril,Product Used For Unknown Indication;Suicide Attempt,Toxicity To Various Agents;Completed Suicide,Serious,Died,Female,-,11-JAN-2011,Expedited,44 YR,Not Specified,Mcneil,Healthcare Professional,Health Professional,Hydrochlorothiazide,31-DEC-2010,11-JAN-2011,US,Not Specified,US-JNJFOC-20110101620,"Bronstein AC, Spyker DA, Cantilena LR, Green JL, Rumack BH, Giffin SL. 2009 Annual Report of the American Association of Poison Control Centers National Poison. Clinical Toxicology Dec-2010;48(10):979-1178.",-
7763829,Salicylates Nos;Lisinopril And Hydrochlorothiazide,Hydrochlorothiazide\Lisinopril;Diphenhydramine;Acetaminophen\Diphenhydramine Hydrochloride;Alcohol;Unspecified Ingredient;Metformin Hydrochloride\Pioglitazone Hydrochloride;Atenolol;Hydrochlorothiazide;Ibuprofen,Product Used For Unknown Indication,Death;Completed Suicide,Serious,Died,Female,-,10-JAN-2011,Expedited,44 YR,Not Specified,Par,Healthcare Professional,Health Professional,-,30-DEC-2010,10-JAN-2011,US,Not Specified,"US-PAR PHARMACEUTICAL, INC-2011SCPR002374","Bronstein A.C., Spyker D.A., Cantilena L.R., Green J.L., Rumack B.H., Giffin S.L.. 2009 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 27th Annual Report. Clinical Toxicology. 2010; 48 (10); 979-1178",-
7752700,Acetaminophen And Diphenhydramine Hydrochloride,Acetaminophen\Diphenhydramine Hydrochloride;Atenolol;Alcohol;Aspirin;Hydrochlorothiazide;Ibuprofen;Metformin Hydrochloride\Pioglitazone Hydrochloride;Diphenhydramine;Hydrochlorothiazide\Lisinopril,-,Completed Suicide,Serious,Died,Female,2009,07-JAN-2011,Expedited,44 YR,Not Specified,Pfizer,Healthcare Professional,Not Specified,-,31-DEC-2010,07-JAN-2011,US,Not Specified,US-PFIZER INC-2011001742,"Alvin C Bronstein, MD. 2009 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 27th Annual Report. Clinical Toxicology. 2010;48:979 - 1178",-
7749259,Competact;Salicylate;Lisinopril And Hydrochlorothiazide,Hydrochlorothiazide\Lisinopril;Alcohol;Salicylic Acid;Acetaminophen\Diphenhydramine;Diphenhydramine;Ibuprofen;Metformin Hydrochloride\Pioglitazone Hydrochloride;Hydrochlorothiazide;Atenolol,-,Completed Suicide;Toxicity To Various Agents,Serious,Died,Female,-,05-JAN-2011,Expedited,44 YR,Not Specified,Astrazeneca,Healthcare Professional,Health Professional,-,31-DEC-2010,05-JAN-2011,US,Not Specified,US-ASTRAZENECA-2011SE00288,-,-
7793887,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Hyperhidrosis;Nausea;Abdominal Pain;Chest Pain;Myocardial Infarction,Serious,Other Outcomes,Male,02-NOV-2010,21-DEC-2010,Expedited,63 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",Gliclazide;Irbesartan;Atorvastatin;Ezetimibe,14-DEC-2010,21-DEC-2010,Not Specified,Not Specified,TUK2010A00299,-,-
7762036,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Diabetes Mellitus,Oedema Peripheral;Joint Swelling;Weight Increased;Dyspnoea;Foot Fracture,Serious,Other Outcomes,Female,-,21-DEC-2010,Direct,Not Specified,249 LB,-,Not Specified,Not Specified,-,-,21-DEC-2010,Not Specified,Not Specified,-,-,-
7756428,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Atrioventricular Block Complete;Acute Myocardial Infarction,Serious,Hospitalized,Female,01-NOV-2010,16-DEC-2010,Expedited,69 YR,Not Specified,Takeda,Not Specified,"Other,Health Professional ,Foreign",Atorvastatin Calcium;Arimidex,06-DEC-2010,16-DEC-2010,Not Specified,Not Specified,TIF2010A00142,-,-
7689703,"Actoplus Met;Influenza Virus Vaccine, Swine Nos","Influenza Virus Vaccine, Swine;Metformin Hydrochloride\Pioglitazone Hydrochloride;Ketoprofen;Irbesartan",Arthralgia;H1n1 Influenza;Hypertension;Type 2 Diabetes Mellitus,Cholestasis;Acute Kidney Injury;Coma Acidotic;Lactic Acidosis;Hepatic Cytolysis,Serious,Hospitalized;Life Threatening,Male,22-NOV-2009,07-DEC-2010,Expedited,40 YR,Not Specified,Bristol Myers Squibb,Consumer,Not Specified,Akineton;Amisulpride;Pravigard Pac;Celebrex;Alfuzosin,30-NOV-2010,02-DEC-2010,FR,Not Specified,FR-BRISTOL-MYERS SQUIBB COMPANY-15407703,-,-
7743762,"Influenza Virus Vaccine, Swine Nos","Influenza Virus Vaccine, Swine;Metformin Hydrochloride\Pioglitazone Hydrochloride;Irbesartan",Hypertension;Influenza Immunisation;Type 2 Diabetes Mellitus,Pneumonia;Haemodynamic Instability;Pulmonary Oedema;Respiratory Distress;Hepatic Cytolysis;Normochromic Normocytic Anaemia;Septic Shock;Arthralgia;Asthenia;Coma Acidotic;Acute Kidney Injury;Body Temperature Decreased;Cholestasis;Vomiting Projectile;Gait Disturbance;Dialysis;Incoherent;Lactic Acidosis;Complex Regional Pain Syndrome;Inflammation,Serious,Hospitalized;Life Threatening,Male,22-NOV-2009,03-DEC-2010,Expedited,40 YR,Not Specified,Takeda,Not Specified,"Other,Health Professional ,Foreign",Akineton,24-NOV-2010,03-DEC-2010,Not Specified,Not Specified,LTI2010A00240,-,-
7192634,Competact;Crestor;Bisoprolol,Bisoprolol\Bisoprolol Fumarate;Allopurinol;Rosuvastatin Calcium;Metformin Hydrochloride\Pioglitazone Hydrochloride;Furosemide;Nitroglycerin;Fluindione;Perindopril Erbumine,Type 2 Diabetes Mellitus,Aspartate Aminotransferase Increased;Alanine Aminotransferase Increased;Haemodynamic Instability;Lactic Acidosis;Septic Shock;Haemodialysis;Hyperkalaemia;Hypercalcaemia;Postoperative Renal Failure;Acute Kidney Injury,Serious,Life Threatening;Died,Female,08-SEP-2009,22-NOV-2010,Expedited,76 YR,120 KG,Astrazeneca,Healthcare Professional,Health Professional,-,25-NOV-2009,30-NOV-2009,FR,Not Specified,FR-ASTRAZENECA-2009SE28767,-,-
7751201,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Fluid Retention;Hypertension;Cardiac Failure,Serious,Hospitalized,Female,01-OCT-2010,19-NOV-2010,Expedited,65 YR,Not Specified,Takeda,Not Specified,"Other,Health Professional ,Foreign",Insulin Nos,12-NOV-2010,19-NOV-2010,Not Specified,Not Specified,TIF2010A00115,-,-
7711824,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Pain In Extremity;Erectile Dysfunction;Pain;Muscle Spasms;Paraesthesia,Serious,Disabled,Male,-,17-NOV-2010,Expedited,62 YR,Not Specified,Takeda,Not Specified,Foreign,Tegretol,05-NOV-2010,17-NOV-2010,Not Specified,Not Specified,TPG2010A00632,-,-
7707052,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Hyperhidrosis;Abdominal Pain Upper;Chest Pain;Nausea,Serious,Other Outcomes,Male,02-NOV-2010,16-NOV-2010,Expedited,Not Specified,Not Specified,Takeda,Not Specified,Foreign,-,03-NOV-2010,16-NOV-2010,Not Specified,Not Specified,TUK2010A00299,-,-
7671873,Actoplus Met;Simcor,Niacin\Simvastatin;Metformin Hydrochloride\Pioglitazone Hydrochloride,Dyslipidaemia;Product Used For Unknown Indication,Fatigue;Flushing;Erythema;Constipation;Back Pain,Non-Serious,Non-Serious,Female,-,16-NOV-2010,Non-Expedited,Not Specified,95.34 KG,Abbott,Consumer,Not Specified,Vitamin B12;Spironolactone;Vitamin D2;Victoza,15-SEP-2010,16-NOV-2010,US,Not Specified,US-ABBOTT-10P-163-0670880-00,-,-
8170724,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Dysentery,Serious,Required Intervention,Male,-,12-NOV-2010,Expedited,50 YR,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Foreign",-,02-NOV-2010,12-NOV-2010,Not Specified,Not Specified,TIF2010A00113,-,-
7609832,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Hypoglycaemia;Brain Injury,Serious,Hospitalized;Disabled,Male,-,04-NOV-2010,Expedited,Not Specified,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",-,26-OCT-2010,15-SEP-2010,Not Specified,Not Specified,TPG2010A00450,-,-
7727760,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Ectopic Pregnancy;Abortion Spontaneous;Maternal Exposure During Pregnancy,Serious,Other Outcomes,Female,2009,01-NOV-2010,Expedited,34 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Study,Foreign",Glucobay;Lantus,15-NOV-2010,25-OCT-2010,Not Specified,Not Specified,THQ2010A01324,-,-
8170695,Januvia,Sitagliptin Phosphate;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 1 Diabetes Mellitus,Neural Tube Defect,Serious,Other Outcomes;Congenital Anomaly,Not Specified,22-OCT-2009,29-OCT-2010,Expedited,0 DAY,Not Specified,Merck,Healthcare Professional,Health Professional,-,25-OCT-2010,29-OCT-2010,FR,Not Specified,FR-MERCK-1010FRA00081B1,-,-
7680390,Januvia,Sitagliptin Phosphate;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Abortion Induced;Maternal Drugs Affecting Foetus;Congenital Musculoskeletal Disorder Of Skull;Neural Tube Defect,Serious,Congenital Anomaly;Other Outcomes,Female,22-OCT-2009,29-OCT-2010,Expedited,13 WEEK,Not Specified,Takeda,Not Specified,"Other,Health Professional ,Foreign",Novorapid;Insulatard Nph Human,13-OCT-2010,29-OCT-2010,Not Specified,Not Specified,LTI2010A00222,-,-
7643248,Imdur;Celebrex;Neurontin,Gabapentin;Celecoxib;Isosorbide Mononitrate;Metformin Hydrochloride\Pioglitazone Hydrochloride;Sitagliptin;Baclofen,Antiinflammatory Therapy;Diabetes Mellitus;Pain In Extremity,Weight Increased,Serious,Other Outcomes,Male,01-JAN-2009,27-OCT-2010,Non-Expedited,65 YR,113.38 KG,Pfizer,Consumer,Not Specified,-,20-OCT-2010,27-OCT-2010,US,Not Specified,US-PFIZER INC-2010133692,-,-
7672063,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Stevens-Johnson Syndrome,Serious,Other Outcomes,Male,07-OCT-2010,25-OCT-2010,Expedited,54 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",-,08-OCT-2010,25-OCT-2010,Not Specified,Not Specified,THQ2010A03081,-,-
7670042,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Bladder Cancer,Serious,Required Intervention;Other Outcomes,Not Specified,-,22-OCT-2010,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,12-OCT-2010,22-OCT-2010,Not Specified,Not Specified,TPA2010A05343,-,-
7653430,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Angioedema;Urticaria;Laryngeal Dyspnoea,Serious,Other Outcomes,Female,18-JUN-2010,07-OCT-2010,Expedited,53 YR,Not Specified,Takeda,Not Specified,"Other,Health Professional ,Foreign",Quinapril Hydrochloride;Spironolactone;Repaglinide;Allopurinol;Furosemide,22-SEP-2010,07-OCT-2010,Not Specified,Not Specified,LTI2010A00214,-,-
7621711,Actoplus Met;Atacand,Metformin Hydrochloride\Pioglitazone Hydrochloride;Candesartan Cilexetil;Indapamide,Hypertension;Type 2 Diabetes Mellitus,Psoriasis;Eczema,Serious,Hospitalized,Male,MAR-2010,23-SEP-2010,Expedited,61 YR,Not Specified,Takeda,Not Specified,"Other,Health Professional ,Foreign",Singulair;Cordarone;Seretide;Plavix;Glucophage;Diltiazem Hydrochloride;Nitroglycerin;Foradil;Repaglinide,09-SEP-2010,23-SEP-2010,Not Specified,Not Specified,LTI2010A00198,-,-
7620895,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Rib Fracture;Surgery;Staphylococcal Infection;Fall;Back Disorder;Abdominal Pain Lower;Osteopenia;Fatigue;Muscle Spasms,Serious,Required Intervention;Disabled,Female,2007,22-SEP-2010,Expedited,62 YR,Not Specified,Takeda,Consumer,Consumer,-,15-SEP-2010,22-SEP-2010,Not Specified,Not Specified,TPA2010A05022,-,-
7615783,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Bladder Cancer;Neoplasm,Serious,Other Outcomes,Male,18-JAN-2010,21-SEP-2010,Direct,65 YR,220 LB,-,Consumer,Not Specified,-,-,21-SEP-2010,Not Specified,Not Specified,-,-,-
7614704,Crestor;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Rosuvastatin Calcium;Bisoprolol Fumarate;Nitroglycerin;Fluindione;Furosemide;Perindopril Erbumine;Allopurinol,Type 2 Diabetes Mellitus,Hyperkalaemia;Pallor;Disorientation;Haemodynamic Instability;Lactic Acidosis;Septic Shock;Acute Kidney Injury;Haemodialysis;Asthenia;Electrolyte Imbalance;Syncope;Abdominal Pain;Diarrhoea;Hypotension;Hyperthermia,Serious,Life Threatening;Died,Female,08-SEP-2009,20-SEP-2010,Expedited,76 YR,Not Specified,Takeda,Not Specified,"Other,Health Professional ,Foreign",-,09-SEP-2010,20-SEP-2010,Not Specified,Not Specified,LTI2010A00203,-,-
7614529,Januvia;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Sitagliptin Phosphate;Metformin Hydrochloride,Type 1 Diabetes Mellitus,Acute Myocardial Infarction;Arteriosclerosis Coronary Artery;Amylase Increased;Lipase Increased,Serious,Hospitalized,Male,11-MAY-2009,20-SEP-2010,Expedited,46 YR,Not Specified,Takeda,Not Specified,"Other,Health Professional ,Foreign",Truvada;Viramune,09-SEP-2010,20-SEP-2010,Not Specified,Not Specified,LTI2010A00193,-,-
7614527,Actoplus Met;Glucovance,Glyburide\Metformin Hydrochloride;Spironolactone;Metformin Hydrochloride\Pioglitazone Hydrochloride,Hypertension;Type 2 Diabetes Mellitus,Pancreatitis Acute;Septic Shock;Respiratory Failure;Pancreatitis Necrotising;Hepatic Cytolysis;Acute Kidney Injury,Serious,Hospitalized;Life Threatening,Female,03-OCT-2007,20-SEP-2010,Expedited,69 YR,Not Specified,Takeda,Not Specified,"Other,Health Professional ,Foreign",-,09-SEP-2010,20-SEP-2010,Not Specified,Not Specified,LTI2010A00191,-,-
7614526,Copegus;Actoplus Met;Pegasys,Peginterferon Alfa-2a;Metformin Hydrochloride\Pioglitazone Hydrochloride;Ribavirin,Hepatitis C;Type 2 Diabetes Mellitus,Right Ventricular Failure;Influenza;Dyspnoea;Oedema Peripheral;Tachycardia;Pericarditis Constrictive;Pericardial Effusion,Serious,Hospitalized,Male,25-MAY-2009,20-SEP-2010,Expedited,39 YR,Not Specified,Takeda,Not Specified,"Other,Health Professional ,Foreign",Metformin Hydrochloride;Mianserin,09-SEP-2010,20-SEP-2010,Not Specified,Not Specified,LTI2010A00192,-,-
7612568,-,Diltiazem Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Hypertension;Type 2 Diabetes Mellitus,Pruritus;Rash,Serious,Hospitalized,Male,22-JUL-2010,17-SEP-2010,Expedited,76 YR,Not Specified,Takeda,Not Specified,"Other,Health Professional ,Foreign",Atenolol;Esomeprazole Magnesium;Aspirin Dl-Lysine;Atorvastatin Calcium,09-SEP-2010,17-SEP-2010,Not Specified,Not Specified,LTI2010A00197,-,-
7564781,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Pleural Effusion,Serious,Disabled,Male,26-JUL-2010,09-SEP-2010,Expedited,71 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",Gliclazide,29-AUG-2010,13-AUG-2010,Not Specified,Not Specified,TPG2010A00466,-,-
7575837,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Renal Disorder,Serious,Hospitalized,Female,26-JUL-2010,27-AUG-2010,Expedited,55 YR,104 LB,Takeda,Consumer,Consumer,-,18-AUG-2010,27-AUG-2010,Not Specified,Not Specified,TPA2010A04603,-,-
7572636,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Coronary Artery Occlusion,Serious,Hospitalized;Other Outcomes;Required Intervention,Male,FEB-2010,25-AUG-2010,Expedited,68 YR,275 LB,Takeda,Consumer,Consumer,Metformin Hydrochloride;Lisinopril,12-AUG-2010,25-AUG-2010,Not Specified,Not Specified,TPA2010A04490,-,-
7131299,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Diabetes Mellitus Inadequate Control;Renal Cancer,Serious,Other Outcomes,Male,JUN-2008,17-AUG-2010,Expedited,66 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",-,05-AUG-2010,14-APR-2009,Not Specified,Not Specified,LTI2009A00103,-,-
7552287,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Peripheral Coldness;Myalgia,Serious,Other Outcomes,Male,19-FEB-2010,13-AUG-2010,Expedited,60 YR,Not Specified,Takeda,Not Specified,"Other,Health Professional ,Foreign",Lipitor;Micardis,05-AUG-2010,13-AUG-2010,Not Specified,Not Specified,TUK2010A00226,-,-
7552235,Atacand;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Indapamide;Candesartan Cilexetil,-,Eczema,Serious,Hospitalized,Male,MAR-2010,13-AUG-2010,Expedited,61 YR,Not Specified,Takeda,Not Specified,"Other,Health Professional ,Foreign",Foradil;Plavix;Cordarone;Repaglinide;Nitroglycerin;Diltiazem Hydrochloride;Singulair;Glucophage,28-JUL-2010,13-AUG-2010,Not Specified,Not Specified,THQ2010A02165,-,-
7536447,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Visual Field Defect,Serious,Other Outcomes,Female,2010,10-AUG-2010,Expedited,56 YR,Not Specified,Takeda,Not Specified,Foreign,Gabapentin;Byetta;Omeprazole,27-JUL-2010,29-JUL-2010,Not Specified,Not Specified,THQ2010A01917,-,-
7504236,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Hepatic Cancer,Serious,Died,Male,-,09-AUG-2010,Expedited,65 YR,Not Specified,Takeda,Not Specified,Foreign,-,14-JUL-2010,09-JUL-2010,Not Specified,Not Specified,THQ2010A01801,-,-
7530467,Actoplus Met;Atacand,Candesartan Cilexetil;Indapamide;Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Eczema,Serious,Hospitalized,Male,01-MAR-2010,06-AUG-2010,Expedited,61 YR,Not Specified,Astrazeneca,Healthcare Professional,Health Professional,Repaglinide;Glucophage;Plavix;Diltiazem Hydrochloride;Singulair;Nitroglycerin;Seretide;Foradil;Cordarone,28-JUL-2010,06-AUG-2010,FR,Not Specified,FR-ASTRAZENECA-2010SE35556,-,-
7504231,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Candesartan Cilexetil\Hydrochlorothiazide,Diabetes Mellitus;Hypertension,Acute Kidney Injury,Serious,Hospitalized,Female,16-FEB-2010,20-JUL-2010,Expedited,73 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Study,Foreign",Amlodipine;Fluvastatin,13-JUL-2010,13-JUL-2010,Not Specified,Not Specified,TPG2010A00420,-,-
7998308,Candesartan Cilexetil And Hydrochlorothiazide,Candesartan Cilexetil\Hydrochlorothiazide;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Hypertension,Acute Kidney Injury,Serious,Other Outcomes,Female,16-FEB-2010,19-JUL-2010,Expedited,73 YR,96 KG,Astrazeneca,Healthcare Professional,Health Professional,Rilmenidine;Amlodipine;Fluvastatin,13-JUL-2010,13-JUL-2010,AT,Not Specified,JP-ASTRAZENECA-2010SE31933,-,-
7463516,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Pulmonary Arterial Hypertension;Coronary Artery Stenosis;Tachycardia,Serious,Life Threatening;Other Outcomes,Female,16-FEB-2010,30-JUN-2010,Expedited,60 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",Ezetimibe And Simvastatin;Ramipril;Insulatard Nph Human;Repaglinide,21-JUN-2010,30-JUN-2010,Not Specified,Not Specified,LTI2010A00140,-,-
7408870,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Erythema;Fatigue;Dehydration;Fluid Intake Reduced;Vomiting;Acute Kidney Injury;Mucosal Disorder;Hypophagia;Dialysis;Sinus Node Dysfunction,Serious,Hospitalized,Female,15-MAR-2010,16-JUN-2010,Expedited,71 YR,Not Specified,Takeda,Not Specified,"Other,Health Professional ,Foreign",Torsemide;Digitoxin,31-MAY-2010,27-MAY-2010,Not Specified,Not Specified,TPG2010A00343,-,-
7429475,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Myocardial Infarction;Coronary Artery Occlusion;Cardiac Failure Congestive,Serious,Hospitalized,Female,12-JAN-2010,15-JUN-2010,Expedited,62 YR,117 LB,Takeda,Consumer,Consumer,Levothyroxine Sodium,04-JUN-2010,15-JUN-2010,Not Specified,Not Specified,TPA2010A03430,-,-
7416063,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Skin Exfoliation;Fungal Infection;Penile Discharge;Therapeutic Response Decreased,Non-Serious,Non-Serious,Male,10-MAR-2010,03-JUN-2010,Direct,61 YR,250 LB,-,Not Specified,Not Specified,-,-,03-JUN-2010,Not Specified,Not Specified,-,-,-
7402097,Actoplus Met;Onglyza,Saxagliptin Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Drug Ineffective,Non-Serious,Non-Serious,Not Specified,-,27-MAY-2010,Non-Expedited,Not Specified,Not Specified,Bristol Myers Squibb,Healthcare Professional,Health Professional,-,09-APR-2010,27-MAY-2010,US,Not Specified,US-BRISTOL-MYERS SQUIBB COMPANY-15059967,-,-
7402041,Onglyza;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Saxagliptin Hydrochloride,-,Blood Glucose Increased,Non-Serious,Non-Serious,Not Specified,-,27-MAY-2010,Non-Expedited,Not Specified,Not Specified,Bristol Myers Squibb,Consumer,Not Specified,-,23-FEB-2010,27-MAY-2010,US,Not Specified,US-BRISTOL-MYERS SQUIBB COMPANY-14989164,-,-
7396625,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Hypoglycaemia,Non-Serious,Non-Serious,Male,2007,14-MAY-2010,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,05-MAY-2010,14-MAY-2010,Not Specified,Not Specified,TPA2010A02638,-,-
7448487,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Tamsulosin Hydrochloride,Product Used For Unknown Indication,Muscle Necrosis;Acute Kidney Injury;Rhabdomyolysis,Serious,Hospitalized;Disabled,Male,01-FEB-2010,06-APR-2010,Expedited,60 YR,Not Specified,Takeda,Healthcare Professional,"Other,Health Professional ,Foreign",Simvastatin;Ramipril,22-MAR-2010,06-APR-2010,Not Specified,Not Specified,TUK2010A00039,-,-
7330776,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Syncope;Subdural Haematoma;Fall;Bundle Branch Block Left;Head Injury;Meningorrhagia;Myocardial Infarction,Serious,Life Threatening;Hospitalized,Male,17-JAN-2010,16-MAR-2010,Expedited,80 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",Fluindione;Acetaminophen;Advil;Allopurinol;Chondroitin Sulfate (Bovine);Bisoprolol Fumarate,09-MAR-2010,05-MAR-2010,Not Specified,Not Specified,LTI2010A00041,-,-
7320458,Actoplus Met;Micardis,Telmisartan;Metformin Hydrochloride\Pioglitazone Hydrochloride,Hypertension;Type 2 Diabetes Mellitus,Diarrhoea,Non-Serious,Non-Serious,Female,01-MAR-2010,15-MAR-2010,Non-Expedited,54 YR,Not Specified,Boehringer Ingelheim,Consumer,Not Specified,-,02-MAR-2010,15-MAR-2010,US,Not Specified,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2010-BP-02562BP",-,-
7292341,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Metformin Hydrochloride,Diabetes Mellitus,Swelling;Rash,Non-Serious,Non-Serious,Female,01-NOV-2008,24-FEB-2010,Non-Expedited,56 YR,Not Specified,Bristol Myers Squibb,Consumer,Not Specified,-,11-AUG-2009,24-FEB-2010,US,Not Specified,US-BRISTOL-MYERS SQUIBB COMPANY-14727598,-,-
7362520,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Repaglinide,Diabetes Mellitus,Acute Kidney Injury;Shock;Lactic Acidosis;Haemodialysis,Serious,Life Threatening;Hospitalized,Female,25-JAN-2010,12-FEB-2010,Expedited,66 YR,Not Specified,Takeda,Healthcare Professional,"Other,Health Professional ,Foreign",Lyrica,01-FEB-2010,12-FEB-2010,Not Specified,Not Specified,TIF2010A00008,-,-
7271538,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Normochromic Normocytic Anaemia,Serious,Other Outcomes,Female,DEC-2007,22-JAN-2010,Expedited,58 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",Levothyroxine Sodium;Simvastatin;Diovan Hct;Bisoprolol Fumarate,12-JAN-2010,22-JAN-2010,Not Specified,Not Specified,TPG2009A00866,-,-
7138401,Rosiglitazone Maleate And Metformin Hydrochloride,Metformin Hydrochloride\Rosiglitazone Maleate;Metformin Hydrochloride\Pioglitazone Hydrochloride,Blood Cholesterol;Blood Pressure Measurement;Depression;Diabetes Mellitus;Gastrooesophageal Reflux Disease;Pain;Product Used For Unknown Indication,Pernicious Anaemia,Serious,Other Outcomes,Male,08-OCT-2008,07-JAN-2010,Expedited,56 YR,93 KG,Glaxosmithkline,Healthcare Professional,Health Professional,Atorvastatin;Hydroxocobalamin;Aspirin;Omeprazole;Ramipril;Simvastatin;Atenolol;Indapamide;Mirtazapine;Felodipine;Cocodamol,04-JAN-2010,02-OCT-2009,GB,Not Specified,B0595996A,-,-
7235208,Crestor;Competact;Bisoprolol,Bisoprolol\Bisoprolol Fumarate;Metformin Hydrochloride\Pioglitazone Hydrochloride;Allopurinol;Rosuvastatin Calcium;Fluindione;Nitroglycerin;Perindopril;Furosemide,-,Acute Kidney Injury;Hyperkalaemia,Serious,Died;Life Threatening,Female,09-SEP-2009,31-DEC-2009,Expedited,27773 DAY,120 KG,Astrazeneca,Healthcare Professional,Health Professional,-,28-DEC-2009,31-DEC-2009,FR,Not Specified,FR-ASTRAZENECA-2009SE33636,-,-
7231372,Crestor,Fluindione;Rosuvastatin Calcium;Furosemide;Perindopril;Metformin Hydrochloride\Pioglitazone Hydrochloride;Nitroglycerin;Bisoprolol Fumarate;Allopurinol,Product Used For Unknown Indication,Hyperkalaemia;Acute Kidney Injury,Serious,Died;Life Threatening,Female,09-SEP-2009,28-DEC-2009,Expedited,76 YR,120 KG,Aventis,Healthcare Professional,Health Professional,-,22-DEC-2009,28-DEC-2009,FR,Not Specified,FR-SANOFI-AVENTIS-2009SA010337,-,-
7362519,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Insulin-Requiring Type 2 Diabetes Mellitus,Myalgia;Weight Increased;Chest Discomfort;Induration;Respiratory Disorder;Diplegia;Gait Disturbance;Paraesthesia;Pharyngeal Oedema,Serious,Required Intervention,Male,DEC-2008,18-DEC-2009,Expedited,58 YR,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Foreign",Lansoprazole;Lantus;Fenofibrate,11-DEC-2009,18-DEC-2009,Not Specified,Not Specified,LTI2009A00307,-,-
7204456,Crestor;Bisoprolol,Bisoprolol\Bisoprolol Fumarate;Perindopril Erbumine;Fluindione;Rosuvastatin Calcium;Furosemide;Nitroglycerin;Allopurinol;Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Hyperkalaemia;Knee Arthroplasty;Acute Kidney Injury;Septic Shock;Aspartate Aminotransferase Increased;Alanine Aminotransferase Increased;Lactic Acidosis,Serious,Died,Female,01-SEP-2009,08-DEC-2009,Expedited,913 MTH,120 KG,Solvay,Healthcare Professional,Health Professional,-,26-NOV-2009,08-DEC-2009,FR,Not Specified,FR-SOLVAY-00209007336,-,-
7204104,Crestor;Bisoprolol,Bisoprolol\Bisoprolol Fumarate;Nitroglycerin;Furosemide;Allopurinol;Metformin Hydrochloride\Pioglitazone Hydrochloride;Perindopril;Rosuvastatin Calcium;Fluindione,Product Used For Unknown Indication,Acute Kidney Injury;Hyperkalaemia;Hyperthermia;Septic Shock;Haemodialysis;Lactic Acidosis,Serious,Died;Life Threatening,Female,08-SEP-2009,08-DEC-2009,Expedited,76 YR,120 KG,Aventis,Not Specified,Not Specified,-,25-NOV-2009,08-DEC-2009,FR,Not Specified,FR-SANOFI-AVENTIS-2009SA004448,-,-
7186643,Lipitor;Tricor;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Fenofibrate;Atorvastatin Calcium,Blood Cholesterol Increased;Diabetes Mellitus;Product Used For Unknown Indication,Rhabdomyolysis;Drug Interaction,Serious,Other Outcomes,Male,01-FEB-2009,24-NOV-2009,Non-Expedited,57 YR,Not Specified,Abbott,Healthcare Professional,Health Professional,Caduet;Hydrochlorothiazide;Lisinopril,24-MAR-2009,24-NOV-2009,US,Not Specified,US-ABBOTT-09P-163-0564562-00,-,-
7155774,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Spinal Fracture;Pulmonary Oedema;Weight Decreased;Coronary Artery Occlusion;Fall;Flatulence,Serious,Required Intervention;Hospitalized;Other Outcomes,Female,27-AUG-2009,18-NOV-2009,Expedited,71 YR,96 LB,Takeda,Healthcare Professional,"Consumer,Health Professional",Lisinopril;Lasix;Alendronate Sodium;Estrace;Alprazolam;Glyburide;Omeprazole,16-NOV-2009,09-OCT-2009,Not Specified,Not Specified,TPA2009A03051,-,-
7141740,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Asthenia;Blood Glucose Increased;Vertigo;Phaeochromocytoma;Paraesthesia;Depressive Symptom;Decreased Appetite;Hypertensive Crisis;Chills,Serious,Hospitalized,Female,JUL-2009,12-NOV-2009,Expedited,53 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",Metformin Hydrochloride;Hydrochlorothiazide\Telmisartan;.Alpha.-Lipoic Acid;Glimepiride,29-OCT-2009,24-SEP-2009,Not Specified,Not Specified,THQ2009A04346,-,-
6810050,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Bisoprolol Fumarate;Furosemide,Diabetes Mellitus,Renal Failure;Metabolic Acidosis;Hyperkalaemia;Cardiac Failure,Serious,Hospitalized,Male,2008,08-OCT-2009,Expedited,71 YR,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Study,Foreign",Candesartan Cilexetil;Allopurinol,16-DEC-2008,30-OCT-2008,Not Specified,Not Specified,TPG2008A01333,-,-
7362516,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Benfluorex Hydrochloride,Type 2 Diabetes Mellitus,Suicidal Ideation,Serious,Other Outcomes,Female,SEP-2009,07-OCT-2009,Expedited,46 YR,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Foreign",-,22-SEP-2009,07-OCT-2009,Not Specified,Not Specified,LTI2009A00270,-,-
7154554,Actoplus Met;Reclast,Zoledronic Acid;Metformin Hydrochloride\Pioglitazone Hydrochloride;Metformin Hydrochloride,Diabetes Mellitus;Osteoporosis,Asthenia;Mental Status Changes;Aphasia;Bone Density Decreased;Diarrhoea;Pulmonary Oedema;Pneumonia;Blood Glucose Increased;Tachycardia,Serious,Hospitalized;Other Outcomes;Required Intervention,Female,2009,06-OCT-2009,Expedited,66 YR,151.8 LB,Takeda,Healthcare Professional,"Company Representative ,Health Professional",Glimepiride,28-SEP-2009,06-OCT-2009,Not Specified,Not Specified,TPA2009A02321,-,-
7362514,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Trimipramine Maleate;Venlafaxine Hydrochloride,Depression;Type 2 Diabetes Mellitus,Depression;Drug Interaction;Condition Aggravated,Serious,Required Intervention,Male,JUN-2009,29-SEP-2009,Expedited,64 YR,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Foreign",Magnesium;Multi-Vitamin;Lovaza,21-SEP-2009,29-SEP-2009,Not Specified,Not Specified,TPG2009A00865,-,-
7114622,Ezetimibe And Simvastatin;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Ezetimibe\Simvastatin,Hyperglycaemia;Type 2 Diabetes Mellitus,Abdominal Discomfort;Tendon Rupture;Hypoglycaemia;Chills;Hand Fracture;Fall;Head Injury;Temperature Regulation Disorder;Loss Of Consciousness;Nausea;Periorbital Haematoma;Dizziness;Headache,Serious,Hospitalized;Disabled,Female,10-JUN-2009,15-SEP-2009,Expedited,61 YR,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Foreign",Furosemide;Lisinopril;Marcumar,03-SEP-2009,02-SEP-2009,Not Specified,Not Specified,TPG2009A00854,-,-
7123248,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Angioedema,Serious,Required Intervention;Other Outcomes,Female,-,09-SEP-2009,Expedited,5 DEC,Not Specified,Takeda,Healthcare Professional,Health Professional,-,02-SEP-2009,09-SEP-2009,Not Specified,Not Specified,TPA2009A02548,-,-
7100070,Diovan;Januvia;Crestor;Actoplus Met;Exforge,Amlodipine Besylate\Valsartan;Metformin Hydrochloride\Pioglitazone Hydrochloride;Rosuvastatin Calcium;Sitagliptin Phosphate;Valsartan,-,Pain;Musculoskeletal Chest Pain;Abdominal Pain Upper;Hypoaesthesia;Hypertension,Serious,Other Outcomes,Female,-,28-AUG-2009,Expedited,Not Specified,Not Specified,Novartis,Consumer,Not Specified,Aspirin;Hydrochlorothiazide;Coreg;Lipitor,24-AUG-2009,28-AUG-2009,US,Not Specified,PHEH2009US09832,-,-
7046809,Copegus;Competact;Pegasys,Peginterferon Alfa-2a;Metformin Hydrochloride\Pioglitazone Hydrochloride;Ribavirin,Hepatitis C,Pericarditis,Serious,Hospitalized,Male,25-MAY-2009,17-AUG-2009,Expedited,39 YR,Not Specified,Roche,Healthcare Professional,Health Professional,-,13-AUG-2009,10-JUL-2009,FR,Not Specified,FR-ROCHE-641781,-,-
7060358,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Cholangitis;Decreased Appetite;Pruritus;Ultrasound Abdomen Abnormal;Nausea;Weight Decreased,Serious,Other Outcomes,Female,06-APR-2009,15-JUL-2009,Expedited,49 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",-,06-JUL-2009,15-JUL-2009,Not Specified,Not Specified,LTI2009A00186,-,-
7051904,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Osteopenia;Back Pain;Osteoporosis,Serious,Other Outcomes,Female,OCT-2008,07-JUL-2009,Expedited,59 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",Gliclazide;Rosuvastatin;Diltiazem;Pantoprazole Sodium;Metformin Hydrochloride;Indapamide,30-JUN-2009,07-JUL-2009,Not Specified,Not Specified,THQ2009A03294,-,-
7049695,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Hypoglycaemia;Dizziness;Feeling Abnormal,Serious,Hospitalized;Other Outcomes,Male,28-DEC-2008,02-JUL-2009,Expedited,66 YR,213 LB,Takeda,Consumer,Consumer,Aspirin,24-JUN-2009,02-JUL-2009,Not Specified,Not Specified,TPA2008A02154,-,-
7047714,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Generalised Oedema;Abnormal Weight Gain,Serious,Hospitalized,Male,-,30-JUN-2009,Expedited,62 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",Barnidipine Hydrochloride,18-JUN-2009,30-JUN-2009,Not Specified,Not Specified,TIF2009A00040,-,-
7038334,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Feeling Cold;Asthenia;Fatigue;Arthralgia;Vision Blurred;Presyncope;Nausea;Impaired Work Ability;Dyspnoea;Dizziness;Pain In Extremity,Serious,Required Intervention;Other Outcomes,Male,-,22-JUN-2009,Direct,Not Specified,200 LB,-,Consumer,Not Specified,-,-,22-JUN-2009,Not Specified,Not Specified,-,-,-
7007170,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Hydrochlorothiazide\Olmesartan Medoxomil,Diabetic Retinopathy;Microalbuminuria,Weight Increased;Neuropathic Arthropathy;Glycosylated Haemoglobin Increased,Serious,Disabled,Female,MAR-2009,11-JUN-2009,Expedited,58 YR,Not Specified,Takeda,Healthcare Professional,"Other,Health Professional ,Foreign",Torsemide,03-JUN-2009,19-MAY-2009,Not Specified,Not Specified,TPG2009A00536,-,-
7131298,Actoplus Met;Amaryl,Glimepiride;Metformin Hydrochloride\Pioglitazone Hydrochloride;Mianserin Hydrochloride,Type 2 Diabetes Mellitus,Transitional Cell Carcinoma,Serious,Life Threatening,Female,APR-2008,03-JUN-2009,Expedited,52 YR,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Foreign",Lisinopril;Aceprometazine\Meprobamate;Kardegic;Isoptin;Escitalopram Oxalate;Xanax,25-MAY-2009,14-APR-2009,Not Specified,Not Specified,LTI2009A00102,-,-
7009631,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Urinary Tract Infection;Syncope;Abdominal Pain;Fall,Serious,Hospitalized,Female,MAY-2009,22-MAY-2009,Expedited,47 YR,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,21-MAY-2009,22-MAY-2009,Not Specified,Not Specified,TPA2009A01028,-,-
7131297,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Myocardial Infarction,Serious,Hospitalized,Male,04-JUN-2008,20-MAY-2009,Expedited,74 YR,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Study,Foreign",Simvastatin,12-MAY-2009,07-APR-2009,Not Specified,Not Specified,TPG2009A00422,-,-
6962362,Novorapid;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Insulin Nos;Insulin Aspart,Diabetes Mellitus,Hypoglycaemic Coma,Serious,Hospitalized,Female,29-JAN-2009,27-APR-2009,Expedited,56 YR,Not Specified,Takeda,Healthcare Professional,"Other,Health Professional ,Foreign",-,17-APR-2009,26-MAR-2009,Not Specified,Not Specified,TIF2009A00021,-,-
6979038,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Treatment Noncompliance;Angioedema,Serious,Hospitalized,Not Specified,-,20-APR-2009,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",Metformin Hydrochloride,14-APR-2009,20-APR-2009,Not Specified,Not Specified,TPA2009A00587,-,-
6970000,Caduet;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Amlodipine Besylate\Atorvastatin Calcium,Hypertension;Type 2 Diabetes Mellitus,Myositis;Rhabdomyolysis,Serious,Other Outcomes;Required Intervention,Male,-,07-APR-2009,Expedited,6 DEC,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",Tricor,27-MAR-2009,07-APR-2009,Not Specified,Not Specified,TPA2009A00512,-,-
6967501,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Weight Increased;Dyspnoea;Bronchial Disorder;Superinfection,Serious,Other Outcomes;Hospitalized,Male,NOV-2008,02-APR-2009,Expedited,Not Specified,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",-,19-MAR-2009,02-APR-2009,Not Specified,Not Specified,LTI2008A00311,-,-
7131295,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Cough;Chest Pain;Haemoptysis;Back Pain;Dyspnoea,Serious,Other Outcomes,Male,23-FEB-2009,26-MAR-2009,Expedited,54 YR,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Foreign",-,17-MAR-2009,26-MAR-2009,Not Specified,Not Specified,LTI2009A00068,-,-
6958091,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Drug Hypersensitivity,Serious,Life Threatening,Female,23-MAY-2007,25-MAR-2009,Direct,58 YR,190 LB,-,Not Specified,Not Specified,-,-,25-MAR-2009,Not Specified,Not Specified,-,-,-
6961640,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Nasopharyngitis;Dizziness;Pharyngitis;Pneumonia;Myocardial Strain Imaging;Blood Iron Decreased;Gait Inability;Pulmonary Thrombosis;Blood Glucose Increased,Serious,Hospitalized;Required Intervention;Other Outcomes,Female,FEB-2009,23-MAR-2009,Expedited,49 YR,278 LB,Takeda,Consumer,Consumer,Furosemide;Alprazolam;Lantus;Ziac;Humalog;Glucotrol Xl;Synthroid,10-MAR-2009,23-MAR-2009,Not Specified,Not Specified,TPA2009A00390,-,-
6956654,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Feeling Cold;Gastric Disorder;Neuropathy Peripheral,Non-Serious,Non-Serious,Male,JAN-2009,23-MAR-2009,Expedited,57 YR,170 LB,Takeda,Healthcare Professional,"Consumer,Health Professional",Plavix;Aspirin;Synthroid;Metoprolol Tartrate;Simvastatin;Aciphex,17-MAR-2009,23-MAR-2009,Not Specified,Not Specified,TPA2009A00387,-,-
6952428,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Dyspnoea;Fibrin D Dimer Increased;Oedema Peripheral;Cardiac Failure Congestive;Brain Natriuretic Peptide Increased,Serious,Hospitalized,Female,09-MAR-2009,19-MAR-2009,Direct,52 YR,205 LB,-,Healthcare Professional,Health Professional,Bystolic,-,19-MAR-2009,Not Specified,Not Specified,-,-,-
6936698,Actos;Actoplus Met;Zyprexa;Depakote,Divalproex Sodium;Olanzapine;Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Product Used For Unknown Indication,Death;Anal Incontinence,Serious,Died,Male,-,12-MAR-2009,Non-Expedited,Not Specified,Not Specified,Abbott,Healthcare Professional,Health Professional,-,27-JAN-2009,12-MAR-2009,US,Not Specified,US-ABBOTT-09P-163-0500021-00,-,-
6936149,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Renal Failure;Hypoglycaemia,Serious,Hospitalized,Male,-,03-MAR-2009,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,25-FEB-2009,03-MAR-2009,Not Specified,Not Specified,TPA2009A00327,-,-
6905399,Actoplus Met;Avandamet,Metformin Hydrochloride\Rosiglitazone Maleate;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Hypoxia;Disease Complication;Haematoma;Haematuria;Pulmonary Hypertension;Decubitus Ulcer;Shock Haemorrhagic;Blood Thyroid Stimulating Hormone Increased;Pericardial Effusion;Weight Increased;Anaemia;Renal Failure;Hepatic Cytolysis;Glycosylated Haemoglobin Increased;Haemodialysis;Hypotension;Overdose;Aortic Arteriosclerosis;Herpes Virus Infection;Pulmonary Embolism;Haemorrhage;Mitral Valve Incompetence;Right Ventricular Failure;Atrial Fibrillation,Serious,Life Threatening;Hospitalized,Female,2007,25-FEB-2009,Expedited,68 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",Gliclazide;Irbesartan;Furosemide;Levothyroxine Sodium;Potassium Chloride;Urapidil;Digoxin;Atorvastatin Calcium,16-FEB-2009,28-JAN-2009,Not Specified,Not Specified,LTI2009A00015,-,-
6871380,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Vascular Occlusion;Anaemia;Cardiac Failure Congestive;Acute Myocardial Infarction,Serious,Required Intervention;Other Outcomes,Male,-,13-FEB-2009,Expedited,73 YR,143 LB,Takeda,Healthcare Professional,Health Professional,Diltiazem;Isosorbide;Lisinopril,06-FEB-2009,23-DEC-2008,Not Specified,Not Specified,TPA2008A02112,-,-
6905221,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Urticaria,Non-Serious,Non-Serious,Male,11-JAN-2009,12-FEB-2009,Expedited,57 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",-,06-FEB-2009,28-JAN-2009,Not Specified,Not Specified,TPG2009A00138,-,-
6917017,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Malaise;Presyncope,Serious,Other Outcomes,Male,DEC-2008,11-FEB-2009,Expedited,73 YR,Not Specified,Takeda,Healthcare Professional,"Other,Health Professional ,Foreign",Aspirin Lysine;Glucophage;Lyrica;Nafronyl Oxalate,29-JAN-2009,11-FEB-2009,Not Specified,Not Specified,LTI2009A00029,-,-
6909813,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Atrial Fibrillation,Non-Serious,Non-Serious,Male,02-DEC-2008,04-FEB-2009,Direct,61 YR,237 LB,-,Healthcare Professional,Health Professional,-,-,04-FEB-2009,Not Specified,Not Specified,-,-,-
6909811,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Strabismus,Serious,Other Outcomes,Male,01-NOV-2008,04-FEB-2009,Direct,65 YR,158 LB,-,Not Specified,Not Specified,Tricor;Cetirizine Hydrochloride;Simvastatin;Astelin,-,04-FEB-2009,Not Specified,Y,-,-,-
6902957,Zyprexa;Actoplus Met;Depakote;Actos,Pioglitazone Hydrochloride;Divalproex Sodium;Metformin Hydrochloride\Pioglitazone Hydrochloride;Olanzapine,Product Used For Unknown Indication,Anal Incontinence;Reaction To Excipient,Serious,Died,Male,-,28-JAN-2009,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,21-JAN-2009,28-JAN-2009,Not Specified,Not Specified,TPA2009A00111,-,-
6895996,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Angioedema,Serious,Hospitalized,Male,2008,21-JAN-2009,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",Metformin Hydrochloride,13-JAN-2009,21-JAN-2009,Not Specified,Not Specified,TPA2009A00048,-,-
6888735,Actoplus Met;Glucophage,Metformin Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride;Glyburide,Type 2 Diabetes Mellitus,Somnolence;Road Traffic Accident,Serious,Died,Female,12-NOV-2008,21-JAN-2009,Expedited,57 YR,Not Specified,Takeda,Healthcare Professional,"Other,Health Professional ,Study,Foreign",Unspecified Ingredient,09-JAN-2009,06-JAN-2009,Not Specified,Not Specified,TPG2008A01510,-,-
6866208,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Angina Pectoris,Non-Serious,Non-Serious,Male,07-NOV-2008,21-JAN-2009,Expedited,73 YR,Not Specified,Takeda,Healthcare Professional,"Other,Health Professional ,Foreign",-,20-JAN-2009,12-DEC-2008,Not Specified,Not Specified,TPG2008A01437,-,-
6882669,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Acute Myocardial Infarction,Serious,Life Threatening,Male,08-DEC-2008,12-JAN-2009,Expedited,65 YR,Not Specified,Takeda,Not Specified,"Other,Health Professional ,Foreign",-,02-JAN-2009,12-JAN-2009,Not Specified,Not Specified,TIF2009A00002,-,-
6888737,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Acute Kidney Injury,Serious,Hospitalized,Male,-,09-JAN-2009,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Foreign",-,05-JAN-2009,09-JAN-2009,Not Specified,Not Specified,TPG2009A00017,-,-
7615821,Tricor;Actoplus Met;Crestor,Rosuvastatin Calcium;Metformin Hydrochloride\Pioglitazone Hydrochloride;Fenofibrate,-,Alanine Aminotransferase Increased;Drug Interaction;Rhabdomyolysis;Aspartate Aminotransferase Increased,Serious,Hospitalized,Female,11-MAR-2008,17-DEC-2008,Non-Expedited,60 YR,Not Specified,Astrazeneca,Healthcare Professional,Health Professional,Glucotrol Xl;Coreg;Benicar;Aspirin;Fosamax;Levothyroxine;Albuterol,09-APR-2008,17-DEC-2008,US,Not Specified,US-ASTRAZENECA-2008UW07253,-,-
6868452,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Cardiac Failure;Pulmonary Congestion;Atrial Fibrillation;Dyspnoea;Tachycardia;Aortic Valve Sclerosis;Oedema Peripheral;Arrhythmia;Pleural Effusion,Serious,Hospitalized,Male,17-JUN-2008,17-DEC-2008,Expedited,68 YR,Not Specified,Takeda,Healthcare Professional,"Other,Health Professional ,Study,Foreign",Carvedilol;Marcumar,09-DEC-2008,17-DEC-2008,Not Specified,Not Specified,TPG2008A01433,-,-
6853440,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Flank Pain;Renal Pain;Haematuria,Serious,Other Outcomes,Male,-,04-DEC-2008,Expedited,57 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Study,Foreign",Aspirin;Olmesartan Medoxomil,25-NOV-2008,04-DEC-2008,Not Specified,Not Specified,TPG2008A01418,-,-
6838762,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Vocal Cord Paralysis,Serious,Hospitalized;Disabled,Female,08-MAY-2008,25-NOV-2008,Expedited,72 YR,Not Specified,Takeda,Not Specified,"Other,Health Professional ,Foreign",-,18-NOV-2008,25-NOV-2008,Not Specified,Not Specified,TUK2008A00147,-,-
6836574,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Condition Aggravated;Conjunctival Oedema;Visual Acuity Reduced;Eyelid Oedema;Amaurosis;Diabetic Retinopathy,Serious,Disabled,Female,-,24-NOV-2008,Expedited,58 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Study,Foreign",Unspecified Ingredient;Insulin Nos;Glimepiride,13-NOV-2008,24-NOV-2008,Not Specified,Not Specified,TPG2008A01349,-,-
6826086,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Skin Disorder;Complication Associated With Device;Urticaria;Pruritus;Blister;Arterial Occlusive Disease,Serious,Hospitalized;Required Intervention,Male,-,20-NOV-2008,Expedited,62 YR,236 LB,Takeda,Consumer,Consumer,Lisinopril;Simvastatin;Alprazolam;Aspirin,13-NOV-2008,20-NOV-2008,Not Specified,Not Specified,TPA2008A02025,-,-
6560699,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride;Metformin Hydrochloride,-,Oedema Peripheral;Musculoskeletal Pain,Non-Serious,Non-Serious,Male,01-JAN-2007,14-NOV-2008,Non-Expedited,Not Specified,Not Specified,Bristol Myers Squibb,Consumer,Not Specified,-,08-JAN-2008,25-FEB-2008,US,Not Specified,US-BRISTOL-MYERS SQUIBB COMPANY-13961040,-,-
7472365,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Palpitations;Arrhythmia,Serious,Other Outcomes,Male,27-SEP-2008,30-OCT-2008,Expedited,28 YR,Not Specified,Takeda,Consumer,Consumer,Glyburide,23-OCT-2008,30-OCT-2008,Not Specified,Not Specified,THQ2008A02133,-,-
6803738,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Cardiac Failure Congestive,Serious,Hospitalized,Male,JUL-2008,29-SEP-2008,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,21-JUL-2008,29-SEP-2008,Not Specified,Not Specified,TPA2008A01162,-,-
6803737,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Fatigue;Asthenia;Decreased Appetite;Blood Glucose Increased;Drug Ineffective;Weight Decreased;Vein Disorder;Jaundice,Serious,Required Intervention;Other Outcomes,Female,MAY-2008,29-SEP-2008,Non-Expedited,70 YR,210 LB,Takeda,Healthcare Professional,Health Professional,Lipitor;Metformin Hydrochloride;Diovan;Amaryl;Armour Thyroid;Metoprolol Tartrate;Celebrex;Prempro,19-JUN-2008,29-SEP-2008,Not Specified,Not Specified,TPA2008A00934,-,-
6780241,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Drug Ineffective;Wrong Technique In Product Usage Process,Non-Serious,Non-Serious,Female,-,24-SEP-2008,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Health Professional,-,08-SEP-2008,24-SEP-2008,Not Specified,Not Specified,TPA2008A01428,-,-
6707988,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Ankle Fracture;Fall;Osteopenia,Serious,Hospitalized,Female,21-JUN-2008,09-SEP-2008,Expedited,61 YR,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Foreign",-,01-SEP-2008,14-JUL-2008,Not Specified,Not Specified,TPG2008A00999,-,-
6552430,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Myocardial Infarction,Serious,Hospitalized,Male,-,03-SEP-2008,Expedited,Not Specified,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",-,27-AUG-2008,30-JAN-2008,Not Specified,Not Specified,TPG2008A00047,-,-
6888723,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Thrombocytopenia;Treatment Noncompliance,Serious,Hospitalized;Life Threatening,Male,09-JUN-2008,20-AUG-2008,Expedited,58 YR,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Foreign",-,12-AUG-2008,26-JUN-2008,Not Specified,Not Specified,TPG2008A00907,-,-
6737180,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Meniscus Injury;Tibia Fracture,Serious,Required Intervention;Other Outcomes,Female,-,14-AUG-2008,Expedited,50 YR,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",Prednisone,05-AUG-2008,14-AUG-2008,Not Specified,Not Specified,TPA2008A01250,-,-
6649567,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Pulmonary Arterial Hypertension;Cardiac Failure Acute,Serious,Other Outcomes,Male,01-APR-2008,14-AUG-2008,Expedited,60 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",Fluindione;Eupantol;Ramipril,08-AUG-2008,09-MAY-2008,Not Specified,Not Specified,LTI2008A00143,-,-
6712566,Actoplus Met;Diovan,Valsartan;Metformin Hydrochloride\Pioglitazone Hydrochloride,Hypertension,Muscle Spasms;Abdominal Pain;Renal Disorder;Blood Creatine Phosphokinase Increased;Glomerular Filtration Rate Decreased;Drug Interaction,Serious,Other Outcomes,Male,01-JUL-2008,29-JUL-2008,Expedited,Not Specified,Not Specified,Novartis,Healthcare Professional,Health Professional,-,21-JUL-2008,29-JUL-2008,US,Not Specified,PHEH2008US06487,-,-
6590952,Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Prostate Cancer,Serious,Other Outcomes,Male,2007,10-JUL-2008,Expedited,47 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",-,07-JUL-2008,07-MAR-2008,Not Specified,Not Specified,LTI2008A00060,-,-
6697810,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Condition Aggravated;Cardiac Failure,Serious,Died,Female,-,01-JUL-2008,Expedited,93 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Study",Unspecified Ingredient,24-JUN-2008,01-JUL-2008,Not Specified,Not Specified,TPG2008A00941,-,-
6730029,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Rash Pruritic;Urticaria;Dizziness;Nausea;Blood Glucose Decreased,Serious,Other Outcomes;Required Intervention,Female,JUL-2007,27-JUN-2008,Non-Expedited,68 YR,140 LB,Takeda,Consumer,Consumer,Lozol;Lotrel;Atenolol;Tricor;Crestor;Benicar,20-MAY-2008,27-JUN-2008,Not Specified,Not Specified,TPA2008A00738,-,-
6730027,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Jaundice,Serious,Hospitalized,Male,-,27-JUN-2008,Non-Expedited,70 YR,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,02-MAY-2008,27-JUN-2008,Not Specified,Not Specified,TPA2008A00639,-,-
6730025,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Cardiac Failure Congestive,Serious,Other Outcomes;Required Intervention,Male,-,27-JUN-2008,Non-Expedited,10 DEC,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,17-APR-2008,27-JUN-2008,Not Specified,Not Specified,TPA2008A00534,-,-
6601069,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Blindness,Serious,Disabled,Male,-,26-JUN-2008,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Foreign",-,20-JUN-2008,18-MAR-2008,Not Specified,Not Specified,TPG2008A00281,-,-
7042926,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Aspirin;Doxazosin Mesylate,Anticoagulant Therapy;Benign Prostatic Hyperplasia;Diabetes Mellitus,Gastritis Erosive;Duodenal Ulcer;Hiatus Hernia,Serious,Hospitalized,Male,12-MAY-2008,27-MAY-2008,Expedited,62 YR,Not Specified,Bayer,Healthcare Professional,Health Professional,Avodart,21-MAY-2008,27-MAY-2008,IT,Not Specified,IT-BAYER-200818840GPV,-,-
6654562,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Weight Increased;Constipation;Inappropriate Schedule Of Product Administration,Serious,Required Intervention;Other Outcomes,Female,MAY-2007,14-MAY-2008,Expedited,57 YR,212 LB,Takeda,Consumer,Consumer,Crestor,06-MAY-2008,14-MAY-2008,Not Specified,Not Specified,TPA2008A00653,-,-
6648431,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,-,No Adverse Event,Non-Serious,Non-Serious,Not Specified,-,08-MAY-2008,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,08-MAY-2008,08-MAY-2008,Not Specified,Not Specified,TPA2008A00570,-,-
6648052,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Oedema Peripheral;Benign Lymph Node Neoplasm;Blood Glucose Increased;Liver Disorder,Serious,Hospitalized,Male,2005,07-MAY-2008,Expedited,61 YR,225 LB,Takeda,Not Specified,Consumer,Metformin Hydrochloride;Meloxicam;Cozaar;Tetracycline,28-APR-2008,07-MAY-2008,Not Specified,Not Specified,TPA2008A00597,-,-
6613148,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Precancerous Skin Lesion;Malignant Melanoma;Glycosylated Haemoglobin Increased;Arthralgia;Blood Glucose Increased;Meniscus Injury,Serious,Required Intervention,Male,2001,07-MAY-2008,Expedited,65 YR,220 LB,Takeda,Healthcare Professional,"Consumer,Health Professional",Avalide;Pravachol,25-APR-2008,01-APR-2008,Not Specified,Not Specified,TPA2008A00372,-,-
6614881,Glucovance,Glyburide\Metformin Hydrochloride;Unspecified Ingredient;Metformin Hydrochloride\Pioglitazone Hydrochloride;Spironolactone,Hypertension,Acute Kidney Injury;Respiratory Failure;Cell Death;Cholelithiasis;Septic Shock;Pancreatitis Acute,Serious,Life Threatening;Hospitalized,Female,03-OCT-2007,15-APR-2008,Expedited,69 YR,Not Specified,Bristol Myers Squibb,Healthcare Professional,Health Professional,-,03-APR-2008,15-APR-2008,FR,Not Specified,FR-BRISTOL-MYERS SQUIBB COMPANY-14146567,-,-
6608033,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Incorrect Dose Administered;Product Quality Issue;Blood Glucose Decreased,Non-Serious,Non-Serious,Female,MAR-2008,26-MAR-2008,Expedited,54 YR,Not Specified,Takeda,Healthcare Professional,Health Professional,-,14-MAR-2008,26-MAR-2008,Not Specified,Not Specified,TPA2008A00331,-,-
6510270,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Joint Swelling;Chest Pain;Pain,Serious,Other Outcomes;Required Intervention,Male,JUL-2007,25-MAR-2008,Expedited,76 YR,225 LB,Takeda,Healthcare Professional,"Consumer,Health Professional",Zetia;Erythromycin;Vitamin E;Hytrin;Lantus;Pravachol;Vitamin C;Avalide;Plavix,11-MAR-2008,06-DEC-2007,Not Specified,Not Specified,TPA2007A02038,-,-
6587322,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Microalbuminuria;Diabetes Mellitus Inadequate Control;Glycosylated Haemoglobin Increased;Hypertensive Crisis,Serious,Hospitalized,Female,06-FEB-2008,18-MAR-2008,Expedited,69 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Study",Glimepiride;Levothyroxine;Unspecified Ingredient,06-MAR-2008,05-MAR-2008,Not Specified,Not Specified,TPG2008A00158,-,-
6589613,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Incorrect Dose Administered;Self-Medication;Treatment Noncompliance,Non-Serious,Non-Serious,Female,FEB-2008,07-MAR-2008,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,15-FEB-2008,07-MAR-2008,Not Specified,Not Specified,TPA2008A00266,-,-
6560725,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride;Metformin Hydrochloride,-,Musculoskeletal Pain;Oedema Peripheral,Non-Serious,Non-Serious,Male,01-JAN-2007,25-FEB-2008,Non-Expedited,Not Specified,Not Specified,Bristol Myers Squibb,Consumer,Not Specified,-,02-NOV-2007,25-FEB-2008,US,Not Specified,US-BRISTOL-MYERS SQUIBB COMPANY-13989108,-,-
6517470,-,Levofloxacin;Metformin Hydrochloride\Pioglitazone Hydrochloride;Sulfamethoxazole\Trimethoprim,Pyelonephritis;Type 1 Diabetes Mellitus,Immune Thrombocytopenia;Thrombocytopenia,Serious,Hospitalized,Female,NOV-2007,06-FEB-2008,Expedited,65 YR,Not Specified,Takeda,Not Specified,Health Professional,Doxepin Hydrochloride;Ramipril,24-JAN-2008,14-DEC-2007,Not Specified,Not Specified,TPG2007A00779,-,-
6507863,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Pulmonary Sepsis;Cardiac Failure;Acute Respiratory Distress Syndrome;Abdominal Infection;Pneumonia;Septic Shock;Acute Kidney Injury;Renal Failure;Haemodynamic Instability,Serious,Died;Hospitalized,Male,-,06-FEB-2008,Expedited,68 YR,Not Specified,Takeda,Not Specified,"Health Professional ,Study",Aldactone;Bisoprolol Fumarate;Aspirin;Lasix;Olmesartan Medoxomil;Zocor;Plavix,21-JAN-2008,05-DEC-2007,Not Specified,Not Specified,TPG2007A00756,-,-
6524543,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Loss Of Consciousness;Fall;Nausea;Malaise;Vomiting;Abdominal Pain Upper,Serious,Hospitalized,Female,22-SEP-2007,18-JAN-2008,Expedited,67 YR,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Foreign",Molsidomine;Zocor;Aspirin Dl-Lysine;Atenolol;Gliclazide,07-JAN-2008,28-DEC-2007,Not Specified,Not Specified,LTI2007A00360,-,-
6514336,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Tachycardia;Therapeutic Product Effect Decreased;Palpitations;Hypertensive Crisis,Serious,Hospitalized,Female,14-NOV-2007,17-JAN-2008,Expedited,65 YR,Not Specified,Takeda,Not Specified,"Other,Health Professional",Aspirin,03-JAN-2008,12-DEC-2007,Not Specified,Not Specified,TIF2007A00240,-,-
6524644,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Haematuria;Bladder Neoplasm,Serious,Hospitalized,Male,-,31-DEC-2007,Expedited,Not Specified,Not Specified,Takeda,Not Specified,"Health Professional ,Foreign",Marcumar,18-DEC-2007,31-DEC-2007,Not Specified,Not Specified,TPG2007A00743,-,-
6514171,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Cardiac Failure,Serious,Hospitalized;Died,Male,2007,21-DEC-2007,Expedited,66 YR,Not Specified,Takeda,Not Specified,Health Professional,-,14-DEC-2007,12-DEC-2007,Not Specified,Not Specified,LTI2007A00273,-,-
6442350,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Cardiac Failure;Dialysis;Renal Failure,Serious,Hospitalized,Male,2007,21-DEC-2007,Expedited,80 YR,Not Specified,Takeda,Not Specified,Health Professional,-,14-DEC-2007,03-OCT-2007,Not Specified,Not Specified,LTI2007A00274,-,-
6888719,Doxazosin,Doxazosin Mesylate;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Left Ventricular Dysfunction;Left Ventricular Failure;Dyspnoea Exertional;Fluid Retention,Serious,Other Outcomes,Male,30-JUL-2007,19-DEC-2007,Expedited,59 YR,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Foreign",Nicorandil;Aspirin;Ismo;Bisoprolol;Valsartan;Lantus;Amlodipine,03-DEC-2007,19-DEC-2007,Not Specified,Not Specified,TUK2007A00140,-,-
6888716,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Somnolence;Flatulence;Cardiac Arrest;Pneumonia;Urinary Tract Infection Enterococcal;Cardiovascular Insufficiency;Anaemia;Lactic Acidosis;Respiratory Failure;Acidosis;Vomiting;Haemodialysis;Bradycardia;Hyperkalaemia;Dry Skin;Diabetic Nephropathy;Nausea;Dysphagia;Aphonia;Renal Failure;Dizziness;Tachypnoea,Serious,Life Threatening;Hospitalized,Female,10-AUG-2007,19-DEC-2007,Expedited,68 YR,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Foreign",Glyburide;Aspirin;Metoprolol,11-DEC-2007,19-DEC-2007,Not Specified,Not Specified,TPG2007A00766,-,-
6516634,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Anaphylactic Reaction;Dysphagia,Serious,Life Threatening;Required Intervention,Female,30-OCT-2007,18-DEC-2007,Expedited,58 YR,223 LB,Takeda,Healthcare Professional,"Company Representative ,Health Professional",Avandia;Cardura Xl;Singulair;Norvasc;Lasix,11-DEC-2007,18-DEC-2007,Not Specified,Not Specified,TPA2007A02261,-,-
6509260,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Angioedema;Erythema;Burning Sensation;Flushing;Throat Tightness;Anaphylactic Reaction;Pruritus;Hypersensitivity,Serious,Life Threatening,Female,19-NOV-2007,18-DEC-2007,Expedited,38 YR,255 LB,Takeda,Healthcare Professional,"Company Representative ,Health Professional",Prilosec;Atorvastatin;Zovirax;Wellbutrin Xl;Requip;Byetta,11-DEC-2007,05-DEC-2007,Not Specified,Not Specified,TPA2007A02406,-,-
6517896,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Weight Increased;Tooth Discolouration;Sciatica,Serious,Required Intervention;Hospitalized,Male,FEB-2006,14-DEC-2007,Expedited,76 YR,153 LB,Takeda,Consumer,Consumer,Avandamet;Hydrochlorothiazide;Pravastatin,06-DEC-2007,14-DEC-2007,Not Specified,Not Specified,TPA2007A02461,-,-
6517471,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Renal Failure;Condition Aggravated;Cardiac Failure,Serious,Died;Hospitalized,Male,-,14-DEC-2007,Expedited,68 YR,Not Specified,Takeda,Healthcare Professional,"Other,Health Professional ,Study,Foreign",Olmesartan Medoxomil;Aldactone;Zocor;Plavix;Lasix;Aspirin,04-DEC-2007,14-DEC-2007,Not Specified,Not Specified,TPH2007A00756,-,-
6514242,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Myocardial Infarction,Serious,Died,Male,JUL-2007,12-DEC-2007,Expedited,Not Specified,Not Specified,Takeda,Consumer,Consumer,-,05-DEC-2007,12-DEC-2007,Not Specified,Not Specified,TPA2007A02453,-,-
6513611,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Lipids Abnormal,Ill-Defined Disorder;Respiratory Arrest,Serious,Died,Male,16-MAR-2007,11-DEC-2007,Direct,52 YR,230 LB,-,Not Specified,Not Specified,-,-,11-DEC-2007,Not Specified,Not Specified,-,-,-
6510321,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Diabetes Mellitus,Macular Oedema,Serious,Required Intervention,Male,15-FEB-2007,11-DEC-2007,Direct,51 YR,160 LB,-,Not Specified,Not Specified,-,-,11-DEC-2007,Not Specified,Not Specified,-,-,-
6452206,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Sudden Cardiac Death;Myocardial Infarction;Treatment Noncompliance,Serious,Other Outcomes;Required Intervention;Died;Life Threatening,Male,JUL-2007,19-NOV-2007,Expedited,67 YR,303.2 LB,Takeda,Healthcare Professional,"Company Representative ,Health Professional",Norvasc;Insulin Nos;Atacand;Aspirin;Zantac;Plavix;Colchicum,13-NOV-2007,18-OCT-2007,Not Specified,Not Specified,TPA2007A02096,-,-
6464412,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Pelvic Pain;Bone Fissure;Pain,Serious,Other Outcomes;Disabled,Female,AUG-2007,09-NOV-2007,Expedited,64 YR,Not Specified,Takeda,Not Specified,Health Professional,Levothyroxine Sodium;Amaryl;Diosmin,31-OCT-2007,31-OCT-2007,Not Specified,Not Specified,LTI2007A00301,-,-
6470535,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Diabetes Mellitus,Macular Oedema,Serious,Disabled,Male,15-FEB-2007,07-NOV-2007,Direct,51 YR,160 LB,-,Healthcare Professional,Health Professional,-,-,07-NOV-2007,Not Specified,Not Specified,-,-,-
6454838,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Blood Glucose Increased,Vision Blurred,Non-Serious,Non-Serious,Male,16-SEP-2007,22-OCT-2007,Expedited,39 YR,309 LB,Takeda,Not Specified,Consumer,Xanax;Cardura;Zoloft;Nexium;Fexofenadine Hydrochloride\Pseudoephedrine Hydrochloride,27-SEP-2007,22-OCT-2007,Not Specified,Not Specified,TPA2007A02008,-,-
6447252,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Cholelithiasis;Pancreatitis,Serious,Hospitalized,Female,OCT-2007,16-OCT-2007,Expedited,65 YR,Not Specified,Takeda,Not Specified,Health Professional,-,08-OCT-2007,16-OCT-2007,Not Specified,Not Specified,LTI2007A00287,-,-
6447236,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Dyspnoea;Discomfort;Body Mass Index Increased;Malaise;Weight Increased,Serious,Other Outcomes,Female,-,16-OCT-2007,Expedited,56 YR,Not Specified,Takeda,Not Specified,Health Professional,Lisinopril,04-OCT-2007,16-OCT-2007,Not Specified,Not Specified,TUK2007A00101,-,-
6429869,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Pancytopenia;Epistaxis,Serious,Hospitalized,Female,-,16-OCT-2007,Expedited,60 YR,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",Lisinopril;Crestor,08-OCT-2007,19-SEP-2007,Not Specified,Not Specified,TPA2007A01861,-,-
6443134,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Circumstance Or Information Capable Of Leading To Medication Error;Product Quality Issue;Intercepted Product Dispensing Error,Non-Serious,Non-Serious,Not Specified,-,05-OCT-2007,Expedited,Not Specified,Not Specified,Takeda,Not Specified,Consumer,-,26-SEP-2007,05-OCT-2007,Not Specified,Not Specified,TPA2007A01996,-,-
6436930,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Muscular Weakness;Paraesthesia;Myopathy;Pruritus;Rash;Pain In Extremity,Serious,Other Outcomes;Required Intervention,Female,JUN-2007,05-OCT-2007,Expedited,65 YR,240 LB,Takeda,Healthcare Professional,"Company Representative ,Health Professional",Fosamax;Lipitor;Aspirin;Detrol La;Enalapril,05-SEP-2007,24-SEP-2007,Not Specified,Not Specified,TPA2007A01860,-,-
6440782,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Oedema Peripheral;Blood Pressure Fluctuation,Serious,Other Outcomes,Male,MAR-2007,27-SEP-2007,Expedited,67 YR,Not Specified,Takeda,Not Specified,Health Professional,Aspirin;Omeprazole;Diovan Hct,20-SEP-2007,27-SEP-2007,Not Specified,Not Specified,TPG2007A00657,-,-
6416110,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Myocardial Infarction,Serious,Hospitalized,Male,27-AUG-2007,06-SEP-2007,Expedited,60 YR,244 LB,Takeda,Healthcare Professional,"Company Representative ,Health Professional",Crestor;Hyzaar,28-AUG-2007,06-SEP-2007,Not Specified,Not Specified,TPA2007A01813,-,-
6416038,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Hunger;Hypoglycaemia;Oedema Peripheral;Weight Increased,Non-Serious,Non-Serious,Female,2006,06-SEP-2007,Expedited,64 YR,210 LB,Takeda,Consumer,Consumer,Lasix;Lipitor;Inderal La;Procardia Xl;Humalog Mix75/25,22-AUG-2007,06-SEP-2007,Not Specified,Not Specified,TPA2007A01789,-,-
6414928,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Treatment Noncompliance;Incorrect Dose Administered;Product Quality Issue,Non-Serious,Non-Serious,Female,-,05-SEP-2007,Expedited,70 YR,Not Specified,Takeda,Consumer,Consumer,-,24-AUG-2007,05-SEP-2007,Not Specified,Not Specified,TPA2007A01804,-,-
6387394,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Pneumonia;Angioedema;Respiratory Tract Infection;Emphysema;Pulmonary Hypertension;Circulatory Collapse;Pulmonary Fibrosis;Weight Increased,Serious,Life Threatening;Hospitalized,Male,JUN-2007,04-SEP-2007,Expedited,70 YR,Not Specified,Takeda,Not Specified,Health Professional,Pravastatin;Isosorbide Dinitrate;Metoprolol Tartrate;Enalapril;Metformin Hydrochloride;Allopurinol;Spiriva,20-AUG-2007,14-AUG-2007,Not Specified,Not Specified,TPG2007A00524,-,-
6381950,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Acute Kidney Injury;Metabolic Acidosis;Lactic Acidosis;Mental Disorder Due To A General Medical Condition;Tumour Marker Increased;Acute Hepatic Failure;Lacunar Infarction;Base Excess Increased;General Physical Health Deterioration;Diabetes Mellitus;Confusional State;Bundle Branch Block;Hyperkalaemia;Multiple Organ Dysfunction Syndrome;Cardiac Failure;Condition Aggravated;Pleural Effusion;Leukocytosis;Sinus Tachycardia;Asthenia;Uterine Leiomyoma;Hyponatraemia;Urinary Tract Infection;Thrombocytopenia,Serious,Hospitalized;Life Threatening,Female,27-JUL-2007,31-AUG-2007,Expedited,70 YR,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Study,Foreign",Oxazepam;Opipramol;Tamoxifen Citrate,16-AUG-2007,06-AUG-2007,Not Specified,Not Specified,TPG2007A00523,-,-
6392483,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Wrong Product Administered;Product Quality Issue,Non-Serious,Non-Serious,Male,-,21-AUG-2007,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,09-AUG-2007,21-AUG-2007,Not Specified,Not Specified,TPA2007A01683,-,-
6888705,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Cerebral Infarction;Hypertension;Dysphagia,Serious,Disabled;Hospitalized,Male,10-MAY-2007,16-AUG-2007,Expedited,76 YR,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Study,Foreign",Unspecified Ingredient;Digitoxin;Metoprolol;Glyburide,10-AUG-2007,06-AUG-2007,Not Specified,Not Specified,TPG2007A00511,-,-
6388485,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Product Quality Issue;Intercepted Medication Error,Non-Serious,Non-Serious,Not Specified,-,15-AUG-2007,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Health Professional,-,03-AUG-2007,15-AUG-2007,Not Specified,Not Specified,TPA2007A01644,-,-
6388430,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Blood Glucose Increased,Abdominal Distension;Asthenia;Dyspnoea;Fluid Retention,Serious,Life Threatening,Male,18-DEC-2006,15-AUG-2007,Direct,42 YR,192 LB,-,Consumer,Not Specified,-,-,15-AUG-2007,Not Specified,Not Specified,-,-,-
6387393,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Product Used For Unknown Indication,Acute Pulmonary Oedema;Cardiac Failure,Serious,Hospitalized,Female,-,14-AUG-2007,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,"Other,Health Professional ,Foreign",Allopurinol;Glyburide,01-AUG-2007,14-AUG-2007,Not Specified,Not Specified,TPG2007A00527,-,-
6888708,Competact,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Condition Aggravated;Hepatic Steatosis,Serious,Hospitalized,Male,-,10-AUG-2007,Expedited,51 YR,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Study,Foreign",Urso;Atorvastatin Calcium;Unspecified Ingredient;Candesartan Cilexetil;Ornithine Aspartate;Acomplia,30-JUL-2007,10-AUG-2007,Not Specified,Not Specified,TPG2007A00431,-,-
6356312,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Eye Disorder;Hypersomnia;Vomiting;Blood Glucose Increased;Abdominal Pain Upper;Urticaria;Feeling Abnormal;Nausea;Fatigue,Serious,Required Intervention;Other Outcomes,Female,29-MAY-2007,02-AUG-2007,Expedited,76 YR,210 LB,Takeda,Healthcare Professional,"Consumer,Health Professional",Vitamin B6;Requip;Lexapro;Lantus;Lisinopril;Hydrochlorothiazide;Hydrocodone;Calcium;Lipitor;Tricor;Metformin Hydrochloride;Folic Acid;Prilosec,26-JUL-2007,05-JUL-2007,Not Specified,Not Specified,TPA2007A01301,-,-
6365010,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Headache;Dizziness;Dyspepsia;Hypersensitivity;Visual Impairment;Nausea,Non-Serious,Non-Serious,Female,JUN-2007,18-JUL-2007,Expedited,57 YR,148 LB,Takeda,Consumer,Consumer,Vytorin;Diovan Hct;Glipizide,25-JUN-2007,18-JUL-2007,Not Specified,Not Specified,TPA2007A01369,-,-
6362944,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Anaemia;Pulmonary Oedema;Cardiomegaly;Cardiac Failure;Influenza;Dyspnoea,Serious,Hospitalized;Required Intervention,Male,DEC-2006,13-JUL-2007,Expedited,64 YR,250 LB,Takeda,Not Specified,Consumer,-,02-JUL-2007,13-JUL-2007,Not Specified,Not Specified,TPA2007A01429,-,-
6376518,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Cardiac Failure Congestive,Serious,Hospitalized,Not Specified,APR-2007,29-JUN-2007,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,23-APR-2007,29-JUN-2007,Not Specified,Not Specified,TPA2007A00862,-,-
6333062,Atacand;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Candesartan Cilexetil,-,Oedema Peripheral;Drug Interaction,Non-Serious,Non-Serious,Male,-,14-JUN-2007,Non-Expedited,Not Specified,Not Specified,Astrazeneca,Consumer,Not Specified,-,19-JUN-2006,14-JUN-2007,US,Not Specified,US-ASTRAZENECA-2006UW12936,-,-
6322786,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Fall;Radius Fracture,Serious,Required Intervention;Other Outcomes,Female,2007,30-MAY-2007,Expedited,6 DEC,260 LB,Takeda,Healthcare Professional,Health Professional,Vytorin;Synthroid,18-MAY-2007,16-MAY-2007,Not Specified,Not Specified,TPA2007A00960,-,-
6334118,Actos;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Incorrect Dose Administered;Diarrhoea,Non-Serious,Non-Serious,Female,APR-2007,09-MAY-2007,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,25-APR-2007,09-MAY-2007,Not Specified,Not Specified,TPA2007A00876,-,-
6308508,-,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Pulmonary Embolism;Peripheral Artery Thrombosis,Serious,Hospitalized,Female,19-JAN-2007,26-APR-2007,Expedited,70 YR,Not Specified,Takeda,Not Specified,Health Professional,Levothyroxine Sodium;Simvastatin,13-APR-2007,26-APR-2007,Not Specified,Not Specified,TPG2007A00326,-,-
6297104,Actoplus Met;Januvia,Sitagliptin Phosphate;Metformin Hydrochloride\Pioglitazone Hydrochloride,Blood Glucose,Blood Potassium Increased,Serious,Hospitalized;Life Threatening,Male,-,26-APR-2007,Expedited,Not Specified,Not Specified,Merck,Healthcare Professional,Health Professional,-,20-APR-2007,26-APR-2007,US,Not Specified,US-MERCK-0704USA04443,-,-
6234837,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Product Quality Issue;Product Dispensing Error;Intercepted Medication Error,Non-Serious,Non-Serious,Not Specified,-,08-MAR-2007,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,"Consumer,Health Professional",-,07-MAR-2007,26-JAN-2007,Not Specified,Not Specified,TPA2007A00114,-,-
6256375,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Imprisonment;Theft;Self-Medication;Nonspecific Reaction;Disorientation,Serious,Required Intervention,Male,15-FEB-2007,22-FEB-2007,Expedited,Not Specified,Not Specified,Takeda,Consumer,Consumer,-,17-FEB-2007,22-FEB-2007,Not Specified,Not Specified,TPA2007A00291,-,-
7615808,Actoplus Met;Byetta,Exenatide;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Blood Glucose Increased;Nausea;Blood Glucose Fluctuation,Non-Serious,Non-Serious,Female,14-OCT-2006,01-FEB-2007,Non-Expedited,58 YR,190 LB,Amylin,Consumer,Consumer,Glipizide,14-NOV-2006,01-FEB-2007,Not Specified,Not Specified,2006PV025375,-,-
6335508,Actoplus Met;Byetta,Exenatide;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Alopecia;Hypotrichosis,Non-Serious,Non-Serious,Female,2006,01-FEB-2007,Non-Expedited,58 YR,Not Specified,Amylin,Consumer,Consumer,-,09-OCT-2006,01-FEB-2007,Not Specified,Not Specified,2006PV022834,-,-
6309154,Byetta;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Exenatide,Type 2 Diabetes Mellitus,Blood Glucose Increased;Joint Swelling,Non-Serious,Non-Serious,Female,OCT-2006,01-FEB-2007,Non-Expedited,45 YR,Not Specified,Amylin,Consumer,Consumer,Prandin;Lantus,16-DEC-2006,01-FEB-2007,Not Specified,Not Specified,2006PV027077,-,-
6136036,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Myocardial Infarction;Blood Glucose Decreased;Product Dispensing Error;Somnolence;Incorrect Dose Administered;Anxiety,Serious,Hospitalized,Female,01-AUG-2006,29-DEC-2006,Expedited,70 YR,203 LB,Takeda,Healthcare Professional,"Consumer,Health Professional",Fish Oil;Vitamin E;Aspirin;Zetia;Vitamin C;Furosemide,14-DEC-2006,12-SEP-2006,Not Specified,Not Specified,TPA2006A01482,-,-
6203404,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Product Dispensing Error;Incorrect Dose Administered,Non-Serious,Non-Serious,Female,-,22-DEC-2006,Expedited,67 YR,Not Specified,Takeda,Healthcare Professional,Health Professional,-,07-DEC-2006,05-DEC-2006,Not Specified,Not Specified,TPA2006A02072,-,-
6058698,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Glyburide,Diabetes Mellitus;Type 2 Diabetes Mellitus,Depressed Level Of Consciousness;Product Dispensing Error;Feeling Hot;Blood Glucose Decreased;Malaise;Anxiety,Serious,Required Intervention;Other Outcomes,Female,MAY-2006,21-DEC-2006,Non-Expedited,75 YR,120 LB,Takeda,Healthcare Professional,"Company Representative ,Consumer,Health Professional",Dyazide;Atenolol;Aspirin;Actos;Actonel;Evista;Pravachol,07-SEP-2006,24-MAY-2006,Not Specified,Not Specified,TPA2006A00835,-,-
7615807,Byetta;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Exenatide,Type 2 Diabetes Mellitus,Weight Decreased;Dysgeusia,Non-Serious,Non-Serious,Female,AUG-2006,01-DEC-2006,Non-Expedited,61 YR,293 LB,Amylin,Consumer,Consumer,Actos;Glipizide;Metformin Hydrochloride,10-AUG-2006,01-DEC-2006,Not Specified,Not Specified,2006PV019228,-,-
7615806,Actoplus Met;Byetta,Exenatide;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Nausea;Blood Glucose Increased,Non-Serious,Non-Serious,Male,APR-2006,01-DEC-2006,Non-Expedited,70 YR,207 LB,Amylin,Consumer,Consumer,Glimepiride,14-AUG-2006,01-DEC-2006,Not Specified,Not Specified,2006PV019470,-,-
6267006,Actoplus Met;Byetta,Exenatide;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Abdominal Distension;Weight Increased,Non-Serious,Non-Serious,Female,MAY-2006,01-DEC-2006,Non-Expedited,Not Specified,Not Specified,Amylin,Consumer,Consumer,Metformin Hydrochloride,05-SEP-2006,01-DEC-2006,Not Specified,Not Specified,2006PV020778,-,-
6241518,Actoplus Met;Byetta,Exenatide;Metformin Hydrochloride\Pioglitazone Hydrochloride;Lisinopril,Type 2 Diabetes Mellitus,Decreased Appetite;Blood Glucose Fluctuation;Feeling Abnormal;Blood Glucose Increased;Hypotension;Fatigue;Weight Decreased,Non-Serious,Non-Serious,Female,2006,01-DEC-2006,Non-Expedited,62 YR,Not Specified,Amylin,Consumer,Consumer,Glucotrol;Metformin Hydrochloride;Actos;Metaglip;Lisinopril,13-JUL-2006,01-DEC-2006,Not Specified,Not Specified,2006PV017486,-,-
6144028,Actoplus Met;Actos,Pioglitazone Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Weight Increased;Nephrolithiasis,Serious,Other Outcomes;Required Intervention,Male,2005,29-NOV-2006,Expedited,65 YR,202 LB,Takeda,Not Specified,Consumer,Lisinopril;Finasteride;Lovastatin;Glucosamine;Docusate Sodium;Naproxen Sodium;Flomax,20-NOV-2006,27-SEP-2006,Not Specified,Not Specified,TPA2006A01558,-,-
6146517,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Seizure,Serious,Other Outcomes;Required Intervention,Male,-,02-OCT-2006,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,22-SEP-2006,02-OCT-2006,Not Specified,Not Specified,TPA2006A01633,-,-
6126186,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Product Quality Issue,Non-Serious,Non-Serious,Male,-,02-OCT-2006,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",-,22-SEP-2006,30-AUG-2006,Not Specified,Not Specified,TPA2006A01369,-,-
6144026,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Wheezing;Rash;Throat Tightness;Urticaria;Dyspnoea,Serious,Other Outcomes;Required Intervention,Female,-,27-SEP-2006,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,"Company Representative ,Health Professional",Metformin Hydrochloride,18-SEP-2006,27-SEP-2006,Not Specified,Not Specified,TPA2006A01557,-,-
6091050,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Myalgia;Hyperaesthesia;Muscular Weakness;Movement Disorder,Serious,Other Outcomes;Required Intervention,Female,2006,27-SEP-2006,Expedited,57 YR,198 LB,Takeda,Healthcare Professional,Health Professional,Lipitor;Unspecified Ingredient,21-SEP-2006,13-JUL-2006,Not Specified,Not Specified,TPA2006A01046,-,-
6090983,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Muscular Weakness;Dyspnoea;Movement Disorder;Hyperaesthesia;Myalgia;Asthenia,Serious,Required Intervention;Other Outcomes,Female,2006,27-SEP-2006,Expedited,61 YR,235 LB,Takeda,Healthcare Professional,Health Professional,Tricor;Unspecified Ingredient,18-SEP-2006,13-JUL-2006,Not Specified,Not Specified,TPA2006A01044,-,-
5996348,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Blood Glucose Increased;Chest Pain;Coronary Artery Disease,Serious,Hospitalized;Required Intervention,Male,2006,30-AUG-2006,Expedited,39 YR,334 LB,Takeda,Healthcare Professional,"Consumer,Health Professional",Aldactone;Seroquel;Celebrex;Klonopin;Humulin 70/30;Oxygen;Toprol Xl;Cozaar;Depakote;Klor-Con,25-AUG-2006,14-FEB-2006,Not Specified,Not Specified,TPA2006A00220,-,-
7615795,Byetta;Diovan;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Valsartan;Exenatide,Type 2 Diabetes Mellitus,Pre-Existing Condition Improved;Weight Decreased,Non-Serious,Non-Serious,Female,NOV-2005,31-JUL-2006,Non-Expedited,48 YR,203 LB,Amylin,Consumer,Consumer,Coreg;Amaryl,17-MAY-2006,31-JUL-2006,Not Specified,Not Specified,2006PV013995,-,-
6085795,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Product Quality Issue;Blood Glucose Increased,Serious,Other Outcomes,Male,16-JUN-2006,11-JUL-2006,Direct,49 YR,190 LB,-,Healthcare Professional,Health Professional,-,-,11-JUL-2006,Not Specified,Not Specified,-,-,-
7615782,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Movement Disorder;Myalgia;Myopathy;Asthenia;Bedridden,Serious,Other Outcomes,Female,15-FEB-2006,05-JUL-2006,Direct,57 YR,197 LB,-,Healthcare Professional,Health Professional,Zoloft;Hydrochlorothiazide;Lotrel;Labetalol;Glucotrol Xl;Lipitor;Aspirin,-,05-JUL-2006,Not Specified,Y,-,-,-
6086071,Actoplus Met;Metformin,Metformin Hydrochloride;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus,Myalgia;Myopathy,Serious,Other Outcomes,Female,08-MAY-2006,05-JUL-2006,Direct,61 YR,289 LB,-,Healthcare Professional,Health Professional,Toprol Xl;Potassium Chloride;Combivent;Zyrtec;Glucotrol Xl;Lasix,-,05-JUL-2006,Not Specified,Y,-,-,-
7615787,Byetta;Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Exenatide,Type 2 Diabetes Mellitus,Nausea;Eructation;Weight Decreased;Vomiting;Abdominal Distension,Non-Serious,Non-Serious,Female,-,01-JUN-2006,Non-Expedited,56 YR,205 LB,Amylin,Consumer,Consumer,Metformin Hydrochloride,27-MAR-2006,01-JUN-2006,Not Specified,Not Specified,2006PV010977,-,-
5986299,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride;Ethinyl Estradiol\Norethindrone,Uterine Haemorrhage,Arteriosclerosis Coronary Artery;Cardio-Respiratory Arrest;Pulmonary Embolism;Pulmonary Congestion;Arteriosclerosis;Hepatic Steatosis;Pulmonary Infarction,Serious,Died;Required Intervention;Other Outcomes,Female,2006,12-APR-2006,Expedited,26 YR,329 LB,Takeda,Healthcare Professional,"Company Representative ,Health Professional",Avandia,07-APR-2006,02-FEB-2006,Not Specified,Not Specified,TPA2006A00164,-,-
6061945,Actoplus Met;Humalog Mix75/25,Insulin Lispro;Metformin Hydrochloride\Pioglitazone Hydrochloride,Diabetes Mellitus;Type 2 Diabetes Mellitus,Blood Glucose Decreased,Serious,Required Intervention,Female,20-DEC-2005,30-MAR-2006,Non-Expedited,81 YR,150 LB,Takeda,Consumer,Consumer,-,21-DEC-2005,30-MAR-2006,Not Specified,Not Specified,TPA2005A01711,-,-
6061942,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Dyspnoea;Oedema;Weight Increased;Cardiac Failure Congestive,Serious,Required Intervention;Other Outcomes,Not Specified,-,30-MAR-2006,Non-Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Health Professional,Lipitor,08-DEC-2005,30-MAR-2006,Not Specified,Not Specified,TPA2005A01639,-,-
6005047,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,-,Product Dispensing Error,Non-Serious,Non-Serious,Not Specified,FEB-2006,01-MAR-2006,Expedited,Not Specified,Not Specified,Takeda,Healthcare Professional,Health Professional,-,23-FEB-2006,01-MAR-2006,Not Specified,Not Specified,TPA2006A00334,-,-
6963840,Actoplus Met,Metformin Hydrochloride\Pioglitazone Hydrochloride,Type 2 Diabetes Mellitus,Pancreatic Carcinoma;Hyperglycaemia;Abdominal Symptom;Fatigue;Metastases To Liver,Serious,Hospitalized,Female,08-JAN-2002,06-MAR-2002,Expedited,72 YR,Not Specified,Takeda,Healthcare Professional,"Health Professional ,Study,Foreign",Bisoprolol;Fluticasone Propionate;Digoxin;Aspirin;Glyburide,28-FEB-2002,28-FEB-2002,Not Specified,Not Specified,ERD2002A00033,-,-
22609767,Januvia,Sitagliptin Phosphate;Glyburide\Metformin,-,Diabetes Mellitus Inadequate Control,Serious,Other Outcomes,Male,-,16-Jun-23,Expedited,82 YR,Not Specified,Merck,Consumer,Not Specified,-,14-Jun-23,16-Jun-23,IT,Not Specified,IT-009507513-2306ITA007993,-,-
8695872,-,Glyburide\Metformin;Nadroparin Calcium;Hydromorphone;Levofloxacin,Deep Vein Thrombosis;Infection;Product Used For Unknown Indication;Respiratory Tract Infection;Type 2 Diabetes Mellitus,Unresponsive To Stimuli;Hypoglycaemia;Drug Interaction,Serious,Other Outcomes,Male,-,2-Feb-23,Expedited,61 YR,Not Specified,Mylan,Healthcare Professional,Not Specified,-,25-Jan-23,1-Aug-12,IT,Not Specified,IT-MYLANLABS-2012S1014973,"Micheli L, Sbrilli M, Nencini e. Severe hypoglycemia associated with levofloxacin in Type 2 diabetie patients receiving polytherapy: two case reports. Intemational Joumal of Clinical Pharmacology and Therapeutics. 2012;4:302-6",-
21833795,-,Nadroparin Calcium;Hydromorphone;Glyburide\Metformin;Levofloxacin,Deep Vein Thrombosis;Product Used For Unknown Indication;Respiratory Tract Infection;Type 2 Diabetes Mellitus,Unresponsive To Stimuli;Drug Interaction;Hypoglycaemia,Serious,Other Outcomes,Male,-,8-Jan-23,Expedited,61 YR,Not Specified,Aurobindo,Healthcare Professional,Not Specified,-,26-Dec-22,8-Jan-23,IT,Not Specified,IT-AUROBINDO-AUR-APL-2023-000872,"Micheli L, Sbrilli M, Nencini e.. Severe hypoglycemia associated with levofloxacin in Type 2 diabetie patients receiving polytherapy: two case reports. Intemational Joumal of Clinical Pharmacology and Therapeutics 50. 2012;No.4:302-6",-
20488658,-,Glyburide\Metformin,Diabetes Mellitus,Foetal Exposure During Pregnancy;Stillbirth;Congenital Anomaly In Offspring;Low Birth Weight Baby,Serious,Died;Other Outcomes;Congenital Anomaly,Female,-,18-Feb-22,Expedited,Not Specified,2.1 KG,Ranbaxy,Healthcare Professional,Not Specified,-,4-Feb-22,18-Feb-22,IN,Not Specified,IN-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-327293,"Saha JK, Sarkar A, Lahiri TK, Dam P. CYCLOPIA- A RARE CASE OF DIABETIC EMBRYOPATHY. J INDIAN MED ASSOC. 2010;Jun; 108(6):379",-
20488293,-,Glyburide\Metformin,Diabetes Mellitus,Oedema Peripheral;Hypertension;Polyhydramnios;Exposure During Pregnancy,Serious,Other Outcomes;Hospitalized,Female,-,18-Feb-22,Expedited,29 YR,Not Specified,Ranbaxy,Healthcare Professional,Not Specified,-,4-Feb-22,18-Feb-22,IN,Not Specified,IN-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-326548,"Saha JK, Sarkar A, Lahiri TK, Dam P. CYCLOPIA- A RARE CASE OF DIABETIC EMBRYOPATHY. J INDIAN MED ASSOC. 2010;Jun; 108(6):379",-
20279242,-,Glyburide\Metformin,-,Hepatic Cancer;Gastrointestinal Disorder;Death;Hospitalisation,Serious,Hospitalized;Other Outcomes;Life Threatening;Died,Male,15-Dec-21,3-Feb-22,Expedited,87 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,-,28-Dec-21,3-Jan-22,SA,Not Specified,SA-SA-2021SA418720,-,-
20138665,-,Hydromorphone;Glyburide\Metformin;Nadroparin;Levofloxacin,Chemotherapy;Deep Vein Thrombosis;Dysphagia;Product Used For Unknown Indication;Respiratory Tract Infection;Type 2 Diabetes Mellitus;Urinary Tract Infection,Drug Interaction;Hypoglycaemia,Serious,Other Outcomes;Hospitalized,Not Specified,-,2-Dec-21,Expedited,Not Specified,Not Specified,Macleods,Healthcare Professional,Not Specified,Cetuximab;Fluorouracil;Cisplatin,23-Nov-21,2-Dec-21,IT,Not Specified,IT-MACLEODS PHARMACEUTICALS US LTD-MAC2012000567,"Micheli L, Sbrilli M, Nencini C.. Severe hypoglycemia associated with levofloxacin in Type 2 diabetic patients receiving polytherapy: two case reports. International Journal of Clinical Pharmacology and Therapeutics. 2013;50(4):302-6",-
20138657,Tramadol,Tramadol\Tramadol Hydrochloride;Glyburide\Metformin;Enalapril\Hydrochlorothiazide;Lansoprazole;Enalapril;Insulin Nos;Levofloxacin;Buprenorphine;Nadroparin;Aspirin,Bacterial Infection;Cerebellar Stroke;Ischaemic Stroke;Pain;Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Drug Interaction;Hypoglycaemia;Blood Glucose Decreased;Coma,Serious,Hospitalized;Other Outcomes,Not Specified,-,2-Dec-21,Expedited,Not Specified,Not Specified,Macleods,Healthcare Professional,Not Specified,-,23-Nov-21,2-Dec-21,IT,Not Specified,IT-MACLEODS PHARMACEUTICALS US LTD-MAC2012000115,"Micheli L, Sbrilli M, Nencini C.. Severe hypoglycemia associated with levofloxacin in Type 2 diabetic patients receiving polytherapy: two case reports. International Journal of Clinical Pharmacology and Therapeutics. 2012;50(4):302-306",-
18916568,-,Metformin Hydrochloride\Pioglitazone Hydrochloride;Glyburide\Metformin,Hypertension;Hypothyroidism;Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Lactic Acidosis;Hypoglycaemia,Serious,Hospitalized;Other Outcomes,Female,-,19-Feb-21,Expedited,80 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,Levothyroxine Sodium;Nebivolol Hydrochloride,16-Feb-21,19-Feb-21,IT,Not Specified,IT-TAKEDA-2021TEU001435,-,-
13967325,Tramadol,Tramadol\Tramadol Hydrochloride;Glyburide\Metformin;Levofloxacin;Nadroparin Calcium;Enalapril Maleate\Hydrochlorothiazide;Buprenorphine;Enalapril,Antiplatelet Therapy;Bacterial Infection;Hypertension;Ischaemic Stroke;Pain;Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Drug Interaction;Skin Warm;Coma;Hypoglycaemia,Serious,Hospitalized;Other Outcomes,Female,-,6-Jan-21,Expedited,91 YR,Not Specified,Aurobindo,Healthcare Professional,Not Specified,Lansoprazole;Aspirin,28-Dec-20,14-Sep-17,IT,Not Specified,IT-AUROBINDO-AUR-APL-2012-01729,"Micheli L, Sbrilli M, Nencini C.. Severe hypoglycemia associated with levofloxacin in Type 2 diabetic patients receiving polytherapy: two case reports.. International Journal of Clinical Pharmacology and Therapeutics.. 2012;50(4):302-306",-
17307552,-,Glyburide\Metformin,Diabetes Mellitus,Lactic Acidosis;Urosepsis;Dehydration,Serious,Hospitalized;Life Threatening,Male,14-Jun-11,6-Jan-20,Direct,72 YR,101.6 KG,Fda-Ctu,Healthcare Professional,Health Professional,-,-,6-Jan-20,US,Not Specified,-,-,-
17221299,-,Glyburide\Metformin;Pioglitazone;Metformin Hydrochloride,Type 2 Diabetes Mellitus,Medication Error;Hypoglycaemia,Serious,Hospitalized,Female,2-Nov-19,31-Dec-19,Expedited,81 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,Lorazepam;Simvastatin;Pantoprazole;Cholecalciferol;Plavix,25-Dec-19,31-Dec-19,IT,Not Specified,IT-TAKEDA-2019TEU015831,-,-
17121761,-,Bisoprolol Fumarate;Sertraline Hydrochloride;Pantoprazole Sodium;Rosuvastatin Calcium;Glyburide\Metformin;Amlodipine Besylate,Product Used For Unknown Indication,Drug Interaction;Anxiety;Frustration Tolerance Decreased;Arrhythmia;Impaired Driving Ability;Dizziness,Serious,Other Outcomes;Disabled,Female,-,24-Dec-19,Expedited,53 YR,Not Specified,Msn Laboratories,Consumer,Not Specified,-,12-Dec-19,6-Dec-19,US,Not Specified,US-MSN LABORATORIES PRIVATE LIMITED-2077542,N/AP,-
16429147,Humira,Adalimumab;Glyburide\Metformin,Product Used For Unknown Indication;Psoriatic Arthropathy,Blood Glucose Decreased,Serious,Hospitalized,Female,-,27-Aug-19,Expedited,Not Specified,64.92 KG,Abbvie,Consumer,Not Specified,Pantoprazole;Iron;Amlodipine Besylate,22-Aug-19,14-Jun-19,US,Not Specified,US-ABBVIE-19K-163-2817719-00,-,-
16458160,Metformin,Metformin Hydrochloride;Glyburide\Metformin,Type 2 Diabetes Mellitus,Vomiting;Lactic Acidosis;Acute Kidney Injury,Serious,Hospitalized,Female,14-Dec-18,20-Jun-19,Expedited,70 YR,Not Specified,Mylan,Healthcare Professional,Not Specified,Hydrochlorothiazide\Olmesartan Medoxomil;Cardura;Aspirin;Tenormin,10-Jun-19,20-Jun-19,IT,Not Specified,IT-MYLANLABS-2019M1056886,-,-
16068147,-,Pioglitazone;Glyburide\Metformin,Diabetes Mellitus,Polyuria;Blood Creatinine Increased;Polydipsia,Serious,Hospitalized,Male,4-Jan-19,13-Mar-19,Expedited,65 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,-,7-Mar-19,13-Mar-19,IT,Not Specified,IT-TAKEDA-2019TEU002180,-,-
15812277,Metformin,Metformin Hydrochloride;Glyburide\Metformin,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Lactic Acidosis;Acute Kidney Injury;Hyponatraemia;Vomiting;Hyperlactacidaemia,Serious,Hospitalized,Female,14-Dec-18,11-Feb-19,Expedited,70 YR,Not Specified,Sandoz,Healthcare Professional,Not Specified,Tenormin;Hydrochlorothiazide\Olmesartan Medoxomil;Aspirin;Cardura,4-Feb-19,11-Jan-19,IT,Not Specified,PHHY2019IT004484,-,-
15883160,-,Metformin Hydrochloride;Glyburide\Metformin,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Lactic Acidosis;Vomiting;Hyponatraemia;Acute Kidney Injury,Serious,Hospitalized;Other Outcomes,Female,14-Dec-18,29-Jan-19,Expedited,70 YR,Not Specified,Aurobindo,Healthcare Professional,Not Specified,Tenormin;Aspirin;Cardura;Hydrochlorothiazide\Olmesartan Medoxomil,15-Jan-19,29-Jan-19,IT,Not Specified,IT-AUROBINDO-AUR-APL-2019-003432,-,-
15710718,Lantus,Insulin Glargine;Glyburide\Metformin;Insulin Lispro,Type 2 Diabetes Mellitus,Hypoglycaemia;Intentional Product Misuse;Diabetes Mellitus;Malaise,Serious,Hospitalized,Male,18-Oct-18,14-Jan-19,Expedited,83 YR,Not Specified,Sanofi Aventis,Healthcare Professional,Not Specified,Atorvastatin;Amlodipine Besylate\Perindopril Erbumine;Metoprolol;Aspirin,7-Jan-19,11-Dec-18,IT,Not Specified,IT-SAKK-2018SA329734AA,-,-
15685266,Lantus;Humalog,Insulin Lispro;Insulin Glargine;Glyburide\Metformin,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Hypoglycaemia;Diabetes Mellitus;Malaise,Serious,Hospitalized,Male,18-Oct-18,14-Jan-19,Expedited,83 YR,Not Specified,Sandoz,Healthcare Professional,Not Specified,Aspirin;Metoprolol;Atorvastatin;Perindopril,7-Jan-19,4-Dec-18,IT,Not Specified,PHHY2018IT171896,-,-
15810669,Metformin,Metformin Hydrochloride;Glyburide\Metformin,Type 2 Diabetes Mellitus,Vomiting;Acute Kidney Injury;Lactic Acidosis,Serious,Hospitalized,Female,14-Dec-18,11-Jan-19,Expedited,70 YR,Not Specified,Teva,Healthcare Professional,Not Specified,Cardura;Aspirin;Tenormin,8-Jan-19,11-Jan-19,IT,Not Specified,IT-TEVA-2019-IT-997397,-,-
15801156,-,Glyburide\Metformin;Metformin Hydrochloride,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Vomiting;Acute Kidney Injury;Lactic Acidosis,Serious,Other Outcomes;Hospitalized,Female,14-Dec-18,9-Jan-19,Expedited,70 YR,Not Specified,Bristol Myers Squibb,Healthcare Professional,Not Specified,Cardura;Aspirin;Tenormin;Hydrochlorothiazide\Olmesartan Medoxomil,4-Jan-19,9-Jan-19,IT,Not Specified,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-000960,-,-
15669629,-,Glyburide\Metformin,Blood Glucose Increased,Blood Glucose Increased;Product Substitution Issue,Non-Serious,Non-Serious,Female,-,29-Nov-18,Non-Expedited,Not Specified,Not Specified,Teva,Consumer,Not Specified,-,7-Nov-18,29-Nov-18,US,Not Specified,US-TEVA-2018-US-974224,-,-
15566122,Novolog;Toujeo,Insulin Glargine;Glyburide\Metformin;Insulin Aspart,Type 2 Diabetes Mellitus,Asthenia;Nervousness;Hypoglycaemic Unconsciousness;Blood Glucose Decreased;Hyperhidrosis,Serious,Hospitalized,Male,19-Sep-18,30-Oct-18,Expedited,69 YR,Not Specified,Sanofi Aventis,Consumer,Not Specified,Metformin;Jardiance,22-Oct-18,30-Oct-18,US,Not Specified,US-SA-2018SA296364,-,-
15424701,-,Glyburide\Metformin,Diabetes Mellitus;Product Used For Unknown Indication,Acute Kidney Injury;Hypoglycaemia;Urinary Retention,Serious,Hospitalized,Male,6-Jul-18,25-Sep-18,Expedited,80 YR,Not Specified,Sandoz,Healthcare Professional,Not Specified,Lorazepam;Ciprofloxacin;Enalapril;Nifedipine,10-Sep-18,25-Sep-18,IT,Not Specified,PHHY2018IT107339,-,-
15405314,Invokana;Victoza,Liraglutide;Glyburide\Metformin;Canagliflozin,Diabetes Mellitus;Product Used For Unknown Indication,Acute Kidney Injury,Serious,Hospitalized,Male,May-14,20-Sep-18,Non-Expedited,60 YR,Not Specified,Janssen,Healthcare Professional,Not Specified,-,5-Sep-18,20-Sep-18,US,Not Specified,US-JNJFOC-20180907003,-,-
15319151,-,Glyburide\Metformin,Diabetes Mellitus,Fall;Confusional State;Dizziness;Blood Glucose Increased;Decreased Appetite;Loss Of Personal Independence In Daily Activities;Hypoaesthesia;Pain In Extremity;Muscle Atrophy;Breast Pain;Therapy Change;Syncope;Abdominal Pain Upper;Feeling Cold;Asthenia;Fatigue;Blood Pressure Inadequately Controlled;Disturbance In Attention,Serious,Disabled,Female,15-May-18,20-Aug-18,Direct,51 YR,62.55 KG,Fda-Ctu,Consumer,Consumer,Insulin Nos;Citalopram;Gabapentin;Levothyroxine,-,20-Aug-18,US,Not Specified,-,-,-
15296316,-,Metformin Hydrochloride;Ramipril;Glyburide\Metformin,Hypertension;Type 2 Diabetes Mellitus,Diarrhoea;Hypoglycaemia;Vomiting;Lactic Acidosis,Serious,Other Outcomes;Life Threatening,Female,-,20-Aug-18,Expedited,71 YR,Not Specified,Pfizer,Healthcare Professional,Not Specified,Sinemet;Bisoprolol;Xalatan;Furosemide;Fluindione;Ezetimibe;Stalevo,9-Aug-18,20-Aug-18,FR,Not Specified,FR-PFIZER INC-2018329825,-,-
15279749,Metformin,Metformin Hydrochloride;Ramipril;Glyburide\Metformin,Hypertension;Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Vomiting;Lactic Acidosis;Diarrhoea;Hypoglycaemia,Serious,Life Threatening,Female,6-Jan-18,20-Aug-18,Expedited,71 YR,Not Specified,Bausch And Lomb,Healthcare Professional,Not Specified,Sinemet;Furosemide;Bisoprolol;Xalatan;Stalevo;Fluindione;Ezetimibe,9-Aug-18,15-Aug-18,FR,Not Specified,FR-BAUSCH-BL-2018-021936,-,-
13946609,Glucophage,Metformin Hydrochloride;Glyburide\Metformin,Diabetes Mellitus;Hypertension,Lactic Acidosis;Vomiting;Electrolyte Imbalance,Serious,Other Outcomes;Hospitalized,Female,2-Mar-17,8-Mar-18,Expedited,68 YR,Not Specified,Bristol Myers Squibb,Healthcare Professional,Not Specified,Glimepiride\Pioglitazone Hydrochloride;Torsemide,23-Feb-18,7-Sep-17,IT,Not Specified,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-079584,-,-
14603252,Invokana,Canagliflozin;Glyburide\Metformin,Type 2 Diabetes Mellitus,Toe Amputation;Diabetic Foot;Osteomyelitis;Skin Ulcer,Serious,Other Outcomes,Male,23-Nov-16,6-Mar-18,Expedited,60 YR,Not Specified,Janssen,Healthcare Professional,Not Specified,-,1-Mar-18,6-Mar-18,US,Not Specified,US-JNJFOC-20180303095,-,-
13692487,Escitalopram,Escitalopram Oxalate;Atorvastatin;Zaleplon;Glyburide\Metformin;Amlodipine Besylate\Olmesartan Medoxomil;Clonazepam,Insomnia;Major Depression,Major Depression;Akathisia,Serious,Other Outcomes,Not Specified,-,27-Jun-17,Expedited,Not Specified,Not Specified,Cipla,Healthcare Professional,Not Specified,-,12-Jun-17,27-Jun-17,TW,Not Specified,TW-CIPLA LTD.-2017TW10854,"Hsieh M-T, Lee Y, Lin P-Y, Tsai C-J, and Chang C-C. Tardive akathisia related to the antihypertensive agent Sevikar-a case report. BMC Pharmacology and Toxicology. 2017;18 (41):1 to 3",-
13610077,-,Aspirin;Simvastatin;Glyburide\Metformin,Product Used For Unknown Indication,Accidental Exposure To Product;Accidental Exposure To Product By Child;Asthenia;Hypoglycaemia,Serious,Hospitalized,Male,1-Jul-16,14-Jun-17,Expedited,3 YR,Not Specified,Accord,Healthcare Professional,Not Specified,-,6-Jun-17,4-Jun-17,IT,Not Specified,IT-ACCORD-052184,-,-
13614596,-,Aspirin;Glyburide\Metformin;Simvastatin,Product Used For Unknown Indication,Hypoglycaemia;Asthenia,Serious,Hospitalized,Male,1-Jul-16,13-Jun-17,Expedited,3 YR,Not Specified,Aurobindo,Healthcare Professional,Not Specified,-,30-May-17,6-Jun-17,IT,Not Specified,IT-AUROBINDO-AUR-APL-2017-34800,-,-
13614026,-,Simvastatin;Glyburide\Metformin;Aspirin,Product Used For Unknown Indication,Hypoglycaemia;Asthenia,Serious,Hospitalized,Male,1-Jul-16,6-Jun-17,Expedited,3 YR,Not Specified,Ranbaxy,Healthcare Professional,Not Specified,-,22-May-17,6-Jun-17,IT,Not Specified,IT-SUN PHARMACEUTICAL INDUSTRIES LTD-2017RR-142039,-,-
12702749,Januvia;Humira,Adalimumab;Losartan;Glyburide\Metformin;Sitagliptin Phosphate,Colitis Ulcerative;Crohn's Disease;Product Used For Unknown Indication;Rheumatoid Arthritis,Renal Failure;Malaise;Blood Pressure Increased;Acute Kidney Injury;Kidney Fibrosis;Pyelonephritis;Diabetes Mellitus,Serious,Hospitalized;Other Outcomes,Female,8-Jul-16,22-Feb-17,Expedited,65 YR,71.28 KG,Abbvie,Consumer,Not Specified,Omeprazole;Zyrtec;Diltiazem;Aspirin;Losartan;Valacyclovir;Gabapentin;Iron;Restasis,15-Feb-17,31-Aug-16,US,Not Specified,US-ABBVIE-16K-163-1710426-00,-,-
13130090,-,Glyburide\Metformin;Metformin Hydrochloride,Diabetes Mellitus;Pemphigoid,Hypoglycaemia;Drug Interaction;Asthenia,Serious,Other Outcomes,Male,13-Jun-16,23-Jan-17,Expedited,76 YR,Not Specified,Teva,Healthcare Professional,Not Specified,-,11-Jan-17,19-Jan-17,IT,Not Specified,IT-TEVA-723771ACC,-,-
13075224,Metformin,Metformin Hydrochloride;Glyburide\Metformin,Diabetes Mellitus;Pemphigoid,Hypoglycaemia;Asthenia;Drug Interaction;Atrial Fibrillation,Serious,Other Outcomes,Male,13-Jun-16,19-Jan-17,Expedited,76 YR,Not Specified,Aurobindo,Healthcare Professional,Not Specified,Prednisone,5-Jan-17,30-Dec-16,IT,Not Specified,IT-AUROBINDO-AUR-APL-2016-15781,-,-
13117562,Metformin,Metformin Hydrochloride;Glyburide\Metformin,Diabetes Mellitus;Pemphigoid,Hypoglycaemia;Asthenia;Drug Interaction,Serious,Other Outcomes,Male,13-Jun-16,16-Jan-17,Expedited,76 YR,Not Specified,Sandoz,Healthcare Professional,Not Specified,Prednisone,16-Dec-16,16-Jan-17,IT,Not Specified,PHHY2016IT175135,-,-
13109282,Tresiba;Apidra,Insulin Glulisine;Insulin Degludec;Glyburide\Metformin,Diabetes Mellitus,Fatigue;Speech Disorder;Hypoglycaemia,Serious,Hospitalized,Female,16-Dec-16,12-Jan-17,Expedited,74 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,Digoxin;Ezetimibe\Simvastatin;Warfarin;Valsartan;Furosemide;Bisoprolol Fumarate,4-Jan-17,12-Jan-17,IT,Not Specified,IT-NOVOPROD-525904,-,-
13100829,Apidra Solostar;Tresiba,Insulin Degludec;Insulin Glulisine;Glyburide\Metformin,Diabetes Mellitus,Speech Disorder;Fatigue;Hypoglycaemia,Serious,Hospitalized,Female,16-Dec-16,10-Jan-17,Expedited,73 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,Warfarin Sodium;Bisoprolol Fumarate;Digoxin;Ezetimibe\Simvastatin;Furosemide;Device;Amlodipine Besylate;Hydrochlorothiazide\Valsartan;Solostar,4-Jan-17,10-Jan-17,IT,Not Specified,IT-SA-2017SA002409,-,-
13040864,Levaquin;Augmentin;Duragesic;Feldene,Fentanyl;Piroxicam;Amoxicillin\Clavulanate Potassium;Clindamycin Hydrochloride;Levofloxacin;Glyburide\Metformin,-,Drug Hypersensitivity,Non-Serious,Non-Serious,Male,-,19-Dec-16,Non-Expedited,63 YR,Not Specified,Pfizer,Healthcare Professional,Not Specified,-,8-Dec-16,19-Dec-16,US,Not Specified,US-PFIZER INC-2016575334,-,-
12928241,-,Glyburide\Metformin;Alprazolam,Anxiety;Depression;Diabetes Mellitus;Hypercholesterolaemia;Hypertension;Product Used For Unknown Indication,Hypoglycaemia;Malaise;Sopor;Asthenia;Drug Abuse,Serious,Hospitalized,Not Specified,18-Oct-16,10-Nov-16,Expedited,86 YR,Not Specified,Ranbaxy,Healthcare Professional,Not Specified,Aspirin Dl-Lysine,26-Oct-16,10-Nov-16,IT,Not Specified,IT-SUN PHARMACEUTICAL INDUSTRIES LTD-2016RR-127037,-,-
12921631,-,Glyburide\Metformin;Alprazolam,Anxiety;Depression;Diabetes Mellitus;Hypercholesterolaemia;Hypertension;Product Used For Unknown Indication,Sopor;Hypoglycaemia;Drug Abuse;Asthenia;Malaise,Serious,Hospitalized,Not Specified,18-Oct-16,8-Nov-16,Expedited,86 YR,Not Specified,Teva,Healthcare Professional,Not Specified,Zoloft;Losartan Potassium;Aspirin Dl-Lysine;Simvastatin,27-Oct-16,8-Nov-16,IT,Not Specified,IT-TEVA-710265ACC,-,-
12681837,Metformin;Amlodipine,Amlodipine Besylate;Clopidogrel Bisulfate;Aspirin;Glyburide;Glyburide\Metformin;Losartan Potassium;Nitroglycerin;Doxazosin Mesylate;Ramipril;Ursodiol;Metformin Hydrochloride;Ivabradine Hydrochloride;Ranolazine;Furosemide;Isosorbide Mononitrate;Carvedilol,Cardiac Failure;Product Used For Unknown Indication,"Photopsia;Hallucination, Visual",Serious,Hospitalized,Male,-,8-Sep-16,Expedited,75 YR,Not Specified,Bausch And Lomb,Healthcare Professional,Not Specified,-,25-Aug-16,24-Aug-16,IT,Not Specified,IT-BAUSCH-BL-2016-020403,-,-
12587036,-,Ledipasvir\Sofosbuvir;Atorvastatin Calcium;Hydrochlorothiazide\Lisinopril;Ibuprofen;Gabapentin;Aspirin;Levetiracetam;Glyburide\Metformin,Product Used For Unknown Indication,Urine Output Decreased;Acute Kidney Injury;Malaise;Rhabdomyolysis;Chromaturia;Muscular Weakness;Leukocytosis;Myalgia,Serious,Life Threatening;Other Outcomes;Hospitalized,Male,-,25-Jul-16,Expedited,60 YR,Not Specified,Sciegen,Healthcare Professional,Not Specified,-,15-Jul-16,25-Jul-16,US,Not Specified,US-SCIEGEN PHARMACEUTICALS INC-2016SCILIT00320,"Venkata Ghanta, Michael Strauss and Roberto Collazo. LIFE THREATENING RHABDOMYOLYSIS FROM THE COMBINATION OF LEDIPASVIR/SOFOSBUVIR AND HIGH DOSE STATINS. American Journal of Kidney Diseases. 2016;67 (5):A1-A118",-
12497677,-,Clarithromycin;Metformin Hydrochloride;Glyburide\Metformin,Product Used For Unknown Indication,Drug Interaction;Hypoglycaemia,Serious,Hospitalized,Female,29-May-16,25-Jun-16,Expedited,81 YR,Not Specified,Bristol Myers Squibb,Healthcare Professional,Not Specified,Lansoprazole,6-Jun-16,25-Jun-16,IT,Not Specified,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-046198,-,-
12478460,Metformin,Metformin Hydrochloride;Glyburide\Metformin;Clarithromycin,Product Used For Unknown Indication,Drug Interaction;Hypoglycaemia,Serious,Hospitalized,Female,29-May-16,18-Jun-16,Expedited,81 YR,Not Specified,Aurobindo,Healthcare Professional,Not Specified,Lansoprazole,6-Jun-16,18-Jun-16,IT,Not Specified,IT-AUROBINDO-AUR-APL-2016-07720,-,-
12477331,Metformin,Metformin Hydrochloride;Glyburide\Metformin;Clarithromycin,Product Used For Unknown Indication,Hypoglycaemia;Drug Interaction,Serious,Hospitalized;Other Outcomes,Not Specified,29-May-16,17-Jun-16,Expedited,Not Specified,Not Specified,Apotex,Healthcare Professional,Not Specified,Lansoprazole,6-Jun-16,17-Jun-16,IT,Not Specified,IT-APOTEX-2016AP008998,-,-
12464610,Metformin,Metformin Hydrochloride;Clarithromycin;Glyburide\Metformin,Product Used For Unknown Indication,Hypoglycaemia;Drug Interaction,Serious,Hospitalized,Female,29-May-16,14-Jun-16,Expedited,81 YR,Not Specified,Teva,Healthcare Professional,Not Specified,Lansoprazole,6-Jun-16,14-Jun-16,IT,Not Specified,IT-TEVA-667322ACC,-,-
12463820,Metformin,Metformin Hydrochloride;Glyburide\Metformin;Clarithromycin,Product Used For Unknown Indication,Hypoglycaemia;Drug Interaction,Serious,Hospitalized,Female,29-May-16,14-Jun-16,Expedited,81 YR,Not Specified,Abbvie,Healthcare Professional,Not Specified,Lansoprazole,6-Jun-16,14-Jun-16,IT,Not Specified,IT-ABBVIE-16P-083-1651629-00,-,-
12448726,Metformin,Metformin Hydrochloride;Clarithromycin;Glyburide\Metformin,Product Used For Unknown Indication,Drug Interaction;Hypoglycaemia,Serious,Hospitalized,Not Specified,29-May-16,8-Jun-16,Expedited,Not Specified,Not Specified,Mylan,Healthcare Professional,Not Specified,Lansoprazole,6-Jun-16,8-Jun-16,IT,Not Specified,IT-MYLANLABS-2016M1023841,-,-
12140832,-,Glyburide\Metformin,Diabetes Mellitus,Nerve Injury;Diabetes Mellitus;Headache;Balance Disorder;Muscle Spasms;Nervousness;Fall;Weight Decreased;Muscle Twitching;Vomiting,Serious,Other Outcomes;Disabled,Female,1-Jan-16,2-Mar-16,Direct,73 YR,250 LB,-,Consumer,Consumer,Tylenol;Vitamins;Aspirin,-,2-Mar-16,Not Specified,Not Specified,-,-,-
12007907,-,Glyburide\Metformin;Metformin Hydrochloride,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Hypoglycaemia;Medication Error,Serious,Hospitalized,Male,2-Apr-15,5-Feb-16,Expedited,84 YR,Not Specified,Bristol Myers Squibb,Healthcare Professional,Not Specified,Cordarone;Aspirin;Olmesartan Medoxomil,21-Jan-16,5-Feb-16,IT,Not Specified,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-093714,-,-
12008267,-,Glyburide\Metformin,-,Blood Glucose Increased,Non-Serious,Non-Serious,Not Specified,-,3-Feb-16,Direct,Not Specified,Not Specified,-,Consumer,Consumer,-,-,3-Feb-16,Not Specified,Not Specified,-,-,-
11971046,-,Glyburide\Metformin,-,Blood Glucose Increased;Product Substitution Issue,Non-Serious,Non-Serious,Female,-,27-Jan-16,Direct,Not Specified,Not Specified,-,Healthcare Professional,Not Specified,-,-,27-Jan-16,Not Specified,Not Specified,-,-,-
11937198,Metformin,Metformin Hydrochloride;Glyburide\Metformin,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Hypoglycaemia;Medication Error,Serious,Hospitalized,Not Specified,2-Apr-15,21-Jan-16,Expedited,Not Specified,Not Specified,Mylan,Healthcare Professional,Not Specified,Cordarone;Aspirin;Olmesartan Medoxomil,1-Jun-15,21-Jan-16,IT,Not Specified,IT-MYLANLABS-2016M1002645,-,-
11889378,Actos,Pioglitazone Hydrochloride;Glyburide\Metformin,Type 2 Diabetes Mellitus,Hypoglycaemia,Serious,Hospitalized,Male,16-Feb-14,8-Jan-16,Expedited,59 YR,130 KG,Takeda,Healthcare Professional,Not Specified,Aspirin;Lasix;Allopurinol;Rosuvastatin Calcium;Bisoprolol,5-Jan-16,5-Jan-16,IT,Not Specified,IT-TAKEDA-2016TEU000030,-,-
11882168,-,Metformin Hydrochloride;Glyburide\Metformin,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Sopor;Confusional State;Hypoglycaemia,Serious,Hospitalized,Male,7-May-03,31-Dec-15,Expedited,63 YR,Not Specified,Bristol Myers Squibb,Healthcare Professional,Not Specified,Candesartan;Simvastatin;Theo-Dur;Aspirin Dl-Lysine,17-Dec-15,31-Dec-15,IT,Not Specified,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-090368,-,-
9301661,Metformin,Metformin Hydrochloride;Glyburide\Metformin,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Confusional State;Sopor;Hypoglycaemia,Serious,Hospitalized,Not Specified,7-May-13,23-Dec-15,Expedited,Not Specified,Not Specified,Mylan,Healthcare Professional,Not Specified,Candesartan;Theo-Dur;Aspirin Dl-Lysine;Simvastatin,11-Dec-15,21-May-13,IT,Not Specified,IT-MYLANLABS-2013S1010241,-,-
11648454,-,Glyburide\Metformin;Metformin Hydrochloride,Diabetes Mellitus;Product Used For Unknown Indication,Heart Sounds Abnormal;Hypoglycaemia;Blood Pressure Decreased;Drug Clearance Decreased,Serious,Hospitalized,Male,Jul-15,9-Dec-15,Expedited,74 YR,Not Specified,Bristol Myers Squibb,Healthcare Professional,Not Specified,Fosinopril Sodium\Hydrochlorothiazide;Avodart;Irbesartan,25-Nov-15,21-Oct-15,IT,Not Specified,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-069926,-,-
11618858,-,Metformin Hydrochloride;Glyburide\Metformin,Diabetes Mellitus;Product Used For Unknown Indication,Hypoglycaemia;Heart Sounds Abnormal;Blood Pressure Decreased;Drug Clearance Decreased,Serious,Hospitalized,Not Specified,Jul-15,2-Dec-15,Expedited,Not Specified,Not Specified,Mylan,Healthcare Professional,Not Specified,Irbesartan;Avodart;Fosinopril Sodium\Hydrochlorothiazide,18-Nov-15,12-Oct-15,IT,Not Specified,IT-MYLANLABS-2015M1033339,-,-
11692768,Metformin,Metformin Hydrochloride;Glyburide\Metformin,Product Used For Unknown Indication,Drug-Induced Liver Injury,Serious,Other Outcomes,Not Specified,-,3-Nov-15,Expedited,Not Specified,Not Specified,Mylan,Healthcare Professional,Not Specified,-,15-Oct-15,3-Nov-15,US,Not Specified,US-MYLANLABS-2015M1036711,"Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, et al. Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. Gastroenterology 2015; 148(7):1340-52 e7.",-
11677579,-,Glyburide\Metformin;Metformin Hydrochloride,Product Used For Unknown Indication,Drug-Induced Liver Injury,Serious,Other Outcomes,Not Specified,-,28-Oct-15,Expedited,Not Specified,Not Specified,Apotex,Healthcare Professional,Not Specified,-,15-Oct-15,28-Oct-15,US,Not Specified,US-APOTEX-2015AP013987,"Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, et al.. Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study.. Gastroenterology. 2015;148(7):1340-52 e7",-
11639710,Actos,Pioglitazone Hydrochloride;Levofloxacin;Glyburide\Metformin,Pneumonia;Type 2 Diabetes Mellitus,Hypoglycaemia;Cough;Drug Interaction;Pyrexia,Serious,Hospitalized,Female,21-Mar-14,27-Oct-15,Expedited,83 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,Ticlopidine Hydrochloride;Atorvastatin;Timolol Maleate;Atenolol;Hydrochlorothiazide\Olmesartan Medoxomil,19-Oct-15,19-Oct-15,IT,Not Specified,IT-TAKEDA-2015TEU008716,-,-
11619708,-,Metformin Hydrochloride;Glyburide\Metformin,Diabetes Mellitus,Hypoglycaemia;Tremor;Cold Sweat;Chest Discomfort;Palpitations;Nausea,Serious,Other Outcomes,Female,17-Feb-12,12-Oct-15,Expedited,82 YR,Not Specified,Bristol Myers Squibb,Healthcare Professional,Not Specified,-,28-Sep-15,12-Oct-15,IT,Not Specified,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-067219,-,-
11599116,-,Metformin Hydrochloride;Glyburide\Metformin,Diabetes Mellitus,Palpitations;Hypoglycaemia;Cold Sweat;Chest Discomfort;Tremor;Nausea,Serious,Other Outcomes,Not Specified,17-Feb-12,6-Oct-15,Expedited,Not Specified,Not Specified,Mylan,Healthcare Professional,Not Specified,-,23-Sep-15,6-Oct-15,IT,Not Specified,IT-MYLANLABS-2015M1032946,-,-
11448416,Actos,Pioglitazone Hydrochloride;Glyburide\Metformin,Diabetes Mellitus,Dysarthria;Loss Of Consciousness;Amnestic Disorder;Head Injury;Hypoglycaemia,Serious,Other Outcomes,Female,5-Aug-13,28-Sep-15,Expedited,85 YR,Not Specified,Takeda,Healthcare Professional,Not Specified,Aspirin;Hydrochlorothiazide,22-Sep-15,2-Sep-15,IT,Not Specified,IT-TAKEDA-2015TEU007268,-,-
11251836,Metformin;Byetta,Exenatide;Glyburide\Metformin;Metformin Hydrochloride\Saxagliptin Hydrochloride;Rosuvastatin;Metformin Hydrochloride;Hydrochlorothiazide;Dapagliflozin,Hypertension;Obesity;Type 2 Diabetes Mellitus,Hypoglycaemia;Blood Glucose Increased;Weight Increased;Hepatic Steatosis;Sleep Apnoea Syndrome;Liposarcoma,Serious,Hospitalized;Other Outcomes,Male,2009,26-Aug-15,Expedited,Not Specified,Not Specified,Astrazeneca,Healthcare Professional,Not Specified,Insulin Glargine;Sibutramine;Vildagliptin;Glyburide;Ramipril;Sitagliptin;Insulin Detemir;Nph Insulin;Valsartan;Orlistat;Insulin Aspart;Pioglitazone,1-May-15,8-Jul-15,BR,Not Specified,BR-ASTRAZENECA-2015SE66389,-,-
11230165,-,Nateglinide;Glyburide\Metformin,Diabetes Mellitus;Hepatitis B,Mental Status Changes;Vomiting;Toxicity To Various Agents;Hypoglycaemia;Acute Kidney Injury;Facial Paralysis;Hemiparesis,Serious,Hospitalized;Other Outcomes,Male,-,1-Jul-15,Expedited,65 YR,Not Specified,Dr Reddys,Healthcare Professional,Not Specified,Tenofovir,24-Jun-15,1-Jul-15,US,Not Specified,US-DRREDDYS-USA/USA/15/0048995,-,-
11211312,-,Nateglinide;Glyburide\Metformin,Diabetes Mellitus;Hepatitis B,Toxicity To Various Agents;Hemiparesis;Blood Lactic Acid Increased;Acute Kidney Injury;Mental Status Changes;Vomiting;Hypoglycaemia;Facial Paralysis,Serious,Hospitalized;Other Outcomes,Not Specified,-,23-Jun-15,Expedited,Not Specified,Not Specified,Par,Healthcare Professional,Not Specified,Tenofovir,9-Jun-15,23-Jun-15,US,Not Specified,"US-PAR PHARMACEUTICAL, INC-2015SCPR014062","Cabot J.C., Morrison J.S., Manini A.F.. Prolonged, refractory glyburide and nateglinide toxicity in the setting of acute renal failure. Clinical Toxicolog. 2015;53 (4):388-389",-
11180659,-,Ciprofloxacin;Glyburide\Metformin,Skin Ulcer,Off Label Use;Drug Interaction;Hypoglycaemia,Serious,Hospitalized,Male,-,11-Jun-15,Non-Expedited,50 YR,Not Specified,Bayer,Healthcare Professional,Not Specified,-,2-Jun-15,11-Jun-15,US,Not Specified,US-BAYER-2015-315994,Supplee SJ; Donato AA. Resistant hypoglycemia from glyburide-ciprofloxacin interaction. Journal of General Internal Medicine. 2014;29:S425,-
10994276,-,Glyburide\Metformin;Repaglinide,Diabetes Mellitus,Hypoglycaemia;Medication Error,Serious,Hospitalized,Male,27-Feb-12,7-Apr-15,Expedited,79 YR,Not Specified,Actavis,Healthcare Professional,Not Specified,-,24-Mar-15,7-Apr-15,IT,Not Specified,IT-ACTAVIS-2015-07160,-,-
10992991,-,Repaglinide;Glyburide\Metformin,Diabetes Mellitus,Urine Output Decreased;Asthenia;Hypoglycaemia;Medication Error;Decreased Appetite,Serious,Hospitalized,Not Specified,27-Feb-12,6-Apr-15,Expedited,Not Specified,Not Specified,Mylan,Healthcare Professional,Not Specified,-,24-Mar-15,6-Apr-15,IT,Not Specified,IT-MYLANLABS-2015M1009965,-,-
10976877,-,Glyburide\Metformin;Repaglinide,Diabetes Mellitus,Hypoglycaemia;Medication Error,Serious,Hospitalized,Male,27-Feb-12,1-Apr-15,Expedited,79 YR,Not Specified,Sandoz,Healthcare Professional,Not Specified,-,24-Mar-15,1-Apr-15,IT,Not Specified,PHHY2015IT038093,-,-
10932662,-,Glyburide\Metformin,Diabetes Mellitus,Hypoglycaemia;Head Injury;Subdural Haematoma;Fall,Serious,Required Intervention;Hospitalized,Male,7-Jan-13,19-Mar-15,Direct,77 YR,90.9 KG,-,Healthcare Professional,Health Professional,-,-,19-Mar-15,Not Specified,Not Specified,-,-,-
10626002,-,Glyburide\Metformin;Nadolol;Prednisone,Product Used For Unknown Indication,Completed Suicide,Serious,Died,Male,2012,4-Dec-14,Expedited,91 YR,Not Specified,Roxane,Healthcare Professional,Not Specified,-,24-Nov-14,4-Dec-14,US,Not Specified,"US-ROXANE LABORATORIES, INC.-2014-BI-58495GD",-,-
10567417,Levemir;Novolog,Insulin Aspart;Glyburide\Metformin;Insulin Detemir,Product Used For Unknown Indication,Hypoglycaemia;Blood Glucose Increased;Tremor;Nervousness,Serious,Other Outcomes,Male,-,10-Nov-14,Expedited,Not Specified,Not Specified,Aurobindo,Consumer,Not Specified,-,4-Nov-14,6-Nov-14,US,Not Specified,US-AUROBINDO-AUR-APU-2014-11462,-,-
10246926,Humulin Nos;Actrapid,Insulin Human;Glyburide\Metformin;Insulin Human,Diabetes Mellitus,Sopor;Hypoglycaemia,Serious,Hospitalized,Female,28-Nov-08,4-Sep-14,Expedited,73 YR,Not Specified,Novo Nordisk,Healthcare Professional,Not Specified,-,28-Aug-14,19-Jun-14,IT,Not Specified,IT-NOVOPROD-413424,-,-
10197131,Glucobay;Lantus,Insulin Glargine;Acarbose;Glyburide\Metformin,Diabetes Mellitus,Hypoglycaemia,Serious,Hospitalized,Female,26-Apr-13,5-Aug-14,Expedited,82 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,Atorvastatin;Aspirin;Isosorbide Mononitrate;Atenolol;Candesartan Cilexetil;Lasix,30-Jul-14,27-May-14,IT,Not Specified,IT-SA-2014SA065456,-,-
9931805,Amlodipine,Amlodipine Besylate;Isosorbide Mononitrate;Aspirin;Clopidogrel Bisulfate;Ursodiol;Doxazosin Mesylate;Ramipril;Glyburide\Metformin;Furosemide;Ranolazine;Nitroglycerin;Losartan Potassium;Carvedilol;Ivabradine Hydrochloride,Cardiac Failure;Product Used For Unknown Indication,"Cardiac Failure;Poor Quality Sleep;Photopsia;Oxygen Saturation Decreased;Hallucination, Visual;Visual Impairment",Serious,Hospitalized,Male,-,27-Jun-14,Expedited,75 YR,Not Specified,Aptalis,Healthcare Professional,"Health Professional ,Literature,Foreign",-,16-Jun-14,26-Feb-14,Not Specified,Not Specified,AXC-2014-000120,-,-
9898029,Clopidogrel,Clopidogrel Bisulfate;Ivabradine Hydrochloride;Isosorbide Mononitrate;Carvedilol;Amlodipine Besylate;Doxazosin Mesylate;Losartan Potassium;Ranolazine;Ramipril;Glyburide\Metformin;Nitroglycerin;Aspirin;Furosemide;Ursodiol,Cardiac Failure,"Photopsia;Hallucination, Visual",Serious,Hospitalized,Male,-,17-Jun-14,Expedited,75 YR,Not Specified,Pfizer,Healthcare Professional,Not Specified,Naphazoline,9-Jun-14,14-Feb-14,IT,Not Specified,IT-PFIZER INC-2014040425,"Patoia, L. Phosphenes and visual hallucinations due to ivabradine: A case report study and a review of the literature. Italian Journal of Medicine. 2013;7(S2):92-93",-
9889208,Metformin;Amlodipine,Amlodipine Besylate;Carvedilol;Ranolazine;Metformin Hydrochloride;Glyburide\Metformin;Glyburide;Ursodiol;Nitroglycerin;Furosemide;Aspirin;Losartan Potassium;Doxazosin Mesylate;Ivabradine Hydrochloride;Clopidogrel Bisulfate;Ramipril;Isosorbide Mononitrate,Cardiac Failure;Product Used For Unknown Indication,"Photopsia;Hallucination, Visual",Serious,Hospitalized,Male,-,13-Jun-14,Expedited,75 YR,Not Specified,Aventis,Healthcare Professional,Not Specified,Naphazoline,9-Jun-14,11-Feb-14,IT,Not Specified,IT-SA-2014SA017125,"Patoia L, Paglialunga L. Phosphenes and visual hallucinations due to ivabradine: A case report study and a review of the literature. Italian Journal of Medicine 2013;7(S2):92-3.",-
10097254,Metformin,Metformin Hydrochloride;Glyburide\Metformin,Product Used For Unknown Indication,Overdose;Multiple Organ Dysfunction Syndrome;Toxicity To Various Agents;Lactic Acidosis,Serious,Life Threatening,Male,18-Dec-12,2-Jun-14,Expedited,63 YR,68 KG,Teva,Healthcare Professional,Not Specified,Micardis;Enoxaparin Sodium;Atorvastatin,22-May-14,22-Apr-14,IT,Not Specified,IT-TEVA-474938ISR,-,-
9508437,Metformin,Metformin Hydrochloride;Glyburide\Metformin,Type 2 Diabetes Mellitus,Acute Kidney Injury;Condition Aggravated;Nausea;Multiple Organ Dysfunction Syndrome;Atrial Fibrillation;Blood Glucose Increased;Abdominal Pain;Toxicity To Various Agents;Overdose;Blood Bilirubin Increased;Drug Level Increased;Metabolic Acidosis;Lactic Acidosis;Vomiting,Serious,Hospitalized;Life Threatening;Other Outcomes,Male,16-Dec-12,23-May-14,Expedited,63 YR,68 KG,Aurobindo,Healthcare Professional,"Health Professional ,Foreign",-,14-May-14,5-Sep-13,Not Specified,Not Specified,AUR-APL-2013-07227,-,-
10094473,-,Glyburide\Metformin;Metformin Hydrochloride,Product Used For Unknown Indication,Toxicity To Various Agents;Lactic Acidosis;Multiple Organ Dysfunction Syndrome,Serious,Life Threatening,Male,18-Dec-12,22-Apr-14,Expedited,63 YR,68 KG,Mylan,Healthcare Professional,Not Specified,Atorvastatin;Micardis;Enoxaparin Sodium,8-Apr-14,22-Apr-14,IT,Not Specified,IT-MYLANLABS-2014S1008513,-,-
10086025,Metformin,Metformin Hydrochloride;Glyburide\Metformin,Product Used For Unknown Indication,Lactic Acidosis;Toxicity To Various Agents;Multiple Organ Dysfunction Syndrome;Dialysis;Overdose;Nausea;Blood Creatinine Increased;Vomiting,Serious,Other Outcomes;Life Threatening,Male,18-Dec-12,22-Apr-14,Expedited,63 YR,68 KG,Aurobindo,Healthcare Professional,"Health Professional ,Foreign",Atorvastatin;Micardis,7-Apr-14,16-Apr-14,Not Specified,Not Specified,AUR-APL-2014-04624,-,-
9489405,Metformin,Metformin Hydrochloride;Glyburide\Metformin,-,Toxicity To Various Agents;Multiple Organ Dysfunction Syndrome,Serious,Life Threatening,Male,18-Dec-12,17-Apr-14,Expedited,63 YR,Not Specified,Sandoz,Healthcare Professional,Not Specified,Enoxaparin Sodium;Micardis;Atorvastatin,8-Apr-14,29-Aug-13,IT,Not Specified,PHHY2013IT093126,-,-
10067854,Sertraline;Cozaar,Sertraline Hydrochloride;Losartan Potassium;Fish Oil;Glyburide\Metformin;Human Clostridium Tetani Toxoid Immune Globulin;Fenofibrate;Buprenorphine;Vitamins;Simvastatin,Depression;Hyperlipidaemia;Hypertension;Neck Pain;Nutritional Supplementation;Prophylaxis;Type 2 Diabetes Mellitus,Hospitalisation,Serious,Hospitalized,Male,24-Mar-14,7-Apr-14,Expedited,50 YR,88.3 KG,Aurobindo,Not Specified,Health Professional,-,24-Mar-14,7-Apr-14,Not Specified,Not Specified,AUR-APL-2014-03950,-,-
10042390,Levemir;Humalog,Insulin Lispro;Glyburide\Metformin;Insulin Detemir;Metformin Hydrochloride,Product Used For Unknown Indication,Hypoglycaemia,Serious,Hospitalized,Female,11-Feb-14,27-Mar-14,Expedited,87 YR,Not Specified,Watson,Healthcare Professional,Not Specified,Gabapentin;Perindopril;Levothyroxine Sodium,13-Mar-14,27-Mar-14,IT,Not Specified,IT-WATSON-2014-05599,-,-
10029629,-,Glyburide\Metformin,Diabetes Mellitus,Laboratory Test Abnormal;Product Quality Issue,Serious,Other Outcomes,Male,19-Nov-12,20-Mar-14,Direct,73 YR,Not Specified,-,Healthcare Professional,Health Professional,-,-,20-Mar-14,Not Specified,Not Specified,-,-,-
9831023,Salicylate,Salicylic Acid;Nadolol;Glyburide\Metformin,Product Used For Unknown Indication,Completed Suicide;Toxicity To Various Agents,Serious,Died,Male,-,20-Jan-14,Expedited,91 YR,Not Specified,Mcneil,Healthcare Professional,Not Specified,-,7-Jan-14,20-Jan-14,US,Not Specified,US-JNJFOC-20140109468,"Mowry JB, Spyker DA, Cantilena Jr LR, Bailey J, Ford M. 2012 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 30th Annual Report. Clinical Toxicology 2013;51:949-1229.",-
9502729,Metformin,Metformin Hydrochloride;Glyburide\Metformin,Product Used For Unknown Indication,Multiple Organ Dysfunction Syndrome;Toxicity To Various Agents;Lactic Acidosis,Serious,Hospitalized;Life Threatening,Male,18-Dec-12,6-Sep-13,Expedited,63 YR,68 KG,Mylan,Healthcare Professional,Not Specified,Micardis;Enoxaparin Sodium;Atorvastatin,24-Aug-13,6-Sep-13,IT,Not Specified,IT-MYLANLABS-2013S1019287,-,-
9400250,Metformin,Metformin Hydrochloride;Glyburide\Metformin,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Toxicity To Various Agents;Metabolic Acidosis;Multiple Organ Dysfunction Syndrome,Serious,Hospitalized,Male,16-Dec-12,3-Sep-13,Expedited,63 YR,Not Specified,Mylan,Healthcare Professional,Not Specified,Atorvastatin;Enoxaparin Sodium;Micardis,21-Aug-13,15-Jul-13,IT,Not Specified,IT-MYLANLABS-2013S1014540,-,-
9458223,Crestor,Rosuvastatin Calcium;Glyburide\Metformin,Intentional Overdose;Overdose,Abdominal Pain;Diarrhoea;Intentional Overdose;Exposure During Pregnancy,Serious,Other Outcomes;Hospitalized,Female,28-Jun-13,14-Aug-13,Expedited,7054 DAY,Not Specified,Astrazeneca,Healthcare Professional,Not Specified,-,7-Aug-13,14-Aug-13,IT,Not Specified,IT-ASTRAZENECA-2013SE62371,-,-
9033244,-,Amlodipine\Atorvastatin;Lisinopril;Glyburide\Metformin;Hydrochlorothiazide\Losartan;Nitroglycerin,-,Completed Suicide,Serious,Died,Male,-,28-Jan-13,Expedited,45 YR,Not Specified,Sandoz,Healthcare Professional,Not Specified,-,22-Jan-13,28-Jan-13,US,Not Specified,PHHY2013US007326,"Bronstein A, Spyker D, Cantilena L, Rumack B, Dart R. 2011 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 29th Annual Report.. Clinical Toxicology. 2012;50:911-1164",-
9058415,-,Amlodipine\Atorvastatin;Lisinopril;Nitroglycerin;Glyburide\Metformin;Hydrochlorothiazide\Losartan,-,Completed Suicide,Serious,Died,Male,2012,18-Jan-13,Expedited,45 YR,Not Specified,Akrimax,Healthcare Professional,"Health Professional ,Literature",-,3-Jan-13,18-Jan-13,Not Specified,Not Specified,NMS-00067,-,-
9005191,Losartan And Hydrochlorothiazide,Hydrochlorothiazide\Losartan Potassium;Nitroglycerin;Amlodipine\Atorvastatin;Lisinopril;Glyburide\Metformin,-,Completed Suicide;Toxicity To Various Agents,Serious,Died,Male,-,8-Jan-13,Expedited,45 YR,Not Specified,Astrazeneca,Healthcare Professional,Not Specified,-,3-Jan-13,8-Jan-13,US,Not Specified,US-ASTRAZENECA-2013SE01013,"Bronstein, A.C.; Spyker, D.A.; Cantilena, L.R.; Rumack, B.H.; Dart, R.C.. 2011 Annual Report of the American Association of Poison Control Centers'  National Poison Data System (NPDS):29th Annual Report. Clinical Toxicology 2012; 50:911-1164.",-
8836625,Enalapril Maleate And Hydrochlorothiazide;Heparin;Tramadol,Tramadol\Tramadol Hydrochloride;Glyburide\Metformin;Levofloxacin;Heparin Sodium;Enalapril;Enalapril Maleate\Hydrochlorothiazide;Buprenorphine,Analgesic Therapy;Bacterial Infection;Hypertension;Ischaemic Stroke;Pain;Type 2 Diabetes Mellitus,Localised Infection;Bacterial Infection;Hypoglycaemic Coma;Drug Interaction;Peripheral Artery Thrombosis,Serious,Other Outcomes;Hospitalized,Female,-,9-Oct-12,Expedited,91 YR,Not Specified,Macleods,Healthcare Professional,"Health Professional ,Literature,Foreign",Aspirin;Lansoprazole,21-Sep-12,9-Oct-12,Not Specified,Not Specified,IT-MACLEODS PHARMA-000019,-,-
8728392,Tramadol,Tramadol\Tramadol Hydrochloride;Levofloxacin;Enalapril\Hydrochlorothiazide;Aspirin;Nadroparin Calcium;Insulin Nos;Buprenorphine;Enalapril;Lansoprazole;Glyburide\Metformin,Antiplatelet Therapy;Bacterial Infection;Hypertension;Ischaemic Stroke;Pain;Prophylaxis;Type 2 Diabetes Mellitus,Drug Interaction;Localised Infection;Peripheral Artery Thrombosis;Coma;Condition Aggravated;Hypoglycaemia,Serious,Other Outcomes;Hospitalized,Female,-,20-Sep-12,Expedited,91 YR,Not Specified,Ranbaxy,Healthcare Professional,Not Specified,-,6-Sep-12,17-Aug-12,IT,Not Specified,IT-RANBAXY-2012RR-58621,"Micheli Lucia, Sbrilli Marcellor, Nencini Cristina. Severe hypoglycemia associated with levofloxacin in Type 2 diabetic patients receiving polytherapy: two case reports. International Journal of Clinical Pharmacology and Therapeutics. 2012;50 (4):302-6",-
8762973,-,Glyburide\Metformin,Diabetes Mellitus,Hypoglycaemia,Serious,Hospitalized,Male,31-Jul-12,30-Aug-12,Direct,75 YR,81.5 KG,-,Healthcare Professional,Health Professional,-,-,30-Aug-12,Not Specified,Not Specified,-,-,-
7622969,-,Ritonavir;Efavirenz;Raltegravir;Glyburide\Metformin;Fosamprenavir;Sildenafil,-,Ventricular Arrhythmia;Metabolic Acidosis;Insomnia;Hyperlactacidaemia;Dyspnoea;Shock,Serious,Life Threatening;Died,Male,-,18-Feb-11,Expedited,Not Specified,Not Specified,Bristol Myers Squibb,Consumer,Consumer,Aceprometazine\Meprobamate;Alprazolam;Risperidone;Venlafaxine Hydrochloride,16-Feb-11,10-Oct-10,US,Not Specified,US-BRISTOL-MYERS SQUIBB COMPANY-15321201,-,-
7759635,Benicar;Clopidogrel,Glyburide\Metformin;Clopidogrel Bisulfate;Olmesartan Medoxomil,Diabetes Mellitus;Hypertension;Product Used For Unknown Indication,Diabetes Mellitus;Drug Ineffective;Condition Aggravated;Infarction;Malaise;Weight Increased;Somnolence,Serious,Hospitalized;Other Outcomes,Female,2007,17-Dec-10,Expedited,8-Dec,Not Specified,Daiichi,Not Specified,"Consumer,Foreign",Metoprolol;Gliclazide;Simvastatin,1-Dec-10,17-Dec-10,Not Specified,Not Specified,DSJ-2010-17599,-,-
7365178,Moduretic 5-50,Amiloride Hydrochloride\Hydrochlorothiazide;Glyburide\Metformin;Hydrochlorothiazide\Losartan Potassium,Benign Prostatic Hyperplasia;Diabetes Mellitus;Hypertension,Acute Kidney Injury;Rhabdomyolysis;Diabetes Mellitus,Serious,Hospitalized,Male,10-Dec-09,11-Jun-10,Expedited,85 YR,Not Specified,Merck,Healthcare Professional,Health Professional,Aspirin;Alfuzosin Hydrochloride,10-Jun-10,23-Apr-10,IT,Not Specified,IT-MERCK-1004ITA00020,-,-
7251560,-,Levofloxacin;Glyburide\Metformin,Diabetes Mellitus;Oropharyngeal Gonococcal Infection,Hypoglycaemia;Depressed Level Of Consciousness,Serious,Life Threatening,Male,2-Dec-09,4-Feb-10,Expedited,61 YR,Not Specified,Ortho,Healthcare Professional,Health Professional,Fat Emulsion Nos;Hydromorphone Hydrochloride;Nadroparin Calcium,1-Feb-10,21-Jan-10,IT,Not Specified,IT-JNJFOC-20100107362,-,-
6907193,Actos,Pioglitazone Hydrochloride;Glyburide\Metformin,Diabetes Mellitus,Hepatic Failure;Tachypnoea;Asthenia;Arteriosclerosis Coronary Artery;Blood Pressure Immeasurable;Anuria;Metabolic Acidosis;Pulmonary Oedema;Pulmonary Congestion;Leukopenia;Hypoglycaemia;Ascites;Aortic Arteriosclerosis;General Physical Health Deterioration,Serious,Died;Hospitalized,Male,4-Dec-08,13-Mar-09,Expedited,61 YR,Not Specified,Takeda,Not Specified,"Other,Health Professional ,Foreign",Aldactone;Irbesartan;Timoptic;Azopt,4-Mar-09,28-Jan-09,Not Specified,Not Specified,TIF2009A00007,-,-
6878602,-,Metformin Hydrochloride;Glyburide\Metformin;Insulin Glargine;Terazosin Hydrochloride;Exenatide;Glimepiride,Product Used For Unknown Indication;Type 2 Diabetes Mellitus,Weight Increased;Hyperhidrosis;Epistaxis;Blood Glucose Increased;Mobility Decreased;Hypophagia;Blood Glucose Decreased;Tremor;Dizziness Postural;Weight Decreased;Dysstasia,Non-Serious,Non-Serious,Male,-,12-Jan-09,Non-Expedited,Not Specified,158 KG,Abbott,Healthcare Professional,Health Professional,Aspirin;Metformin Hydrochloride;Pravastatin;Furosemide;Atenolol;Allopurinol,11-Jul-08,12-Jan-09,US,Not Specified,US-ABBOTT-08P-163-0462429-00,-,-
6427561,-,Glyburide\Metformin,Product Used For Unknown Indication,Hypoglycaemic Coma,Serious,Hospitalized,Male,26-May-07,13-Sep-07,Expedited,Not Specified,Not Specified,Merck Kgaa,Not Specified,"Other,Health Professional",-,28-Aug-07,13-Sep-07,Not Specified,Not Specified,6037409,-,-
4138111,Raptiva,Efalizumab;Glyburide\Metformin,Diabetes Mellitus;Psoriasis,Hemianopia;Hepatic Steatosis;Cerebral Ischaemia;Splenomegaly,Serious,Hospitalized;Other Outcomes,Male,2-Jan-07,12-Mar-07,Expedited,59 YR,Not Specified,Genentech,Healthcare Professional,"Health Professional ,Foreign",-,22-Feb-07,28-Apr-04,Not Specified,Not Specified,236364,-,-
5761894,-,Glyburide\Metformin,Diabetes Mellitus,Product Quality Issue;Diabetes Mellitus Inadequate Control,Serious,Other Outcomes,Female,-,10-Mar-05,Direct,68 YR,175 LB,-,Healthcare Professional,Health Professional,-,-,10-Mar-05,Not Specified,Not Specified,-,-,-
5758836,-,Glyburide\Metformin,Diabetes Mellitus,Blood Glucose Increased;Product Quality Issue,Serious,Other Outcomes,Female,19-May-04,1-Mar-05,Direct,41 YR,Not Specified,-,Healthcare Professional,Health Professional,-,-,1-Mar-05,Not Specified,Not Specified,-,-,-
5834898,-,Glyburide\Metformin,Hyperglycaemia,Blood Glucose Increased;Therapeutic Response Unexpected,Serious,Required Intervention,Female,Jun-04,8-Feb-05,Direct,69 YR,Not Specified,-,Healthcare Professional,Health Professional,-,-,8-Feb-05,Not Specified,Not Specified,-,-,-
4180077,-,Glyburide\Metformin,Type 2 Diabetes Mellitus,Product Quality Issue;Diarrhoea;Vomiting;Hyperglycaemia;Hypoglycaemia,Serious,Other Outcomes,Female,13-May-04,22-Jul-04,Direct,54 YR,259 LB,-,Healthcare Professional,Health Professional,-,-,22-Jul-04,Not Specified,Not Specified,-,-,-
4162957,-,Glyburide\Metformin,Diabetes Mellitus,Blood Glucose Fluctuation;Blood Glucose Increased;Hypoaesthesia;Product Quality Issue,Serious,Hospitalized,Male,20-May-04,12-Jul-04,Expedited,57 YR,180 LB,Ivax,Consumer,Consumer,Aspirin;Lisinopril;Vitamin E;Zocor;Metoprolol,6-Jul-04,22-Jun-04,Not Specified,Not Specified,04-06-0868,-,-
4158984,-,Glyburide\Metformin,Type 2 Diabetes Mellitus,Product Quality Issue;Blood Glucose Increased;Hypersensitivity,Serious,Other Outcomes,Female,7-Jun-04,18-Jun-04,Direct,34 YR,202 LB,-,Healthcare Professional,Health Professional,Atenolol;Nexium;Synthroid,-,18-Jun-04,Not Specified,Not Specified,-,-,-
4158994,-,Glyburide\Metformin,Diabetes Mellitus,Product Quality Issue;Hypoglycaemia;Sedation;Asthenia;Dizziness,Serious,Other Outcomes,Male,29-May-04,17-Jun-04,Direct,68 YR,220 LB,-,Healthcare Professional,Health Professional,-,-,17-Jun-04,Not Specified,Not Specified,-,-,-
3983955,-,Glyburide\Phenformin Hydrochloride,Type 2 Diabetes Mellitus,Hypertension;Lactic Acidosis,Serious,Other Outcomes,Female,12-May-03,30-Jul-03,Expedited,84 YR,Not Specified,Aventis,Not Specified,"Other,Foreign",Nimotop;Pindolol,15-Jul-03,30-Jul-03,Not Specified,Not Specified,200312196EU,-,-
3436310,-,Glyburide\Phenformin Hydrochloride,Diabetes Mellitus,Dialysis;Cardiogenic Shock;Lactic Acidosis,Serious,Other Outcomes;Died;Hospitalized,Female,21-Jan-00,17-Feb-00,Expedited,72 YR,Not Specified,Aventis,Not Specified,"Other,Health Professional ,Foreign",-,9-Feb-00,17-Feb-00,Not Specified,Not Specified,200010724DDC,-,-
